<SEC-DOCUMENT>0000950170-22-006901.txt : 20220502
<SEC-HEADER>0000950170-22-006901.hdr.sgml : 20220502
<ACCEPTANCE-DATETIME>20220502170813
ACCESSION NUMBER:		0000950170-22-006901
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220502
DATE AS OF CHANGE:		20220502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Axsome Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001579428
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				454241907
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37635
		FILM NUMBER:		22883102

	BUSINESS ADDRESS:	
		STREET 1:		22 CORTLANDT STREET, 16TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10007
		BUSINESS PHONE:		(212) 332-3241

	MAIL ADDRESS:	
		STREET 1:		22 CORTLANDT STREET, 16TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10007
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>axsm-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-05-02T16:59:15.5130+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:axsm="http://axsome.com/20220331" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_532497aa-4ade-4d72-8db1-44a2373f74cb" name="dei:EntityCentralIndexKey" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c">0001579428</ix:nonNumeric><ix:nonNumeric id="F_3564befc-c2f1-49a8-b9cb-3fe71364b65b" name="dei:DocumentFiscalPeriodFocus" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c">Q1</ix:nonNumeric><ix:nonNumeric id="F_50964fc1-b913-49d5-9e79-a77051394e37" name="dei:AmendmentFlag" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c">false</ix:nonNumeric><ix:nonNumeric id="F_94398959-42ea-49ba-9af0-943b9d4f9861" name="axsm:ConsecutiveTradingDays" contextRef="C_d123927e-7029-4dd1-878a-36b68f4a9e6e">P10D</ix:nonNumeric><ix:nonNumeric id="F_f4629aff-5441-4573-b028-ad83f8f53b51" name="dei:CurrentFiscalYearEndDate" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c">--12-31</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="axsm-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_cc7591c2-a315-4ba0-8ba7-30d3937ab8ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d518ab07-50e1-4f22-8ead-a8eb4564ed95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6854c542-e5e2-4d67-b182-044dbba449bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-14</xbrli:startDate><xbrli:endDate>2021-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fda19f6a-c507-42ec-b932-514114edee24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2357bd34-be20-473a-9a97-21a5de4d2722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43574450-92b4-4988-81e4-50b6b102e732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d2b4eb6-939a-4140-adcf-dc65291830f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8499400d-f664-4e71-b17e-d1301c2cb375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c8df518-2cca-4db3-a63e-69a63815b2f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa561b4e-b6ea-4fd4-8d9a-70f77c8de67f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae13ec89-1fa4-4e02-b9fc-58d4fca0deaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e3cc36d-423a-457f-931c-9109e9833261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee66dee5-84e1-46c5-b128-680ea4f73cbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58506d7a-5c75-4b99-8279-0688e8c43429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21a3ddfb-93a7-4cbb-82fd-5e3bc5f0961b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7171c32-68b1-44fb-bc72-6ca42e63f926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2dda7b7d-4eb5-4947-be5a-64886b352ff5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_133a145c-e960-4fc8-b6d5-388d2e167e6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f1dee24-d9e9-4cd0-809c-31fbba3bb1c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df3f324f-9e88-4cd0-becb-e386dfb62dde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-14</xbrli:startDate><xbrli:endDate>2021-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_044ac2dd-a43b-4bf0-a117-1190f9ff7f2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axsm:MarchTwoThousandTwentyTwoSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">axsm:LeerinkPartnersLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a94eb90c-f0d3-4b2c-9a0c-9754a3a9a0a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f6dcc9c-a3d6-4cf1-8464-0d285bc4d9a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80117ee7-80d8-4a57-96a2-e2ea5118fefe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52720a6e-acc3-4746-a598-7a3115ffa670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6b4b679-0646-4f99-b733-4c1487965f80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73c76e5f-6946-415b-ac4a-5f14307e04c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_525e81c7-d46e-4ea7-9684-74def5e30aac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93fc45bb-69f6-4b6b-ba71-8a6735312525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:SunosiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">axsm:JazzPharmaceuticalsPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-24</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb885263-2c35-4cf7-8ae9-82fc64c0f7a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-14</xbrli:startDate><xbrli:endDate>2021-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3c1be52-c032-4a53-856d-c71d3887807f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4dbaf2a-a0d5-4d55-b135-ec0dd9346cc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c1d2970-ecdc-417a-8c38-beb830e327cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9bc5005-9c34-42dc-a103-770e8beb2d78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad457fe7-35cb-4f1c-adfe-9364d3096822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4a98684-d57a-4c5f-b5a6-c9b492ff4e17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_303637a5-8b91-4570-a728-6f97f2270ef4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">axsm:Axs05AndAxs07Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b4195b45-d05d-44d6-967c-803d41a1847f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">axsm:LeerinkPartnersLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axsm:DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c83df33-9153-49e3-a55c-f2a68eb4045a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3922af5a-d586-4a59-a748-dca027a9e1b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7dd348d4-cefb-4639-92c0-78e13450f2b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d352228-7b5b-4785-b9bd-1cfc63c353da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">axsm:Axs02Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ec01d46-909a-44bc-befd-1d1a23e4ab9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_203ed062-9609-4a15-a548-eb77d8ad1188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf72b4a0-6c33-4db5-9316-0eaa208085c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4afe19c-11d0-445b-b47f-99cea4fdcb9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_008bb3dd-4868-4984-8e42-390d9ffd5c65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fa0e148-2225-4c34-bcbe-ec944991768c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78a1f202-d9b2-477b-b649-06874c29753a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheTwoSubTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56c3f743-f85c-4b20-9622-f711609bcf18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e79659be-62a0-4d7f-8919-a6af22ec548f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8eda348-341b-4541-93f2-83c532439893"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99cf65ea-42df-4c36-87cb-c410c3027f8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb2f9874-656b-41a0-87d5-d87935757fb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5109b34-436f-4349-abc0-b0c0dca35cfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46bc8e64-2627-43a1-9043-0b5495dccc01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-14</xbrli:startDate><xbrli:endDate>2021-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6555893-bd98-4700-a5a7-8076bf2d8d0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dacb844-4b15-4c03-acb3-09a6b640217c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">axsm:SecondAmendmentToLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdddd48e-24d8-466b-85d6-b30c067ffe9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axsm:DecemberTwoThousandNineteenSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">axsm:LeerinkPartnersLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d123927e-7029-4dd1-878a-36b68f4a9e6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3170278-1391-4a56-9d86-0add7cd33446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b988683-b18d-41ce-bc31-605656e6a4f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13dea1cb-aa1f-4a8f-94bb-ccbf522d6b7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47fac860-11d6-4b0d-8e1c-85902d5c680c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-14</xbrli:startDate><xbrli:endDate>2021-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2abbcf3-4402-4301-9f22-3638b33916cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4616eca2-d061-41e6-b773-9b50623ea068"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e07b08d9-2bba-42e4-bf1e-6aa9c55ce68c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">axsm:HerculesCapitalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">axsm:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_838ee7b0-8654-4765-abd6-662f63a4c8c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7fe0f8e-7fa9-4070-979d-a3234fed3fa1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c22e247-ede4-4b63-a5a8-09b68eef26a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8689f73-8b90-434a-8cae-7e991d869064"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75b98a95-0d49-477b-bc05-e21aa024dc87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4d05faf-ec2b-48f5-8a76-5f0bc4fe39a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5af5223-2fe5-4213-acad-7c31eefaf440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f4ab0e3-713f-4c51-8c3a-4b2e440fc6c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1882e4f2-eb93-4210-b724-5c9bb20bebf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d91b4b62-4ebe-490a-a88e-6f69afcf5a05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c74abd6-a2c2-4c0f-9355-8d60eb862eb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheTwoSubTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_234c04e9-be43-4c65-8294-bca64c8b14d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2038d698-c757-4fc1-8d54-847b886c8572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7beabbcc-8b62-4676-8c90-7970bd0c23b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axsm:DecemberTwoThousandNineteenSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">axsm:LeerinkPartnersLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9fad345-924e-408f-93e8-d534f64b717a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">axsm:Axs04Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c213636-da72-4c96-a325-3f0b156f4462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axsm:TwoThousandFifteenEquityCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed7f64ac-9d3d-4975-a4ad-4adbcbe2e765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d49b89d1-f1b7-475f-9685-738cdbff9497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aac9dd6a-0f39-4dca-9c62-e17e1926a68c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39b63eb4-ca27-40bd-82f5-858e406e3701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheTwoSubTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_766126cd-3c63-4018-b6f6-3bc6d4b038fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheThreeSubTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81597194-9eed-48c4-a703-a29a052262b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70fafa52-2071-4fb1-b999-e133e767989d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">axsm:Axs05Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27e2a477-b3de-4e25-a8a8-015812de985a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-14</xbrli:startDate><xbrli:endDate>2021-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6e03d77-74bc-438d-ac62-681542cd683c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb6e9275-c30c-46d5-9e05-d49f1beb2c70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc41918b-50a0-4e0c-ae3a-cc2fea3bfbfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87baa8d3-aef8-4d44-b758-b03bb30059dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_965ed3a9-df64-4456-ade2-24619ff19b45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd3b09d8-962f-4a8d-95b5-a2380be0bb5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebcc446a-08e2-4b02-a7fc-b6339311af4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axsm:MarchTwoThousandTwentyTwoSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">axsm:LeerinkPartnersLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21a8a9ca-0b07-4cdd-ac95-7ef4b8971c9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-14</xbrli:startDate><xbrli:endDate>2021-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d7b6b8c-7fba-4794-bad1-9528cd8b0a02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_839cd5d9-6625-4c96-98f0-b8b61c6a4475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d6af9b1-56a3-4f2a-b2f7-a25d457c6cbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheTwoSubTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_724babf7-6fd0-424b-9476-154cb4318da6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-14</xbrli:startDate><xbrli:endDate>2021-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ba10b02-2ba9-41b3-b76d-552fff659baa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ba32c09-ff41-4912-b05b-767b2f5e43d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_148374f5-3d5c-4b2e-ade2-fb6cd32a789e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_144b60f0-d4f4-4610-977c-bd99ba58cc09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a6da949-18b2-470e-9fe3-f0d2c926ef8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:SunosiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-24</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caa50054-de64-4723-b525-0cfcc3b7185f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheTwoSubTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6291cbc-4212-426f-966c-f9d236bef96a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e075509a-46d1-46e0-8bb0-6f2bbee2ca82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheThreeSubTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41c6af09-fd7f-47cc-bdbe-fdeca00ab829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axsm:TwoThousandNineteenShelfRegistrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-05</xbrli:startDate><xbrli:endDate>2019-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7fb4e8a-2ebf-48fc-8a1b-f5d6d9833933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001579428</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Product"><xbrli:measure>axsm:Product</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>axsm:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Item"><xbrli:measure>axsm:Item</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_D"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:unit id="U_Institution"><xbrli:measure>axsm:Institution</xbrli:measure></xbrli:unit><xbrli:unit id="U_Market"><xbrli:measure>axsm:Market</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>axsm:Vote</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:Times New Roman;min-width:fit-content;">FORM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:13.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:13.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d64b852-52d9-4fc6-81b2-f4db7e5c398b" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_579615d3-9f61-4c33-b0dc-c1daf4f1e6ff" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="text-indent:2.253%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4a061a5-f298-4362-836f-86c63821d957" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6d284a3-fd66-446a-b67f-85712c7a67fc" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7290102-7876-46fb-92ac-39332cd2d110" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from ________ to ________</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28cb7ceb-0db7-4c33-baa0-f95acd0353cd" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">001-37635</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:13.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92c27eab-1d3c-4034-998b-f7776ac4aed4" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:Times New Roman;min-width:fit-content;">AXSOME THERAPEUTICS, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_369ebb12-42e2-4f7e-b51d-78dd42bf6020" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37788250-8c36-4a43-b2ab-4f02f1d2c2fd" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45-4241907</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(State or other jurisdiction of incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(I.R.S. Employer Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7755d9e2-5e27-4dc6-b4e2-a0fba9d9f5b1" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">22 Cortlandt Street</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17b8897e-785f-46f8-9964-560a7716ceb9" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">16th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Floor</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fe6ba23-6990-46c2-8f39-e137d26ea236" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">New York</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13da5860-90d1-4865-bb43-7c867b9f0ff8" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">New York</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de6b4972-b3f4-4828-99ad-a93c1bf8fddb" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">10007</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_809be6bb-6789-4572-9ce4-710e4e01fc0d" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">212</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f06cf604-493e-470b-af83-55b517103dac" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">332-3241</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5fedfe08-bee7-4eb8-9df3-24435820406e" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">    No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bfdbe36-d5ac-4794-93b3-da8aafa16e59" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;    No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.0%;"></td>
    <td style="width:25.0%;"></td>
    <td style="width:25.0%;"></td>
    <td style="width:25.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ddc8662-a01b-4a3a-bf55-49097d135a16" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Accelerated Filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44e09ddb-9639-4593-8ea1-a52697daa49b" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fce7f4b5-f115-4fe6-a758-40bb7c6285da" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cbc40848-28e1-4833-96cd-02ccb2b87ab5" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.001%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:32.001%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:32.001%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Title of each class:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Name of each exchange on which registered:</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fde2c811-e271-4d39-9f22-303da4b2abbf" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock, Par Value $0.0001 Per Share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7ba5c7d-b15e-4794-b1c9-182a5ddb52c7" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">AXSM</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6cac6772-62ad-4e54-b618-3650835ed0ae" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b828ced4-b96a-4ee0-aee7-a7ed0eb0307d" contextRef="C_3f4ab0e3-713f-4c51-8c3a-4b2e440fc6c3" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38,913,550</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of the registrant&#x2019;s common stock, $0.0001 par value, outstanding as of April 26, 2022.</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">AXSOME THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">QUARTERLY REPORT ON FORM 10-Q</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">FOR THE QUARTER ENDED MARCH 31, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">TABLE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">OF</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">CONTENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.12%;"></td>
    <td style="width:84.615%;"></td>
    <td style="width:0.641%;"></td>
    <td style="width:6.624%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#cautionary_note_regarding_forwardlooking"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i_financial_information"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">PART I &#x2014; FINANCIAL INFORMATION</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Quantitative and Qualitative Disclosure About Market Risk</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">PART II &#x2014; OTHER INFORMATION</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="cautionary_note_regarding_forwardlooking"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">CAUTIONARY NOTE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">REGARDING </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Certain matters discussed in this report, including matters discussed under the caption &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;may,&#x201d; &#x201c;expect&#x201d; and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the captions &#x201c;Risk Factors,&#x201d; &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and elsewhere in this report, as well as other factors which may be identified from time to time in our other filings with the Securities and Exchange Commission, or the SEC, or in the documents where such forward-looking statements appear. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements. Such forward-looking statements include, but are not limited to, statements about:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our expectations for increases or decreases in expenses;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our expectations for the clinical and preclinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidates or any other products that we may acquire or in-license;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our estimates of the sufficiency of our existing capital resources combined with future anticipated cash flows to finance our operating requirements;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our expectations for generating revenue or becoming profitable on a sustained basis;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our expectations or ability to enter into marketing and other partnership agreements;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our expectations or ability to enter into product acquisition and in-licensing transactions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our expected losses;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain intellectual property protection for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the acceptance of our products by doctors, patients, or payors;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our stock price and its volatility;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to attract and retain key personnel;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the performance of our third-party manufacturers;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our expectations for future capital requirements; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully implement our strategy.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The forward-looking statements contained in this report reflect our views and assumptions only as of the date that this report is signed. Except as required by law, we assume no responsibility for updating any forward-looking statements.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i_financial_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">PART I. FINANC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">IAL INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1. FINANC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">IAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Balance Sheets</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.996%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.116%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.116%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d2b02986-1752-46d8-8dfc-d844f04b9266" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">84,707,782</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5f8467d7-ca13-4cd7-a845-8b95880bff9a" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">86,472,854</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prepaid and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_653bc318-6f66-404c-aa79-4b19e3df9db3" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,122,144</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_da4b34cb-66ef-4feb-817f-88c566f1a33a" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">45,286</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_32c49e73-c17d-43fb-a217-350d79c7f474" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:AssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">86,829,926</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_09757e7e-08d7-46cb-b59a-25c1c731c28e" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:AssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">86,518,140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Equipment, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_02d2ecd5-28bd-473e-9dda-b8564bd1c238" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">460,946</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7eedf5fc-7d09-4cb7-b2a1-4703479dcfc1" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">283,846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use asset - operating lease</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7622794d-3df6-48d9-a98e-baa39facaa10" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">946,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6ebac1f7-e2c8-4f0f-b5fb-975474b1127e" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">660,162</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7a5f5553-5fd2-4e95-9e61-37e7657116c0" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">322,910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b9b27b81-c69a-4aac-a7b0-e3e53d8c4043" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">322,910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2f010700-67e4-44ce-b5ab-22f5304bdd57" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:Assets" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">88,560,261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_df0618ee-499a-415a-87bb-ce80aa7590d7" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:Assets" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">87,785,058</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0ba99af9-1eec-43ab-a34b-e18a6853f007" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">12,595,112</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cb3a77a0-6002-4032-bfdf-eac1e616f9c3" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">13,149,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_791c1c42-be33-4687-89bb-ce0d5bb3e732" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,987,222</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b4051252-0333-4689-8396-86c30df9ccd9" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,295,180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease liability, current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_267c01c6-5928-4241-9005-83a360671734" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">967,248</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1eeefb48-27a8-4f4f-90c7-5693f62c1564" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">620,675</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4e1ecf29-cafe-4662-b4e1-d3a86d1119ad" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">24,549,582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_76df5e3c-8d68-4c22-ada7-165af8d30cbc" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">23,065,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loan payable, long-term</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b46a49af-ab0b-4be3-83ce-497ad2a16437" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">49,312,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e937a59a-7b9f-4e08-837b-548fa8aeba66" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">49,089,522</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6be2ab6a-5dde-47d0-b7cc-6e1b4f2a5458" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:Liabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">73,862,247</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9c55a634-0241-46bc-a3f1-cb071fd2e927" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:Liabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">72,154,706</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_12c1c503-a081-4041-ad16-5f3fd0bd7074" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_3001dbab-516c-4c02-8583-da3c623e9ab3" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value per share (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c7cbaf19-ad1b-44d8-b40e-3be7918667fa" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_2549e8bf-5252-4b82-b05c-f8b46e3a8e0c" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a0551316-e183-41f2-a3e3-aca940e4d854" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b5788e5d-d8a3-4c2b-b8c2-dc4d824f431b" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4768a764-a059-4d48-aadc-23fc623116d3" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b6a3ffae-610b-42a6-a6ec-2ddfa31eccbe" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;issued and outstanding at March 31, 2022 and December 31, 2021, respectively)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1f6def08-6324-47c1-8f03-a96077b94776" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_14bb5fc4-018f-47dd-a0b4-5a708228ad88" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value per share (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3ed74f32-efa9-4ef3-92ee-bb7b1347e937" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_a53be23b-df3a-48da-ab94-53c3d899b03e" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e26f66bf-32c1-44ca-a551-018774797e80" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_f5410c3b-49b8-49ab-9a46-628005cde7ca" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38,883,445</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_89ed3514-82af-49cc-aec1-33d53ddd463e" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_ba16560b-8d61-4517-a237-b813057eaf03" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,816,794</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_686c62d1-bcd0-44ce-8b23-a2d5aee4e414" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:CommonStockValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b256abab-87ff-465e-a941-42527c413318" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:CommonStockValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,782</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9a291dad-4d1d-4a19-a0f3-a2a7db9b2e7e" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">463,525,522</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_18b6f865-fa29-4835-9dda-00d7d88e5972" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">424,825,655</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b0a44387-b512-45d0-8a43-263304048766" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">448,831,396</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f8087c42-d499-451e-8826-f06f978f7920" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">409,199,085</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_98c922eb-1250-4e4e-b555-01f69aa28678" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">14,698,014</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7245243b-f084-4c37-9a97-f4ec3cc1876c" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">15,630,352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0dea413e-4947-4e39-91d6-d0288f648acc" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">88,560,261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_10f340b4-110b-497d-b025-5c35da5fe3fb" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">87,785,058</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.93%;"></td>
    <td style="width:1.628%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.481%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.628%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:10.751%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_34ca7351-727c-4e1a-b2cf-f0082e97857a" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">12,585,141</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0f4cce61-a359-4946-a38a-5827456a9898" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">16,595,689</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_988bc06a-6269-4542-8032-1dfb62a5abaf" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">25,703,731</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7dd606d5-32b8-4321-ac49-617d0d20e6fb" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">11,248,372</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d0a50230-88f8-4cfb-bfe1-43f0bbdd5d85" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:OperatingExpenses" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">38,288,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_59e13c4c-824d-4cba-a145-0bd8c3a335e7" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:OperatingExpenses" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">27,844,061</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7ef8ecb3-0cda-47d3-8ff2-d42d28eefca2" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">38,288,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_61f02343-40cc-48ff-8609-990fe970805a" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">27,844,061</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Interest income (expense)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0749d5ab-afa7-4d32-b17f-262a771eecc3" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">1,343,439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b9be52d1-8fa9-40b6-bcbf-5b5f99fccc44" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">1,415,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_31bce4d2-f40b-4404-9101-c7ad03908177" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">39,632,311</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5162048b-5f04-43be-8e42-dfe8b4756baa" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">29,259,970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4f63c11d-a6da-494d-89fa-5d253b6909ba" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.03</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_506d74a0-9fc5-400c-a61b-084057a5e039" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.78</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b29f1e04-0185-4641-a987-d428ccbecfc6" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">38,323,167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ed4b6f13-53d5-415d-a1ce-95013ea6ebe3" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">37,429,450</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Stockholders&#x2019; Equity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.004%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:9.003%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:8.875%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:9.635%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:10.277%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:9.635%;"></td>
    <td style="width:0.835%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Additional</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Total<br />stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_941473b7-45ca-421a-ac13-ae90592702c5" contextRef="C_a7171c32-68b1-44fb-bc72-6ca42e63f926" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,374,088</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_859fa57e-150a-4bf6-9c2a-67a2c92ce440" contextRef="C_a7171c32-68b1-44fb-bc72-6ca42e63f926" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,737</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_42f13969-b1d8-4233-bb11-9f95c27c6f65" contextRef="C_8ec01d46-909a-44bc-befd-1d1a23e4ab9f" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">392,585,265</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a7750a75-96c2-41fa-be12-590d0886785a" contextRef="C_b8689f73-8b90-434a-8cae-7e991d869064" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">278,796,093</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d1df4558-c005-46c1-9169-8a7c528c0c23" contextRef="C_b4a98684-d57a-4c5f-b5a6-c9b492ff4e17" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">113,792,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0ca8dd8d-1a56-4db5-891a-6e4ee47867db" contextRef="C_a5109b34-436f-4349-abc0-b0c0dca35cfc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,731,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_77677036-9cab-42e0-bbd7-00359b52f127" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,731,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock upon exercise of options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_51d7ab5e-4f6c-4c6a-ade4-f80507bef421" contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">94,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_77f06d08-3062-411d-9157-c8a6f0e24dd6" contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_831cda4a-74ef-402d-bedd-28927926785d" contextRef="C_a5109b34-436f-4349-abc0-b0c0dca35cfc" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,913,289</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f52314b6-f420-4b11-a378-1a7f8d89d74c" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,913,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock upon vesting of RSUs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_167b6210-cba9-4158-b40e-11d4e5cd0c1f" contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a" name="axsm:StockVestedDuringPeriodSharesRestrictedCommonStockAward" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,917</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d40612e9-4228-45af-a80a-de197ed45eb3" contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a" name="axsm:StockVestedDuringPeriodValueRestrictedCommonStockAward" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock upon financing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9e35940b-dd82-4671-b368-723d5993329b" contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a" name="axsm:StockIssuedDuringPeriodSharesFinancing" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">93,877</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3296c7b9-458a-4ae5-b03b-b5399bac89c3" contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a" name="axsm:StockIssuedDuringPeriodValueFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e0a2551a-4811-428b-a865-d9f148d71132" contextRef="C_a5109b34-436f-4349-abc0-b0c0dca35cfc" name="axsm:StockIssuedDuringPeriodValueFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,115,855</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8e1a6640-fa92-4702-8079-a1c1bd04fa86" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="axsm:StockIssuedDuringPeriodValueFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,115,864</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f55832fb-f393-481a-89eb-0ba5d9dc5086" contextRef="C_73c76e5f-6946-415b-ac4a-5f14307e04c8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">29,259,970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fbbba2ec-2069-485b-9d41-f6d91887c1cf" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">29,259,970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_00560f85-08a6-4038-b5e0-4d864d19dad0" contextRef="C_525e81c7-d46e-4ea7-9684-74def5e30aac" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,563,882</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_aeb54b8e-0917-4065-9888-b7fb973f67c1" contextRef="C_525e81c7-d46e-4ea7-9684-74def5e30aac" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,756</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9cb7d24c-22f8-4e80-a14d-8d2ed3a121c5" contextRef="C_144b60f0-d4f4-4610-977c-bd99ba58cc09" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">404,345,506</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b4230731-2385-4b89-a62f-859df8182b71" contextRef="C_2038d698-c757-4fc1-8d54-847b886c8572" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">308,056,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e88e179f-f487-4eec-8269-685ea2863442" contextRef="C_ee66dee5-84e1-46c5-b128-680ea4f73cbe" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">96,293,199</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d6c0d4fd-f6de-4d7d-af73-d26e4041a202" contextRef="C_bf72b4a0-6c33-4db5-9316-0eaa208085c8" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,816,794</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_60754ea9-25b2-4859-b59e-e4e4445b2d5d" contextRef="C_bf72b4a0-6c33-4db5-9316-0eaa208085c8" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,782</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_547bb82d-e530-4829-97a3-cd00a8b67e0d" contextRef="C_008bb3dd-4868-4984-8e42-390d9ffd5c65" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">424,825,655</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fcf03b86-77e1-49a7-b9c3-627334e82fe9" contextRef="C_cb2f9874-656b-41a0-87d5-d87935757fb7" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">409,199,085</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_876780cc-a7e0-4394-ab6c-fca3474990e7" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">15,630,352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6cc6907f-57a1-4cad-8fd7-13389764ca18" contextRef="C_1882e4f2-eb93-4210-b724-5c9bb20bebf2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">7,598,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c1cff78a-2c86-4881-a6ab-1a0d2cc59660" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">7,598,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock upon exercise of options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_71caafcd-a88c-46ff-9802-37517069774d" contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,015</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b9e41308-f1fb-4a3c-9090-9d3b3971d24a" contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2d827e6e-7e92-4c96-903b-df7303aa12e4" contextRef="C_1882e4f2-eb93-4210-b724-5c9bb20bebf2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">181,635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_79c8af0a-a99b-4153-b420-a42d4a95004c" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">181,637</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock upon vesting of RSUs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3d76ead8-db6e-4555-bf28-ac1eeef827d4" contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5" name="axsm:StockVestedDuringPeriodSharesRestrictedCommonStockAward" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1272ce5d-973e-486c-aff8-33343ddfed29" contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5" name="axsm:StockVestedDuringPeriodValueRestrictedCommonStockAward" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock upon financing</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_34022d61-09a5-4ddf-801e-c5a6d2d3be0b" contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5" name="axsm:StockIssuedDuringPeriodSharesFinancing" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,044,081</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af064529-3638-4fd1-a46c-edce809b9711" contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5" name="axsm:StockIssuedDuringPeriodValueFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">104</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0a434dfa-1b06-49cc-9d5e-f9755cdd90c9" contextRef="C_1882e4f2-eb93-4210-b724-5c9bb20bebf2" name="axsm:StockIssuedDuringPeriodValueFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">31,008,497</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a1e14c03-fd4e-4ef5-91df-36b9adb01086" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:StockIssuedDuringPeriodValueFinancing" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">31,008,601</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Shares tendered for withholding taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6d963f6d-c9b1-409f-b85d-9d7fc5055b48" contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5" name="axsm:AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4295b678-06bc-4c1f-867f-b3510d9f6102" contextRef="C_1882e4f2-eb93-4210-b724-5c9bb20bebf2" name="axsm:AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">88,594</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9128eed4-8592-44e6-9deb-304e09e124a1" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">88,594</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_16358588-b85a-45f9-b473-c56f1851c4c7" contextRef="C_e6b4b679-0646-4f99-b733-4c1487965f80" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">39,632,311</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d05f6802-b66d-40b1-8c32-6f03cb1377db" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">39,632,311</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3b842ff7-5379-421a-b4ec-aac17991d5f9" contextRef="C_a94eb90c-f0d3-4b2c-9a0c-9754a3a9a0a0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38,883,445</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_45442568-c8d9-4829-8e03-7b8a7b79ef53" contextRef="C_a94eb90c-f0d3-4b2c-9a0c-9754a3a9a0a0" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_94c8a500-ae2c-4eef-8d64-41ffd5c22db0" contextRef="C_148374f5-3d5c-4b2e-ade2-fb6cd32a789e" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">463,525,522</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6b9407c1-e7d8-46b8-b53c-0bbdf4fe4807" contextRef="C_81597194-9eed-48c4-a703-a29a052262b3" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">448,831,396</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3632a038-37db-4439-a615-092301d09047" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">14,698,014</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.035%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.096%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.096%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ca832e99-1a74-4405-9925-e6e9f1805bcb" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">39,632,311</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_24ea9e7b-8624-49c2-927c-12ef81837d93" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">29,259,970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d7e42545-313f-4b66-b05b-5d82e1ed6d10" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">7,598,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c000d895-0159-4f58-bc3b-af1312e77f12" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,731,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortization of debt discount</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_258efade-5964-4237-9b8b-7a50743f4118" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">223,143</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_28c676ce-e92f-4d5e-808f-2a7594c27687" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">276,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Depreciation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a64c3360-f086-4cdf-85fe-d169f0950f9a" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">36,636</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_92a14575-0fe9-4ce0-baf2-b220249fc228" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,326</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortization of operating lease right-of-use asset</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_855fe9e6-08e1-4502-9495-ce0d509bf2d0" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">275,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2b7b5845-23c8-4b4d-8310-12fcd5c90095" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">262,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Change in operating lease liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_387818a4-a1a7-4891-a573-fcfc07aa1821" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:ChangeInOperatingLeaseLiability" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">214,807</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_78390498-6cd1-4db7-81e2-c3cdb660f078" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="axsm:ChangeInOperatingLeaseLiability" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">275,840</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c1ca69b6-5309-4732-a13c-29d18c1c8f2e" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,076,858</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7b2a61a6-8508-4559-867a-89d2b9a04259" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="axsm:IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">226,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_62a32120-fbf5-4ad9-a2d0-d92bcccee798" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">554,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ad549146-08b2-485e-85d7-81bccbb0ec1b" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,117,695</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a0ecad13-839b-4312-a944-bdc78d5e37b7" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,692,042</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_531039a2-e14f-40c4-a6de-0f8df32f8e02" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">2,848,723</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7537d89c-84bc-4eb7-9619-3938c9d1b666" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">32,652,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_37d625cc-aef2-4143-8062-e5a6f6ccd335" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">27,215,489</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Purchases of equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_18cc1e5b-8cac-4e9f-8f08-cd9b4be6d033" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">213,736</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_73cb96ca-314c-4773-af62-aefc58f7dbae" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">29,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8660a982-e982-47ee-ada8-aaacd35edf44" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">213,736</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ef525d78-9e74-435a-834b-ff4b5c1da8ab" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">29,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from issuance of common stock upon financing, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_99f62563-0c2c-4e53-965a-86d2ab3b7ff4" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">31,008,601</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_873ed22a-1eba-493b-9956-305c8053883b" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,115,864</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from issuance of common stock upon exercise of options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8003afba-f12f-40f8-b548-33952f3b07a1" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">181,637</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f51f3276-0ef2-4d63-88b3-7acdadcbcf9e" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,913,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Payments of tax withholdings on stock award</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e2c81213-3aa8-4eee-b2ab-f7f81253db3c" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">88,594</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash (used in) provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7e877b6a-218e-448f-9147-6c5094f91cb8" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">31,101,644</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_122c10d0-6c20-45d2-9b7b-6504a34064c0" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,029,163</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net (decrease) increase in cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5d31f9f5-f9a0-48a6-97a9-ee84f4099994" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">1,765,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2280aa31-a302-41a4-bab0-7447ceca8c54" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">19,216,321</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash at beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e1a8d37b-ef4b-4c12-a6a0-74fd34674ddd" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">86,472,854</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_049b209c-13a2-4715-a745-51dd72ed2645" contextRef="C_b4a98684-d57a-4c5f-b5a6-c9b492ff4e17" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">183,876,453</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash at end of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_290cf371-bcdc-45d9-87fd-55b5f32d1306" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">84,707,782</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cfdbb2f8-cea8-4cb5-a114-e3c994448eb6" contextRef="C_ee66dee5-84e1-46c5-b128-680ea4f73cbe" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">164,660,132</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Supplemental disclosures of cash flow information:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Interest paid</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_27b90ac9-f33e-42f5-b2fd-aa9034172746" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:InterestPaidNet" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,118,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c7178ade-7c23-42d8-be53-2cf8dbda00a4" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:InterestPaidNet" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,143,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease right-of-use asset obtained in exchange for operating lease liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3def91f7-82e8-49b1-89bd-1c8a25b61638" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">561,380</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Unaudited)</span></p>
  <div style="font-size:11.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02254cf0-fe86-450c-bf45-11d46c64810d" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Nature of Business and Basis of Presentation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc. (&#x201c;Axsome&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company developing novel therapies for central nervous system (&#x201c;CNS&#x201d;) disorders for which there are limited treatment options. By focusing on this therapeutic area, the Company is addressing significant and growing markets where current treatment options are limited or inadequate. The Company&#x2019;s core CNS portfolio includes </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f43abe17-77f0-491d-a421-70c13dbb668d" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="axsm:NumberOfLateStageProductCandidates" unitRef="U_Product" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> product candidates, AXS-05, AXS-07, AXS-12, and AXS-14, which are being developed for multiple indications. The Company aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with CNS disorders. The Company was incorporated on January 12, 2012 in the State of Delaware.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited interim consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, which are normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the operating results for the full fiscal year or any future period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Acquisition of Assets of Jazz Pharmaceuticals</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On March 25, 2022, the Company entered into an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with Jazz Pharmaceuticals plc (&#34;Jazz Pharmaceuticals&#34;), pursuant to which the Company will acquire Sunosi&#174; from Jazz Pharmaceuticals (&#34;the Acquisition&#34;), a dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients living with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, which was approved by the U.S. Food and Drug Administration, or the FDA, in 2019 and by the European Medicines Agency (the &#x201c;EMA&#x201d;) in 2020.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Asset Purchase Agreement, the Company will receive from Jazz Pharmaceuticals worldwide commercial, development, manufacturing, and intellectual property rights to Sunosi, except for certain Asian markets. Jazz Pharmaceuticals will receive from the Company a total upfront payment of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e970f475-1e38-4195-b725-8c8ecf8bee1c" contextRef="C_93fc45bb-69f6-4b6b-ba71-8a6735312525" name="axsm:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">53</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, a high single-digit royalty on the Company's U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on the Company's U.S. net sales of Sunosi in future indications. The Company will also assume the commitments of Jazz Pharmaceuticals to SK Biopharmaceuticals (&#x201c;SK)&#x201d; and Aerial Biopharma (&#x201c;Aerial&#x201d;). SK is the originator of Sunosi and retains rights in </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_470231b6-b8c4-40c3-a48a-4c00ee469ba2" contextRef="C_93fc45bb-69f6-4b6b-ba71-8a6735312525" name="axsm:NumberOfAsianMarkets" unitRef="U_Market" decimals="INF" format="ixt:numdotdecimal">12</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Asian markets, including China, Korea, and Japan. In 2014, Jazz Pharmaceuticals acquired from Aerial worldwide rights to Sunosi excluding those Asian markets. The assumed commitments to SK and Aerial include single-digit tiered royalties based on the Company's sales of Sunosi, and up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e8db2567-a450-428d-a4ca-e97bb3ca606d" contextRef="C_6a6da949-18b2-470e-9fe3-f0d2c926ef8b" name="axsm:RevenueMilestones" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">165</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in revenue milestones and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d8a5e90f-74bb-4769-af92-44b30943c2c7" contextRef="C_6a6da949-18b2-470e-9fe3-f0d2c926ef8b" name="axsm:DevelopmentMilestones" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in development milestones. The Company expects to finance the transaction via its existing $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5266dd43-eb11-4550-b178-8ec81c99a8d2" contextRef="C_e07b08d9-2bba-42e4-bf1e-6aa9c55ce68c" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">300</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million term loan facility with Hercules Capital, Inc. (see below).<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Purchase Agreement also provides for customary conditions to closing, including the receipt of antitrust approval from the Federal Trade Commission pursuant to the Hart-Scott-Rodino Act, and the receipt of certain required financial statements from Jazz required by Regulation S-X of the Securities Exchange Act of 1934, as amended. The Company expects the closing to occur in the second quarter of 2022 and therefore, purchase accounting is not reflected in these consolidated financial statements.<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment to the Loan and Security Agreement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On March 27, 2022, in connection with the Acquisition (as described above), the Company entered into a Second Amendment to the Loan and Security Agreement (the &#x201c;Second Amendment&#x201d;) with Hercules Capital, Inc. The Second Amendment amends the terms of that certain Loan and Security Agreement, dated as of September 25, 2020 (as amended by the First Amendment to the Loan and Security Agreement, dated of October 14, 2021) (the &#x201c;Loan Agreement&#x201d;). The changes in the Term Loan Advances (as defined in the Loan Agreement) amounts and dates are as follows: (i) increasing the Tranche 1 (as defined in the Loan Agreement) from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fb0dce63-d148-4946-b106-6b32b5245979" contextRef="C_8e3cc36d-423a-457f-931c-9109e9833261" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af95082e-7a49-4921-8350-d9eb93c726c5" contextRef="C_6ba10b02-2ba9-41b3-b76d-552fff659baa" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">95.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, whereby $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d7178071-2915-4cda-a05c-13a48e701f13" contextRef="C_6dacb844-4b15-4c03-acb3-09a6b640217c" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">45.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million is available upon the Second Amendment closing date (ii) changing the Tranche 2 Advances (as defined in the Loan Agreement) from two sub-tranches of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4d2030f3-eb20-4cd8-99c8-f1cca69fdb7c" contextRef="C_3c74abd6-a2c2-4c0f-9355-8d60eb862eb8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_67c3f579-16c6-4e84-aa28-4d074f545080" contextRef="C_78a1f202-d9b2-477b-b649-06874c29753a" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">50.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million each to three sub-tranches of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e26c8990-5a14-4ecd-abbc-a1f41649e04e" contextRef="C_caa50054-de64-4723-b525-0cfcc3b7185f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_68c83b8a-08e9-44f3-8dd2-1f6126578579" contextRef="C_2d6af9b1-56a3-4f2a-b2f7-a25d457c6cbf" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2c8bfa16-2aee-4a2c-a716-53e2625d39a8" contextRef="C_39b63eb4-ca27-40bd-82f5-858e406e3701" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, (iii) changing the Tranche 3 Advance (as defined in the Loan Agreement) from one tranche of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2ec7e8da-6e4a-4aa4-88a2-0591e8817a85" contextRef="C_e7fe0f8e-7fa9-4070-979d-a3234fed3fa1" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million to two sub-tranches of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f150f3b7-3efb-4746-8c17-67cc4e51f36b" contextRef="C_e075509a-46d1-46e0-8bb0-6f2bbee2ca82" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_178dbfcb-4312-4d65-9fec-c4e10a63ff58" contextRef="C_766126cd-3c63-4018-b6f6-3bc6d4b038fc" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, (iv) decreasing the Tranche 4 Advance (as defined in the Loan Agreement) from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_399aaf4f-cf0d-4eb0-84ab-35188a52f773" contextRef="C_d3c1be52-c032-4a53-856d-c71d3887807f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">55.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_180e1eac-cced-45a8-8f08-4812b7f0da15" contextRef="C_839cd5d9-6625-4c96-98f0-b8b61c6a4475" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, and (v) decreasing the Tranche 5 Advance (as defined in the Loan Agreement) from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8f087ff1-a274-43dd-a070-c122a1f21217" contextRef="C_fa561b4e-b6ea-4fd4-8d9a-70f77c8de67f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">75.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_03086db4-e760-4e05-8353-ef81cc1d247f" contextRef="C_d91b4b62-4ebe-490a-a88e-6f69afcf5a05" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million. In connection with the Second Amendment, the parties also clarified certain terms of the Warrant Agreement previously issued to Hercules. The Second Amendment shall only be effective upon the closing of the Acquisition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Conditioned upon the closing of the Second Amendment, Hercules will also purchase between $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7f9ca1f9-fb94-485a-89c4-bde1c9c51c0b" contextRef="C_b4dbaf2a-a0d5-4d55-b135-ec0dd9346cc6" name="axsm:UnregisteredCommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0fced09e-2761-41d2-bfeb-2d773653eeaf" contextRef="C_75b98a95-0d49-477b-bc05-e21aa024dc87" name="axsm:UnregisteredCommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#x2019;s unregistered common stock, at a share price equal to the lesser of (a) the three-day volume weighted average price as of the date of the Second Amendment, or (b) the three-day volume weighted average price as of the Second Amendment Effective Date, pursuant to a stock purchase agreement to be agreed upon by the parties; provided, that, in no case shall the share price be less than a </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_188847fd-ca39-4adf-8e79-b77b519b8d89" contextRef="C_c4d05faf-ec2b-48f5-8a76-5f0bc4fe39a0" name="axsm:SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% discount to the three-day volume weighted average price of the Company&#x2019;s common stock at the time of the purchase.</span></p><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred operating losses since its inception and expects to continue to incur operating losses for the foreseeable future and may never become profitable. As of March 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d10c2ee1-3190-4d8f-b394-e19d56a52244" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">448.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s primary sources of cash have been proceeds from the issuance and sale of its common stock in public offerings and the issuance of debt. The Company has not yet commercialized any of its product candidates and cannot be sure if it will ever be able to do so. The Company&#x2019;s ability to achieve profitability depends on a number of factors, including its ability to obtain regulatory approval for its product candidates, successfully complete any post-approval regulatory obligations and successfully commercialize its product candidates alone or in partnership. The Company may continue to incur substantial operating losses even if it begins to generate revenues from its product candidates.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company believes its existing cash will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing. The actual amount of cash that the Company will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for its product candidates. The Company may use a combination of public and private equity offerings, debt financings, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements if market conditions are favorable or as a result of other strategic considerations to finance its future cash needs.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s common stock is listed on</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the Nasdaq Global Market</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">and trades under the symbol &#x201c;AXSM&#x201d;.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Impact of COVID-19</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People&#x2019;s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency in the United States on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a global pandemic. The full impact of the ongoing COVID-19 pandemic is still unknown and rapidly evolving. While the potential economic impact brought by and over the duration of the COVID-19 pandemic may be difficult to assess or predict, the COVID-19 pandemic has resulted in significant disruption of global financial markets, which could in the future negatively affect the Company&#x2019;s liquidity. In addition, a recession or market volatility resulting from the COVID-19 pandemic could affect the Company&#x2019;s business. Given the nature and type of the Company&#x2019;s short-term investments, the Company does not believe the COVID-19 pandemic has had or will have a material impact on the Company&#x2019;s current investment liquidity.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8a5b580-3531-437c-ab5e-bce7271655a5" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97fc6110-6d65-4eb6-b5f8-327eadffb6d6" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Significant Risks and Uncertainties</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company&#x2019;s product candidates; the Company&#x2019;s ability to obtain regulatory approval to market its products, if approved; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company&#x2019;s products, if approved; the Company&#x2019;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, if approved; and the Company&#x2019;s ability to raise additional financing. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve and maintain profitability.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df055793-4bba-4b12-bcb3-42342a3f6fe5" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock&#x2011;based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; and the recoverability of the Company&#x2019;s net deferred tax assets and related valuation allowance.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ecfb8c5-f839-4a32-96b8-baaf23060a33" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency Translation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Expenses denominated in foreign currency are translated into U.S. dollars at the exchange rate on the date the expense is incurred. Assets and liabilities of foreign operations are translated at period-end exchange rates. The effect of exchange rate fluctuations on translating foreign currency into U.S. dollars is included in the Statements of Operations and is not material to the Company&#x2019;s financial statements.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14e61e1a-117c-4bd1-951f-3b6e15a94978" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Segment and Geographic Information</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3c601263-e079-4ab2-ad4f-553de694d119" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> operating segment, which is the business of developing novel therapies for the management of CNS disorders.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_688868f7-a7ca-4a4c-abb0-cfb9a34ad11f" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Cash Equivalents</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company&#x2019;s cash and cash equivalents includes holdings in checking and overnight sweep accounts. The Company&#x2019;s cash equivalents, which are money market funds held in a sweep account, are measured at fair value on a recurring basis. As of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the balance of cash and cash equivalents was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f45b18a8-7e97-4091-99b4-82cb44ec24d1" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">84.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, which approximates fair value and was determined based upon Level 1 inputs. The sweep account is valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level 1.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4cd6e39-3795-4ed2-963d-139f4b6b8c4e" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the majority of the Company&#x2019;s cash was held by </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8d95e50a-9ca4-47c1-bd47-cee92f86c7dd" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="axsm:NumberOfFinancialInstitutionsHoldingDeposits" unitRef="U_Institution" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d10e179-797e-4076-88f6-d732afc8f219" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three&#x2011;level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#x2014;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#x2014;Inputs that are unobservable for the asset or liability.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s financial instruments are cash, accounts payable, accrued liabilities, and current and long-term debt. The carrying values for cash, accounts payable and accrued liabilities reported in the accompanying consolidated financial statements approximate their respective fair values due to their short-term maturities. The carrying value of debt on the Company&#x2019;s balance sheet (see Note 6 &#x2013; Loan and Security Agreement), is estimated to approximate its fair value as the interest rate approximates the market rate for loans with similar terms and risk characteristics.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c9afe01-eb07-483c-bd4f-10e6880919af" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:DebtPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Debt Issuance Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs consist of costs incurred in obtaining long-term financing. These costs are classified on the consolidated balance sheet as a direct deduction from the carrying amount of the related debt liability. These expenses are deferred and amortized as part of interest expense in the consolidated statement of operations using the effective interest rate method over the term of the debt agreement.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c972473e-df08-4395-bb93-5b0d409c670e" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Equipment</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Equipment consists primarily of computer equipment and is recorded at cost. Equipment is depreciated on a straight&#x2011;line basis over its estimated useful life, which the Company estimates to be </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0acdc90-ebf5-4632-b9e2-542c9ba25186" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is included in operating expenses.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c685d02-9ced-449a-9b9e-a5f2ca6fe7b3" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related expenses including salaries, benefits, travel, and stock&#x2011;based compensation expense, contract services, costs incurred to third-party service providers for the conduct of research, preclinical and clinical studies, laboratory supplies, product license fees, consulting and other related expenses. We estimate research, preclinical and clinical study expenses based on services performed, pursuant to contracts with third-party research and development organizations that conduct and manage research, preclinical and clinical activities on our behalf. We estimate these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments associated with licensing agreements to acquire licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternative future use are expensed as incurred. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ae5947b-52aa-40cb-9def-d62985bb640b" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates an annual effective tax rate of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_065449c7-0759-48c3-965a-352f327cf6b4" contextRef="C_b7fb4e8a-2ebf-48fc-8a1b-f5d6d9833933" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="INF">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% for the year ending </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and has </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8f023759-6f4c-4727-840c-8c1b45597f9e" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e339eb52-33d2-4b6c-8edf-36f1483de4e5" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">t recorded an income tax benefit for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021 since it determined that a full valuation allowance is required against the Company&#x2019;s deferred tax assets.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position as well as consideration of the available facts and circumstances. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. As of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company does not believe any material uncertain tax positions are present. In the event the Company determines that accrual of interest or penalties are necessary in the future, the amount will be presented as a component of income tax expense.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e52cc4f2-4637-4b5c-b2cb-6e19b5359ff2" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For stock options issued, the Company estimates the grant date fair value of each option using the Black&#x2011;Scholes option pricing model. The Black-Scholes model takes into account the expected volatility of the Company&#x2019;s common stock, the risk-free interest rate, the estimated life of the option, the closing market price of the Company&#x2019;s common stock and the exercise price. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management&#x2019;s judgment. In addition, the Company recognizes expense for equity award forfeitures as they occur.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For restricted stock units (&#x201c;RSUs&#x201d;), the Company issues them in the form of Company common stock. The fair market value of these awards is based on the market closing price per share on the grant date.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense using the accelerated attribution method when it is probable that the performance condition will be achieved. The expense related to the stock-based compensation is recorded within the same financial statement line item as the grantee&#x2019;s cash compensation.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s policy upon exercise of stock options and RSUs is that shares will be issued as new shares drawing on the Company&#x2019;s 2015 Omnibus Incentive Compensation Plan share pool that was adopted by the stockholders in November 2015.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_267e4b37-420c-49bb-b22c-71f8da5e0713" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Basic and Diluted Net Loss per Common Share</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options, and RSUs, which would result in the issuance of incremental shares of common stock. As the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted net loss per share of common stock for the three months ended March 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ac3b4e9-9e03-4220-bd54-c7bc495560b1" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company&#x2019;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. When evaluating whether a contract contains a lease, the Company considers whether (1) the contract explicitly or implicitly identifies assets that are contractually defined and (2) the Company obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s lease agreement contains lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. The Company has applied the practical expedient to combine fixed payments for non-lease components with lease payments and account for them together as a single lease component, which increases the amount of lease assets and corresponding liabilities. Payments under the Company&#x2019;s lease arrangement are primarily fixed, however variable payments, are expensed as incurred and not included in the operating lease asset and liability.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses the implicit interest rate when readily determinable and uses the Company&#x2019;s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s operating leases are reflected in the right-of-use operating asset; operating lease liability, current portion; and operating lease liability, long-term portion in the Company&#x2019;s consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, and do not include an option to extend the term or purchase the underlying asset that the Company is reasonably certain to exercise, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</span></p></ix:nonNumeric></div><div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3475eac0-069a-493e-ad5f-9266c8d7e19e" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2021-08, Business Combinations (Topic 805) . This update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 606. This differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The amendments in this update should be applied prospectively, and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cea657a0-caf3-495c-bb6f-abf58e1d53f5" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 3. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3616852-ac79-4c96-8181-2e3edba0ae37" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022 and December 31, 2021 accrued expenses and other current liabilities consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.688%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.807%;"></td>
        <td style="width:0.91%;"></td>
        <td style="width:1.553%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.817%;"></td>
        <td style="width:0.932%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#x200b;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,<br />2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3ca1a91a-4705-4f40-bb63-2a21e8c9ee0f" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="axsm:AccruedResearchAndDevelopmentCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,726,847</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_def4ac24-72f1-4cc9-9e65-1e1fb416eee6" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="axsm:AccruedResearchAndDevelopmentCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,416,897</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bc562137-af52-4a3e-a413-c8436fdcb0a2" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,013,040</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d07d3b62-0d01-4e22-a4fc-98dde35ac45d" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">4,050,236</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued general and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7d5e5e00-273a-4a3a-b71f-ce562434b7cf" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="axsm:AccruedGeneralAndAdministrativeCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,856,779</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7bf1a5c9-1be2-48c7-b0e3-8369a538f46f" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="axsm:AccruedGeneralAndAdministrativeCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,442,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued Interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_da4c9e4a-d543-4636-8221-eaa78784b056" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">390,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fb9d9148-95bc-4e35-9b40-601c83f948f9" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">385,347</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_34e9c0f0-67f8-481d-b56b-db86d861c35e" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">10,987,222</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6d176cab-3ef1-41e3-b425-31bf70ad46b8" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">9,295,180</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c56b5f0-7ecb-4b8b-b9cc-70dc90efb469" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:LongTermDebtTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 4. Loan and Security Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hercules Capital, Inc.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, the Company entered into a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender (in such capacity, the &#x201c;Agent&#x201d; or &#x201c;Hercules&#x201d;) and the other financial institutions that from time to time become parties to the Loan Agreement as lenders (collectively, the &#x201c;Lenders&#x201d;). The Loan Agreement provides for term loans in an aggregate principal amount of up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_de06861a-6b32-4c40-b2f5-08363e1c52a1" contextRef="C_52720a6e-acc3-4746-a598-7a3115ffa670" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5">225.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million under multiple tranches (the &#x201c;2020 Term Loan&#x201d;). The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f47e68ea-7172-4464-b41f-2a3a64fbc701" contextRef="C_8e3cc36d-423a-457f-931c-9109e9833261" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5aa059f5-3488-4e93-8d94-f52dd6db3d79" contextRef="C_e79659be-62a0-4d7f-8919-a6af22ec548f" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="6" decimals="-5">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million was funded to the Company on the Closing Date (the &#x201c;First Advance&#x201d;), and of which the remaining $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_98c80e22-784a-4128-b53e-cec6a22d319d" contextRef="C_8e3cc36d-423a-457f-931c-9109e9833261" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million was available at the Company&#x2019;s option at any time through September 15, 2021; (ii) subject to the approval of the Company&#x2019;s AXS-05 product candidate for the treatment of major depressive disorder (the &#x201c;First Milestone&#x201d;), a second tranche consisting of additional term loans in an aggregate principal amount of up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_81bb4f75-2c8f-45e0-82f3-f3984189f8cd" contextRef="C_7dd348d4-cefb-4639-92c0-78e13450f2b6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, available at the Company&#x2019;s option beginning on the date that the First Milestone is achieved through the earlier of (A) </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a5aaa31-7435-4e93-b999-eebb1355860f" contextRef="C_aac9dd6a-0f39-4dca-9c62-e17e1926a68c" name="axsm:ThresholdDaysToAchieveFirstMilestone" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">181</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> days following such date and (B) June 30, 2022; (iii) subject to the approval of the Company&#x2019;s AXS-07 product candidate for the treatment of migraine (the &#x201c;Second Milestone&#x201d;), a third tranche consisting of additional term loans in an aggregate principal amount of up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2c4a7e88-ccaf-467b-b12c-4a2338cc4988" contextRef="C_21a3ddfb-93a7-4cbb-82fd-5e3bc5f0961b" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, available at the Company&#x2019;s option beginning on the date that the Second Milestone is achieved through the earlier of (A) </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7cc4a03-0ac4-4a54-96cc-f1f2776fb01a" contextRef="C_4c1d2970-ecdc-417a-8c38-beb830e327cb" name="axsm:ThresholdDaysToAchieveSecondMilestone" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">181</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> days following such date and (B) June 30, 2022; (iv) subject to the achievement of either the First Milestone or the Second Milestone and so long as the Company is in compliance with a required ratio of Lender indebtedness to net product revenue, a fourth tranche consisting of additional term loans in an aggregate principal amount of up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e23f9336-dbf8-4b58-868c-e3e212095c19" contextRef="C_c6555893-bd98-4700-a5a7-8076bf2d8d0c" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, available at the Company&#x2019;s option beginning on January 1, 2022 and continuing through March 31, 2023; and (v) subject to approval by the Lenders&#x2019; in their discretion, a fifth tranche of additional term loans in an aggregate principal amount of up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6c5ef56d-2206-4285-bd6e-b1b95f4c46cf" contextRef="C_0d2b4eb6-939a-4140-adcf-dc65291830f9" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, available through December 31, 2023. The remaining $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_828f85b3-3a0e-49ae-85d9-71353b33f6db" contextRef="C_a8eda348-341b-4541-93f2-83c532439893" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million on the first tranche was not utilized and such tranche and future tranches were amended upon the execution of the First Amendment to the Loan and Security Agreement. See &#34;First Amendment to the Loan and Security Agreement&#34; below for further information. The Company intends to use the proceeds of the Term Loan Advances for working capital and general corporate purposes. In addition, approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c6436bfa-f721-4b78-a2b4-5b2f3448fbac" contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd" name="axsm:ProceedsFromFirstAdvanceUsedToRepayPreviousDebt" unitRef="U_USD" scale="6" decimals="-5">21.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of the proceeds from the First Advance was used to satisfy in full and retire the Company&#x2019;s indebtedness under the 2019 Term Loan (as defined below), as amended.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The outstanding principal balance of the term loans bears interest at an annual rate equal to the greater of either (i) the prime rate as reported in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">plus </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1eaf80e0-eb07-43b1-9508-69fbd433b444" contextRef="C_d518ab07-50e1-4f22-8ead-a8eb4564ed95" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4">5.90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% or (ii) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d88cb128-4469-4d52-a310-ca0d751e4838" contextRef="C_56c3f743-f85c-4b20-9622-f711609bcf18" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF">9.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">%, subject to an ability by the Company, during certain periods (each, a &#x201c;PIK Deferral Period&#x201d;), to request a reduction of the then-effective cash-pay interest rate by up to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f3369d18-d037-4f56-bdd3-5a776dc54886" contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd" name="axsm:DebtInstrumentThresholdCashPayInterestRate" unitRef="U_pure" scale="-2" decimals="4">1.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% per annum (the &#x201c;Cash Interest Reduction Amount&#x201d;). Accrued interest is payable monthly following the funding of each term loan. During each PIK Deferral Period, the term loans will bear cash-pay interest, at the reduced amount, and will accrue paid-in-kind interest at a rate equal to the Cash Interest Reduction Amount multiplied by </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6d9f5a9c-aa1b-4982-9de4-3845dcb06c86" contextRef="C_56c3f743-f85c-4b20-9622-f711609bcf18" name="axsm:DebtInstrumentCashPayInterestMultiplier" unitRef="U_pure" scale="0" decimals="2">1.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, which amount will be capitalized and added to the outstanding principal balance of the term loans on each monthly interest payment date during the PIK Deferral Period.&#x200c;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to repay the term loans in equal installments of principal and interest commencing on May 1, 2023 through October 1, 2025 (the &#x201c;Maturity Date&#x201d;). However, if either the First Milestone or the Second Milestone are achieved prior to May 1, 2023, and no default exists, the amortization commencement date will be automatically extended to November 1, 2023; if both the First Milestone and the Second Milestone are achieved prior to November 1, 2023, and no default exists, the amortization commencement date will be further automatically extended to May 1, 2024 and if any term loans are funded under the fourth tranche noted above prior to May 1, 2024, and no default exists, the amortization commencement date will be further automatically extended to November 1, 2024. On the Maturity Date, all unpaid term loans will be due and payable.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As collateral for the obligations, the Company has granted to Hercules a senior security interest in all of Company&#x2019;s right, title, and interest in, to and under all of Company&#x2019;s property, inclusive of intellectual property, which includes one of the Company&#x2019;s existing license agreements (the &#x201c;License Agreement&#x201d;) with Antecip Bioventures II LLC (&#x201c;Antecip&#x201d;), an entity owned by Axsome&#x2019;s Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., subject to limited exceptions</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Antecip consented to the collateral assignment of the License Agreement, among other things, under a direct agreement (the &#x201c;Direct Agreement&#x201d;) with the Company and Hercules.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement contains customary representations, warranties and covenants, including covenants by the Company limiting additional indebtedness, liens (including a negative pledge on intellectual property and other assets), guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates and fundamental changes. At the initial closing, there were no applicable financial covenants contained in the Loan Agreement. Only after additional amounts are drawn down by the Company in the future, if the Company decides to do so, under the terms set forth in the Loan Agreement, there will be certain limited financial covenants that will apply, including:</span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Effective upon the date the outstanding principal amount of the advances under the Loan Agreement equals or exceeds $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6068f956-86af-4813-a245-91f1b28eefe6" contextRef="C_9f1dee24-d9e9-4cd0-809c-31fbba3bb1c1" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5">55.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, which has not yet occurred, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest, in an aggregate amount greater than or equal to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_14443ee4-e176-4955-9337-7c59fc81e20d" contextRef="C_4b988683-b18d-41ce-bc31-605656e6a4f0" name="axsm:LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest" unitRef="U_USD" scale="6" decimals="-5">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, plus the amount of the Company&#x2019;s accounts payable under U.S. GAAP not paid after the </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f216811e-0f7d-495e-a4ed-16db121c4628" contextRef="C_80117ee7-80d8-4a57-96a2-e2ea5118fefe" name="axsm:LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">180</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">th day following the invoice for such account payable (such amount, the &#x201c;Qualified Cash A/P Amount&#x201d;).</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Effective upon the later of (i) the last calendar month of the calendar quarter that is twelve months following the earlier of (x) the date that the First Milestone is achieved and (y) the date that the Second Milestone is achieved, or (ii) the date on which the outstanding principal amount of the term loan advances under the Loan Agreement is equal to or greater than $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ffcf2601-8748-4624-ae39-22247deebe89" contextRef="C_bc41918b-50a0-4e0c-ae3a-cc2fea3bfbfd" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5">65.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, neither of which have occurred yet, the Company is required to (A) ensure that at all times its market capitalization exceeds $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_63235dfd-3410-4dc7-84a0-123926a3e949" contextRef="C_58506d7a-5c75-4b99-8279-0688e8c43429" name="axsm:LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount" unitRef="U_USD" scale="9" decimals="-8">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> billion, and that it maintains cash in an account which Hercules has a first priority security interest in an amount not less than </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ed98b35e-4445-43ca-86ea-4ac1cdbc3986" contextRef="C_58506d7a-5c75-4b99-8279-0688e8c43429" name="axsm:LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent" unitRef="U_pure" scale="-2" decimals="2">65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the sum of the outstanding principal amount of the term loan advances </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> the Qualified Cash A/P Amount, (B) ensure that at all times that it maintains cash in an account which Hercules has a first priority security interest in an amount not less than </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d9c55a52-123d-4fb6-8b8b-06a2af9ff586" contextRef="C_58506d7a-5c75-4b99-8279-0688e8c43429" name="axsm:LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent" unitRef="U_pure" scale="-2" decimals="2">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the sum of the outstanding principal amount of the term loan advances </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> the Qualified Cash A/P Amount, or (C) achieve at least </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0b479239-913d-4c2c-82a7-bb7db3461eb7" contextRef="C_303637a5-8b91-4570-a728-6f97f2270ef4" name="axsm:LongTermDebtAdditionalDrawnMinimumRevenuePercent" unitRef="U_pure" scale="-2" decimals="2">60</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the net product revenue per the board of directors approved forecast solely from the sale of AXS-05 and AXS-07 (which may include royalty, profit sharing, or sales-based milestone revenue recognized in accordance with GAAP, but will not include any upfront or non-sales-based milestone payments under business development or licensing transactions), measured on a trailing six-month basis as of the date of the Company&#x2019;s most recent quarterly financial statement, determined on a quarterly basis.</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on the Company&#x2019;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions.</span></div></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s obligations under the Loan Agreement are subject to acceleration upon the occurrence of specified events of default, including payment default, insolvency and a material adverse change in the Borrower&#x2019;s business, operations or financial or other condition.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company is required to pay a final payment fee equal to the greater of (A) $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bcd6a63b-a830-4b8b-9808-6487a36579eb" contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd" name="axsm:ExtinguishmentOfDebtFeeAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,910,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and (B) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6d37f594-d29b-420a-a688-ae33d4116bd1" contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd" name="axsm:DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding" unitRef="U_pure" scale="-2" decimals="4">4.85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate amount of all term loan advances minus the aggregate amount of repayments made. The final payment fee is being accreted and amortized into interest expense using the effective interest rate method over the term of the loan.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company may, at its option prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_02b788e5-de03-41c5-bcfc-da5c81b62092" contextRef="C_133a145c-e960-4fc8-b6d5-388d2e167e6b" name="axsm:DebtInstrumentPrepaymentPenaltyPercentage" unitRef="U_pure" scale="-2" decimals="3">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs prior to the first anniversary of the Closing Date, (ii) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_01ba3617-4485-4ef1-b19b-5bec824f1fb5" contextRef="C_ae13ec89-1fa4-4e02-b9fc-58d4fca0deaf" name="axsm:DebtInstrumentPrepaymentPenaltyPercentage" unitRef="U_pure" scale="-2" decimals="3">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs on or after the first anniversary and prior to the second anniversary of the Closing Date, and (iii) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_60b01954-24ef-4c6f-9837-25a885f663a3" contextRef="C_3922af5a-d586-4a59-a748-dca027a9e1b9" name="axsm:DebtInstrumentPrepaymentPenaltyPercentage" unitRef="U_pure" scale="-2" decimals="3">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs on or after the second anniversary and prior to the third anniversary of the Closing Date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">First Amendment to the Loan Agreement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On October 14, 2021 (&#34;First Amendment Closing Date&#34;), the Company entered into the first amendment to the Loan Agreement (the &#x201c;First Amendment to the Loan Agreement&#x201d;).</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the First Amendment to the Loan Agreement, the First Amendment amended the terms of that certain Loan and Security Agreement, dated as of September 25, 2020, by and among the Company, Hercules and the Lenders (the &#x201c;Loan Agreement&#x201d;) to, among other things, (i) increase the aggregate principal amount of the loan, available at the Company&#x2019;s option, from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1a4a6836-e2f5-458d-920a-7a6795e21530" contextRef="C_52720a6e-acc3-4746-a598-7a3115ffa670" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">225,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_39655eee-2523-4a89-a519-cdaab1146547" contextRef="C_43574450-92b4-4988-81e4-50b6b102e732" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, (ii) change the draw amounts and dates available in Tranche 2 through Tranche 5 including increasing the amount available under Tranche 2 subject to FDA approval of the Company&#x2019;s AXS-05 product candidate for the treatment of major depressive disorder from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7d7759cc-808a-4bd6-a4fc-ea5099b2ed8f" contextRef="C_7dd348d4-cefb-4639-92c0-78e13450f2b6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">35,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ebf8d965-910d-4571-9209-92c512c9be4d" contextRef="C_965ed3a9-df64-4456-ade2-24619ff19b45" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, maintaining the amount available under Tranche 3 subject to FDA approval of the Company&#x2019;s AXS-07 product candidate for the acute treatment of migraine of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b96db4fd-192e-4d9b-a644-5c6f4a306441" contextRef="C_e7fe0f8e-7fa9-4070-979d-a3234fed3fa1" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">20,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, reducing the amount under Tranche 4 available upon achievement of certain combined sales and outstanding debt criteria from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_94ee447b-ee61-440d-a17d-55b0c020d45c" contextRef="C_c6555893-bd98-4700-a5a7-8076bf2d8d0c" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">60,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_15093f34-4435-4021-9af3-5053c613494f" contextRef="C_d3c1be52-c032-4a53-856d-c71d3887807f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">55,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, and increasing the amount available under Tranche 5 to support future strategic initiatives, including further pipeline advancement or expansion from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_76bc364b-62ba-45a4-b6a2-20a05329bcbd" contextRef="C_0d2b4eb6-939a-4140-adcf-dc65291830f9" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_97b9068f-42f8-4d3b-85d1-885209c59084" contextRef="C_fa561b4e-b6ea-4fd4-8d9a-70f77c8de67f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">75,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> subject to the approval from Hercules, (iii) extend the maturity date of the facility from the original </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd409dc7-2134-4153-9529-b365729b55de" contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd" name="axsm:DebtInstrumentsMaturityMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">October 2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17a77bb4-2dfd-4fc1-9ef7-7190332763c8" contextRef="C_27e2a477-b3de-4e25-a8a8-015812de985a" name="axsm:DebtInstrumentsMaturityMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">October 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, and optionally to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc49c851-9f5a-4074-ab4e-3d60eb31bf7c" contextRef="C_46bc8e64-2627-43a1-9043-0b5495dccc01" name="axsm:DebtInstrumentsMaturityMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">October 2027</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, subject to certain conditions, (iv) reset and extend the interest only period from the initial </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a2f7f88-236f-4b35-93cb-3bc06b9bd698" contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd" name="axsm:DebtInstrumentInterestPaymentPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">30 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> from the original loan closing to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f12ad36-a39b-4f9a-b01f-11f671044366" contextRef="C_df3f324f-9e88-4cd0-becb-e386dfb62dde" name="axsm:DebtInstrumentInterestPaymentPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">48 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> from the First Amendment and extendable up to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37791d25-283b-4c27-a8d3-6bf1ffab3ef1" contextRef="C_47fac860-11d6-4b0d-8e1c-85902d5c680c" name="axsm:DebtInstrumentInterestPaymentPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">60 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> subject to FDA approval of the Company&#x2019;s AXS-05 product candidate for the treatment of major depressive disorder and subject to FDA approval of AXS-07 in the acute treatment of migraine, and (v) decrease the interest rate from </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7bdde9c9-9cf4-424c-811e-678110d3211f" contextRef="C_56c3f743-f85c-4b20-9622-f711609bcf18" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">9.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% (floating rate based on the greater of (a) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a42bc292-5ba2-4fc5-ba11-93764d0b8aeb" contextRef="C_56c3f743-f85c-4b20-9622-f711609bcf18" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">9.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% or (b) US WSJ Prime + </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5071d811-bbed-475f-b035-f8aeda15ae72" contextRef="C_d518ab07-50e1-4f22-8ead-a8eb4564ed95" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">%) to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d36cb077-4da9-4970-a3c4-845b3c138d4c" contextRef="C_43574450-92b4-4988-81e4-50b6b102e732" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">8.95</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% (floating rate based on the greater of (a) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3031eef2-fc5d-4f9d-b1fa-44753e50586f" contextRef="C_43574450-92b4-4988-81e4-50b6b102e732" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">8.95</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% or (b) US WSJ Prime + </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f70806ec-fbe9-47d7-bd45-38abf48ec6fd" contextRef="C_724babf7-6fd0-424b-9476-154cb4318da6" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.70</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">%).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company is required to pay a final payment fee equal to (A) $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c7e4087d-951c-4945-a838-45ea7642d00d" contextRef="C_df3f324f-9e88-4cd0-becb-e386dfb62dde" name="axsm:ExtinguishmentOfDebtFeeAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,910,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> plus (B) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cf04d0a0-7d98-43c1-87f5-f76f4377d426" contextRef="C_df3f324f-9e88-4cd0-becb-e386dfb62dde" name="axsm:DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate amount of all term future loan advances. The final payment fee is being accreted and amortized into interest expense using the effective interest rate method over the term of the loan.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company may, at its option prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_17e5796d-babe-47c0-9768-92803349b73b" contextRef="C_21a8a9ca-0b07-4cdd-ac95-7ef4b8971c9a" name="axsm:DebtInstrumentPrepaymentPenaltyPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs prior to the first anniversary of the First Amendment Closing Date, (ii) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5ba49847-860a-430a-a272-233d3efd11a0" contextRef="C_bb885263-2c35-4cf7-8ae9-82fc64c0f7a0" name="axsm:DebtInstrumentPrepaymentPenaltyPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs on or after the first anniversary and prior to the second anniversary of the First Amendment Closing Date, and (iii) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_66fa5912-a6ae-4685-b8a1-77a0199b3888" contextRef="C_6854c542-e5e2-4d67-b182-044dbba449bd" name="axsm:DebtInstrumentPrepaymentPenaltyPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs on or after the second anniversary and prior to the third anniversary of the First Amendment Closing Date. These percentages are unchanged from the Loan Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Second Amendment to the Loan Agreement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On March 27, 2022, the Company entered into the Second Amendment to the Loan Agreement subject to the closing of the Sunosi&#174; Acquisition. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Note 1 - Nature of Business and Basis of Presentation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">for more detail.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loan Interest Expense and Amortization</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company incurred interest expense of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_59dda81e-7070-4a94-8fcd-a904d264677a" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,123,958</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d4f082c4-6729-495b-b038-5e103a73213f" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,143,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively. In addition, amortization of the final payment fee was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_71f71f16-68f2-4619-bf62-9ad066994990" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">97,860</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8fe3fd97-d60d-40fc-9c39-7b69430c2076" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">143,589</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Amortization of the debt discount in relation to warrants and debt issuance costs was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7fbfc270-6fa9-48d5-b6c6-7e2a96b5d07c" contextRef="C_99cf65ea-42df-4c36-87cb-c410c3027f8e" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">125,497</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ce0eafec-d9e4-46a3-8669-ab93c7db4e56" contextRef="C_c3170278-1391-4a56-9d86-0add7cd33446" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">132,508</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2021, respectively.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_225caa5b-fd2a-4cee-8729-715f78af3321" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The outstanding debt and unamortized debt discount balances are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.074%;"></td>
        <td style="width:1.596%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:13.076%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.596%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:13.076%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#x200b;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,<br />2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total Outstanding Debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_73bbb74a-601f-4948-886b-aee13701b617" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dfb8580e-48e2-41ea-a62e-6e2f1a6963bc" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Add: accreted liability of final payment fee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7e5a66e9-7da7-47bf-b6eb-b94d92532943" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="axsm:DebtInstrumentAccretedLiabilityOfFinalPaymentFee" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">804,053</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8c9a28f4-afd3-4d34-9d1e-f5e1cd71b419" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="axsm:DebtInstrumentAccretedLiabilityOfFinalPaymentFee" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">706,407</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less: unamortized debt discount, long-term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_46906c3c-646c-46db-9260-d88e82abaade" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,491,388</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c62c9669-4b69-41c0-a64c-14b4b740cf89" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,616,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less: current portion of long-term debt</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loan payable, long-term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_56c0ccd2-34bd-4d7b-bf19-3329560c9994" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">49,312,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_44bd4d78-e3da-43a5-b4d6-2d77b33bb067" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">49,089,522</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the entry into the Hercules Term Loan, the Company issued to Hercules a warrant to purchase a number of shares of the Company&#x2019;s common stock equal to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2bd04210-18b7-4086-973b-d73e6437a46f" contextRef="C_99cf65ea-42df-4c36-87cb-c410c3027f8e" name="axsm:DebtInstrumentAggregateAmountPercentage" unitRef="U_pure" scale="-2" decimals="3">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate amount of the Term Loan Advances that are funded. Further information on warrants issued related to this loan and prior debt financings and amendments are disclosed in Note 7 - Stockholders&#x2019; Equity under the &#x201c;Warrants&#x201d; section.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4838814-aef4-4da3-99f5-6a51b1faae65" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Scheduled Principal Payments on Outstanding Debt, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022, are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.137%;"></td>
        <td style="width:1.814%;"></td>
        <td style="width:1.376%;"></td>
        <td style="width:15.714%;"></td>
        <td style="width:0.96%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e7fe1fa8-1fe7-4e4a-a1d2-3e883018e6f8" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">8,026,818</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e3db0be5-f5ae-47c4-85d8-06b45d68bd4b" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">41,973,182</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total principal payments outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ac76876a-3a25-4c46-bae3-6a7e0ccbdcc2" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company was in compliance with all covenants and requirements of its financing arrangements as of and during the three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51631803-923f-42d2-97c1-9f11432bb7e9" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 5. Net Loss per Common Share</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f449e1b5-28c8-4fea-a279-dad434262756" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per common share:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.056%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:13.085%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:13.085%;"></td>
        <td style="width:0.921%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per common share:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_40557c49-68d9-4e0d-ac24-e8e18e914188" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">39,632,311</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_83f1ab48-e7fc-4ced-8c16-6b9bb77dd7f1" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:numdotdecimal">29,259,970</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted average common shares outstanding&#x2014;basic<br />&#160;&#160;&#160;and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6bd50fa6-ea6a-46da-92ff-930e6e42a663" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">38,323,167</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cd224ff2-5d2d-47b0-8e89-a5b7444d7888" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">37,429,450</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss per common share&#x2014;basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bee25b21-b5da-4840-b8d0-3413b142b684" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.03</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_09685e11-7908-419e-8ae6-9266b4c262cd" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">0.78</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_092a4d31-23dc-47e1-83c6-e637145d6d7c" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive securities outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.927%;"></td>
        <td style="width:1.627%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:12.897%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.627%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:12.897%;"></td>
        <td style="width:1.006%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3cd1bf61-c0d6-4a05-8501-f8ef643d15f3" contextRef="C_1f6dcc9c-a3d6-4cf1-8464-0d285bc4d9a6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,219,030</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_50c0390e-967f-44ab-b9c6-5e10019ef1cd" contextRef="C_a6291cbc-4212-426f-966c-f9d236bef96a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,385,598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d441581b-e811-401c-8496-50272c451505" contextRef="C_3c22e247-ede4-4b63-a5a8-09b68eef26a4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">667,366</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9152783c-7640-402d-bc09-93832956b0cc" contextRef="C_4616eca2-d061-41e6-b773-9b50623ea068" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">303,983</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_11c25c99-acba-4d68-b491-4d4d7ba5472f" contextRef="C_b2abbcf3-4402-4301-9f22-3638b33916cb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,541</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_17c5840a-cee6-4ae1-9949-b09c9a5b62b3" contextRef="C_ad457fe7-35cb-4f1c-adfe-9364d3096822" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,541</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_89d13552-03e9-4c1d-8d8a-5da94eafa3fc" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,901,937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1e89daab-ce9f-40ff-a475-773c1b0ed6b4" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,705,122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cad6ede2-da7a-4638-89b0-736772a8cd32" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 6. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Operating Leases</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc25ae0e-afde-441f-8a28-1819b7eb3bf9" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021, the Company had the following operating lease expense:</span></p><p style="text-indent:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.459%;"></td>
        <td style="width:1.692%;"></td>
        <td style="width:30.534%;"></td>
        <td style="width:1.692%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:14.052%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.692%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:14.052%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.692%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Statement of Operations Location</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e7b8001e-6af5-4ac6-a881-705869481b2f" contextRef="C_7ba32c09-ff41-4912-b05b-767b2f5e43d0" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">290,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_09500908-2491-40c4-aaf5-18f9987289a2" contextRef="C_fda19f6a-c507-42ec-b932-514114edee24" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">286,923</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1ad80ec0-49e9-455e-bc7b-f904ed91cb03" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">290,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_60a7456a-3615-40cf-8010-c7de51b17ffa" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">286,923</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c2531ac-3451-44dc-a983-93f09472fc8d" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments of the Company&#x2019;s operating leases as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022 were as follows:</span></p><p style="text-indent:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.809%;"></td>
        <td style="width:1.934%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:15.972%;"></td>
        <td style="width:0.914%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a032c9d4-b1da-49b3-ac91-ef0b818cf893" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">885,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_93e1341a-39c0-4cfc-9133-ca757eed58c6" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">105,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5ea95d2c-3b5e-445b-a930-7b7dcdfcb51a" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">990,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_409849f0-9471-4c92-b71f-1bb0c8076c11" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">22,752</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_214e91e4-f534-4748-a5d3-935450aa10d2" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">967,248</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb204685-e6ea-4773-a87b-6b3afd596a2d" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In January 2022, the Company entered into an agreement to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e28be1eb-3744-4d7c-90a3-4bcbdc142b35" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_167175b9-678a-4d3d-9612-304f110a6030" contextRef="C_ed7f64ac-9d3d-4975-a4ad-4adbcbe2e765" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">extend</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> the lease of 22 Cortlandt Street for a term of</span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91e739cf-c1d4-4e60-b1c0-deef6fb83ece" contextRef="C_2dda7b7d-4eb5-4947-be5a-64886b352ff5" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> six months</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> from August 1, 2022 through January 31, 2023.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> As of  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the remaining lease term for our operating lease was </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ea0e1f9-2cb7-40b9-99bd-dbbf3cc30775" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0.8</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> years with a discount rate of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_77ea11ac-ab99-44a7-bb4e-9ca61543fe46" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">%. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d5cf7da-0b39-4a99-ab35-13790f335cfd" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 7. Stockholders&#x2019; Equity</span></p><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Capital Structure</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the Company entered into the December 2019 Sales Agreement with SVB Leerink, pursuant to which the Company may sell up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9dc75894-e29c-4343-8146-621e06f9f2d0" contextRef="C_bdddd48e-24d8-466b-85d6-b30c067ffe9b" name="axsm:CommonStockSalesAgreementAuthorizedAmount" unitRef="U_USD" scale="6" decimals="INF">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company&#x2019;s common stock from time to time through SVB Leerink, acting as the Company&#x2019;s sales agent, in one or more at-the-market offerings utilizing the 2019 Shelf Registration Statement. SVB Leerink is entitled to receive a commission of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fde932fb-91e0-455f-8e36-380bbbd20480" contextRef="C_7beabbcc-8b62-4676-8c90-7970bd0c23b7" name="axsm:CommonStockSalesAgreementCommissionPercentage" unitRef="U_pure" scale="-2" decimals="3">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds for any shares sold under the December 2019 Sales Agreement. The December 2019 Sales Agreement was replaced by the March 2022 Sales Agreement (see below).</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, the Company entered into the March 2022 Sales Agreement with SVB Leerink, pursuant to which the Company may sell up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6d8874c8-f24d-44ac-b2c5-1025745bb40b" contextRef="C_ebcc446a-08e2-4b02-a7fc-b6339311af4e" name="axsm:CommonStockSalesAgreementAuthorizedAmount" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">200</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company&#x2019;s common stock from time to time through SVB Leerink, acting as the Company&#x2019;s sales agent, in one or more at-the-market offerings utilizing the 2019 Shelf Registration Statement. SVB Leerink is entitled to receive a commission of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c64b361c-262e-430a-8794-8460f002fbfb" contextRef="C_044ac2dd-a43b-4bf0-a117-1190f9ff7f2e" name="axsm:CommonStockSalesAgreementCommissionPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds for any shares sold under the March 2022 Sales Agreement. The March 2022 Sales Agreement supersedes the December 2019 Sales Agreement, dated December 5, 2019, by and between the Company and SVB Leerink LLC.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the December 2019 Sales Agreement and March 2022 Sales Agreement, for the three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company received approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_52d40f98-6e64-4244-a1cf-b0247d05dbd3" contextRef="C_b4195b45-d05d-44d6-967c-803d41a1847f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">32.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in gross proceeds through the sale of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_918406ab-a3b6-41a4-845c-2e1d1b9f147c" contextRef="C_b4195b45-d05d-44d6-967c-803d41a1847f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,044,081</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> shares, of which net proceeds were approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ea5cad97-7745-444a-a30b-017d23e24843" contextRef="C_b4195b45-d05d-44d6-967c-803d41a1847f" name="axsm:StockIssuedDuringPeriodValueNewIssuesNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">31.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The holders of shares of common stock are entitled to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3753dc59-939a-415d-8656-d0c4b30831ce" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:EquityInstrumentVotingRightsPerShare" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. The holders of shares of common stock are entitled to receive dividends, if and when declared by the board of directors.</span></p><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Shelf Registration Statement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On December 5, 2019, the Company filed an automatic shelf registration statement (&#x201c;2019 Shelf Registration&#x201d;) with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for the issuance of common stock, preferred stock, warrants, rights, debt securities and units. It became effective upon filing with the SEC and is currently the Company&#x2019;s only active shelf registration. Through the date of this report, the Company has issued common stock of approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e822c528-9fee-4add-813f-3db10df67b01" contextRef="C_41c6af09-fd7f-47cc-bdbe-fdeca00ab829" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">261.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million pursuant to such shelf registration statement.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under SEC rules, the 2019 Shelf Registration Statement allows for the potential future offer and sale by the Company, from time to time, in one or more public offerings, of an indeterminate amount of the Company&#x2019;s common stock, preferred stock, debt securities, and units at indeterminate prices. At the time any of the securities covered by the 2019 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_642e9f95-59ca-4614-a56d-15806cb6ac17" contextRef="C_3c213636-da72-4c96-a325-3f0b156f4462" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,187,058</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> shares available for the issuance of stock options or stock-based awards under the Company&#x2019;s 2015 Omnibus Incentive Compensation Plan at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock Options</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb55cefa-86d3-46fa-8470-987b8c7092d1" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the stock option activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.963%;"></td>
        <td style="width:1.049%;"></td>
        <td style="width:0.835%;"></td>
        <td style="width:9.037%;"></td>
        <td style="width:0.921%;"></td>
        <td style="width:1.028%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:9.016%;"></td>
        <td style="width:0.846%;"></td>
        <td style="width:1.049%;"></td>
        <td style="width:0.857%;"></td>
        <td style="width:9.027%;"></td>
        <td style="width:0.846%;"></td>
        <td style="width:1.049%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:10.868%;"></td>
        <td style="width:0.846%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#x200b;Number<br />of shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#x200b;Weighted<br />average<br />exercise price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted<br />average<br />contractual<br />term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#x200b;Aggregate<br />intrinsic<br />value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_72619c62-777e-4eb1-966b-d02df1f7822d" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,090,377</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e29174f1-688b-48c7-93fc-79b0d0e25160" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">28.89</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f7f5becc-e990-4e49-88fa-459fb5fa64a2" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,223,019</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2840b311-ed29-4e6c-b2f7-5f8aaccbc286" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">30.05</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e81fc71f-eed9-4f86-b569-df382ba7b75d" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,015</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a0b73d34-3083-4baa-99ba-ee6041814ffb" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.08</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ffee1ffd-2e30-46f0-a32f-9aca09fc95a8" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">67,139</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_259eaad2-3df8-4fb6-b0c3-a31cf58b38c0" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">43.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_17629ea4-e34c-4d8c-a379-fac135e57e0d" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,212</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_66937464-1495-4c04-ae6c-9eae9c296caa" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">53.10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3c8df0d0-6e5b-4377-b552-7071b966e75f" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,219,030</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8ef018ed-2140-495e-8c0b-2058272d76f8" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">28.98</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cfd1b48d-f580-4713-b4e5-f6d9e9a66a9d" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_42b8ceb9-105b-49b2-9454-dab63e1abb71" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">106,188,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Vested and expected to vest at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2398fb3c-3338-4055-a867-0ca508d75ec4" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,219,030</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7ba1e5ed-6930-4931-ae7c-09a7914f2ead" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">28.98</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bbb7169-00ad-4451-84fa-a262839259d9" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_206bb63f-f030-4794-a242-41cc436484f7" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">106,188,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exercisable at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0fd6f754-b4b8-46ce-86a6-a681bab37616" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,932,835</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e8c6d4f2-9f32-4742-97b8-5e4977d07771" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">15.85</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7407870-be2a-41eb-a0e4-36a4adbee7ce" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5.7</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c0cfb877-4829-4716-b652-2d229f9c5924" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">82,434,018</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method as described in the SEC&#x2019;s Staff Accounting Bulletin No. 107 relating to stock-based compensation. The simplified method was chosen because the Company has limited historical option exercise experience due to its short operating history. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for a period approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. Expected volatility is based on historical volatilities of similar entities within the Company&#x2019;s industry which were commensurate with the Company&#x2019;s expected term assumption.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value of options granted was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f7912a89-c4f0-4a2c-80b9-0bb6edeb1b6b" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">21.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> per option for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022. As of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, there was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_00bb7d06-3567-4081-a9db-b048349ea6fe" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">91.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of total unrecognized compensation cost related to non-vested stock options which is expected to be recognized over a weighted average period of </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cab74e76-cd4a-41fb-b619-79ff2a5d63a9" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> years. These amounts do not include </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_74f3931c-7d51-4c02-b4d9-da6b42618366" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,169</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> options outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022, which are performance-based and vest upon the achievement of certain corporate milestones. Stock&#x2011;based compensation will be measured and recorded if and when it is probable that the milestone will occur.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In 2020, the Company began granting RSUs covering an equal number of its shares of common stock to employees. The fair value of RSUs is determined on the date of the grant based on the market price of its shares of common stock as of that date. The fair value of the RSUs is recognized as an expense ratably over the vesting period of </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_302a6813-a6e8-47d9-826a-2b3c68c73ba8" contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, total compensation cost not yet recognized related to unvested RSUs was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2578175b-3c42-49a2-b0aa-a17544e0e73f" contextRef="C_7fa0e148-2225-4c34-bcbe-ec944991768c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca8a50eb-4058-4c1c-b961-515bd082dc61" contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc43d87a-d786-44dd-bfcd-4b6316749c1e" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the RSU activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:0.985%;"></td>
        <td style="width:12.857%;"></td>
        <td style="width:0.985%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.857%;"></td>
        <td style="width:0.985%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#x200b;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Number<br />of shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted<br />average<br />grant date<br />fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0ef6e2a0-c96a-4274-ad62-1866fe58aeea" contextRef="C_e5af5223-2fe5-4213-acad-7c31eefaf440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">302,764</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fa1071a8-5ea3-45e1-b965-d679b60071aa" contextRef="C_e5af5223-2fe5-4213-acad-7c31eefaf440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">42.93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6fa5f770-78fa-485c-b769-90d7c67604a1" contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">429,902</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e2206770-d29c-4240-9a5b-58192a77b976" contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">23.27</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a852e80f-d1bb-41ac-a8ff-1340a03efa93" contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">61,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e93b792c-4c2f-4a88-91e5-afab9866e23e" contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">41.49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_db1d7a56-977d-43f1-9e43-1f068ca65143" contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_15e0d61d-8ca3-48a1-a38f-ea82740f9889" contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">48.73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c7238d0e-fdf5-41f8-af4e-697346685f55" contextRef="C_7fa0e148-2225-4c34-bcbe-ec944991768c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">667,366</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3181b95a-e38c-460c-82f5-0a724ae1d13e" contextRef="C_7fa0e148-2225-4c34-bcbe-ec944991768c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">30.36</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_454b127d-633b-454d-8f5b-f4dcfa8b02eb" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021 was allocated as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.149%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.243%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.243%;"></td>
        <td style="width:0.696%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#x200b;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#x200b;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_87b32e65-b884-48c0-8392-a133d8baea15" contextRef="C_bb6e9275-c30c-46d5-9e05-d49f1beb2c70" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,809,477</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2dbc80c4-6fbc-4953-8231-61ce2b36818b" contextRef="C_d9bc5005-9c34-42dc-a103-770e8beb2d78" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,534,395</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d3a1c46d-da39-4a7c-a135-3b40e82ade6d" contextRef="C_7ba32c09-ff41-4912-b05b-767b2f5e43d0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">5,788,852</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7d73f20e-a4ba-4ccf-a80c-bb1e61fcce7e" contextRef="C_fda19f6a-c507-42ec-b932-514114edee24" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">2,196,702</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2741d067-206d-4cf4-a007-16df2ade74b5" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">7,598,329</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_28073dc2-5ffe-47fa-b31e-aa3ac0fed1a1" contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">3,731,097</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_694f84c8-5c9b-40b7-8e42-a2c9e39e7f24" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes warrant activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:0.985%;"></td>
        <td style="width:12.857%;"></td>
        <td style="width:0.985%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:12.857%;"></td>
        <td style="width:0.985%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">exercise price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9628b6ce-da64-4ea3-a7ae-93f2287a37b9" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,541</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6a20dc6d-b0c0-4fb8-be3e-71508febbc6e" contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">80.43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_84997054-e05a-4e2e-96bf-e2847d116015" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:WarrantsIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_181b5d71-6a1d-45e6-a008-b69501b9a243" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:WarrantsIssuedInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0e5e8f79-77cd-4baf-bf36-eec64b106c87" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:WarrantsExercisedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_74580b84-6e5e-4cea-9312-50390c09a5b2" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:WarrantsExercisedInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a7963d98-b87c-4238-9090-ab2b5c4e1a2a" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,541</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bdebcb4a-9945-4a54-b7d7-2d81b1e201ec" contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">80.43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Outstanding Warrants</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the first advance of the 2020 Term Loan, Hercules Capital Inc. received warrants to purchase an aggregate </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_851ddb8b-9871-4b7e-ab9f-1864d806e016" contextRef="C_3d7b6b8c-7fba-4794-bad1-9528cd8b0a02" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,541</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#x2019;s common stock at an exercise price of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3dfb15e3-a7f0-402d-9f0f-20a946012944" contextRef="C_3d7b6b8c-7fba-4794-bad1-9528cd8b0a02" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">80.43</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> per share, which was the volume weighted average price of the Company&#x2019;s common stock over the </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8e6c9850-4a9e-4883-9dbc-ad0f1b420de7" contextRef="C_234c04e9-be43-4c65-8294-bca64c8b14d4" name="axsm:ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays" unitRef="U_D" decimals="INF" format="ixt-sec:numwordsen">ten</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">-day trading period immediately preceding the initial closing, subject to certain limited adjustments as specified in the warrant. The warrants are exercisable for </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ccd646e7-2bcb-498d-816b-2a0023531fb1" contextRef="C_234c04e9-be43-4c65-8294-bca64c8b14d4" name="axsm:ClassOfWarrantOrRightTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> from the date of issuance. The warrants were classified as a component of stockholders&#x2019; equity. The relative fair value of the warrants of approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_755a5911-d3e0-4721-ae40-fa112a229e7f" contextRef="C_3d7b6b8c-7fba-4794-bad1-9528cd8b0a02" name="axsm:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the debt. The discount on the debt is being amortized to interest expense over the term of the debt utilizing the effective interest rate method.</span></p></ix:nonNumeric></div>
  <div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8569c9c-b8b2-46b2-bc9c-ae781562a911" contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c" name="axsm:LicenseAgreementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 8. License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive License Agreement with Pfizer</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In January 2020, the Company entered into an exclusive license agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;) for Pfizer&#x2019;s clinical and nonclinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which the Company is developing for the treatment of narcolepsy. The agreement also provides the Company exclusive rights to develop and commercialize esreboxetine, a new late-stage product candidate referred to as AXS-14, in the U.S. for the treatment of fibromyalgia.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the agreement, Pfizer received </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2e51140f-1d37-466a-8c7f-484e6cfe0cf8" contextRef="C_bd3b09d8-962f-4a8d-95b5-a2380be0bb5b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">82,019</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#x2019;s common stock having a stated value of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dc317c00-69c3-41a6-b078-6227c0108b0d" contextRef="C_bd3b09d8-962f-4a8d-95b5-a2380be0bb5b" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, based on the average closing price of the Company&#x2019;s common stock for the </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_94398959-42ea-49ba-9af0-943b9d4f9861;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ten</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> prior trading days of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a39794dd-6e82-45d8-ae5d-ca876bd7edb9" contextRef="C_bd3b09d8-962f-4a8d-95b5-a2380be0bb5b" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">97.54</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, in consideration for the license and rights and also received an upfront cash payment of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_318d20da-c3d4-4f5b-bc0b-2f49d6ae2fc7" contextRef="C_d123927e-7029-4dd1-878a-36b68f4a9e6e" name="axsm:InitialCashPaymentPerCollaborationAgreement" unitRef="U_USD" scale="6" decimals="-5">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company determined that the fair value of each share of common stock granted to Pfizer on the closing date of January 9, 2020 was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_aeff018b-40f5-4041-a95d-c2205a27ad2e" contextRef="C_c4afe19c-11d0-445b-b47f-99cea4fdcb9b" name="axsm:SharePriceFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">87.24</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, based on the closing price of the Company&#x2019;s stock on that date. As a result, the fair value of the stock issued was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9ef376c9-40f3-4371-ba9f-c8647abeaeca" contextRef="C_c4afe19c-11d0-445b-b47f-99cea4fdcb9b" name="axsm:CommonStockFairValue" unitRef="U_USD" scale="6" decimals="-5">7.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and therefore, the total research and development expense recognized was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ead86fa5-b053-4f48-b252-b82fc722ea31" contextRef="C_cc7591c2-a315-4ba0-8ba7-30d3937ab8ef" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5">10.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million related to the Pfizer license agreement during the year ended 2020.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Pfizer can also receive up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_35e0bece-3702-4a3c-93c6-66ef1642e29f" contextRef="C_13dea1cb-aa1f-4a8f-94bb-ccbf522d6b7d" name="axsm:CollaborationArrangementFuturePotentialPayments" unitRef="U_USD" scale="6" decimals="-6">323</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in regulatory and sales milestones, and tiered mid-single to low double-digit royalties on future sales related to the licensed products. Pfizer will also have a right of first negotiation on any potential future strategic transactions involving AXS-12 and AXS-14. During the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d8166d53-413b-4784-8c72-99e168790feb" contextRef="C_6c8df518-2cca-4db3-a63e-69a63815b2f7" name="us-gaap:RoyaltyExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_967b5f93-9495-479a-a8e9-201fd1a74b04" contextRef="C_838ee7b0-8654-4765-abd6-662f63a4c8c8" name="us-gaap:RoyaltyExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> milestone payments or royalties were paid to Pfizer by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive License Agreements with Antecip</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In 2012, the Company entered into </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cad06444-bf4c-49a4-bf2a-55f593ea8d5d" contextRef="C_d49b89d1-f1b7-475f-9685-738cdbff9497" name="axsm:NumberOfLicenseAgreements" unitRef="U_Item" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> exclusive license agreements with Antecip, in which it was granted exclusive licenses to develop, manufacture, and commercialize Antecip&#x2019;s patents and applications related to the development of AXS-02, AXS-05, and AXS-04, anywhere in the world for human therapeutic, veterinary, and diagnostic use. Pursuant to the agreements, the Company is required to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize AXS-02, AXS-05, and AXS-04. Under the terms of the agreements, the Company is required to pay to Antecip a royalty equal to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7177e4a0-2023-4e34-a80c-5379304f4e9d" contextRef="C_5d352228-7b5b-4785-b9bd-1cfc63c353da" name="axsm:LicenseAgreementRoyaltyDuePercentageOfNetSales" unitRef="U_pure" scale="-2" decimals="3">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% for AXS-02, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a46274e0-54ea-4e33-85fa-caf355787ef9" contextRef="C_70fafa52-2071-4fb1-b999-e133e767989d" name="axsm:LicenseAgreementRoyaltyDuePercentageOfNetSales" unitRef="U_pure" scale="-2" decimals="3">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% for AXS-05, and </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2f74793d-3232-41eb-ae03-0b3137414679" contextRef="C_d9fad345-924e-408f-93e8-d534f64b717a" name="axsm:LicenseAgreementRoyaltyDuePercentageOfNetSales" unitRef="U_pure" scale="-2" decimals="3">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% for AXS-04, of net sales of products containing the licensed technology by the Company, its affiliates, or permitted sublicensees. These royalty payments are subject to reduction by an amount up to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d44b336e-0b0f-444d-803c-61cabbe582b9" contextRef="C_d49b89d1-f1b7-475f-9685-738cdbff9497" name="axsm:LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties" unitRef="U_pure" scale="-2" decimals="INF">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of any required payments to third parties. Unless earlier terminated by a party for cause or by the Company for convenience, the agreements shall remain in effect on a product-by-product and country-by-country basis until the later to occur of (i) the applicable product is no longer covered by a valid claim in that country or (ii) </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36f41e30-a446-40f3-9dcf-5146d0803034" contextRef="C_d49b89d1-f1b7-475f-9685-738cdbff9497" name="axsm:LicenseAgreementTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> from the first commercial sale of the applicable product in that country. Upon expiration of the agreements with respect to a product in a country, the Company&#x2019;s license grant for that product in that country will become a fully paid-up, royalty-free, perpetual non-exclusive license. If Antecip terminates any of the agreements for cause, or if the Company exercises its right to terminate any of the agreements for convenience, the rights granted to the Company under such terminated agreement will revert to Antecip. To date, the Company has not been required to make any payments to Antecip under any of the license agreements.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the 2020 Term Loan, the Company entered into a Direct Agreement with Antecip pursuant to which Antecip consented to the collateral assignment of the License Agreement to Hercules, among other things.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 2. MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">F FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis contains forward-looking statements about our plans and expectations of what may happen in the future. Forward-looking statements are based on a number of assumptions and estimates that are inherently subject to significant risks and uncertainties, and our results could differ materially from the results anticipated by our forward-looking statements as a result of many known or unknown factors, including, but not limited to, those factors discussed in &#x201c;Risk Factors.&#x201d; See also the &#x201c;Cautionary Note Regarding Forward-Looking Statements&#x201d; set forth at the beginning of this report.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis in conjunction with the unaudited interim consolidated financial statements, and the related footnotes thereto, appearing elsewhere in this report, and in conjunction with management&#x2019;s discussion and analysis and the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> which wa</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">s filed with the Securities and Exchange Commission, or SEC, on March 1, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We are a biopharmaceutical company developing novel therapies for the management of central nervous system, or CNS, conditions that have limited treatment options. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our core CNS portfolio includes four CNS product candidates, AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple indications. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">AXS-05 is being developed for the treatment of major depressive disorder, or MDD, for which a New Drug Application, or NDA, has been submitted and accepted for filing by the FDA. The FDA had set a Prescription Drug User Fee Act (PDUFA) target action date for the AXS-05 NDA of August 22, 2021, which was not completed on such date and therefore the review of the application is ongoing. AXS-05 is also under development for the treatment of Alzheimer's disease agitation, or AD agitation. AXS-05 is also being developed for smoking cessation. AXS-07 is being developed for the acute treatment of migraine, for which an NDA has been submitted and accepted for filing by the FDA. The FDA had set a PDUFA target action date for the AXS-07 NDA of April 30, 2022.  On April 29, 2022, we received a Complete Response Letter (CRL) from the FDA regarding the NDA for AXS-07 for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for the treatment of fibromyalgia. Additionally, we are currently evaluating other product candidates, which we intend to develop for CNS disorders. We aim to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that increase available treatment options and improve the lives of patients living with CNS disorders. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">AXS-05 is a novel, oral, investigational NMDA, or N-methyl-D-aspartate, receptor antagonist with multimodal activity under development for the treatment of CNS disorders. AXS-05 consists of a proprietary formulation and dose of dextromethorphan and bupropion and utilizes our metabolic inhibition technology. The dextromethorphan component of AXS-05 is an uncompetitive antagonist of the NMDA, an ionotropic glutamate receptor. The dextromethorphan component of AXS-05 is also a sigma-1 receptor agonist. The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan and is a norepinephrine and dopamine reuptake inhibitor. We are seeking FDA approval for AXS-05 utilizing the 505(b)(2) regulatory development pathway. AXS-05 has been granted FDA Breakthrough Therapy designation for both the treatment of MDD and the treatment of Alzheimer&#x2019;s disease agitation, as well as Fast Track designations for the treatment of Alzheimer&#x2019;s disease agitation and treatment resistant depression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have completed two pivotal trials, one Phase 2 and one Phase 3, of AXS-05 in MDD, which we refer to as the ASCEND and GEMINI trials, respectively. AXS-05 achieved the primary endpoint in both the ASCEND and GEMINI trials. A Phase 3, open-label, long-term safety study with AXS-05 in patients with MDD and TRD known as the COMET trial has also been completed. Additionally, three Phase 2 open-label efficacy sub-studies of the COMET trial have been completed. These sub-studies evaluated the efficacy and safety of AXS-05 in three clinically pertinent MDD patient populations: the COMET-TRD trial in treatment resistant MDD (TRD), the COMET-AU trial in antidepressant unresponsive MDD, and the COMET-SI trial in MDD with suicidal ideation. In the overall COMET trial, AXS-05 treatment resulted in rapid, substantial, and durable improvement in depressive symptoms, measured using the MADRS, which was sustained or increased with long-term treatment. Additionally, AXS-05 was well tolerated with long-term dosing. Similar findings of rapid and durable improvements in depressive symptoms were demonstrated in the COMET-AU and COMET-TRD sub-studies. In the COMET-SI trial, a rapid reduction in suicidal ideation was observed with AXS-05 treatment, as demonstrated by reductions in the MADRS-SI score. We have completed a Phase 3 trial of AXS-05 in TRD, which we refer to as the STRIDE-1 trial, which met key secondary endpoints but did not reach statistical significance on the primary endpoint. Additionally, we have completed a Phase 2, double-blind, placebo-controlled, multi-center, relapse prevention study in patients with TRD, which we call the MERIT trial. In the MERIT trial, AXS-05 achieved its primary and secondary endpoints by delaying time to relapse and preventing relapse as compared to placebo. We have also completed a Phase 2/3 trial of AXS-05 in AD agitation, which we refer to as the ADVANCE trial. AXS-05 achieved the primary endpoint in the ADVANCE trial. We are conducting the ACCORD trial, a Phase 3, double blind, placebo-controlled, randomized withdrawal trial in patients with AD agitation, and one open-label long-term safety study in AD agitation. AXS-05 is also being developed as an aid to smoking cessation treatment and a positive Phase 2 trial in this indication has been completed under a research collaboration with Duke University. We have submitted an NDA for AXS-05 for the treatment of MDD supported by the positive results from the ASCEND and GEMINI trials which was accepted for filing by the FDA and was granted Priority Review, resulting in a PDUFA target action date of August 22, 2021. On August 20, 2021, the FDA informed us that its review would not be completed by the PDUFA target action date and the review of the application is ongoing.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine. AXS-07 consists of MoSEIC&#153;, or Molecular Solubility Enhanced Inclusion Complex, meloxicam and rizatriptan. Meloxicam is a long-acting nonsteroidal anti-inflammatory drug, or NSAID, with COX-2, an enzyme involved in inflammation and pain pathways, preferential inhibition and potent pain-relieving effects. However, standard meloxicam has an extended time to maximum plasma concentration, or Tmax, which delays its onset of action. AXS-07 utilizes our proprietary MoSEIC&#153; technology to substantially increase the solubility and speed the absorption of meloxicam while potentially maintaining durability of action. Meloxicam is a new molecular entity for migraine enabled by our MoSEIC&#153; technology. Rizatriptan is a 5-HT1B/1D agonist that inhibits calcitonin gene-related peptide (CGRP)-mediated vasodilation, has been shown to have central trigeminal antinociceptive activity, and may reduce the release of inflammatory mediators from trigeminal nerves. Rizatriptan is approved as a single agent for the acute treatment of migraine. We are seeking FDA approval for AXS-07 utilizing the 505(b)(2) regulatory development pathway.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have completed two Phase 3 trials of AXS-07 for the acute treatment of migraine, which we refer to as the MOMENTUM and INTERCEPT trials. AXS-07 achieved the co-primary endpoints in both the MOMENTUM and INTERCEPT trials. An open-label, long-term, safety study of AXS-07 in patients with migraine known as the MOVEMENT trial has also been completed. In the MOVEMENT trial, administration of AXS-07 resulted in rapid, and substantial relief of migraine pain and associated symptoms and was well tolerated with long term dosing. We have submitted an NDA for AXS-07 for the acute treatment of migraine supported by the positive results from the MOMENTUM and INTERCEPT trials which was accepted for filing by the FDA with a PDUFA target action date of April 30, 2022.  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On April 29, 2022, the Company received a CRL from the FDA regarding its NDA for AXS-07 for the acute treatment of migraine. The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval of AXS-07. The principal reasons given in the CRL relate to chemistry, manufacturing, and controls considerations. The Company believes that the issues raised in the CRL are addressable and intends to provide potential timing for a resubmission following consultation with the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">AXS-12, reboxetine, is a novel, oral, investigational medicine in development for the treatment of narcolepsy. AXS-12 is a highly selective and potent norepinephrine reuptake inhibitor. AXS-12 has been granted FDA Orphan Drug Designation for the treatment of narcolepsy. We have completed a Phase 2 trial with AXS-12, which we refer to as the CONCERT study. A randomized, placebo-controlled Phase 3 trial with AXS-12 in narcolepsy was initiated in the third quarter of 2021, which we refer to as the SYMPHONY study, and one open-label long-term safety extension study was also initiated.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">AXS-14, esreboxetine, is a novel, oral, investigational medicine in development for the treatment of fibromyalgia. AXS-14 is a highly selective and potent norepinephrine reuptake inhibitor. We are initially developing esreboxetine for the management of fibromyalgia. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine. We have in-licensed data from Pfizer which includes a completed Phase 2 trial and Phase 3 trial in fibromyalgia, both of which were positive. We plan to submit an NDA for AXS-14 in 2023 for the management of fibromyalgia based on a pre-NDA meeting with the FDA which occurred in the second quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Since our incorporation in January 2012, our operations to date have included organizing and staffing our company, business planning, raising capital, developing our compounds, and engaging in other discovery and preclinical activities. Subsequent to our IPO, through proceeds from sales of our common stock and warrants to purchase shares of our common stock to equity investors and debt borrowings. For a further discussion, see the section entitled &#x201c;Liquidity and Capital Resources&#x201d; below.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our ability to become profitable depends on our ability to generate revenue. We do not expect to generate significant revenue unless and until we or our collaborators obtain marketing approval for and successfully commercialize one of our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating expenses and net losses since inception. We incurred net losses of $39.6 million and $29.3 million for the three months ended March 31, 2022 and 2021, respectively. Our accumulated deficit as of March 31, 2022 was $448.8 million, and we expect to incur significant expenses and increasing operating losses for the foreseeable future. We expect to continue to incur expenses in connection with the development of our product candidates, including with respect to conducting clinical trials and seeking regulatory approval for our current product candidates and any other product candidates that we develop or in-license and advance to clinical development. In preparation for obtaining regulatory approval for our product candidates, we expect to incur significant expenses in order to create an infrastructure and market readiness to support the commercialization of the product candidates, including manufacturing, sales, marketing, and distribution functions. Further, we have incurred and will continue to incur additional costs associated with operating as a public company. Accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations through public and/or private equity, debt financings or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Year to Date and Recent Developments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquisition of Assets of Jazz Pharmaceuticals</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On March 25, 2022, the Company entered into an Asset Purchase Agreement with Jazz Pharmaceuticals plc (&#34;Jazz Pharmaceuticals&#34;), pursuant to which the Company will acquire Sunosi&#174; from Jazz Pharmaceuticals (the &#34;Acquisition&#34;), a dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients living with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, which was approved by the FDA in 2019 and by the European Medicines Agency (the &#x201c;EMA&#x201d;) in 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">AXS-05</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In January 2022, we provided a response to the FDA addressing the two, previously disclosed, deficiencies related to analytical methods in the Chemistry, Manufacturing, and Controls, or CMC, section of our NDA for AXS-05 for the treatment of major depressive disorder. At this time, we have not been made aware of any other deficiencies related to the NDA by the FDA.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, we announced that it has received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the NDA for our AXS-05 product candidate for the treatment of major depressive disorder.<br /> Based on this interaction, we anticipate potential FDA action on the NDA in the second quarter of 2022. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">AXS-07</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On February 2022, we entered into a Litigation Discontinuance Agreement with Baudax Bio, Inc. (&#x201c;Baudax&#x201d;) pursuant to which Baudax was to voluntarily dismiss, with prejudice, its lawsuit against us in the United States District Court for the District of Delaware (the &#x201c;Baudax Action&#x201d;). The Baudax Action, which was never served on us, alleged that our AXS-07 drug</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">product candidate infringes on U.S. Patents 8,512,727 and 10,471,067, both owned by assignment by Baudax. A notice of dismissal with prejudice was filed by Baudax in the Baudax action on February 7, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, we </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> received a Complete Response Letter, or CRL, from the FDA regarding our NDA for AXS-07 for the acute treatment of migraine. The CRL did not identify or raise any concerns about the clinical efficacy or safety data in the NDA, and the FDA did not request any new clinical trials to support the approval of AXS-07. The principal reasons given in the CRL relate to chemistry, manufacturing, and controls (CMC) considerations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, we entered into a Sales Agreement with SVB Securities LLC, or SVB Securities, with respect to an at the market offering program, under which we may, from time to time in our sole discretion, issue and sell through SVB Securities, acting as sales agent, shares of our common stock of up to $200 million. The Agreement supersedes the prior Sales Agreement, dated December 5, 2019, by and between us and SVB Leerink LLC.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, in connection with the Acquisition (as described above), the Company entered into a Second Amendment to Loan and Security Agreement (the &#x201c;Second Amendment&#x201d;) with Hercules Capital, Inc. The Second Amendment amends the terms of that certain Loan and Security Agreement, dated as of September 25, 2020, by and among the Company, Hercules and the Lenders (as amended by that certain First Amendment to Loan and Security Agreement, dated as of October 14, 2021. In connection with the Second Amendment, the parties also clarified certain terms of the Warrant Agreement previously issued to Hercules. The Second Amendment shall only be effective upon the closing of the Acquisition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have not generated any revenue and have incurred significant operating losses since inception, and we do not expect to generate any revenue from the sale of any products unless or until we obtain regulatory approval. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially and adversely affected. If we enter into licensing or collaboration arrangements, such agreements may generate revenue in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses primarily include preclinical studies, clinical trials, manufacturing costs, employee-related expenses including salaries, benefits, travel, and stock&#x2011;based compensation expense, contract services, including external research and development expenses incurred under arrangements with third parties, such as contract research organizations, or CROs, facilities costs, overhead costs, depreciation, and other related costs.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development activities are central to our business model. We have and will incur substantial costs beyond our present and planned clinical trials in order to file a new drug application, or NDA, for any of our product candidates. It is difficult to determine with certainty the costs and duration of our current or future clinical trials and preclinical studies, or if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates if we obtain regulatory approval. We may never succeed in achieving regulatory approval. The duration, costs, and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rate, and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability, and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#x2019;s commercial potential.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses for our primary programs for the three months ended March 31, 2022 and 2021:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.142%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.267%;"></td>
    <td style="width:0.696%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.267%;"></td>
    <td style="width:0.696%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AXS-05</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,030,440</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10,044,146</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AXS-07</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,146,487</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,531,549</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AXS-12</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,881,536</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">733,858</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AXS-14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">241,347</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">475,854</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,751,741</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,809,477</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,534,395</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12,585,141</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16,595,689</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Other research and development expenses primarily consist of employee salaries and benefits, facilities, and overhead costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses primarily consist of salaries and related costs for personnel in executive, commercial, finance, and operational functions, including stock-based compensation and travel expenses. Also included in general and administrative expenses are pre-commercialization costs, facility-related costs, insurance expense, professional fees for legal and accounting services, and patent filing and prosecution costs. General and administrative expenses are expensed when incurred.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest income (expense)</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Interest income (expense) primarily consists of cash interest and non-cash costs related to our term loans (see &#x201c;Liquidity and Capital Resources&#x201d; below for a further discussion). We amortize these costs over the term of our debt agreements as interest expense in our consolidated statement of operations. Interest income (expense) also includes interest income earned on cash.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reported period. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">There have been no material changes to our critical accounting policies since the beginning of our fiscal year. Our critical accounting policies are described in &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; included in our Annual Report on Form 10-K for the year ended December 31, 2021 and in the notes to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the periods indicated:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.042%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.093%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.093%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12,585,141</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16,595,689</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25,703,731</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">11,248,372</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">38,288,872</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27,844,061</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(38,288,872</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(27,844,061</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Interest income (expense)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(1,343,439</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(1,415,909</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(39,632,311</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(29,259,970</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the three months ended March 31, 2022 and 2021</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Our research and development expenses for the three months ended March 31, 2022 were $12.6 million, compared to $16.6 million for the three months ended March 31, 2021, a decrease of $4.0 million. The decrease was driven by expenses related to the NDA filing which occurred in the prior comparable period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Our general and administrative expenses for the three months ended March 31, 2022 were $25.7 million, compared to $11.2 million for the three months ended March 31, 2021, an increase of $14.5 million. The increase was primarily related to pre-commercial activities and personnel expense, along with an increase in non-cash stock compensation expense.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest income (expense).</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Interest and amortization of debt discount expense for the three months ended March 31, 2022 was $1.3 million, compared to $1.4 million for the three months ended March 31, 2021, a decrease of $0.1 million. The decrease is mainly due to a lower interest rate on our debt as compared to the prior comparable period since we amended our loan and security agreement with Hercules in October 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Since our inception through March 31, 2022, we have financed our operations primarily through proceeds from equity offerings and debt borrowings. See discussion below.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On December 5, 2019, we filed an automatic shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an unlimited amount, which we refer to as the 2019 Shelf Registration Statement. It was declared effective by the SEC upon filing. As discussed in greater detail below, we entered into a sales agreement in December 2019 pursuant to which we sold shares of our common stock from time to time in an at-the-market offering and completed an offering of common stock in December 2019, each utilizing the 2019 Shelf Registration Statement. In the future, we may conduct additional offerings of one or more of these securities utilizing the 2019 Shelf Registration Statement in such amounts, prices and terms to be announced when and if the securities are offered. At the time any of our securities covered by the 2019 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, we entered into the December 2019 Sales Agreement with SVB Leerink, pursuant to which we may sell up to $80 million in shares of our common stock from time to time through SVB Leerink, acting as our sales agent, in one or more at-the-market offerings utilizing the 2019 Shelf Registration Statement. SVB Leerink is entitled to receive a commission of 3.0% of the gross proceeds for any shares sold under the December 2019 Sales Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, we entered into the March 2022 Sales Agreement with SVB Securities, pursuant to which we may sell up to $200 million in shares of our common stock from time to time through SVB Securities, acting as our sales agent, in one or more at-the-market offerings utilizing the 2019 Shelf Registration Statement. SVB Securities is entitled to receive a commission of 3.0% of the gross proceeds for any shares sold under the March 2022 Sales Agreement. The March 2022 Sales Agreement supersedes the December 2019 Sales Agreement, dated December 5, 2019, by and between the Company and SVB Leerink LLC.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under both the December 2019 and March 2022 Sales Agreements, for the three months ended March 31, 2022, we received approximately $32.0 million in gross proceeds through the sale of 1,044,081 shares, of which net proceeds were approximately $31.0 million.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, we entered into the Loan Agreement with Hercules for the 2020 Term Loan, which consists of several tranches in an aggregate amount of up to $225.0 million. The first tranche consists of term loans in the amount of $60.0 million, of which $50.0 million was funded shortly after executing the Loan Agreement and the remaining $10.0 million was available at our option at any time through September 15, 2021. A portion of the initial tranche was used to repay the 2019 Term Loan along with associated final payment fees. The remaining $115 million may be drawn at our option, in three separate tranches, as described below under &#x201c;Contractual Obligations and Commitments - September 2020 Loan and Security Agreement &#x2013; Hercules.&#x201d; An additional $50 million is available, subject to the approval of Hercules, to support future strategic initiatives, including further pipeline advancement or expansion. The 2020 Term Loan bears interest at a calculated prime-based variable rate currently at 9.15%. It matures in October 2025 and has an initial interest-only payment period of 30 months, which may be extended to up to 48 months upon the drawing of future tranches. The remaining $10 million on the first tranche was not utilized and such tranche and future tranches were amended upon the execution of the First Amendment to the Loan and Security Agreement (see below).</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, we amended the Loan Agreement with Hercules. which expanded the facility amount of up to $300 million and now has a maturity date of October 2026. See 'Contractual Obligations and Commitments - October 2021 First Amendment to the Loan and Security Agreement &#x2013; Hercules' section below for more information.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, we entered into a Second Amendment to Loan and Security Agreement with Hercules Capital, Inc. The Second Amendment amends the terms of that certain Loan and Security Agreement, dated as of September 25, 2020, by and among us, Hercules and the Lenders (as amended by that certain First Amendment to Loan and Security Agreement, dated as of October 14, 2021, and as further amended by the Second Amendment). In connection with the Second Amendment, the parties also clarified certain terms of the Warrant Agreement previously issued to Hercules. The Second Amendment shall only be effective upon the closing of the Acquisition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In the future, we may conduct additional offerings of one or more of the securities covered by the 2019 Shelf Registration Statement in such amounts, prices and terms to be announced when and if the securities are offered. At the time any of our securities covered by the 2019 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We believe that our current available cash, along with the remaining committed capital from the $300 million term loan facility, is sufficient to fund anticipated operations into 2024, based on the current operating plan, which includes the potential launch of AXS-05 in MDD, and the acquisition and commercialization of Sunosi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Because the process of commercializing products and evaluating product candidates in clinical trials is costly and the timing of progress in these trials is uncertain, it is possible that the assumptions upon which we have based this estimate may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our primary sources and uses of cash for the periods indicated:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.642%;"></td>
    <td style="width:1.531%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:12.804%;"></td>
    <td style="width:0.942%;"></td>
    <td style="width:1.552%;"></td>
    <td style="width:1.381%;"></td>
    <td style="width:12.825%;"></td>
    <td style="width:0.942%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash (used in) provided by:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(32,652,980</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(27,215,489</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(213,736</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(29,995</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31,101,644</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8,029,163</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net increase (decrease) in cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(1,765,072</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(19,216,321</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Cash used in operating activities for the three months ended March 31, 2022 was $32.7 million as compared to $27.2 million for the three months ended March 31, 2021. The increase of $5.5 million in net cash used was mainly due to the pre-commercialization activities.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Cash used in investing activities for the purchase of property and equipment for the three months ended March 31, 2022 was $0.2 million and was less than $0.1 million for the three months ended March 31, 2021. The increase of $0.2 million was due to pre-commercialization activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Cash provided by financing activities was $31.1 million for the three months ended March 31, 2022, which included net proceeds from the sale of common stock through our Sales Agreement with SVB Securities of $31.0 million and proceeds from the issuance of common stock upon exercise of employee stock options of $0.2 million. Cash provided by financing activities was $8.0 million for the three months ended March 31, 2021, which included net proceeds from the sale of common stock through our Sales Agreement with SVB Leerink of $6.1 million and proceeds from the issuance of common stock upon exercise of employee stock options of $1.9 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Funding requirements</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have not achieved profitability since our inception and we expect to continue to incur significant losses for the foreseeable future. We expect our losses to increase as we continue the development of and seek regulatory approvals for our product candidates and begin to commercialize any approved products. We are subject to all of the risks pertinent to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may need to raise additional financing in the future to fund our operations. In the event that we need additional financing, we may incur additional debt, license certain intellectual property, and seek to sell additional equity or convertible securities that may result in dilution to our stockholders. If we raise additional funds through the issuance of equity or convertible securities, these securities could have rights or preferences senior to those of our common stock and could contain covenants that restrict our operations. There can be no assurance that we will be able to obtain additional equity or debt financing on terms acceptable to us, if at all. Our future capital requirements will depend on many factors, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the scope, rate of progress, results, and cost of our clinical studies and other related activities;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into collaborative agreements for the development and commercialization of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the number and development requirements of any other product candidates that we pursue;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing, and outcome of regulatory reviews of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">any product liability or other lawsuits related to our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the expenses needed to attract and retain skilled personnel;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the general and administrative expenses related to being a public company;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the costs involved in preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending our intellectual property&#x2011;related claims.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Please see &#x201c;Risk Factors&#x201d; for additional risks associated with our substantial capital requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License agreement with Pfizer</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In January 2020, we entered into a license agreement with Pfizer. Under the terms of our exclusive license agreement with Pfizer, Pfizer received 82,019 shares of our common stock having a stated value of $8.0 million, based on the average closing price of our common stock for the ten prior trading days of $97.54, in consideration for the license and rights. Pfizer also received an upfront cash payment of $3.0 million. We determined that the fair value of each share of common stock granted to Pfizer on the closing date of January 9, 2020 was $87.24, based on the closing price of our common stock on that date. As a result, the fair value of the stock issued was $7.2 million.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Pfizer can also receive up to $323 million upon the achievement of certain regulatory and sales milestones, and tiered mid-single to low double-digit royalties on future sales. Pfizer will also have a right of first negotiation on any potential future strategic transactions involving AXS-12 and AXS-14.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License agreements with Antecip Bioventures</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under three exclusive license agreements with Antecip Bioventures II LLC, or Antecip, an entity owned by our Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., we are obligated to make specified royalty payments ranging from 1.5% to 4.5%, subject to up to a 50% reduction depending on required payments to third parties, on net sales of licensed products. The amount, timing, and likelihood of such payments are not known.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the 2020 Term Loan, Antecip consented to the collateral assignment of one of the license agreements, among other things, under a direct agreement with us and Hercules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">September 2020 Loan and Security Agreement &#x2013; Hercules</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, we entered into the Loan Agreement with Hercules, in its capacity as administrative agent and collateral agent and as a lender, and the other financial institutions that may from time to time become parties to the Loan Agreement as lenders, which we collectively refer to as the Lenders. The Loan Agreement provides for term loans in an aggregate principal amount of up to $225.0 million under multiple tranches. The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $60.0 million, of which $50.0 million, or the First Advance, was funded at closing, and of which the remaining $10.0 million was available at our option at any time through September 15, 2021; (ii) subject to the FDA approval of our AXS-05 product candidate for the treatment of major depressive disorder, or the First Milestone, a second tranche consisting of additional term loans in an aggregate principal amount of up to $35.0 million, available at our option beginning on the date that the First Milestone is achieved through the earlier of (A) 181 days following such date and (B) June 30, 2022; (iii) subject to the approval of our AXS-07 product candidate for the treatment of migraine, or the Second Milestone, a third tranche consisting of additional term loans in an aggregate principal amount of up to $20.0 million, available at our option beginning on the date that the Second Milestone is achieved through the earlier of (A) 181 days following such date and (B) June 30, 2022; (iv) subject to the achievement of either the First Milestone or the Second Milestone and so long as we are in compliance with a required ratio of Lender indebtedness to net product revenue, a fourth tranche consisting of additional term loans in an aggregate principal amount of up to $60.0 million, available at our option beginning on January 1, 2022 and continuing through March 31, 2023; and (v) subject to approval by the Lenders in their discretion, a fifth tranche of additional term loans in an aggregate principal amount of up to $50.0 million, available through December 31, 2023.  The remaining $10 million on the first tranche was not utilized and such tranche and future tranches were amended upon the execution of the First Amendment to the Loan and Security Agreement. See &#34;</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">October 2021 First Amendment to the Loan and Security Agreement &#x2013; Hercules</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#34; below for further information. We intend to use the proceeds of the Term Loan Advances for working capital and general corporate purposes. In addition, approximately $21.7 million of the proceeds from the First Advance was used to satisfy in full and retire our indebtedness under the 2019 Term Loan, as amended.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The outstanding principal balance of the term loans bears interest at an annual rate equal to the greater of either (i) the prime rate as reported in The Wall Street Journal plus 5.90% or (ii) 9.15%, subject to an ability by us, during certain periods, each such period a PIK Deferral Period, to request a reduction of the then-effective cash-pay interest rate by up to 1.00% per annum, which we refer to as the Cash Interest Reduction Amount. Accrued interest is payable monthly following the funding of each term loan. During each PIK Deferral Period, the term loans will bear cash-pay interest, at the reduced amount, and will accrue paid-in-kind interest at a rate equal to the Cash Interest Reduction Amount multiplied by 1.15, which amount will be capitalized and added to the outstanding principal balance of the term loans on each monthly interest payment date during the PIK Deferral Period. We are required to repay the term loans in equal installments of principal and interest commencing on May 1, 2023 through October 1, 2025, which is the Maturity Date. However, if either the First Milestone or the Second Milestone are achieved prior to May 1, 2023, and no default exists, the amortization commencement date will be automatically extended to November 1, 2023; if both the First Milestone and the Second Milestone are achieved prior to November 1, 2023, and no default exists, the amortization commencement date will be further automatically extended to May 1, 2024 and if any term loans are funded under the fourth tranche noted above prior to May 1, 2024, and no default exists, the amortization commencement date will be further automatically extended to November 1, 2024. On the Maturity Date, all unpaid term loans will be due and payable.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As collateral for the obligations, we have granted to Hercules a senior security interest in all our right, title, and interest in, to and under all of our property, inclusive of intellectual property, which includes one of our existing license agreements with Antecip, subject to limited exceptions. Antecip consented to the collateral assignment of the License Agreement, among other things, under a Direct Agreement with us and Hercules.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement contains customary representations, warranties and covenants, including covenants by us limiting additional indebtedness, liens (including a negative pledge on intellectual property and other assets), guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates and fundamental changes. At the initial closing, there were no applicable financial covenants contained in the Loan Agreement. Only after additional amounts are drawn down by us in the future, if we decide to do so, under the terms set forth in the Loan Agreement, there will be certain limited financial covenants that will apply, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Effective upon the date the outstanding principal amount of the advances under the Loan Agreement equals or exceeds $55.0 million, which has not yet occurred, we at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest, in an aggregate amount greater than or equal to $15.0 million, plus the amount of our accounts payable under U.S. GAAP not paid after the 180th day following the invoice for such account payable which amount we refer to as the Qualified Cash A/P Amount.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Effective upon the later of (i) the last calendar month of the calendar quarter that is twelve months following the earlier of (x) the date that the First Milestone is achieved and (y) the date that the Second Milestone is achieved, or (ii) the date on which the outstanding principal amount of the term loan advances under the Loan Agreement is equal to or greater than $65.0 million, neither of which have occurred yet, we are required to (A) ensure that at all times its market capitalization exceeds $2.0 billion, and that it maintains cash in an account which Hercules has a first priority security interest in an amount not less than 65% of the sum of the outstanding principal amount of the term loan advances plus the Qualified Cash A/P Amount, (B) ensure that at all times that it maintains cash in an account which Hercules has a first priority security interest in an amount not less than 100% of the sum of the outstanding principal amount of the term loan advances plus the Qualified Cash A/P Amount, or (C) achieve at least 60% of the net product revenue per the board of directors approved forecast solely from the sale of AXS-05 and AXS-07 (which may include royalty, profit sharing, or sales-based milestone revenue recognized in accordance with GAAP, but will not include any upfront or non-sales-based milestone payments under business development or licensing transactions), measured on a trailing six-month basis as of the date of our most recent quarterly financial statement, determined on a quarterly basis.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on our ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our obligations under the Loan Agreement are subject to acceleration upon the occurrence of specified events of default, including payment default, insolvency and a material adverse change in our business, operations or financial or other condition.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are required to pay a final payment fee equal to the greater of (A) $2,910,000 and (B) 4.85% of the aggregate amount of all future term loan advances. The final payment fee is being accreted and amortized into interest expense using the effective interest rate method over the term of the loan.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may, at our option prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) 2.0% of the principal amount prepaid if the prepayment occurs prior to the first anniversary of the initial closing, (ii) 1.5% of the principal amount prepaid if the prepayment occurs on or after the first anniversary and prior to the second anniversary of the initial closing, and (iii) 1.0% of the principal amount prepaid if the prepayment occurs on or after the second anniversary and prior to the third anniversary of the initial closing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">October 2021 First Amendment to the Loan and Security Agreement &#x2013; Hercules</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On October 14, 2021 (&#34;First Amendment Closing Date&#34;), we entered into the first amendment to the Loan Agreement (the &#x201c;First Amendment to the Loan Agreement&#x201d;).</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the First Amendment to the Loan Agreement, the First Amendment amended the terms of that certain Loan and Security Agreement, dated as of September 25, 2020, by and among the Company, Hercules and the Lenders (the &#x201c;Loan Agreement&#x201d;) to, among other things, (i) increase the aggregate principal amount of the loan, available at the Company&#x2019;s option, from $225,000,000 to $300,000,000, (ii) change the draw amounts and dates available in Tranche 2 through Tranche 5 including increasing the amount available under Tranche 2 subject to FDA approval of the Company&#x2019;s AXS-05 product candidate for the treatment of major depressive disorder from $35,000,000 to $100,000,000, maintaining the amount available under Tranche 3 subject to FDA approval of the Company&#x2019;s AXS-07 product candidate for the acute treatment of migraine of $20,000,000, reducing the amount under Tranche 4 available upon achievement of certain combined sales and outstanding debt criteria from $60,000,000 to $55,000,000, and increasing the amount available under Tranche 5 to support future strategic initiatives, including further pipeline advancement or expansion from $50,000,000 to $75,000,000 subject to the approval from Hercules, (iii) extend the maturity date of the facility from the original October 2025 to October 2026, and optionally to October 2027, subject to certain conditions, (iv) reset and extend the interest only period from the initial 30 months from the original loan closing to 48 months from the First Amendment and extendable up to 60 months subject to FDA approval of the Company&#x2019;s AXS-05 product candidate for the treatment of major depressive disorder and subject to FDA approval of AXS-07 in the acute treatment of migraine, and (v) decrease the interest rate from 9.15% (floating rate based on the greater of (a) 9.15% or (b) US WSJ Prime + 5.90%) to 8.95% (floating rate based on the greater of (a) 8.95% or (b) US WSJ Prime + 5.70%).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are required to pay a final payment fee equal to (A) $2,910,000 plus (B) 4.5% of the aggregate amount of all future term loan advances. The final payment fee is being accreted and amortized into interest expense using the effective interest rate method over the term of the loan.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may, at our option prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) 2.0% of the principal amount prepaid if the prepayment occurs prior to the first anniversary of the First Amendment Closing Date, (ii) 1.5% of the principal amount prepaid if the prepayment occurs on or after the first anniversary and prior to the second anniversary of the First Amendment Closing Date, and (iii) 1.0% of the principal amount prepaid if the prepayment occurs on or after the second anniversary and prior to the third anniversary of the First Amendment Closing Date. These percentages are unchanged from the Loan Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">March 2022 Second Amendment to the Loan and Security Agreement &#x2013; Hercules</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, we entered into a Second Amendment to Loan and Security Agreement with Hercules Capital, Inc. The Second Amendment amends the terms of that certain Loan and Security Agreement, dated as of September 25, 2020, by and among us, Hercules and the Lenders (as amended by that certain First Amendment to Loan and Security Agreement, dated as of October 14, 2021, and as further amended by the Second Amendment). In connection with the Second Amendment, the parties also clarified certain terms of the Warrant Agreement previously issued to Hercules. The Second Amendment shall only be effective upon the closing of the Acquisition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Employees and Human Capital Management</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As of April 26, 2022, we had 116 full&#x2011;time employees. None of our employees is represented by a collective bargaining agreement and we have never experienced any work stoppage. We believe that we maintain good relations with our employees. Our employees are highly skilled, and many hold advanced degrees. Most of our employees have experience with drug development. Our future performance depends significantly upon the continued service of our key scientific, technical and senior management personnel and our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives. In addition to salaries, these programs include potential annual discretionary bonuses, stock awards, healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, and flexible work schedules, among other benefits. We took proactive steps throughout the COVID-19 pandemic to protect the health and safety of our employees. We expect to continue to implement these measures until we determine that the COVID-19 pandemic is adequately contained for purposes of our business. We may take further actions, in compliance with all appropriate government regulations, that we determine to be in the best interest of our employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Impact of the CARES Act</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">	On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) was enacted and signed into law, and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act, among other things, includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act, including, permitting net operating losses (&#x201c;NOLs&#x201d;), carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The CARES Act provides other reliefs and stimulus measures. We have evaluated the impact of the CARES Act, however, at present we do not expect that any provision of the CARES Act would result in a material cash benefit to us or have a material impact on our financial statements or internal controls over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Impact of COVID-19 on our Business</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, a novel coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People&#x2019;s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, which has spread globally. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency in the United States on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a global pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operations and Liquidity</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The full impact of the COVID-19 pandemic is still unknown and constantly evolving. While the potential economic impact brought by and over the duration of the COVID-19 pandemic may be difficult to assess or predict, the COVID-19 pandemic has resulted in significant disruption of global financial markets, which could in the future negatively affect our liquidity. In addition, a recession or market volatility resulting from the COVID-19 pandemic could affect our business. We have taken proactive, aggressive action throughout the COVID-19 pandemic to protect the health and safety of our employees and expect to continue to implement these measures until we determine that the COVID-19 pandemic is adequately contained for purposes of our business. We may take further actions as government authorities require or recommend or as we determine to be in the best interests of our employees. To date, the COVID-19 pandemic has not had significant effects on the progression of our clinical trials. Given the nature and type of our short-term investments, we do not believe that the COVID-19 pandemic will have a material impact on our current investment liquidity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Outlook</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Although there is uncertainty related to the continuous impact of the COVID-19 pandemic on our future results, we believe our current cash reserves, coupled with our access to additional capital through the March 2022 Sales Agreement and debt facility, leave us well-positioned to manage our business through this crisis as it continues to unfold. However, the impacts of the COVID-19 pandemic are broad-reaching and continuing and the financial impacts associated with the COVID-19 pandemic are still uncertain.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As a result of the ongoing COVID-19 pandemic and its dynamic nature, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the pandemic, and actions that have been or may be taken by governmental authorities to contain the pandemic or to treat its impact, it is difficult to forecast the effects of the COVID-19 pandemic on our results for the fiscal year ending December 31, 2022.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Despite the economic uncertainty resulting from the COVID-19 pandemic, we intend to continue to focus on the development of our product candidates. We continue to monitor the rapidly evolving situation and guidance from international and domestic authorities, including federal, state and local public health authorities and we may take additional actions based on their recommendations. In these circumstances, there may be developments outside of our control requiring us to adjust our operating plan. As such, given the dynamic nature of this situation, we cannot reasonably estimate the impacts of the COVID-19 pandemic on our financial condition, results of operations or cash flows in the future. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Off-Balance Sheet Arrangements</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined by applicable SEC regulations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 2 &#x2013; Summary of Significant Accounting Policies to our consolidated financial statements included in Part I, Financial Information, Item 1, Financial Statements, of this Quarterly Report on Form 10-Q for a discussion of recently issued accounting pronouncements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 3. QUANTITATIVE AND QUALITA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">TIVE DISCLOSURE ABOUT MARKET RISK</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business and from changes in the interest rate on our debt borrowings. These market risks are principally limited to interest rate fluctuations. We had cash of $84.7 million and $86.5 million as of March 31, 2022 and December 31, 2021, respectively. The primary objective of our investment activities is to preserve principal and liquidity while maximizing income without significantly increasing risk. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of our investment portfolio and debt agreement, we do not believe an immediate 100 basis point increase in interest rates would have a material effect on the fair market value of our portfolio, and, accordingly, we do not expect our operating results or cash flows to be materially affected by a sudden change in market interest rates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Exchange Risk</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We contract with vendors and third-party manufactures located in Europe and certain invoices are denominated in foreign currencies. We are therefore subject to fluctuations in foreign currency rates in connection with these agreements, and recognize foreign exchange gains or losses in our statement of operations. We have not historically hedged our foreign currency exchange rate risk. To date, we have not incurred any material effects from foreign currency changes on these contracts.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We do not believe a 10% change in these currencies on March 31, 2022 would have had a material effect on our results of operations or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inflation Risk</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and pricing of contracts. We do not believe that inflation has had a material effect on our business, financial condition, or results of operations during the three months ended March 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 4.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">CONTROLS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> AND PROCEDURES</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disclosure Controls and Procedures.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures, as of such date, were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> There has been no change in internal controls over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">PART II. OTHE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">R INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1. LEGAL </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">PROCEEDINGS.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We, and our subsidiaries, are currently not a party to, and our property is not currently the subject of, any material pending legal proceedings; however, we may become involved in various claims and legal actions arising in the ordinary course of business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1A. RI</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">SK FACTORS.</span></p>
  <p style="text-indent:6.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors set forth below as well as the other information contained in this Quarterly Report on Form 10-Q and in our other public filings in evaluating our business. Any of the following risks could materially and adversely affect our business, financial condition or results of operations. The risks described below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently view to be immaterial may also materially adversely affect our business, financial condition or results of operations. In these circumstances, the market price of our common stock would likely decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Risk Factors Summary</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to a number of risks and uncertainties, including those risks discussed at length below. These risks include, among others, the following:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception, anticipate that we will incur substantial losses for the foreseeable future, and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may need additional funding to conduct our future clinical trials and to complete development and commercialization of our product candidates. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our product development programs or commercialization efforts.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operating activities may be restricted as a result of covenants related to the outstanding indebtedness under our loan and security agreement with Hercules and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a limited operating history and no history of commercializing products, which may make it difficult to evaluate our business and prospects.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are substantially dependent on the success of our product candidates and cannot guarantee that any of our product candidates will successfully complete any planned or ongoing clinical trials, receive regulatory approval, or be successfully commercialized.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If safety and efficacy data for our product candidates, a reference drug, or published literature does not satisfactorily demonstrate safety and efficacy to the FDA, or if the FDA and other regulators do not permit us to rely on the data of a reference drug or published literature, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Although Breakthrough Therapy, Fast Track, and other designations are designed to expedite the development and review of drugs, they may not ultimately lead to a faster approval process or faster development of regulatory review and they will not increase the likelihood that our product candidates will receive marketing approval, for example, Breakthrough Therapy designation by the FDA for AXS-05 for the treatment of MDD and for the treatment of AD agitation.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition from other pharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations. Our operating results will suffer if we fail to compete effectively.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain FDA approval of an NDA for our product candidates, if we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market, sell and distribute our product candidates, if they are approved, we may be unable to generate product revenues.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our current or future product candidates do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the manufacturers upon whom we rely fail to produce our product candidates in the volumes that we require on a timely basis, or to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, our products and may lose potential revenues.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business operations, financial condition, results of operations and cash flows may be adversely affected by the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the ongoing COVID-19 pandemic.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">As an NDA applicant and a potential commercial &#x201c;virtual manufacturer,&#x201d; we may rely in many cases on third parties to perform many essential services for any products that we commercialize, including services related to warehousing and inventory control, distribution, government price reporting, customer service, accounts receivable management, cash collection, and adverse event reporting. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize any of our current or future product candidates will be significantly impacted and we may be subject to regulatory sanctions.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are dependent on third parties to decide to utilize our product candidates effectively, including by making them readily available at the point of care throughout their networks of pharmacies.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have licensed and may need to license certain intellectual property from third parties in the future. Such licenses may not be available or may not be available on commercially reasonable terms. Our business may be materially harmed if the licenses are not available or terminated for any reason.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with federal, state, and foreign healthcare laws, including fraud and abuse and transparency and health and other data protection, information privacy and security laws, we could face substantial penalties and our business, financial condition, results of operations, and prospects could be adversely affected.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the government or third-party payors fail to provide adequate coverage and payment rates for any of our current or future product candidates, or if health maintenance organization (HMOs) or long-term care facilities choose to use therapies that are less expensive, our revenue and prospects for profitability will be limited.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to significantly increase the size of our organization, and we may experience difficulties in managing growth. If we are unable to implement appropriate controls and procedures to manage our growth, we will not be able to implement our business plan successfully.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and may be able to exert significant control over matters subject to stockholder approval.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The use of our net operating loss carryforwards and research tax credits may be limited.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception, anticipate that we will incur substantial losses for the foreseeable future, and may never achieve or maintain profitability.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We are a biopharmaceutical company with a limited operating history. For the last several years, we have focused our efforts primarily on developing CNS product candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14, which we refer to herein as our product candidates, with the goal of achieving regulatory approval and commercialization. Since inception, we have incurred significant operating losses. Our net losses were $39.6 million for the three months ended March 31, 2022 and $130.4 million for the year ended December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2022, we had an accumulated deficit of $448.8 million. To date, we have not received regulatory approvals for any of our product candidates or generated any revenue from the sale of products. We expect to continue to incur substantial expenses and operating losses over the next several years, as we continue to develop our current and future product candidates. In addition, we expect to incur significant sales, marketing, and manufacturing expenses related to the commercialization of our current and future product candidates, if they are approved by the FDA. As a result, we expect to continue to incur significant losses for the foreseeable future. We anticipate that our expenses will increase substantially as we:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approval for any product candidates that successfully complete late&#x2011;stage clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">hire additional commercial, clinical, medical, quality, regulatory, and scientific personnel;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">add operational, financial, and management information systems and personnel, including personnel to support our product candidate development and planned future commercialization efforts;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">further establish a sales, marketing, and distribution infrastructure; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">expand external manufacturing capabilities and production to commercialize any products for which we may obtain regulatory approval and that we choose not to license to a third-party;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">undertake additional manufacturing activities of our product candidates to satisfy FDA requirements for marketing application submissions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">conduct our clinical trials with AXS&#x2011;05 in depression and AD agitation;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">conduct our clinical trials with AXS-12 in narcolepsy;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">continue to evaluate, plan for, and conduct, clinical trials for AXS-05 as an aid to smoking cessation treatment and other CNS disorders;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">continue to evaluate, plan for, and potentially submit an NDA for AXS-14 in fibromyalgia;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">develop, in&#x2011;license, or acquire additional product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">conduct late&#x2011;stage clinical trials for any product candidates that successfully complete early&#x2011;stage clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">conduct additional non&#x2011;clinical studies with any product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">conduct clinical studies with any additional product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">require larger quantities of product; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand, and protect our intellectual property portfolio.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. We do not expect to generate significant revenue unless and until we are able to obtain marketing approval for and successfully commercialize one or more of our product candidates, of if we acquire approved commercial products. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, potentially entering into collaboration and license agreements, obtaining regulatory approval for product candidates and manufacturing, marketing, and selling any products for which we may obtain regulatory approval, achieving market acceptance of our products, satisfying any post-marketing requirements, maintaining appropriate distribution, setting prices, and obtaining reimbursement for our products from private insurance or government payors. We are only in the preliminary stages of some of these activities. We may never succeed in these activities and, even if we do, may never achieve profitability.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we may incur or when, or if, we will be able to achieve profitability. If we are required by the FDA or comparable foreign regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our product candidates, our expenses could increase.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings, or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may need additional funding to conduct our future clinical trials and to complete development and commercialization of our product candidates. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our product development programs or commercialization efforts.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Conducting clinical trials, pursuing regulatory approvals, establishing outsourced manufacturing relationships, and successfully manufacturing and commercializing our product candidates is, and will be, a very time&#x2011;consuming, expensive, and uncertain process that takes years to complete. We may need to raise additional capital to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">fund our future clinical trials for our current product candidates, especially if we encounter any unforeseen delays or difficulties in our planned development activities;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">fund our operations and continue our efforts to hire additional personnel and build a commercial infrastructure to prepare for the commercialization of our current and future product candidates, if approved by the FDA or other comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">qualify and outsource the commercial&#x2011;scale manufacturing of our products under current good manufacturing practices, or cGMP;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">develop additional product candidates; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">in&#x2011;license other product candidates.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We believe that our current available cash, along with the remaining committed capital from the $300 million term loan facility, is sufficient to fund anticipated operations into 2024, based on the current operating plan, which includes the potential launch of AXS-05 in MDD, and the acquisition and commercialization of Sunosi. We have based this estimate on the assumption that AXS-05 will be approved in 2022, which will give us access to additional funds under the 2020 Term Loan.  However, if AXS-05 is not approved, or such approval is delayed, we believe our current available cash is sufficient to fund our anticipated operations, based on the current operating plan, for at least 12 months. Our assumptions may prove to be wrong, and we could spend our available financial resources faster than we currently expect. Further, we may not have sufficient financial resources to meet all of our objectives if any product candidate is approved, which could require us to postpone, scale back, or eliminate some, or all, of these objectives, including our potential launch activities relating to our product candidates. Our future funding requirements will depend on many factors, including, but not limited to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the rate of progress and costs related to the development of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the costs associated with conducting additional clinical and non-clinical studies with any of our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the potential for delays in our efforts to seek regulatory approval for our product candidates, and any costs associated with such delays;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the costs of establishing a commercial organization to sell, market, and distribute our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the rate of progress and costs of our efforts to prepare for the submission of an NDA, for any product candidates that we may in&#x2011;license or acquire in the future, and the potential that we may need to conduct additional clinical or preclinical trials to support applications for regulatory approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the costs of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights associated with our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of manufacturing, or having third parties manufacture, sufficient supplies of our product candidates in preparation for commercialization;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">revenue, if any, received from commercial sales of our product candidates, subject to the receipt of regulatory approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the terms and timing of any collaborative, licensing, co&#x2011;promotion, or other arrangements that we may establish; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the success of the commercialization of any of our current or future product candidates.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Future capital requirements will also depend on the extent to which we acquire or invest in additional businesses, products, and technologies. Until we can generate a sufficient amount of product revenue, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings, royalties, and corporate collaboration and licensing arrangements, as well as through interest income earned on cash and investment balances. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our development programs or our commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operating activities may be restricted as a result of covenants related to the outstanding indebtedness under our loan and security agreement with Hercules and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, we entered into a Loan and Security Agreement, or the Loan Agreement, for a term loan of up to $225.0 million, which we refer to as the 2020 Term Loan, with Hercules Capital, Inc., or Hercules, in its capacity as administrative agent and collateral agent and as a lender, and the other financial institutions that from time to time become parties to the Loan Agreement, collectively referred to as the Lenders, secured by a lien on substantially all of our assets, including intellectual property. In October 2021, we entered into a First Amendment to the Loan Agreement to, among other things, increase the size of the 2020 Term Loan to $300.0 million. In March 2022, we entered into a Second Amendment to the 2020 Term Loan that will, among other things, change the terms of the Term Loan Advances (as defined in the 2020 Term Loan) upon the consummation of the Acquisition. The Loan and Agreement contains various covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things, sell, transfer, lease or dispose of certain assets; incur indebtedness; encumber or permit liens on certain assets; make certain investments; make certain restricted payments, including paying dividends on, or repurchasing or making distributions with respect to, our common stock; and enter into certain transactions with affiliates. Our business may be adversely affected by these restrictions on our ability to operate our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The covenants also include, to the extent the principal amount of the advances under the Loan Agreement equals or exceeds $55.0 million, maintaining cash in an account or accounts in which the Lenders have a first priority security interest, in an aggregate amount greater than or equal to $15.0 million, plus the amount of our accounts payable under U.S generally accepted accounting principles not paid after the 180th day following the invoice for such account payable, which we refer to as the Qualified Cash A/P Account. Further, effective upon the later of (i) the last calendar month of the calendar quarter that is twelve months following the earlier of (x) the date of approval of our NDA for our AXS-05 product candidate for the treatment of major depressive disorder reasonably satisfactory to the Lenders, and (y) the date of approval of our NDA for our AXS-07 product candidate for the treatment of migraine, or (ii) the date on which the outstanding principal amount of the term loan advances under the Loan Agreement is equal to or greater than $65.0 million, we are obligated to (A) ensure that at all times our market capitalization exceeds $1.0 billion, and that we maintain cash in an account in which the Lenders have a first priority security interest in an amount not less than 50% of the sum of the outstanding principal amount of the term loan advances plus the Qualified Cash A/P Amount, (B) ensure that at all times that we maintain cash in an account in which the Lenders have a first priority security interest in an amount not less than 85% of the sum of the outstanding principal amount of the term loan advances plus the Qualified Cash A/P Amount, or (C) achieve at least 60% of the net product revenue per our board of directors approved forecast solely from the sale of AXS-05 and AXS-07 (which may include royalty, profit sharing, or sales-based milestone revenue recognized in accordance with GAAP, but will not include any upfront or non-sales-based milestone payments under business development or licensing transactions), measured on a trailing six-month basis as of the date of our most recent quarterly financial statement, included in the projections we delivered to Hercules on September 9, 2020, as updated from time to time, determined on a quarterly basis.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">A breach of any of the covenants under the Loan Agreement could result in a default under the 2020 Term Loan. Upon the occurrence of an event of default under the 2020 Term Loan, the Lenders could elect to declare all amounts outstanding, if any, to be immediately due and payable and terminate all commitments to extend further credit. If there are any amounts outstanding that we are unable to repay, the Lenders could proceed against the collateral granted to it to secure such indebtedness.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a limited operating history and no history of commercializing products, which may make it difficult to evaluate our business and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We commenced operations in 2012, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, and developing our product candidates, including undertaking preclinical studies and conducting clinical trials of our product candidates. We have not yet demonstrated an ability to obtain regulatory approval for, or successfully commercialize, a product candidate. In addition, as a relatively nascent business, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown difficulties. If our product candidates are approved by the FDA, we will need to expand our capabilities to support commercial activities. We may not be successful in adding such capabilities. Consequently, any predictions about our future performance may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR BUSINESS AND THE DEVELOPMENT OF OUR PRODUCT CANDIDATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are substantially dependent on the success of our product candidates and cannot guarantee that any of our product candidates will successfully complete any planned or ongoing clinical trials, receive regulatory approval, or be successfully commercialized.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We currently have no products approved for commercial distribution. We have invested a significant portion of our efforts and financial resources in the development of our product candidates. Our business depends entirely on the successful development and commercialization of our product candidates, which may never occur. Our ability to generate revenues in the near term is substantially dependent on our ability to develop, obtain regulatory approval for, and then successfully commercialize our product candidates. We currently generate no revenues from sales of any products, and we may never be able to develop or commercialize a marketable product. Furthermore, given the nature of our business, the biopharmaceutical industry in general and the uncertainty and costs associated with developing our product candidates within a complicated and costly regulatory regime, our goals, plans and assumptions with respect to our product candidates may evolve or change. For example, we may not continue to emphasize, focus our research and development efforts on or direct resources to certain of our product candidates, and we may shift our focus and resources to our other current or future product candidates. Any such change in our business strategy could harm our business, cause uncertainty or confusion in the marketplace or harm the clinical prospects of our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates will require additional clinical and non-clinical development, regulatory approval, commercial manufacturing arrangements, establishment of a commercial organization, significant marketing efforts, and further investment before we generate any revenues from product sales. A Phase 3 trial with AXS-05 in AD agitation and a Phase 3 trial with AXS-12 in narcolepsy are ongoing. As a result of one or more risks discussed in this section, we cannot assure you that we will meet projected timelines related to these trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Even if our product candidates are approved, they may be subject to limitations on the indicated uses for which they may be marketed, distribution restrictions, or to other conditions of approval, may contain significant safety warnings, including boxed warnings, contraindications, and precautions, may not be approved with label statements necessary or desirable for successful commercialization, or may contain requirements for costly post-market testing and surveillance, or other requirements, including the submission of a risk evaluation and mitigation strategy, or REMS, to monitor the safety or efficacy of the products. If we do not receive regulatory approval for, and successfully commercialize, our product candidates, we will not be able to generate revenue from these product candidates in the foreseeable future, or at all. Any significant delays in obtaining approval for and commercializing our product candidates will have a material adverse impact on our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Although we submitted NDAs to the FDA for AXS-05 for the treatment of MDD and for AXS-07 for the acute treatment of migraine, we have not previously submitted an NDA to the FDA, or similar drug approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that our current or future product candidates will be successful in clinical trials or receive regulatory approval.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are susceptible to the risks of failure inherent at any stage of product development, including the appearance of unexpected adverse events or failure to achieve its primary endpoints in subsequent clinical trials, including our initiated and planned Phase 3 clinical trials. We conducted one interim analysis for the Phase 2/3 trial of AXS-05 in TRD and one interim analysis for the Phase 2/3 trial of AXS-05 for the treatment of AD agitation. We may elect to conduct interim analyses for our other clinical trials. Interim results of a clinical trial do not necessarily predict final results, and interim results may result in early stoppage of our clinical trials for futility or modifications to our clinical trials, including the addition of additional subjects. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If approved for marketing by applicable regulatory authorities, our ability to generate revenues from our product candidates depend on our ability to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">create market demand for our product candidates through our own marketing and sales activities, and any other arrangements to promote these product candidates that we may otherwise establish;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">receive regulatory approval for claims that are necessary or desirable for successful marketing;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">hire, train, and deploy a sales force to commercialize our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">manufacture (or have manufactured by third parties) our product candidates in sufficient quantities and at acceptable quality and manufacturing cost to meet commercial demand at launch and thereafter;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">establish and maintain agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">create partnerships with, or offer licenses to, third parties to promote and sell our product candidates in foreign markets where we receive marketing approval: </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">maintain patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">launch commercial sales of our product candidates, whether alone or in collaboration with others;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">achieve market acceptance of our product candidates by patients, the medical community, and government and private third&#x2011;party payors;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">achieve appropriate reimbursement for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">effectively compete with other therapies; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">maintain a continued acceptable safety profile of our product candidates following launch.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Potential conflicts of interest exist with respect to the intellectual property rights that we license from an entity owned by our Chief Executive Officer and Chairman of the Board, and it is possible that our interests and their interests may diverge.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In 2012, we entered into three exclusive license agreements with Antecip Bioventures II LLC, or Antecip, an entity owned by our Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., in which we were granted exclusive licenses to develop, manufacture, and commercialize Antecip&#x2019;s patents and applications related to the development of our current product candidates. Although Dr. Tabuteau dedicates all of his working time to us because Antecip is an inactive intellectual property holding company, he may face potential conflicts of interest regarding these licensing transactions as a result of his ownership of Antecip. The license agreements provide that, subject to the reasonable consent of Antecip, we have the right to control the prosecution or defense, as the case may require, of a patent infringement claim involving the licensed intellectual property. Our interests with respect to pleadings and settlements in such cases may be at odds with those of Antecip. If there is a dispute between us and Antecip, Dr. Tabuteau will have a conflict of interest because he may, at the time of a prospective dispute, simultaneously have a financial interest in and owe a fiduciary duty to Antecip and simultaneously have a financial interest in and owe a fiduciary duty to us. For example, if a contractual dispute arises between us and Antecip under any of the license agreements we have with Antecip, Dr. Tabuteau may be in a position where he would benefit if Antecip prevails, to the detriment of our business or our investors, even though he is an officer and director of our company, because he is the sole owner of Antecip. Similarly, if we have a claim of any kind against Antecip, Dr. Tabuteau may be, even as our Chief Executive Officer and Chairman of the Board, reluctant to assert a claim by us against Antecip because of his financial interest in Antecip. We cannot assure you that any conflicts will be resolved in our favor, and as a result, our business could be impeded or materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on developing product candidates for specific indications that we identify as most likely to succeed, in terms of both its regulatory approval and commercialization. As such, we are currently primarily focused on the development of AXS-05 for the treatment of depression, agitation associated with AD, and smoking cessation, AXS-07 for the acute treatment of migraine, AXS-12 for the treatment of narcolepsy and AXS-14 for the treatment of fibromyalgia. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential. Additionally, as more fully described in &#x201c;Business&#x2014;Material License Agreements,&#x201d; we are required to pay to an entity owned by our Chief Executive Officer and Chairman of the Board certain royalty payments related to the development of AXS-05, as well as two product candidates that are not currently in active development, but not with respect to the development of other product candidates, which may influence management&#x2019;s decision concerning which product candidates or indications to pursue. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future growth may depend on our ability to identify and develop product candidates and if we do not successfully identify and develop product candidates or integrate them into our operations, we may have limited growth opportunities.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">A component of our business strategy is to continue to develop a pipeline of product candidates by developing products that we believe are a strategic fit with our focus on central nervous system, or CNS, therapeutics. However, these business activities may entail numerous operational and financial risks, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">difficulty or inability to secure financing to fund business activities for such development;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">disruption of our business and diversion of our management&#x2019;s time and attention;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">higher than expected development costs;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">exposure to unknown liabilities;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">difficulty in managing multiple product development programs; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">inability to successfully develop new products or clinical failure.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For instance, our prior efforts have resulted in our decision not to further develop certain product candidates that, at one time, appeared to be promising. We have limited resources to identify and execute the developments of products. Moreover, we may devote resources to potential development that are never completed, or we may fail to realize the anticipated benefits of such efforts. If we do not successfully develop and commercialize product candidates, we may not be able to obtain product revenues in future periods.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If safety and efficacy data for our product candidates, a reference drug, or published literature does not satisfactorily demonstrate safety and efficacy to the FDA, or if the FDA and other regulators do not permit us to rely on the data of a reference drug or published literature, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We are not permitted to commercialize, market, promote, or sell any product candidate in the United States without obtaining marketing approval from the FDA. Comparable foreign regulatory authorities, such as the European Medicines Agency, or EMA, impose similar restrictions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In the United States, we currently plan to, at least initially, seek approval of most of our product candidates using the 505(b)(2) pathway, with the exception of AXS-12 and AXS-14. The FDA interprets Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FDCA, for purposes of approving an NDA, to permit the applicant to rely, in part, upon published literature or the FDA&#x2019;s previous findings of safety and efficacy for an approved product. The FDA, though, requires companies to perform additional clinical trials or preclinical studies to support any deviation from the previously approved product and to support reliance on the FDA&#x2019;s prior findings of safety and efficacy or published literature.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the 505(b)(2) pathway, the FDA may approve our product candidates for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought pursuant to the Section 505(b)(2) process. The label, however, may require all or some of the limitations, contraindications, warnings, or precautions included in the reference product&#x2019;s label, including a box warning (commonly referred to as a &#x201c;black box warning&#x201d;), or may require additional limitations, contraindications, warnings, or precautions, including class&#x2011;wide warnings. For instance, antidepressants, including bupropion, include a class&#x2011;wide black box warning regarding the increased risk of suicidal thoughts and behavior.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Based on the side effects disclosed in FDA product labeling for marketed drugs that contain the same active molecules as our product candidate, AXS&#x2011;05 may result in dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, seizure, increase in blood pressure and heart rate, hepatoxicity, hypoglycemia, thrombocytopenia or other hypersensitivity reactions, QT prolongation, left ventricular hypertrophy or left ventricular dysfunction, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, rash, seizure, hypertension, activation of mania or hypomania, psychosis and other neuropsychiatric reactions, suicidal ideation, suicide attempt, completed suicide, angle closure glaucoma, allergic or anaphylactoid or anaphylactic reactions, diarrhea, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma&#x2011;glutamyl transferase, flatulence, or other adverse events or potential adverse events reported or discussed in the product labels for bupropion&#x2011;containing products or dextromethorphan&#x2011;containing products including Wellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin, Forfivo, Zyban, Contrave, and Nuedexta.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Based on the side effects disclosed in FDA product labeling for marketed drugs that contain the same active molecules as our product candidate, AXS-07 may result in fatigue, confusion, dry mouth, diarrhea, nausea, insomnia, anemia, increased appetite, anxiety, sweating, dizziness, palpitations, arrythmia, tachycardia, abnormal vision, syncope, seizure, tremor, tinnitus, dizziness, somnolence, paresthesia, dysgeusia, dyspepsia, constipation, weight increase or decrease, gastritis, hematuria, flatulence, esophagitis, gastric ulcers, gastroesophageal reflux, gastrointestinal hemorrhages, colitis, rash, pain or tightness in the chest, neck, throat or jaw, upper respiratory tract infections, influenza-like symptoms, or other adverse events or potential adverse events reported or discussed in the product labels for meloxicam&#x2011;containing or rizatriptan-containing products including Anjeso, Vivlodex, Mobic, and Maxalt.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Based on the side effects disclosed in EMA required product label for marketed drugs that contain the same active molecule as our product candidate, AXS-12 and AXS-14 may result in decreased appetite, insomnia, agitation, anxiety, dizziness, headache, paresthesia, akathisia, dysgeusia, accommodation disorder, mydriasis, glaucoma, vertigo, tachycardia, palpitations, vasodilation, hypotension, hypertension, dry mouth, vomiting, hyperhidrosis, rash, sensation of incomplete bladder emptying, urinary tract infection, dysuria, urinary retention, erectile dysfunction, ejaculatory pain, ejaculatory delay, chills, or other adverse events or potential adverse events reported or discussed in the product labels for reboxetine containing products including Edronax.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, because we plan to file certain product candidates under an NDA submitted pursuant to 505(b)(2), we will rely, at least in part, upon a reference drug and published literature. For example, we intend to rely on third-party studies in the published literature as well as FDA findings of safety and efficacy for approved drug products containing the same active molecules in AXS-05 and AXS-07. If the FDA disagrees with our conclusions regarding the appropriateness of our reliance on a reference drug or published literature, we could be required to conduct additional clinical trials or other studies to support our NDA, which could lead to unanticipated costs and delays or to the termination of our development program. If we are unable to obtain approval for our pharmaceutical formulations through the 505(b)(2) NDA process, we may be required to pursue the more expensive and time consuming 505(b)(1) approval process, which consists of full reports of investigations of safety and effectiveness conducted by or for the applicant. In addition, because we have submitted NDAs for AXS-05 and AXS-07 pursuant to the 505(b)(2) process, we have not conducted certain additional clinical trials for these product candidates and, as such, we will have less experience with actual testing of the product candidate.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">There may also be circumstances under which the FDA would not allow us to pursue a 505(b)(2) application. For instance, should the FDA approve a pharmaceutically equivalent product to our product candidates before we obtain approval, we would no longer be able to use the 505(b)(2) pathway. In that case, it is the FDA&#x2019;s policy that the appropriate submission would be an Abbreviated New Drug Application, or ANDA, for a generic version of the approved product. We may, however, not be able to immediately submit an ANDA or have an ANDA approval made effective, as we could be blocked by others&#x2019; periods of patent and regulatory exclusivity protection.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the approval of a number of products by the FDA under 505(b)(2) over the last few years, pharmaceutical companies and others have objected to the FDA&#x2019;s interpretation of Section 505(b)(2). If the FDA&#x2019;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may change its policies and practices with respect to Section 505(b)(2) regulatory approvals, which could delay or even prevent the FDA from approving any NDA that we submit pursuant to the 505(b)(2) process. Moreover, our inability to pursue a 505(b)(2) application could result in new competitive products reaching the market more quickly than our product candidates, which could hurt our competitive position and our business prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may never receive approval for any of our product candidates, and even if our product candidates are approved under 505(b)(2), the approval may be subject to limitations on the indicated uses for which the products may be marketed, distribution restrictions, or to other conditions of approval; may contain significant safety warnings, including boxed warnings, contraindications, and precautions; may not be approved with label statements necessary or desirable for successful commercialization; or may contain requirements for costly post&#x2011;market testing and surveillance or other requirements, including REMS, to monitor the safety or efficacy of the products. Moreover, any future actions or inquiries by the FDA with respect to the reference listed drug may require that we make changes to our labeling, discontinue development, or, possibly, withdraw the product from the market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An NDA submitted under Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit or regulatory actions that would delay or prevent the review or approval of our product candidate.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the Hatch Waxman Act, the holder of patents listed in the Orange Book for NDAs that a 505(b)(2) application references may file a patent infringement lawsuit after receiving notice of the paragraph IV certification. Filing of a patent infringement lawsuit against the filer of the 505(b)(2) applicant within 45 days of the patent or NDA owner&#x2019;s receipt of notice triggers a one time, automatic, 30 month stay of the FDA&#x2019;s ability to make the 505(b)(2) NDA approval effective. In such a case, the FDA may not make the 505(b)(2) NDA approval effective until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#x2019;s favor or settled, or such shorter or longer period as may be ordered by a court. Accordingly, we may invest a significant amount of time and expense in the development of one or more product candidates only to be subject to significant delay and patent litigation before such product candidates may be commercialized, if at all. In addition, a 505(b)(2) application approval will not be made effective until any existing non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, or NCE, or exclusivities for changes to NCEs listed in the Orange Book for the referenced product have expired or, if possible, are carved out from the label.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In practice, companies that produce branded reference listed drugs often bring patent litigation against applicants that seek regulatory approval to market generic or reformulated versions of their products. Litigation to enforce or defend intellectual property rights is often complex and often involves significant expense and can delay or prevent introduction or sale of our product candidates. If a court finds patents valid and infringed by our product candidates, we may be required to cease selling, relinquish or destroy existing stock, or pay monetary damages unless we can obtain a license from the patent holder. There may also be situations where we use our business judgment and decide to market and sell our approved products, notwithstanding the fact that allegations of patent infringement have not been finally resolved by the courts, an approach known as an &#x201c;at risk launch.&#x201d; The risk involved in doing so can be substantial because the remedies available to the owner of a patent for infringement may include, among other things, damages measured by the profits lost by the patent owner which may be greater than the profits earned by the infringer. In the case of willful infringement, such damages may be increased up to three times. An adverse</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">decision in patent litigation could have a material adverse effect on our business, financial position, and results of operations and could cause the market value of our common stock to decline. Should we need to file a paragraph IV certification in the future for our product candidates, we may risk patent litigation and substantial delays.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates as expected, and our ability to generate revenue will be materially impaired.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities and the availability and prioritization of regulatory agency resources. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions, and may require us to amend our clinical trial protocols or conduct additional studies that require regulatory or institutional review board, or IRB, approval, or otherwise cause delays in the approval or rejection of an application. Even though we have submitted two NDAs to the FDA we have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval. Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any of our collaborators to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States, and by the EMA and similar regulatory authorities outside the United States and Europe. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have no experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third&#x2011;party contract research organizations, or CROs, and consultants to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#x2019;s safety and efficacy for that indication and the submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial sites by, the regulatory authorities.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies; our product candidates&#x2019; mechanism of action; studies conducted by third parties in different patient populations, using different products, or using different study designs; and early clinical trials of our product candidates may not be predictive of the results of later&#x2011;stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Preclinical studies may also reveal unfavorable product candidate characteristics, including safety concerns. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful. Moreover, should there be a flaw in a clinical trial, it may not become apparent until the clinical trial is well advanced.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may also experience numerous unforeseen events during, or as a result of, clinical trials and in the course of our preparation, submission, and review of NDA filings that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">regulators or IRBs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or amend trial protocols;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and our CROs;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, or our studies may fail to reach the necessary level of statistical or clinical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">interim analyses may result in our clinical trials being discontinued for safety or futility reasons or may result in modifications to our clinical trials that prolong the trials or make them difficult and more expensive to complete, such as increases in the number of subjects;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our third&#x2011;party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, or we may be required to engage in additional clinical trial site monitoring;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">we, the regulators, or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects, or other unexpected characteristics of the product candidate, or due to findings of undesirable effects caused by a chemically or mechanistically similar drug or drug candidate. We may also discontinue clinical research and programs due to changing business priorities;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">changes in marketing approval policies during the development period rendering our data insufficient to obtain marketing approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">changes in or the enactment of additional statutes or regulations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory review for each submitted product application;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate or we may have insufficient funds for a clinical trial or to pay the substantial user fees required by the FDA upon the filing of an NDA;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">we may decide, or regulators may require us, to conduct additional clinical trials, analyses, reports, data, or preclinical/nonclinical studies than we currently plan, or we may abandon product development programs. For instance, although we believe that we are able to rely on the completed Phase 2 ASCEND trial and Phase 3 GEMINI trial in MDD to support an NDA for AXS-05 for the treatment of MDD; the Phase 3 ADVANCE trial and the ongoing ACCORD trial to support an NDA for AXS-05 for the treatment of AD agitation; the Phase 2 CONCERT trial and ongoing SYMPHONY trial to support an NDA for AXS-12 for the treatment of cataplexy and narcolepsy; and the completed Phase 2 trial and Phase 3 trial to support an NDA for AXS-14 for the management of fibromyalgia, the FDA could still require additional studies to support the approval of an NDA for these product candidates. The outcome of our studies may further necessitate additional clinical or preclinical work;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">we may fail to reach an agreement with regulators regarding the scope or design of our clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">we may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">we may experience delays in our clinical trials due to the ongoing COVID-19 pandemic;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the study or clinical trial, increase the needed enrollment size for the study or clinical trial, or extend the study&#x2019;s or clinical trial&#x2019;s duration;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">there may be regulatory questions regarding interpretations of data and results, or new information may emerge regarding our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our study design or our interpretation of data from preclinical studies and clinical trials or find that a product candidate&#x2019;s benefits do not outweigh its safety risks. For instance, in our communications with the FDA, the FDA has raised questions and had comments regarding our preclinical studies and clinical trials, such as comments on the acceptability of the proposed trial designs for our product candidates, the number of patients planned for our studies, our data analysis plans, the species and doses used in our preclinical studies, and the results of our preclinical studies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our belief that certain product attributes are advantageous or may require further study of product attributes that are different than our reference listed drugs. Pharmacokinetic differences between our product candidates and the reference listed drugs, may also make bridging studies more difficult or may prevent us from using the 505(b)(2) pathway. If we are prevented from using the 505(b)(2) pathway, we will need to use the more time consuming and expensive NDA pathway to receive product approval; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our intended indications;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or our manufacturing facilities for clinical and future commercial supplies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">in connection with the chemistry, manufacturing, and controls (CMC) data necessary for our NDA filing and approval, we will need to conduct stability studies and provide stability data to establish appropriate retest or expiration dating period;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">applicable to all future drug substance and drug product batches manufactured, packaged, and stored under similar circumstances, to establish the long-term storage conditions, and to provide evidence of the effect of various environmental conditions on the quality of the drug substance and drug product. Our product candidates may not demonstrate sufficient long-term stability to support an NDA filing or obtain approval, or the product shelf life may be limited by stability results;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">there may be delays in the FDA&#x2019;s ability to conduct necessary Pre-Approval Inspections, or PAIs, due to the COVID-19 pandemic or for other reasons, and more generally the FDA or comparable foreign regulatory authorities may take longer than we anticipate to make a decision on our product candidates; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future competitive therapies in development.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Moreover, if we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials or other testing of our product candidates, if the results of these trials or tests are not positive, or are only modestly positive or if there are safety concerns, we may:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">not obtain marketing approval at all;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired or are not covered by our intellectual property;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions, including restrictions on the intended patient population, or safety warnings, including boxed warnings, contraindications, and precautions, or may not include label statements necessary or desirable for successful commercialization: </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">be subject to additional post&#x2011;marketing testing and surveillance requirements, including REMS; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">have the product removed from the market after obtaining marketing approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our product candidate development costs will also increase if we experience delays in testing or approvals and we may not have sufficient funding to complete the testing and approval process for any of our product candidates. We may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any additional preclinical tests or clinical trials will be required, will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant delays relating to any preclinical studies or clinical trials also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors, or the competitors of our collaborators, to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, such delays may ultimately lead to the denial of marketing approval of any of our product candidates. If any of this occurs, our business, financial condition, results of operations, and prospects will be materially harmed.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. During the course of review, the FDA may also request or require additional CMC, or other data and information, and the development and provision of these data and information may be time consuming and expensive. Furthermore, there is the possibility that the FDA or comparable foreign regulatory authorities have not previously reviewed product candidates for the indications we are pursuing, such as Alzheimer's disease agitation or smoking cessation. As a result, we may experience delays in regulatory approval due to uncertainties in the approval process.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Finally, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications or uses than we request, may contain significant safety warnings, including black box warnings, contraindications, and precautions, may grant approval contingent on the performance of costly post&#x2011;marketing clinical trials, surveillance, or other requirements, including REMS to monitor the safety or efficacy of the product, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of these scenarios could compromise the commercial prospects for our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays in obtaining approval, if we fail to obtain approval of a product candidate or if the label for a product candidate does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate, the commercial prospects for such product candidate may be harmed and our ability to generate revenues from that product candidate will be materially impaired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we cannot demonstrate an acceptable safety and toxicity profile for our product candidates, we will not be able to continue our clinical trials of or obtain approval for those product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In order to obtain approval of a product candidate we must demonstrate safety in various nonclinical tests (including, for example, carcinogenicity studies, drug-drug interaction studies, and toxicity studies), in addition to human clinical trials. At the time of initiating human clinical trials, we may not have conducted or may not conduct all the types of nonclinical testing ultimately required by regulatory authorities, or future nonclinical tests may indicate safety concerns regarding our product candidates. Nonclinical testing and clinical testing are both expensive and time-consuming and have uncertain outcomes. Even if initial tests appear favorable, later testing may have unfavorable results. We may experience numerous unforeseen events during, or as a result of, the testing process, which could delay or prevent our ability to develop or commercialize our product candidates, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our preclinical or nonclinical testing may produce inconclusive or negative safety results, which may require us to conduct additional nonclinical testing or to abandon product candidates; </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our product candidates may have unfavorable pharmacology or toxicity characteristics or suggest possible drug-drug interaction;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our product candidates may cause undesirable side effects; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA or other regulatory authorities may determine that additional safety testing is required.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Any such events would increase our costs and could delay or prevent our ability to commercialize our product candidates, which could adversely impact our business, financial condition and results of operation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA may determine that any of our current or future product candidates have undesirable side effects that could delay or prevent their regulatory approval or commercialization.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Undesirable side effects caused by our product candidates could cause us, IRBs, and other reviewing entities or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. For example, if concerns are raised regarding the safety of a new drug as a result of undesirable side effects identified during clinical or preclinical testing, the FDA may order us to cease further development, decline to approve the drug, or issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve the drug.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The number of requests for additional data or information issued by the FDA in recent years has increased and resulted in substantial delays in the approval of several new drugs. Undesirable side effects caused by any of our current or future product candidates could also result in denial of regulatory approval by the FDA or other comparable foreign authorities for any or all targeted indications or the inclusion of unfavorable information in our product labeling, such as limitations on the indicated uses for which the products may be marketed or distributed, a label with significant safety warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for successful commercialization, or may result in requirements for costly post&#x2011;marketing testing and surveillance, or other requirements, including REMS, to monitor the safety or efficacy of the products, and in turn prevent us from commercializing and generating revenues from the sale of any of our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">To date, the most commonly reported adverse events (incidence of &#x2265;5% of subjects) observed in the completed clinical trials of AXS-05 include dizziness, nausea, headache, dry mouth, and decreased appetite. Some reported adverse events resulted in discontinuations from our trials of AXS-05. The most frequent adverse events (incidence of &#x2265;1% of subjects) resulting in discontinuation included dizziness, nausea, and headache. AXS-05 consists of dextromethorphan and bupropion, and this combination may exacerbate any known adverse events for each individual component or may result in new toxicities as compared to those of the individual components.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">To date, the most commonly reported adverse events observed in the completed clinical trials of AXS-07 include nausea, dizziness, somnolence, and paresthesia. AXS-07 consists of meloxicam and rizatriptan, and this combination may exacerbate any known adverse events for each individual component or may result in new toxicities as compared to those of the individual components.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">To date, the most commonly reported adverse events observed in the completed clinical trial of AXS-12 include anxiety, constipation, and insomnia.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">To date, the most commonly reported adverse events observed in the completed clinical trials of AXS-14 include anxiety, constipation, and insomnia.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If any of our other product candidates are associated with serious adverse events or undesirable side effects or have properties that are unexpected, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk&#x2011;benefit perspective. The drug&#x2011;related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may significantly harm our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to initiate or continue conducting clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#x2019; product candidates. Patient enrollment is affected by other factors including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the size and nature of the patient population;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the severity of the disease under investigation;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the eligibility criteria for, and design of, the clinical trial in question, including factors such as frequency of required assessments, length of the study, and ongoing monitoring requirements;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the perceived risks and benefits of the product candidate under study, including the potential advantages or disadvantages of the product candidate being studied in relation to other available therapies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">competition in recruiting and enrolling patients in clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the patient referral practices of physicians;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">effectiveness of publicity created by clinical trial sites regarding the trial;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">patients&#x2019; ability to comply with the specific instructions related to the trial protocol, proper documentation, and use of the drug product;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">inability to obtain or maintain patient informed consents;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">risk that enrolled patients will drop out before completion;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the ability to identify patients for enrollment and maintain a sufficient level of patient participants in our clinical studies due to the ongoing COVID-19 pandemic;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays which would cause us to miss our projected timelines and could require us to abandon one or more clinical trials altogether. For instance, because we are seeking regulatory approval for certain indications that may have a narrow or small patient population, it may be difficult to find patients eligible to participate in our clinical studies at a sufficient rate or in a sufficient quantity. We may be required by the FDA to modify the entry criteria for our planned Phase 3 clinical trials and these changes may make it more difficult to enroll patients in our clinical trials. Moreover, patients in our clinical trials, especially patients in our control groups, may be at risk for dropping out of our studies if they are not experiencing relief of their symptoms. A significant number of withdrawn patients would compromise the quality of our data.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Enrollment delays or slower periods of enrollment in our clinical trials may result in increased development costs for our product candidates, or the inability to complete development of our product candidates, which would cause the value of our company to decline, limit our ability to obtain additional financing, and materially impair our ability to generate revenues.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Currently approved products containing bupropion are subject to restrictive marketing and distribution regulations, which if applied to our product candidates could restrict their use and potentially reduce our ability to generate profits.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Currently approved products containing bupropion and meloxicam require medication guides. Medication guides can be required independently or as part of REMS programs. REMS programs, in addition to medication guides, may require special communication plans to healthcare professionals, or elements to assure safe use, such as restricted distribution methods, distribution only to certain medical professionals, training for medical professionals prescribing our product candidates, patient registries, or other risk minimization tools. The FDA may determine that our product candidates will require a REMS program in addition to a medication guide. We cannot predict whether that will be required as part of the FDA&#x2019;s approval of our product candidates. Any limitations on approval or marketing could restrict the commercial promotion, distribution, prescription, or dispensing of our product candidates, if approved. If a REMS program is required, depending on the extent of the REMS requirements, the program might significantly increase our costs to commercialize these product candidates or could place a substantial burden on medical professionals, discouraging their use of our product candidates, if approved. Furthermore, risks of our product candidates that are not adequately addressed through proposed REMS or medication guides for such product candidates may also prevent or delay their approval for commercialization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Development of combination product candidates may present more or different challenges than development of single agent product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Certain product candidates of ours including AXS-05 and AXS-07 are combination therapies. A combination therapy is a single drug product that consists of two or more active ingredients, with each component making a contribution to the claimed effect of the drug. The development of combination drugs may be more complex than the development of single agent products and generally requires that sponsors demonstrate the contribution of each component to the claimed effect and the safety and efficacy of the product as a whole. This requirement may make the design and conduct of clinical trials more complex, requiring more clinical trial subjects. We also may not be able to meet the FDA&#x2019;s approval standards required for combination products. The FDA&#x2019;s requirements concerning combination products may change in the future. Moreover, the applicable requirements for approval may differ from country to country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in product candidate manufacturing or formulation may result in additional costs or delay.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As product candidates are developed through preclinical studies to late stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. For instance, as we begin scale-up efforts for commercial-size manufacturing batches, formulation changes may be necessary to improve tablet robustness. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification, or FDA approval. This could delay completion of clinical trials; require the conduct of bridging clinical trials or studies, or the repetition of one or more clinical trials; increase clinical trial costs; delay approval of our product candidates; and jeopardize our ability to commence product sales and generate revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In order to market and sell our products in the European Union, or EU, and many other jurisdictions, we or our third&#x2011;party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, the failure to obtain approval in one jurisdiction may compromise our ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A Fast Track product designation or other designation to facilitate product candidate development may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have received a Fast Track product designation for AXS-05 for both the treatment of TRD as well as for the treatment of AD agitation, and we may seek Fast Track designation for other of our current or future product candidates. Receipt of a designation to facilitate expedited review for product candidate development is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree. In any event, the receipt of such a designation for a product candidate may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that the products no longer meet the designation conditions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Although Breakthrough Therapy, Fast Track, and other designations are designed to expedite the development and review of drugs, they may not ultimately lead to a faster approval process or faster development of regulatory review and they will not increase the likelihood that our product candidates will receive marketing approval, for example, Breakthrough Therapy designation by the FDA for AXS-05 for the treatment of MDD and for the treatment of AD agitation.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We received Breakthrough Therapy designation for AXS-05 for both the treatment of MDD and the treatment of AD agitation. A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Breakthrough Therapy designation also allows the sponsor to request a Priority Review or file sections of the NDA on an ongoing basis for rolling review where the FDA may consider beginning review portions of a marketing application before the full submission is complete. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the NDA.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Designation as a breakthrough therapy is within the discretion of the FDA. The receipt of a Breakthrough Therapy designation for a product candidate may not ultimately result in a faster development process or review, and it does not in any way assure approval of product candidates by the FDA. In addition, the FDA may later decide to rescind the Breakthrough Therapy designation for one or more of our applicable product candidates if such product candidates no longer meet the conditions for qualification of this program. For example, we were initially granted Breakthrough Therapy designation for AXS-12 for the treatment of cataplexy in patients with narcolepsy in August 2020. In July 2021, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the FDA rescinded our Breakthrough Therapy designation due to the FDA approving an additional drug product for the treatment of cataplexy in narcolepsy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory approval is limited by the FDA or comparable foreign regulatory authorities to those specific indications and conditions for which clinical safety and efficacy have been demonstrated, and we may be subject to fines, penalties, injunctions, or other enforcement actions if we are determined to be promoting the use of our products for unapproved or &#x201c;off&#x2011;label&#x201d; uses, resulting in damage to our reputation and business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We, and any of our collaborators, must comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and continuing review by the FDA, Department of Justice, Department of Health and Human Services&#x2019; Office of Inspector General, state attorneys general, members of Congress, and the public. When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited to those specific uses and indications for which a product is approved. If we are not able to obtain FDA approval for any desired uses or indications for our products and product candidates, we may not market or promote our products for those indications and uses, referred to as off&#x2011;label uses, and our business may be adversely affected. We further must be able to sufficiently substantiate any claims that we make for our products including claims comparing our products to other companies&#x2019; products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">While physicians may choose to prescribe drugs for uses that are not described in the product&#x2019;s labeling and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, we are prohibited from marketing and promoting the products for indications and uses that are not specifically approved by the FDA or comparable foreign regulatory authorities. These off&#x2011;label uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States and in many other major markets do not generally restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by pharmaceutical companies concerning off&#x2011;label use.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If we are found to have impermissibly promoted any of our product candidates, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off&#x2011;label uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off&#x2011;label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed. Thus, we and any of our collaborators will not be able to promote any products we develop for indications or uses for which they are not approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In the United States, engaging in the impermissible promotion of our products, following approval, for off&#x2011;label uses can also subject us to false claims and other litigation under federal and state statutes, including fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which we promote or distribute drug products and do business through, for example, corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and debarment from government contracts and refusal of future orders under existing contracts. Recent court decisions have impacted the FDA&#x2019;s enforcement activity regarding off-label promotion in light of First Amendment considerations; however, there are still significant risks in this area in part due to the potential False Claims Act exposure. The False Claims Act allows any individual to bring a lawsuit against a pharmaceutical company on behalf of the federal government alleging submission of false or fraudulent claims, or causing others to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government decides to intervene and prevails in the qui tam lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. Under the False Claims Act, a penalty may be imposed for each false claim, for example, a claim for payment for each prescription for the product, and, when aggregated, these penalties often total millions of dollars and incentivize qui tam lawsuits. These False Claims Act lawsuits against pharmaceutical companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, up to $3.0 billion, pertaining to certain sales practices and promoting off&#x2011;label drug uses. This growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action; pay settlement fines or restitution, as well as criminal and civil penalties; agree to comply with burdensome reporting and compliance obligations; and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If we or our collaborators do not lawfully promote our approved products, if any, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the distribution of product samples to physicians must further comply with the requirements of the U.S. Prescription Drug Marketing Act. If the FDA determines that our promotional materials or activities violate its regulations and policies pertaining to product promotion, it could request that we modify our promotional materials or activities or subject us to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions, or criminal prosecution. These regulatory and enforcement actions could significantly harm our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are, and if any of our product candidates receive regulatory approval, will continue to be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, any of our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Any product candidate for which we obtain marketing approval will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities, including requirements related to the manufacturing processes, post approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, marketing, and promotional activities for such product. These requirements further include submissions of safety and other post-marketing information, including manufacturing deviations and reports; registration and listing requirements; the payment of annual program fees for our product candidates, if approved; continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents; requirements regarding the distribution of samples to physicians and recordkeeping; and GCP, for any clinical trials that we conduct post approval. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses and populations for which the product may be marketed or to the conditions of approval, including significant safety warnings, including boxed warnings, contraindications, and precautions that are not desirable for successful commercialization and any requirement to implement a REMS that render the approved product not commercially viable or other post-market requirements or restrictions. Any such restrictions could limit sales of the product.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We and any of our collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMP and GCP. Application holders must further notify the FDA, and depending on the nature of the change, obtain FDA pre-approval for product and manufacturing changes. Application fees may apply to certain changes.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or that the drug is less effective than previously thought or other problems with our products, manufacturers, or manufacturing processes, or failure to comply with regulatory requirements both before and after approval, may yield various results, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">restrictions on manufacturing or distribution, or marketing of such products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the labeling, including required additional warnings, such as black box warnings, contraindications, precautions, and restrictions on the approved indication or use;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">modifications to promotional pieces;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">requirements to conduct post&#x2011;marketing studies or clinical trials; clinical holds or termination of clinical trials;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">requirements to establish or modify a REMS or a comparable foreign authority may require that we establish or modify a similar strategy, that may, for instance, require us to create or modify a medication guide outlining the risks of the previously unidentified side effects for distribution to patients, or restrict distribution of the product, if and when approved, and impose burdensome implementation requirements on us:</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">changes to the way the drug is administered;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">liability for harm caused to patients or subjects;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">reputational harm;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the drug becoming less competitive;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">warning; or untitled letters;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">suspension of marketing or withdrawal of the products from the market;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information about the drug;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">recall of products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">fines, damages, restitution, or disgorgement of profits or revenues;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">refusal to permit the import or export of our products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">FDA debarment, debarment from government contracts, and refusal of future orders under existing contracts, exclusion from federal healthcare programs, consent decrees, or corporate integrity agreements; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties, including imprisonment.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, or could substantially increase the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating significant revenues from its sale. Any of these events could further have other material and adverse effects on our operations and business and could adversely impact our stock price and could significantly harm our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The FDA&#x2019;s policies may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidates or that could impose additional regulatory obligations on us if our product candidates are approved. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and be subject to regulatory enforcement action.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Should any of the above actions take place, they could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post&#x2011;approval regulations may have a negative effect on our operating results and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Timelines for the review of our regulatory submissions, including our NDA for AXS-05, by the FDA and other regulatory agencies are subject to change and uncertainty, which may delay the potential approval of any product candidates we seek to develop or commercialize.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the timeline for review of submissions to any regulatory authorities or when any of our product candidates will receive marketing approval, if at all. The timeline for regulatory approval can be affected by a variety of factors, including disruptive effects of the COVID-19 pandemic, budget and funding levels, agency staffing, and statutory, regulatory and policy changes.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For example, although the FDA set a PDUFA target action date of August 22, 2021, for our NDA for AXS-05 for the treatment of MDD, its review of our NDA was not completed on such date and remains ongoing. Although we believe that we have addressed all deficiencies known to us related to the NDA in our responses to the FDA, the FDA&#x2019;s review process for the NDA is not yet complete.   Delays or uncertainty in the timing of regulatory action in response to our submissions could adversely impact our development and commercialization efforts and our business prospects.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we obtain approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates are approved for commercialization, we may enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to entering into international business relationships, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">different regulatory requirements for approval of drugs in foreign countries;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the potential for so&#x2011;called parallel importing, particularly within Europe, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market (with low or lower prices) rather than buying them locally with EU laws supporting such &#x201c;free movement of goods&#x201d; within the EU;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">stricter harmonized EU rules on data privacy particularly in relation to health data than is the case in the United States which are being further toughened with the EU General Data Protection Regulation, or the GDPR, which became enforceable beginning May 25, 2018;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">unexpected changes in tariffs, trade barriers, and regulatory requirements and in the health care policies of foreign jurisdictions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States and worker rights tend to be stronger;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">costs of compliance with U.S. laws and regulations for foreign operations, including the Foreign Corrupt Practices Act or comparable foreign regulations, and the risks and costs of noncompliance;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods, and fires.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to obtain FDA approval (and that of comparable foreign regulatory authorities) of any proposed product names, and any failure or delay associated with such approval may adversely affect our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Any name we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the U.S. Patent and Trademark Office, or USPTO. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product name if it believes the name inappropriately implies medical claims or contributes to an overstatement of efficacy. If the FDA objects to any of our proposed product names, we may be required to adopt alternative names for our product candidates. If we adopt alternative names, we would lose the benefit of any existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO THE COMMERCIALIZATION OF OUR PRODUCT CANDIDATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition from other pharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations. Our operating results will suffer if we fail to compete effectively.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of pain and CNS disorders. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Specifically, there are a large number of companies developing or marketing therapies for CNS disorders, including many major pharmaceutical and biotechnology companies. Among the companies that currently market or are developing therapies that, if approved, our product candidates would potentially compete with include: AbbVie Inc.; Amgen Inc.; Avadel Pharmaceuticals plc; Biogen Inc.; Biohaven Pharmaceutical Holding Company Ltd.; Eli Lilly and Company; H. Lundbeck A/S; Harmony Biosciences; Intra-Cellular Therapies, Inc.; Janssen; Jazz Pharmaceuticals plc; Otsuka Pharmaceutical Co. Ltd.; Relmada Therapeutics Inc.; Sage Therapeutics, Inc.; and Takeda Pharmaceutical Company Limited.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, are more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third&#x2011;party payors seeking to encourage the use of generic products or therapeutically similar lower cost brands. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic products, which would further impact our commercialization efforts.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Generic forms of the active ingredients of our product candidates, including zoledronic acid, dextromethorphan, bupropion, meloxicam, rizatriptan, reboxetine, and esomeprazole, are available in the United States and abroad and could be used off-label. Any such off-label use could adversely affect our profitability and have a negative effect on our operating results and financial condition. For example, even though meloxicam is not currently approved for the treatment of acute migraine, we would not be able to prevent a physician from prescribing it for such treatment. Nor could we prevent a payor from offering favorable coverage for such product and disadvantaging our product candidates, even if the generics would be used off-label.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with, or acquisition by large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the FDA or comparable foreign regulatory authorities approve generic or similar versions of any of our products that receive marketing approval, or such authorities do not grant our products appropriate periods of data exclusivity before approving generic or similar versions of our products, the sales of our products could be adversely affected.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Once an NDA is approved, the covered product becomes a &#x201c;reference listed drug&#x201d; in the FDA&#x2019;s Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of ANDAs in the United States. In support of an ANDA, a generic manufacturer need not conduct full clinical studies. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration, and conditions of use or labeling, among other commonalities, as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Recently, the FDA and Congress have also taken steps to encourage increased generic drug competition in the market. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices, and are generally preferred by third&#x2011;party payors. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Moreover, in addition to generic competition, we could face competition from other companies seeking approval of drug products that are similar to ours using the 505(b)(2) pathway. Such applicants may be able to rely on our product candidates, if approved, or other approved drug products or published literature to develop drug products that are similar to ours. The introduction of a drug product similar to our product candidates could expose us to increased competition.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Further, if we do not file a patent infringement lawsuit against a generic manufacturer within 45 days of receiving notice of its paragraph IV certification, the ANDA or 505(b)(2) applicant may not be subject to a 30&#x2011;month stay. Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be expensive and time consuming, may divert our management&#x2019;s attention from our core business, and may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our products. Accordingly, upon approval of our product candidates we may be subject to generic competition or competition from similar products, or may need to commence patent infringement proceedings, which would divert our resources.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We currently anticipate that we may be eligible for three years of non-patent marketing exclusivity in the United States for our product candidates if they are approved. These three years, however, would only protect our modifications in formulation or approved uses in comparison to the reference listed drug and would not prevent other companies from submitting full NDAs, and would not prevent physicians from prescribing other products off-label or third-party payors from reimbursing for them, since providers are not prohibited from prescribing medications for indications other than the approved indications listed on the label. Moreover, a 505(b)(2) applicant could rely on a reference listed drug that is not one of our product candidates, or published literature, in which case any periods of patent or non-patent protection may not prevent FDA making an approval effective.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Competition that our products may face from generic or similar versions of our products could materially and adversely impact our future revenue, profitability, and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">AXS-12 received Orphan Drug Designation from the FDA. However, there is no guarantee that we will receive this designation for any of our other product candidates or receive or maintain any corresponding benefits for any of our other product candidates that may receive Orphan Drug Designation in the future, including periods of exclusivity.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">AXS-12 received Orphan Drug Designation from FDA for the treatment of narcolepsy. We may also seek Orphan Drug Designation for our other product candidates, as appropriate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Orphan Drug Designation, however, may be lost if the indications for which we develop any of our future product candidates do not meet the orphan drug criteria. Moreover, following product approval, orphan drug exclusivity may be lost if the FDA determines, among other reasons, that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. Even if we obtain orphan drug exclusivity for any of our current or future product candidates, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve a product containing the same principal molecular features for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer or more effective or makes a major contribution to patient care.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The FDA or the EMA may grant orphan exclusivity to two different sponsors for the same compound or active molecule and for the same indication. For example, if another sponsor had received FDA approval for a reboxetine&#x2011;containing product for the treatment of narcolepsy before we had obtained FDA approval for AXS&#x2011;12 for the treatment of narcolepsy, we would have been prevented from launching our product in the United States for this indication for a period of at least 7 years. If another sponsor had received EMA approval for a reboxetine&#x2011;containing product for the treatment of narcolepsy before we had obtained EMA approval for AXS&#x2011;12 for the treatment of narcolepsy, we would have been prevented from launching our product in the EU for this indication for a period of at least 10 to 12 years.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The FDA may undertake a reevaluation of aspects of its orphan drug regulations and policies at any time and may possibly do so in response to a recent court decision regarding the plain meaning of the exclusivity provision of the Orphan Drug Act. We do not know if, when, or how the FDA may change the orphan drug regulations and policies, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business, financial condition, results of operations, and prospects could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain FDA approval of an NDA for our product candidates, if we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market, sell and distribute our product candidates, if they are approved, we may be unable to generate product revenues.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We are currently building a commercial infrastructure for the marketing, sale, and distribution of pharmaceutical products, which include the creation of a sales force to launch product candidates throughout the United States. This may require additional compliance with a range of federal and state laws. If we commercialize our product candidates outside the United States, we intend to partner with marketing and sales collaborators, rather than with our own sales force.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have no prior experience in the marketing, sale, and distribution of pharmaceutical products, and there are significant risks involved in the building and managing of a commercial infrastructure. Our role as an NDA holder (if we obtain approval) and a virtual manufacturer along with the establishment and development of our commercial infrastructure, our own sales force, and related compliance plans to market any products we may develop, will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop these capabilities. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train, manage, and retain marketing and sales personnel. In the event we are unable to develop a marketing and sales infrastructure, we may not be able to commercialize any of our current or future product candidates, which would limit our ability to generate product revenues. Factors that may inhibit our efforts to commercialize any of our current or future product candidates on our own include:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any of our current or future product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the inability of sales personnel to travel and/or arrange in-person meetings with physicians due to the ongoing COVID-19 pandemic;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our inability to effectively oversee a geographically dispersed sales and marketing team;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the application of federal and state drug distribution and supply chain requirements to our business;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">an inability to secure adequate coverage and reimbursement by government and private health plans;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications and labeled claims for which the product is approved;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">limitations or warnings, including distribution or use restrictions, contained in the product&#x2019;s approved labeling;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">any distribution and use restrictions imposed by the FDA or to which we agree as part of a mandatory REMS or voluntary risk management plan;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As we build our commercial infrastructure prior to approval of a product candidate by the FDA, we will incur expenses prior to product launch in recruiting this sales force and developing a compliant marketing and sales infrastructure. If a commercial launch is delayed as a result of FDA requirements or other reasons, we would incur these expenses prior to being able to realize any revenue from sales of our product candidates. Even if we are able to effectively hire a sales force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing any of our current or future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our current or future product candidates do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have never commercialized a product candidate for any indication. Even if any of our current or future product candidates are approved by the appropriate regulatory authorities for marketing and sale, it may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If any product candidates for which we obtain regulatory approval do not gain an adequate level of market acceptance, we may not generate significant product revenues or become profitable. Market acceptance of any of our current or future product candidates by the medical community, patients, and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. Even if physicians prescribe our products, third-party payors may not consider them cost effective without a significant price concession, which could negatively impact our revenue. Third-party payors may also implement onerous access controls, which could further impede our efforts to effectively transition eligible patients to our therapies.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of any of our product candidates will depend on a number of factors, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the efficacy of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of adverse events associated with such product candidate;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the product is approved and the approved claims that we may make for the product;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">limitations or warnings contained in the product&#x2019;s FDA&#x2011;approved labeling, including potential limitations or warnings for such product candidate, that may be more restrictive than other competitive products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">changes in the standard of care for the targeted indications for such product candidate, which could reduce the marketing impact of any claims that we could make following FDA approval, if obtained;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the relative convenience and ease of administration of such product candidate;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">cost of treatment versus economic and clinical benefit in relation to alternative treatments or therapies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicare and Medicaid;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the willingness of third-party payors to prefer similar but less expensive products even if not approved for our product&#x2019;s indication;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the extent and strength of our marketing and distribution of such product candidate;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be approved for any of our intended indications;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">distribution and use restrictions imposed by the FDA with respect to such product candidate or to which we agree as part of a mandatory risk evaluation and mitigation strategy or voluntary risk management plan;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of such product candidate, as well as competitive products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to offer such product candidate for sale at competitive prices, including prices that are competitive with generic products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the extent and strength of our third&#x2011;party manufacturer and supplier support;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the approval of other new products for the same indications;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">adverse publicity about the product or favorable publicity about competitive products; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">potential product liability claims.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our efforts to educate the medical community and third&#x2011;party payors on the benefits of our product candidates may require significant resources and may never be successful. Even if the medical community accepts that one of our product candidates is safe and effective for its approved indications, physicians and patients may not immediately be receptive to such product candidate and may be slow to adopt it as an accepted treatment of the approved indication. It is unlikely that any labeling approved by the FDA will contain claims that one of our product candidates is safer or more effective than competitive products or will permit us to promote such product candidate as being superior to competing products. Further, the availability of inexpensive generic forms of pain management products for acute pain may also limit acceptance of certain of our product candidates among physicians, patients, and third&#x2011;party payors. If any of our current or future product candidates is approved but does not achieve an adequate level of acceptance among physicians, patients, and third&#x2011;party payors, we may not generate meaningful revenues from our product candidates, and we may not become profitable.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The ability of patients to purchase certain of the active ingredients of our product candidates in generic form could put us at a competitive disadvantage. For example, in some foreign jurisdictions, generic oral forms of dextromethorphan and bupropion are currently available individually for consumer purchase. In addition, physicians may prescribe generic zoledronic acid for the treatment of pain off&#x2011;label. Any use of these generic forms of the active molecules of our product candidates could adversely affect our business and our results of operations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The potential market opportunities for our product candidates are difficult to precisely estimate. Our estimates of the potential market opportunities are predicated on many assumptions including industry knowledge and publications, third&#x2011;party research reports, and other surveys. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management and are inherently uncertain, and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for any of our current or future product candidates and may have to limit their commercialization.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The use of any of our current or future product candidates in clinical trials, and the sale of any of our product candidates for which we obtain regulatory approval, exposes us to the risk of product liability claims. We face inherent risk of product liability related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any product candidates that we may develop. For example, we may be sued if any product candidate we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. Product liability claims might be brought against us by consumers, healthcare providers, or others using, administering, or selling our products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">significant financial and management resources. Regardless of merit or eventual outcome, liability claims may result in loss of revenue from including from:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for our products and/or product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">impairment of our business reputation or financial stability;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">costs of related litigation;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to patients or other claimants;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">diversion of management attention;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">loss of revenues;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">significant negative media attention;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">decrease in our stock price;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">initiation of investigations and enforcement actions by regulators; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals, or labeling, marketing, or promotional restrictions.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have obtained limited product liability insurance coverage for our products and our clinical trials with a $8.0 million annual aggregate coverage limit. We have also obtained local policies in those foreign jurisdictions where it was appropriate. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage to include the sale of commercial products if we obtain FDA approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing, or at all. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business and our prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials, and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We rely on third&#x2011;party CROs to conduct, supervise, and monitor our preclinical studies and certain clinical trials for our product candidates and do not currently plan to independently conduct preclinical studies or clinical trials of any other potential product candidates. We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct our preclinical studies and clinical trials. While we have agreements governing their activities, we have limited influence over their actual performance and control only certain aspects of their activities. The failure of these third parties to successfully carry out their contractual duties or meet expected deadlines could substantially harm our business because we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all. Moreover, these agreements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that could delay our product development activities and adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on these third parties for development activities will reduce our control over these activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial and for ensuring that our preclinical trials are conducted in accordance with good laboratory practice, or GLP, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with standards, such as GCP for conducting, monitoring, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. As a clinical trial sponsor, we also have regulatory requirements that directly apply to us. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites. If we or any of our CROs fail to comply with applicable GCP, we or our CROs may be subject to enforcement or other legal actions, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, when we submit an NDA for review, we are required to report certain financial interests of our third&#x2011;party investigators if these relationships exceed certain financial thresholds or meet other criteria. The FDA and comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by investigators who previously served or currently serve as scientific advisors or consultants to us from time to time and receive cash compensation in connection with such services or otherwise receive compensation from us that could be deemed to impact study outcome, proprietary interests in a product candidate, certain company equity interests, or significant payments of other sorts.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product candidates that were produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government&#x2011;sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so or to meet the related submission requirements can result in enforcement actions, including civil monetary penalties and adverse publicity.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our CROs may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical, non&#x2011;clinical, and preclinical programs. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed, or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates, or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of third&#x2011;party service providers in the future, our business may be materially and adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If any of our relationships with these third&#x2011;party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the manufacturers upon whom we rely fail to produce our product candidates in the volumes that we require on a timely basis, or to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, our products and may lose potential revenues.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We do not manufacture any of our product candidates, and we do not currently plan to develop any capacity to do so. We currently outsource all manufacturing of our product candidates to third parties typically without any guarantee that there will be sufficient supplies to fulfill our requirements or that we may obtain such supplies on acceptable terms. Any delays in obtaining adequate supplies with respect to our product candidates may delay the development or commercialization of our product candidates. Moreover, we do not yet in all cases have agreements established regarding commercial supply of our product candidates, and we may not be able to establish or maintain commercial manufacturing arrangements on commercially reasonable terms for any of our current or future product candidates for which we obtain approval in the future.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may not succeed in our efforts to establish manufacturing relationships or other alternative arrangements for any of our existing or future product candidates and programs. Our product candidates may compete with other products and product candidates for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing for us and willing to do so. If our existing third&#x2011;party manufacturers, or the third parties that we engage in the future to manufacture a product for commercial sale or for our clinical trials, should cease to continue to do so for any reason, we likely would experience delays in obtaining sufficient quantities of our product candidates for us to meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers. If for any reason we are unable to obtain adequate supplies of our product candidates or the drug substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively. Further, even if we do establish such collaborations or arrangements, our third&#x2011;party manufacturers may breach, terminate, or not renew these agreements.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Any problems or delays we experience in preparing for commercial&#x2011;scale manufacturing of a product candidate may result in a delay in FDA approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and could adversely affect our business. For example, our manufacturers will need to produce specific batches of our product candidates to demonstrate acceptable stability under various conditions and for commercially viable lengths of time. We and our contract manufacturers will need to demonstrate to the FDA and other regulatory authorities that this is acceptable stability data for our product candidates, as well as validate methods and manufacturing processes, in order to receive regulatory approval to commercialize any of our current or future product candidates. Furthermore, if our commercial manufacturers fail to deliver the required commercial quantities of bulk drug substance or finished product on a timely basis and at commercially reasonable prices, we would likely be unable to meet demand for our products and we would lose potential revenues.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have a limited number of contract manufacturers for our products. At times we may have only one manufacturer for a product. In addition, we do not have any long&#x2011;term commitments from our suppliers of clinical trial material or guaranteed prices for our product candidates. The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields; quality control, including stability of the product candidate and quality assurance testing; shortages of qualified personnel; and compliance with strictly enforced federal, state, and foreign regulations. Our manufacturers may not perform as agreed. If our manufacturers were to encounter any of these difficulties, our ability to provide product candidates to patients in our clinical trials and for commercial use, if approved, would be jeopardized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, all manufacturers of our product candidates must comply with cGMP requirements enforced by the FDA and comparable foreign regulatory authorities that are applicable to both finished drug products and active pharmaceutical ingredients used both for clinical and commercial supply, through its facilities inspection program. The FDA must verify our contract manufacturers&#x2019; compliance with cGMP requirements and comparable foreign regulatory authorities will similarly inspect our contract manufacturers&#x2019; facilities after we submit our marketing applications to the agency and comparable foreign regulatory authorities. The cGMP requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our product candidates may be unable to comply with our specifications, these cGMP requirements and with other FDA, state, and foreign regulatory requirements. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure or maintain regulatory approval for their manufacturing facilities. While we are ultimately responsible for the manufacture of our product candidates, other than through our contractual arrangements, we have little control over our manufacturers&#x2019; compliance with these regulations and standards. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or market our product candidates, if approved. A failure to comply with these requirements may result in regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, including imprisonment; suspension or restrictions of production; suspension, delay, or denial of product approval or supplements to approved products; clinical holds or termination of clinical studies; warning or untitled letters; regulatory authority communications warning the public about safety issues with the drug; refusal to permit the import or export of the products; product seizure, detention, or recall; suits under the civil False Claims Act; corporate integrity agreements; consent decrees; or withdrawal of product approval. If the safety of any quantities supplied is compromised due to our manufacturers&#x2019; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Any failure or refusal to supply our product candidates or components for our current or future product candidates that we may develop could delay, prevent, or impair our clinical development or commercialization efforts. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business operations, financial condition, results of operations and cash flows may be adversely affected by the effects of health epidemics, pandemics, or outbreaks of infectious diseases, including the ongoing COVID-19 pandemic.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our business could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business operations and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For example, in December 2019, a novel strain of coronavirus, COVID-19, was identified in Wuhan, China. This virus continues to spread globally and in March 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. The evolving COVID-19 pandemic may impact the pace of enrollment in clinical trials, and we may be affected by similar delays as patients may avoid or may not be able to travel to healthcare facilities and physicians&#x2019; offices unless due to a health emergency and clinical trial staff can no longer get to the clinic. Such facilities and offices have been and may continue to be required to focus limited resources on non-clinical trial matters, including treatment of COVID-19 patients, thereby decreasing availability, in whole or in part, for clinical trial services. In addition, employee disruptions and remote working environments related to the COVID-19 pandemic and the federal, state and local responses to such virus, has impacted and could continue to impact the efficiency and pace with which we work and develop our product candidates and our manufacturing capabilities. In addition, the COVID-19 pandemic has affected and may continue to affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We utilize contract manufacturers to manufacture our investigational products and plan to utilize contract manufacturers if and when we obtain FDA approval. The FDA announced it would resume domestic facility inspections, after a previous temporary delay, and more recently the agency stated that it is transitioning back to standard operations for conducting domestic facility inspections. The agency continues its general suspension of foreign facility inspections (other than &#x201c;mission-critical&#x201d; inspections). Because of the global pandemic, decision-making around facility inspections by the FDA (including Pre-Approval and for cause inspections) continues to evolve. For example, the FDA recently announced an extension to a previous pause on domestic inspections through February 4, 2022, due to the omicron variant of COVID-19, with the goal of restarting inspections as soon as possible. Due to the uncertainty of the COVID-19 pandemic and the FDA&#x2019;s related internal policies, this could impact future applications and approval of product candidates. The FDA has indicated that under certain circumstances it will utilize remote interactive evaluations which include inspection activities &#x201c;in advance of or in lieu of&#x201d; on-site drug inspections. Nevertheless, we cannot predict at this time whether this or other developments will cause delays or cause other situations that may adversely impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The FDA continues to periodically update its guidance, Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency, which was implemented to assist sponsors in assuring the safety of trial participants, maintaining compliance with GCP, and minimizing risks to trial integrity during the COVID-19 Pandemic, or the COVID-19 Guidelines. The policy is intended to remain in effect only for the duration of the public health emergency related to COVID-19 declared by the Department of Health and Human Services on January 31, 2020. We have implemented several procedures in accordance with the COVID-19 Guidelines to address patient safety and clinical trial conduct during the COVID-19 pandemic, including remote monitoring of patients through telemedical visits, remote monitoring of sites by our clinical trial monitors, remote data entry, and follow-up visits at sites other than the site where the patient was initially treated. Our implementation of the COVID-19 Guidelines and potential disruptions to patient follow up, site monitoring or the timely completion of our trials may have a negative effect on our ability to complete trials and associated regulatory filings.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects may have a material impact on our liquidity, capital resources, operations and business and those of the third parties on which we rely and a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. We will continue to monitor the COVID-19 situation closely.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">As an NDA applicant and a potential commercial &#x201c;virtual manufacturer,&#x201d; we may rely in many cases on third parties to perform many essential services for any products that we commercialize, including services related to warehousing and inventory control, distribution, government price reporting, customer service, accounts receivable management, cash collection, and adverse event reporting. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize any of our current or future product candidates will be significantly impacted and we may be subject to regulatory sanctions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may retain third&#x2011;party service providers to perform a variety of functions related to the sale and distribution of any of our current or future product candidates, key aspects of which will be out of our direct control. These service providers may provide key services related to warehousing and inventory control, distribution, government price reporting, customer service, accounts receivable management, and cash collection, and, as a result, most of our inventory may be stored at a single warehouse maintained by one such service provider. If we retain a service provider, we would substantially rely on it as well as other third&#x2011;party providers that perform services for us, including entrusting our inventories of products to their care and handling. If these third&#x2011;party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines, or otherwise do not carry out their contractual duties to us, or encounter physical or natural damage at their facilities, our ability to deliver product to meet commercial demand would be significantly impaired and we may be subject to regulatory enforcement action.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may engage third parties to perform various other services for us relating to adverse event reporting, safety database management, fulfillment of requests for medical information regarding our product candidates and related services. If the quality or accuracy of the data maintained by these service providers is insufficient, or these third parties otherwise fail to comply with regulatory requirements related to adverse event reporting, we could be subject to regulatory sanctions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if a third-party errs in calculating government pricing information from transactional data in our financial records, it could impact our discount and rebate liability and potentially cause government programs to overpay providers for our products, which could expose us to significant False Claims Act liability and other civil monetary penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any collaboration arrangements that we are a party to or may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our business model is to commercialize our product candidates in the United States and generally to seek future collaboration arrangements with pharmaceutical or biotechnology companies, or academic institutions, for the development or commercialization of our product candidates in the rest of the world. For example, in December 2017, we entered into a research collaboration agreement with Duke University for the conduct of a Phase 2 clinical trial of AXS-05 for smoking cessation treatment, which was completed in April 2019. We currently have not entered into any sub&#x2011;license agreements. Our current and future collaboration arrangements may not be successful, and the success of them will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaboration arrangements. For clinical trials of our product candidates being conducted by our collaborators, for example, the Phase 2 clinical trial of AXS-05 for smoking cessation in collaboration with Duke University, we rely on timeline estimates provided by our collaborators for these trials. Such timeline estimates may differ materially from actual trial completion dates. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may license the right to market and sell our product candidates under our collaborators&#x2019; labeler codes. Alternatively, we may enter into agreements with collaborators to market and sell our product candidates under our own labeler code, in which case errors and omissions by collaborators in capturing and transmitting transactional data may impact the accuracy of our government price reporting.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Collaborations with pharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation. Any future collaborations we might enter into may pose a number of risks, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not perform their obligations as expected;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates which achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators could fail to make timely regulatory submissions for a product candidate;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory requirements;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product candidate or product;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation, or the preferred course of development, might cause delays or termination of the research, development, or commercialization of product candidates, lead to additional responsibilities for us with respect to product candidates, or result in litigation or arbitration, any of which would be time consuming and expensive;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If any collaborations we might enter into in the future do not result in the successful development and commercialization of products or if one of our collaborators subsequently terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under the agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates and our product platform.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if any future collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the business and financial communities could be adversely affected.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may in the future determine to collaborate with additional pharmaceutical and biotechnology companies and academic institutions for the development and potential commercialization of any of our current or future product candidates. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for collaboration will depend upon, among other things, our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#x2019;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product platform and our business may be materially and adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are dependent on third parties to decide to utilize our product candidates effectively, including by making them readily available at the point of care throughout their networks of pharmacies.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition to extensive internal efforts, the successful commercialization of our product candidates will require many third parties, over whom we have no control, to decide to utilize our product candidates, and to make them readily available at the point of care throughout their networks of pharmacies. These third parties include HMOs, long term care facilities, and pharmacy benefit managers, or PBMs, which use pharmacy and therapeutics committees, commonly referred to as P&amp;T committees, to make purchasing and reimbursement decisions. Generally, before an HMO or long-term care facility will acquire any of our product candidate for its own pharmacies, or a PBM will pay retail network pharmacies on behalf of its health plans, any such product candidates must be approved for addition to that organization&#x2019;s list of approved drugs, or formulary list, by the organization&#x2019;s P&amp;T committee. An institutional P&amp;T committee typically governs all matters pertaining to the use of medications within the institution, including review of medication formulary data and recommendations for the appropriate use of drugs within the institution to the medical staff. PBM P&amp;T committees develop the criteria for plan beneficiaries to access prescription medication, including such cost control measures as step therapy and prior authorization. The frequency of P&amp;T committee meetings varies considerably, and P&amp;T committees often require additional information to aid in their decision-making process, so we may experience substantial delays in obtaining formulary approvals. Additionally, P&amp;T committees may be concerned that the cost of acquiring any of our product candidates for use in their institutions or reimbursing retail pharmacies outweighs clinical benefits and will resist efforts to add any such product candidate to the formulary or implement restrictions on the usage of the drug in order to control costs. Third-party payors often have tiered formularies in which the non-preferred drugs have significantly higher co-pays, causing prescription rejections, and define therapeutic class broadly to increase competition for preferred status. We cannot guarantee that we will be successful in getting the approvals we need from enough P&amp;T committees quickly enough to maintain and grow sales of any of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO INTELLECTUAL PROPERTY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">It is difficult and costly to protect our proprietary rights and as a result we may not be able to ensure their protection. In addition, patents have a limited lifespan and will eventually expire.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Market exclusivity awarded by the FDA upon the approval of an NDA is limited in scope and duration. Our commercial success will depend in part on obtaining, maintaining, enforcing, and defending against third&#x2011;party challenges, patent and trade secret protection for our current and future product candidates that we may develop, license, or acquire, as well as the related manufacturing methods. We will be able to protect our technologies from unauthorized use by third parties to the extent that the technologies are covered by valid and enforceable patents or trade secrets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, should we enter into additional collaborations we may be required to consult with or cede control to collaborators regarding the prosecution, maintenance, and enforcement of our patent applications and patents. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents has emerged to date in the United States. The patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents and patent applications or in third&#x2011;party patents and patent applications. The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. Moreover, the patent application process is also subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting any of our current or future product candidates that we may develop, license, or acquire by obtaining and defending patents. For example:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">we may not have been the first to conceive of and reduce to practice the inventions covered by each of our pending patent applications and issued patents;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">we may not have been the first to file patent applications for these inventions;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our product candidates or technologies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">it is possible that none of the pending patent applications will result in issued patents;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the issued patents may not cover commercially viable active products, may not provide us with any competitive advantages, or may be successfully challenged by third parties;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">patents of others may have an adverse effect on our business;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">noncompliance with requirements of governmental patent agencies can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction, potentially allowing competitors to enter the market earlier than would otherwise have been the case;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use, and sell our potential product candidates; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of available patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In most countries, including the United States, the expiration of a patent is typically 20 years from the date that the application for the patent is filed. Various extensions of patent term may be available in particular countries; however, in all circumstances the life of a patent, and the protection it affords, has a limited term. If we encounter delays in obtaining regulatory approvals, the period of time during which we could market a product under patent protection could be reduced. We expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents. Such possible extensions include those permitted under the Drug Price Competition and Patent Term Restoration Act of 1984 in the United States, which permits a patent term extension of up to five years to cover an FDA&#x2011;approved product. The actual length of the extension will depend on the amount of patent term lost while the product was in clinical trials. However, the applicable authorities, including the U.S. Patent and Trademark Office, or USPTO and the FDA in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data, and then may be able to launch their product earlier than might otherwise be the case.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#34;first to file&#34; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO and may become involved in post-grant proceedings including reexamination, post-grant review, inter-partes review, or derivation or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding, or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The USPTO has developed regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, did not become effective until March 16, 2013. However, the full impact of the Leahy-Smith Act and the courts' review of any appeals to related proceedings is in its early stages. Accordingly, the full impact that the Leahy-Smith Act will have on the operation of our business is not clear. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, as well as our ability to bring about timely favorable resolution of any disputes involving our patents and the patents of others. Patent applications in the United States are maintained in confidence for at least 18 months after their earliest effective filing date. Consequently, we cannot be certain we were the first to invent or the first to file patent applications of our current or future product candidates that we may develop, license, or acquire. In the event that a third-party has also filed a U.S. patent application relating to our product candidates or a similar invention, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial and it is possible that our efforts would be unsuccessful, resulting in a material adverse effect on our U.S. patent position. The results of these types of proceedings may reduce the scope of, or invalidate, our patent rights, may allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or may result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future product candidates. Such results could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the patentability of claims in pending patent applications covering any of our current or future product candidates can be challenged by third parties during prosecution before the USPTO, for example by third-party observations and derivation proceedings, and the validity of claims in issued patents can be challenged by third parties in various post-grant proceedings such as post-grant review, reexamination, and inter-partes review proceedings. We may incur increased expenses related to the growth of our intellectual property portfolio and to its defense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, we may not have identified all United States and foreign patents or published applications that affect our business either by blocking our ability to commercialize our drugs or by covering similar technologies that affect our drug market. In addition, some countries, including many in Europe, do not grant patent claims directed to methods of treating humans, and in these countries patent protection may not be available at all to protect our product candidates. Even if patents issue, we cannot guarantee that the claims of those patents will be valid and enforceable or provide us with any significant protection against competitive products, or otherwise be commercially valuable to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We also rely on trade secrets to protect our technology, particularly where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. While we use reasonable efforts to protect our trade secrets, our licensors, employees, consultants, contractors, outside scientific collaborators, and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third-party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods, and know-how.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent prosecution process. Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents or patent applications will be due to be paid to the USPTO and various patent agencies outside of the United States in several stages over the lifetime of the patents and applications. We have systems in place to remind us to pay these fees, and we employ and rely on reputable law firms and other professionals to effect payment of these fees to the USPTO and non&#x2011;U.S. patent agencies for the patents and patent applications we own and those that we in&#x2011;license. We also employ reputable law firms and other professionals to help us comply with the various documentary and other procedural requirements with respect to the patents and patent applications that we own and those that we in&#x2011;license. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or any future collaboration partner are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in any litigation would harm our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our ability to develop, manufacture, market, and sell any of our current and future product candidates depends upon our ability to avoid infringing the proprietary rights of third parties, and our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market, and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties, exist in the general field of treatment and management of pain and other CNS disorders and cover the use of numerous compounds and formulations in our targeted markets. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. Because of the uncertainty inherent in any patent or other litigation involving proprietary rights, we and our licensors may not be successful in defending intellectual property claims by third parties, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Regardless of the outcome of any litigation, defending against litigation may be expensive, time consuming, and distracting to management. In addition, because patent applications can take many years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that any of our current or future product candidates may infringe. There could also be existing patents of which we are not aware that any of our current or future product candidates may inadvertently infringe.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If a third-party claims that we infringe their intellectual property rights, we could face a number of issues, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">infringement and other intellectual property claims which, whether meritorious or not, can be expensive and time consuming to litigate and can divert management&#x2019;s attention from our core business;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">substantial damages for past infringement which we may have to pay if a court decides that our product infringes on a competitor&#x2019;s patent;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">a court prohibiting us from selling or licensing our product unless the patent holder licenses the patent to us, which it would not be required to do;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">if a license is available from a patent holder, we may have to pay substantial royalties or grant cross licenses to our patents; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">redesigning our product candidates and processes so they do not infringe, which may not be possible or could require substantial funds and time.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If we are found to infringe a third-party&#x2019;s intellectual property rights, we could be required to obtain a license from such third-party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be non&#x2011;exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe our issued patents, our in-licensed patents, or other intellectual property that we own or in-license. Under the terms of our license agreements with Antecip, if we believe a third-party is infringing on the patents subject to the licenses, we are obligated, at our own expense, to initiate suit against those third parties. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part; construe the patent&#x2019;s claims narrowly; or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Most of our competitors are larger than we are and have substantially greater resources than we do. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, in-license needed technology, or enter into development partnerships that would help us bring our product candidates to market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have licensed and may need to license certain intellectual property from third parties in the future. Such licenses may not be available or may not be available on commercially reasonable terms. Our business may be materially harmed if the licenses are not available or terminated for any reason.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We are a party to certain license agreements under which we are granted rights to intellectual property, including patent rights that are important to our business. We expect that we may need to enter into additional license agreements in the future to commercialize our products, in which case we would be required to obtain a license from additional third parties. Such licenses may not be available on commercially reasonable terms, or at all, which could materially harm our business, financial condition, results of operations, and prospects. We rely on these licenses to use intellectual property that may be material to our business and important or necessary to the development or commercialization of our products. Our existing license agreements impose, and we expect that future license agreements will impose on us, various exclusivity obligations. If we fail to comply with our obligations under these agreements, the applicable licensor may have the right to terminate our license, in which case we may not be able to develop or commercialize the products covered by such license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In January 2020, we entered into an agreement with Pfizer Inc., or Pfizer, for an exclusive U.S. license to Pfizer&#x2019;s clinical and nonclinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which Axsome is developing for the treatment of narcolepsy. The agreement also provides Axsome exclusive rights to develop and commercialize esreboxetine, a new late-stage product candidate now referred to as AXS-14, in the U.S. for the treatment of fibromyalgia. Under the terms of the agreement, we received from Pfizer an exclusive U.S. license to Pfizer data for reboxetine and esreboxetine encompassing a full range of nonclinical studies, and short-term and long-term clinical trials involving more than five thousand patients. The licensed data includes results of a positive Phase 3 trial and a positive Phase 2 trial of esreboxetine in the treatment of fibromyalgia. We will have the exclusive right and sole responsibility of developing AXS-14 (esreboxetine) in the U.S. for the treatment of fibromyalgia and for other indications. Pfizer received 82,019 shares of our common stock having a value of $8.0 million, based on the average closing price of our common stock for the 10 prior trading days of $97.538, in consideration for the license and rights. Pfizer also received an upfront cash payment of $3.0 million and will receive up to $323 million in regulatory and sales milestones, and tiered mid-single to low double-digit royalties on future sales. Pfizer will also have a right of first negotiation on any potential future strategic transactions involving AXS-12 and AXS-14. Under the agreement, we are obligated to use commercially reasonable efforts to develop, manufacture and commercialize the compounds and products in the United States and to seek and maintain regulatory approvals for the compounds and products. The agreement will expire on a product-by-product basis upon expiration of the last-to-expire royalty term for such product. On expiration (but not earlier termination), we will have a perpetual, non-exclusive, fully paid, royalty-free and irrevocable license under the licensed patent rights and related data to develop, manufacture, use, commercialize and otherwise exploit the compounds. Either party may terminate the agreement for the other party&#x2019;s material breach following a cure period. Pfizer may immediately terminate the agreement upon certain insolvency events relating to us. We may terminate the agreement for any reason upon ninety days written notice to Pfizer at any time after the first anniversary of the agreement. If the license agreement with Pfizer is terminated for any reason, our business, financial condition, results of operations, and prospects will be materially harmed.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In 2012, we entered into three exclusive license agreements with Antecip Bioventures II LLC, or Antecip, an entity owned by our Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., in which we were granted exclusive licenses to develop, manufacture, and commercialize Antecip&#x2019;s patents and applications related to the development of AXS-05, as well as two product candidates that are not currently in development, anywhere in the world for human therapeutic, veterinary, and diagnostic use. The agreements were amended in August 2015 to update the schedule of patents and applications subject to the license agreements. Pursuant to the agreements, we are required to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize AXS-05. Under the terms of the agreements, we are required to pay to Antecip a royalty equal to 3.0% for AXS-05, of net sales of products containing the licensed technology by us, our affiliates, or permitted sublicensees. These royalty payments are subject to reduction by an amount up to 50.0% of any required payments to third parties. Unless earlier terminated by a party for cause or by us for convenience, the agreements remain in effect on a product-by-product and country-by-country basis until the later to occur of (1) the applicable product is no longer covered by a valid claim in that country or (2) 10 years from the first commercial sale of the applicable product in that country. Upon expiration of the agreements with respect to a product in a country, our license grant for that product in that country will become a fully paid up, royalty free, perpetual non&#x2011;exclusive license. If Antecip terminates any of the agreements for cause, or if we exercise our right to terminate any of the agreements for convenience, the rights granted to us under such terminated agreement will revert to Antecip. To date, we have not been required to make any payments to Antecip under any of the license agreements. We are dependent upon the license agreements with Antecip and if any of the license agreements with Antecip are terminated for any reason, our business, financial condition, results of operations, and prospects will be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, independent contractors, or consultants have wrongfully used or disclosed alleged trade secrets of their former employers or other third parties.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these individuals or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We rely on trade secrets to protect our proprietary technological advances and know&#x2011;how, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, contractors, outside scientific collaborators, sponsored researchers, and other advisors, including the third parties we rely on to manufacture our product candidates, to protect our trade secrets and other proprietary information. However, any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets. Accordingly, these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Costly and time&#x2011;consuming litigation could be necessary to enforce and determine the scope of our proprietary rights. In addition, others may independently discover our trade secrets and proprietary information. Further, the FDA, as part of its Transparency Initiative, a proposal to increase disclosure and make data more accessible to the public, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#x2019;s disclosure policies may change in the future, if at all. Failure to obtain or maintain trade secret protection could enable competitors to use our proprietary information to develop products that compete with our products or cause additional, material adverse effects upon our competitive business position and financial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We or our licensors may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting, and defending patent applications and patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement rights are not as strong as those in the United States. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our or our licensors&#x2019; intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO LEGAL AND COMPLIANCE MATTERS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with federal, state, and foreign healthcare laws, including fraud and abuse and transparency and health and other data protection, information privacy and security laws, we could face substantial penalties and our business, financial condition, results of operations, and prospects could be adversely affected.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As a pharmaceutical company, we are subject to many federal and state healthcare laws, including those described in the &#x201c;Business&#x2014;Government Regulation and Product Approval&#x201d; section of the filed Annual Report on Form 10&#x2011;K, such as the federal Anti-Kickback Statute, the federal civil and criminal False Claims Act, the civil monetary penalties statute, the Medicaid Drug Rebate statute and other price reporting requirements, the Veterans Health Care Act of 1992, the Physician Payments Sunshine Act, the Foreign Corrupt Practices Act of 1977, the Patient Protection and Affordable Care Act of 2010, and similar state and foreign laws. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid, or other third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#x2019; rights are and will be applicable to our business. We would be subject to healthcare fraud and abuse laws by both the federal government and the states in which we conduct our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns, and some state privacy and security laws apply more broadly than the Health Insurance Portability and Accountability Act (HIPAA) and its implementing regulations. For example, California enacted legislation &#x2013; the California Consumer Privacy Act, or CCPA &#x2013; which went into effect in January 2020. The CCPA, among other things, creates data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Further, many data privacy and security laws within the U.S. have concurrent jurisdiction, which could subject us to enforcement by multiple agencies under multiple statutes for the same conduct (e.g., FTC enforcement under Section 5, HHS-Office for Civil Rights enforcement under HIPAA, and actions by state Attorneys General for violation of applicable state laws).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, EU member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations. Moreover, the collection and use of personal health data in the EU, which was formerly governed by the provisions of the EU Data Protection Directive, was replaced with the EU General Data Protection Regulation, or the GDPR, in May 2018. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU to the U.S., provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#x20ac;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. The GDPR requirements apply not only to third-party transactions, but also to transfers of information between us and our subsidiaries, including employee information. The recent implementation of the GDPR has increased our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#x2019;s attention and increase our cost of doing business. Moreover, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If we or our operations are found to be in violation of any federal or state healthcare, data or information privacy law, or any other governmental regulations that apply to us, we may be subject to penalties, including civil, criminal, and administrative penalties, damages, fines, disgorgement, debarment from government contracts, refusal of orders under existing contracts, exclusion from participation in U.S. federal or state health care programs, corporate integrity agreements, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including our collaborators, is found not to be in compliance with applicable laws, it may be subject to criminal, civil, or administrative sanctions, including but not limited to, exclusions from participation in government healthcare programs, which could also materially affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state fraud laws may prove costly. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the government or third-party payors fail to provide adequate coverage and payment rates for any of our current or future product candidates, or if health maintenance organization (HMOs) or long-term care facilities choose to use therapies that are less expensive, our revenue and prospects for profitability will be limited.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In both domestic and foreign markets, sales of our future products will depend in part upon the availability of coverage and reimbursement from third-party payors. Such third-party payors include government health programs such as Medicare and Medicaid, managed care providers, private health insurers, and other organizations. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Many private payors employ &#x201c;new-to-market blocks&#x201d; for newly launched medications and other products until the payors have had the opportunity to make a coverage decision based upon their internal review of such products. When a medication or other product is not covered, the patient is responsible to pay the full price, which can significantly limit utilization. If reimbursement is not available, or is available only to limited levels, our product candidates may be competitively disadvantaged, and we, or our collaborators, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us, or our collaborators, to establish or maintain a market share sufficient to realize a sufficient return on our or their investments. Alternatively, securing favorable reimbursement terms may require us to compromise pricing and prevent us from realizing an adequate margin over cost.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing, and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Additionally, drug pricing is a key state and federal issue within the U.S., with recent legislation and additional proposals designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare and Medicaid, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. We expect continued focus and pressure on drug pricing going forward. Adverse pricing limitations may hinder our ability or the ability of our collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval. Our ability, and the ability of our collaborators, to commercialize our product candidates will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Regulatory authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Several third-party payors are requiring that drug companies provide them with predetermined discounts from list prices, are using preferred drug lists to leverage greater discounts in competitive classes, are disregarding therapeutic differentiators within classes, and are challenging the prices charged for drugs. Brand drugs without generic equivalents are often included in therapeutic classes with other brands that have generic versions and may be similarly disadvantaged by the availability of low cost alternatives within the class, particularly if a generic version of the same agent is available in another form.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. Further, we believe that future coverage and reimbursement will likely be subject to increased restrictions both in the United States and in international markets. Third-party coverage and reimbursement for our products or product candidates for which we receive regulatory approval may not be available or adequate in either the United States or international markets, which could have a negative effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Assuming coverage is approved, the resulting reimbursement payment rates might not be adequate. If payors subject our product candidates to maximum payment amounts or impose limitations that make it difficult to obtain reimbursement, providers may choose to use therapies which are less expensive or have fewer access restrictions when compared to our product candidates. Additionally, if payors require high copayments, beneficiaries may decline prescriptions and seek alternative therapies. We may need to conduct post-marketing studies in order to demonstrate the cost effectiveness of any future products to the satisfaction of hospitals and other target customers and their third-party payors. Such studies might require us to commit a significant amount of management time and financial and other resources. Our future products might not ultimately be considered cost effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, federal programs impose penalties on manufacturers of drugs marketed under an NDA, including 505(b)(2) drugs, in the form of mandatory additional rebates and/or discounts if commercial prices increase at a rate greater than the Consumer Price Index Urban, and these rebates and/or discounts, which can be substantial, may impact our ability to raise commercial prices. Regulatory authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of our collaborators to sell our product candidates profitably. These payors may not view our products, if any, as cost effective, and coverage and reimbursement may not be available to our customers, or those of our collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost control initiatives could cause us, or our collaborators, to decrease, discount, or rebate a portion of the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If the realized prices for our products, if any, decrease or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our prospects for revenue and profitability will suffer.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">There may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary, by way of example, according to the use of the drug and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Prices paid for a drug also vary depending on the class of trade. Prices charged to government customers are subject to price controls, including ceilings, and private institutions obtain discounts through group purchasing organizations. Net prices for drugs may be further reduced by mandatory discounts or rebates required by government healthcare programs and demanded by private payors. Drugs approved under NDAs, including 505(b)(2) drugs, are subject to greater discounts and reporting obligations under federal programs than drugs approved under ANDAs, and the inflation penalty applicable to these products can equal the selling price. It is also not uncommon for market conditions to warrant multiple discounts to different customers on the same unit, such as purchase discounts to institutional care providers and rebates to the health plans that pay them, which reduces the net realization on the original sale.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We, and our collaborators, cannot be sure that coverage will be available for any product candidate that we, or they, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government funded and private payors for any our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to new legislation, regulatory proposals, and healthcare payor initiatives that may increase our costs of compliance, and adversely affect our ability to market our products, obtain collaborators, and raise capital.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post&#x2011;approval activities, and affect our ability, or the ability of our collaborators, to profitably sell any products for which we obtain marketing approval. It is unclear what impact these various efforts have and will have on our business operations and resulting financial condition. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or our collaborators, may receive for any approved products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For example, there have been numerous attempts by Congress and the former Trump Administration, through legislation and executive orders, to repeal or materially modify various aspects of ACA. In addition, there have been multiple lawsuits challenging the constitutionality of the ACA as well as various components of the ACA. After proceeding through more recent appellate challenges, in June 2021, the Supreme Court upheld the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">It is unclear how regulations and sub-regulatory policy, which fluctuate continually, may affect interpretation and further implementation of the ACA and its practical effects on our business. We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare, including drugs and biologics. Any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations. Furthermore, we anticipate that the Biden Administration will issue a number of Executive Orders, which may alter the policies of the previous administration. Additionally, certain agency rules and policy statements of the prior four years may be rescinded. Further, the Biden Administration may propose substantial changes to the U.S. healthcare system, including expanding government-funded health insurance options. We are uncertain of the impact or outcome of these potential Executive Orders, rescission of rules and policy statements, or new legislation, especially any relative impact on the healthcare regulatory and policy landscape, or the impact they may have on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">While the full effect that the ACA may have on our business continues to evolve, we expect that the ACA, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, increased regulatory burdens and operating costs, decreased net revenue from our pharmaceutical products, decreased potential returns from our development efforts, and additional downward pressure on the price that we receive for any approved drug. There is also an increasing focus on the price of drugs, both at the state and federal levels, and it is likely that additional pricing controls will be enacted and could harm our business, financial condition and results of operations. For instance, states such as California have begun enacting transparency laws aimed at curbing drug price increases and with the change in administration it is possible that President Biden may issue Executive Orders with the potential to change a number of prior executive branch actions on drug pricing. We continue to monitor the potential impact of proposals to lower prescription drug costs at the federal and state level.  For example, under the Biden Administration&#x2019;s Build Back Better Agenda, Medicare negotiation of prescription drug costs with biopharmaceutical companies is proposed to lower prescription drug costs. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Legislative and regulatory proposals may also be made to expand post approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#x2019;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, there have been a number of other legislative and regulatory proposals aimed at changing the pharmaceutical industry. For instance, the enacted Drug Supply Chain Security Act, or DSCSA imposes obligations on manufacturers of prescription drug products for commercial distribution, regulating the distribution of the products at the federal level, and sets certain standards for federal or state registration and compliance of entities in the supply chain (manufacturers and repackagers, wholesale distributors, third-party logistics providers, and dispensers). The DSCSA preempts certain previously enacted state pedigree laws and the pedigree requirements of the Prescription Drug Marketing Act, or PDMA. Trading partners within the drug supply chain must now ensure certain product tracing requirements are met that they are doing business with other authorized trading partners; and they are required to exchange transaction information, transaction history, and transaction statements. Product identifier information (an aspect of the product tracing scheme) is also now required. The DSCSA requirements, development of standards, and the system for product tracing have been and will continue to be phased in over a period of years, with the FDA indicating it would permit certain exemptions and exclusions, and enforcement discretion on certain aspects due to the COVID-19 pandemic, although this situation may continue to evolve. The distribution of product samples continues to be regulated under the PDMA, and some states also impose regulations on drug sample distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Compliance with the federal track and trace requirements may increase our operational expenses and impose significant administrative burdens. As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits, or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In international markets, reimbursement and health care payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In some countries, particularly the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost&#x2011;effectiveness of our product candidate to other available therapies. There can be no assurance that our products will be considered cost&#x2011;effective by third&#x2011;party payors, that an adequate level of reimbursement will be available, or that the third&#x2011;party payors&#x2019; reimbursement policies will not adversely affect our ability to sell our products profitably. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants, commercial partners, principal investigators, or CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, independent contractors, consultants, commercial partners, principal investigators, or CROs could include intentional, reckless, negligent, or unintentional failures to comply with FDA regulations, comply with applicable fraud and abuse laws, provide accurate information to the FDA, report financial information or data accurately, or disclose unauthorized activities to us. This misconduct could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter this type of misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, and results of operations, including the imposition of significant fines or other sanctions. Further, even if we are successful in mounting a defense, we may incur substantial costs in preparing and maintaining our defense and any such action would be time- and resource-intensive and potentially divert management&#x2019;s attention from the business, which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our third&#x2011;party manufacturers may use hazardous materials in the production of our product candidates and if so, they must comply with environmental laws and regulations, which can be expensive and restrict how we or they do business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing activities for the production of our product candidates involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates, and other hazardous compounds. Our third&#x2011;party manufacturers and we are subject to federal, state, and local laws and regulations governing the use, manufacture, storage, handling, release, and disposal of, and exposure to, these hazardous materials. Violation of these laws and regulations could lead to substantial fines and penalties. Although we believe that our safety procedures, and those of our third&#x2011;party manufacturers, for handling and disposing of these materials comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In the event of an accident, state or federal authorities may curtail our use of these materials and interrupt our business operations. In addition, we could become subject to potentially material liabilities relating to the investigation and cleanup of any contamination, whether currently unknown or caused by future releases.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous, or radioactive materials.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. These current or future laws and regulations may impair our research, development, or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR BUSINESS OPERATIONS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to significantly increase the size of our organization, and we may experience difficulties in managing growth. If we are unable to implement appropriate controls and procedures to manage our growth, we will not be able to implement our business plan successfully.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As of April 26, 2022, we had 116 full&#x2011;time employees. We will need to substantially expand our managerial, commercial, financial, manufacturing, and other personnel resources in order to manage our operations and prepare for the commercialization of our product candidates, if approved. Our management, personnel, systems, and facilities currently in place may not be adequate to support this future growth. In addition, we may not be able to recruit and retain qualified personnel in the future, particularly for sales and marketing positions, due to competition for personnel among pharmaceutical businesses, and the failure to do so could have a significant negative impact on our future product revenues and business results. Further, the value to employees of stock options or restricted stock units that vest over time is significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Our need to effectively manage our operations, growth and various projects requires that we:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">continue the hiring and training of personnel for an effective commercial organization in anticipation of the potential approval of our product candidates, and establish appropriate systems, policies and infrastructure to support that organization;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ensure that our consultants and other service providers successfully carry out their contractual obligations, provide high quality results, and meet expected deadlines;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">continue to carry out our own contractual obligations to our licensors and other third parties; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">continue to improve our operational, financial, and management controls, reporting systems, and procedures.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our development and commercialization goals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our continued growth could strain our personnel resources and infrastructure, and if we are unable to implement appropriate controls and procedures to manage our growth, we will not be able to implement our business plan successfully.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As we continue to complete our clinical trials and prepare for commercialization of our product candidates, and as our company continues to grow, we may experience significant strains on our resources, including to our administrative, operational and financial infrastructure, which will result in additional burdens on management. Our success will depend in part upon the ability of our senior management to manage this growth effectively. To do so, we must continue to hire, train and manage new employees as needed. If our new hires perform poorly, or if we are unsuccessful in hiring, training, managing and integrating these new employees, or if we are not successful in retaining our existing employees, our business would be harmed. To manage the expected growth of our operations and personnel, we will need to continue to improve our operational, financial and management controls and our reporting systems and procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may acquire businesses or products, or form strategic alliances in the future, and we may not realize the benefits of such acquisitions or alliances.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing, and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to manage our business effectively if we are unable to attract and retain key personnel.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to attract or retain qualified management and commercial, scientific, and clinical personnel due to the intense competition for qualified personnel among biotechnology, pharmaceutical, and other businesses. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the skills and leadership of our management team, including Dr. Herriot Tabuteau, our Chief Executive Officer and Chairman of the Board. We do not have formal employment agreements with any of our management team. However, we typically enter into offer letters with our executive officers and key personnel. Our senior management may terminate their employment with us at any time. If we lose one or more members of our senior management team, our ability to successfully implement our business strategy could be seriously harmed. Replacing these employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of, and commercialize products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain, or motivate additional key personnel. We do not maintain &#x201c;key person&#x201d; insurance for any of our executives or other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and the Nasdaq Global Market, impose various requirements on public companies, including requiring establishment and maintenance of effective disclosure controls and internal control over financial reporting and changes in corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. Under Section 404(a) of the Sarbanes-Oxley Act, we are required to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This report must include disclosure of any material weaknesses identified by our management during its periodic assessment of our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section 404(b) of the Sarbanes-Oxley Act also requires our independent auditors to attest to, and report on, this management assessment. Ensuring that we have adequate internal controls in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort. If we are not able to comply with the requirements of Section 404 or if we or our independent registered public accounting firm are unable to attest to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities, which would require additional financial and management resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we would be required to implement remediation procedures aimed at mitigating the control weakness or weaknesses. Until such remediation procedures succeed in mitigating the control weakness or weaknesses, we would be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to timely and accurately report our financial condition, results of operations or cash flows. The cost of compliance with Section 404 requires us to incur substantial accounting expense and expend significant management time on compliance related issues as we implement additional corporate governance practices and comply with reporting requirements. Although we currently use the services of a third-party accounting firm to assist us with internal controls, we currently do not have an internal audit group, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Moreover, if we are not able to comply with these requirements in a timely manner or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline, we could lose investor confidence in the accuracy and completeness of our financial reports, and we could be subject to sanctions or investigations by the Nasdaq Global Market, the SEC or other regulatory authorities, which would require additional financial and management resources. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, as discussed above, the Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In particular, Section 404 of the Sarbanes-Oxley Act requires us to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on, and our independent registered public accounting firm to attest to, the effectiveness of our internal control over financial reporting. Pursuant to Section 404, we are required to provide an annual management report on the effectiveness of our internal control over financial reporting and we will also be required to include with such annual report an attestation report on internal controls over financial reporting issued by our independent registered public accounting firm. In the future, our independent registered public accounting firm may issue a report that is adverse in the event that we have not maintained effective internal controls over financial reporting, in all material respects. Any failure to maintain effective disclosure controls and internal control over financial reporting could have a material and adverse effect on our business, results of operations and financial condition and could cause a decline in the trading price of our common stock.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business and operations would suffer in the event of system failures.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Despite our implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development programs. For example, the loss of clinical trial data from completed, ongoing, or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential, or proprietary information, we could incur liability and the further development of any of our product candidates could be delayed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An active trading market for our common stock may not be sustained.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In November 2015, we closed our initial public offering. Prior to our initial public offering, there was no public market for shares of our common stock. Although we have completed our initial public offering and shares of our common stock are listed and trading on The Nasdaq Global Market, an active trading market for our shares may not be sustained. If an active market for our common stock does not continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or sell their shares at or above the prices at which they acquired their shares or sell their shares at the time they would like to sell. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market price of our common stock may be highly volatile.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock is likely to be highly volatile. For example, in 2019, we experienced an extraordinary level of appreciation in our stock price. Such levels of gain are unlikely to continue in the future. For example, throughout the course of fiscal years 2020, 2021, and thus far in 2022, we saw both significant appreciations and depreciations in our stock price. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by many factors, including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">delays in the commencement, enrollment, and ultimate completion, of our planned and ongoing Phase 3 clinical trials for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">any delay or refusal on the part of the FDA in approving an NDA for any of our current and future product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the commercial success of any of our current and future product candidates, if approved by the FDA;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">operating and stock price performance of other companies that investors deem comparable to ours;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">recommendations by securities analysts;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">news relating to our industry as a whole and news relating to trends in our markets;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">results of clinical trials of any of our current and future product candidates or those of our competitors;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated variations in quarterly or annual operating results;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">failure to meet or exceed financial projections we provide to the public, if any;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">failure to meet or exceed the estimates and projections of the investment community, including securities analysts;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">introduction of competitive products or technologies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">changes or developments in laws or regulations applicable to our product candidates;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">general economic and market conditions and overall fluctuations in U.S. equity markets;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">data or security breaches;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">developments concerning our sources of manufacturing supply, warehousing, and inventory control;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments relating to patents or other proprietary rights;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">additions or departures of key scientific or management personnel;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">capital commitments;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">investors&#x2019; general perception of our company and our business;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">announcements and expectations of additional financing efforts, including the issuance of debt, equity or convertible securities;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock, including sales by our directors and officers or significant stockholders;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">changes in the market valuations of companies similar to us;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships, or divestitures;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">general conditions or trends in our industry; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the other factors described in this &#x201c;Risk Factors&#x201d; section.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the stock market in general, and the market for mid-cap pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Further, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#x2019; stocks. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#x2019;s attention and resources from our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. We do not have any control over the equity research analysts that provide research coverage of our common stock or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrades our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our quarterly operating results may fluctuate significantly.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">whether the FDA requires us to complete additional, unanticipated studies, tests, or other activities prior to approving any of our current and future product candidates, which would likely further delay any such approval;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">if any of our current or future product candidates is approved, our ability to establish the necessary commercial infrastructure to launch this product candidate without substantial delays, including hiring sales and marketing personnel and contracting with third parties for warehousing, distribution, cash collection, and related commercial activities;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to identify and enter into third&#x2011;party manufacturing arrangements capable of manufacturing any of our current or future product candidates in commercial quantities;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">our execution of other collaborative, licensing, or similar arrangements and the timing of payments we may make or receive under these arrangements;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">variations in the level of expenses related to our future development programs;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">any product liability or intellectual property infringement lawsuit in which we may become involved;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments affecting our current and future product candidates, or the product candidates of our competitors; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">if any of our current or future product candidates receive regulatory approval, the level of underlying demand for such product candidate and wholesaler buying patterns.</span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If our quarterly or annual operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional funds by issuing securities may cause dilution to existing stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, grants, and license and development agreements in connection with any collaborations. To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#x2019; ownership will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances, or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. Any debt financing we enter into may involve covenants that restrict our operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of our assets as well as prohibitions on our ability to create liens, pay dividends, redeem our stock, or make investments. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and may be able to exert significant control over matters subject to stockholder approval.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As of April 26, 2022, our executive officers, directors, and 5% stockholders and their affiliates beneficially owned an aggregate of approximately 33% of our outstanding common stock. As a result, these stockholders have significant influence and may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This concentration of ownership could delay or prevent any acquisition of our company on terms that other stockholders may desire and may adversely affect the market price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Some of these persons or entities may have interests different than our other stockholders. For example, these stockholders, if they acted together, could significantly influence all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. These stockholders may be able to determine all matters requiring stockholder approval. The interests of these stockholders may not always coincide with our interests or the interests of other stockholders. This may also prevent or discourage unsolicited acquisition proposals or offers for our common stock that other stockholders may feel are in their best interest and our large stockholders may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause our stock price to fall.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise adequate capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As of April 26, 2022, we have outstanding 38,913,550 shares of common stock and 6,998,245 shares of common stock equivalents that would increase the number of common stock outstanding if these instruments were exercised or converted, including stock options to purchase common stock based on vesting requirements and warrants to purchase common stock, as well as outstanding restricted stock units. Of our currently outstanding shares of common stock, 30,911,550 are freely tradable. The remainder of the outstanding shares of common stock are held by our affiliates and may be considered &#x201c;control securities&#x201d; for purposes of Rule 144 under the Securities Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, we have filed one or more registration statements on Form S&#x2011;8 registering the issuance of an aggregate of 10,453,341 shares of common stock subject to options or other equity awards issued or reserved for future issuance under our 2015 Omnibus Incentive Compensation Plan, or the Plan. Shares registered under registration statements on Form S&#x2011;8 will be available for sale in the public market subject to vesting arrangements and exercise of options, the lock&#x2011;up agreements described above and the restrictions of Rule 144 in the case of our affiliates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our management will have broad discretion in the use of the net proceeds from our capital raises, including the proceeds from sales pursuant to our Sales Agreement, and may not use them effectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our management will have broad discretion in the application of the net proceeds from our capital raises, which we refer to as our Capital Raises, including the proceeds from sales pursuant to our March 2022 &#x201c;at-the-market&#x201d; sales agreement with SVB Securities, which provides for the sale of up to $200.0 million of our common stock from time to time, and our stockholders will not have the opportunity as part of their investment decision to assess whether the net proceeds from our Capital Raises are being used appropriately. Our stockholders may not agree with our decisions, and our use of the proceeds may not yield any return on investment for our stockholders. Because of the number and variability of factors that will determine our use of the net proceeds from our Capital Raises their ultimate use may vary substantially from their currently intended use. Our failure to apply the net proceeds of our Capital Raises effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of those net proceeds. Our stockholders will not have the opportunity to influence our decisions on how to use our net proceeds from our Capital Raises. Pending their use, we may invest the net proceeds from our Capital Raises in short-term, investment-grade, interest-bearing instruments and U.S. government securities. These temporary investments are not likely to yield a significant return.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The use of our net operating loss carryforwards and research tax credits may be limited.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our net operating loss carryforwards and any future research and development tax credits may expire and not be used. As of December 31, 2021, we had U.S. federal net operating loss, NOL, carryforwards of approximately $364 million. Net operating loss carry forwards amounting to $60 million generated before the 2018 tax year will start expiring beginning 2032, if we have not used them prior to that time, and the net operating losses of approximately $304 million generated in 2018 and later have an indefinite carryforward period. Net operating loss carry forwards arising in taxable years ending after December 31, 2017, are no longer subject to expiration under the Internal Revenue Code of 1986, as amended, or the Code. Additionally, our ability to use any net operating loss and credit carryforwards to offset taxable income or tax, respectively, in the future will be limited under Sections 382 and 383 of the Code, respectively, if we have a cumulative change in ownership of more than 50% within a three-year period. The completion of our initial public offering, together with our other public and private Capital Raises, and other transactions that have occurred, may trigger, or may have already triggered, such an ownership change. In addition, since we may need to raise additional funding to finance our operations, we may undergo further ownership changes in the future. We have never completed an analysis as to whether such a change of ownership has occurred, but in such an event, we will be limited regarding the amount of net operating loss carryforwards and research tax credits that could be utilized annually in the future to offset taxable income or tax, respectively. Any such annual limitation may significantly reduce the utilization of the net operating loss carryforwards and research tax credits before they expire. In addition, certain states have suspended use of net operating loss carryforwards for certain taxable years, and other states are considering similar measures. As a result, we may incur higher state income tax expense in the future. Depending on our future tax position, continued suspension of our ability to use net operating loss carryforwards in states in which we are subject to income tax could have an adverse impact on our results of operations and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted and signed into law, and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act, among other things, includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act including permitting NOLs, carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The CARES Act provides other reliefs and stimulus measures. We have evaluated the impact of the CARES Act, however, at present we do not expect that any provision of the CARES Act would result in a material cash benefit to us or have a material impact on our financial statements or internal controls over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we do not intend to pay dividends on our common stock, returns for our stockholders will be limited to any increase in the value of our stock.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividends on our capital stock. In addition, the terms of our existing credit facility with Hercules preclude us from paying cash dividends without Hercules&#x2019; consent. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business and do not anticipate declaring or paying any cash dividends on our common stock for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock, if any. Investors seeking cash dividends should not purchase our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">There are provisions in our amended and restated certificate of incorporation and amended and restated bylaws that may make it difficult for a third-party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by you and other stockholders. For example, our board of directors will have the authority to issue up to 10,000,000 shares of preferred stock and to fix the price, rights, preferences, privileges, and restrictions of the preferred stock without any further vote or action by our stockholders. We do not currently have any preferred stock outstanding. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are subject to the anti&#x2011;takeover provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which regulates corporate acquisitions by prohibiting Delaware corporations from engaging in specified business combinations with particular stockholders of those companies. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternate form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, (3) any action asserting a claim arising pursuant to the DGCL, or (4) any other action asserting a claim against us that is governed by the internal affairs doctrine, in each such case subject to such Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees or agents, which may discourage such lawsuits against us and our directors, officers, employees, and agents. Further, this choice of forum provision does not preclude or contract the scope of exclusive federal or concurrent jurisdiction for any actions brought under the Securities Act or the Exchange Act. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Securities Act or any other claim for which the federal and state courts have concurrent jurisdiction. Accordingly, our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition, and results of operations. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Item 6.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibits.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">INDEX OF EXHIBITS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.996%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:90.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit<br />Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.625pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">   </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.625pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">10.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="axsm-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment to Hercules Loan and Security Agreement, dated March 27, 2022, by and among Axsome Therapeutics, Inc., the Lenders who from time to time may be party thereto, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the Lenders.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1579428/000095017022005231/axsm-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Asset Purchase Agreement, dated as of March 25, 2022, between Jazz Pharmaceuticals, plc and Axsome Therapeutics, Inc. (Incorporated by reference, Exhibit 10.1 to the Company&#x2019;s Current Report on Form 8-K, filed March 31, 2022).</span><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">31.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="axsm-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">31.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="axsm-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">32.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="axsm-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Certification of Principal Executive Officer pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">32.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="axsm-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Database Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">**Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><a href="#table_contents"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">SIGNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">TURES</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:51.02%;"></td>
    <td style="width:3.056%;"></td>
    <td style="width:45.924%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">AXSOME THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Date: May 2, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">By</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Herriot Tabuteau, M.D.</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Herriot Tabuteau, M.D.</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Date: May 2, 2022</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">By</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Nick Pizzie</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Nick Pizzie</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>axsm-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Execution Version</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">[Exhibit B intentionally omitted. It is not material and would be competitively harmful if publicly disclosed.]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), dated as of March 27, 2022, is entered into by and among AXSOME THERAPEUTICS, INC., a Delaware corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and the several banks and other financial institutions or entities party hereto as Lender, constituting the Required Lenders and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for Lender (in such capacity, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">A.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower, Lenders and Agent are parties to that certain Loan and Security Agreement, dated as of September 25, 2020, (as amended by the First Amendment to Loan and Security Agreement, dated as of October 14, 2021, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Existing Loan Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;; and the Existing Loan Agreement, as amended by this Amendment and as further amended, restated, supplemented or otherwise modified from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">B.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower, Lenders and Agent desire to modify the terms of the Existing Loan Agreement as set forth in this Amendment. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">SECTION 1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Definitions; Interpretation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Terms Defined in Loan Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Rules of Construction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  The rules of construction that appear in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Section 1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">SECTION 2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amendments to the Loan Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Upon satisfaction of the conditions set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> hereof, the Existing Loan Agreement is hereby amended as follows:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> attached hereto sets forth a clean copy of the Loan Agreement as amended hereby;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> hereto, deletions of the text in the Existing Loan Agreement (including, to the extent included in such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, each Schedule or Exhibit to the Existing Loan Agreement) are indicated by </font><font style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:line-through;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">struck-through text</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and insertions of text are indicated by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">bold, double-underlined text</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">References Within Existing Loan Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  Each reference in the Existing Loan Agreement to &#x201c;this Agreement&#x201d; and the words &#x201c;hereof,&#x201d; &#x201c;herein,&#x201d; &#x201c;hereunder,&#x201d; or words of like import, shall mean and be a reference to the Existing Loan Agreement as amended by this Amendment.  This Amendment shall be a Loan Document.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">SECTION 3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Conditions to Effectiveness of this Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  The effectiveness of this Amendment shall be subject to Agent&#x2019;s receipt of the following documents, in form and substance satisfactory to Agent, or, as applicable, the following conditions being met:</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Agent&#x2019;s receipt of this Amendment, executed by Agent, each Lender and Borrower; </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">on the date hereof, (i) the representations and warranties contained in Section 6 shall be true and correct on and as of the date hereof as though made on and as of such date; and (ii) there exist no Events of Default or events that with the passage of time would result in an Event of Default; </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">an amendment fee equal to $100,000 payable to the Agent on behalf of the Lender on the date hereof.  If the due date of such fee would otherwise fall on a day that is not a Business Day (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amendment Fee Due Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), such fee shall be considered paid on the Amendment Fee Due Date, if received on the next succeeding Business Day; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall have paid (i) all invoiced costs and expenses then due in accordance with Section 8(e), and (ii) all other fees, costs and expenses, if any, due and payable as of the date hereof under the Loan Agreement.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">SECTION 4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Section 2 Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Section 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of this Amendment shall become effective (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) when Agent receives evidence, in form and substance satisfactory to Agent, that all the conditions to effectiveness set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> below have been met which may be delivered at Borrower&#x2019;s discretion; provided that Borrower shall deliver all the conditions to effectiveness set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> below within one Business Day of the effectiveness of that certain Asset Purchase Agreement, dated as of March 25, 2022, by and among Borrower and Jazz Pharmaceuticals PLC with terms and conditions substantially consistent with those represented to Lender as of the date hereof (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Project Light Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">SECTION 5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Conditions to Section 2 Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Section 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of this Amendment shall be subject to Agent&#x2019;s receipt of each of the following documents, in form and substance satisfactory to Agent, or, as applicable, each of the following conditions being met: </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Agent&#x2019;s receipt of  Warrants for each Lender, dated the Second Amendment Effective Date, in form and substance satisfactory to Agent with respect to this Amendment (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Tranche 1B Warrants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a duly executed certificate of an officer of Borrower certifying and attaching copies of (A) the Charter, certified as of a recent date by the jurisdiction of organization of Borrower and as in effect as of the Second Amendment Effective Date; (B) the bylaws of Borrower, as in effect as of the Second Amendment Effective Date; (C) resolutions of Borrower&#x2019;s board of directors evidencing approval of this Amendment, the Tranche 1B Warrants and the Advance to be made on the Second Amendment Effective Date, as such resolutions remain in full force and effect as of the Second Amendment Effective Date; and (D) a schedule setting forth the name, title and specimen signature of officers or other authorized signers on behalf of Borrower; </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a certificate of good standing for Borrower from its jurisdiction of organization; </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">evidence, satisfactory to Agent in its sole discretion of the effectiveness of the Project Light Agreement;</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a perfection certificate, executed by Borrower, in form and substance reasonably satisfactory to Agent;</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a legal opinion of Borrower&#x2019;s counsel in form and substance reasonably acceptable to Agent;</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">such other documents as Agent may reasonably request;</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a California law governed Joinder Agreement, executed by Axsome Malta Ltd., a limited company organized under the laws of Malta (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Malta Subsidiary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Agent, in form and substance reasonably acceptable to Agent;</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a California law governed Joinder Agreement, executed by Axsome International Holdings LLC and Agent, in form and substance reasonably acceptable to Agent;</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a California law governed Amended and Restated Pledge Agreement, executed by Borrower, Axsome International Holdings LLC and Agent, in form and substance reasonably acceptable to Agent; </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall have issued and sold to Agent, between $5,000,000 and $8,000,000 of the Borrower&#x2019;s common stock, at a share price equal to the lesser of (a) the three-day volume weighted average price as of the date hereof or (b) the three-day volume weighted average price as of the Second Amendment Effective Date pursuant to that certain Stock Purchase Agreement, dated the Second Amendment Effective Date, by and between the Borrower and Agent; provided that in no case shall the share price be less than a 20% discount to the three-day volume weighted average price of Borrower&#x2019;s common stock at the time of the purchase;</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On the Second Amendment Effective Date, after giving effect to the amendment of the Existing Loan Agreement contemplated hereby: (i) the representations and warranties contained in Section 6 shall be true and correct </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">on and as of the Second Amendment Effective Date as though made on and as of such date; and (ii) there exist no Events of Default or events that with the passage of time would result in an Event of Default; and</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(m)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall have paid (i) all invoiced costs and expenses then due in accordance with Section 8(e), and (ii) all other fees, costs and expenses, if any, due and payable as of the Second Amendment Effective Date under the Loan Agreement.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">SECTION 6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Representations and Warranties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  To induce Agent and Lender to enter into this Amendment, Borrower hereby confirms, as of the date hereof, (a) that the representations and warranties made by it in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of the Loan Agreement and in the other Loan Documents are true and correct in all material respects; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof and that any representations and warranties made as of a specific date are only true and correct in all material respects as of such date, and that no Event of Default has occurred and is continuing, (b) that no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing and Borrower is not aware of any event likely to occur that is reasonably expected to result in a Material Adverse Effect; (c) that the information included in the Perfection Certificate delivered to Agent on the date hereof is true and correct; (d) Lenders have and shall continue to have valid, enforceable and perfected first-priority liens, subject only to Permitted Liens, on and security interests in the Collateral and all other collateral heretofore granted by Borrower to Lenders, pursuant to the Loan Documents or otherwise granted to or held by Lenders; (e) the agreements and obligations of Borrower contained in the Loan Documents and in this Amendment constitute the legal, valid and binding obligations of Borrower, enforceable against Borrower in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditors&#x2019; rights or by the application of general principles of equity; and (f) the execution, delivery and performance of this Amendment by Borrower will not violate any law, rule, regulation, order, contractual obligation or organizational document of Borrower and will not result in, or require, the creation or imposition of any lien, claim or encumbrance of any kind on any of its properties or revenues.  For the purposes of this Section 6, each reference in Section 5 of the Loan Agreement to &#x201c;this Agreement,&#x201d; and the words &#x201c;hereof,&#x201d; &#x201c;herein,&#x201d; &#x201c;hereunder,&#x201d; or words of like import in such Section, shall mean and be a reference to the Loan Agreement as amended by this Amendment.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">SECTION 7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Post-Closing. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding any provision herein or in the Loan Documents to the contrary, to the extent not actually delivered on or prior to the Second Amendment Effective Date, Borrower shall deliver to Agent:</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Within forty-five (45) days of the Second Amendment Effective Date, (i) a Maltese debenture or security agreement granting a lien in substantially all of the assets of the Malta Subsidiary, (ii) a Maltese law governed bank account pledge agreement in favor of Agent, as applicable, (iii) a Maltese law governed receivables pledge agreement in favor of Agent, as applicable, (iv) a Maltese law governed intellectual property pledge agreement in favor of Agent, as applicable, (v) a customary legal opinion of local Malta counsel for the Malta Subsidiary and (vi) such other documentation relating to such categories of assets as the Borrower and Agent may reasonably agree, in each case, in form and substance satisfactory to Agent in its sole discretion.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">SECTION 8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loan Documents Otherwise Not Affected; Reaffirmation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Except as expressly amended pursuant hereto or referenced herein, the Loan Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects.  Lender&#x2019;s and Agent&#x2019;s execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower hereby expressly (1) reaffirms, ratifies and confirms all Secured Obligations under the Loan Agreement and the other Loan Documents, (2) reaffirms, ratifies and confirms the grant of security under Section 3.1 of the Loan Agreement, (3) reaffirms that such grant of security in the Collateral secures all Secured Obligations under the Loan Agreement, and with effect from (and including) the Second Amendment Effective Date, such grant </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">of security in the Collateral: (x) remains in full force and effect notwithstanding the amendments expressly referenced herein; and (y) secures all Secured Obligations under the Loan Agreement, as amended by this Amendment, and the other Loan Documents, (4) agrees that this Amendment shall be a &#x201c;Loan Document&#x201d; under the Loan Agreement and (5) agrees that the Loan Agreement and each other Loan Document shall remain in full force and effect following any action contemplated in connection herewith.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">This Amendment is not a novation and the terms and conditions of this Amendment shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents.  Nothing in this Amendment is intended, or shall be construed, to constitute an accord and satisfaction of Borrower&#x2019;s Secured Obligations under or in connection with the Loan Agreement and any other Loan Document or to modify, affect or impair the perfection or continuity of Agent&#x2019;s security interest in, (on behalf of itself and the Lenders) security titles to or other liens on any Collateral for the Secured Obligations.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Conditions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of determining compliance with the conditions specified in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Section 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless Agent shall have received notice from such Lender prior to the Second Amendment Effective Date specifying its objection thereto.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  In consideration of the agreements of Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Releasees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and individually as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Releasee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, both at law and in equity, to the extent Borrower has actual knowledge as of the date hereof that it owns, holds, has or claims to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, including, without limitation, for or on account of, or in relation to, or in any way in connection with the Loan Agreement, or any of the other Loan Documents or transactions thereunder or related thereto.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.  Borrower agrees that no fact, event, circumstance, evidence or transaction which Borrower has actual knowledge of could now be asserted or shall affect in any manner the final, absolute and unconditional nature of the release set forth above.  The provisions of this section shall survive payment in full of the Secured Obligations, full performance of all the terms of this Amendment and the other Loan Documents.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">No Reliance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower hereby acknowledges and confirms to Agent and Lenders that Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Costs and Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower agrees to pay to Agent on the date hereof the reasonable out-of-pocket costs and expenses of Agent and Lender party hereto, and the fees and disbursements of counsel to Agent and Lender party hereto in connection with the negotiation, preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the Second Amendment Effective Date. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Binding Effect</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment binds and is for the benefit of the successors and permitted assigns of each party.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Governing Law.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">THE INTERNAL LAWS OF THE STATE OF CALIFORNIA (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THAT WOULD RESULT IN the application of ANY laws OTHER THAN THE LAWS OF THE STATE OF CALIFORNIA), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, REGARDLESS OF THE LOCATION OF THE COLLATERAL.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Complete Agreement; Amendments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Severability of Provisions.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment.  Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loan Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment and the documents related thereto shall constitute a Loan Document.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Electronic Execution of Certain Other Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  The words &#x201c;execution,&#x201d; &#x201c;execute&#x201d;, &#x201c;signed,&#x201d; &#x201c;signature,&#x201d; and words of like import in or related to any document to be signed in connection with this Amendment and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Collateral Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transactions Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">[remainder of page intentionally left blank]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above written.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">BORROWER:</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AXSOME THERAPEUTICS, INC.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Signature:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Herriot Tabuteau, M.D.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Herriot Tabuteau, M.D.</font></p>
  <p style="margin-left:46.667%;text-indent:-33.333%;padding-left:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Title: 	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">[SIGNATURES CONTINUE ON THE NEXT PAGE]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to Second Amendment to Loan and Security Agreement]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129792129.9||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AGENT:</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Signature:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Seth Meyer		</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	Seth Meyer</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Title:		Chief Financial Officer</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">LENDER:</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Signature:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Seth Meyer		</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	Seth Meyer</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Title:		Chief Financial Officer</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Hercules Private CREDIT FUND I L.P.</font></p>
  <p style="margin-left:46.667%;text-indent:-6.667%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By: Hercules Private Global Venture Growth Fund GP I LLC, its general partner</font></p>
  <p style="margin-left:46.667%;text-indent:-6.667%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By: Hercules Adviser LLC, its sole member</font></p>
  <p style="margin-left:46.667%;text-indent:-6.667%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Signature:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Seth Meyer		</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	Seth Meyer</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Title:		Authorized Signatory</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to Second Amendment to Loan and Security Agreement]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129792129.9||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Hercules Private Global Venture Growth Fund I L.P.</font></p>
  <p style="margin-left:46.667%;text-indent:-6.667%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By: Hercules Private Global Venture Growth Fund GP I LLC, its general partner</font></p>
  <p style="margin-left:46.667%;text-indent:-6.667%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By: Hercules Adviser LLC, its sole member</font></p>
  <p style="margin-left:46.667%;text-indent:-6.667%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Signature:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Seth Meyer		</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	Seth Meyer</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Title:		Authorized Signatory</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to Second Amendment to Loan and Security Agreement]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129792129.9||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">See Attached</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">[Exhibit B intentionally omitted. It is not material and would be competitively harmful if publicly disclosed.]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">LOAN AND SECURITY AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 25, 2020 and is entered into by and among </font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">., a Delaware corporation, and each of its Subsidiaries other than Excluded Subsidiaries (individually and collectively referred to as the &#x201c;Borrower&#x201d;), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as the &#x201c;Lenders&#x201d;) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;Agent&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="ole_link4"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">A.	Borrower has requested the Lenders make available to Borrower a loan in an aggregate principal amount of up to Three Hundred Million Dollars ($300,000,000) (the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Term Loan&#x201d;); and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">B.	The Lenders are willing to make the Term Loan on the terms and conditions set forth in this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, Borrower, Agent and the Lenders agree as follows:</font></p>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">DEFINITIONS AND RULES OF CONSTRUCTION</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, the following capitalized terms shall have the following meanings:</font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Account Control Agreement(s)&#x201d; means any agreement entered into by and among the Agent, Borrower and a third party bank or other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which perfects Agent&#x2019;s first priority security interest in the subject account or accounts.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;ACH Authorization&#x201d; means the ACH Debit Authorization Agreement in substantially the form of Exhibit H, which account numbers shall be redacted for security purposes if and when filed publicly by the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;ACH Failure&#x201d; means the failure of the Automated Clearing House (ACH) system to effect a transfer of funds requested by Lender to be used to satisfy all or part of Borrower&#x2019;s obligations to pay principal and interest due hereunder, unless any such failure results from insufficient funds in Borrower&#x2019;s account(s).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Acquisition&#x201d; means any transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in (a) the acquisition of all or substantially all of the assets of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> IF &#34;1&#34; = &#34;1&#34; &#34;WEST\296323106.2&#34; &#34;&#34; WEST\296323106.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">a Person, or any division, line of business or other business unit of another Person, (b) the acquisition of fifty percent (50%) or more of the Equity Interests of any Person, whether or not involving a merger,  consolidation or similar transaction with such other Person, or otherwise causing any Person to become a Subsidiary of Borrower, or (c) the acquisition of, or the right to use, develop or sell (in each case, including through licensing), any product that would constitute a Borrower Product upon acquisition.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Acquisition Deferred Payments&#x201d; means, with respect to an Acquisition, any &#x201c;earnouts,&#x201d; holdbacks, performance based-milestones, royalties, purchase price adjustments, profit sharing arrangements, deferred purchase money amounts, indemnifications, non-competition agreements, incentive payments, and other similar payment obligations, and other contingent obligations and agreements consisting of the adjustment of purchase price or similar adjustments.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Advance(s)&#x201d; means a Term Loan Advance.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Advance Date&#x201d; means the funding date of any Advance.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Advance Request&#x201d; means a request for an Advance submitted by Borrower to Agent in substantially the form of Exhibit A, which account numbers shall be redacted for security purposes if and when filed publicly by the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Affiliate&#x201d; means with respect to any Person (a) any Person that directly or indirectly controls, is controlled by, or is under common control with such Person, (b) any Person directly or indirectly owning, controlling or holding with power to vote ten percent (10%) or more of the outstanding voting securities of such Person, and (c) any Person ten percent (10%) or more of whose outstanding voting securities are directly or indirectly owned, controlled or held by such Person with power to vote such securities.  As used in the definition of &#x201c;Affiliate,&#x201d; the term &#x201c;control&#x201d; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Agreement&#x201d; means this Loan and Security Agreement, as amended from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Amortization Date&#x201d; means November 1, 2025; provided however, (x) if the First Interest Only Extension Conditions are satisfied, then May 1, 2026, and (y) if the Second Interest Only Extension Conditions are satisfied, then November 1, 2026.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Antecip License Agreement&#x201d; means that certain License Agreement, dated as of April 17, 2012 by and between Borrower and Antecip Bioventures II LLC, as amended by the First Amendment to License Agreement dated as of August 21, 2015, as amended by the Antecip Direct Agreement and as may be further amended from time to time pursuant to terms of the Antecip Direct Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Antecip Direct Agreement&#x201d; means that certain Direct Agreement dated as of the date hereof, by and among the Company, Antecip Bioventures II LLC and the Agent (as amended, supplemented or otherwise modified from time to time).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Anti-Corruption Laws&#x201d; means all laws, rules, and regulations of any jurisdiction applicable to Borrower or any of its Affiliates from time to time concerning or relating to bribery or corruption, including without limitation the United States Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010 and other similar legislation in any other jurisdictions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Anti&#x2011;Terrorism Laws&#x201d; means any laws, rules, regulations or orders relating to terrorism or money laundering, including without limitation Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Australian Subsidiary&#x201d; means Axsome Therapeutics Australia Pty Ltd, a company organized under the laws of Australia.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;AXS-05&#x201d; means Borrower&#x2019;s AXS-05 product candidate (bupropion and dextromethorphan) for the treatment of Major Depressive Disorder (MDD) and other indications.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;AXS-05 Milestone&#x201d; means Borrower shall have provided evidence reasonably satisfactory to Agent that the FDA has approved Borrower&#x2019;s New Drug Application for AXS-05 for the treatment of MDD with a label claim that is generally consistent with that sought in Borrower&#x2019;s New Drug Application filing.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;AXS-05 Milestone Date&#x201d; means the date on which the Borrower achieves the AXS-05 Milestone.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;AXS-07&#x201d; means Borrower&#x2019;s AXS-07 product candidate (MoSEIC meloxicam and rizatriptan) for the acute treatment of migraine.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;AXS-07 Milestone&#x201d; means Borrower shall have provided evidence reasonably satisfactory to Agent that the FDA has approved Borrower&#x2019;s New Drug Application for AXS-07 for the acute treatment of migraine with a label claim that is generally consistent with that sought in Borrower&#x2019;s New Drug Application filing.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;AXS-07 Milestone Date&#x201d; means the date on which the Borrower achieves the AXS-07 Milestone.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;AXS-12&#x201d; means Borrower&#x2019;s AXS-12 product candidate (reboxetine) for the treatment of narcolepsy.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;AXS-14&#x201d; means Borrower&#x2019;s AXS-14 product candidate (esreboxetine) for the treatment of fibromyalgia.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Blocked Person&#x201d; means any Person:  (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports &#x201c;terrorism&#x201d; as defined in Executive Order</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No. 13224, or (e) a Person that is named a &#x201c;specially designated national&#x201d; or &#x201c;blocked person&#x201d; on the most current list published by OFAC or other similar list.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Borrower Products&#x201d; means all products currently being designed, manufactured or that are under preclinical or clinical investigation or development by Borrower or which Borrower intends to sell, license, or distribute in the future subject to applicable regulatory approvals including any products under development, collectively, together with all products that have been sold, licensed or distributed by Borrower since its incorporation.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Borrower&#x2019;s Books&#x201d; means Borrower&#x2019;s or any of its Subsidiaries&#x2019; books and records including ledgers, federal, state, local and foreign tax returns, records regarding Borrower&#x2019;s or its Subsidiaries&#x2019; assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Business Day&#x201d; means any day other than Saturday, Sunday and any other day on which banking institutions in the State of California are closed for business.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Cash&#x201d; means all cash, cash equivalents and liquid funds.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Change in Control&#x201d; means any (x) reorganization, recapitalization, consolidation or merger (or similar transaction or series of related transactions) of Borrower, sale or exchange of outstanding shares (or similar transaction or series of related transactions) of Borrower in which the holders of Borrower&#x2019;s outstanding shares immediately before consummation of such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related transactions, retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent), in each case without regard to whether Borrower is the surviving entity or (y) &#x201c;change of control&#x201d;, &#x201c;fundamental change&#x201d;, &#x201c;make-whole fundamental change&#x201d; or any comparable term under and as defined in any indenture governing any Permitted Convertible Debt has occurred.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Closing Date&#x201d; means the date of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Code&#x201d; means the Internal Revenue Code of 1986, as amended.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Common Stock&#x201d; means the Common Stock, $0.0001</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">par value per share, of the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Company IP&#x201d; means any and all of the following, as they exist in and throughout the United States: (a) Current Company IP; (b) improvements, continuations, continuations-in-part, divisions, provisionals or any substitute applications, any patent issued with respect to any of the Current Company IP, any patent right claiming the composition of matter of, or the method of making or using, the Borrower Products in the United States, any reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent; (c) trade secrets or trade secret rights, including any rights to unpatented inventions, know-how, show-how, operating manuals, confidential or proprietary information, research in progress, algorithms, data, databases, data collections, designs, processes, procedures, methods,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">protocols, materials, formulae, drawings, schematics, blueprints, flow charts, models, strategies, prototypes, techniques, and the results of experimentation and testing, including samples, in each case, as specifically related to any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Borrower Products; (d) any and all IP Ancillary Rights specifically relating to any of the foregoing; and (e) regulatory filings, submissions and approvals related to any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Borrower Products and all data provided in any of the foregoing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Contingent Obligation&#x201d; means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any Indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term &#x201c;Contingent Obligation&#x201d; shall not include endorsements for collection or deposit in the ordinary course of business or guaranties of operating leases that do not constitute Indebtedness.  The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement. For the avoidance of doubt, no Permitted Bond Hedge Transaction or Permitted Warrant Transaction will be considered a Contingent Obligation of Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Copyright License&#x201d; means any written agreement granting any right to use any Copyright or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Copyrights&#x201d; means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States of America, any State thereof, or of any other country.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Cross-Default Reference Obligation&#x201d; has the meaning assigned to such term in the definition of &#x201c;Permitted Convertible Debt.&#x201d;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Deposit Accounts&#x201d; means any &#x201c;deposit accounts,&#x201d; as such term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Domestic Subsidiary&#x201d; means any Subsidiary organized under the laws of the United States of America, any State thereof, the District of Columbia, or any other jurisdiction within the United States of America.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Due Diligence Fee&#x201d; means $75,000, which fee has been paid to the Lenders prior to the Closing Date, and shall be deemed fully earned on such date regardless of the early termination of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Equity Interests&#x201d; means, with respect to any Person, the capital stock, partnership or limited liability company interest, or other equity securities or equity ownership interests of such Person.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;ERISA&#x201d; means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Excluded Account&#x201d; means (i) accounts used solely to fund payroll or employee benefits in an aggregate amount not to exceed the then-next two payroll cycles, (ii) any Account (including, for the avoidance of doubt, any cash, cash equivalents, or other property contained therein) to the extent, and for so long as, such Account is pledged and used exclusively to secure performance of obligations arising and permitted under clauses (vi), (xiv) and (xv) of the definition of &#x201c;Permitted Liens&#x201d; and (iii) other Accounts that have a balance not to exceed One Hundred Thousand Dollars ($100,000.00) in the aggregate at any time.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Excluded Subsidiary&#x201d; means (a) the Irish Subsidiary, (b) the Australian Subsidiary, and (c) each Foreign Subsidiary of Borrower designated by Borrower as an &#x201c;Excluded Subsidiary&#x201d;; provided that, in each of the foregoing cases, the Excluded Subsidiary Condition is satisfied with respect to such Subsidiary at all times, and in each case as long as no Excluded Subsidiary owns any Intellectual Property.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Excluded Subsidiary Condition&#x201d; means (a) the aggregate revenues (under GAAP) of all Excluded Subsidiaries does not exceed five percent (5%) of the consolidated revenues (under GAAP) of Borrower and its Subsidiaries; and (b) value of the total assets of all Excluded Subsidiaries does not exceed five percent (5%) of the consolidated total assets of Borrower and its Subsidiaries.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;FDA&#x201d; means the U.S. Food and Drug Administration or any successor thereto.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;FDA Good Manufacturing Practices&#x201d; means the applicable requirements and standards set forth in the Food, Drug, and Cosmetic Act (&#x201c;FDCA&#x201d;) and its implementing regulations (for example, for pharmaceuticals being used in Phase 2 or 3 studies, and commercial pharmaceuticals, 21 C.F.R. Parts 210 and 211) and relevant FDA guidance documents (for example, for pharmaceuticals in Phase 1, FDA guidance entitled &#x201c;CGMP for Phase 1 Investigational Drugs&#x201d;). </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;FDA Laws&#x201d; means all applicable statutes, rules, regulations, standards, guidelines, policies and orders and Requirements of Law administered, implemented, enforced or issued by FDA or any comparable governmental authority.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Federal Health Care Program Laws&#x201d; means collectively, federal Medicare or federal or state Medicaid statutes, Sections 1128, 1128A, 1128B, 1128C or 1877 of the Social Security Act (42 U.S.C. &#167;&#167; 1320a-7, 1320a-7a, 1320a-7b, 1320a-7c, 1320a-7h and 1395nn), the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">6</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;" id="docxtextref103"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">federal TRICARE statute (10 U.S.C. &#167; 1071 et seq.), the civil False Claims Act of 1863 (31 U.S.C. &#167; 3729 et seq.), criminal false claims statutes (e.g., 18 U.S.C. &#167;&#167; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">287</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> and </font><font id="docxtextref104"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1001</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">), the Program Fraud Civil Remedies Act of 1986 (31 U.S.C. &#167; 3801 et seq.), HIPAA, or related regulations or other Requirements of Law that directly or indirectly govern the health care industry, programs of governmental authorities related to healthcare, health care professionals or other health care participants, or relationships among health care providers, suppliers, distributors, manufacturers and patients, and the pricing, sale and reimbursement of health care items or services including the collection and reporting requirements, and the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to the Medicaid Drug Rebate Program (42 U.S.C. &#167; 1396r-8) and any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. &#167; 1395w-3a), the Public Health Service Act (42 U.S.C. &#167; 256b), the VA Federal Supply Schedule (38 U.S.C. &#167; 8126) or under any state pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement, and any successor government programs.</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;First Amendment Closing Date&#x201d; means October 14, 2021.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;First Interest Only Extension Conditions&#x201d; shall mean satisfaction of each of the following events: (a) no default or Event of Default shall have occurred and be continuing; and (b) either the AXS-05 Milestone or the AXS-07 Milestone have been achieved on or prior to October 31, 2025.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Forecast&#x201d; means the projections for Borrower as delivered and accepted by Agent on or before the Second Amendment Closing Date; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, that Borrower may from time to time update the Forecast with a forecast approved by the board of directors of the Borrower, subject to the consent of Agent in its reasonable discretion; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that, it is acknowledged that the Forecast is premised on, among other things, certain assumptions about (i) the effectiveness of the Project Light Agreement and (ii) possible timing of a launch date for AXS-05 and AXS-07 and to the extent the assumed launch dates are deferred or delayed, then, for purposes of this Agreement and the other Loan Documents, the Forecast shall be deemed to be automatically updated and revised to defer the expected dates for receipt or recognition of revenues from AXS-05 and AXS-07, as applicable, by the same amount of time as the deferral or delay of the actual launch dates; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that the Forecast must be updated prior to December 31, 2023 to include projections for 2024 and beyond based on a forecast approved by the board of directors demonstrating reasonable growth rates. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Foreign Subsidiary&#x201d; means any Subsidiary other than a Domestic Subsidiary.</font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;GAAP&#x201d; means generally accepted accounting principles in the United States of America, as in effect from time to time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Hedge Agreement&#x201d; means any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, fuel or mineral or other commodity hedge or exchange agreement or any other agreement or arrangement entered into for non-speculative purposes designated to protect a Person against fluctuation in interest rates, currency exchange rates, commodity or mineral prices.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Indebtedness&#x201d; means (a) all indebtedness for borrowed money or the deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business not past due for more than one hundred eighty (180) days), including reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, (d) equity securities of any Person subject to repurchase or redemption other than at the sole option of such Person, (e) non-contingent &#x201c;earnouts&#x201d;, purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations arising out of purchase and sale contracts but only as and to the extent of the amount required to be reflected as a liability on the balance sheet of such Person in accordance with GAAP, (f) non-contingent obligations to reimburse any bank or Person in respect of amounts paid under a letter of credit, banker&#x2019;s acceptance or similar instrument, and (g) all Contingent Obligations. For the avoidance of doubt no Permitted Bond Hedge Transaction or Permitted Warrant Transaction shall be considered Indebtedness of the Borrower.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Initial Facility Charge&#x201d; means $737,500, which is payable to the Lenders in accordance with Section 4.1(f).</font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Initial Performance Covenant Test Date&#x201d; means the last calendar month of the calendar quarter that is nine months following the earlier of (i) the AXS-05 Milestone Date, (ii) the AXS-07 Milestone Date, or (iii) the Final Closing Date (as defined in the Project Light Agreement).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Insolvency Proceeding&#x201d; means any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other similar relief.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Intellectual Property&#x201d; means all of Borrower&#x2019;s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; mask works; Borrower&#x2019;s applications therefor and reissues, extensions, or renewals thereof; and Borrower&#x2019;s goodwill associated with any of the foregoing, together with Borrower&#x2019;s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Intellectual Property Security Agreement&#x201d; means the Intellectual Property Security Agreement dated as of the Closing Date between the Borrower and Agent, as the same may from time to time be amended, restated, modified or otherwise supplemented.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Investment&#x201d; means (a) any beneficial ownership (including stock, partnership, limited liability company interests, or other securities) of or in any Person, (b) any loan, advance or capital contribution to any Person or (c) any Acquisition.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;IP Ancillary Rights&#x201d; means, with respect to any Copyright, Trademark, Patent, software, trade secrets or trade secret rights, including any rights to unpatented inventions, know-how, show-how and operating manuals, all income, royalties, proceeds and liabilities at any time due or payable or asserted under or with respect to any of the foregoing or otherwise with respect thereto, including all rights to sue or recover at law or in equity for any past, present or future</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">8</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">infringement, misappropriation, dilution, violation or other impairment thereof, and, in each case, all rights to obtain any other intellectual property right ancillary to any Copyright, Trademark, Patent, software, trade secrets or trade secret rights.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Irish Subsidiary&#x201d; is Axsome Therapeutics Limited, a company organized under the laws of Ireland.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;IRS&#x201d; means the United States Internal Revenue Service.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Joinder Agreements&#x201d; means for each Subsidiary (other than an Excluded Subsidiary), a completed and executed Joinder Agreement in substantially the form attached hereto as Exhibit F.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;License&#x201d; means any Copyright License, Patent License, Trademark License or other license of rights or interests.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Lien&#x201d; means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security interest.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Loan&#x201d; means the Advances made under this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Loan Documents&#x201d; means this Agreement, the promissory notes (if any), the ACH Authorization, the Account Control Agreements, the Joinder Agreements, all UCC Financing Statements, the Warrant, the Pledge Agreement, the Intellectual Property Security Agreement, the Antecip Direct Agreement, and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Malta Subsidiary&#x201d; is Axsome Malta Ltd., a company organized under the laws of the Republic of Malta.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Market Capitalization&#x201d; means, as of any date of determination, the product of (a) the number of outstanding shares of Common Stock publicly disclosed in the most recent filing of Borrower with the United States Securities Exchange Commission as outstanding as of such date of determination and (b) the closing price of Borrower&#x2019;s Common Stock (as quoted on Bloomberg L.P.&#x2019;s page or any successor page thereto of Bloomberg L.P. or if such page is not available, any other commercially available source).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Material Adverse Effect&#x201d; means a material adverse effect upon: (i) the business, operations, properties, assets or financial condition of Borrower and its Subsidiaries taken as a whole; or (ii) the ability of Borrower to perform or pay the Secured Obligations in accordance with the terms of the Loan Documents, or the ability of Agent or the Lenders to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii) the Collateral or Agent&#x2019;s Liens on the Collateral or the priority of such Liens.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">9</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Material Agreement&#x201d; means (a) the Antecip License Agreement, (b) that certain license agreement dated as of January 10, 2020 by and between Borrower and Pfizer, Inc., (c) the Project Light Agreement and (d) any other license, agreement or other contractual arrangement whereby Borrower or any of its Subsidiaries is required to transfer, either in-kind or in cash, prior to the Term Loan Maturity Date, assets or property valued (book or market) at more than Ten Million Dollars ($10,000,000.00) in the aggregate.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Material Regulatory Liabilities&#x201d; means (a)(i) any liabilities arising from the violation of Public Health Laws, Federal Health Care Program Laws, and other applicable comparable Requirements of Law, or from any non-routing terms, conditions of or requirements imposed relative to any Registrations (including costs of actions required under applicable Requirements of Law, including FDA Laws and Federal Health Care Program Laws, or necessary to remedy any violation of any terms or conditions applicable to any Registrations), including, but not limited to, withdrawal of approval, recall, revocation, suspension, import detention and seizure of any Borrower Product, and (ii) any loss of recurring annual revenues as a result of any loss, suspension or limitation of any Registrations, which, in the case of the foregoing clauses (i) and (ii), exceed $2,000,000 individually or in the aggregate, or (b) any Material Adverse Effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Maturity Extension Conditions&#x201d; means (i) the Borrower achieves T6M Net Product Revenue of at least 60% of the T6M Net Product Revenue included in the Forecast and (ii) the Borrower notifies the Agent in writing of its desire to extend the Term Loan Maturity Date on or within five (5) Business Days of the third anniversary of the First Amendment Closing Date.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Maximum Term Loan Amount&#x201d; means Three Hundred Million Dollars ($300,000,000).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Net Product Revenue Ratio&#x201d; means, as of any date of determination, the ratio of (a) the outstanding amount of the Term Loan Advances to (b) T3M Net Product Revenue.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;New Drug Application&#x201d; means a new drug application in the United States for authorization to market a product, as defined in the applicable laws and regulations and submitted to the FDA.</font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Non-Disclosure Agreement&#x201d; means that certain Non-Disclosure Agreement by and between Borrower and Agent, dated as of August 11, 2020.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;OFAC&#x201d; is the U.S. Department of Treasury Office of Foreign Assets Control.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;OFAC Lists&#x201d; are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Patent License&#x201d; means any written agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">10</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Patents&#x201d; means all letters patent of, or rights corresponding thereto, in the United States of America or in any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States of America or any other country.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Performance Covenant A&#x201d; means satisfaction of each of the following at all times:  (i) Borrower&#x2019;s Market Capitalization exceeds One Billion Dollars ($1,000,000,000) and (ii) Borrower maintains Qualified Cash in an amount not less than fifty percent (50%) of the sum of the outstanding principal amount of the Term Loan Advances </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> the Qualified Cash A/P Amount.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Performance Covenant B&#x201d; means Borrower at all times maintains Qualified Cash in an amount not less than eighty five percent (85%) of the sum of the outstanding principal amount of the Term Loan Advances</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> plus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> the Qualified Cash A/P Amount.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Performance Covenant C&#x201d; means Borrower achieves T6M Net Product Revenue of at least 60% of the T6M Net Product Revenue included in the Forecast, determined on a quarterly basis.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Permitted Acquisition&#x201d; means: (a) the Acquisition conducted in accordance with the Project Light Agreement and (b) any Acquisition (including by way of merger), in each case located entirely within the United States of America, which is conducted in accordance with the following requirements:</font></p>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">of assets, Equity Interests, businesses, Persons or products engaged in a line of business incidental or related to that of the Borrower or its Subsidiaries or reasonable extensions thereof;</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">unless otherwise agreed by Agent in its sole discretion, if such Acquisition is structured as a stock acquisition, then the Person so acquired shall either (i) become a wholly-owned (other than issuance of shares necessary under local law for the qualification of directors) Subsidiary of Borrower or of a Subsidiary and the Borrower shall comply, or cause such Subsidiary to comply, with 7.13 hereof, as applicable, or (ii) such Person shall be merged with and into Borrower (with the Borrower being the surviving entity);</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">if such Acquisition is structured as the acquisition or in-licensing of assets, such assets shall be acquired by a Borrower, and shall be free and clear of Liens other than Permitted Liens;</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the Borrower shall have delivered to the Lenders not less than ten (10) days (or such shorter period as Agent may agree in its sole discretion) nor more than forty five (45) days prior to the date of such Acquisition, notice of such Acquisition together with pro forma projected financial information, copies of all material documents relating to such acquisition reasonably requested by Agent, and historical financial statements for such acquired entity (to the extent available), division or line of business, in each case in form reasonably satisfactory to the Lenders and demonstrating compliance with the covenants set forth in Section 7.20 hereof on a pro forma basis as if the Acquisition occurred on the first day of the most recent measurement period;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">11</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">both immediately before and after such Acquisition no Default or Event of Default shall have occurred and be continuing; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(vi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the sum of the purchase price of such proposed new Permitted Acquisition (together with all prior Permitted Acquisitions consummated during the term of this Agreement), computed on the basis of total acquisition consideration paid or incurred, or to be paid or incurred, by Borrower with respect thereto (but excluding for such purpose: any unpaid Acquisition Deferred Payments, in each case except to the extent required to be reflected as liabilities on the balance sheet of Borrower), including the amount of Permitted Indebtedness assumed or to which such assets, businesses or business or ownership interest or shares, or any Person so acquired, is subject, shall not be greater than Twenty Five Million Dollars $25,000,000 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> the aggregate amount of Tranche 5 Advances approved by Lenders&#x2019; investment committee for Acquisitions </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">minus </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the aggregate amount of all Acquisition Deferred Payments that have been paid. </font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Permitted Bond Hedge Transaction&#x201d; means any call or capped call option (or substantively equivalent derivative transaction) relating to the Common Stock (or other securities or property following a merger event or other change of the Common Stock) purchased by Borrower in connection with the issuance of any Permitted Convertible Debt and as may be amended in accordance with its terms; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that, the net purchase price of any such call option transaction, less the amount received by Borrower in respect of any Permitted Warrant Transaction in connection with such issuance of Permitted Convertible Debt, shall not exceed 25% of the gross proceeds to Borrower from such issuance of Permitted Convertible Debt; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that the terms, conditions and covenants of each such call option transaction are customary for agreements of such type, as determined in good faith by the board of directors of the Borrower or a committee thereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Permitted Convertible Debt&#x201d; means Indebtedness of the Borrower that is convertible into a fixed number (subject to customary anti-dilution adjustments, &#x201c;make-whole&#x201d; increases and other customary changes thereto) of shares of Common Stock (or other securities or property following a merger event or other change of the Common Stock), cash or any combination thereof (with the amount of such cash or such combination determined by reference to the market price of such Common Stock or such other securities); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that such Indebtedness shall (a) not require any scheduled amortization or otherwise require payment of principal prior to, or have a scheduled maturity date, earlier than, one hundred eighty (180) days after the Term Loan Maturity Date, (b) be unsecured, (c) not be guaranteed by any Subsidiary of Borrower, (d) contain usual and customary subordination terms for underwritten offerings of senior subordinated convertible notes as determined in good faith by the board of directors of the Borrower or a committee thereof, (e) shall specifically designate this Agreement and all Secured Obligations as &#x201c;designated senior indebtedness&#x201d; or similar term so that the subordination terms referred to in clause (d) of this definition specifically refer to such notes as being subordinated to the Secured Obligations pursuant to such subordination terms and (f) be on terms and conditions customary for Indebtedness of such type, as determined in good faith by the board of directors of the Borrower or a committee thereof; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, that any cross-default or cross-acceleration event of default (each howsoever defined) provision contained therein that relates to indebtedness or other payment obligations of Borrower (or any of its Subsidiaries) (such indebtedness or other payment obligations, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Cross-Default Reference Obligation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) contains a cure period of at least thirty (30) </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">12</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">calendar days (after written notice to the issuer of such Indebtedness by the trustee or to such issuer and such trustee by holders of at least 25% in aggregate principal amount of such Indebtedness then outstanding) before a default, event of default, acceleration or other event or condition under such Cross-Default Reference Obligation results in an event of default under such cross-default or cross-acceleration provision.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Permitted Indebtedness&#x201d; means:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness of Borrower in favor of the Lenders or Agent arising under this Agreement or any other Loan Document; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness existing on the Closing Date which is disclosed in Schedule 1A; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness of up to $500,000 outstanding at any time secured by a Lien described in clause (vii) of the defined term &#x201c;Permitted Liens,&#x201d; provided such Indebtedness does not exceed the cost of the Equipment and related software financed with such Indebtedness; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness to trade creditors incurred in the ordinary course of business (other than any trade credit that is past due for more than one hundred eighty (180) days); </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness that also constitutes a Permitted Investment; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(vi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Subordinated Indebtedness; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(vii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness, including reimbursement obligations, in connection with (A) letters of credit, (B) foreign exchange services, ACH Services, and, cash management services (including credit cards, debit cards and similar instruments) and (C)  Hedge Agreements (entered into in order to manage existing or anticipated interest rate, exchange rate or commodity price risks and not for speculative purposes), in each case that may or be unsecured or secured by Cash and issued on behalf of the Borrower or a Subsidiary thereof in an aggregate amount not to exceed $3,000,000 at any time outstanding, </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(viii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">other unsecured Indebtedness in an amount not to exceed $250,000 at any time outstanding, </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(ix)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">intercompany Indebtedness as long as either (A) each of the Subsidiary obligor and the Subsidiary obligee under such Indebtedness is a Subsidiary that has executed a Joinder Agreement, or (B) it is Indebtedness of an Excluded Subsidiary permitted under clause (x) of the definition of Permitted Investments; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(x)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Permitted Convertible Debt not to exceed Five Hundred Million Dollars ($500,000,000) in principal amount at any one time outstanding; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness with respect to a Permitted Royalty Transaction that (a) is subordinated to the Secured Obligations pursuant to a subordination or intercreditor agreement on terms and conditions reasonably satisfactory to Agent, (b) does not have a scheduled maturity date earlier than one hundred eighty (180) days after the Term Loan </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">13</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Maturity Date, (c) is in an aggregate amount not to exceed $250,000,000, and (d) shall specifically designate this Agreement and all Secured Obligations as &#x201c;designated senior indebtedness&#x201d; or similar term so that the subordination terms referred to in clause (a) of this clause specifically refer to such notes as being subordinated to the Secured Obligations pursuant to such subordination terms;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of business;</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xiii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness in respect of surety bonds and other indemnities and similar obligations up to an aggregate amount of Five Hundred Thousand Dollars ($500,000) at any one time outstanding; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xiv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness arising with respect to Borrower&#x2019;s real property lease and operating lease obligations in the ordinary course of Borrower&#x2019;s business; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness in respect of Acquisition Deferred Payments incurred in connection with Permitted Acquisitions;  </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xvi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">extensions, refinancings, renewals, modifications, amendments or restatements of any items of Permitted Indebtedness; provided that the principal amount is not increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be.</font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Permitted Investment&#x201d; means:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Investments existing on the Closing Date which are disclosed in Schedule 1B;</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one year from the date of acquisition thereof currently having a rating of at least A-2 or P-2 from either Standard &amp; Poor&#x2019;s Corporation or Moody&#x2019;s Investors Services, (b) commercial paper maturing no more than one year from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either Standard &amp; Poor&#x2019;s Corporation or Moody&#x2019;s Investors Service, (c) certificates of deposit issued by any bank with assets of at least $500,000,000 maturing no more than one year from the date of investment therein, (d) money market accounts, and (e) Investments permitted by Borrower&#x2019;s Investment Policy and Guidelines dated as of August 2016 and provided to the Agent and Lenders, as amended from time to time; provided that any material amendments thereto have been approved by Agent and the Lenders in their reasonable discretion; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">repurchases of Equity Interests from current or former employees, officers, directors, or consultants of Borrower under the terms of applicable repurchase agreements at the original issuance price of such securities (1) in an aggregate amount not to exceed $250,000 in any fiscal year; provided that no Event of Default has occurred, is continuing or would exist after giving effect to the repurchases or (2) in any amount where the consideration for the repurchase is the cancellation of indebtedness owed by such former employees, officers, directors or consultants to Borrower; </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Investments accepted in connection with Permitted Transfers; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower&#x2019;s business; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(vi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business; provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(vii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by Borrower&#x2019;s board of directors; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(viii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Investments consisting of travel advances and employee relocation loans in the ordinary course of business; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(ix)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Investments in Subsidiaries (including creation of a Subsidiary in anticipation of a proposed Permitted Acquisition); provided that, unless such Subsidiary is an Excluded Subsidiary (after giving pro forma effect to such Investment), each such Subsidiary enters into a Joinder Agreement promptly after its formation by Borrower and execute such other related documents as shall be reasonably requested by Agent; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(x)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Investments in Excluded Subsidiaries to cover ordinary course of business operating and entity maintenance and regulatory (and, if applicable, wind-down and liquidation) costs and expenses in an aggregate amount not to exceed $500,000 in any fiscal year, and other amounts approved in advance in writing by Agent; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">joint ventures or strategic alliances in the ordinary course of Borrower&#x2019;s business consisting of the nonexclusive licensing of technology, the development of technology or the providing of technical support; provided that any cash Investments by Borrower do not exceed $250,000 in the aggregate in any fiscal year; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Permitted Acquisitions;</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xiii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower&#x2019;s entry into (including payments of premiums in connection therewith), and the performance of obligations under, any Permitted Bond Hedge Transactions and Permitted Warrant Transactions in accordance with their terms; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xiv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Hedge Agreements constituting Permitted Indebtedness pursuant to clause (vii) thereof; and </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">additional Investments that do not exceed $250,000 in the aggregate in any fiscal year.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">15</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Permitted Liens&#x201d; means:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens in favor of Agent or the Lenders; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens existing on the Closing Date which are disclosed in Schedule 1C; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens for taxes, fees, assessments or other governmental charges or levies, either not yet delinquent or being contested in good faith by appropriate proceedings diligently conducted; provided, that Borrower maintains adequate reserves therefor on Borrower&#x2019;s Books in accordance with GAAP; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of Borrower&#x2019;s business and imposed without action of such parties; provided, that the payment thereof is not yet delinquent or remain payable without penalty, or that are being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto;</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(vi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the following Liens, to the extent made in the ordinary course of business:  deposits and pledges under worker&#x2019;s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than Liens arising under ERISA or environmental Liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(vii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens on Equipment or software or other intellectual property constituting purchase money Liens and Liens in connection with capital leases securing Indebtedness permitted in clause (iii) of &#x201c;Permitted Indebtedness&#x201d;;  </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(viii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens incurred in connection with Subordinated Indebtedness;</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(ix)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">leasehold interests in leases or subleases and licenses and sublicenses granted in the ordinary course of business and not interfering in any material respect with the business of the licensor; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(x)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">16</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">statutory and common law rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xiii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xiv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(A) Without duplication of any Indebtedness incurred pursuant to clause (vii) of the definition of Permitted Indebtedness, Liens on Cash securing obligations permitted under clause (vii) of the definition of Permitted Indebtedness, and (B) security deposits in connection with real property leases, the combination of (A) and (B) in an aggregate amount not to exceed $3,000,000 at any time; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens solely on any Cash earnest money deposits made by Borrower or any of its Subsidiaries in connection with any letter of intent or purchase agreement that constitutes a Permitted Acquisition in an aggregate amount not to exceed five percent (5%) of the aggregate purchase consideration paid in connection thereto;</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xvi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens solely on the royalty interests purchased pursuant to a Permitted Royalty Transaction and proceeds thereof and Intellectual Property being financed by such facility; </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xvii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Licenses that qualify as Permitted Transfers; and </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(xviii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of the type described in clauses (i) through (xvii) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase.</font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Permitted Royalty Transaction&#x201d; means any synthetic royalty participations (and not royalty purchases or buyouts) with respect to any of AXS-05, AXS-07, AXS-12, AXS-14 and/or any other proprietary assets of the Borrower whereby Borrower receives upfront unrestricted (including, not subject to any redemption, clawback, escrow or similar encumbrance or restriction) net cash proceeds of at least $100,000,000 in exchange for rights to participation payments based on net sales of AXS-05, AXS-07, AXS-12, AXS-14 and/or any other proprietary assets of the Borrower in an amount not to exceed 7.5% of net sales, and on terms (including without limitation, that any security granted in connection with such Permitted Royalty Transaction is limited solely to the respective Intellectual Property being financed by such facility) and with a purchaser satisfactory to Agent.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Permitted Transfers&#x201d; means:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">sales of Inventory in the ordinary course of business, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">17</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(A) licenses and similar arrangements for the use of Intellectual Property in the ordinary course of business that could not result in a legal transfer of title of the licensed property that are non-exclusive or may be exclusive in respects other than territory or may be exclusive as to territory but only as to discreet geographical areas outside of the United States of America in the ordinary course; and (B) the abandonment, permitted lapse, cancellation, termination and/or cessation of any immaterial Company IP that is, in the reasonable judgment of the Borrower, no longer economically practicable, commercially desirable to maintain or useful, in each case, in the conduct of business of the Borrower and its Subsidiaries taken as a whole,</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business, </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">to the extent constituting Transfers, Permitted Liens and Permitted Investments,</font></div></div>
  <div style="margin-left:16.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.999615998463994%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Permitted Royalty Transactions, </font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(vi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the disposition of any Permitted Convertible Debt, any Hedge Agreement or in connection with any Permitted Bond Hedge Transaction or Permitted Warrant Transaction, in each case as permitted hereunder,</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(vii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the use or transfer of Cash in a manner that is not prohibited by the terms of this Agreement or the other Loan Documents and in the ordinary course of business,</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(viii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">transfers by and among the Borrower and any of its Subsidiaries (other than Permitted Investments); provided that (a)(x) such transfers are in the ordinary course of business and (y) with respect to any transfers to an Excluded Subsidiary, such transfers do not involve any transfer of any Intellectual Property and are in an aggregate amount not to exceed $500,000 in any fiscal year or (b) such Subsidiary has entered into a Joinder Agreement and such other documents as shall reasonably be required by Agent, and</font></div></div>
  <div style="margin-left:6.667%;text-indent:10.714%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:10.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:10.7143239797285%;">(ix)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">other transfers of assets having a fair market value of not more than $500,000 in the aggregate in any fiscal year. </font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Permitted Warrant Transaction&#x201d; means any call option, warrant or right to purchase (or substantively equivalent derivative transaction) relating to Common Stock (or other securities or property following a merger event or other change of the Common Stock) and/or cash (in an amount determined by reference to the price of such Common Stock) sold by Borrower substantially concurrently with any purchase by Borrower of a related Permitted Bond Hedge Transaction and as may be amended in accordance with its terms; provided that (x) that the terms, conditions and covenants of each such call option transaction are customary for agreements of such type, as determined in good faith by the board of directors of the Borrower or a committee thereof and (y) such call option transaction would be classified as an equity instrument in accordance with GAAP.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">18</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Person&#x201d; means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Pledge Agreement&#x201d; means the Pledge Agreement dated as of the Closing Date between Borrower and Agent, as the same may from time to time be amended, restated, modified or otherwise supplemented.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Project Light Agreement&#x201d; means that certain Asset Purchase Agreement, dated as of March 25, 2022, by and among Borrower and Jazz Pharmaceuticals PLC, the effectiveness of which is solely conditioned on the early termination or expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Public Health Laws&#x201d; means all Requirements of Law relating to the procurement, development, clinical and non-clinical evaluation, product approval or licensure, manufacture, production, analysis, distribution, dispensing, importation, exportation, use, handling, quality, sale, labeling, promotion, clinical trial registration or post market requirements of any drug, biologic or other product (including, without limitation, any ingredient or component of the foregoing products) subject to regulation under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.) and the Public Health Service Act (42 U.S.C. &#167; 201 et seq.), including without limitation the regulations promulgated by the FDA at Title 21 of the Code of Federal Regulations and all applicable regulations promulgated by the National Institutes of Health (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">NIH</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and codified at Title 42 of the Code of Federal Regulations, and guidance, compliance, guides, and other policies issued by the FDA, the NIH and other comparable governmental authorities.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Qualified Cash&#x201d; means the amount of Borrower&#x2019;s Cash held in accounts subject to an Account Control Agreement in favor of Agent.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Qualified Cash A/P Amount&#x201d; means the amount of Borrower&#x2019;s accounts payable under GAAP not paid after the 180th day following the invoice for such account payable.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Receivables&#x201d; means (i) all of Borrower&#x2019;s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of Credit Rights, and (ii) all customer lists, software, and business records related thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Redemption Conditions&#x201d; means, with respect to any payment of cash in respect of the principal amount of any Permitted Convertible Debt, satisfaction of each of the following events: (a) no Default or Event of Default shall exist or result therefrom, and (b) both immediately before and at all times after such redemption, Borrower&#x2019;s Qualified Cash shall be no less than 150% of the outstanding principal amount of the Secured Obligations plus the Qualified Cash A/P Amount.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Register&#x201d; has the meaning specified in Section 11.7.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Registrations&#x201d; shall mean authorizations, approvals, licenses, permits, certificates, registrations, listings, certificates, or exemptions of or issued by any governmental authority (including marketing approvals, investigational new drug applications, product recertifications, drug manufacturing establishment registration and product listing, pricing and reimbursement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">19</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">approvals, labeling approvals or their foreign equivalent) that are required for the research, development, manufacture, commercialization, distribution, marketing, storage, transportation, pricing, governmental authority reimbursement, use and sale of Borrower Products.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref194"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Regulatory Action&#x201d; means an administrative or regulatory enforcement action, proceeding or investigation, warning letter, untitled letter, Form 483 or similar inspectional observations, other notice of violation letter, recall, seizure, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Section </font><font id="docxtextref195"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">305</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> notice or other similar written communication, or consent decree, issued or required by the FDA or under the Public Health Laws, the NIH or a comparable governmental authority in any other regulatory jurisdiction.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Required Lenders&#x201d; means at any time, the holders of more than 50% of the sum of the aggregate unpaid principal amount of the Term Loans then outstanding.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Requirements of Law&#x201d; means, with respect to any Person, collectively, the common law and all federal, state, provincial, local, foreign, multinational or international laws, statutes, codes, treaties, standards, rules and regulations, guidelines, ordinances, orders, judgments, writs, injunctions, decrees (including administrative or judicial precedents or authorities) and the interpretation or administration thereof by, and other determinations, directives, requirements or requests of, any governmental authority, in each case that are applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Restricted License&#x201d; means any Material Agreement with respect to which Borrower is the licensee (other than over-the-counter software and software that is commercially available to the public) (a) that prohibits or otherwise restricts Borrower from granting a security interest in Borrower&#x2019;s interest in such Material Agreement or any other property, or (b) for which a default under or termination of could reasonably be expected to interfere in any material respect with the Agent&#x2019;s right to sell any Collateral.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Sanctioned Country&#x201d; means, at any time, a country or territory which is the subject or target of any Sanctions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Sanctioned Person&#x201d; means, at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations Security Council, the European Union or any EU member state, (b) any Person operating, organized or resident in a Sanctioned Country or (c) any Person controlled by any such Person.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Sanctions&#x201d; means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or (b) the United Nations Security Council, the European Union or Her Majesty&#x2019;s Treasury of the United Kingdom.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Second Amendment&#x201d; means that certain Second Amendment to Loan and Security Agreement, effective as of the Second Amendment Closing Date, by and among the Borrower, Agent and the Lenders.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">20</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Second Amendment Closing Date&#x201d; means the effective date of the Project Light Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Second Amendment Signing Date&#x201d; means the date on which the Second Amendment is executed by the Borrower, Agent and the Lenders.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Second Interest Only Extension Conditions&#x201d; shall mean satisfaction of each of the following events: (a) no default or Event of Default shall have occurred and be continuing; (b) the AXS-05 Milestone has been achieved; and (c) the AXS-07 Milestone has been achieved on or prior to April 30, 2026.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Secured Obligations&#x201d; means Borrower&#x2019;s obligations under this Agreement and any Loan Document (other than the Warrant), including any obligation to pay any amount now owing or later arising.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Subordinated Indebtedness&#x201d; means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory to Agent in its sole discretion and subject to a subordination agreement in form and substance satisfactory to Agent in its sole discretion.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Subsequent Financing&#x201d; means the closing of any equity financing which becomes effective after the Closing Date in which Borrower receives net cash proceeds in excess of $25,000,000 from the sale and issuance of its Equity Interests for Cash primarily for capital raising purposes and that is broadly marketed to multiple investors, which shall not include any Permitted Convertible Debt offering (or any Permitted Bond Hedge Transaction or Permitted Warrant Transaction) or any issuance or sale by Borrower of its Equity Interests (i) pursuant to benefit plans or arrangements, including under Borrower&#x2019;s equity incentive plans (whether currently in effect or adopted by Borrower after the Closing Date) or otherwise as equity compensation, (ii) as dividends or distributions or upon stock splits, recapitalizations or similar transactions, (iii) pursuant to a merger, consolidation, acquisition, strategic alliance or similar business combination or acquisition, (iv) to banks, funds, equipment or real property lessors or other financial institutions pursuant to a non-convertible debt financing, equipment lease, loan or credit arrangement or commercial leasing transaction entered into for primarily non-equity financing purposes, (v) in connection with strategic transactions, including (A) joint ventures, manufacturing, marketing, OEM, sponsored research, collaboration or distribution arrangements or (B) technology transfer or development arrangements, (vi) securities issued or issuable to suppliers or third party service providers in connection with the provision of goods or services, (vii) in an at-the-market (ATM) offering, and (viii) securities issued in connection with options, warrants, convertible securities or other arrangement in existence on the Closing Date or issued in transactions excluded from the definition of Subsequent Financing pursuant to clause (i) through (vii) above; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, that, if Borrower or its agents attempts to &#x201c;wall-cross&#x201d; the Lender or its assignee or nominee in conjunction with any Subsequent Financing and the Lender or its assignee or nominee declines to be &#x201c;wall-crossed,&#x201d; then the issuance and sale of such equity securities shall not be considered a Subsequent Financing hereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">21</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Subsidiary&#x201d; means an entity, whether a corporation, partnership, limited liability company, joint venture or otherwise, in which Borrower owns or controls 50% or more of the outstanding voting securities, including each entity listed on Schedule 1 hereto.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;T3M Net Product Revenue&#x201d; means Borrower&#x2019;s net product revenue (as determined in accordance with GAAP) solely from the sale of AXS-05, AXS-07, AXS-12, AXS-14, any products acquired pursuant to the Project Light Agreement and any other proprietary assets of the Borrower (which may include royalty, profit sharing, or sales-based milestone revenue recognized in accordance with GAAP, but which shall not include any upfront or non-sales-based milestone payments under business development or licensing transactions), measured on a trailing three-month basis as of the date of the most recently delivered monthly financial statement in accordance with Section 7.1(a). For the avoidance of doubt, net product revenue shall not include any of the following to the extent not recognizable as revenue in accordance with GAAP (i) trade, quantity and cash discounts allowed by Borrower, (ii) discounts, refunds, rebates, charge backs, retroactive price adjustment and any other allowances which effectively reduce net selling price, (iii) product returns and allowances, (iv) allowances for shipping or other distribution expenses, (v) set-offs and counterclaims, and (vi) any other similar and customary deductions that are typically deducted from gross revenue and not included in net revenue in accordance with GAAP. Notwithstanding anything to the contrary herein, T3M Net Product Revenue shall not include any royalty payments associated with a Permitted Royalty Transaction or otherwise.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;T6M Net Product Revenue&#x201d; means Borrower&#x2019;s net product revenue (as determined in accordance with GAAP) solely from the sale of AXS-05, AXS-07 and any products acquired pursuant to the Project Light Agreement (which may include royalty, profit sharing, or sales-based milestone revenue recognized in accordance with GAAP, but which shall not include any upfront or non-sales-based milestone payments under business development or licensing transactions), measured on a trailing six-month basis as of the date of the most recently quarterly financial statement filed with its most recent 10-Q filing. For the avoidance of doubt, net product revenue shall not include any of the following to the extent not recognizable as revenue in accordance with GAAP (i) trade, quantity and cash discounts allowed by Borrower, (ii) discounts, refunds, rebates, charge backs, retroactive price adjustment and any other allowances which effectively reduce net selling price, (iii) product returns and allowances, (iv) allowances for shipping or other distribution expenses, (v) set-offs and counterclaims, and (vi) any other similar and customary deductions that are typically deducted from gross revenue and not included in net revenue in accordance with GAAP.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Taxes&#x201d; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any governmental authority, including any interest, additions to tax or penalties applicable thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Term Commitment&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to the Borrower in a principal amount not to exceed the amount set forth under the heading &#x201c;Term Commitment&#x201d; opposite such Lender&#x2019;s name on Schedule 1.1.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Term Loan Advance&#x201d; means each Tranche 1 Advance, Tranche 2 Advance, Tranche 3 Advance, Tranche 4 Advance, Tranche 5 Advance and any other Term Loan funds advanced under this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">22</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Term Loan Cash Interest Rate&#x201d; means for any day a per annum rate of interest equal to the greater of either (i) the prime rate as reported in The Wall Street Journal plus 5.70%, and (ii) 8.95% but in no event greater than 10.70%.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Term Loan Maturity Date&#x201d; means October 1, 2026; provided however, if on or within five (5) Business Days of the third anniversary of the First Amendment Closing Date the Maturity Extension Conditions are satisfied, then, October 1, 2027; provided further that if such day is not a Business Day, the Term Loan Maturity Date shall be the immediately preceding Business Day.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Trademark License&#x201d; means any written agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Trademarks&#x201d; means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States of America, any State thereof or any other country or any political subdivision thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 1A Commitment&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 1A Term Commitment&#x201d; opposite such Lender&#x2019;s name on Schedule 1.1.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 1B Facility Charge&#x201d; means three-quarter percent (0.75%) of the Tranche 1B Advances funded, which is payable to the Lenders in accordance with Section 4.2(d).</font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 1B Commitment&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 1B Term Commitment&#x201d; opposite such Lender&#x2019;s name on Schedule 1.1.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 2B Draw Period&#x201d; means the period beginning on the AXS-05 Milestone Date and ending on, as of the applicable date of determination, (A) if the full amount of the Tranche 2A Advances have not been drawn, the earlier of (x) 181 days following the AXS-05 Milestone Date and (y) March 31, 2023 and (B) if the full amount of the Tranche 2A Advances have been drawn, March 31, 2023.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 2C Advance Aggregate Amounts Facility Charge&#x201d; means $300,000, which is payable to the Lenders in accordance with Section 4.2(j).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 2C Availability Conditions&#x201d; means (i) that the Tranche 2C Draw Period has expired without Borrower requesting a Tranche 2C Advance, and (ii), if the Tranche 2C Advance Aggregate Amounts are to be added to the Tranche 4 Advances, (x) the Tranche 4 Draw Conditions have been met and (y) the Tranche 2C Advance Aggregate Amounts Facility Charge has been paid in accordance with Section 2.2(vii).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">23</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 2C Draw Period&#x201d; means the period beginning on the AXS-05 Milestone Date and ending on, December 31, 2023 and subject to approval by the Lenders&#x2019; investment committee in its sole and unfettered discretion based on the launch of AXS-05 and other factors.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 2 Facility Charge&#x201d; means three-quarter percent (0.75%) of the Tranche 2 Advances funded, which is payable to the Lenders in accordance with Section 4.2(e).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 3B Advance Facility Charge&#x201d; means $50,000, which is payable to the Lenders in accordance with Section 4.2(k).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 3B Availability Conditions&#x201d; means (i) that the Tranche 3B Draw Period has expired without Borrower requesting the Tranche 3B Advance, and (ii), if the Tranche 3B Advance is to be added to the Tranche 4 Advances, (x) the Tranche 4 Draw Conditions have been met and (y) the Tranche 3B Advance Facility Charge has been paid in accordance with Section 2.2(viii).  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 3B Draw Period&#x201d; means the period beginning on the AXS-07  Milestone Date and ending on, December 31, 2023 and subject to approval by the Lenders&#x2019; investment committee in its sole and unfettered discretion based on the launch of AXS-07 and other factors. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">17.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 3 Facility Charge&#x201d; means three-quarter percent (0.75%) of the Tranche 3 Advances funded, which is payable to the Lenders in accordance with Section 4.2(f).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">18.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 4 Draw Conditions&#x201d; means (i) Borrower&#x2019;s achievement of the AXS-05 Milestone or the AXS-07 Milestone and (ii) both before and after giving effect to any such Tranche 4 Advance, (a) the Net Product Revenue Ratio shall be no greater than 4.00:1.00 and (b) no Default or Event of Default shall have occurred and be continuing.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">19.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 4 Facility Charge&#x201d; means (i) with respect to each Tranche 4 Advance (other than any Tranche 2C Advance Aggregate Amounts and/or the Tranche 3B Advance), one percent (1.00%) of the Tranche 4 Advances funded, which is payable to the Lenders in accordance with Section 4.2(g) and (ii) with respect to each Tranche 4 Advance consisting of the Tranche 2C Advance Aggregate Amounts and/or the Tranche 3B Advance, zero percent (0.00%) of the Tranche 5 Advances funded from such amounts.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">20.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 5 Facility Charge&#x201d; means one percent (1.00%) of the Tranche 5 Advances funded, which is payable to the Lenders in accordance with Section 4.2(h).</font></div></div>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;UCC&#x201d; means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Agent&#x2019;s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term &#x201c;UCC&#x201d; shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">24</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;U.S. Person&#x201d; means any Person that is a &#x201c;United States person&#x201d; as defined in Section 7701(a)(30) of the Code.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Warrant&#x201d; means any warrant entered into in connection with the Loan, as may be amended, restated or modified from time to time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> The following terms are defined in the Sections or subsections referenced opposite such terms:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">25</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:55.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.567%;"></td>
    <td style="width:47.433%;"></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,1);word-break:break-word;border-left:0.500pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Defined Term</font></p></td>
    <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Section</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Agent</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Preamble</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Assignee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">11.14</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Preamble</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Claims</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">11.11</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Collateral</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3.1</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">11.13</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Current Company IP</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5.10(a)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">End of Term Charge</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.6</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Event of Default</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Extension End of Term Charge</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.6</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">7.1</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indemnified Person</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">6.3</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Initial End of Term Charge</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.6</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Preamble</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Liabilities</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">6.3</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Maximum Rate</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.3</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Open Source License</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5.10(p)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Participant Register</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">11.8</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Prepayment Charge</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.5</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Publicity Materials</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">11.19</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Register</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">11.7</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Rights to Payment</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3.1</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Specified Disputes</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5.10(g)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Third Party IP</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5.10(i)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Tranche 1A Advance</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.2(a)(i)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Tranche 1B Advance</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.2(a)(ii)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Tranche 1 Advance</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.2(a)(ii)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Tranche 2A Advance</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.2(a)(iii)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Tranche 2B Advance</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.2(a)(iii)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Tranche 2 Advance</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.2(a)(iii)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Tranche 3 Advance</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.2(a)(iv)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Tranche 4 Advance</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.2(a)(v)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;border-left:0.500pt solid rgba(102,102,102,1);padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Tranche 5 Advance</font></p></td>
    <td style="background-color:rgba(204,204,204,1);border-right:0.500pt solid rgba(102,102,102,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(102,102,102,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.2(a)(vi)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a &#x201c;Section,&#x201d; &#x201c;subsection,&#x201d; &#x201c;Exhibit,&#x201d; &#x201c;Annex,&#x201d; or &#x201c;Schedule&#x201d; shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement.  Unless otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">26</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied; provided that if at any time any change in GAAP would affect the computation of any financial covenant or ratio or requirement set forth in any Loan Document, and either Borrower or Agent shall so request, Borrower, Agent and the Lenders shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP; provided, further, that, until so amended, (a) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (b) Borrower shall provide Agent financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio covenant or requirement made before and after giving effect to such change in GAAP.  Notwithstanding the foregoing, any obligations of a Person that are or would have been treated as operating leases for purposes of GAAP prior to the issuance by the Financial Accounting Standards Board on February 25, 2016 of an Accounting Standards Update (the &#x201c;ASU&#x201d;) shall continue to be accounted for as operating leases for purposes of all financial definitions, calculations and covenants for purpose of this Agreement (whether or not such operating lease obligations were in effect on such date) notwithstanding the fact that such obligations are required in accordance with the ASU (on a prospective or retroactive basis or otherwise) to be treated as capitalized lease obligations in accordance with GAAP (other than for purposes of the delivery of financial statements prepared in accordance with GAAP). Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC.  For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#x2019;s laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary in this Agreement or any other Loan Document, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein shall be made without giving effect to any treatment of Indebtedness in respect of convertible debt instruments under Accounting Standards Codification 470-20 (or any other Accounting Standards Codification or Financial Accounting Standard having a similar result or effect) to value any such Indebtedness in a reduced or bifurcated manner as described therein, and such Indebtedness shall at all times be valued at the full stated principal amount thereof. For the avoidance of doubt, and without limitation of the foregoing, Permitted Convertible Debt shall at all times be valued at the full stated principal amount thereof and shall not include any reduction or appreciation in value of the shares deliverable upon conversion thereof.</font></div></div>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">THE LOAN</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">[Reserved]</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Term Loan.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Advances.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">27</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement, the Lenders will severally (and not jointly) make in an amount not to exceed their respective Tranche 1A Commitments, and Borrower agrees to draw, a Term Loan Advance of Fifty Million Dollars ($50,000,000) on the Closing Date (the &#x201c;Tranche 1A Advance&#x201d;). </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement, Lenders will severally (and not jointly) make, in an amount not to exceed their respective Tranche 1B Commitments, an additional Term Loan Advance in an aggregate principal amount of Forty-Five Million Dollars ($45,000,000) on the Second Amendment Closing Date (the &#x201c;Tranche 1B Advance&#x201d; and together with the Tranche 1A Advance, each a &#x201c;Tranche 1 Advance&#x201d;). </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement, (A) beginning on the AXS-05 Milestone Date and continuing through the earlier of (x) 90 days following the AXS-05 Milestone Date and (y) December 31, 2022, Borrower may request and the Lenders shall severally (and not jointly) make additional Term Loan Advances in an aggregate principal amount of up to Thirty Five Million Dollars ($35,000,000), in minimum increments of Five Million Dollars ($5,000,000) (each, a &#x201c;Tranche 2A Advance&#x201d;) (B) during the Tranche 2B Draw Period, Borrower may request and the Lenders shall severally (and not jointly) make additional Term Loan Advances in an aggregate principal amount of up to Thirty Five Million Dollars ($35,000,000), in minimum increments of Five Million Dollars ($5,000,000) (each, a &#x201c;Tranche 2B Advance&#x201d;) and (C) during the Tranche 2C Draw Period, subject to approval by the Lenders&#x2019; investment committee in its sole and unfettered discretion based on the launch of AXS-05 and other factors, Borrower may request and the Lenders shall severally (and not jointly) make additional Term Loan Advances in an aggregate principal amount of up to Thirty Million Dollars ($30,000,000) (the &#x201c;Tranche 2C Advance Aggregate Amount&#x201d;), in minimum increments of Five Million Dollars ($5,000,000) (each, a &#x201c;Tranche 2C Advance&#x201d;  and together with each Tranche 2B Advance and Tranche 2A Advance, each a &#x201c;Tranche 2 Advance&#x201d;).  </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement, (A) beginning on the AXS-07 Milestone Date and continuing through the earlier of (x) 181 days following the AXS-07 Milestone Date and (y) June 30, 2023, Borrower may request and the Lenders shall severally (and not jointly) make additional Term Loan Advances in an aggregate principal amount of up to Fifteen Million Dollars ($15,000,000), in minimum increments of Five Million Dollars ($5,000,000) (each, a &#x201c;Tranche 3A Advance&#x201d;)and (B) during the Tranche 3B Draw Period, subject to approval by the Lenders&#x2019; investment committee in its sole and unfettered discretion based on the launch of AXS-07 and other factors, Borrower may request and the Lenders shall severally (and not jointly) make an additional Term Loan Advance in an aggregate principal amount of up to Five Million Dollars ($5,000,000) (the &#x201c;Tranche 3B Advance&#x201d; and together with the Tranche 3A Advances, each, a &#x201c;Tranche 3 Advance&#x201d;).  </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement, and subject to the satisfaction of Tranche 4 Draw Conditions, beginning on January 1, 2022 and </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">28</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">continuing through December 31, 2024, Borrower may request additional Term Loan Advances in an aggregate principal amount of up to Fifty Million Dollars ($50,000,000) (the &#x201c;Tranche 4 Commitments&#x201d;), plus subject to the Tranche 2C Availability Conditions, the Tranche 2C Advance Aggregate Amount, plus, subject to the Tranche 3B Availability Conditions, the Tranche 3B Advance, in minimum increments of Five Million Dollars ($5,000,000) (each, a &#x201c;Tranche 4 Advance&#x201d;). Tranche 4 Advances shall be funded first from the Tranche 4 Commitments, second from the Tranche 2C Advance Aggregate Amounts, if any and third from the Tranche 3B Advance, if any.</font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement, and conditioned on approval by the Lenders&#x2019; investment committee in its sole and unfettered discretion, on or before December 31, 2025, Borrower may request additional Term Loan Advances in an aggregate principal amount of up to Thirty Five Million Dollars ($35,000,000) plus subject to the Tranche 2C Availability Conditions, the Tranche 2C Advance Aggregate Amount if such amount has not been added to the Tranche 4 Advance, plus, subject to the Tranche 3B Availability Conditions, the Tranche 3B Advance if such advance has not been added to Tranche 4 Advance, in minimum increments of Five Million Dollars ($5,000,000) (each, a &#x201c;Tranche 5 Advance&#x201d;).  </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall elect and give written notice to Agent to add the Tranche 2C Advance Aggregate Amount upon the occurrence of the Tranche 2C Availability Conditions to either the Tranche 4 Advance or the Tranche 5 Advance on or prior to December 31, 2023; provided that as a condition to selecting to add the Tranche 2C Advance Aggregate Amount to the Tranche 4 Advance, Borrower shall have paid the Tranche 2C Advance Aggregate Amounts Facility Charge.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall elect and give written notice to Agent to add the Tranche 3B Advance upon the occurrence of the Tranche 3B Availability Conditions to either the Tranche 4 Advance or the Tranche 5 Advance on or prior to December 31, 2023; provided that as a condition to selecting to add the Tranche 3B Advance to the Tranche 4 Advance, Borrower shall have paid the Tranche 3B Advance Facility Charge.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The aggregate outstanding Term Loan Advances may be up to the Maximum Term Loan Amount.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> Advance Request.  To obtain a Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request (at least one (1) Business Day before the Closing Date and at least five (5) Business Days before each Advance Date other than the Closing Date) to Agent. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Lenders shall fund the Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions precedent to such Term Loan Advance is satisfied as of the requested Advance Date.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Interest.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">29</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Term Loan Cash Interest Rate.  The principal balance of each Term Loan Advance shall bear interest thereon from such Advance Date at the Term Loan Cash Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed.  The Term Loan Cash Interest Rate will float and change on the day the prime rate changes from time to time.</font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">[Reserved]. </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">[Reserved].</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iv.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Payment.  Borrower will pay interest on each Term Loan Advance on the first Business Day of each month, beginning the month after the Advance Date (each an &#x201c;Interest Payment Date&#x201d;).  Borrower shall repay the aggregate Term Loan principal balance that is outstanding on the day immediately preceding the Amortization Date, in equal monthly installments of principal and interest (mortgage style) beginning on the Amortization Date and continuing on the first Business Day of each month thereafter until the Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) are repaid; provided, that if the Term Loan Cash Interest Rate is adjusted in accordance with its terms, the amount of each subsequent monthly installment shall be recalculated so that the remaining payments shall be equal monthly installments of principal and interest beginning on the first Business Day of the month following such recalculation and continuing on the first Business Day of each month thereafter until the Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) are repaid in full. The entire Term Loan principal balance and all accrued but unpaid interest hereunder, shall be due and payable on the Term Loan Maturity Date.  Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense.  If a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day.  The Lenders will initiate debit entries to the Borrower&#x2019;s account as authorized on the ACH Authorization (i) on each payment date of all periodic obligations payable to the Lenders under each Term Loan Advance and (ii) reasonable, documented, out-of-pocket legal fees and costs incurred by Agent or the Lenders in connection with Section 11.12 of this Agreement; provided that, with respect to clause (i) above, in the event that the Lenders or Agent informs Borrower that the Lenders will not initiate a debit entry to Borrower&#x2019;s account for a certain amount of the periodic obligations due on a specific payment date, Borrower shall pay to the Lenders such amount of periodic obligations in full in immediately available funds on such payment date; provided, further, that, with respect to clause (i) above, if the Lenders or Agent informs Borrower that the Lenders will not initiate a debit entry as described above later than the date that is three (3) Business Days prior to such payment date, Borrower shall pay to the Lenders such amount of periodic obligations in full in immediately available funds on the date that is three (3) Business Days after the date on which the Lenders or Agent notifies Borrower of such; provided, further, that, with respect to clause (ii) above, in the event that the Lenders or Agent informs Borrower that the Lenders will not initiate a debit entry to Borrower&#x2019;s account for certain amount of such reasonable, documented out-of-pocket legal fees and costs incurred by Agent or the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">30</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Lenders, Borrower shall pay to the Lenders such amount in full in immediately available funds within three (3) Business Days.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Maximum Interest.  Notwithstanding any provision in this Agreement or any other Loan Document, it is the parties&#x2019; intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the &#x201c;Maximum Rate&#x201d;).  If a court of competent jurisdiction shall finally determine that Borrower has actually paid to the Lenders an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall be applied as follows:  first, to the payment of the Secured Obligations consisting of the outstanding principal; second, after all principal is repaid, to the payment of the Lenders&#x2019; accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower.  </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Default Interest.  In the event any payment is not paid on the scheduled payment date  (or promptly following resolution of an ACH Failure (and in no event later than three (3) Business Days of the scheduled payment date); provided that such late payment is due to an ACH Failure), an amount equal to five percent (5%) of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.2(c) plus five percent (5%) per annum.  In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.2(c) or Section 2.4, as applicable.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Prepayment.  At its option, upon at least seven (7) Business Days prior written notice to Agent (or such shorter notice period as agreed by Agent in its sole discretion), Borrower may at any time and from time to time, prepay all or a portion of the outstanding Advances by paying the entire principal balance, or such portion thereof in minimum increments of Five Million Dollars ($5,000,000), all accrued and unpaid interest thereon, together with a prepayment charge equal to the following percentage of the Advance amount being prepaid: with respect to each Advance, if such Advance amounts are prepaid in any of the first twelve (12) months following the First Amendment Closing Date, 2.0%; on or after the date that is twelve (12) months following the First Amendment Closing Date but prior to twenty four (24) months following the First Amendment Closing Date, 1.5%; and on or after the date that is twenty four (24) months following the First Amendment Closing Date but prior to thirty six (36) months following the First Amendment Closing Date, 1.0% (each, a &#x201c;Prepayment Charge&#x201d;). If at any time Borrower elects to make a prepayment, and at such time, there are outstanding Advances under multiple Tranches, the Prepayment Charge shall be determined by applying the amount of such prepayment in the following order: first, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances outstanding under the Tranche with the latest initial funding date; second, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">31</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">outstanding under the Tranche with the next latest initial funding date and so on until the entire principal balance of all Advances made hereunder (and all accrued but unpaid interest thereon) is paid in full.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower agrees that the Prepayment Charge is a reasonable calculation of the Lenders&#x2019; lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the Advances.  Borrower shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and the Prepayment Charge, if any, upon the occurrence of a Change in Control or any other prepayment hereunder. Notwithstanding the foregoing, Agent and the Lenders agree to waive the Prepayment Charge if Agent and the Lenders (in their sole and absolute discretion) agree in writing to refinance the Advances prior to the Term Loan Maturity Date. Any amounts paid under this Section shall be applied by Agent to the then unpaid amount of any Secured Obligations (including principal and interest) in such order and priority as Agent may choose in its sole discretion.  For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day.  Notwithstanding anything to the contrary contained in this Agreement, so long as Borrower provided notice to the Agent no less than seven (7) Business Days prior to the proposed prepayment date, Borrower may rescind any notice of prepayment if such prepayment would have resulted from a refinancing of all or a portion of the Term Loan Advances, which refinancing shall not be consummated or shall otherwise be delayed.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">End of Term Charge.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">On any date that Borrower partially prepays the outstanding Secured Obligations pursuant to Section 2.5, Borrower shall pay the Lenders (x) with respect to any repayment of any Tranche 1A Advances, a charge of 4.85% of the principal amount of such Term Loan Advances being repaid and (y) for all other Advances repaid, a charge of 4.50% of the principal amount of such Term Loan Advances being repaid.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">On the earliest to occur of (i) October 1, 2026, (ii) the date that Borrower prepays the outstanding Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) in full, or (iii) the date that the Secured Obligations become due and payable in full (other than regularly scheduled interest and amortization payments), Borrower shall pay the Lenders a charge equal to (x) Two Million Nine Hundred and Ten Thousand Dollars ($2,910,000), plus (y) 4.50% of the aggregate amount of all Term Loan Advances (other than Tranche 1A Advances) funded, minus (z) the aggregate amount of payments made pursuant to Section 2.6(a) (the &#x201c;Initial End of Term Charge&#x201d;). </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If the Maturity Extension Conditions are satisfied, on the earliest to occur of (i) October 1, 2027, (ii) the date that Borrower prepays the outstanding Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) in full, or (iii) the date that the Secured Obligations become due and payable in full (other than regularly scheduled interest and amortization payments), Borrower shall pay the Lenders an additional charge equal to 1.50% of the aggregate amount of all Term Loan Advances outstanding as of the date on which the Maturity Extension Conditions are satisfied (the &#x201c;Extension End of Term </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">32</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Charge&#x201d;, collectively with any charge made pursuant to Section 2.6(a) and the Initial End of Term Charge, the &#x201c;End of Term Charge&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iv.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the required payment date of such End of Term Charge, the applicable pro rata portion of the End of Term Charge shall be deemed earned by the Lenders as of each date a Term Loan Advance is made.  For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pro Rata Treatment.  Each payment (including prepayment) on account of any fee and any reduction of the Term Loans shall be made pro rata according to the Term Commitments of the relevant Lender.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Taxes; Increased Costs.  The Borrower, the Agent and the Lenders each hereby agree to the terms and conditions set forth on Addendum 1 attached hereto.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Treatment of Prepayment Charge and End of Term Charge.  Borrower agrees that any Prepayment Charge and any End of Term Charge payable shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, and Borrower agrees that it is reasonable under the circumstances currently existing and existing as of the Closing Date and the Second Amendment Closing Date.  The Prepayment Charge and the End of Term Charge shall also be payable in the event the Secured Obligations (and/or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure, or by any other means.  Borrower expressly waives (to the fullest extent it may lawfully do so) the provisions of any present or future statute or law that prohibits or may prohibit the collection of the foregoing Prepayment Charge and End of Term Charge in connection with any such acceleration.  Borrower agrees (to the fullest extent that each may lawfully do so): (a) each of the Prepayment Charge and the End of Term Charge is reasonable and is the product of an arm&#x2019;s length transaction between sophisticated business people, ably represented by counsel; (b) each of the Prepayment Charge and the End of Term Charge shall be payable notwithstanding the then prevailing market rates at the time payment is made; (c) there has been a course of conduct between the Lenders and Borrower giving specific consideration in this transaction for such agreement to pay the Prepayment Charge and the End of Term Charge as a charge (and not interest) in the event of prepayment or acceleration; (d) Borrower shall be estopped from claiming differently than as agreed to in this paragraph.  Borrower expressly acknowledges that their agreement to pay each of the Prepayment Charge and the End of Term Charge to the Lenders as herein described was on the Closing Date and the Second Amendment Closing Date and continues to be a material inducement to the Lenders to provide the Term Loans.</font></div></div>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">SECURITY INTEREST</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">As security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, Borrower grants to Agent a security interest in all of Borrower&#x2019;s right, title, and interest in, to and under all of Borrower&#x2019;s personal property and other assets including without limitation the following </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">33</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(except as set forth herein) whether now owned or hereafter acquired (collectively, the &#x201c;Collateral&#x201d;):  (a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles; (e) Inventory; (f) Investment Property; (g) Deposit Accounts; (h) Cash; (i) Goods; (j) the Antecip License Agreement and all proceeds thereof; and all other tangible and intangible personal property of Borrower whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located, and any of Borrower&#x2019;s property in the possession or under the control of Agent; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the broad grant of the security interest set forth in Section 3.1, above, the Collateral shall not include (collectively, the &#x201c;Excluded Property&#x201d;) (a) any &#x201c;intent to use&#x201d; trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, provided, that upon submission and acceptance by the United States Patent and Trademark Office of an amendment to allege use of an intent-to-use trademark application pursuant to 15 U.S.C. Section 1060(a) (or any successor provision) such intent-to-use application shall constitute Collateral, (b) non-assignable property, licenses or contracts, which by their terms require the consent of the licensor thereof or another party (but only to the extent such prohibition on transfer is enforceable under applicable law, including, without limitation, Sections 9406, 9407 and 9408 of the UCC), (c) any particular asset if the pledge thereof or the security interest therein is prohibited or restricted by applicable law, rule or regulation (including any requirement to obtain the consent of any governmental authority, regulatory authority or third party), provided that the foregoing exclusion of this clause (c) shall in no way be construed (1) to apply to the extent that any described prohibition or restriction is unenforceable under Section 9406, 9407 or 9408 of the UCC or other applicable law or (2) to apply to the extent that any consent or waiver has been obtained, or is hereafter obtained, that would permit the Agent&#x2019;s security interest or Lien notwithstanding the prohibition or restriction on the pledge of such asset, (d) any Excluded Accounts, including cash pledged pursuant to Permitted Liens and any Deposit Account, securities account, commodities account or other account to the extent solely and exclusively used to hold any cash pledged as a Permitted Lien, and (e) Equipment and software (and the products and proceeds thereof) subject to Permitted Liens of the type described in clause (vii) of the definition of Permitted Liens, but only to the extent and for so long as the agreements under which the equipment is financed prohibit granting a security interest therein to Lender. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	Upon termination of this Agreement and repayment if full of all Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement), all security interest in the Collateral granted under this Agreement shall terminate and all rights on the Collateral shall revert to Borrower. Agent shall execute such documents and take such other steps as are reasonably necessary for Borrower to accomplish the foregoing, all at Borrower&#x2019;s sole cost and expense.</font></div></div>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CONDITIONS PRECEDENT TO LOAN</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">34</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The obligations of the Lenders to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions:</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Initial Advance.  On or prior to the Closing Date, Borrower shall have delivered to Agent the following:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">executed copies of the Loan Documents (other than the Warrant, which shall be an original), Account Control Agreements, and all other documents and instruments reasonably required by Agent to effectuate the transactions contemplated hereby or to create and perfect the Liens of Agent with respect to all Collateral, in all cases in form and substance reasonably acceptable to Agent;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">a legal opinion of Borrower&#x2019;s counsel in form and substance reasonably acceptable to Agent,</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">certified copy of resolutions of Borrower&#x2019;s board of directors evidencing approval of (i) the Loan and other transactions evidenced by the Loan Documents; and (ii) the Warrant and transactions evidenced thereby;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iv.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">v.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">a certificate of good standing for Borrower from its state of incorporation and similar certificates from all other jurisdictions in which it does business and where the failure to be qualified could have a Material Adverse Effect;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">vi.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">payment of the Due Diligence Fee, Initial Facility Charge and reimbursement of Agent&#x2019;s and the Lenders&#x2019; current expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance; </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">vii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">all certificates of insurance and copies of each insurance policy required hereunder; </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">viii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">executed copy of the Antecip Direct Agreement; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ix.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">such other documents as Agent may reasonably request.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">All Advances.  On each Advance Date:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Agent shall have received (i) an Advance Request for the relevant Advance as required by Section 2.2(b), each duly executed by Borrower&#x2019;s Chief Executive Officer or Chief Financial Officer, and (ii) any other documents Agent may reasonably request.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The representations and warranties set forth in this Agreement shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">35</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iv.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">with respect to any Tranche 1B Advance, the Borrower shall have paid the Tranche 1B Facility Charge.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">v.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">with respect to any Tranche 2 Advance, the Borrower shall have paid the Tranche 2 Facility Charge. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">vi.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">with respect to any Tranche 3 Advance, the Borrower shall have paid the Tranche 3 Facility Charge. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">vii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">with respect to any Tranche 4 Advance, the Borrower shall have paid the Tranche 4 Facility Charge. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">viii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">with respect to any Tranche 5 Advance, the Borrower shall have paid the Tranche 5 Facility Charge. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ix.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">with respect to any Advance on and after the Second Amendment Effective Date, a Warrant substantially in the form of Exhibit K which shall be in form and substance satisfactory to Agent.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">x.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">upon adding any Tranche 2C Advance Aggregate Amounts to the Tranche 4 Advances in accordance with Section 2(a)(vii), the Borrower shall have paid the Tranche 2C Advance Aggregate Amounts Facility Charge on or prior to December 31, 2023.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">xi.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">upon adding the Tranche 3B Advance to the Tranche 4 Advances in accordance with Section 2(a)(viii), the Borrower shall have paid the Tranche 3B Advance Facility Charge on or prior to December 31, 2023.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">xii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Prior to the funding of any Tranche 4 Advance, Borrower shall deliver to Agent a calculation detailing the Net Product Revenue Ratio and demonstrating compliance with the Tranche 4 Draw Conditions in form and substance reasonably acceptable to Agent. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">xiii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No Default.  As of the Closing Date and each Advance Date, (i) no fact or condition exists that could (or could, with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Post-Close Obligations. Notwithstanding any provision herein or in any other Loan Document to the contrary, to the extent not actually delivered on or prior to the Closing Date, Borrower shall deliver to Agent (or its designated attorney or representative), within </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">36</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">two (2) Business Days after the Closing Date, an Account Control Agreement for Borrower&#x2019;s accounts (other than Excluded Accounts) maintained with Silicon Valley Bank.</font></div></div>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">REPRESENTATIONS AND WARRANTIES OF BORROWER</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower represents and warrants that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Corporate Status.  Borrower is a corporation duly organized, legally existing and in good standing under the laws of its state of incorporation, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect.  Borrower&#x2019;s present name, former names (if any), locations, place of formation, tax identification number, organizational identification number and other information are correctly set forth in Exhibit B, as may be updated by Borrower in a written notice (including any Compliance Certificate) provided to Agent after the Closing Date. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Collateral.  Borrower owns the Collateral, free of all Liens, except for Permitted Liens.  Borrower has the power and authority to grant to Agent a Lien in the Collateral as security for the Secured Obligations.  </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Consents.  Borrower&#x2019;s execution, delivery and performance of this Agreement and all other Loan Documents, and Borrower&#x2019;s execution of the Warrant, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower&#x2019;s Certificate or Articles of Incorporation (as applicable), bylaws, or any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on Schedule 5.3, do not violate any material contract or agreement or require the consent or approval of any other Person which has not already been obtained.  The individual or individuals executing the Loan Documents and the Warrant are duly authorized to do so.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Effect.  No event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing. Borrower is not aware of any event likely to occur that is reasonably expected to result in a Material Adverse Effect.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Actions Before Governmental Authorities.  There are no actions, suits or proceedings at law or in equity or by or before any governmental authority now pending or, to the knowledge of Borrower, threatened in writing against Borrower or its property, that is reasonably expected to result in a Material Adverse Effect. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Laws.  Neither Borrower nor any of its Subsidiaries is in violation of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect.  Borrower is not in default in any manner under any provision </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">37</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">of any agreement or instrument evidencing (i) material Indebtedness, or any other Material Agreement to which it is a party or by which it is bound or (ii) any other agreement which default is reasonably expected to result in a Material Adverse Effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <p style="margin-left:5.0%;text-indent:8.772%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Neither Borrower nor any of its Subsidiaries is an &#x201c;investment company&#x201d; or a company &#x201c;controlled&#x201d; by an &#x201c;investment company&#x201d; under the Investment Company Act of 1940, as amended.  Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors).  Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act.  Neither Borrower nor any of its Subsidiaries is a &#x201c;holding company&#x201d; or an &#x201c;affiliate&#x201d; of a &#x201c;holding company&#x201d; or a &#x201c;subsidiary company&#x201d; of a &#x201c;holding company&#x201d; as each term is defined and used in the Public Utility Holding Company Act of 2005.  Neither Borrower&#x2019;s nor any of its Subsidiaries&#x2019; properties or assets has been used by Borrower or such Subsidiary or, to Borrower&#x2019;s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws.  Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.</font></p>
  <p style="margin-left:5.0%;text-indent:8.772%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">None of Borrower, any of its Subsidiaries, or any of Borrower&#x2019;s or its Subsidiaries&#x2019; Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person.  None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law.  None of the funds to be provided under this Agreement will be used, directly or indirectly, (a) for any activities in violation of any applicable anti-money laundering, economic sanctions and anti-bribery laws and regulations laws and regulations or (b) for any payment to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as amended.</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Information Correct and Current.  No information, report, Advance Request, financial statement, exhibit or schedule furnished, by or on behalf of Borrower to Agent in connection with any Loan Document or included therein or delivered pursuant thereto contained, or, when taken as a whole, contains any material misstatement of fact or, when taken together with all other such information or documents, omitted or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not materially misleading at the time such </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">38</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">statement was made or deemed made. Additionally, any and all financial or business projections provided by Borrower to Agent, whether prior to or after the Closing Date, shall be (i) provided in good faith and based on the most current data and information available to Borrower and subject to normal year-end adjustments, and (ii) the most current of such projections provided to Borrower&#x2019;s board of directors (it being understood that such projections are subject to significant uncertainties and contingencies, many of which are beyond the control of Borrower, that no assurance is given that any particular projections will be realized, that actual results may differ).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Tax Matters.  Except as described on Schedule 5.8, (a) Borrower and its Subsidiaries have filed all federal and state income Tax returns and other material Tax returns that they are required to file, (b) Borrower and its Subsidiaries have duly paid all federal and state income Taxes and other material Taxes or installments thereof that they are required to pay, except Taxes being contested in good faith by appropriate proceedings and for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP, and (c) to the best of Borrower&#x2019;s knowledge, no proposed or pending Tax assessments, deficiencies, audits or other proceedings with respect to Borrower or any Subsidiary have had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property Claims.  Borrower is the sole owner of, or otherwise has the right to use, the Intellectual Property material to Borrower&#x2019;s business.  Except as described on Schedule 5.9 and as may be updated by Borrower in a written notice provided from time to time after the Closing Date, (i) each of the material Copyrights, Trademarks and Patents (other than patent applications) is valid and enforceable, (ii) no material part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (iii) except as set forth in the most recently delivered Compliance Certificate in accordance with Section 7.1(d), no claim has been made to Borrower in writing that any material part of the Intellectual Property violates the rights of any third party. Exhibit C (and as may be updated by Borrower in a written notice provided from time to time after the Closing Date) is a true, correct and complete list of each of Borrower&#x2019;s registered Patents and filed Patent applications, registered Trademarks, registered Copyrights, and Material Agreements under which Borrower licenses Intellectual Property from third parties (other than shrink-wrap software licenses, licenses that are commercially available to the public, open source licenses, licenses disclosed in writing to Agent as required under this Agreement and immaterial Intellectual Property licensed to Borrower in the ordinary course of business), together with application or registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing contracts, licenses or agreements and, to Borrower&#x2019;s knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder.  </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">j.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">A true, correct and complete list of each pending, registered, issued or in-licensed Intellectual Property that, individually or taken together with any other such Intellectual </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">39</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Property, is material to the business of Borrower and its Subsidiaries, taken as a whole, relating to the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Borrower Products, and is owned or co-owned by or exclusively or non-exclusively licensed to the Borrower or any of its Subsidiaries (collectively, the &#x201c;Current Company IP&#x201d;), including its name/title, current owner or co-owners (including ownership interest), registration, patent or application number, and registration or application date, issued or filed in the United States, is set forth on Schedule 5.10(a).  Except as set forth on Schedule 5.10(a), (i) (A) each item of owned Current Company IP is valid, subsisting and (other than with respect to Patent applications) enforceable and no such item of Current Company IP has lapsed, expired, been cancelled or invalidated or become abandoned or unenforceable, and (B) no written notice has been received challenging the inventorship or ownership, or relating to any lapse, expiration, invalidation, abandonment or unenforceability, of any such item of Current Company IP, and (ii) (A) each such item of Current Company IP which is licensed from another Person is valid, subsisting and enforceable and no such item of Current Company IP has lapsed, expired, been cancelled or invalidated, or become abandoned or unenforceable, and (B) no written notice has been received challenging the inventorship or ownership, or relating to any lapse, expiration, invalidation, abandonment or unenforceability, of any such item of Current Company IP. To the knowledge of Borrower, there are no published patents, patent applications, articles or prior art references that would reasonably be expected to materially adversely affect the exploitation of the Borrower Products.  Except as set forth on Schedule 5.10(a), (x) each Person who has or has had any rights in or to owned Current Company IP or any trade secrets owned by the Borrower or any of its Subsidiaries, including each inventor named on the Patents within such owned Current Company IP filed by the Borrower or any of its Subsidiaries, and has executed an agreement assigning his, her or its entire right, title and interest in and to such owned Current Company IP and such trade secrets, and the inventions, improvements, ideas, discoveries, writings, works of authorship, information and other intellectual property embodied, described or claimed therein, to the stated owner thereof, and (y) no such Person has any contractual or other obligation that would preclude or conflict with such assignment or the exploitation of the Borrower Products or entitle such Person to ongoing payments.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> (i) The Borrower or any of its Subsidiaries possesses valid title to the Current Company IP for which it is listed as the owner or co-owner, as applicable, on Schedule 5.10(a); and (ii) there are no Liens on any Current Company IP.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">There are no maintenance, annuity or renewal fees that are currently overdue beyond their allotted grace period for any of the Current Company IP which is owned by or exclusively licensed to the Borrower or any of its Subsidiaries, nor have any applications or registrations therefor lapsed or become abandoned, been cancelled or expired.  There are no maintenance, annuity or renewal fees that are currently overdue beyond their allotted grace period for any of the Current Company IP which is non-exclusively licensed to the Borrower or any of its Subsidiaries, nor have any applications or registrations therefor lapsed or become abandoned, been cancelled or expired.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">There are no unpaid fees or royalties under any Material Agreements that have become due, or are expected to become overdue.  Each Material Agreement is in full force and effect and is legal, valid, binding, and enforceable in accordance with its respective terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">40</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">to or limiting creditors&#x2019; rights generally or by equitable principles relating to enforceability.  Except as set forth on Schedule 5.10(d), neither Borrower nor any of its Subsidiaries, as applicable, is in breach of or default in any manner that could reasonably be expected to materially affect the Borrower Products under any Material Agreement to which it is a party or may otherwise be bound, and no circumstances or grounds exist that would give rise to a claim of breach or right of rescission, termination, non-renewal, revision or amendment of any of the Material Agreements, including the execution, delivery and performance of this Agreement and the other Loan Documents.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No payments by the Borrower or any of its Subsidiaries are due to any other Person in respect of the Current Company IP, other than pursuant to the Material Agreements and those fees payable to patent offices in connection with the prosecution and maintenance of the Current Company IP, any applicable taxes and associated attorney fees. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Neither the Borrower nor any of its Subsidiaries has undertaken or omitted to undertake any acts, and no circumstance or grounds exist that would invalidate or reduce, in whole or in part, the enforceability or scope of (i) the Current Company IP in any manner that could reasonably be expected to materially adversely affect the Borrower Products, or (ii) in the case of Current Company IP owned or co-owned or exclusively or non-exclusively licensed by the Borrower or any of its Subsidiaries, except as set forth on Schedule 5.10(f), the Borrower&#x2019;s or Subsidiary&#x2019;s entitlement to own or license and exploit such Current Company IP.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Except as described on Schedule 5.9 or in the most recently delivered Compliance Certificate in accordance with Section 7.1(d), there is no requested, filed pending, decided or settled opposition, interference proceeding, reissue proceeding, reexamination proceeding, inter-partes review proceeding, post-grant review proceeding, cancellation proceeding, injunction, litigation, paragraph IV patent certification or lawsuit under the Hatch-Waxman Act, hearing, investigation, complaint, arbitration, mediation, demand, International Trade Commission investigation, decree, or any other dispute, disagreement, or claim, in each case alleged in writing to Borrower or any of its Subsidiaries (collectively referred to hereinafter as &#x201c;Specified Disputes&#x201d;), nor to the knowledge of Borrower, has any such Specified Dispute been threatened in writing, in each case challenging the legality, validity, enforceability or ownership of any Current Company IP, in each case that would have a material adverse effect on the Borrower Products.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">In each case where an issued Patent within the Current Company IP is owned or co-owned by the Borrower or any of its Subsidiaries by assignment, the assignment has been duly recorded with the U.S. Patent and Trademark Office.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Except as set forth on Schedule 5.10(i) there are no pending or, to the knowledge of Borrower, threatened claims against Borrower or any of its Subsidiaries alleging (i) that any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Borrower Products in the United States infringes or violates (or in the past infringed or violated) the rights of any third parties in or to any Intellectual Property (&#x201c;Third Party IP&#x201d;) or constitutes a misappropriation of (or in the past constituted a misappropriation of) any Third Party IP, or (ii) that any Current Company IP is invalid or unenforceable.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">41</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Except as set forth on Schedule 5.10(j), the manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Borrower Products does not, to the knowledge of Borrower, infringe or violate (or in the past infringed or violated) any issued or registered Third Party IP (including any issued Patent within the Third Party IP) or constitute a misappropriation of (or in the past constituted a misappropriation of) any Third Party IP.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Except as set forth on Schedule 5.10(k), there are no settlements, covenants not to sue, consents, judgments, orders or similar obligations which: (i) restrict the rights of the Borrower or any of its Subsidiaries to use any Intellectual Property relating to the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Borrower Products (in order to accommodate any Third Party IP or otherwise), or (ii) permit any third parties to use any Company IP.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Except as set forth on Schedule 5.10(l), to the knowledge of Borrower (i) there is no, nor has there been any, infringement or violation by any Person of any of the Company IP or the rights therein, and (ii) there is no, nor has there been any, misappropriation by any Person of any of the Company IP or the subject matter thereof.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(m)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Borrower and each of its Subsidiaries has taken all commercially reasonable measures customary in the biopharmaceutical industry to protect the confidentiality and value of all trade secrets owned by the Borrower or any of its Subsidiaries or used or held for use by the Borrower or any of its Subsidiaries, in each case relating to the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of the Borrower Products.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(n)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Except as set forth on Schedule 5.10(n), at the time of any shipment of Borrower Product in the United States occurring prior to the Closing Date, the units thereof so shipped complied with their relevant specifications and were manufactured in all material respects in accordance with current FDA Good Manufacturing Practices. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(o)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Except as described on Schedule 5.10(o), Borrower has all material rights with respect to Intellectual Property necessary or material in the operation or conduct of Borrower&#x2019;s business as currently conducted and proposed to be conducted by Borrower.  Without limiting the generality of the foregoing, and in the case of Licenses, except for restrictions that are unenforceable under Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower&#x2019;s business, to freely transfer, license or assign Intellectual Property necessary or material in the operation or conduct of Borrower&#x2019;s business as currently conducted and proposed to be conducted by Borrower, without condition, restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid licenses, all software development tools, library functions, compilers and all other third-party software and other items that are material to Borrower&#x2019;s business and used in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products that are material to Borrower&#x2019;s business except customary covenants in inbound license agreements and equipment leases where Borrower is the licensee or lessee. Except as has been disclosed in the Perfection Certificate or pursuant to Section 7.1(d),</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower is not a party to, nor is it bound by, any Restricted License.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">42</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No material software or other materials used by Borrower or any of its Subsidiaries (or used in any Borrower Products or any Subsidiaries&#x2019; products) are subject to an open-source or similar license (including but not limited to the General Public License, Lesser General Public License, Mozilla Public License, or Affero License) (collectively, &#x201c;Open Source Licenses&#x201d;) in a manner that would cause such software or other materials to have to be (i) distributed to third parties at no charge or a minimal charge (royalty-free basis); (ii) licensed to third parties to modify, make derivative works based on, decompile, disassemble, or reverse engineer; or (iii) used in a manner that does could require disclosure or distribution in source code form.</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">k.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower Products.  Except as described on Schedule 5.11 or in the most recently delivered Compliance Certificate in accordance with Section 7.1(d), no material Intellectual Property owned by Borrower or Borrower Product has been or is subject to any actual or, to the knowledge of Borrower, threatened in writing litigation, proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any manner Borrower&#x2019;s use, transfer or licensing thereof or that could reasonably be expected to affect the validity, use or enforceability thereof.  Except as described in the most recently delivered Compliance Certificate in accordance with Section 7.1(d),there is no decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any future Intellectual Property related to the operation or conduct of the business of Borrower or Borrower Products. Except as described in the most recently delivered Compliance Certificate in accordance with Section 7.1(d), Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning Borrower&#x2019;s ownership in any Intellectual Property material to Borrower&#x2019;s business (or written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property material to Borrower&#x2019;s business of the owner thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto nor, to Borrower&#x2019;s knowledge, is there a reasonable basis for any such claim.  Neither Borrower&#x2019;s use of its Intellectual Property material to Borrower&#x2019;s business nor the production and sale of Borrower Products material to Borrower&#x2019;s business infringes the Intellectual Property or other rights of others. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">l.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Accounts.  Exhibit D, as may be updated by the Borrower in a written notice provided to Agent after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">m.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Employee Loans.  Except for Permitted Investments, Borrower has no outstanding loans to any employee, officer or director of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by a third party.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">43</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">n.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Capitalization and Subsidiaries.  Borrower&#x2019;s capitalization as of the Closing Date is set forth on Schedule 5.14 annexed hereto.  Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments.  Attached as Schedule 5.14, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct and complete list of each Subsidiary.</font></div></div>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">INSURANCE; INDEMNIFICATION</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Coverage.  Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence form, against risks customarily insured against in Borrower&#x2019;s line of business.  Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms of the indemnification agreement found in Section 6.3.  Borrower must maintain a minimum of $2,000,000 of commercial general liability insurance for each occurrence.  Borrower has and agrees to maintain a minimum of $2,000,000 of directors&#x2019; and officers&#x2019; insurance for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations  (other than inchoate indemnity obligations and other obligations which are expressly stated to survive termination of this Agreement) outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral; provided that such insurance may be subject to standard exceptions and deductibles.  If Borrower fails to obtain the insurance called for by this Section 6.1 or fails to pay any premium thereon or fails to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document or which may be required to preserve the Collateral, Agent may obtain such insurance or make such payment, and all amounts so paid by Agent are immediately due and payable, bearing interest at the then highest rate applicable to the Secured Obligations, and secured by the Collateral.  Agent will make reasonable efforts to provide Borrower with notice of Agent obtaining such insurance at the time it is obtained or within a reasonable time thereafter.  No payments by Agent are deemed an agreement to make similar payments in the future or Agent&#x2019;s waiver of any Event of Default. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Certificates.  Borrower shall deliver to Agent certificates of insurance that evidence Borrower&#x2019;s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2.  Borrower&#x2019;s insurance certificate shall state Agent (shown as &#x201c;Hercules Capital, Inc., as Agent&#x201d;) is an additional insured for commercial general liability, a lenders loss payable for all risk property damage insurance, subject to the insurer&#x2019;s approval, and a lenders loss payable for property insurance and additional insured for liability insurance for any future insurance that Borrower may acquire from such insurer.  Attached to the certificates of insurance will be additional insured endorsements for liability and lender&#x2019;s loss payable endorsements for all risk property damage insurance.  All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Agent of cancellation (other than cancellation for non-payment of premiums, for which ten (10) days&#x2019; advance written notice shall be sufficient) or any other change adverse to Agent&#x2019;s interests.  Any failure of Agent to scrutinize such insurance certificates for compliance is not a waiver of any of Agent&#x2019;s rights, all of which are reserved.  Borrower shall provide Agent with copies of each insurance policy, and upon entering or amending </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">44</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">any insurance policy required hereunder, Borrower shall provide Agent with copies of such policies and shall promptly deliver to Agent updated insurance certificates with respect to such policies.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indemnity.  Borrower agrees to indemnify and hold Agent, the Lenders and their officers, directors, employees, agents, in-house attorneys, representatives and shareholders (each, an &#x201c;Indemnified Person&#x201d;) harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable, documented, out-of-pocket attorneys&#x2019; fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal) (collectively, &#x201c;Liabilities&#x201d;), that may be instituted or asserted against or incurred by such Indemnified Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases Liabilities to the extent resulting solely from any Indemnified Person&#x2019;s gross negligence or willful misconduct.  This Section 6.3 shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.  In no event shall any Indemnified Person be liable on any theory of liability for any special, indirect, consequential or punitive damages (including any loss of profits, business or anticipated savings). This Section 6.3 shall survive the repayment of indebtedness under, and otherwise shall survive the expiration or other termination of, this Agreement.  </font></div></div>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">COVENANTS OF BORROWER</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower agrees as follows:</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Reports.  Borrower shall furnish to Agent the financial statements and reports listed hereinafter (the &#x201c;Financial Statements&#x201d;):</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">as soon as practicable (and in any event within thirty (30) days unless extended by Agent in connection with quarter-end closes) after the end of each month, unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that could reasonably be expected to have a Material Adverse Effect, all certified by Borrower&#x2019;s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year-end adjustments, and (iii) they do not contain certain non-cash items that are customarily included in quarterly and annual financial statements; </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">as soon as practicable (and in any event within forty-five (45) days) after the end of each calendar quarter, unaudited interim and year-to-date financial statements as of the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">45</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">end of such calendar quarter (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that could reasonably be expected to have a Material Adverse Effect, certified by Borrower&#x2019;s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year-end adjustments;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">as soon as practicable (and in any event within ninety (90) days) after the end of each fiscal year, unqualified audited financial statements as of the end of such year (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Agent, accompanied by any management report from such accountants; </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iv.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> as soon as practicable (and in any event within thirty (30) days unless extended by Agent in connection with quarter-end closes) after the end of each month, a Compliance Certificate in the form of Exhibit E;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">v.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">as soon as practicable (and in any event within thirty (30) days unless extended by Agent in connection with quarter-end closes) after the end of each month, a report showing agings of accounts receivable and accounts payable;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">vi.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">promptly and in any event within 5 days after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements or reports that Borrower has made generally available to holders of its Common Stock and copies of any regular, periodic and special reports or registration statements that Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange;</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">vii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">[Reserved];</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">viii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">financial and business projections promptly following their approval by Borrower&#x2019;s board of directors, and in any event, within sixty (60) days after the end of Borrower&#x2019;s fiscal year, as well as budgets, operating plans and other financial information reasonably requested by Agent; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ix.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">prompt notice if Borrower or any Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists or (a) is convicted on, (b) pleads </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">nolo contendere</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering. </font></div></div>
  <p style="text-indent:-5.263%;padding-left:5.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	Borrower shall not (without the consent of Agent, such consent not to be unreasonably withheld or delayed), make any change in its (a) accounting policies or reporting practices, except as required by GAAP or (b) fiscal years or fiscal quarters, unless Borrower shall have</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">46</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">notified Agent in writing within thirty (30) days in advance of such change. The fiscal year of Borrower shall end on December 31.</font></p>
  <p style="text-indent:-5.263%;padding-left:5.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	The executed Compliance Certificate, and all Financial Statements required to be delivered pursuant to clauses (a), (b), (c) and (d) shall be sent via e-mail to financialstatements@htgc.com with a copy to legal@htgc.com and mdutra@htgc.com provided, that if e-mail is not available or sending such Financial Statements via e-mail is not possible, they shall be faxed to Agent at: (650) 473-9194, attention Account Manager: Axsome Therapeutics, Inc.</font></p>
  <p style="text-indent:-5.263%;padding-left:5.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	Notwithstanding the foregoing, documents required to be delivered under Sections 7.1(a), (b), (c) or (f) pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower emails a link thereto to Agent.</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Management Rights.  Borrower shall permit any representative that Agent or the Lenders authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal business hours; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">, however, that so long as no Event of Default has occurred and is continuing, such examinations shall be limited to no more often than twice per fiscal year.  In addition, any such representative shall have the right to meet with management and officers of Borrower to discuss such books of account and records in connection with such examinations. In addition, Agent or the Lenders shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning significant business issues affecting Borrower. Such consultations shall not unreasonably interfere with Borrower&#x2019;s business operations. The parties intend that the rights granted Agent and the Lenders shall constitute &#x201c;management rights&#x201d; within the meaning of 29 C.F.R. Section 2510.3- 101(d)(3)(ii), but that any advice, recommendations or participation by Agent or the Lenders with respect to any business issues shall not be deemed to give Agent or the Lenders, nor be deemed an exercise by Agent or the Lenders of, control over Borrower&#x2019;s management or policies. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Further Assurances.  Borrower shall from time to time following Agent&#x2019;s written request execute, deliver and file, alone or with Agent, any financing statements, security agreements, collateral assignments, notices, control agreements, or other documents to perfect, give the highest priority to Agent&#x2019;s Lien on the Collateral (subject to Permitted Liens) or otherwise evidence Agent&#x2019;s rights herein.  Borrower shall from time to time procure any instruments or documents as may be reasonably requested by Agent, and take all further action that may be necessary, or that Agent may reasonably request, to perfect and protect the Liens granted hereby and thereby.  In addition, and for such purposes only, Borrower hereby authorizes Agent to execute and deliver on behalf of Borrower and to file such financing statements (including an indication that the financing statement covers &#x201c;all assets or all personal property&#x201d; of Borrower in accordance with Section 9-504 of the UCC), collateral assignments, notices, control agreements, security agreements and other documents without the signature of Borrower either in Agent&#x2019;s name or in the name of Agent as agent and attorney-in-fact for Borrower.  Borrower shall protect and defend </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">47</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower&#x2019;s title to the Collateral and Agent&#x2019;s Lien thereon against all Persons claiming any interest adverse to Borrower or Agent other than Permitted Liens.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness.  Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except for (a) the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion, (b) payment and prepayment of purchase money Indebtedness and capital leases pursuant to its then applicable payment schedule, (c) prepayment by any Subsidiary of (i) inter-company Indebtedness owed by such Subsidiary to any Borrower, or (ii) if such Subsidiary is not a Borrower, intercompany Indebtedness owed by such Subsidiary to another Subsidiary that is not a Borrower or (d) as otherwise permitted hereunder or approved in writing by Agent.</font></div></div>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary in the foregoing, the issuance of, performance of obligations under (including any payments of interest), and conversion, exchange, exercise, repurchase, redemption (including, for the avoidance of doubt, a required repurchase in connection with the redemption of Permitted Convertible Debt upon satisfaction of a condition related to the stock price of the Common Stock), settlement or early termination or cancellation of (whether in whole or in part and including by netting or set-off) (in each case, whether in cash, Common Stock, following a merger event or other change of the Common Stock, other securities or property), or the satisfaction of any condition that would permit or require any of the foregoing, any Permitted Convertible Debt shall not constitute a prepayment of Indebtedness by Borrower for the purposes of this Section 7.4; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> that principal payments in cash (other than cash in lieu of fractional shares) shall only be allowed if the Redemption Conditions are satisfied in respect of such payment and at all times after such payment; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> further that, to the extent both (a) the aggregate amount of cash payable upon conversion or payment of any Permitted Convertible Debt (excluding any required payment of interest with respect to such Permitted Convertible Debt and excluding any payment of cash in lieu of a fractional share due upon conversion thereof) exceeds the aggregate principal amount thereof and (b) such conversion or payment does not trigger or correspond to an exercise or early unwind or settlement of a corresponding portion of the Permitted Bond Hedge Transactions relating to such Permitted Convertible Debt (including, for the avoidance of doubt, the case where there is no Bond Hedge Transaction relating to such Permitted Convertible Debt), the payment of such excess cash shall not be permitted by the preceding sentence.</font></p>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Borrower may repurchase, exchange or induce the conversion of Permitted Convertible Debt by delivery of shares of Common Stock and/or a different series of Permitted Convertible Debt and/or by payment of cash (in an amount that does not exceed the proceeds received by Borrower from the substantially concurrent issuance of Common Stock and/or Permitted Convertible Debt plus the net cash proceeds, if any, received by Borrower pursuant to the related exercise or early unwind or termination of the related Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, pursuant to the immediately following proviso); provided that, substantially concurrently with, or a commercially reasonable period of time before or after, the related</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">48</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">settlement date for the Permitted Convertible Debt that is so repurchased, exchanged or converted, Borrower shall exercise or unwind or terminate early (whether in cash, shares or any combination thereof) the portion of the Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, corresponding to such Permitted Convertible Debt that are so repurchased, exchanged or converted.</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Collateral.  Borrower shall at all times keep the Collateral and all other property and assets used in Borrower&#x2019;s business or in which Borrower now or hereafter holds any interest free and clear from any legal process or Liens whatsoever (except for Permitted Liens), and shall give Agent prompt written notice of any legal process affecting the Collateral, such other property and assets, or any Liens thereon, provided however, that the Collateral and such other property and assets may be subject to Permitted Liens.  Borrower shall not enter into or suffer to exist or become effective any agreement that prohibits or limits the ability of any Borrower to create, incur, assume or suffer to exist any Lien upon any of its property (including Intellectual Property), whether now owned or hereafter acquired, to secure its obligations under the Loan Documents to which it is a party other than (a) this Agreement and the other Loan Documents, (b) any agreements governing any purchase money Liens or capital lease obligations otherwise permitted hereby (in which case, any prohibition or limitation shall only be effective against the assets financed thereby) and (c) customary restrictions on the assignment of leases, licenses and other agreements. Borrower shall cause its Subsidiaries to protect and defend such Subsidiary&#x2019;s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary&#x2019;s property and assets free and clear from any legal process or Liens whatsoever (except for Permitted Liens), and shall give Agent prompt written notice of any legal process affecting such Subsidiary&#x2019;s assets. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Investments.  Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries to do so, other than Permitted Investments.</font></div></div>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, and for the avoidance of doubt, this Section 7.6 shall not prohibit the conversion by holders of (including any payment upon conversion, whether in cash, Common Stock or a combination thereof), or required payment of any principal or premium on (including, for the avoidance of doubt, in respect of a required repurchase in connection with the redemption of Permitted Convertible Debt upon satisfaction of a condition related to the stock price of the Common Stock) or required payment of any interest with respect to, any Permitted Convertible Debt in each case, in accordance with the terms of the indenture governing such Permitted Convertible Debt; provided that principal payments in cash (other than cash in lieu of fractional shares) shall only be allowed if the Redemption Conditions are satisfied in respect of such payment and at all times after such payment; provided further that, to the extent both (a) the aggregate amount of cash payable upon conversion or payment of any Permitted Convertible Debt (excluding any required payment of interest with respect to such Permitted Convertible Debt and excluding any payment of cash in lieu of a fractional share due upon conversion thereof) exceeds the aggregate principal amount thereof and (b) such conversion or payment does not trigger or correspond to an exercise or early unwind or settlement of a corresponding portion of the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">49</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Bond Hedge Transactions relating to such Permitted Convertible Debt (including, for the avoidance of doubt, the case where there is no Bond Hedge Transaction relating to such Permitted Convertible Debt), the payment of such excess cash shall not be permitted by the preceding sentence.</font></p>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Borrower may repurchase, exchange or induce the conversion of Permitted Convertible Debt by delivery of Common Stock and/or a different series of Permitted Convertible Debt and/or by payment of cash (in an amount that does not exceed the proceeds received by Borrower from the substantially concurrent issuance of Common Stock and/or Permitted Convertible Debt plus the net cash proceeds, if any, received by Borrower pursuant to the related exercise or early unwind or termination of the related Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, pursuant to the immediately following proviso); provided that, substantially concurrently with, or a commercially reasonable period of time before or after, the related settlement date for the Permitted Convertible Debt that is so repurchased, exchanged or converted, Borrower shall exercise or unwind or terminate early (whether in cash, shares or any combination thereof) the portion of the Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, corresponding to such Permitted Convertible Debt that are so repurchased, exchanged or converted.</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Distributions.  Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other Equity Interest other than pursuant to employee, director or consultant repurchase plans or other similar agreements that are Permitted Investments or the conversion of any of its convertible securities pursuant to the terms of such convertible securities; provided, however, in each case the repurchase or redemption price does not exceed the original consideration paid for such stock or Equity Interest unless required by the terms of such agreement or plan, or pursuant to a public repurchase of securities in compliance with the requirements of SEC Rule 10b-18, or (b) declare or pay any cash dividend or make any other cash distribution on any class of stock or other Equity Interest, except that a Subsidiary may pay dividends or make other distributions to Borrower or any Subsidiary of Borrower, (c) except for Permitted Investments, lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party in excess of $100,000 in the aggregate or (d) waive, release or forgive any Indebtedness owed by any employees, officers or directors in excess of $100,000 in the aggregate other than cancellation of Indebtedness in connection with the repurchase of Equity Interests permitted under clause (a) above.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Borrower may redeem or repurchase stock and other Equity Interests and may declare and pay dividends and make distributions in any amount, so long as the Redemption Conditions (as applied to such redemption, repurchase, dividend or distribution) are satisfied.</font></div></div>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, and for the avoidance of doubt, this Section 7.7 shall not prohibit the conversion by holders of (including any payment upon conversion, whether in cash, Common Stock or a combination thereof), or required payment of any principal or premium on (including, for the avoidance of doubt, in respect of a required repurchase in connection with the redemption of Permitted Convertible Debt upon satisfaction of a condition related to the stock price of the Common Stock) or required payment of any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">50</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">interest with respect to, any Permitted Convertible Debt in each case, in accordance with the terms of the indenture governing such Permitted Convertible Debt; provided that principal payments in cash (other than cash in lieu of fractional shares) shall only be allowed if the Redemption Conditions are satisfied in respect of such payment and at all times after such payment; provided further that, to the extent both (a) the aggregate amount of cash payable upon conversion or payment of any Permitted Convertible Debt (excluding any required payment of interest with respect to such Permitted Convertible Debt and excluding any payment of cash in lieu of a fractional share due upon conversion thereof) exceeds the aggregate principal amount thereof and (b) such conversion or payment does not trigger or correspond to an exercise or early unwind or settlement of a corresponding portion of the Bond Hedge Transactions relating to such Permitted Convertible Debt (including, for the avoidance of doubt, the case where there is no Bond Hedge Transaction relating to such Permitted Convertible Debt), the payment of such excess cash shall not be permitted by the preceding sentence.</font></p>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Borrower may repurchase, exchange or induce the conversion of Permitted Convertible Debt by delivery of Common Stock and/or a different series of Permitted Convertible Debt and/or by payment of cash (in an amount that does not exceed the proceeds received by Borrower from the substantially concurrent issuance of Common Stock and/or Permitted Convertible Debt plus the net cash proceeds, if any, received by Borrower pursuant to the related exercise or early unwind or termination of the related Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, pursuant to the immediately following proviso); provided that, substantially concurrently with, or a commercially reasonable period of time before or after, the related settlement date for the Permitted Convertible Debt that is so repurchased, exchanged or converted, Borrower shall exercise or unwind or terminate early (whether in cash, shares or any combination thereof) the portion of the Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, corresponding to such Permitted Convertible Debt that are so repurchased, exchanged or converted.</font></p>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary set forth in this Section 7, and for the avoidance of doubt:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower may make any required payment of premium to a counterparty thereunder due in connection with entering into any Permitted Bond Hedge Transaction;</font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower may make any payment in connection with any Permitted Warrant Transaction by (i) delivery of shares of the Borrower&#x2019;s Common Stock (together with cash in lieu of fractional shares) upon net share settlement thereof, (ii) set-off, netting and/or payment of an early termination payment or other payment thereunder, in each case, in the Borrower&#x2019;s Common Stock and (iii) solely to the extent the Borrower does not have the option of satisfying such payment obligations through the delivery of shares of the Borrower&#x2019;s Common Stock or is otherwise required to satisfy such payment obligations in cash, set-off, netting and/or payment of an early termination payment or other payment thereunder, in each case, in cash (it being understood and agreed that any payment made in cash </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">51</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">in connection with Permitted Warrant Transactions by set-off, netting and/or payment of an early termination payment or similar payment thereunder, in each case, after using commercially reasonable efforts to satisfy such obligation (or the portion thereof remaining after giving effect to any netting or set-off against termination or similar payments under an applicable Permitted Bond Hedge Transaction) by delivery of shares of the Borrower&#x2019;s Common Stock shall be deemed to be a payment obligation required to be satisfied in cash); and</font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower may acquire shares or other Equity Interests or cash or a combination thereof under the terms of any Permitted Bond Hedge Transaction or Permitted Warrant Transaction.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Transfers.  Except for Permitted Transfers, Borrower shall not, and shall not allow any Subsidiary to, voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of its assets.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Mergers and Consolidations.  Except for Permitted Acquisitions, Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of (a) a Subsidiary which is not a Borrower into another Subsidiary or into Borrower or (b) a Borrower into another Borrower).</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">j.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Taxes.  Borrower shall, and shall cause each of its Subsidiaries to, pay when due all material Taxes of any nature whatsoever now or hereafter imposed or assessed against Borrower or the Collateral or upon Borrower&#x2019;s ownership, possession, use, operation or disposition thereof or upon Borrower&#x2019;s rents, receipts or earnings arising therefrom.  Borrower shall, and shall cause each of its Subsidiaries to, accurately file on or before the due date therefor (taking into account proper extensions) all federal and state income Tax returns and other material Tax returns required to be filed.  Notwithstanding the foregoing, Borrower and its Subsidiaries may contest, in good faith and by appropriate proceedings diligently conducted, Taxes for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">k.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Corporate Changes.  Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without twenty (20) days&#x2019; prior written notice to Agent.  Neither Borrower nor any Subsidiary shall suffer a Change in Control. Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal place of business unless: (i) it has provided prior written notice to Agent; and (ii) such relocation shall be within the continental United States of America.  Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than (u) sales of Inventory in the ordinary course of business and Permitted Transfers, (v) relocations of Equipment and other property having an aggregate value of up to $250,000 in any fiscal year, (w) relocations of Collateral from a location described on Exhibit B to another location described on Exhibit B, (x) locations of mobile equipment, including phones, tablets and computers with employees and consultants in the ordinary course of business, (y) locations where Collateral may be temporarily located for sales, testing or demonstration purposes in </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">52</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the ordinary course of business, (z) locations where biopharmaceutical compounds and therapeutic materials are located in the ordinary course of business in connection with clinical trials and development arrangements) unless (i) it has provided prompt written notice to Agent, (ii) such relocation is within the continental United States of America and, (iii) if such relocation is to a third party bailee, it has delivered a bailee agreement in form and substance reasonably acceptable to Agent.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">l.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Deposit Accounts.  Neither Borrower nor any Subsidiary (other than Excluded Subsidiaries) shall maintain any Deposit Accounts, or accounts holding Investment Property, except with respect to which Agent has an Account Control Agreement; provided that no Account Control Agreement shall be required for Excluded Accounts. No Excluded Subsidiary shall maintain any Deposit Accounts, or accounts holding Investment Property holding more than Five Hundred Thousand Dollars ($500,000) in the aggregate for all such Accounts of all Excluded Subsidiaries at any time.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">m.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall notify Agent of each Subsidiary formed or acquired subsequent to the Closing Date and, at within 20 days such formation or acquisition (including, without limitation, pursuant to a division), as applicable, unless otherwise approved in writing by Agent in its sole discretion, shall cause any such Subsidiary (other than Excluded Subsidiaries) to execute and deliver to Agent a Joinder Agreement.  If at any time, the Excluded Subsidiary Condition is not satisfied, Borrower shall promptly cause one or more Subsidiaries to execute and deliver to Agent a Joinder Agreement such that, after giving effect to such Joinder Agreement, the Excluded Subsidiary Conditions is satisfied.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">n.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Excluded Subsidiaries.  Borrower shall not permit the Excluded Subsidiaries to: (a) have outstanding liabilities in excess of $750,000 in the aggregate at any time, or (b) own any Intellectual Property material to the business of Borrower or Borrower and its Subsidiaries, taken as a whole.  </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">o.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notification of Event of Default.  Borrower shall notify Agent immediately of the occurrence of any Event of Default.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">p.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Regulatory and Product Notices.  The Borrower shall promptly (but in any event within three (3) days) after the receipt or occurrence thereof notify Agent of:  </font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(1,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> any written notice received by Borrower or its Subsidiaries alleging potential or actual violations of any Public Health Law by Borrower or its Subsidiaries,</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(1,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">any written notice that the FDA (or international equivalent) is limiting, suspending or revoking any Registration (including, but not limited to, by the issuance of a clinical hold),</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(1,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">any written notice that Borrower or its Subsidiaries has become subject to any Regulatory Action,</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(1,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the exclusion or debarment from any governmental healthcare program or debarment or disqualification by FDA (or international equivalent) of Borrower or its Subsidiaries or its or their authorized officers,</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">53</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(1,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(v)</font><div style="display:inline;" id="docxtextref387"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">any notice that a Borrower or any Subsidiary, or any of their licensees or sublicensees (including licensees or sublicensees under any Material Agreement), is being investigated or is the subject of any allegation of potential or actual violations of any Federal Health Care Program Laws,</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(1,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(vi)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">any written notice that any product of Borrower or its Subsidiaries has been seized, withdrawn, recalled, detained, or subject to a suspension of manufacturing, or the commencement of any proceedings in the United States or any other jurisdiction seeking the withdrawal, recall, suspension, import detention, or seizure of any Borrower Product are pending or threatened in writing against Borrower or its Subsidiaries,</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(1,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(vii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">changing the scope of marketing authorization or the labeling of the products of Borrower and its Subsidiaries under any such Registration, or</font></div></div>
  <div style="text-indent:20.0%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:20.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(1,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:20.0%;">(viii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">considering or implementing any other such regulatory action,</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref388"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">except, in each case of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> through (viii) above, where such action would not reasonably be expected to have, either individually or in the aggregate, Material Regulatory Liabilities.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">q.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Proceeds.  Borrower agrees that the proceeds of the Loans shall be used solely to refinance existing indebtedness, to pay related fees and expenses in connection with this Agreement and for working capital and general corporate purposes.  The proceeds of the Loans will not be used in violation of Anti-Corruption Laws or applicable Sanctions.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">r.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Material Agreement. The Borrower shall not, without the consent of the Agent, materially amend or terminate the Antecip License Agreement. The Borrower shall give prompt written notice to the Agent of entering into a Material Agreement or materially amending or terminating a Material Agreement. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">s.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Compliance with Laws.</font></div></div>
  <p style="margin-left:5.84%;text-indent:14.16%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall maintain, and shall cause its Subsidiaries to maintain, compliance in all material respects with all applicable laws, rules or regulations (including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations), and shall, or cause its Subsidiaries to, obtain and maintain all required governmental authorizations, approvals, licenses, franchises, permits or registrations reasonably necessary in connection with the conduct of Borrower&#x2019;s business except where a failure to do so could not reasonably be expected to have a Material Adverse Effect.</font></p>
  <p style="margin-left:5.84%;text-indent:14.16%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate controlled by Borrower to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists.  Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate controlled by Borrower to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">54</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti&#x2011;Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti&#x2011;Terrorism Law.</font></p>
  <p style="margin-left:5.0%;text-indent:14.035%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower has implemented and maintains in effect policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and Borrower, its Subsidiaries and their respective officers and employees and to the knowledge of Borrower its directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects.</font></p>
  <p style="margin-left:5.0%;text-indent:14.035%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">None of Borrower, any of its Subsidiaries or any of their respective directors, officers or employees, or to the knowledge of Borrower, any agent for Borrower or its Subsidiaries that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person.  No Loan, use of proceeds or other transaction contemplated by this Agreement will violate Anti-Corruption Laws or applicable Sanctions.</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">t.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Covenants.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Minimum Cash.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Upon the Second Amendment Closing Date, Borrower shall thereafter maintain Qualified Cash in an amount greater than or equal to the sum of Forty Million Dollars ($40,000,000) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the Qualified Cash A/P Amount at all times; provided that beginning on the AXS-05 Milestone Date, Borrower shall thereafter maintain Qualified Cash in an amount greater than or equal to the sum of Twenty Five Million Dollars ($25,000,000) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the Qualified Cash A/P Amount at all times.</font></div></div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If Borrower makes any payment in respect to the last sentence of the first paragraph of Section 7.7 or makes any other cash payment in respect of Permitted Convertible Debt, subject to satisfaction of the Redemption Conditions, Borrower shall, at all times thereafter, maintain Qualified Cash in the amount required by the defined term &#x201c;Redemption Conditions&#x201d;.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Performance Covenant. If the Initial Performance Covenant Test Date has occurred, Borrower shall thereafter satisfy either of (i) Performance Covenant A or Performance Covenant B, tested at all times, or (ii) Performance Covenant C, tested quarterly.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">u.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property.  Each Borrower shall (i) protect, defend and maintain the validity and enforceability of its Intellectual Property that is material to the conduct of Borrower&#x2019;s business; (ii) promptly advise Agent in writing of material infringements of its Intellectual Property; and (iii) not allow any Intellectual Property material to Borrowers&#x2019; business to be abandoned, forfeited or dedicated to the public without Agent&#x2019;s written consent.  If a Borrower (a) obtains any Patent, registered Trademark, registered Copyright, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">55</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise, or (b) applies for any Patent or the registration of any Trademark, then such Borrower shall concurrently with the delivery of the next Compliance Certificate required under Section 7.1(d), provide written notice thereof to Agent and shall execute such intellectual property security agreements and other documents and take such other actions as Agent may request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Agent in such property.  If a Borrower decides to register any Copyrights or mask works in the United States Copyright Office, such Borrower shall: (x) provide Agent with at least fifteen (15) days prior written notice of such Borrower&#x2019;s intent to register such Copyrights or mask works together with a copy of the application it intends to file with the United States Copyright Office (excluding exhibits thereto); (y) execute an intellectual property security agreement and such other documents and take such other actions as Agent may request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Agent in the Copyrights or mask works intended to be registered with the United States Copyright Office; and (z) record such intellectual property security agreement with the United States Copyright Office contemporaneously with filing the Copyright or mask work application(s) with the United States Copyright Office. Except as set forth in the most recently delivered Compliance Certificate in accordance with Section 7.1(d), provide to Agent (x) copies of all applications that it files for Patents or for the registration of Trademarks, Copyrights or mask works, or (y) evidence that it has acquired any registered Trademarks, in each case, together with evidence of the recording of the intellectual property security agreement required for Agent to perfect and maintain a first priority perfected security interest in such property.  Borrower shall, together with the delivery of the next Compliance Certificate referred to in Section 7.01(d), provide written notice to Agent of entering into or becoming bound by any Restricted License (other than over-the-counter software that is commercially available to the public).  Borrower shall use its commercially reasonable efforts take such steps as Agent reasonably requests to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for (1) any Restricted License to be deemed &#x201c;Collateral&#x201d; and for Agent to have a security interest in it that might otherwise be restricted or prohibited by law or by the terms of any such Restricted License, whether now existing or entered into in the future, and (2) Agent to have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with Agent&#x2019;s rights and remedies under this Agreement and the other Loan Documents.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">v.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Transactions with Affiliates.  Borrower shall not and shall not permit any Subsidiary to, directly or indirectly, enter into or permit to exist any transaction of any kind with any Affiliate of Borrower or such Subsidiary except for (a) transactions on terms that are not less favorable to Borrower or such Subsidiary, as the case may be, than those that might be obtained in an arm&#x2019;s length transaction from a Person who is not an Affiliate of Borrower or such Subsidiary, (b) transactions between or among the Borrowers not involving any other Affiliate, (c) any Permitted Investment, (d) any Permitted Indebtedness, (e) any Distributions permitted by Section 7.7, (f) any Permitted Transfers, (g) to the extend approved by the Borrower&#x2019;s board of directors, the payment of reasonable fees to directors of Borrower who are not employees of Borrower or any Subsidiary, and compensation and employee benefit arrangements paid to, and indemnities provided for the benefit of, directors, officers or employees of Borrower or its Subsidiaries in the ordinary course of </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">56</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">business, and (h) any contribution to the capital of Borrower or any purchase of Equity Interests of Borrower, in each case solely to the extent such transaction does not cause a Change in Control to occur.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">w.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Malta Subsidiary.  The Malta Subsidiary shall not hold Cash outside of the United States in excess of $3,000,000 in the aggregate at any time outstanding.</font></div></div>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">RIGHT TO invest</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall provide (or in the case of a Subsequent Financing that is a registered offering, the Borrower shall use its commercially reasonable efforts to provide) the Lenders or their permitted assignees or nominees, designated as such in writing to Borrower, the opportunity, in their discretion, to participate in each Subsequent Financing in an amount of up to Five Million Dollars ($5,000,000), in the aggregate for all Lenders and their permitted assignees or nominees, in such Subsequent Financing on substantially the same terms, conditions and pricing afforded to other investors participating in such Subsequent Financing. If the Lenders (or their permitted assignees or nominees) elect to participate in any Subsequent Financing, the Lenders (or their permitted assignees or nominees, as applicable) participating in such Subsequent Financing agree to become a party to the agreements executed by the other investors participating in such Subsequent Financing, including with respect to obligations of confidentiality or as may otherwise be required by the Securities Act of 1933, as amended, and the rules and regulations promulgated by the Securities and Exchange Commission thereunder.  Borrower, or an investment bank or underwriter engaged on Borrower&#x2019;s behalf, shall provide the Lenders or their permitted assignees or nominees at least three (3) Business Days&#x2019; written notice of any planned Subsequent Financing and the opportunity to exercise the right to invest under this Section 8.1 with respect to any such Subsequent Financing.  This Section 8.1, and all rights and obligations hereunder, shall terminate upon the earliest to occur of (a) termination of this Agreement or (b) such time that the Lenders or their permitted assignees or nominees have purchased $5,000,000 of Borrower&#x2019;s Equity Interests in the aggregate in Subsequent Financings.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">In addition to the foregoing provision, upon the Second Amendment Closing Date, the Lenders have agreed to purchase between $5,000,000 and $8,000,000 of unregistered Common Stock of the Borrower at a share price equal to the lesser of (a) the three-day volume weighted average price as of the Second Amendment Signing Date or (b) the three-day volume weighted average price as of the Second Amendment Closing Date; provided that in no case shall the share price be less than a 20% discount to the three-day volume weighted average price of Borrower&#x2019;s common stock at the time of the purchase.   Prior to the Second Amendment Closing Date, the parties will execute a mutually agreed upon stock purchase agreement with customary terms and provisions.  For the avoidance of doubt, this investment will not count towards Lender&#x2019;s existing $5,000,000 Right to Invest provided above. </font></div></div>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EVENTS OF DEFAULT</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any one or more of the following events shall be an Event of Default:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">57</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Payments.  Borrower fails to pay any amount due under this Agreement or any of the other Loan Documents (other than the Warrant) on the due date; provided, however, that an Event of Default shall not occur on account of a failure to pay due solely to an administrative or operational error of Agent or the Lenders or Borrower&#x2019;s bank if Borrower had the funds to make the payment when due and makes the payment within three (3) Business Days following Borrower&#x2019;s knowledge of such failure to pay; or</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Covenants.  Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, or any of the other Loan Documents or any other agreement among Borrower, Agent and the Lenders, and (a) with respect to a default under any covenant under this Agreement (other than under Sections 4.4, 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.15, 7.17, 7.18, 7.19, 7.20. 7.21, 7.22 and 7.23), any other Loan Document, or any other agreement among Borrower, Agent and the Lenders, such default continues for more than ten (10) days after the earlier of the date on which (i) Agent or the Lenders has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 4.4, 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.15, 7.17, 7.18, 7.19, 7.20. 7.21, 7.22 and 7.23, the occurrence of such default; or </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Effect.  A circumstance has occurred that could reasonably be expected to have a Material Adverse Effect; provided that, solely for purposes of this Section 9.3, the occurrence of any of the following, in and of itself, shall not constitute a Material Adverse Effect: (a) failure to achieve the AXS-05 Milestone, (b) failure to achieve the AXS-07 Milestone, or (c) adverse results or delays in any nonclinical or clinical trial, (d) the denial, delay or limitation of approval of the FDA with respect to any drug. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Representations.  Any representation or warranty made by Borrower in any Loan Document or in the Warrant shall have been false or misleading in any material respect when made or when deemed made; or </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Insolvency.  Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay or perform under the Loan Documents, or shall become insolvent; or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the assets or property of Borrower; or (vi) shall cease its operations of its business as its business has normally been conducted, or terminate substantially all of its employees; or (vii) Borrower or its directors or majority stockholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) forty-five (45) days shall have expired after the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower shall file </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">58</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or (v) forty-five (45) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such appointment being vacated; or</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Attachments; Judgments.  Any portion of Borrower&#x2019;s assets is attached or seized, or a levy is filed against any such assets, or a judgment or judgments is/are entered for the payment of money (not covered by independent third party insurance as to which liability has not been rejected by such insurance carrier), individually or in the aggregate, of at least $500,000, or Borrower is enjoined or in any way prevented by court order from conducting any part of its business as its business has normally been conducted and such attachment, seizure, levy, judgment or injunction is not, within fifteen (15) days after the occurrence thereof, satisfied, discharged, paid or stayed (whether through the posting of a bond or otherwise); or  </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Other Obligations.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any default in the payment of any Indebtedness under any agreement or obligation of Borrower involving Indebtedness in excess of $1,000,000, beyond the period of grace if any, provided in the instrument or agreement under which such Indebtedness was created; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">There is, under any agreement to which Borrower is a party with a third party or parties, any default resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount individually or in the aggregate in excess of One Million Dollars ($1,000,000); or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any early payment is required or unwinding or termination occurs with respect to any Permitted Bond Hedge Transaction or Permitted Warrant Transaction, or any condition giving rise to the foregoing is met, in each case, with respect to which Borrower or its Affiliate is the &#x201c;affected party&#x201d; or &#x201c;defaulting party&#x201d; under the terms of such Permitted Bond Hedge Transaction or Permitted Warrant Transaction, if a Material Adverse Effect could reasonably be expected to result from such default, early payment, unwinding or termination; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iv.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any default under, (i) subject to the Antecip Direct Agreement, the Antecip License Agreement that permits the counterparty thereto to terminate such agreement or (ii) any other Material Agreement that permits the counterparty thereto to terminate such Material Agreement or accelerate payments in excess of $5,000,000 owed thereunder.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Stop Trade.  At any time, an SEC stop trade order or NASDAQ market trading suspension of the Common Stock shall be in effect for five (5) consecutive days or five (5) days during a period of ten (10) consecutive days, excluding in all cases a suspension of all trading on a public market; provided that Borrower shall not have been able to cure such </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">59</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">trading suspension within thirty (30) days of the notice thereof or list the Common Stock on another public market within sixty (60) days of such notice.</font></div></div>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">REMEDIES</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">General.  Upon the occurrence and during the continuation of any one or more Events of Default, Agent may, and at the direction of the Required Lenders shall, accelerate and demand payment of all or any part of the Secured Obligations together with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in Section 9.5, all of the Secured Obligations (including, without limitation, the Prepayment Charge and the End of Term Charge) shall automatically be accelerated and made due and payable, in each case without any further notice or act).  Borrower hereby irrevocably appoints Agent as its lawful attorney-in-fact to:  (a) exercisable following the occurrence and during the continuation of an Event of Default, (i) sign Borrower&#x2019;s name on any invoice or bill of lading for any account or drafts against account debtors; (ii) demand, collect, sue, and give releases to any account debtor for monies due, settle and adjust disputes and claims about the accounts directly with account debtors, and compromise, prosecute, or defend any action, claim, case, or proceeding about any Collateral (including filing a claim or voting a claim in any bankruptcy case in Agent&#x2019;s or Borrower&#x2019;s name, as Agent may elect); (iii) make, settle, and adjust all claims under Borrower&#x2019;s insurance policies; (iv) pay, contest or settle any Lien, charge, encumbrance, security interest, or other claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; (v) transfer the Collateral into the name of Agent or a third party as the UCC permits; and (vi) receive, open and dispose of mail addressed to Borrower; and (b) regardless of whether an Event of Default has occurred, (i) endorse Borrower&#x2019;s name on any checks, payment instruments, or other forms of payment or security; and (ii) notify all account debtors to pay Agent directly.  Borrower hereby appoints Agent as its lawful attorney-in-fact to sign Borrower&#x2019;s name on any documents necessary to perfect or continue the perfection of Agent&#x2019;s security interest in the Collateral regardless of whether an Event of Default has occurred until all Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been satisfied in full and the Loan Documents (other than the Warrant) have been terminated.  Agent&#x2019;s foregoing appointment as Borrower&#x2019;s attorney in fact, and all of Agent&#x2019;s rights and powers, coupled with an interest, are irrevocable until all Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been fully repaid and performed and the Loan Documents (other than the Warrant) have been terminated.  Agent may, and at the direction of the Required Lenders shall, exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral.  All Agent&#x2019;s rights and remedies shall be cumulative and not exclusive.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Collection; Foreclosure.  Upon the occurrence and during the continuance of any Event of Default, Agent may, and at the direction of the Required Lenders shall, at any </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">60</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Agent may elect.  Any such sale may be made either at public or private sale at its place of business or elsewhere.  Borrower agrees that any such public or private sale may occur upon ten (10) calendar days&#x2019; prior written notice to Borrower.  Agent may require Borrower to assemble the Collateral and make it available to Agent at a place designated by Agent that is reasonably convenient to Agent and Borrower.  The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Agent in the following order of priorities:</font></div></div>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	First, to Agent and the Lenders in an amount sufficient to pay in full Agent&#x2019;s and the Lenders&#x2019; reasonable costs and professionals&#x2019; and advisors&#x2019; fees and expenses as described in Section 11.12;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	Second, to the Lenders in an amount equal to the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Agent may choose in its sole discretion; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	Finally, after the full and final payment in Cash of all of the Secured Obligations (other than inchoate obligations), to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Agent shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC.</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No Waiver.  Agent shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Agent to marshal any Collateral.  </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Cumulative Remedies.  The rights, powers and remedies of Agent hereunder shall be in addition to all rights, powers and remedies given by statute or rule of law and are cumulative.  The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Agent.</font></div></div>
  <div style="margin-left:26.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">MISCELLANEOUS</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Severability.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Notice.  Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">61</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(i) the day of transmission by electronic mail or hand delivery or delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States of America mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If to Agent:</font></div></div>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.<br>Legal Department<br>Attention:  Chief Legal Officer and Michael Dutra<br>400 Hamilton Avenue, Suite 310<br>Palo Alto, CA  94301<br>email: legal@htgc.com and mdutra@htgc.com<br>Telephone:  650-289-3060</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If to the Lenders:</font></div></div>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.<br>Legal Department<br>Attention:  Chief Legal Officer and Michael Dutra<br>400 Hamilton Avenue, Suite 310<br>Palo Alto, CA  94301<br>email: legal@htgc.com and mdutra@htgc.com<br>Telephone:  650-289-3060</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If to Borrower:</font></div></div>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">22 Cortlandt Street, 16th Floor</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">New York, NY, 10007</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Attention:  Nick Pizzie, Chief Financial Officer<br>email: npizzie@axsome.com</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Telephone:  +1-646-844-6270</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">or to such other address as each party may designate for itself by like notice.</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement; Amendments.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, non-disclosure or confidentiality agreements, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Agent&#x2019;s revised proposal letter dated September 2, 2020 and the Non-Disclosure Agreement).  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Neither this Agreement, any other Loan Document (other than the Warrant which is subject to the amendment provisions therein), nor any terms hereof or thereof may be amended, supplemented or modified except in accordance with the provisions of this Section 11.3(b).  The Required Lenders and Borrower party to the relevant Loan Document </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">62</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">may, or, with the written consent of the Required Lenders, the Agent and the Borrower party to the relevant Loan Document may, from time to time, (i) enter into written amendments, supplements or modifications hereto and to the other Loan Documents for the purpose of adding any provisions to this Agreement or the other Loan Documents or changing in any manner the rights of the Lenders or of the Borrower hereunder or thereunder or (ii) waive, on such terms and conditions as the Required Lenders or the Agent, as the case may be, may specify in such instrument, any of the requirements of this Agreement or the other Loan Documents or any default or Event of Default and its consequences; provided, however, that no such waiver and no such amendment, supplement or modification shall (A) forgive the principal amount or extend the final scheduled date of maturity of any Loan, extend the scheduled date of any amortization payment in respect of any Term Loan, reduce the stated rate of any interest (or fee payable hereunder) or extend the scheduled date of any payment thereof, in each case without the written consent of each Lender directly affected thereby; (B) eliminate or reduce the voting rights of any Lender under this Section 11.3(b) without the written consent of such Lender; (C) reduce any percentage specified in the definition of Required Lenders, consent to the assignment or transfer by the Borrower of any of its rights and obligations under this Agreement and the other Loan Documents, release all or substantially all of the Collateral or release a Borrower from its obligations under the Loan Documents, in each case without the written consent of all Lenders; or (D) amend, modify or waive any provision of Section 11.18 or Addendum 3 without the written consent of the Agent.  Any such waiver and any such amendment, supplement or modification shall apply equally to each Lender and shall be binding upon Borrower, the Lender, the Agent and all future holders of the Loans.  Notwithstanding the foregoing, the Warrant may be amended in accordance with its terms, and this Section 11.3(b) shall not apply to such amendments.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No Strict Construction.  The parties hereto have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No Waiver.  The powers conferred upon Agent and the Lenders by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Agent or the Lenders to exercise any such powers.  No omission or delay by Agent or the Lenders at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Agent or the Lenders is entitled, nor shall it in any way affect the right of Agent or the Lenders to enforce such provisions thereafter.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Survival.  All agreements, representations and warranties contained in this Agreement and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Agent and the Lenders and shall survive the execution and delivery of this Agreement. Sections 6.3, 11.15 and 11.18 shall survive the termination of this Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">63</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns.  The provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any).  Borrower shall not assign its obligations under this Agreement or any of the other Loan Documents (other than the Warrant which may be assigned in accordance with its terms) without Agent&#x2019;s express prior written consent, and any such attempted assignment shall be void and of no effect.  Agent and the Lenders may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior notice to Borrower (provided that any assignment, transfer or endorsement of the Warrant shall be subject to the terms thereof), and all of such rights shall inure to the benefit of Agent&#x2019;s and the Lenders&#x2019; successors and assigns; provided that as long as no Event of Default has occurred and is continuing, neither Agent nor any Lender may assign, transfer or endorse its rights hereunder or under the Loan Documents to any party that is a direct competitor of Borrower or any &#x201c;vulture fund&#x201d; &#x201c;distressed debt fund&#x201d; or similar entity (in each case, as reasonably determined by Agent in good faith), it being acknowledged that in all cases, any transfer to an Affiliate of any Lender or Agent shall be allowed.  Notwithstanding the foregoing, (x) in connection with any assignment by a Lender as a result of a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Agent and the Lenders may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party (provided that any assignment, transfer or endorsement of the Warrant shall be subject to the terms thereof) and (y) in connection with a Lender&#x2019;s own financing or securitization transactions, the restrictions set forth herein shall not apply and Agent and the Lenders may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction (provided that any assignment, transfer or endorsement of the Warrant shall be subject to the terms thereof); provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Agent shall have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such assignee as Agent reasonably shall require.  The Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at one of its offices in the United States a register for the recordation of the names and addresses of the Lender(s), and the Term Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#x201c;Register&#x201d;).  The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Agent and the Lender(s) shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement.  The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Participations.  Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each participant and the principal amounts (and stated interest) of each participant&#x2019;s interest in the Loans or other obligations under the Loan Documents (the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">64</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Participant Register&#x201d;); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant's interest in any commitments, loans, its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations.  The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.  For the avoidance of doubt, the Agent (in its capacity as Agent) shall have no responsibility for maintaining a Participant Register.  Borrower agrees that each participant shall be entitled to the benefits of the provisions in Addendum 1 attached hereto (subject to the requirements and limitations therein, including the requirements under Section 7 of Addendum 1 attached hereto (it being understood that the documentation required under Section 7 of Addendum 1 attached hereto shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section 11.7; provided that such participant shall not be entitled to receive any greater payment under Addendum 1 attached hereto, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a change in law that occurs after the participant acquired the applicable participation.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Governing Law.  This Agreement and the other Loan Documents have been negotiated and delivered to Agent and the Lenders in the State of California, and shall have been accepted by Agent and the Lenders in the State of California.  Payment to Agent and the Lenders by Borrower of the Secured Obligations is due in the State of California.  This Agreement and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">j.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Consent to Jurisdiction and Venue.  All judicial proceedings (to the extent that the reference requirement of Section 11.11 is not applicable) arising in or under or related to this Agreement or any of the other Loan Documents may be brought in any state or federal court located in the State of California.  By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement or the other Loan Documents.  Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2.  Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">k.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Mutual Waiver of Jury Trial / Judicial Reference.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">65</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert Person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws.  EACH OF BORROWER, AGENT AND THE LENDERS SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, &#x201c;CLAIMS&#x201d;) ASSERTED BY BORROWER AGAINST AGENT, THE LENDERS OR THEIR RESPECTIVE ASSIGNEE OR BY AGENT, THE LENDERS OR THEIR RESPECTIVE ASSIGNEE AGAINST BORROWER.  This waiver extends to all such Claims, including Claims that involve Persons other than Agent, Borrower and the Lenders; Claims that arise out of or are in any way connected to the relationship among Borrower, Agent and the Lenders; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If the waiver of jury trial set forth in Section 11.11(a) is ineffective or unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of the Santa Clara County, California.  Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding.    </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in Section 11.10, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">l.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Professional Fees.  Borrower promises to pay Agent&#x2019;s and the Lenders&#x2019; reasonable, documented out-of-pocket fees and expenses necessary to finalize the loan documentation, including but not limited to reasonable, documented attorneys&#x2019; fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable, documented out-of-pocket attorneys&#x2019; and other professionals&#x2019; fees and expenses incurred by Agent after the Closing Date in connection with or related to:  (a) the Loan; (b) the administration, collection, or enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, audit, field exam, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Agent or the Lenders in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower&#x2019;s estate, and any appeal or review thereof.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">66</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">m.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Confidentiality.  Agent and the Lenders acknowledge that certain items of Collateral and information provided to Agent and the Lenders by Borrower, including items provided in connection with the Non-Disclosure Agreement, are confidential and proprietary information of Borrower, if and to the extent such information either (x) is marked as confidential by Borrower at the time of disclosure, or (y) should reasonably be understood to be confidential (the &#x201c;Confidential Information&#x201d;).  Accordingly, Agent and the Lenders agree that any Confidential Information it may obtain in the course of acquiring, administering, or perfecting Agent&#x2019;s security interest in the Collateral shall not be disclosed to any other Person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Agent and the Lenders may disclose any such information:  (a) to its Affiliates and its partners, investors, lenders, directors, officers, employees, agents, advisors, counsel, accountants, counsel, representative and other professional advisors if Agent or the Lenders in their sole discretion determines that any such party should have access to such information in connection with such party&#x2019;s responsibilities in connection with the Loan or this Agreement and; provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the public through no fault of Agent or any Lender; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Agent or the Lenders and any rating agency; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Agent&#x2019;s or the Lenders&#x2019; counsel; (e) to comply with any legal requirement or law applicable to Agent or the Lenders or demanded by any governmental authority; (f) to the extent reasonably necessary in connection with the exercise of, or preparing to exercise, or the enforcement of, or preparing to enforce, any right or remedy under any Loan Document (including Agent&#x2019;s sale, lease, or other disposition of Collateral after default), or any action or proceeding relating to any Loan Document; (g) to any participant or assignee of Agent or the Lenders or any prospective participant or assignee, provided, that such participant or assignee or prospective participant or assignee is subject to confidentiality restrictions no less stringent than this Section 11.13 and in any event that reasonably protect against the disclosure of Confidential Information; (h) otherwise to the extent consisting of general portfolio information that does not identify Borrower; or (i) otherwise with the prior consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its Affiliates or any guarantor under this Agreement or the other Loan Documents.  Agent&#x2019;s and the Lenders&#x2019; obligations under this Section 11.13 shall supersede all of their respective obligations under the Non-Disclosure Agreement.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">n.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Assignment of Rights.  Borrower acknowledges and understands that Agent or the Lenders may, subject to Section 11.7, sell and assign all or part of its interest hereunder and under the Loan Documents (other than the Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(229,33,56,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">which is subject to any assignment, transfer or endorsement provisions therein) to any Person or entity (an &#x201c;Assignee&#x201d;).  After such assignment the term &#x201c;Agent&#x201d; or &#x201c;Lender&#x201d; as used in the Loan Documents (other than the Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(229,33,56,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">which is subject to any assignment, transfer or endorsement provisions therein) shall mean and include such Assignee, and such Assignee </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">67</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">shall be vested with all rights, powers and remedies of Agent and the Lenders hereunder with respect to the interest so assigned; but with respect to any such interest not so transferred, Agent and the Lenders shall retain all rights, powers and remedies hereby given.  No such assignment by Agent or the Lenders shall relieve Borrower of any of its obligations hereunder.  the Lenders agrees that in the event of any transfer by it of the promissory note(s) (if any), it will endorse thereon a notation as to the portion of the principal of the promissory note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">o.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Revival of Secured Obligations.  This Agreement and the Loan Documents shall remain in full force and effect and continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower&#x2019;s assets, or if any payment or transfer of Collateral is recovered from Agent or the Lenders.  The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Agent, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Agent, the Lenders or by any obligee of the Secured Obligations, whether as a &#x201c;voidable preference,&#x201d; &#x201c;fraudulent conveyance,&#x201d; or otherwise, all as though such payment, performance, or transfer of Collateral had not been made.  In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Agent or the Lenders in Cash.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">p.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Counterparts.  This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">q.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No Third-Party Beneficiaries.  No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any Person other than Agent, the Lenders and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal and solely among Agent, the Lenders and the Borrower. </font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">r.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Agency.  Agent and each Lender hereby agree to the terms and conditions set forth on Addendum 3 attached hereto.  Borrower acknowledges and agrees to the terms and conditions set forth on Addendum 3 attached hereto.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">s.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Publicity.  None of the parties hereto nor any of its respective member businesses and Affiliates shall, without the other parties&#x2019; prior written consent (which shall not be unreasonably withheld or delayed), publicize or use (a) the other party's name (including a brief description of the relationship among the parties hereto), logo or hyperlink </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">68</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:5.833%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">to such other parties&#x2019; web site, separately or together, in written and oral presentations, advertising, promotional and marketing materials, client lists, public relations materials or on its web site (together, the &#34;Publicity Materials&#34;); (b) the names of officers of such other parties in the Publicity Materials; and (c) such other parties&#x2019; name, trademarks, servicemarks in any news or press release concerning such party; provided however, notwithstanding anything to the contrary herein, no such consent shall be required (i) to the extent necessary to comply with the requests of any regulators, legal requirements or laws applicable to such party, pursuant to any listing agreement with any national securities exchange (so long as such party provides prior notice to the other party hereto to the extent reasonably practicable) and (ii) to comply with Section 11.13.</font></div></div>
  <div style="margin-left:5.833%;text-indent:7.08%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.079974938141811%;">t.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Electronic Execution of Certain Other Documents.  The words &#x201c;execution,&#x201d; &#x201c;execute&#x201d;, &#x201c;signed,&#x201d; &#x201c;signature,&#x201d; and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transaction Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(SIGNATURES TO FOLLOW)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">69</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, Borrower, Agent and the Lenders have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">BORROWER:</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Accepted in Palo Alto, California:</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">AGENT:</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">LENDERS:</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">70</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Table of Addenda, Exhibits and Schedules</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Addendum 1:	Taxes; Increased Costs</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Addendum 2:	[Reserved]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Addendum 3:	Agent and Lender Terms</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A:	Advance Request <br>		Attachment to Advance Request</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B:	Name, Locations, and Other Information for Borrower</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit C:	Borrower&#x2019;s Patents, Trademarks, Copyrights and Licenses</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit D:	Borrower&#x2019;s Deposit Accounts and Investment Accounts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit E:	Compliance Certificate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit F:	Joinder Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit G:	[Reserved]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit H:	ACH Debit Authorization Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit I:	[Reserved]</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-1:	Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-2:	Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-3:	Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-4:	Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit K:	Form of Warrant</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1		Commitments</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1		Subsidiaries<br>Schedule 1A		Existing Permitted Indebtedness<br>Schedule 1B		Existing Permitted Investments<br>Schedule 1C		Existing Permitted Liens<br>Schedule 5.3		Consents, Etc.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">71</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.8		Tax Matters<br>Schedule 5.9		Intellectual Property Claims<br>Schedule 5.10(a)	Current Company IP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.10(d)	Matters Relating to current Material Agreements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.10(f)	Enforceability, Entitlement and Exploitation of Current Company IP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.10(i)	Claims of Infringement on Third Party IP By Current Company IP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.10(j)	Infringement on Third Party IP By Current Company IP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.10(k)	Obligations Relating to Company IP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.10(l)	Third Party Infringements of Company IP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.10(n)	FDA Good Manufacturing Practices Compliance Matters</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.10(o)		Intellectual Property</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.11		Borrower Products<br>Schedule 5.14		Capitalization</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">72</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">ADDENDUM 1 to LOAN AND SECURITY AGREEMENT</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">TAXES; INCREASED COSTS</font></p>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Defined Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this Addendum 1:</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Connection Income Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Excluded Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (A) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (B) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Term Commitment pursuant to a law in effect on the date on which (A) such Lender acquires such interest in the Loan or Term Commitment or (B) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 2 or Section 4 of this Addendum 1, amounts with respect to such Taxes were payable either to such Lender&#x2019;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient&#x2019;s failure to comply with Section 7 of this Addendum 1 and (iv) any withholding Taxes imposed under FATCA.</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">FATCA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code, and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among governmental authorities and implementing such Sections of the Code.</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Foreign Lender</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Lender that is not a U.S. Person.</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indemnified Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of the Borrower under any Loan Document and (ii) to the extent not otherwise described in clause (i), Other Taxes.</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Other Connection Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">73</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.537%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">g.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Other Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment.</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">h.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Recipient</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Agent or any Lender, as applicable.</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Withholding Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Borrower and the Agent.</font></div></div>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Payments Free of Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Any and all payments by or on account of any obligation of the Borrower under any Loan Document (other than the Warrant) shall be made without deduction or withholding for any Taxes, except as required by applicable law.  If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant governmental authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the Borrower shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 2 or Section 4 of this Addendum 1) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.</font></div></div>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Payment of Other Taxes by Borrower</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Borrower shall timely pay to the relevant governmental authority in accordance with applicable law, or at the option of the Agent timely reimburse it for the payment of, any Other Taxes.</font></div></div>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indemnification by Borrower</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  The Borrower shall indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under Section 2 of this Addendum 1 or this Section 4) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant governmental authority.  A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Agent), or by the Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error. </font></div></div>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Indemnification by the Lenders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Each Lender shall severally indemnify the Agent, within 10 days after demand therefor, for (a) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (b) any </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">74</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.87%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Taxes attributable to such Lender&#x2019;s failure to comply with the provisions of Section 11.8 of the Agreement relating to the maintenance of a Participant Register and (c) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant governmental authority.  A certificate as to the amount of such payment or liability delivered to any Lender by the Agent shall be conclusive absent manifest error.  Each Lender hereby authorizes the Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Agent to the Lender from any other source against any amount due to the Agent under this Section 5.</font></div></div>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Evidence of Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  As soon as practicable after any payment of Taxes by the Borrower to a governmental authority pursuant to the provisions of this Addendum 1, the Borrower shall deliver to the Agent the original or a certified copy of a receipt issued by such governmental authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Agent.</font></div></div>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Status of Lenders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Agent, at the time or times reasonably requested by the Borrower or the Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Agent as will permit such payments to be made without withholding or at a reduced rate of withholding.  In addition, any Lender, if reasonably requested by the Borrower or the Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Agent as will enable the Borrower or the Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements.  Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Sections 7(b)(i), 7(b)(ii) and 7(b)(iv) of this Addendum 1) shall not be required if in the Lender&#x2019;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Without limiting the generality of the foregoing, in the event that the Borrower is a U.S. Person,</font></div></div>
  <div style="margin-left:15.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:1.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.9814572685130158%;">i.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">any Lender that is a U.S. Person shall deliver to the Borrower and the Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax;</font></div></div>
  <div style="margin-left:15.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:1.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.9814572685130158%;">ii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">75</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:15.87%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:1.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.9814572685130158%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), whichever of the following is applicable:</font></div></div>
  <div style="margin-left:20.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.212056110198408%;">A.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#x201c;interest&#x201d; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#x201c;business profits&#x201d; or &#x201c;other income&#x201d; article of such tax treaty;</font></div></div>
  <div style="margin-left:20.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.212056110198408%;">B.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">executed copies of IRS Form W-8ECI;</font></div></div>
  <div style="margin-left:20.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.212056110198408%;">C.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit J-1 to the effect that such Foreign Lender is not a &#x201c;bank&#x201d; within the meaning of Section 881(c)(3)(A) of the Code, a &#x201c;10 percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, or a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">U.S. Tax Compliance Certificate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E; or</font></div></div>
  <div style="margin-left:20.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.212056110198408%;">D.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of Exhibit J-2 or Exhibit J-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit J-4 on behalf of each such direct and indirect partner;</font></div></div>
  <div style="margin-left:15.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:1.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.9814572685130158%;">iii.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">76</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:15.87%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:1.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.9814572685130158%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Agent to determine the withholding or deduction required to be made; and</font></div></div>
  <div style="margin-left:15.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:1.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.9814572685130158%;">iv.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Agent as may be necessary for the Borrower and the Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#x2019;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment.  Solely for purposes of this clause (iv), &#x201c;FATCA&#x201d; shall include any amendments made to FATCA after the date of this Agreement.</font></div></div>
  <div style="margin-left:7.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6046851172901593%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Agent in writing of its legal inability to do so.</font></div></div>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Treatment of Certain Refunds</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to the provisions of this Addendum 1 (including by the payment of additional amounts pursuant to the provisions of this Addendum 1), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under the provisions of this Addendum 1 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant governmental authority with respect to such refund).  Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this Section 8 (plus any penalties, interest or other charges imposed by the relevant governmental authority) in the event that such indemnified party is required to repay such refund to such governmental authority.  Notwithstanding anything to the contrary in this Section 8, in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 8 the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.  This Section 8 shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">77</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Increased Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  If any change in applicable law shall subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (ii) through (iv) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto, and the result shall be to increase the cost to such Recipient of making, converting to, continuing or maintaining any Term Loan or of maintaining its obligation to make any such Loan, or to reduce the amount of any sum received or receivable by such Recipient (whether of principal, interest or any other amount), then, upon the request of such Recipient, the Borrower will pay to such Recipient such additional amount or amounts as will compensate such Recipient for such additional costs incurred or reduction suffered.</font></div></div>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Mitigation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">. If any Lender requires the Borrower to pay any Indemnified Taxes or additional amounts pursuant to this Addendum, then such Lender shall (at the request of the Borrower) use reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its branches, offices, or affiliates, if, in the judgment of such Lender, such designation or assignment: (i) would eliminate or reduce amounts payable pursuant to this Addendum in the future, and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with such designation or assignment.</font></div></div>
  <div style="margin-left:0.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.362251588822758%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">.  Each party&#x2019;s obligations under the provisions of this Addendum 1 (including any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of the Loan Documents) shall survive the resignation or replacement of the Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Term Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document (other than the Warrant).</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">78</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">ADDENDUM 2 to LOAN AND SECURITY AGREEMENT</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">[Reserved.]</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> IF &#34;1&#34; = &#34;1&#34; &#34;WEST\296323106.2&#34; &#34;&#34; WEST\296323106.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">ADDENDUM 3 to LOAN AND SECURITY AGREEMENT</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Agent and Lender Terms</font></p>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Each Lender hereby irrevocably appoints Hercules Capital, Inc. to act on its behalf as the Agent hereunder and under the other Loan Documents (other than the Warrant) and authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Each Lender agrees to indemnify the Agent in its capacity as such (to the extent not reimbursed by Borrower and without limiting the obligation of Borrower to do so), according to its respective Term Commitment percentages (based upon the total outstanding Term Commitments) in effect on the date on which indemnification is sought under this Addendum 3, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever that may at any time be imposed on, incurred by or asserted against the Agent in any way relating to or arising out of, this Agreement, any of the other Loan Documents (other than the Warrant) or any documents contemplated by or referred to herein or therein (other than the Warrant) or the transactions contemplated hereby or thereby or any action taken or omitted by the Agent under or in connection with any of the foregoing; The agreements in this Section shall survive the payment of the Loans and all other amounts payable hereunder.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Agent in Its Individual Capacity.  The Person serving as the Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Agent and the term &#x201c;Lender&#x201d; shall, unless otherwise expressly indicated or unless the context otherwise requires, include each such Person serving as Agent hereunder in its individual capacity. </font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Exculpatory Provisions.  The Agent shall have no duties or obligations except those expressly set forth herein and in the other Loan Documents.  Without limiting the generality of the foregoing, the Agent shall not:</font></div></div>
  <div style="margin-left:20.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">be subject to any fiduciary or other implied duties, regardless of whether any default or any Event of Default has occurred and is continuing;</font></div></div>
  <div style="margin-left:20.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Agent is required to exercise as directed in writing by the Lenders; provided that the Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Agent to liability or that is contrary to any Loan Document or applicable law; and</font></div></div>
  <div style="margin-left:20.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and the Agent shall not be liable for the failure to disclose, any information relating to the Borrower or any of its </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:20.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.16625%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Affiliates that is communicated to or obtained by any Person serving as the Agent or any of its Affiliates in any capacity.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Lenders or as the Agent shall believe in good faith shall be necessary, under the circumstances or (ii) in the absence of its own gross negligence or willful misconduct.</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any default or Event of Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Section 4 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Agent. Reliance by Agent.  Agent may rely, and shall be fully protected in acting, or refraining to act, upon, any resolution, statement, certificate, instrument, opinion, report, notice, request, consent, order, bond or other paper or document that it has no reason to believe to be other than genuine and to have been signed or presented by the proper party or parties or, in the case of cables, telecopies and telexes, to have been sent by the proper party or parties.  In the absence of its gross negligence or willful misconduct, Agent may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to Agent and conforming to the requirements of this Agreement or any of the other Loan Documents.  Agent may consult with counsel, and any opinion or legal advice of such counsel shall be full and complete authorization and protection in respect of any action taken, not taken or suffered by Agent hereunder or under any Loan Documents in accordance therewith.  Agent shall have the right at any time to seek instructions concerning the administration of the Collateral from any court of competent jurisdiction.  Agent shall not be under any obligation to exercise any of the rights or powers granted to Agent by this Agreement and the other Loan Documents at the request or direction of the Lenders unless Agent shall have been provided by the Lenders with adequate security and indemnity against the costs, expenses and liabilities that may be incurred by it in compliance with such request or direction.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">ADVANCE REQUEST</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">To: 	Agent:	Date:		__________, 2006</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Hercules Capital, Inc. (the &#x201c;Agent&#x201d;)<br>	400 Hamilton Avenue, Suite 310<br>	Palo Alto, CA 94301<br>	email: legal@htgc.com<br>	Attn:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc. (&#x201c;Borrower&#x201d;) hereby requests from Hercules Capital, Inc. (&#x201c;Lender&#x201d;) an Advance in the amount of _____________________ Dollars ($________________) (the &#x201c;Advance Amount&#x201d;) on ______________, _____ (the &#x201c;Advance Date&#x201d;) pursuant to the Loan and Security Agreement, dated September 25, 2020 among Borrower, Agent and the Lender (the &#x201c;Agreement&#x201d;). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Please:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(a)	Issue a check payable to Borrower	________</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">or</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(b)	Wire Funds to Borrower&#x2019;s account	________ [IF FILED PUBLICLY, ACCOUNT INFO REDACTED FOR SECURITY PURPOSES]</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	Bank:                        _____________________________<br>	Address:                    _____________________________<br>	                                  _____________________________<br>	ABA Number:          _____________________________<br>	Account Number:     _____________________________<br>	Account Name:        _____________________________</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	Contact Person:        _____________________________<br>	Phone Number</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">        </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	To Verify Wire Info: _____________________________</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">	Email address:           _____________________________</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower represents that the conditions precedent to the Advance set forth in the Agreement are satisfied or waived and shall be satisfied upon the making of such Advance, including but not limited to:  (i) that no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing; (ii) that the representations and warranties set forth in the Agreement and in the Warrant are and shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date; (iii) that Borrower is in compliance with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (iv) that as of the Advance Date, no fact or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">condition exists that could (or could, with the passage of time, the giving of notice, or both) constitute an Event of Default under the Loan Documents.  Borrower understands and acknowledges that Agent has the right to review the financial information supporting this representation and, based upon such review in its sole but reasonable discretion, the Lender may decline to fund the requested Advance.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower hereby represents that Borrower&#x2019;s corporate status and locations have not changed since the date of the Agreement or, if the Attachment 1 to this Advance Request is completed, are as set forth in the Attachment to this Advance Request.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advances requested under Tranche 4, Borrower represents and warrants that the information provided on Attachment 2 to this Advance Request is true and correct in all respects.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower agrees to notify Agent promptly before the funding of the Loan if any of the matters which have been represented above shall not be true and correct on the Advance Date and if Agent has received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed to be true and correct as of the Advance Date.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Executed as of [              ], 20[   ].</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">BORROWER: </font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURE:________________________<br>TITLE:_____________________________<br>PRINT NAME:______________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">ATTACHMENT 1 TO ADVANCE REQUEST</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Dated: _______________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower hereby represents and warrants to Agent that Borrower&#x2019;s current name and organizational status is as follows:</font></p>
  <p style="margin-left:6.667%;text-indent:-55.556%;padding-left:33.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Name:	[                                      ]</font></p>
  <p style="margin-left:6.667%;text-indent:-55.556%;padding-left:33.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Type of organization:	[                                      ]</font></p>
  <p style="margin-left:6.667%;text-indent:-55.556%;padding-left:33.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">State of organization:	[                                      ]</font></p>
  <p style="margin-left:6.667%;text-indent:-55.556%;padding-left:33.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Organization file number:	[                                      ]	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower hereby represents and warrants to Agent that the street addresses, cities, states and postal codes of its current locations are as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">[ &#xf098; ]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower hereby represents and warrants to Agent that the Advance Amount does not exceed the Maximum Term Loan Amount as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">a.	Advance Amount: $________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">b.	Maximum Term Loan Amount: $300,000,000</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">c.	Is clause a. less than or equal to clause b.?</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">					Yes/Compliant _______ No/Non-Compliant _______</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1.  Borrower represents and warrants to Agent that Borrower&#x2019;s current name and organizational status as of the Closing Date is as follows:</font></p>
  <p style="text-indent:-36.364%;padding-left:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Name:	[                                               ]</font></p>
  <p style="text-indent:-36.364%;padding-left:26.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Type of organization:	[                                               ]</font></p>
  <p style="text-indent:-36.364%;padding-left:26.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">State of organization:	[                                               ]</font></p>
  <p style="text-indent:-36.364%;padding-left:26.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Organization file number:	[                                               ]	</font></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2.  Borrower represents and warrants to Agent that for five (5) years prior to the Closing Date, Borrower did not do business under any other name or organization or form except the following:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Name:	<br>Used during dates of:	<br>Type of Organization:	<br>State of organization:	<br>Organization file Number:	<br>Borrower&#x2019;s fiscal year ends on _____<br>Borrower&#x2019;s federal employer tax identification number is: _______________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">       3.  Borrower represents and warrants to Agent that its chief executive office is located at _______________.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT C</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">BORROWER&#x2019;S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT D</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">BORROWER&#x2019;S DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT E</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">COMPLIANCE CERTIFICATE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Hercules Capital, Inc. (as &#x201c;Agent&#x201d;)<br>400 Hamilton Avenue, Suite 310<br>Palo Alto, CA 94301</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Reference is made to that certain Loan and Security Agreement dated September 25, 2020 and the Loan Documents (as defined therein) entered into in connection with such Loan and Security Agreement all as may be amended from time to time (hereinafter referred to collectively as the &#x201c;Loan Agreement&#x201d;) by and among Hercules Capital, Inc. (the &#x201c;Agent&#x201d;), the several banks and other financial institutions or entities from time to time party thereto (collectively, the &#x201c;Lender&#x201d;) and Axsome Therapeutics, Inc. (the &#x201c;Company&#x201d;) and each of its Subsidiaries (as defined therein) other than Excluded Subsidiaries (as defined therein), as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is authorized to provide certification of information regarding the Company; hereby certifies, in such capacity, that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance for the period ending _____ of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained therein are true and correct on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties.  Attached are the required documents supporting the above certification.  The undersigned further certifies that these are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year-end adjustments) and are consistent from one period to the next except as explained below.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:47.474%;"></td>
    <td style="width:29.427%;"></td>
    <td style="width:23.098%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">REPORTING REQUIREMENT</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">REQUIRED</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CHECK IF ATTACHED</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Interim Financial Statements</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Monthly within 30 days</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Interim Financial Statements</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Quarterly within 45 days</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Audited Financial Statements</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">FYE within 90 days</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Accounts Receivable and Payable Agings</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Monthly within 30 days</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Following registering new Intellectual Property or the acquisition thereof (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 7.21 of Loan Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted License</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Following entering into or becoming bound by new Restricted Licenses (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 7.21 of Loan Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:0.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Section 5.9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2013; Intellectual Property</font></p>
  <p style="margin-left:0.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Has any claim been made to Borrower that any material part of the Intellectual Property violates the rights of any third party?  Yes____       No_____</font></p>
  <p style="margin-left:0.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Section 5.11 &#x2013; Borrower Products</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(a)  To Borrower&#x2019;s knowledge, is any material Intellectual Property owned by Borrower or any Borrower Product subject to any actual or, to the knowledge of Borrower, threatened in writing litigation, proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any manner Borrower&#x2019;s use, transfer or licensing thereof or that could reasonably be expected to affect the validity, use or enforceability thereof?  Yes____       No_____</font></p>
  <p style="margin-left:0.84%;text-indent:6.723%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(b) Has Borrower received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning Borrower&#x2019;s ownership in any Intellectual Property material to Borrower&#x2019;s business (or written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property material to Borrower&#x2019;s business of the owner thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto or, to Borrower&#x2019;s knowledge, is there a reasonable basis for any such claim?  Yes____       No_____</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">ACCOUNTS OF BORROWER AND ITS SUBSIDIARIES AND AFFILIATES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The undersigned hereby also confirms the below disclosed accounts represent all depository accounts and securities accounts presently open in the name of each Borrower or Borrower&#x2019;s Subsidiary/Affiliate, as applicable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Each new account that has been opened since delivery of the previous Compliance Certificate is designated below with a &#x201c;*&#x201d;.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:22.773%;"></td>
    <td style="width:3.781%;"></td>
    <td style="width:15.52%;"></td>
    <td style="width:15.178%;"></td>
    <td style="width:16.193%;"></td>
    <td style="width:13.277%;"></td>
    <td style="width:13.277%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Depository AC #</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Institution</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Account Type (Depository / Securities)</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Last Month Ending Account Balance</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Purpose of Account</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">BORROWER Name/Address:</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td rowspan="7" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="7" style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">SUBSIDIARY / AFFILIATE Name/Address</font></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td rowspan="7" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="7" style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Section 7.20 - Financial Covenants</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21.058%;"></td>
    <td style="width:49.744%;"></td>
    <td style="width:12.479%;"></td>
    <td style="width:16.72%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Covenant</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Required</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Actual</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">In Compliance?</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Minimum Cash</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 7.20(a)(i) of the Loan Agreement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Greater than or equal to the sum of $40,000,000 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;the Qualified Cash A/P Amount; provided that beginning on the AXS-05 Milestone Date, such sum shall be greater than or equal to $25,000,000 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">the Qualified Cash A/P Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">[ &#xf098; ]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">N/A</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Performance Covenant A</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 7.20(b) of the Loan Agreement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(i) Borrower&#x2019;s Market Capitalization exceeds One Billion Dollars ($1,000,000,000) and (ii) Borrower maintains Qualified Cash in an amount not less than fifty percent (50%) of the sum of the outstanding principal amount of the Term Loan Advances </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;the Qualified Cash A/P Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">[ &#xf098; ]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">N/A</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Performance Covenant B</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 7.20(b) of the Loan Agreement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower maintains Qualified Cash in an amount not less than eighty five percent (85%) of the sum of the outstanding principal amount of the Term Loan Advances</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#160;plus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;the Qualified Cash A/P Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">[ &#xf098; ]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">N/A</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Performance Covenant C</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 7.20(b) of the Loan Agreement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Borrower achieves T6M Net Product Revenue of at least 60% of the T6M Net Product Revenue included in the Forecast, determined on a quarterly basis</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">[ &#xf098; ]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">No</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">N/A</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Is Borrower complying with at least one Performance Covenant?  Yes____       No_____     N/A_____</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Section 7.21 &#x2013; Intellectual Property</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Has Borrower filed any application for any Patent or the registration of any Copyright, mask work or Trademark, or acquired any new registered Trademark since the last reported period?  Yes____       No_____</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">If yes: Borrower shall supplement such intellectual property security agreements and or other documents as needed to maintain a first priority perfected security interest in favor of Agent within 90 days of the date hereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Very Truly Yours,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">AXSOME THERAPEUTICS, INC.</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Name:   _____________________________</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Its:	____________________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT F</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">FORM OF JOINDER AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">This Joinder Agreement (the &#x201c;Joinder Agreement&#x201d;) is made and dated as of [          ], 20[  ], and is entered into by and between__________________., a ___________ corporation (&#x201c;Subsidiary&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation (as &#x201c;Agent&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">A.  Subsidiary&#x2019;s Affiliate, Axsome Therapeutics, Inc. (&#x201c;Company&#x201d;) has entered into that certain Loan and Security Agreement dated September 25, 2020, with the several banks and other financial institutions or entities from time to time party thereto as lender (collectively, the &#x201c;Lenders&#x201d;) and the Agent, as such agreement may be amended (the &#x201c;Loan Agreement&#x201d;), together with the other agreements executed and delivered in connection therewith;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">B.  Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company&#x2019;s execution of the Loan Agreement and the other agreements executed and delivered in connection therewith;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">NOW THEREFORE, Subsidiary and Agent agree as follows:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The recitals set forth above are incorporated into and made part of this Joinder Agreement.  Capitalized terms not defined herein shall have the meaning provided in the Loan Agreement.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:9.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that (a) with respect to (i) Section 5.1 of the Loan Agreement, Subsidiary represents that it is an entity duly organized, legally existing and in good standing under the laws of [        ], (b) neither Agent nor the Lenders shall have any duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other Loan Documents, (c) that if Subsidiary is covered by Company&#x2019;s insurance, Subsidiary shall not be required to maintain separate insurance or comply with the provisions of Sections 6.1 and 6.2 of the Loan Agreement, and (d) that as long as Company satisfies the requirements of Section 7.1 of the Loan Agreement, Subsidiary shall not have to provide Agent separate Financial Statements.  To the extent that Agent or the Lenders has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other Loan Documents, those duties, responsibilities or obligations shall flow only to Company and not to Subsidiary or any other Person or entity.  By way of example (and not an exclusive list): (i) Agent&#x2019;s providing notice to Company in accordance with the Loan Agreement or as otherwise agreed among Company, Agent and the Lenders shall be deemed provided to Subsidiary; (ii) a Lender&#x2019;s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (iii) Subsidiary shall have no right to request an Advance or make any other demand on the Lenders.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:9.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary agrees not to certificate its equity securities without Agent&#x2019;s prior written consent, which consent may be conditioned on the delivery of such equity securities to Agent in order to perfect Agent&#x2019;s security interest in such equity securities.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:9.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary acknowledges that it benefits, both directly and indirectly, from the Loan Agreement, and hereby waives, for itself and on behalf on any and all successors in interest (including without limitation any assignee for the benefit of creditors, receiver, bankruptcy trustee or itself as debtor-in-possession under any bankruptcy proceeding) to the fullest extent provided by law, any and all claims, rights or defenses to the enforcement of this Joinder Agreement on the basis that (a) it failed to receive adequate consideration for the execution and delivery of this Joinder Agreement or (b) its obligations under this Joinder Agreement are avoidable as a fraudulent conveyance.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:9.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">As security for the prompt, complete and indefeasible payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, Subsidiary grants to Agent a security interest in all of Subsidiary&#x2019;s right, title, and interest in and to the Collateral.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-1</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of ________ ___, 20___ (as amended, supplemented or otherwise modified from time to time, the &#x201c;Loan Agreement&#x201d;) by and among Axsome Therapeutics, Inc., a Delaware corporation and each of its Subsidiaries (as defined in the Loan Agreement) other than Excluded Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;Borrower&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;Lenders&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;Agent&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) it is not a &#x201c;bank&#x201d; within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished the Agent and the Borrower with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform the Borrower and the Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF LENDER]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-2</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of ________ ___, 20___ (as amended, supplemented or otherwise modified from time to time, the &#x201c;Loan Agreement&#x201d;) by and among Axsome Therapeutics, Inc., a Delaware corporation and each of its Subsidiaries (as defined in the Loan Agreement) other than Excluded Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;Borrower&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;Lenders&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;Agent&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the participation in respect of which it is providing this certificate, (ii) it is not a &#x201c;bank&#x201d; within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished its participating Lender with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform such Lender in writing, and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF PARTICIPANT]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-3</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of ________ ___, 20___ (as amended, supplemented or otherwise modified from time to time, the &#x201c;Loan Agreement&#x201d;) by and among Axsome Therapeutics, Inc., a Delaware corporation and each of its Subsidiaries (as defined in the Loan Agreement) other than Excluded Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;Borrower&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;Lenders&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;Agent&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the participation in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such participation, (iii) with respect to such participation, neither the undersigned nor any of its direct or indirect partners/members is a &#x201c;bank&#x201d; extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished its participating Lender with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner&#x2019;s/member&#x2019;s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform such Lender and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF PARTICIPANT]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-4</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of ________ ___, 20___ (as amended, supplemented or otherwise modified from time to time, the &#x201c;Loan Agreement&#x201d;) by and among Axsome Therapeutics, Inc., a Delaware corporation and each of its Subsidiaries (as defined in the Loan Agreement) other than Excluded Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;Borrower&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;Lenders&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;Agent&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such Loan(s) (as well as any promissory note(s) evidencing such Loan(s)), (iii) with respect to the extension of credit pursuant to this Loan Agreement or any other Loan Document, neither the undersigned nor any of its direct or indirect partners/members is a &#x201c;bank&#x201d; extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished the Agent and the Borrower with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner&#x2019;s/member&#x2019;s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform the Borrower and the Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF LENDER]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40.0%;text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:13.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT K</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.3pt;line-height:13.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">FORM OF WARRANT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:11.85pt;line-height:12.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#x201c;ACT&#x201d;), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.1pt;line-height:25.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">WARRANT AGREEMENT <br>To Purchase Shares of the Common Stock of <br>AXSOME THERAPEUTICS, INC. <br>Dated as of [ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;">&#xf098; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">] (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.3pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Axsome Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has entered into a Loan and Security Agreement, dated September 25, 2020 (as amended and in effect from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) with Hercules Capital, Inc., a Maryland corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrantholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in its capacity as administrative agent, and the lender parties thereto;</font></p>
  <p style="text-indent:6.757%;font-size:10.0pt;margin-top:13.2pt;line-height:12.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, pursuant to the Loan Agreement and as additional consideration to the Warrantholder for, among other things, its agreements in the Loan Agreement, the Company has agreed to issue to the Warrantholder this Warrant Agreement, evidencing the right to purchase shares of the Company&#x2019;s Common Stock (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;, or this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;);</font></p>
  <p style="text-indent:6.711%;font-size:10.0pt;margin-top:11.8pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, in consideration of the Warrantholder having executed and delivered the Loan Agreement and provided the financial accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.25pt;line-height:12.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">GRANT OF THE RIGHT TO PURCHASE COMMON STOCK.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:6.15pt;line-height:12.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(a)	For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to the number of fully paid and non-assessable shares of Common Stock (as defined below) as determined pursuant to Section 1(b) below, at a purchase price per share equal to the Exercise Price (as defined below). The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As used herein, the following terms shall have the following meanings:</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.5pt;line-height:12.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:9.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:7.246%;font-size:10.0pt;margin-top:0.3pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Charter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s Certificate of Incorporation, as may be amended and in effect from time to time.</font></p>
  <p style="margin-left:6.667%;text-indent:7.246%;font-size:10.0pt;margin-top:12.05pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s common stock, $0.0001 par value per share, as presently constituted under the Charter, and any class and/or series of Company capital stock for or into which such common stock may be converted or exchanged in a reorganization, recapitalization or similar transaction.</font></p>
  <p style="margin-left:6.667%;text-indent:7.353%;font-size:10.0pt;margin-top:11.9pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means $[ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Verdana;min-width:fit-content;">&#149; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">, subject to adjustment from time to time in accordance with the provisions of this Warrant.</font></p>
  <p style="margin-left:6.667%;text-indent:7.246%;font-size:10.0pt;margin-top:11.95pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Liquid Sale</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the closing of a Merger Event in which the consideration received by the Company and/or its stockholders, as applicable, consists solely of cash and/or Marketable Securities.</font></p>
  <p style="margin-left:6.667%;text-indent:7.194%;font-size:10.0pt;margin-top:12.05pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in connection with a Merger Event means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by the Warrantholder in connection with the Merger Event were the Warrantholder to exercise this Warrant on or prior to the closing thereof is then traded on a national securities exchange or over-the-counter market, and (iii) following the closing of such Merger Event, Warrantholder would not be restricted from publicly re-selling all of the issuer&#x2019;s shares and/or other securities that would be received by Warrantholder in such Merger Event were Warrantholder to exercise this Warrant in full on or prior to the closing of such Merger Event, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Merger Event.</font></p>
  <p style="margin-left:6.667%;text-indent:7.194%;font-size:10.0pt;margin-top:12.0pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Merger Event</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any of the following: (i) a sale, lease or other transfer of all or substantially all assets of the Company, (ii) any merger or consolidation involving the Company in which the Company is not the surviving entity or in which the outstanding shares of the Company&#x2019;s capital stock are otherwise converted into or exchanged for shares of capital stock or other securities or property of another entity, or (iii) any sale by holders of the outstanding voting equity securities of the Company in a single transaction or series of related transactions of shares constituting a majority of the outstanding combined voting power of the Company.</font></p>
  <p style="margin-left:6.667%;text-indent:7.194%;font-size:10.0pt;margin-top:11.95pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Purchase Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any exercise of this Warrant, an amount equal to the then-effective Exercise Price multiplied by the number of shares of Common Stock as to which this Warrant is then exercised.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.75pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:19.8pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrant Coverage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means [ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Verdana;min-width:fit-content;">&#149; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.2pt;line-height:11.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:4.355pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> NTD: To equal the 10-day volume weighted average price of the Common Stock at the time of the applicable Term Loan Advance and issuance of this Warrant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.15pt;line-height:11.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:4.355pt;font-family:Times New Roman;min-width:fit-content;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> NTD: To equal 2.50% </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">times</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> the aggregate principal amount of the applicable Term Loan Advance.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:9.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.7pt;line-height:12.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.	This Warrant shall be exercisable for a number of shares of</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.55pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock equal to the quotient derived by dividing (i) the Warrant Coverage by (ii) the Exercise Price, subject to adjustment from time to time in accordance with the provisions of this Warrant.</font></p>
  <p style="margin-left:11.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.8pt;line-height:12.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TERM OF THE AGREEMENT.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:6.1pt;line-height:12.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">The term of this Agreement and the right to purchase Common Stock as granted herein shall commence on the Effective Date and, subject to Section 8(a) below, shall be exercisable for a period ending upon the seventh (7th) anniversary of the Effective Date.</font></p>
  <p style="margin-left:11.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.3pt;line-height:12.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">EXERCISE OF THE PURCHASE RIGHTS.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:6.3pt;line-height:12.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The purchase rights set forth in this Agreement are exercisable by the</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:12.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Warrantholder, in whole or in part, at any time, or from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit I</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Notice of Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than three (3) business days thereafter, the Company shall issue to the Warrantholder , via book entry, the number of shares of Common Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit II</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Acknowledgment of Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) indicating the number of shares which remain subject to future purchases under this Warrant, if any.</font></p>
  <p style="text-indent:13.423%;font-size:10.0pt;margin-top:12.65pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">The Purchase Price may be paid at the Warrantholder&#x2019;s election either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Common Stock to be exercised under this Agreement and, if applicable, an amended Agreement setting forth the remaining number of shares purchasable hereunder, as determined below (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Net Issuance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). If the Warrantholder elects the Net Issuance method, the Company will issue shares of Common Stock in accordance with the following formula:</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.8pt;line-height:12.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">X = </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Y(A-B)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:12.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.8pt;line-height:12.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Where:	X = the number of shares of Common Stock to be issued to the Warrantholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:6.05pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:7.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Y = the number of shares of Common Stock requested to be exercised under this Agreement.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:6.05pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">A = the then-current fair market value of one (1) share of Common Stock at the time of exercise.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:6.1pt;line-height:12.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">B = the then-effective Exercise Price.</font></p>
  <p style="text-indent:6.803%;font-size:10.0pt;margin-top:6.0pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">For purposes of the above calculation, the current fair market value of shares of Common Stock shall mean with respect to each share of Common Stock:</font></p>
  <div style="text-indent:13.605%;font-size:0;margin-top:12.55pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:2.0%;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">at all times when the Common Stock shall be traded on a national securities exchange, inter-dealer quotation system or over-the-counter bulletin board service, the fair market value of one (1) share of Common Stock shall be deemed to be the prior day closing price before the day the current fair market value of the securities is being determined;</font></div></div>
  <div style="text-indent:13.699%;font-size:0;margin-top:13.0pt;line-height:12.45pt;justify-content:flex-start;margin-bottom:32.25pt;margin-right:2.667%;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">if the exercise is in connection with a Merger Event, the fair market value of a share of Common Stock shall be deemed to be the per share value received by the holders of the</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.0pt;line-height:12.45pt;font-family:Times New Roman;margin-bottom:32.25pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">outstanding shares of Common Stock pursuant to such Merger Event as determined in accordance with the definitive transaction documents executed among the parties in connection therewith; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.55pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(iii)	in cases other than as described in the foregoing clauses (i) and (ii), the current fair market value of a share of Common Stock shall be determined in good faith by the Company&#x2019;s Board of Directors.</font></p>
  <p style="text-indent:13.513%;font-size:10.0pt;margin-top:12.35pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Upon partial exercise by either cash or Net Issuance, prior to the expiration or earlier termination hereof, the Company shall promptly amend this Agreement to reflect the remaining number of shares and/or other securities purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exercise Prior to Expiration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. To the extent this Warrant is not previously exercised as to all shares subject hereto, and if the then-current fair market value of one share of Common Stock is greater than the Exercise Price then in effect, or, in the case of a Liquid Sale, where the value per share of Common Stock (as determined as of the closing of such Liquid Sale in accordance with the definitive agreements executed by the parties in connection with such Merger Event) to be paid to the holders thereof is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically exercised on a Net Issuance basis pursuant to Section 3(a) (even if not surrendered) as of immediately before its expiration determined in accordance with Section 2. For purposes of such automatic exercise, the fair market value of one share of Common Stock upon such expiration shall be determined pursuant to Section 3(a). To the extent this Warrant or any portion hereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder, upon written request, of the number of shares of Common Stock if any, the Warrantholder is to receive by reason of such automatic exercise, and shall issue the Warrantholder such shares via book entry.</font></p>
  <p style="margin-left:11.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.55pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">RESERVATION OF SHARES.</font></p>
  <p style="text-indent:13.793%;font-size:10.0pt;margin-top:5.75pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Common Stock to provide for the exercise of the rights to purchase Common Stock as provided for herein.</font></p>
  <p style="margin-left:11.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.1pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">NO FRACTIONAL SHARES OR SCRIP.</font></p>
  <p style="text-indent:13.513%;font-size:10.0pt;margin-top:5.75pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares the Company shall make a cash payment therefor upon the basis of the then fair market value of one share of Common Stock.</font></p>
  <p style="margin-left:11.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.1pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">NO RIGHTS AS STOCKHOLDER.</font></p>
  <p style="text-indent:13.793%;font-size:10.0pt;margin-top:5.75pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Without limitation of any provision hereof, Warrantholder agrees that this Agreement does not entitle the Warrantholder to any voting rights or other rights as a stockholder of the Company prior to the exercise of any of the purchase rights set forth in this Agreement.</font></p>
  <p style="margin-left:11.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.05pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">WARRANTHOLDER REGISTRY.</font></p>
  <p style="text-indent:13.513%;font-size:10.0pt;margin-top:5.8pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:36.0pt;margin-right:1.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Warrantholder&#x2019;s initial address, for purposes of such registry, is set forth in Section 12(g) below. Warrantholder may change such address by giving written notice of such changed address to the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.8pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\129794038.5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:12.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">ADJUSTMENT RIGHTS.</font></p>
  <p style="text-indent:13.699%;font-size:10.0pt;margin-top:5.8pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment from time to time, as follows:</font></p>
  <p style="text-indent:13.423%;font-size:10.0pt;margin-top:11.9pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Merger Event</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. In connection with a Merger Event that is a Liquid Sale, this Warrant shall, on and after the closing thereof, automatically and without further action on the part of any party or other person, represent the right to receive the consideration payable on or in respect of all shares of Common Stock that are issuable hereunder as of immediately prior to the closing of such Merger Event less the Purchase Price for all such shares of Common Stock (such consideration to include both the consideration payable at the closing of such Merger Event and all deferred consideration payable thereafter, if any, including, but not limited to, payments of amounts deposited at such closing into escrow and payments in the nature of earn-outs, milestone payments or other performance-based payments, subject to the terms of the definitive agreements governing the Merger Event), and such Merger Event consideration shall be paid to Warrantholder as and when it is paid to the holders of the outstanding shares of Common Stock. In connection with a Merger Event that is not a Liquid Sale, the Company shall cause the successor or surviving entity to assume this Warrant and the obligations of the Company hereunder on the closing thereof, and, thereafter this Warrant shall be exercisable for the same number and type of securities or other property as the Warrantholder would have received in consideration for the shares of Common Stock issuable hereunder had it exercised this Warrant in full as of immediately prior to such closing, at an aggregate Exercise Price no greater than the aggregate Exercise Price in effect as of immediately prior to such closing, and subject to further adjustment from time to time in accordance with the provisions of this Warrant. The provisions of this Section 8(a) shall similarly apply to successive Merger Events.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:11.9pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Reclassification of Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Except for Merger Events subject to Section 8(a), if the Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes of securities, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. The provisions of this Section 8(b) shall similarly apply to successive combination, reclassification, exchange, subdivision or other change.</font></p>
  <p style="text-indent:13.605%;font-size:10.0pt;margin-top:12.15pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Subdivision or Combination of Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If the Company at any time shall combine or subdivide its Common Stock, (i) in the case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares for which this Warrant is exercisable shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased and the number of shares for which this Warrant is exercisable shall be proportionately decreased.</font></p>
  <p style="text-indent:13.699%;font-size:10.0pt;margin-top:11.9pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Stock Dividends</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If the Company at any time while this Agreement is outstanding and unexpired shall:</font></p>
  <p style="text-indent:20.27%;font-size:10.0pt;margin-top:12.15pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">pay a dividend with respect to the outstanding shares of Common Stock payable in additional shares of Common Stock, then the Exercise Price shall be adjusted, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Common Stock outstanding immediately after such dividend or distribution, and the</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:9.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">number of shares of Common Stock for which this Warrant is exercisable shall be proportionately increased; or</font></p>
  <p style="text-indent:20.134%;font-size:10.0pt;margin-top:12.0pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">make any other dividend or distribution on or with respect to Common Stock, except any dividend or distribution (A) in cash, or (B) specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the Common Stock (or other stock for which the Common Stock is convertible) as of the record date fixed for the determination of the stockholders of the Company entitled to receive such dividend or distribution.</font></p>
  <p style="text-indent:13.605%;font-size:10.0pt;margin-top:12.1pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Notice of Certain Events</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If: (i) the Company shall declare any dividend or distribution upon its outstanding Common Stock, payable in stock, cash, property or other securities (provided that Warrantholder in its capacity as lender under the Loan Agreement consents to such dividend); (ii) the Company shall offer for subscription pro rata to the holders of its Common Stock any additional shares of stock of any class or other rights; (iii) there shall be any Merger Event; or (iv) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall give the Warrantholder notice thereof at the same time and in the same manner as it gives notice thereof to the holders of outstanding Common Stock.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.353%;padding-left:6.667%;font-size:10.0pt;margin-top:12.6pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 9.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.</font></p>
  <div style="text-indent:6.711%;font-size:0;margin-top:6.0pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Reservation of Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company covenants and agrees that all shares of Common Stock, if any, that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and non-assessable. The Company further covenants and agrees that the Company will, at all times during the term hereof, have authorized and reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any time during the term hereof the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant in full, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes.</font></div></div>
  <div style="text-indent:6.711%;font-size:0;margin-top:6.05pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Due Authority</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Common Stock, have been duly authorized by all necessary corporate action on the part of the Company. This Agreement: (1) does not violate the Company&#x2019;s Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting creditors&#x2019; rights generally (including, without limitation, fraudulent conveyance laws) and by general principles of equity, regardless of whether considered in a proceeding in equity or at law.</font></div></div>
  <div style="text-indent:6.711%;font-size:0;margin-top:5.85pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:36.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Consents and Approvals</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.85pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.993%;font-size:0;margin-top:0.2pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:4.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exempt Transaction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Subject to the accuracy of the Warrantholder&#x2019;s representations in Section 10, the issuance of the Common Stock upon exercise of this Agreement will constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section 4(a)(2) thereof, and (ii) the qualification requirements of the applicable state securities laws.</font></div></div>
  <div style="text-indent:6.711%;font-size:0;margin-top:6.2pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Information Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. At all times (if any) prior to the expiration or earlier termination of this Warrant, when the Company shall not be required to file reports pursuant to Section 13 or 15(d) of the Exchange Act or shall not have timely filed all such required reports, Warrantholder shall be entitled to the information rights contained in Sections 7.1(b) and 7.1(c) of the Loan Agreement, provided that the confidentiality provisions contained in Section 11.13 of the Loan Agreement shall apply to any information received under this section, and in any such event Sections 7.1(b), 7.1(c) and 11.13 of the Loan Agreement are hereby incorporated into this Agreement by this reference as though fully set forth herein. In receiving any such information, Warrantholder shall at all times comply with all securities laws applicable to the resale of this Warrant or the shares of Common Stock issuable upon exercise of this Warrant, including relevant insider trading laws.</font></div></div>
  <div style="text-indent:6.711%;font-size:0;margin-top:5.95pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Rule 144 Compliance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.	The Company shall, at all times prior to the earlier to occur of (x) the date of sale or other disposition by Warrantholder of this Warrant or all shares of Common Stock issued on exercise of this Warrant, or (y) the expiration or earlier termination of this Warrant if the Warrant has not been exercised in full or in part on such date, use all commercially reasonable efforts to timely file all reports required under the 1934 Act and otherwise timely take all actions necessary to permit the Warrantholder to sell or otherwise dispose of this Warrant and the shares of Common Stock issued on exercise hereof pursuant to Rule 144 promulgated under the Act as amended and in effect from time to time, provided that the foregoing shall not apply in the event of a Merger Event following which the successor or surviving entity is not subject to the reporting requirements of the 1934 Act. If the Warrantholder proposes to sell Common Stock issuable upon the exercise of this Agreement in compliance with Rule 144, then, upon Warrantholder&#x2019;s written request to the Company, the Company shall furnish to the Warrantholder, within five (5) business days after receipt of such request, a written statement confirming the Company&#x2019;s compliance with the filing and other requirements of such Rule.</font></div></div>
  <p style="margin-left:6.667%;text-indent:-11.765%;padding-left:8.0%;font-size:10.0pt;margin-top:5.9pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:17.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 10.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER.</font></p>
  <p style="text-indent:13.793%;font-size:10.0pt;margin-top:5.9pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder:</font></p>
  <p style="text-indent:6.711%;font-size:10.0pt;margin-top:12.05pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Investment Purpose</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. This Warrant and the shares issued on exercise hereof will be acquired for investment and not with a view to the sale or distribution of any part thereof in violation of applicable federal and state securities laws, and the Warrantholder has no present intention of selling or engaging in any public distribution of the same except pursuant to a registration or exemption.</font></p>
  <div style="text-indent:6.711%;font-size:0;margin-top:6.1pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Private Issue</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Warrantholder understands (i) that the Common Stock issuable upon exercise of this Agreement is not, as of the Effective Date, registered under the Act or qualified under applicable state securities laws on the grounds that the issuance contemplated by this Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that the Company&#x2019;s reliance on exemption from such registration is predicated on the representations set forth in this Section 10.</font></div></div>
  <div style="text-indent:6.711%;font-size:0;margin-top:6.0pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Risk</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment.</font></div></div>
  <div style="text-indent:6.849%;font-size:0;margin-top:5.95pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:36.0pt;margin-right:2.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Accredited Investor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Warrantholder is an &#x201c;accredited investor&#x201d; within the meaning of Rule 501 of Regulation D promulgated under the Act, as presently in effect (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Regulation D</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.95pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.711%;font-size:10.0pt;margin-top:0.2pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">No Short Sales</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">.	Warrantholder has not at any time on or prior to the Effective Date engaged in any short sales or equivalent transactions in the Common Stock. Warrantholder agrees that at all times from and after the Effective Date and on or before the expiration or earlier termination of this Warrant, it shall not engage in any short sales or equivalent transactions in the Common Stock.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:6.1pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 11.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TRANSFERS.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:5.95pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Subject to compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company&#x2019;s books, shall be treated by the Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Transfer Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. Notwithstanding anything herein or in any legend to the contrary, the Company shall not require an opinion of counsel in connection with any sale, assignment or other transfer by Warrantholder of this Warrant (or any portion hereof or any interest herein) or of any shares of Common Stock issued upon any exercise hereof to an affiliate (as defined in Regulation D) of Warrantholder, provided that such affiliate is an &#x201c;accredited investor&#x201d; as defined in Regulation D.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.85pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">SECTION 12.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">MISCELLANEOUS.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:5.9pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company.</font></div></div>
  <div style="text-indent:6.803%;font-size:0;margin-top:5.85pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:2.0%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Remedies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where Warrantholder will not have an adequate remedy at law and where damages will not be readily ascertainable. The Company expressly agrees that it shall not oppose an application by the Warrantholder or any other person entitled to the benefit of this Agreement requiring specific performance of any or all provisions hereof or enjoining the Company from continuing to commit any such breach of this Agreement.</font></div></div>
  <div style="text-indent:6.757%;font-size:0;margin-top:6.1pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">No Impairment of Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:5.9pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Additional Documents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. In the event the Company shall not be required to file reports pursuant to Section 13 or 15(d) of the Exchange Act or shall not have timely filed all such required reports, the Company agrees to supply such other documents as the Warrantholder may from time to time reasonably request to value this Warrant for Warrantholder&#x2019;s accounting or reporting requirements and/or to evaluate whether to exercise (in cash or a net issuance basis) this Warrant.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6.15pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:25.5pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Attorneys&#x2019; Fees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto, the prevailing party shall be entitled to reasonable attorneys&#x2019; fees and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.15pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:25.5pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this Section 12(e), attorneys&#x2019; fees shall include without limitation reasonable fees incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment.</font></p>
  <div style="margin-left:0.667%;text-indent:6.04%;font-size:0;margin-top:5.85pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.040288725801094%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision.</font></div></div>
  <div style="margin-left:0.667%;text-indent:6.04%;font-size:0;margin-top:6.15pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.0%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.040288725801094%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (a) personal delivery to the party to be notified, (b) when sent by confirmed telex, electronic transmission or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt, and shall be addressed to the party to be notified as follows:</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:5.85pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If to the Warrantholder:</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:11.95pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Legal Department</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Attention: Chief Legal Officer and Michael Dutra</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">400 Hamilton Avenue, Suite 310</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Palo Alto, CA 94301</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Facsimile: 650-473-9194</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Telephone: 650-289-3060</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">With a copy to (which shall not constitute notice)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:11.95pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">LATHAM &amp; WATKINS LLP</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">505 Montgomery Street, Suite 2000</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">San Francisco, CA 94111</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Attn: Haim Zaltzman</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Facsimile: 415-395-8095</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Telephone: 415-395-8870</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If to the Company:</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:11.85pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AXSOME THERAPEUTICS, INC. <br>Attention: Chief Financial Officer <br>22 Cortlandt Street, 16</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Floor <br>New York, New York</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:11.5pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">With a copy to (which shall not constitute notice)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DLA PIPER LLP (US)</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">51 John F. Kennedy Pkwy, Suite 120</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:31.75pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short Hills, NJ 07078</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.55pt;font-family:Times New Roman;margin-bottom:31.75pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:11.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Attn: Emilio Ragosa, Esq. <br>Facsimile: 973-215-2804 <br>Telephone: 973-307-3004</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:11.65pt;line-height:12.65pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">or to such other address as each party may designate for itself by like notice.</font></p>
  <div style="text-indent:6.711%;font-size:0;margin-top:11.95pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement; Amendments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof (including the Warrantholder&#x2019;s proposal letter dated September 2, 2020). None of the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto.</font></div></div>
  <div style="text-indent:6.897%;font-size:0;margin-top:6.15pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:3.333%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof.</font></div></div>
  <div style="text-indent:7.092%;font-size:0;margin-top:5.95pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:6.0%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Advice of Counsel</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Each of the parties represents to each other party hereto that it has discussed (or had an opportunity to discuss) with its counsel this Agreement and, specifically, the provisions of Sections 12(n), 12(o), 12(p), 12(q) and 12(r).</font></div></div>
  <div style="text-indent:6.757%;font-size:0;margin-top:5.9pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">No Strict Construction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.</font></div></div>
  <div style="text-indent:6.849%;font-size:0;margin-top:6.1pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:2.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">No Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. No omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Warrantholder at any time designated, shall be a waiver of any such right or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce such provisions thereafter during the term of this Agreement.</font></div></div>
  <div style="text-indent:6.803%;font-size:0;margin-top:5.95pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:2.0%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(m)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. All agreements, representations and warranties contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:5.95pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(n)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement has been negotiated and delivered to Warrantholder in the State of California, and shall be deemed to have been accepted by Warrantholder in the State of California. Delivery of Common Stock to Warrantholder by the Company under this Agreement is due in the State of California. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:6.0pt;line-height:12.65pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(o)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Consent to Jurisdiction and Venue</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. All judicial proceedings arising in or under or related to this Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (i) consents to personal jurisdiction in Santa Clara County, State of California; (ii) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (iii) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (iv) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 12(g), and shall be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:9.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.</font></p>
  <div style="text-indent:6.711%;font-size:0;margin-top:5.3pt;line-height:12.7pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(p)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Mutual Waiver of Jury Trial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes arising under or in connection with this Warrant be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, &#x201c;CLAIMS&#x201d;) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY RELATING TO THIS WARRANT. This waiver extends to all such Claims, including Claims that involve persons or entities other the Company and Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement.</font></div></div>
  <div style="text-indent:6.711%;font-size:0;margin-top:5.8pt;line-height:12.7pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(q)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Judicial Reference</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If the waiver of jury trial set forth above is ineffective or unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury before a mutually acceptable referee.</font></div></div>
  <div style="text-indent:6.711%;font-size:0;margin-top:5.85pt;line-height:12.7pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(r)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-arbitration Relief</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. In the event Claims are to be resolved by arbitration, either party may seek from a court of competent jurisdiction identified in Section 12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.</font></div></div>
  <div style="text-indent:6.711%;font-size:0;margin-top:5.85pt;line-height:12.7pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(s)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts (including by facsimile or electronic delivery (PDF), and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.</font></div></div>
  <div style="text-indent:6.711%;font-size:0;margin-top:5.7pt;line-height:12.7pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(t)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Specific Performance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. The parties hereto hereby declare that it is impossible to measure in money the damages which will accrue to Warrantholder by reason of the Company&#x2019;s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable by Warrantholder. If Warrantholder institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that Warrantholder has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists.</font></div></div>
  <div style="text-indent:6.803%;font-size:0;margin-top:5.6pt;line-height:12.7pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:2.0%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(u)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Lost, Stolen, Mutilated or Destroyed Warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.</font></div></div>
  <div style="text-indent:6.711%;font-size:0;margin-top:5.85pt;line-height:12.7pt;justify-content:flex-start;margin-bottom:0.0pt;margin-right:0.667%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(v)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Legends</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">. To the extent required by applicable laws, this Warrant and the shares of Common Stock issuable hereunder (and the securities issuable, directly or indirectly, upon conversion of such shares of Common Stock, if any) may be imprinted with a restricted securities legend in substantially the following form:</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.55pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:25.55pt;margin-right:0.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#x201c;ACT&#x201d;), OR ANY APPLICABLE STATE SECURITIES LAWS, AND</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.55pt;line-height:12.7pt;font-family:Times New Roman;margin-bottom:25.55pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:12.6pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.85pt;line-height:12.6pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">[Remainder of Page Intentionally Left Blank]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.85pt;line-height:12.6pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.45pt;line-height:12.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by its officers thereunto duly authorized as of the Effective Date.</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:25.65pt;line-height:12.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">COMPANY:</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:13.2pt;line-height:12.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">AXSOME THERAPEUTICS, INC.</font></p>
  <p style="margin-left:39.333%;text-indent:0.0%;font-size:10.0pt;margin-top:25.7pt;line-height:12.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:39.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Name: <br>Title:</font></p>
  <p style="margin-left:39.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:39.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:11.85pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">WARRANTHOLDER:</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.95pt;line-height:12.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:39.333%;text-indent:0.0%;font-size:10.0pt;margin-top:25.7pt;line-height:12.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:39.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:12.25pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Name:</font></p>
  <p style="margin-left:32.667%;text-indent:9.901%;font-size:10.0pt;margin-top:0.5pt;line-height:12.25pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Title:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;line-height:12.25pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">SCHEDULE 1.1</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">COMMITMENTS</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.437%;"></td>
    <td style="width:8.84%;"></td>
    <td style="width:8.84%;"></td>
    <td style="width:8.84%;"></td>
    <td style="width:8.84%;"></td>
    <td style="width:9.381%;"></td>
    <td style="width:8.84%;"></td>
    <td style="width:9.381%;"></td>
    <td style="width:8.84%;"></td>
    <td style="width:9.381%;"></td>
    <td style="width:9.381%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">LENDERS</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TRANCHE 1A TERM COMMITMENT</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TRANCHE 1B TERM COMMITMENT</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TRANCHE 2A TERM COMMITMENT</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TRANCHE 2B TERM COMMITMENT</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TRANCHE 2C TERM COMMITMENT*</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TRANCHE 3A TERM COMMITMENT</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TRANCHE 3B TERM COMMITMENT*</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TRANCHE 4 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TRANCHE 5 TERM COMMITMENT*</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TERM COMMITMENT*</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Hercules Capital, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$50,000,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$31,725,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$24,675,000</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$24,675,000</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$30,000,000*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$10,575,000</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$5,000,000*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$50,000,000*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$35,000,000*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$261,650,000</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Hercules Private Credit Fund I L.P.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$7,650,000</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$5,950,000</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$5,950,000</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$2,550,000</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$22,100,000</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Hercules Private Global Venture Growth Fund I L.P.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$5,625,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$4,375,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$4,375,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$1,875,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$16,250,000</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">TOTAL COMMITMENTS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$50,000,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$45,000,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$35,000,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$35,000,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$30,000,000*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$15,000,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$5,000,000*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$50,000,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$35,000,000*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">$300,000,000*</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">			* Funding of Tranches 2C, 3B and 5 are subject to approval by Lender&#x2019;s investment committee in its sole discretion.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">|US-DOCS\129794038.5||</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>axsm-ex10_1.pdf
<DESCRIPTION>PDF COURTESY COPY
<TEXT>
<PDF>
begin 644 axsm-ex10_1.pdf
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M QO:R,8VL:G-;&X+6]K*UK:QK>UL;P<[VLG.=K&KW>QN#WO:R][VL:_][.\
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M[S.Q\O(^U_Q6GD)9IRYG"UZ.8I]W)^_WX*\ ?P7HX@1G ]7D<PVU_R["_O4
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MG9I9MX+.1-G-,=?YNZG'X1Y'_<T'J)WU +4'^EM+(.</4";&::C5#O8%IRO
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M:!;;M$E,=.-&40TC&T1X3$/7I*#4/%]^J3>07!K0DWT%!9W9[RM#0%E(0&G
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M+SJF16S>K,R :'&>Z.EV?.%87^'HB<7>/'^IT[>%1;5\=GR?FCC')>P(='A
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M:;#GM4X V(M8H\\@N!OPVWG<>JQ;@.F.K7#0SAM\QJY;\>?4J?*ZO.X.\[<
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M:O%YQ$*,WU%@$A;CM#/A-,I92R/ASW+27@O,MMT<9UWEA&<YY<^VTW#>T_^
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M5=YDOA?UH]E[.2#+$:H+E,VPSJ43H\(&B%&GHPZ8^RB_F\E!,SN3?0#\L?W
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M4ZFCK'P(\"56WIQN/\C*W8 GKR'L&JH[%J>Q&R &T &P#D! Y\DBT+N+:/^
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M*I(\4I:4*64H3 J#0J?0*%0*A4)4\ I.@109R8E+<@B!'&9 - %$Y"GF6=K
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MFT7U6NH4*#1Y$$1E=3WJI6Z_DN3EL] *%H*$DPKSL6Y8@JRD]&FBVZ"]L<\
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M!9@^9IH7:#.L%_ U52N@PX_U=>5>('G=>#X /;+++4;(/=4+C#'\BJE-$U;
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MU\J<1Y01#&$,YLV!'<DTJ!%)R1#]&8>\5!+KY ZO?-+C\?+"+I[7[FHE=43
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M*V%BO%Q=YX>?I:8NF^$81)^63+?,Q\E43)*B>?C'TO2+\'%0*H<8=6EIB;4
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MO#@3$Q<QDB=X?P)$*=DAQ.K4N.$280X8/GM-<2 7LPOLQ^UJ5-8("B+!7)'
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MHT\F+2'^:5N(_]D..U+L:  /RP%M[M(B.05/SI%3\.1_DE,T.,4+IVB4QS1
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M9.28 HEPF2I@,0UN-O8:^PS&*+*RG\'&\#1$\@LXCO\7.!IJCN*5I?HL7*Z
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M9EJKM1JY?(4_TCV+\P*6?@_\+JA'"F # -*] /)K (K[ 90^Q/, ZI, FH<
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M[<_GO.3UCS:/JK50=Q,+]E\"S:$F=)H6TPZZDSY45,H1K:B8-%&7ZI$BTJA
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MH:I7[:9.4Y>HGZJ7M/OUMOBMTS?I%XP3K@3WGLO/7#GL)_\H_V+_,V8J9-&
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MZ6[$QXW"$X.!\,3_ A\W*M<;#(1[;\)?03 07O K^+A1/S<)!L*;W(2/WL%
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M(Y6A#T.?W03:/= CC(Z8.P'N:O>)0:CNW7UU[^R#W\T'^]4TV D,1S_Q?@:
MKFAH[Z5YOW#*VDO+.YE-0#^@>Y!;6'=U3.7Y51/@=AM/!"'%NA,RV_&=L&/7
MRSU]P/=&_+V0=;_C]SO?!&'MJU<MN'^07FU*C9765%M,)[[[G<+[ S[;<%_]
M?JM7\'B(@33?V9,'OUNKLC?^ Z6),Y3FK!M\GRWK2#/?UU:8C]780N1^&G.)
M[]HF8!]@[R?TE2BS'_3A/DK7)UI[*XF]F.?K:+T^ #))5.*VSUU"7\9ZFT&I
MZH^0WS$4K3Q$"6X2!:Z7J38#^<@UFR;:Y1P LER3,;]K (+6LXVM]3.OJ/^D
M7D G\,AIEW!>=FN_A?U? KUK^8=I2\##U[!S,3<8\GO.0;3/<8O=5N^YJX'^
M/4V]SGG%-6N7O%\?07%B -6SO_..9S_@ ;RV.\8!]$P;(,(.K_PV_%?E76Z=
M__$>6YX!KJ,6\LQONW7N9ZR%'@!XW^M&W^MO4@]7/=B((ZB[?@_U='V*_JQM
M^EQ=J:;K%/2,M:>KQ] ?-O^AC:4Z^EJL[<>M[W'U2RCC'-8Y[ 5Y#^8:31.-
MP=8=F0/7,FH;LA(VH?4=:[RZSOH&%;J]MC(#-@.?5R,.>3?K2310K0T]=HYF
MZ0]#=QRGSNYSD(^NU$9/P7YM#K7&7&ZN/4$%RK/4PM6>"D/.8&R'401_LVI_
M8]Y</R"__7P ^;LP](&F7]]MO@$9X/UT2^C&YDJ:_PW]6?*@/TI<4=0L] =J
M9G]3D>>.LRA_7P%$V)3]\>JKL//CL,XWI.201I3L/B'WK)'N(Q19XRA%AG\%
M]TD9%@X:7N,4;.:!LB_XO"^6UVFYSQN'_>X+0)1\JU8+_-9RCZ-:H2_ ;;U?
M2S%:P,8< AW)W_MB?R_OL==23\R]@5R63<>#K[[Z;-A$=AC\<9#G60'(=Z@Z
MQ<;@  RY"F,3OWEE<XKQLXGY6JJ54P3:4 !TD>_$2)ZA#I5W'^78%]AYV<VP
MYVJ!,V<=BGF3R]"&4C^@'N:=SYF+0 '*G(1T7_(WZ)#=?:@["Q@$L/VS!/%E
M&HGIH.7VVX+S#,3SGMX'/.*<Z7!>>0YLI9W*>WHE@<K%^U3NT,HSBYFPX\-@
M-_%;5SXC^1K[<P!KK83<<V&O$U( &;Y(@[%V2NJ>A'UZ# V&_$3JBZI2\'*O
M?-.7)N\U N^Z+?__$N_E\5%5U^-W>;//FWFS;TG>;)F$F6Q,]H7,RP:$& B(
M2)1 B!)!K! VBQN@5=P06I<*MH)5%*V6Y W@("(I^'5IM>"W]HNM5&*EM5O$
MMA&_M63R/??-(-B?G\_O^_G]\WN3<\Y]]YZ[G7O.O>>\]_(#%*&S+[SKAACF
M"SA+'X 8ZGG8M^Y$,_0KX3QO_^K=M$OU'8B-9DW\3OT^\-PR\<&%YQZ::> '
MQ=!,\&7B$-?'P6>*<^N0]._OBKD>5,A1@ OO63+4!?MB(5V#HF!;E0RX';"^
M.Y0U3BC/)6Y3WH?/ MN-::GROFDJW0_Z\!S8]0C,X=>H#,:2K[Q;J51TM8.;
M#6/+0G9^+O9<ASL(95D>R)]-5RGRB=$_*^_)LN_L)]ZF6R9.9W5^*NBS'N09
M9]\A*]\>-$*["T%7\X$6 7T:[&6YXD^S?=ZBT-7*GI.;I>P[(&?V.X0V-7OO
MS/YO_%$8VU] EK7@V\Q3W@W=I'I868]"KAKU:Y+*MTRS5&L@!GT#]M2WE#WT
M,N4[IH\SW[VP=X*Z6> 7W30QJGH,+: _!/W9,O$%R!0I/CO[MC.(].0)Q)/U
MRMI>!K'C5&X>0!CFQP!L#/91Y3T5 [;FRKHWP9S9LX9"D-D[J(..P%S\</_?
MJ%"U&Q6R;U6SW_HF6+M*V\\A'95A/U1@XG[EN1]*G\_"CYE\8%P%Y'MP)OP-
MZ0&*R<Z),^IE,,]-* KQS$PU:Y,]^X3X7WD>.2_SOSS_F_<$U .^E^=BS/GO
M?MG_XO\MO_9<'7PDB%#2YS+?X(S#RJ6_E7U78F'?Z&=@O ?VJW+V_12D&X '
MICG^>/;YXG7T//I4=P=JAA]J,J*YG(,]<8;XR $_.V=##9"V)=6YHC_%&9-&
M4YQ1V>:*ISA#LM OFIL$SHHV A!D!IP 6 1 %8PA@K7*WRZ74D!69<B-&7)]
MALPMEUX!QAFH?&*8LR9=[CC+3NJ-\8V,:G7LWB)?52XUZ3@+FJ?P6=#E&2IW
ME2O%G:P5"YJ6R4VVMF5J-6>R&[/,=>5B4QCN_0 2P$J O0"? :AA]!;0!PO:
M!C !P"EWC&\#P%: 70 CC%=I35MN;O)Q I0(RMP%D!3[,E. N?=R.IC[H(+-
MG!:DHD6S '9R&L1Q>AG=(!Z$1FBR31DI3<9*%"H73HHK!;(W)WZ8HV0[*D B
M9&#9Z5-*D-S<G$U4U602R6AQ_'23'M:5O=XC'.(P*LS42A:6Q#\[ O>8II$9
M8Y9+SR<%._1&QY-F6UQJ$B!69O$R08-T" T#$-B;/T<;  BP[Y6+)[..Z-ZD
MWA07@/\L[!EGT48 BG8!QLJ]!,#XSR9M3M;\)[+9HM0[+9=59!))P1WO:K+3
M4S">M^A_HA 2Z>^ Y@%] R@H'GV=OHEX99Q/)\U"?"/T]Q2P/T77HTE0O)O>
M#*>P2/?0VY%/8?NU;,KT\VNY,!IOTM-GZ:T*RVH*#CC0&^AR.2[Z#]&GF3[2
MOR9U!C:^O\J"(WZ8_@E"'SMPG0$NEV@^3&^$:.A&92:II(Z/;VLRTA1,,P5B
M$6&,&.U4L$3_4X:&H+_GZ$8(6D1ZG&Y"#J#/TSMDASA\B'ZAL)UCK4!_/P*-
M823)F^+#33KZ(Z8A].\@\;\KO8TE(S5QU!2A#X K]P#TYJ<?0^IC2 GT4TA]
M"LOT*2S-I[ TG\(H/@6E17042D:!IY1^B%;2#] V@)V0YJ#)]3)(\*"2"!?&
M#]+;Z*T@">$0R Y#[NU)G8F-[%;9:E/8;F4&GCA,3\*!=A+:E.C[S")7'*(/
M*E/9EG3[6(7W9)T11'=+9BV@XLUL#0[3C?0.11*;% D,O@JWH/_T3J7R1-)H
MB6^ U9\+MRL ;P4X 7 6@ .VN3"'N6@1  7VKJ3)'#<?HE<IE=ME4[EXF$Z'
MJ4]7I#5==@25,4_+)CBS[,N+O\H2J!BS?X$Q<6JY5)Q]B': _LRB,^5K11C[
M;!G:915G)FOJXF6'Z$Q%%C-E,93)EFT>)3%5UF7TJB6IM["1M"J,,5EK4K)C
M69.DT:3=%1=!3^N4V9:S?Q>GU;!\U; TU6 GY<IBQ)."%;3_6AI79A1'O0"[
M  8!.%CC.+#'88WC:$3),=,JF&X5F@"@L+95Z#, V&KH9)0 V IP!& $0*7D
M]@(0R"^#'GH!;P,@T&(IW N )8!>@(T NP"& 3X#T*#CM!CZ*0;N,L ; 08!
M3@-PL%9%,(XB*+-2/QH'ETE$&\AVJ0YO0!OP!K*!;N VJ#8(&RQ:J3*_*"Y=
MSU )0X6 JGMU*W4;=;1,)^FZ=%30^74D-3$L:^K*@4A6=5WY;SK_W/EE)[56
M;U-OTY#C349L0:<!S@)0=!P+<"? G2!MIL<;3S>>;:3'.T]WGNVDQS\\_>'9
M#^GQXM/%9XNIU.FKBU<OPBOP!KP5<R(NQ0D\"W.+Z JZ@6ZEG$A+:0)T@>LU
MK#1L-- R@V3H,E#!X#>0;89=AD'#L.&$036H'E:?4(^H/U.KNM2]ZI7JC>IM
MZEUJM:@IU20TDIK[K*F%? !"W05X$(! ! &FIZ0$I608\ GE?IMRWPMXI7(O
M >Y24B' 92P%$(*V?@-\&P%O V!\[#X$N(S= X1@=_\UY*T$O V D%]+.<&R
ML!0F0M@?)BB,/POC$^&1,!D,#X?)<%,=>5\9Y?LPRO>54;X/-=]7^GX?VH44
M0 A&>U+A.PE\)Q6^D\#'4M^4UPMXI9*2 '<IJ1#@,I8B)^50M;G)!=$U1HL
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MD6A,XK7E:G')XJFU.:DH$^E9>I+([H7)RH,[+OACPK-ARY8;T265FPEM?8K
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MX1PFL%S,OB2($PXW8E2?]7<G?@_1P5GK?YQ(33FN6V*O7:7-W#@?)WC4G.-
M2+[X0"5((<8U=_.%\#MXE7]1V89(A8<'JW^"]@$/@.@NX$5W&G$/>[@)7:O8
M#C?QUZH((AYX61O!<U54,8S^K\$!TK ,( ^7PWYHA<_!!X '/@AO R?;]W!:
MG)LH26,-FSECYHQ9,WR>DSFM8&K8+^"=^6EYP6JK/SU?V48?R4::+_[[%\O=
M227YM5W<K4;4@B#L!A8_ !;\/R,, Y] =11\ M19GSMD<0!S)S=/BF>U?=QX
M_>I+OD:HHNO@\]\FN[B)=DVO;(/OF>^]T/!__4V].'6PL6;-"+]M-3TA;^L&
M'(2$N"!8M_JR7O"_\"J:Q 5!39/?U'-RYV[*+-W ]RIK3[XC->=O77JXY2+*
MN=RMJFD QT<J,ZV^RFMD%[CA!-T6&*9 R#J[Q^SMYS\E??WU)4LBD/!9]>._
MJKQV(\Z[EH[_U?*AY250#SK04B- \WS9*O/E!J-C1M/_(]Q;H-NHSG5GST@S
M>L]H-'I+,Y)F)%D:22/;([]MC9W$<=ZFD! '3 *$%!(>MGDF*74@X4T)A9)
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M=.7<FJM+YWER+4;R$:CR70;?VF5DLGJ7(4IP\(?T<A= 'X_Q(;UKG+(8?D%
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MV/."STAV5WW&DJ6ZS^BL^(Q%\']K&SPIU\,A6P<'M0B'E ('J-T^@_/JK_L
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M=WY''G<^(SNM+JO;EO.[ECI7N&C#:;A(OD$B#I 2  AM )2'/X@9($L,'W&
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MYS%?AOV0#X9X'WF YIGP3'HH3UA>O= Z@G<)7*DYLSKSN5H-W$:F%VHU*);
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M$&2OEX?'/&>A2(N](/IX0-!>9P+\*?%9@DRH64E-2/"JE[, 1R&;"04==KI
MD82SA'2^8)9\FUO,TFXB:99V0^&(7C)0&Q'\3>3A$B@%@Y'L]0EI'!2/&9N\
M0U[2^R(H$@G"/M]G9A^US]FILMVP]]LI>[A8&B?784U<8!,.8T;8X)F4L$'3
M87R.&895<Q@>U4B&"Y2P8<^_'F&-/9MXJ'ZAZL[3$%$MPV1I0">$X8,X=Q)U
M<'#C"_)O$""T!FQ":Q#^!_.J2\G4O/::RIL]@REVMBI34W/$9_K?6[+A1O!6
M64G<M<<A%C7P3HL8WW-3)-,,_*4F=?8?,?)',U\B'S^@)3PP'N&]:V<?!%>%
M5N10%20<#*R I_U]D:QB@9I>^<I,&&FZ!N.3=Z"FMY$_-U9DXX](9"3&M9'\
M$R)H<]]4?KZ-XCV"E)%N)/=YOEG_*GBGP\8QG(U#46LH:&-0_DQB^IF/8-3
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M$ @$ H% (! (! *!0" 0" 0"@4 @$ @$ H% (! (!/]O@ 0$V,\.,I.("S'
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M+N#S'.Y;9TUO[9O5OQ9!9UJ0\S3+\6/X9=&8=R?(.F#CY'G/4O,;FT]>GR1
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MM'\PZ>X6T,9N-\#W>X[?I+!1C7NE.VG3\9O/\SSGG.?\/N_['K]^0[,BS5;
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M/+XDGJ<@Z -._EP>U13XLWEOEQZJX3_C/Z1:C/A/^8^D_@FN6D+_F/^'U,]
M>Z#G^--YCTZAQ4@GY'&)70AT*]++^+_/-%7KQ5 5MM^89LA6T EZP1YP#-CY
M+%^9C^O5*.0,S>'\UGF>?BWUM^DQ)P7OU(/>K5B AA#>S9^$!3%E3'EYT'O\
M802%\![]*BPAO/=^"980WL_= TL(;_(@+"&\\3MA">'=O0>6$-[> 5@0!?[/
M3S:MT@.]!Y@1JN23&*5)C-(D1FF2;'Q2''3%)MKVC7Q+"T;LD:!O=8N>/<VR
M3[%L/\L^QK(FRQYFV7M8MH-E[V!9'\NZ6=;#LD&6/<,V82BR+/C$AX(W!^M8
M=HYEO\^R:9;ULFPSRS:QK,$"P0)OR._8(%6W5#,A<=)!?W(+KCZ5O $CVH U
MWX!KPBSDLZ H0T$X&2M+SLL]0J^<:>DLA==M]J=P^IQ#QG.8AG/T*V##!)W#
M,CJ'0LZA@$K(3K 'G 6701'8X;T2#3\F925D*^@$>\#=X#*PR^9<!IQ25A-/
MR(:)1K=:#>\%-GX.QTH<#;PA6.]RNWRN[=HQ-ZOTL%Y/T<,#5%.##6=UE;.J
MP"I._K[BOW]?0>6A<GZ4'Q.7;OX52Q_+7\&EFWT][SVCAY:QA[ -P,IC-Y.7
M-4-OHK0,WX1MK- ;R<V_!^W/NV]'MLJ\=XU^FBT1N4[J5]R7]%^["QSF&^XS
M^B^,@HWE]1<1\[V3^@ON!_1G6@M.Q#SE+3"HTX9T/>7>I']_3KK>@X1'\OIA
MH4[J_^3>IA]PRP2SE'!'&J%@I=[OW:UO1WEA][ >3*/,DWJG^PZ]H^1UD\AS
M4E^/)OA*9@L:N]HM*VWT(.8)_:9/?SI08"/!-8[CCD%'K^,3#K]CC:/!H3OJ
M'2L<2YW53I=SB?,ZYR*GTVEWVIS<2<ZEA>*%H(\P@4OM+J'$KRR,;-)V<2'E
M3\8XKQF^$^RDW/5:#^_9U<5Z<F=CU#-LY-[9U5A@BV[;G2MK[&*YZA[J&>C*
M;?+U%!S%_ES UY-S]'UF<)JQHQ'$YOC]!48#@P56%%%'5N2JMPZ>(L:JCGQY
MA= W'OER)$)U-0<[ZSJKMU3=_*GP1XB]EO1=_=1]R*[ORAWOV368O^F[WZWO
MBN3\TBX68??DOK;+&!H\Q=YF;W:'3[&WA(H,GM*VL+>[^T6\MB4<B?04V.W2
MCPSV%ORP=-Z2?D[<I84?&4Y/R>^1DE\S\L.O22CXE9=3L_1K+B^7?C8F_*;3
M3=WAZ:8FZ5-K4%KZI&N-#_K,-<.GN5GZU&1I3OK,U62%3VZ+='&[X>)Q2Q=V
M [FEBYO=(%UNO^K2:KD\L.#R@*Q)8U=]W"6?B@OS/A47X./[N!^SR^=C,^V1
MV%"WV=B]M[';!'MS#QX<J<MEAPUC.A81"49.\^X=CHT('35SD48SG(LUAHWI
M]J&/2!X2R>V-X6D:ZAX8G!X*FN%\>["]NS$:CLQLZ]L8^%!=#RS4M;'O(PKK
M$X5M%'5M"WQ$<D D;Q-U!41= 5'7MN V61?)I=XW..VDKLC6H9*>X8L78=GN
M7=$0Z:IQC6V1:[B]H>[PBM/8NGR'%OLBN>L:NW(50"2M#:T-B22<6B)I":(K
MK:2ZP^T-*TZS[UA)+D17-7:1+S.1GJ"Z[D2X])?&!U&9"3'@)>E+7^N#M.Y<
M,!I.9XAZ<BV[>G*=M^T>G'8X$+M7="FW>3YN\>+N0O%L*7(=(C>+2$U;<!1Q
M'2*NO-QR_//YG[#T5G$69/F9&1;TL RE(UK.TS/ <448V(V^#NT>/(V-E;A7
MI"/H8)KY6'J^#*O9/A^5PB3Z/$]FPK*LL<A8NI036=+S0[+P$8/E6QBQC"Q6
M#J=O:#"T1/N$UDHA[)W70Z^%7@OMA_9KK<%JKZ[Q@%[N#.B+%X5UASVLSY<:
M\8G+H'A3!@?N8 [J>H*S2W9'@3\<O)[*;)<T6N2P76*TW&DON\2UIW@;E;.'
MV3JJ\[G>Z7BOXQ]<O^VX];T.ZH3M>A>B;7U#54-5,P0NNO2NH9U]-UA&?R3#
M=G;^ 4M2H5 H% J%0J%0*!0*A4*A4"@4"H5"H5 H% J%0J%0*!0*A4*A4"@4
M"H5"H5 H% J%0J%0*!0*A4*A4"@4?W=P8B0^2TD3%KL!V.DO?C3Z.__8R)#2
M)L?'*!9+LGC1&J^/,P1+Z%_G_?@-"WD<%$?(*H55\,.6K=%UVH.6;8/]D&7;
M8?^+93NH33LA9LI6CC(]V@7+9E17]KYE<UIBK[%LC>KL399M@]UAV7;8 Y;M
MH&%[DAY'?_VTGMHH &N 1LB$OI52- HR=(C&9,Q6A,9A"QE%?$)ZK$-*".LI
M"=V/N/W(GZ&T#)G0)KP/0L:E9P6.[0@-(]:D2<3TRM)'4>]\/;>@]$,H>P+E
M&"@WA3(3%(,=@SV&M/&%>HR%UJ^G#;"\"Z$ K9%MB**$,?@:J#>*>D09,3I@
M^>Y$: 2Q(G4";4PO]$F,0T+V(WG-]NR38V%0%\+#2!&Q43D2'^YCJ9R4U5-#
MUC*!U)CLKPCM0]F3R#LN8R;@%9<C9R!^?CYVH$UB=!(RWZ@<VW:9WY0>)MV%
M.L5(QZ4TK!;-^QHR/HT8,7YC"S-XM1\B/8-6)) SC5$(2<]2C^9[$95M$BL@
M+FL4;3X@>[?O_[)Z'C?\Z]L"QL"(:=R:&DUE#HV9QM;4^%AJ/)I)I$;7&:%D
MTNA/[!_)I(U^,VV.'S3CZXR*BNWF\+@Y:?2.F:,#(L\MT4.IB8R13.U/Q(Q8
M:NS0N,ACB.+7;S"\0@76&/W1Y-B(L3TZ&DO%#B!V9VIDU-@^$4^+F@9&$FDC
M^<%R]J7&C:[$<#(1BR8-JT;XI%"ID4Y-C,=,J'V9R>BX:4R,QLUQ(R/ZL6/
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MR&4Z_K9B5;YD95A9</D\.\0?E5)64E.A(4G4#IS>3?UH!-V/VM-H)N711W2
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MVET:\G9J8<VCOF(5T%U]8QU&?U6-O.O*^E1.Q*MCHKO9+\KQ9;2?$,C'NK^
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MMO$-P=\5:Z3:)EZ$[KU&2>@7\0K!5E,-YVY$K<0XH[5^Z>\"S+N"-!J.O)W
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M:L4Y-#C?R#GK>041G)_YKAC0\PS'=>?\I3/G</QIWN#'VXSRO.?A]RS%.?4
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M(P']W?K;P%E@D9M>%@3TK!7+50\@78X/@\\\3!T'O@4N(D\"\4 /(,I->X-
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M 7__1/\C2D#^']-2)W>*_@G]:KJ.0RTF^@5PT"\@ >@@T#B0!.VASZ,QH,-
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M88:T<Z;#%Z$W>SK< LR<=E=P&?RC=,H%[%PZ=3^P'Z93%[BS^$QN)'PRS6V
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M)ON94,?JFVE+D<5K209G<3NXW<&'U,^J#YH/6@X'3W"?N[06@\YL4]*_V:_
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M)2JAI@70' 2^ ,HV0/M1-"(^]0/O!^EK(>T3)37P-QN>UD)I/]H!)?/%WK?
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M[MFO' =H<\ )IO[U+-=X"J6[N*?>1(]'(G->4#4&>:1^!6UB-/4H]SIQ3YU
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MNTCX\^L>IRR\<WODAPK9PX^CG^#6@87<M@.0(H_F:R_].^ -/Q*'2MBTE0F
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MC?8VA@"/&*;9:BZ86P%*8-B;_7MG.!@%06H)Y#48CX$36CGJ R<[-$R.O9M
M<#0KM[T$?9-918"-8=59_*E;=H)P3W37)QA+>%="28L!P'J:@THE^K0$_>M=
M+D44.4IEH[U3+G/L>P:<+]5Y9JRS9RT!@7?JU)+Z-/Q!^+ 1I3K)6R92]!?D
M]L+1,*OBS)T.I,P'1L<@H%&2\%$ 0*K![=> Y[B/>27<)I.W3,G)5#*_T0WP
MSQ[CU]^[_O5LFR/!=J3ELT"U@8,!!,K4EL]XE(R3A9)[E5:<G(JS((A$%O?
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MB3UW]RG<Q6_K!.E.X Q$!ZRHL7=9"KS[@4.RTCNYXN9-!0!S9AR)Z*6CF5.
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M*!H28@(4M30!B0(Y9B".&90#,LH2ICZ@*#\Y.+4D6C_ Q4T_)+6B)-;.#B#
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M5BT/".JI-=VM^>%!'HH$H ?+NE8UY;XIVU*V=:I[H3\#4X8]8#7TXF&&]+4
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M"N%')A6M*H'U=5=]$\'^V$G](<-)>_VUWW@3\,9!J)A1#N.KV!0?R7I)&#P
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MEJ*Z%@70_/]/Y][3W55"LG<2%!6KYAQGG%8> 0+JJCQ* 0
M                                        +JNJ @
MX(!J,@( P)55>0T X,*JN 8 <&72&@# A56-:P  5R:M 0!<F;0&P"G\FL"S
M/ES2&@# E4EK  !7IG$- .#*I#4 @"N3U@  +DU< X".WT:N]#A*:P  %R:M
M 0!<6)76   N3%H# +@R:0T X,JD-0" *Q/6 ( GD3'.J49I#0#@NG2$ @!<
MF;0& '!EPAH P)5):P  %Z8C% #@RJ0U ( K$]8  *Y,6@, N#)I#0#@P@Q;
M P"X,FD- .#*A#4 @"O3M@8 <&7"&@# E4EK   7IB,4 .#2I#4 @"N3U@
MKDQ: P"X,FD- .#*I#4 @"N3U@  KDQ: P"X,FD- .#2I#4 @"O3N 8 <&72
M&@# E4EK  "7)JT! %R9M 8 <&72&@# E1FX!@!P9=(: ,"526L  %<FK0$
M7)FT!@!P:=+:U>^/.@" WTU:N_X=4@< \)OI"OV$>Z0. .#W.I#69(:WWBA5
M  "_D[8U (!+D]8  *Y,6@, N#)=H0  ER:M 0!<FK@& '!ETAH P*6):P
M5R:M 0!<FK@& '!ETAH P*6):P  UR:M 0
M                                                \#/4J@X  *Y,
M7 ,
M                                                        X+>K
M51T  %R9O 8 /X@?=@
M                        @->HJ@  X-+D-0
M                                                        )FI5
M!P  5R:O 0!<G+P&
M                        7%Y5!0  ER:O0?3!\,D @(!?2"[T,'H: 2#@
M!Y(+/8T>1P" 2Y/7   N37\H ,"UR6L  )=6Y34 @&L3UP
M                                         +A3_<^??_[]CZ?4LCH
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MKYOX5IK755X# 'B!?;_I[DV;WIJ7VM<  *Y.7 ,          (#?RS!"
M                                    @#>JJ@
M
M
M
M                                X/IJ8[B5Z@( >(,ZBVSQNM%.LAT
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MT]J_4HJ\!@#P#&>TK?W97UX# 'B"D]*:\6L  $]Q3D_HMB@  ,YS8EJ3UP
M3G=J6I/7  #.=FY:$]<  ,YU<EJ3UP  3G5Z6OM_645> P XRY^<=FZ#V']Y
M3<4" )SBNW'MU#(UKP$ G.09<4U> P XR_DCU_X5JSL4 . ,3QBY]K=8S6L
M "=X2E?HWX+E-0" QSVI<4U< P XQ[,:U^0U ( S/*UQ[;^RB]D&   />FI<
MT[P& /"HK[CVG,(UKP$ /.AY0]>*YC4 @(?5I\:U/WE-)0, W.^90]>*YC4
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MLC_[07E%;ZB\!L!5O?4'*@Q28>#:K0RWVK7-K06V3?"+>#@N\Y"^IGG-/0>
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MO-='KOYT@RT?SFLE/8'1\B;H)=N.TF"?YO*!>=D\W/W]V0;$TY^3YS^,XAH
M=&Z)(%D;C=%J6XG"I9MMOUZ%B:J,\UI77+CEN7EM,HDUNKC=?NW0NCJHH4U<
MV^V]O2UY6BN#WMAA]-E/K"WS;">O <"[; -!LCX895[3D6A)"?]>)1-(C^2U
MX>&.Y;5R:EYK>U6WK];R6E!HC3MZ@X36[KLPW763U[*&O^UAMEEP6WNG/HWB
M&@#T5O):.J=SV.BV7?SULL1S%?)0-6LAFBVJ2U&PCF933.LA.%:;FN[.:_'
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M] +B"F$RPNV.O+9U&Q[,:SL26U@T71]JN>C,/"6N 4!L*^V,\EI<ATN21G_
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M#IGW=-;15-CHN*N_DG-K\EJV?IW-:X.ORZU^EVV5-6%\'K^W8]6*9V4J<0T
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M'7P' '!"O/K>O#:(:\N5\G);%-U$. #X>F?DM>\,;'4JKJW6WTIC:8#SW +
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MM[T?  "\@]<6V,Y,:P^?6SD_YKWTQ@ML / FKE1@>__&_+VBV?[:E]YX>0T
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MLQV=>D4!@)?XXJCVVP!E/H/576L# #RLRVK?V0A[(IA.40#@:6ZQX]L3R/[
MIL8& )SN+Z$I%OW7"+L"F&%L ,#)A+6@16:GB?ZUH,0& )Q$6$M:95=@4V(#
M $Y2_P9?"6M=RPAL ,"KU75:TR!MZ^P+;!(; '"P93>HUH@;:.>T3\$7 #A4
MK3M[06O=O<G;M]#.P&8,( !PI,GL50-?U$3W!C:9#0!X7+W']S72'8&M"&P
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M'GJW,;<SFWR1Y[7QA T  '[TDU?+HKMTN208>[8*9LTWZUVM^V*3R;CN!@#
M [:F'-P6_72E_OWUMS0+:T5> P!XW)UQ:G8S<0T X#'R% # I8EK  "7)JX!
M %R9N0   -<FK0'[^9<# .#2U.4! *Y-7 ,
M                                 ( W4ZLV
M
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MRJO_77S3U_O*:DFWV]HMW-LTA[5Q'$?"GN<=!YDY]EODM6$Y</W-8K*&P ;
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M)N"NOHM73!*<.P, \( :SQ1=?+%,8%D^:_:7=]H" /!<-9QGVG:/:B<
M
M
M
M
M@.]6-0$ P)6):P  ER:N 0!<F+ &
M         .^M:@( @&NJOU:+M L P%6T>6WY]W)9E.*6&XIX  #G6)?6;G$M
MRG E6_'_?R;K94N+(AX P)2N*[3>/M7EXBBNW3[UGZ-UUTNC4^G\]XW[! !\
MKU64:O^(ORA1REO&O"BP#8^[VK9/;/$8N_;+N(KG#@, [RZ-:*L*6-!KFNTD
MSFOCXZY7:X)8B2MTB^I;%MEJR0IVJ^W^6W7<1'(? / R]^2U<2(+L]7XN,T^
MUD/GXK67.^VBV_HP69H;U>6BM4H?Z_J-!3L X&AM:6SU5;C61GB*![M%AVV6
MQN<QD]=*-S=B?9QHHS;CY:U3EV6Z[KMF>1C_:E<J_/O#M L 8-.@*[-F"2HL
MEZUVTB6;Z+"GY+7@(FJTU>85=5_4=-!>"1);<KGI&+UED!N&ON;2?[_U) /
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MJ*^-SWWKZ$E>VQJ[GQSOH/D&Z]/:,P!NJS]TYFIJ7%Z+_C,G?IYJ_'/9?,X
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M!@!P;?(: ,"UR6L S^:?76!6_:,M )[)/[O +'D- . ]B&L
M                     / _]NW !($8 ()@_U6?%2@B2/;#3 D'"4L@
M
M                                                    A\P$
M
M                                 ,"79@(                  &[C
M$RUPC L(                    ;C 3  "D3; ! *3I-0
M (#/?,,"
M                                                          !X
MGID
M
M
M
M
M
M
M
M         ("'F D  -(FV   VO0: $";7@, B!-L  !M>@T ($ZP 0"TZ34
M@#:]!@#0IM<  -KT&@! FUX#    @-]Y7P, :--K  !M>@T H$VO 0"TZ34
M@#:]!@#0IM<  -KT&@! FUX# &C3:P
M                                          # 69L-
M
M
M
M
M                 . 6,P$
M
M                                    <(F9  "@3; ! /1I-@
M
M
M
M
M
M
M
M
M
M
M         .#OMAD!GGI^30
M
M
M                                                        P!LS
M 0
M                         "4S 0! FEX#
M
M@#O-!     !<;A[!  #2]!H 0)M> P
M
M
M
M                                             .#%OAVL- P%0!3]
M_Z^^@H)%*%JLMI/TG$6V@5E=7O(
M    KLH$
M                                 )Q6)@    " WW/ !@ P3K ! &Q+
ML $ 3--K  #3Y!H P#:]!@"PK10; , TO08          ,##]?D  &#1^UT#
MO08 ,,O=4 " <7H-                 . H<C44 &":7@,
M                 'Y6-@                                     X
MMK(!
M
M
M                    P$TR 0# LO0: , TO08
M
M
M                                                 'S(!   T_0:
M                             ,#MR@;7AS$! , R'0L
M                    P)9,
M                                                      "\K$P
M +"L!!L P#*Y!@!PL9A&>@T X$(: 0#P*-H3
M                GJ!L  #PO5[X[0  1Z"8        @)/R.10
M                                @/ME @
M
M
M                                    3B\3  !,2[ ! $S3:P
M     #R#W]<
M
M      #.*A,
M
M                                                      # GZN,
M   P3*\!
M
M
M
M                                                         /"J
M,@$ P#2]!@
M
M                                                  "<5"8  -@F
MV
M
M
M                                                @&O*!@  RTJQ
M 0!,2[$! (Q3;   \_0:
M      #P2&4# (!E>@T          (##*;^_ 0!,TVL  ./T&@# .,$&
M          !\X;(! , VO08 ,$ZO 0
M
M     ,!_R@0
M
M                                                        O*!,
M   P+<$& #!.L $ C!-L     ' '!VP  --<.0  V*;7  !FO9>:7@, F*74
M  #&.5L#
M
M
M      #>V+<7)<5M( J@^O^?[J2R6<:6NB4#AO$,YU0JRQ@_9-G@BQX
M             !\O_OL/ ("+DM4  *Y-7@, N#9Y#0
M
M                  !X0(0Z  "XL B!#0#@TN0U
M
M                          " 9T2H P" *Y/7
M
M                                              !@*D(=  !<FL &
M
M
M
M
M       ?(U0!     #PNM+ ! %R:O 8 <&7"&@# I8EK
M
M
M
M
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M6V=_D&&F2%5G  #74(>4>M)$L4UDP2X)?F/_;[E%MJ1,;O/^WV&]W>QD>0T
M^%4>#3;[EKR_:2D/;..2&-XOVP#KA->RX8&W/UU: ."7>##8'&NE6VX:FXD'
M0W_NU_ICJU[WNHW->"XM / [/-.\=L)NGB]Z)-,]Y#4 X%?XVRSUV,87R&OS
MXLEK ,!/%_\/-WM\X_V"ZYT< ,"/%LD$T/NVWO]YO;-SC0& G^VIN#9. ;C@
MV;G& , /%T_EK-B[XLFYQ # 3_=DI+EP6I/7  #^N&0JNG"*! "@R6L
M
M
M
M                        4Z$*
M                >)$(=0                                  \$E"
M%0                                   , )0A4
M
M              !PDE %
M
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MYXK3L?'!'&2T:A2W4@ 5^>*NQ^*78FMO&OV54;UV Z^.*'8\*!T%*]<4NRR
M>N*NQJHJ5X@"IJ:>.*NQV*NRBBFE0-NF*NR\5=FH,5=FQ5V;%79B*XJ[*=N(
M) +$=A_;BKLA/^&;W7M=MM;U6);>UT\.;>&H9VD?8R2T^$4H"H!)KO7)6P M
ME&G^:H-*\OWFBVD9>ZU-XA<3-0*D4+>HD<0'Q$N]"[,0* *%_:R;Y%FQ?-3O
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[,0#L>F*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS?+%79'[#3M4DN&EU*8</V5A8A=C4 B@/S/7;KA8 'JV:=L
M/U7B*8&;67BKLV*NS8J[-BKLV*NS8J[-BKL+]7UF#3%4S&AD/%1[TPAB33L*
M_*^B\1^D+E5]6;X]EI0G<GON=NYR1DQB.K9R29!L:S8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL(M?\YZ;H8(NI091_
MNM/B?MV[;&N],D!;$R 5(H'E-$!.<[O//6O^:95L]'B:WC8&O \CU&[/1>
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M;&UX2>;J^&#K'R'8VL443<G,+F0&I')C_-UKA,RR$ VS%C4X:IH-DCB58@'
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MSU'/DU>1J*U'V?#%C8;\K:AYPA\QQ>8M=U6U]%G,=T&U&WX+#0["..4@+O\
MNPH^UN:5KG0OR U6[NM%>SO!)_HLG&-G4CX#^R">O$U^6"39 L&_/2TTR+S'
M)<Z,\#6]W''.RP.KJKL/CKP^%2Q'+C4]?H!_Y6_+B#R_J4VIQSM+Z@951A3B
M&/(U:OQ?<,!*QA185=:I)<P);L %C[CO04&3# V(+-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKL"7^IPV(7UC\3L%50*DD]A_;MB@FG8"MM0N=4
M200HULH#*KM0M7L:;K^O)F-(NV\0T'2;^!@^H2^I\-&!-:MM0_+KM_MX"4 '
MJX]=L/?24-SH.5*5]LBS:QV*NS8J[-BKLV*NSG]C%'>^8/6D);C-)QV)%8PZ
M_P"QXG<>^6=''&Y7;C8YT#*W(6YL5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78
ME=745I$T\[!(T%68] !BAL DT&Y.0W4?S CN-.>ZLF]"IXHTE.6XJ"$W\??^
MEPQM9FN,95^!&X-",BV@^==,M8&-_6[NI6+4*]/'F?!CN/A.QWRZ>-B"%5[2
M0?%QHOCVPS'YGW\KQQ6-C2(_  16M-OA*D"GAL<IX&7$6C;J 29%Z5H*U^73
M%9-;\U:NSQ6ML;:-F*@L*4H/YC0]B*COMB  MDM<(Q0EJ[;TP./R]U^_)_2U
M_P#NJ].3-TITKM0_?_ \8')>$GFJ//  /3CW%=V-:X8VOY<6S$"]NWE*J1Q4
M@48M4MW^6XZY'B3PJ'J=@ ,&1:%Y;TPF:5E?[%.;<J<*A:4\/IV]LB24[!HR
M,10DTW_'#:/6=%LB61XH^*\BP'16/C3N<&Y6PT 3TQ[><])4T:<#X>6ZMTZ>
M'X8\)7B#J8V+SMI$JEUN4X@T-:BAW\1[8\)3Q!O@W2AWP?:ZW978#6\\;AJT
MXL#TZ_=@I-M$$&AV."XY%D')"&'B#7 EK'8J[-BKLV*NPOU?6K?3$_>NHE<-
MZ:,W'F1^S4]*D@?3A 8DTV 3D'NEU[S+=&TNHC;6RL".&Z%&/$U8[,P7ML>]
M ,MV#6;DJLJ(JNC<B:U'0@C)?HWE6STQ$ C5Y(S42%1RK2A/>A/MD#*VP1I2
MJ<.<@R:S8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ&W'QR?ZW\!B@.Q;%+LV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J["SS/>366E7EU;,$FAMY71B*@,J%@2/GB$%&Z-!%/?6
M\-RKO"\J*ZQD!RI8!@A((#$=*CK@#\OO,G^(]$M=19@TSQA9:4_O%^%]ATJ1
M6GAA*(FPF7G_ ,N?X:U^_P!'576.VN)$CY_:,=:Q,>GVDXG()^??E73AI?Z8
M18[>[20 L %,H?JK4W8]_OR4"UY R;\EM=OHM9BTJ*-[NWGK^YZ\&7XUE3D0
M%92-_$$CPP__ ":O)[CRE;-< L461%+?M(K,%^BFWT8)<V4.27_G-9V]IYMU
M&*T"JGJ*S!#4"1D5I1U-")"U0-@=A0;9"?\ G&G:;4P10TA^C>3;#)$&<_\
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M3M3I2G7*Z#*RIXY(-<<\6>,*XJ:]5/\ *./^=-^N-A=W8BOE&Z><S3W7)0M
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M?6+O1KN+4=.E:&ZA;DCKU!^G8@C8@[$;';.5#_G&NS-US:_D-GRWC],<^/\
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ML5=G&K[\B]1TN[:\\I:@;4$U$;EEXBM>/-:\U]F7YY*VK@[GKMI^>5CJ]O\
M5O.NDQZI(4*-<JP24_#Q5OL&C[ %D9=@*@D89Z5Y$\X:B@C\PZNR6SD^K%
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MAJ#ZF'4(88Z"M/M?UPUC\@ZG$O"/6+A5Z4""G_$OU8.)/#YJ'UA/]]+][?\
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M@7"U(U:_J?\ BS^SPVQM/"VUZII^YC%/];_FKZ?[,IO(5[Q 75[P4-=VKO\
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MID@&,I4N5"V_8=3D3M/+=_YFC%WJ<@YL59:$\$&]0J?9)'0FOTUKEHGP\FL
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MQ@:#*?S&T>#S7YLM]"BN[>UNX(([65I2Y0S!V_=JT:-\:JP#<N(Y!EK7J/\
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MC2RO@#Q:->*-X*Z+MU_: KD@6)@R[R+^<&L>6)(XII&O-/4BL$K$\17<PO\
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MF4<9 M(022.+2=FVZ4P 6F4J2/\ +_\ +V3SG<-;17EM:E-RLS'U&4#DQBC
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M6^^ LHBDK\_^;/\ %NLSZXT?I/<K$76M1S6-$<CV+*2/ &F<D_-KG'YYLG+
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MRL!6M&64CL<8OY[>4V.]TP]S#)X]/L_3C2\813?\XZ^>14?HZI )H+BW)V\
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M5YX\J6FMVT^HZ3#93AR(KI)Y6AA8BD<CPSM(:JW5_4HOV@H*USL,2\45178
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M,H_RT;[?X'YXD*)TBO-/Y%66IK^D?*US"HG9Q% 91)"[*=T@N5^%? ++3?\
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MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J["?5O-VEZ2O*[N$!_E4\F/\
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M(Q:<BA%I0*)IPM*=B-ZU-:UKD0_,'0KO\O\ S-'YBMQRM)K@SJ5%*$FLL3;
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MH%2I- JMU!)[Y,2IJ,+>B^5OSC'E>T;3M-TRW-NY#N9G=Y'<#C5VJJ\:?L!
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MD1@31DCFY I3O2AZGI7J-_E8(US87?)L>^#-(T2=5#:I()Y1TJ*@5IXU\.V
MR[E [VL.8H5B 5!0  ?=D&3L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV%.J^9;;3V$1)>9@2%45.PP@,3*G8#CL]1U,D7A]"#8@*=V!KM[4V]Z]\E=,
M=R[#:TTJ"U;U%7E+W<@5WZ] .O>F09 .P9BR=@'4M56TB=HP)9D&T0.Y)W [
M]?EA 06\)+6!O--K!=W2O;\2P>,[4(V-/D>A/3)WPL>;;J%8@&H'?)':VD=J
M@CB% ._<^Y/<Y6R I;BV*79L5=FQ5V;%79L5=FQ5V;%79L5=B<]Q';QF69@D
M:BI9C0 >Y./-6P*[#(-YG_,J*,K8:'_I%Y*> 902J'I7P)\.WCE@CWM9GW(B
M"R+J97^%%%=S0GY5R_*/Y=>A,VJZ[_I%\YJ QY!:=SU!/AX#WQ,^Y8Q[VY[T
MN@A3X8U[9/,K;$+FQ5V%^KZ[9Z3'ZM[($!Z#N=Z;#KA M!--@$[#(8OGZ^UN
MY:RTA%C#BD;.#R'B3U7W&QRW@'5KXB>2YDX=<7T'\N&]5;K6W$[H*!.H.Y:K
MM05JQ)I]Y.,YWR40[VVE[+L*Y.(+>.W010J$110 =!E+8IXIBEV;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V(P#XY/];^ Q0'8MBEV;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=F(J*'IBKL\U>9O*&M_EIJ9U+1Y'^IL&X3JG((K'^[F!!'AOW
MZC?83NV@CA?0N@^;]#_,G2ETS6X(SJ<00-&93&\Q5"GK6[[+ZN^\3 ACV;]G
MH7DC\Z]/U]!IVO".WN9?@WJ8I>6U-Z@5'4,<!#(2OF\[\Y_E!J.AB6^TWE=V
M$(Y.U.,T/B)HJ\AQ.W-:KM6HZ#H=WILBV/U+2Y!9E45(G5 P0+0 !&^'H*9%
ML8/]=:6Y^N7E;EV?U)/49B9"3R;FP(;XNYK7WKG)_P H/-6L:EYDO=/U6\>Z
M2"&0 $ *6655Y!12FU<D0UQ.[U+\V/*6BZ=Y?TW6M(L#8OJ#"4CUI)0J/$KK
M'R<T/<UH#AOYY\[WM[Y@@\EZ-*;=Y=KF=:<U#(6XIR&QX_%R&_2E#B LCO02
MORKY$CL_+-UYZU2-9HX61;.VD#<)F]5(W>3@RMZ:U(I4<F[T%&*OS"L=8_+V
MUBU31-3O)XVD$<L=VXF&X)!7DOP]#7YXC=9;)OY'U70_S O3HWF/3;2UE:&0
MV]Q8)]5?F#RXLBGT7^&O'DE=N]<,M!N_-6L>7I-9.JP(LL9E1DM>3($KS45*
MCJ"-T;V.*BZMC_F!?+7E[7/J+Z3=R1V4CQ313WJCUJ5"LQBA^"O7X'((I0]S
M#/RWUKS?YH-U9Z=?D E'FN+@LYC#5'&%=P*[]ATZC"6(LL[_ #)\N^5O*LUK
M>:SI]*1R16^GVC\4D6-A^]NKFK2<CS(^&I-!N *$78ZMYA\B^;+;1M1OI=1M
MKMXUI([-59&X*P#UXLK=@=^F/-.X+M0T[0/S)\J7>NZ?IL.D:EIJ.Q^K@)&_
MIJ)'7BM.09*D54,&H.3#)/\ GAYSU+1Q9Z5I#M!->L095&]!1>*MV-6K4;]/
M'  F9IB7Y+>3=,UG]*:WKB">RT>U,Y@Y%2[T9EK2E4 1@14;E>V1_P ^^7-7
M\@V%MJ^G:O>2RK)Z3K*_)/B!(HAJ*;?M5[81N@BF1?E_YNT;SSJ+Z%KNA:9#
M!<1LZR647U>16C'+[?.M"H/PK2I[=</]6>\\[^1TU;ZW+:LEM+),J 4E:*JL
M&X@$*Q0[#;?IM@Y%)W#&K:SB_+_SP^F36D&H+#=)''ZP8\4<@QNHY!?4X,/M
MJP!^5<B_Y+>3I]<TRYGCU"ZL8?7X%+5@E2J*>1>A/[708241%LL_.'S3'Y;U
MZW$VGV>J7"VW(37RRR&CR2_"8A,(]MR.2L=Z[= *OY[_ ,O^?++38[Z[FM7]
M(%9I6>JO4$$=ZL,>B\BD=A;66J_EYJ.H365LE[!=42>.+B_VX#3D&H%XR,.(
M4+T_:WR8_G9#/;Z(^K6=Y<VD]N4H(9717#,%HP7Y]< 922/\DIXCYD@L;BRM
M[^&[#1O'<1+)Q !?U$Y$49>/TBHI6F /)=[K>L^2ENH[YXKZ/UCZSJKLP3EQ
M5BX/>GQ==L2@72M^8<6BZ!YUN4CL8Y=*1XF-LLCA>+QQO)P=&4J:EN._%3M0
M@4SGGD6Y\X^;8KJRT[4)?3HKR2RR-4-\7&.-MV4/WXT&WWDL19>A?F'!Y1\I
M7=G=ZAI<)E2L<-I#7B\(:@N+C>CNM& 4GXS]LT R8)KFN?EQY7F.NS-/J<\Q
M2U#R>KQ!4?$2:[+0M3<=/$X.;*R QNXTG0?S4\X01>6+4Z;I26ZR7@X1PFD;
M'U&1$=D#/R1%I^T:D4J<+=7LH[G2CK4WF:7],&$3B)+A%2H0,8TB0J1\0I4?
M=A8^=K_+_F,P7?Z,@\JVDFD)<&!GFLY)+A5=^(]2X8M24 ^%*_94;4E/Y'^?
M[CS'9R:?J+<[NS"_O"U6D1JT)'6JTH3WJ.^ AG VDGYW_E[;>5=22[TRHTZ_
M:4Q1E64Q-&P#QU;[2BH*]Z&A&U2::1Y<U^U\QR7UQ<<].?D:%SN#7@O#MQ)^
M7@<;0 ;8')<6S6JQ+'2<'=O')UD6U!9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V8F@J>
MF*NR,Z[YSCL6,%JAFF# &@JHK3PZ]0/G].3$;:S*FP,#7WDDZS<Q7][(RGB>
M2*3M6A5=]OA^+>GT8W2\-KA)12M!OWIODJBMHXCR10I(H2!O0>^1ML68K@5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V ]1U:#3T,D[!:"N^$!!--@5V&%!
MNK[6BILP(K1J$R-O4;_9&QZ@4/3#R8;EV&5AH5M92M<(M9G !9B2=O"O08"6
M0C3JX8X&364[J@JQ 'OBKL(;OS(996M;%&E/ GU$W 8GB!2A^D]!DP&!EW-X
MGH/E:6PF:YN[AIY"217W^[M[=L3*T@.8UZ"F2/(,FLV*NS8J[-BKLV*NS8J[
M-BKLV*NRF8*.3&@'<XJ[(QKOG^QTR/U(SZQ/3B?A/3OO78U% :Y;'&9,#.ER
MH6/$#?(9<6FL>?91R!@LHV:A<?"17M_,:4ZC?)D"##>2(AD2V^(4=R!2A/PG
M)]Y:\FV'E]*6J\I.AD;=M_?*#*VP1I1FG>9N<AJ</<#)3P'J6K6VG1F2ZD5-
MB0"=R!UH.IPH)IL"N0/5OS&O-2<VF@1-SW'-EJ>U"N]!WZUJ-QE@@U&=\E40
M!*&0BA\#O@J#\M&U&87VMS-+."M/D-Z'M]V$S[DB-\W)=2(I1#136H^>36PT
MZ#3XA!:H(XU[#^/CE);!LI8)Q2UFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%78C!]N3_ %OX#% =BV*79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M80^4?,MMYNTI-0C2D<O-'C:C4*DJ5;MOU^1P\F(-IKYG\N7'ER_?3+LHTJ+&
M_)"2I61%D0BH!W5AVSF/YL_E#IMC82ZWI8]#T:M)#7X&#'JH_985Z#;) M<H
MT]"_+'\VM734+?2[J7U6GEABBN6 ,L1Y!5!<_;CILRL?<'J&D_Y#:M<:CY=
MNG+_ %>9X4)'["A2HKWI7K@+*')(_P [-%@TGS/<16T:P+*L<S1H255I%#M0
M$#B"34+V!VVID-_)H\O.NK,W4K<;_P#/=<)8PYLS_-\\/(_ER*-@(_2B)0?S
M&%34]?$]^_08(_-C1GT+S/8>9M.K/=3RKRMEW=C& /@ WH4V.VWTXA9;%"?E
M?Y@CUSROJGDW5V6WLHX3-#>N#P@9I$98Y6%:(\P6E!7[77;B(_,#4M1_,.TM
M])T?3+J(B59)I+J/TEC(! 'Q&C?:)/T8!LI-H;R'8:9Y U&?5]=U*UF$4,J0
M0V,HG:Y)6E.<0;T%/C)P;P&3^T\KKH'EI]%LW)]*WE4._P#,P9BU!VY-6F!G
M5!YYKWF*;S!JLNL:BH9YY.;JFPITX*34[** FI\:G.;_ /.,S'CJ2DU%8#2G
MM)ODI,8/5O\ G)Z&-;W3Y$B*,T<RERX/(!QQ7B.A4'?QK@/\Y7$/G;3)>->*
M6S'KVG?$(GS17Y1S<?R_UV/U2A875!1:?[S"M217XAMUR8_FQ^8'Z!N;33=/
MMX[G5I65XC,G)4#$IR!J"&)%!3MUP ,I%A/Y7_EQ#YCAO=8UB:2VT2PB=IVA
MH97*KS$:*:CM4D[=!U-1$/S/\D7^GZ'^E]7O9[Z_,J<XR_[B/D"&X1T['84I
MA!8$,C_+CSE9ZCKEOH>G6EKIFGGU@DRI_I;A09$$MRS%BQ*BH%$[!:<0)'Y2
M4_\ *LG502?JEW_Q*6N \V8Y)9YXO"WYEM<3,J 7]L>3?$H53'0M0;[#>GXX
MG_SC<_\ N&NH]]KHG?INB?TWQDL%?_G)242^8X6#*U;./[/;]Y+L=A]'M3"/
MSF*_F58U)/Q6_P!'7".3$\U;RO+Q_*[5UY*"UX*+7<T-M7;Y9//SO/\ SJEV
M*5J8O^3B9$,Y\F+_ )+D+YLL&+!.+N03TJ(W(!Z?:.V%/Y1RK)Y'>.,<WC%R
MC+O]KXFX_2",)YL1R1/YZ/ZOF^\F *I*MNZU_E,$=#L!M_F=\(_^<9GK%J*\
MM@T/P^&S[_3ADL&5?\Y0VQBU:RD:-N3V[5F)^W\9V%/A^&M=@*\N@Q__ #DM
M;S&WT^X2OHH\JL?!F"\?OXM@BLU+_G&<VDNJWMK<J'FEMU*!FHI".K/7L:?"
MU*'8$TI7)9Y7\A^4=7TZWO[6Q@D26-6J14UIN&WZ@U!]\24B(+"]8\Z>;]'N
MIM+O-3OHI;=VC>,7,@4%30@!6XT\*;4Z88^6(=!L=5N]+T2T2&XMTC,\D:J!
M^\J5CK7E7:M*4&!(JT%YBEUZ_P!.L]5UNYN+BUG>>.U^L22/_=>F)&3G4<:L
MJU7J5(_9R6X&;',V*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J["_4M>M-.*K</1F-  "=S^
M ^G)"-L2:=A/>V.KZE,8I?3%B[5I4A@ 01]FM2>_45]NI!IB02W^O#W3M+M]
M/C$5L@10 -O;;(DVS IQ-=S@O EK-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[&2RI"I>1@JCJ2:#%7827FOR2"-+.)RTST4D4^$=6(.ZCW(Z9(!@2[%(_+4<
M]&U1OK;BI 8?"/"B^/O@M>'O;!(Z8=  "@V&!FUFQ5V$.L>;;:S#0V[)+=UX
MJE=N5*T9AT\/GMDA%@94V!7 HT2;6I8-0NV>%H7#",5[5Y+UH0WC3<>(PW2*
MO=P:E1XY(XK6.(\D4!B*$TW^_(,Z:Q7%+LV*NS8J[-BKLV*NS8J[-BKLQ-,5
M=D:UOS]IVF\HU?U9U!^!.Q'B?Z9(1+ RI<$)Z#KD+DG\P^<W]2S4P6AH%:0E
M4_F#<0:MX; []Z=+ >%KWDB?0B@-)CR(K55/O2G3;)5HWY;6%HPGO2;R<#K)
M]@'H:(-J>QJ,@96V" 46N"053X5\!\ZY+414 1  H% !T &09J6)W5Y#:(9;
MAUC0=2QH,5=D%UO\S']86NCQ>H6IQD8&C _R+L:CY'Y9?'';49]RH(]N1--Z
M4[X6Z9^76J:G>_I#6YR*J:5HS_%^S0U4+1CL*4/; 9]R!$GFKM>*(C$BTJ17
M?;;OD]TSRO8:8XEMH@)0./,DEJ=.I]LJ)ML$0$*6)ZX:X&36;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78E!]I_];^ Q0'8K
MBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V<8\I_EGYP\GNT^E75K(CDM);R%^+TZ;\=
MF]ZCZ1DK#4(D/5?-?YD^6/.,*1:KIT]M<P11QPW-NZ,P"J 5>-@@9 PJHY5%
M31AAEYB\N>=?.-LVF:B;&QLV92W NSL :[;L/U8[!2"4M\H>:/*GE*>+5[>"
M]O\ 4[=F,:S&** $@A695$KDBM?M#)UHWE]?+6E)INC1JYA6BB1R@9B:LS.%
M<@G<_9/ATP,P*8CJ^N3^8=3DU/696,EPX:5U4$@=/@2JBBJ**M0* #.?>2/R
M\\P^7=?FUJ=+247BR"0)*ZA.;B3:L>]*=*?2,)+  AG7GC\PM&UOR_;>7K)K
MS_03$8GFCBHX2'TB&"N63XMQ\34&W882_F-Y?U/S#YPX>7[@O=6]NA:CA!;[
MD4Y>+5K0;[X0B0LIA^7_ )GT[R]Y4D@\QV//3]0NF9"JDO<F$)\.[)1(6(WY
M;EB "0V(P>7_ ,T;28K#,[#IS::)U^'I0.217Y?/'9:*81:S^4C6BSSV5QZP
M.\*^J'^([_%ZO"BCI\623RKYL\TZQ!?^7;ZWA_2]JG%I)'X+20'BQ$:.">^U
M 1X8"$@D[,9\]^3_ "QI\]AK>DW<[>7M4,I"B,//"T)3U(J.\8.[CB2W3^;9
MF?\ E+^7>O>3;J;ZXUK):7 4/P=^8*5XLH].A&Y!!(_JDVF((1'YO_F!Y>\Z
M103Z;'>07L#,.,JH8RC4_:$A8,"/ UJ<!?F#^5GF+S3K U:%[.!8E5(E,DA-
M%)8%J1#<D].V(*#$E%?E[^9'EKR]H$V@ZDE],;UG-PT21+Q5T$12,N[5VWY4
M6O2E!@S\TORRU3S;':ZA;K!'J<"E)%$C%&6O)>#%!N#4[@=>NV(*RB2E_P"4
M_P"95AY/EOK'41//I-XA%$C3GR *@LC/QXLC,' ?PWPLU?\ ++SCYBL&&MZA
M&\T2@P0)LC$&I]5E516FPZ_,8;08DH^P_,/R9Y=U**7R_I<_U:3D+B>X97G1
M64IQM5+,BTKRJQ+-NG)1OAQY$_++5K+3+C3==NA]7F@D@CMXMTC#GD9":"KU
MZ?KP$I$4D\^^?=*U+58M6\O6TD=S'*MP]U<L3+)(E.(]-7:-$6G;<GP%%R-^
M5_RB\UZ9--I\=\++3Y'4O- QYN%K3@HH5)_:W'TX;0(EE'F7\V/*6K"'5GTR
M6[U>&-E2*YXFV4OO\;*W.9(VKP4JM034]*2;\U_RNN_,$T.K:')Z6H0@*06X
M\@M65@_7FI\>OM3 "RE&V.?E7^9%AY;6?2_,-H+[2;FK<0H9XW(XLRABH(=0
M%;<'96!JNY5J?Y9>;/,NGR?XAOTENHU5K:%*+&&K\1F*QBIIL*5W[XV@Q)32
M#\Q?*.A:E"_EG3)H+-V9;N>9O4N3$WPE+<&0I'0;\JEF/PD\:AC#RKY#\V>5
M+"2RL;FSG692W"4.JI(Q'(AD7DPXCVW[8VHB0E'FKS;Y8\U:Q%>W-I=V-JG&
M.5H9$EDDCC3A&>,@1$DV -"5IV)%61_*S\M->\FZA)-.]K):3H$D"/)R%#56
M4&.A[[$CKB3:8Q(33\U?S&T'SII\(MQ?QW]H[&(3")HBDG'DI9&5EH%!6BD=
MJ;U'0_-7EFU\RZ?+IE\*QR#8]U8?98?(X R(MYYY=\PWGEV_AU737]*Z@;DC
M4!Z@JP(.Q#*2"/ YQ:V_(KS/I5S_ +C+Z.)'JK31R/&W"O[2*-S[!B/?)6U\
M)>Q7?YY^6M93U-;TIIS&.4=N51T$E*,%N&8.B-0;<&I0=:9USR)Y*@\IV/U2
M-O6N)&+SSD4:1R>K5)Z= *^_4G(DM@%/+//7G.X\W:B;^9%@A11%;V\>T<,*
M_8B0  47Y"IJ:#"S1_(^I6FO2ZQ/>%K=V9@@8U8'95<4"_"*>/3;#; 1-VE4
MM]&]LMNL2AAU>F^WOU_S^Z;Y%M0>;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B%Y?062>I<R+&N^[&G3
M%!--Y&-=UF^OY5T_2E>,-P=I5H3P8T##P'B=S3MDP&!-[!PVW."]"\G0V,/"
M\*W,G,2591LU*&GX]<3)(C3B?#;)&  *#8#(,VLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NPG\Q>:;/0$1KLL6E)"*@J33KX#;W/RP@,3*E\<325I^R*
MG &F:1>:E<?I'5'K :/!;CHO=2VP^(?3]&$EB!>Y6DBE!DE$:@\@!R/4Y%L:
MQV*NPNU37K73E?U'5I5 (B##FQ/V0%K6I[8:8DTV!7(^^IZGYCMHI-- MQZC
M>I5B".+4"GIU'7;[\G0#"S+DV0 :'?#G1?+L>GH/5(DD*A6) H>))4^-=]]\
MB9,Q&EN'&19.S8J[-BKLV*NS8J[-BKLQ( J>F*NPMN_,NFVB&66XC"BG1@3O
MTV6IPTQX@&P">F0W5/S?ME)ATZ)I92/AK6M3L/A -?E7,CP#U8F:K':N^_1?
M$[#"B\F\T^9.:06[I&RC>3]TGC\*$U-?G7L33'TQ002JQ0VZ4:=R=_LH*G_@
MCM^O!.E_E1?02I/<3QM*M#510*1O\.W6O4D&HVPG*$"!6S72D%(EXIOWJ3\S
MDLF\G2S HU[.BG^1R/EW^_H/ #*>-GPH=6H:XB_DF55^&^E /$2<JGD%W/[0
M(KOO6M-C7(VC@;Y>/OD(\RZO#:VJQ6%[)-<VW)25JJ[DUW/4BO4?,>U\0P)5
MH(274.**_CB>E^0K[S?I\=WJ$\IF!' REJ<#WW!K[4V[U[8SJ)3PDHV'5VTZ
M:3ZH%"ML:@'[B=Z8;P_E_JWE^))-*F$DJ*S,64$UJ-DY5I4==O;?;$3!YIX2
M.2"GN1<2&1U"U[+L!AI/^85YHT@@UFU)H%J\1/@ :*VS?%X-2A^^O@3Q5S6+
M$)#132OCDMTC7;/5X_6LI5D% 2 =UKTJ.V5D,P;6.C(>+ @^^#\"5N;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78E!]J3_6_
M@,4!V*XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V<9U;\M_-7E_5
M+O5_*%Q&RWCF1HWX\JLW(K^\!0@$[&H.2MJX2.3V#2_S)\I^8M,L-*\\V5QZ
MFFP_5H)K-@%X<>(9T+ \A0$TY D5I0D89+??F;>_N3;65GRV,E0Q6O>GJ.-O
M]7'9;DEEQ;_EA9@NDNL7LBU*HHAC1J?95F8<E#=R 2!VKDR\G>3T\O1RO),]
MU?W)#7%PY-9&%>/PU(55!H ,!+,"F'^;?-)U^X4PP1V5C;KZ=M;1#X8T]V/Q
M2.W5Y'^)FWV% )%@9)%FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79%)AYN!/IG3R"33:6H&'9K]2)0VM/B$G+V(I^K*_P"=O<$?[CT\#^]K
M_$8[+ZG5M:#:2O?<?TQ/ZOYQ'^[K$U->C[=J=.G?QKWIAV7U.!M>XD^\?TRQ
M'YQK]NPI\I/Z?Y^&!.[?^B4_W97Z/O\ [/QPDN?,7FGZS]4LWLKB4]1&'(2A
M5=R:=S[Y*F!D52#ZA_NX2@?Y)7^(Q*[\E^;=0/JWMW;2,01Q(-!7PHE/I%#[
MY(2 08DMS2V!VBCD '<L"3^&WXX9KH_G*,!(KJS10*;(?XH3D+#.BI\K2OV9
M*?ZP_IBL>F^<P06O+0TZC@?^:!^%,=EHK6:U[*_WC^F*O9><64 7-DIKN0C=
M-_%3^K!LM2<6M=Z+)TV^(=?^!RQIOF\DL;RU%>PC-!\MJGZ<=EJ31>W[(_\
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MBKLS,%%3L!BKL!:+K%MK5I'J-BW.WF%48@BHK3H<4 VB=1T^?3;F6QNT,=Q
M[1R(:?"RFC#;;8X-Q2ALXQ^8NL>>_*Q;4Q>0/IY?B!'$OP@_9YAU+?%[,<L%
M%JD2'JOY=:9Y(\R11:+>6M['JS MZJ3J1(0"75:H$3BHY*&4UW4OTK-_RV_,
M*#SA9<S2*^BVGA\#_,M=^+?ATR)%,HRMB'G[R//Y2OO09O6LY@7MKA:<94K3
ML2 Z]'7L?8@F0:]:WMS9R1:9.+:Z(^"0H' /NK9%D4ATZ:"&YBENXS/;JZF2
M,-P+J#\2AZ'C4=Z&GAG./ROUKS+Y@U"\_2>H)Z.GRB%X4ACI(1R!/.BLH^')
M%KB27H?YHZ1Y<T/3M-@T6RF2XU"W2^-S/,694D+<8 BTC/&GVJ5^1KG5\BVO
M-,V*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLYK^;7YBW.B/#H6C#_ ')W@%)&IQC5R4#5K]KETKL,
MD URE3T'\K/(5EK*W.O:^Y31M.!>2-*^I<,JF0PQTZ? IY-44%*4KR7)^5FL
M);"5=?O_ -(@5),A,/+P](GI]/T=L;7A*LWYK:2_^AOY:TO]&<OL*)%N>%?L
M_7 _/E_E<?\ 8Y7Y3ZYYBO-0U+3_ #/(&GLQ H4! !S#M7]V*&HIWQ*Q)ZKO
MS7T'RS9Z;I.J^4DG6"_^LLYF))!C9%$>^U4J:TZU!J<Z7D6QYMFQ5V!M2U"'
M3;:6]N3QAA1G<]=E%3B@FE6UM9+N9+>!2\LK!$4=2S&@'TG"O2[]/-VB1W43
MR6R7D5:Q-1TKUXO3J.E:8>2!N$?JNG2^7-6FL9Q'+-8W#QN".2,T3\3L>JDC
M[LXQ^3]M]4\\7L!DD<QK<1\I#R9N,BCXSW.V2+7'F]L_.34)+KR!I+&&W@CF
MF@G].WC$:(7@D:B(JCB"2>52=^FV>A,@W/G_ #8J[ FJ:<NHP-;.\D:M^U"[
M1N/DZ$'%!5K.[>TE6>,(70U =%D7Z4<,I^D9YE\P:YK'E/6KBTM-2NY8[.<,
MHDD<\QLY#@U!\#44.6B-N.94^AM%M]$\X:59_6M*L;2XU*WFB:>"-8Q%(KO%
M',J*4WY ,1_ YZ8T758M7LH-1@KZ5Q&LB@]0&%:'W'?*G(!M\^ZKILVEW<^G
MW-!-;2/$]#4<D)5J$==Q@FXN([:-YYF"1QJ69CT  J2?EBJ'1&=@J@EB: #J
M3GF&?SEJGFGS)$JWUS#:W5VD4:PR-&$C9^ *J#2O'J?'+*:+LOI.P\MZ9Y2\
MMSP2Z;9R:C:V+3SO>11S2?663D4J_01U 5%';>I).>F-.TZ/3XO1B:1UJ6K+
M(\C5/^5(S&GMTRMO I\X75T]R_J2!0:*OP(J"B@*/A0 5VW/4G<U)K@K%*CF
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78C ?CD_UOX#% =BV*79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79YQU. W/YEA2OHD7L3_ !'J$56KM_ORE0/>F6]'
M'/-[G8WOU3\LC(2LBF"6&A6OQ27.W'ETX5))'C\B>K_G!KMEIWE^Y@O&4RW,
M9CBC)W9CT('^3]JN5AMF=GFOY9Z'>:MKUI]3C=UMYHYI60$\(T8%F;P\!7J:
M#J<YO^4T^J>5])O]>CL9+JVE5&2DJ(I$8;U'/(UVKV4^&2+7$UNS[\SIM*\S
M:O8:%+=QV#VC30SR20R$QUD 2*B(2Y%#3<+4G<5.&.G?G]J-Y;W/I:<9KQ07
MB2$,RI'0U:5@23QVZ!:^V-)XT+>_D996=];I<ZO#:Z6[>E)<7(])S*#1ECB/
M;<?$S44;L1L#(+;\UM2D\J+YD_1YDFJX?B0L:A3Q]2C$N4W[5Z&I'7!3+B-)
M+J7Y865OYRD\H+J4:0"142=E+$EU#+'1/A,E6X;LJU[CIB_D/\Q=7\R:'=:H
MMG'<7L$_IQP0OZ0=:(?MR%J$!B?>E*8"%C*U_GS\NM'\M>8;31WOI;>QGMTE
MEN)XB[1LW,']U'0D54;>_4]<CVD_GU>ZAJ4EJNGEE,9$-O%5YFF!%0S_ &0@
MWK\.V2X5$TPU;\EK;3](AO\ Z]'R:4-+=.P2V6W="T12-E]>21Z5HBD]N/[6
M.NOSGU_R]J,<'FC34M[6;XE]-B752U.7+DRN5[K13\L%(XB.:-C_ "8\O:_I
MDD_E#66O[^WJ'CDA,0=N+,JJKT9>=*(3R!.Q(PP_/36]7M],*6*(-+G""2</
M\9+'["KML0!OO6N(698_^3&EZ/?ZO$+]I9+Y2SV\'I*T+%%Y\I'Y5^&A/#A3
M;=OV<0_(^]UX65M:?5HOT'PE*3\OCY<VJ*<CWK^R/GB5A:*_.==,N-0N[Z6Y
MF;7VN$6>!HP(_3](?&CCN" *'Q[TY'KN1;7F6<^_/A^/E2YVK\<6_A^\7?\
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M+HOYIZUI.OCRWYKAC+S.D<4L (%7-%;XC\2&H'8COC2B1ZJFL?E?HVK>7?\
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MC+<_VJU( IW/3)EY,UL:G81!X9[>:*.-9$GA>*C4H0O-0K=/V2>W3 0D//\
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M7.F>=-%MH[.>VBBL;/FWI IZL[-R(0.255>1%6V-,)8BPGOYG:EY-U>YGO\
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MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)0_:D_UOX#%
M=BN*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)0?:?_6_@,4!V*XI=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%78G%]I_P#6_P"-1BAV*8I=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78E"/B?_6_@
M,4!V*XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%7918#KMBKLO%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B4!JS_P"M_ 8H#L5Q2[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NP#KVJ#2;"XU%AR%O$\M":5X*6I7WIB@FD5I6G2ZG=PV%N*
MRW$B1( ":LY"C8;]3D TGSQYTU6UAO+;1H1%*H<.UP &4[J0E>0V^>2IA99S
MYD\D>4="N)[)M>FN+BW=HV6'3S3FAHPY/<*I%=J@TVVVI4I\K_G-KWF:\:ST
MW3(7>*,O(C3%3LP6H8BG?I3"8TQ$R4=YI_*?1?+-K%?7NK326]RRB%H;-6+
MIZA)5KE>-*J.O?YT.K#\P_,%IJ]II/F/38[5+V1DCF27DNPJH[@M6G<=>F"F
M7$>J77?D'R_<:'>:UH>LM=3V*1/):2VIBD(DD6(M7U67BI;?CRIT-*@DS\W:
MSYDMM2AM=&MA);'BQ?B2":_$KO\ 94?<??$(D3>S"K6*V>)VF<JXZ ?A^.3*
MXGCMXVGF8)&@+,S&@ &Y)/@!D6Q#(C2,$0%F8T &Y).)07R7EL+JQ9)DD3E&
M0WPM4;?$ VQ\:'%52YM9;29[:Z1HI8F*2(RD,K*:,K*:$$'J#G)8/S0\PP^;
M(?+NJI;0Q>L(W$*LW(.M4HS&O<;T'N,E37Q&WIUW^77EU_)\_F73)KV:Z14*
MB411I42K%*60,[4W^&CUW'7?.QY%M>5YL5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V%OF#S#9^7[1]1U&3T[>.E30DDG8  =2?\ /;%!-([1
M-$O-<O(]-TV,S74Q(1!05H*G<T   )))H!N<YQIGFGSGYW5KO05MM/TQF(CF
MF^.0@'BVWQ"M?%0/?)<FNR7HNL^4O*'D5_T=YB>\U'78*--!:LL5LI(#+$TS
MKZA^$[L@[]J8*U:W\_\ EZ-KVWO+?5XD6K1/"(W]RHCXUH-_M_1CLDV%*UU#
M\NO,,P@N[*[\OUV26"X-S%7QE65#(/ <*]=\6\A^;=9\ZZ!/=PSP6U^L[H&$
M1=54*" $+]=_M'E\CB12@DA _F-Y+T[R'YD&G7,-S<Z>(HI5#2I')(&7<B01
MNH7F&'V:[4KWPD_(/S)J6N7.I2ZK=2W#KZ1578E5J7Y%%^RO0= ,2Q@;9'_S
MD%Y=TG0[?2(=%LH[.)TG<E>1D>IC($C/\3<:[&I&Y VSLF1;GCF%7FBVOKK3
MIX=*?T[ME^!JT^8![$CH?U=<(8RY;*ENR+(K2CD@.X]L ^0K+5;/3A'KCE[C
MD2.3<F"GLS5-=Z]S0?<$HB#6ZI?/"\I-N*)VR1X&:'S8J[(U^8?G!/*6D2ZF
M1SE^Q$O8R-]FOL.I^6$"V,C3(/(/E&7S=K5MHL3B(3O\<AZ(BCD[>Y"@T'<T
M&<]/D_S+YDT"'7K?5;H:K.@E](2^G$5W*HBQA0K$4W.U>OCA.S"B1;T*T\\>
M6O*WF.?1;G0[*;1+:XE@:1XS+<D*?3]4R2LP)^'EQ4*-_AH<Z1Y%.K'1[<:^
M M^%H^]21^R6[<J?:ZX"SCYO-O.*Z4NKW8\O,[:7ZK?5RX(/#M]KXJ?R\OBI
M3D :C()^;_F+S'Y2X7UA>@VES(4$;0(3$0M11Z?$#O\ :_')1%M<B0R_\HO*
MVA^;)Y-.U*";ZU!$9E>.<(D@#HI1U,;M4<MBAZ=1BOEC3_.VN:9!J:ZVD0GC
M#JC6D1(KT!:GXY&PR%E%>9-;\DZ3J-UIG^''8VLTD/-=1E ;TW*EJ&-NM/N^
M_%;.X\W>7M=M;;6KQ;[3+IC&KK"B?$>@8(H*FIKU(I\L)I%D%*/,^I>4=7T@
M2Z)I[Z7JL4HYQF=YHWC(ZJTAZJ1N*#KMR%>)OYZT#S#J-W!)H]SZ4 H&4.4X
MGNS4/Q?0*^V(60)Y,1L+BVB5Q<QER1M0Y.$!  8U--SD6U!9>*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKL)?..F7NIZ;+;:9,8+AJ4(-*@=5Y=5KX_P ,(8R%
MC96M)4BE5Y%YJ#N,1\BZ+=Z-I45G?N'F4L:#?B&->->].Y\?:F)1$4&[Z:.:
M9I(5X(:4'T9(,#-0S8J[."_\Y!+?:=-;F._N7BO/4K;\@L:A"A% G&OVMN0)
M]\F&F;W7_G'.#2]0AOOTE86)CLUC9KJ9#(]7+\04E+)QVWX!.F]>H[K: +"@
M!+ *-R:D[=2>^0;0\*Q7%+LY=YV_-BX&HKY9\J1BXU-W]-I2*QH:;TH=RO[1
M.RT-:]I -9ET#TSR3^5-O-I<GFSS=.UEHD2EDC0@7%PW["Q!A0!S4!CUH?V:
MLHN/\KM6N8VEU'7[\WC]X']*)=NGICK\QQKX8VO">]8WYM:99T@TCRUI4=HI
MJ%ND>ZEJ>O*=G5B/ 4H,)#YPUS\N]1@TOS')]?TF=J)>,")!6E>7Q'[)Z@[T
MW![8U:+,>:/C\FZ%^8&EW>J>58VL-:LQZDNF\S*DD8%.=L2/4J3U4EOB(7:J
MUZ[;W$=Q&LT+!XY%#*RFH(.X(/OD6QY2Z-&Q1P5930@[$$9QV;6)?S#\UW/E
MUKB:VTFRCE#)"_!IF5EC?F16J\CL/ =B3DB*:_J+UZ/R^GD'R9;>:4A@N=8U
M.9 CSQ+,EO$5>1#&C@IZS< 2S T&P -3B^D^0=4_+W4I=3L;OEY=C22::%F)
M:@4GB$IQ+=*-4'Q]V4K6B$/KWYAZ;^8.C1:=J.GU\WM+%%!>0JD:2@LJ_OMU
MW(J*<>(/Q J*KA=Y,\O_ /*U+:]U;S#/.W[YHH(E<K'%15(94&Q(Y?3WJ3A.
MR .+FFGG;69_R>O+#2/+"VJW"VB2W5T8DEEFD=F66,R2+R2+X/A1>)IN34X"
M7\D/-=Z\5O>ZBGU6V=1&3)(Q51OR1.-*CH 2/NQM> HD?G5Y,M(KF>PT()=W
MT$BS(5C"<W7@45P2PB.['BJFM,[[D&YX5FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B4(HS_ .M_ 8H#L5Q2[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NP'K&DP:O:2Z?> M!.A1P#0T/OB@BT3INHSZ9=0W]FWI
MW%O(LL;T!XNA#*U#4;$=\$PPI BQ1 *B *H'0 ; 8JAL\\?D 7'F:Y 8'_1I
M>7O21-\MER:,?-[I^<2*?)VG,D!1!+;%'--@]L2T=>^XK]&^=XUKR_::R(!>
M*6^JSI<QT-*/']D_+?IE3>1;QO2-=O-',QL9#']9@>WEV!Y12"CH>0/7QZCJ
M-\A6O_G3;Z7J4>D)8W+322K'RF7T5XLW'U$Y LPK_DBOCDJ8&;,- _)ZYU;1
M9_,+7UG';P6TL_I)*))JQJ76-T39"X'[35'AVPJ_//SIJ&GVYT:UA>&"Y7B]
MV?L$$'E$NW4CKOTQ 1,HG\F/+5C>7@UB[=;F6Q<2)8(&,DA6A$K;<?20FIH6
M)(H5XFN&WY0^8[RZTVUTZ73YHH(8547+$>FX -"M:$U]JXD)B4F_-"P@36;N
M^CO8;F2ZNIY'C19 \19^163DBI6I(^%FZ?+(1YAMA<_F?#&YX 30."=OL1JX
M'O4BF'HQ/-F^@3_5_P L+^6, L7]-JGD/CEC!JI^R0.A%?D*USL?FWS99^5[
M)M0ON17D$5$ +NQZ*@)%3D0&PFGE_E;RQ>>9KY-.L.(=@SO)(W&.-%')Y97.
MRHHW)^@5-!D#U7\Y]5T5(KG5M"FM[28CBYF!-/=?3V;_ "6(PTQXV?Z3^3FA
MZZ6LM$\R6UQJB(6,+P211LRCXA'.Y^,#Q"]/BI3.B:-YBL]9L$U6Q;U+=U+"
M@WVZK3^8=*9%F"\UUC1[O1KN73M1B:"Z@;BZ-U!_B#U!&Q&XVPC\F?F"GFBX
MF@BMWB6(<E<FH(K3XJ#X3X"I[^&$BF$96U?:<UF%Y,"6ZT[?UR78&Q"9L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=G /\ G(?S'-=7\.@1T]&%5F8#<F1ZJH/R
M7I\\G%IF7NW_ #CQI%KI]G=>:9V;U [VU*41(D5)I7+5K\7PK]G85_FJO<-
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M?:AK$4MG^7\,.EZ,DE'N)PSREZ+R9%8LM>--C7YKMB6(WY)[YTT^UT*\6?\
M,N:[U;S \$4D=M!*BPHE67T9YMW#;$D1*/'DW*H)_P GHI;?SQJ$,SM/*B7"
M22D4Y,LJU8CM4C">2QYI[^;II^76D%8H[6":XAEA@1V;@C02&@+L6(W%:[U.
MY)W([_G)W[.F;][C;_D5C%,UG_.)KJMYJ8>.M8HAZ@^TGQ-L/"IWKX@9VVT
M6% HH HH!\L@V!X'@3S#IGZ5TZYL*D?6(7CJ.HY*5[TQ4HO2M1DTR\@OX0K2
M6\B2J&%5)1@PJ.XVS@__ #C_ *K^BM<N-'NE99KE>%"/LO!R+!M]MJY,M4#N
M]U_YR'L9-6TBQUFR"FQ@>27D*@,EX(Y(G7FJDBJD$ ;;;#/1&0;GS_G._P ^
MK]+?RQ+;,*O=211J!UJ'$G3Y+D@US.ST3\@5=?-]I<J0B6\=Q*[L:*BK#)\3
MGLM2*G%OR4\MMHOEZ-Y@5GO&-PX/4<MD[;? !]. I@-D%^<?F>/7_,,IM2K6
M=FJVD!0#B4BKR92">2M(796KN".G3.>?DC<&X\XZA,Y!9XIV/S,R?9R180YO
M0_S=@]+\O=#5110;78*1N;7E5OB()))I0>/RSKGYE\O\-ZCQZ_5I/NIOD0V2
MY/)/R_%?,6ECI_IMO_R=7(?_ ,XY2,= F1A15NGXGQJJ89,8,Q_YR,CC_P 5
M/,C R301-*H->#@%./0'[*JV_C7ID2_/>=D\U6!)J$AB90>E?5>M?NPAA/FR
M#\FX0/)>OR(@+21S1NP^V%%NY7MNM2:CE[TP;_SDNK^KIK&ICI-MVK^[K]XQ
MBRFJ?\XQ31J-6BJB3.MN%<TYHI,BEUKM169"WT9V'R[?VVJZ9;W5J@6WGB5E
M2FP!'V:>W3(EF.3Q75=.FTR[FL+FGK6\CQ/0U')"5:A'7<9!_P RY]+L?+FJ
MZ3I"1P2Q+&\T<,7!1ZCIUXJ%Y,OO6E*[80QE54S/\O)KW4O-.BWFK2RS!KF-
M(GEEY.!$PX<?4)/!6^SM0D%5W!I$?RM_++0?-FBQWDSW"744CK*$DXCEU%!O
MMQ(WVPDL8QMEWYM_F'YB\O>8;RPY6SVTT:>D6MH).4) 9*N\?,_%6H8T#5H,
ME47Y4>5O*][97LLMP+AKA$@Y.6Y2D\E!"K[;UH/'!;+A 8K<_FMYM\P6%YIW
MJ1-8>B&N(TMH%58E*(O^ZZKQ8KQX[@T(WR):K"#^::)$HJ9(F:HV/[D,Q_S[
MX>C$\V86*2/^45Q),W.-)BL0#?8K<0G<=ZU;[Q[9WW(-SP[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[$H?M/_ *W\!B@.Q7%+LV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKL*O,7F&QT6V:;4+F.V!5BI<@$D"OPJ?MD?RCKA8DTC]&T&_U
MN?ZKI=O+=34KQB0N0*A:GCT%2!4[9YY_)'S%8Z/KQEOYU@BFMWC#R$*I;FKC
MDQV793^K)%JB:?0GYP^2]7U/06AL+)I9+2\B9HH*R-$AAX%44#E(O,BK#YTI
M4CTQ#,DZ++$P>-P&5E-00=P0>X.0;GS:RE"58$$&A![9YS_.?S+:3>:+:[TZ
M6.0VL<7*13S4,LC-3X:] =Z?+)AID=WO_P"3?DO4-0\H:A%,DGHWKR)!#R6)
MI&]'[:M)164L5&_P[')S^=M/,7EB'4-)Y7,*S),6C!-$X."Q%*[5W\.^ ,Y;
MAA/Y)7L>@^:'M-5*6YDBFM7$U%"O_*6)' \EI7QV[XG^4OYD)?6=IH]M Q2S
MA8W=P[!(XE6O$[UY5I[4^70F+&,EGYJ_EI>^6;RYO=6ECCDNYW>UA4\Y)59N
M3,>.R!.5/BW+;*"*L(3J?FJP7\QTU2VG1K3UHT:6M4WC$3,&Z4'CT[Y+A-,2
M=V>V/E+5E_*ZYL;FU=+D5E2,KQD"+.CDNAHW0,1M4@B@IODC_/3R=<W,D'FS
M1N4A55$GI?$0%J\<R\>P[GY8(GHF8ZL9_([SEIL,5QY5UX1"UN2\D3RD(O-T
M$<L+N?L"5%6C5'%E]]@^B?\ .1EW.@M9-.-S>,H""!C5V]TXDBO7:N$P9<:8
M:K_SC2]I6Z;4XK6P1_WLUXOIJB$BG"169)6WI2J5.V='_+K2[[3]-EO=7Y&_
MOI7NI4[H6 XQ**G90-A7;IE991>9^>M4L+V_$&CQJFGV4:VT#@4:54)K/)L#
MSE8LYJ/A!"_LX1_EA^;4_G*_N;&6U$"Q*9%=2=AR"A'!_:WK4?=A(1&5LE_-
M'\GQY#L;"\:_BNWO0?A1:#95?G$_(\X_BIR(4]"!0[=*R+8\XS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[(C^97D*'SCI_H$\+N'DT#UV#$?9;K\+;5P@TPD+
M9-^7WGBX\G:DM]$/4@?X)XC^W&2"0#^RXZJW8^(J#S7RMYM\T_E^@TS6].FN
M;",A8V2AX"I/PR*"K@]E)'S&2JV )B]$\W>7/)GG5FUG0]9@L-0FJ\T%TC1*
M[M\52=PC_P _#FC-]FF2B7\V=6U<"'RWHMS+*U0)+@<(U/N?L_>RX*9<5\F-
MV7Y9:)9GUO,'F&PBMQOQLN=U*W^3Q55"U[$DT[C#GR[H2^3=+DN;X2WNIW1Y
MW,D4;RR.Y&RC@">"=!6@[[5I@YJ!02/S3YCD\VWL5K9(EIIMJABLK9I$2.*,
M;DEW*J9)#\4CL>3L?D,@7Y"66H:#>74&J65U;_643TW:"0)\)-5)I0$\N_AU
MR<@B(IZ'_P Y#ZKH^N065YHM_!>&!Y$G ?\ >!G5.)56 9D_=GXAL"1_-N#_
M #BMM0UC7HKS3["\FAM$5&80.H)5R_P,1N-^M,(")"T/^4\^GVGEZ_LM1U.U
ML9=2Y)&LC\_A:)XRTB(K<-VV):NQ^'[)R<_F9K<VK>6)(+"SO6N;U5 C^KR<
MDHRLWJ?#\.P(]^U1D8C=E([,1_+K2[:R\U6_Z2N;6.UL)_4DF:9?381FJF-A
M7U.34H%!]Z"M"K\EM-FBT6Y\OZQ9W-NUQ)*6]2)U4QNBH?C(I78[8R1'N3+\
MZ[^UFUZ+5-%O8[N(11<9(FW21*U'$_%M]H'IOUK4"$W7ESS5^65^\FC^I-:R
M4 E5 R2 #EQ>/<J1OOUI6F'FBB&<R><?)_YDV"'S,T=C?Q%CQ#.C*SD<WCF8
M.C(QW]-A537]FK9,_)MMYH\YZI;ZWYA M-.LWYQ0!>/-Z%>0#5:@.]6/LO?
M=D@$EAOG*7R9Y;TF71O+9;4]2O HFO7)"PHKI*(XU "EFXCD16FXY;\0W\^)
M+W688M&TZQNIVBE$K2K"YC^R5"J]*$_%VQBF2O\ D//9Z%>RZ]JE_:VEL8S
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MUS>N7#S\:D1\7^+TPU'(-*LH^$<0217WEWS;+YN7S7;Z4RA2A,37$)JO#TV
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M3_Y;U_Y%R?\ -&-+QA.O^5/^;C6FDW9XD@TB)W'7IB9_.[RB"1]?&W_%4O\
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M/0TN'UIN9()7<T38@L I:A(V&V23 R8WA+YO\V6GE6P;5+\.8E95XQ@%B6-
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MK>*AE#2%&45W(%*'[Z^QPAA(D,B\B>7;#S%J<>E:A>-8FX(2&00^JID8T5&
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M1\Z4PAA/FR7\EK:\'E'4[A&XP"60@MQXH$AK,[5W(*46G\<]":4DJ6D*W/\
M?"- _P#K #E^.0;@\*/M@K%+6;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=B<7VGZ?:_@,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKL\Z?F*MROY@(UBJ&[,MKZ7JGX.5%"EN.X%<F.30>;W/\MYK>7R)>0:C+)%I
MZR7#3>@!ZI'&(\4+_ 2=A_JD[YTP?\K$IQ/Z(KX_O\CLV;L6 _*WE4GS!QIT
MI:5K\Z_PSD/YT-K?UV!?,C6YF$),2VO+@!RW+!]ZG+\;5*V<_E3^A"]ROE$7
M:VS31+<O?-&KLA63BB-%\*G[1-0:[$=,])6_*:T6K<&:,?$H H2.HK4;9CAO
MZ/GS/,_Y/V6NW-Y.GER6*"<1TDEE4, I;]GX6ZD>&7S:(WT?0?YR7>CP-9R:
M_#<31,6:."W<0[JD?(2F17:@J%7:M*[Y-?S%\L^>FT]UN;R+4+)7C+1Q1!)&
MHPH2JIT#4V#>^5BF4@6.^0/,?D".\=IK*YT^YFAN(TEEN/6ABYQ.NU$1JL"5
M%5:A(_UAV[(-SQ[/-&H27\'YA3OI:J]]]9;TA/4+NG?OQX_9I[9<.3C]7OMD
M+-_RULTU:66+3RLAE-NJNY(NFX*%=E7D3N:GIOOBGG'SCKVL:F?+/FB9-/M?
M4C69;=*K0[J]22Q7<'[5/;$ =%D3U7^5O+6A^7]+3SAY5@?5;U4EDA^O,J"-
MHO[Q?1C/Q2(GQ <C7JN_'.\^4?*5EY6L5T_3P> /)G:G)V_F8@ 5RHMP%/%/
M,WF:]\RWTFI:BY>60F@J2J+4D1QAB>*+7X5[9PW\^6 \TP?6P3!]7BK3J4YO
MRI^.2#5/F]I_)9+AO)EZ;"HO!=3F%@5%)1;HT1WIT8&G^8/H:SM8K2%+>V4)
M#&H5%7H% H ,@W/!)IGG=IIF+R.2S,QJ23N22>I.+8I69L5=GG_\F03YSOR2
M*\+BM!L?WJ_=DRTQYO</S7*_X$T:C%C2TV)-5_T4[4H :]:]A0;]<] 9!N>'
MYRW\[HUDGT17'PF_0$_,KV/P_?D@U3>D?DLC,/,/$D4T&])IW'[OPW_SWVSH
MVL;V4]#Q/I/N>@^$^.V1;#R>;YQ/_G&E_P#2-13MPA/W%\G)K@]R_P"<F(BJ
M:9(QJ7>Z\:@?N* AMQ\CN.AWSO&0;7AN;%79YA\KZ;?ZAYPO+71+I;.?UKD^
MM2OP!S4*O<G+CR<8#=]#^;+S3[#RCH]_K]H^HVXMK5([8R-$ _HG@[2)1@G
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M J=B:5%#EG1HZOH.QO;9/R^AU'4;1[VQB@C26W:9HU9EN3&CJRFJT%.@W_'
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MW3J DF1A0&G5&'7.<?E#^75MYFTN6^N+J\MW2Y9%%O*$794/*G$[_%UR1+"
MMG7YK><CY7U6"PM[33KY1:1,S75K'-("Q9N+.U6V\*]#D\_+C\MI_)NIWK^L
M;FUN8XRLC;/R#/56ZU(%/B_# 3;*,:8;^9'YG1^==/TRW^J1V4^G^NK);CC
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M?RELY+;R];B7K)R<"E* G:N K#D\Z\PRK+?SLGV>9'W;9,<#8EV>??,BK/\
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MF%S=LM2BE64JO)=N5 1\S\\D-FH[EZAY,'^#/+.J:[J<+K+K-LVG6"E@A=9
M3/-Q/Q&)*)\0%"2%[U'2M<F$-A<2MT2&1NW92>^WWY%L/)Y@JEB .ISA_P#S
MC9+$E]?1,:2O$C*/%0QY?<2,G)JAS>X_\Y+LTR:;( .$;7$9(J?B_='<MON-
MQ7?QWSMVLZ]9:+ ;K4)D@B .[L!4@5HM>I]AD&TFGB^FZ7=:G,MK80R3SMT2
M-2S'Z%R/?EAYAOO,>FRZM?']U/<RFV% "L(/%5/'J00=SOA+&)MD7YF^6;;R
MOJ_Z#@'[ZU@@6Y8/R5IVC5Y6CJ 0E6H![5[YR7\I9;=?/-P6:H8W/I%NI):O
MAU*URR7)IAS>C?F:6?R!I3 'D/J7J<0>(46\BIOR/^R_RCVST.\R)7FP%!4U
M/;*G(>&Y$/+OGIO,6NW=EIW!],L8@KRT-7F8_LGIP 5A[G?IAIB)665:]Y*;
M0-$L=1U'FE[J;-)#%4#C;H /4D6G*LK,/3[<5)WY"A#^3/YDVVK:='IFIW(_
M2D3,I$K4:0%B5*D_:._&G7;"0B,F1?G9^6<GEG4VU#2[5H] NDCDMY%Y.B\D
M7DC.:T/.I6IW'3V'?GDUBWER:.[9?K!*&W6HYEPRCX!U.QWIV.(6?)*OR96\
M_P 3VDEF/W:,3<,VR+;T(G>1CLJA*[GO3O3'?D=H<VE>7(S<U#W,C3\2""H:
MB@;^(6OTXE8<FOSDURTUCS-=2Z?0VT/&W1U(8/Z2A"X9:@JQ'PT_9IG0,BV,
M)SSG_P Y%R!M>@6H/&T3Z*R/DXM,^;Z!_P"<=;>0:/<S0AN;716H4$'C U%H
M?M$ENGRST3!(DD:O$0R,H*D&H((V-<@VOG['XI=GG;\X;Z&+SI;RR-^[@%L9
M*=@'Y'_A=\F&B7-[K^4EG+/Y)U2&&/E+.;Q8R*AF_P!&7X1T%*_CG9//?DRT
M\WZ:UI. 95!>"2M.#T^$UW^$]QX>],B#3;(6\G\E^<;[REJ"ZEI[4-.$J'[,
MD1(YQM[-3Y@[@@@'.0_E-YZE\G7TGEC7J0P%S3EMZ4G>I)'P,-_U=<D1;5&5
M/6/S:\F1><+(>=_+2RS@A1-L29(^*A' %?WD6\<PY'[(;I5CU3\U3#-Y7ON;
M@(T55:HH34%0"=MSD0V2Y/*_R[,B^8]-:)#(PNX3Q 8D@."=D^+IX9$?^<;Y
M5;2[Q.0+BX!('4 HM"?8T-,,D09G_P Y$6XAUJT"HR#ZD@W! )$DM>-0.G0C
ML<Z[D6QY7G&O^<A_*PE@A\Q1[M!2"4?Y#$E3_L6/X^V2B6J8>L?D/YED^L3>
M56($=^1+"W$%EFB'+;_70%?G2G>HS_G'_0>-C-Y@F+/->-P!;?X8R1M\S^K&
M2P" _/"]FL]2C\J>G##:Z0O[M85(^*=(Y9.6YJ:T';ITSJTTZ0(TLK!(T%69
MC0 #N2<BV/-P"30;DYR3RKJ">=/.]UJ1=7M-+C,-NH8'D22ID7V-&W'8KDN0
M:QN7JGF_1W\E^1]/TQT=+W79?KMPVZTBA%((&V^+^\]0@_9;Z#G6XX(X@%C4
M* *  4VR+8\JSS7YV5?(_G7Z];?#$)4N0 03P?\ O5IVJ>5!X9,;M)V+Z"\@
MVLWGKR9+I;1M+*J-:(0./[Z,++:$MTI3]VWMUI]K/1VFZE;ZG;1WMFXD@E4,
MC+T(R#<#;P.[M)K.9[:Y1HIHF*.C@AE8&A5@=P0<C'YNF(>5[\3&BF,4_P!;
MDO$?\%3"&,N2?_EHDK^9M,$"LS?6X20HJ>(<%]AX+7(;_P XX:G;'3[JP#CZ
MT)S*4KOQ*JH(^D89,8%FW_.1]E=1ZO9W$L<BVQLTBB=U*UX.Y9=^I4M]Q&=@
MDD6-2[D*HW).P&1;7DF>:_*.KV-CY^DO9IXDL_K-WQE+@)1@_$\JTH:]:Y/H
MT#F^A?-?EW4[[R#:VUM97#72169=/2<OQ4.M0./3[/0=.N=X/G[R\/\ I9V?
M_21'_P U9&FZP\>_Y5KYHZ?HB_Z5_P!Y9>G_  &$'ECSX_FS7I8])>ND6<8Y
MOQVED;M\0##C^-#V(PTP!LJWF[R#>>4K2T.L+Z-_><I!;M]M(A0([TZ%VY?"
M=QQW\!/<BV,5SE'YZ?E]<:[#'K.G*9+FU0H\:UY/'6HX ?M*233OD@6N8ZO3
MOR2\_P!MY?NI-*U-ECLKUXV$K@,L4B5 +@U_=NK%7\!0]L2_+_\ /#3#90Z=
MYAE:VOX0(V>16XO0\0216C4^URH*UQ(1&2-\]_D%K$%Q+JGE: :CHDM987MI
M%D*J1RX<0>3<>@*\JBG<TR7:I^:WEVQ4<+M+J5@2D5M^^=B.P"5 /^L1@ID9
M!B%E^5?F2<E[BRELK=:<[B]'U:% 2%JTL_!>I&PJ3V!.#O*DNJRP27VN$0M,
MQ:. 4I#&.@+4!+$;M7I[=,2HOJQ_5!:+($L"S1*BU=QQ9GXCG\(9AQ#5"^*T
M)WS@_EO4K&W_ #$:]>XC%HUU<N)>0X?&KT^,T&Y-/#)]&L'=]#:]I^J7/Y7"
M.:TF$T=O;H492'58Y_A;T]]N&_8T^+I7.M?FKY#B\XZ7]9LN+7T*\X'7?FO7
MTZCJ&[>]/?(@TSD+>/\ Y6>?#Y/U99YPSV$M$N$!W [2H.GJ15Y+]*[<LA/Y
M.?F?'I8;RWY@E,'HGC THIQI]J)V[4/V:_*O3"0QC*F=?G%^5=Y>J/.6@P?6
M;*Z#2W#6X+ L3R^L*N[<)%-6I]A@W+CMAM_SD+JMG<:';1Q3Q,[W*2*JN"63
MA(.:TZK4]>F"*9E*/^<>-/N9==N'BMY90EI,C%5/%&:G$.=J<J$#WP9^3_GC
M1+;RW:VUU>6UM/%S5TDD2,UYL0U&(.XIOAD-UC+91_-#\M/,TOF2^D@T^^NX
MI).:2I#+(I5E#!5=5((0'@-]J4[8+\__ )R:5I&GR#2+J*YU%QQA6(B102:<
MF*U7X>H!Z^%, #(R4?(7Y&Z]KNIQQ:O9W.GZ9&>=U//&80L8!9N)E JQ H*
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M,TWFC4[6%&DF-]<J$0%B2)6V %:YPGR+YNTW1_-\^K7<U+*5[BDI5CL[%E-
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M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[,RAA0[@XJ[/,_G'2+%OS
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M0+Z].F6M[%+<!2WPDE: 5/[RG T'@V-(X@BM4\@Z[I-@NKZC936UF[B,/*O
MEB"P^%J-0@&AI3WPN@_./RS/>C3X[L%RP0/Q;TRQ[<Z4^GI[XTCC"/OORE\T
M6%@-5NM/ECM3&TM3QYA%^T[15]156M22NPWZ8(_,+\P[+RA:%IF#7LB,8(J$
M\F&V].B@G??Y8@+*5*'D+\OM1\YW?H6,;?5HF3ZS/0<84:OQ-4BIHK47J:4R
M#_E;^:VE66F_5=<NF74);B5R/3D;D9&Y?#P4C<GIA(8QE3,?S&_*O4;R^N=6
M\NV9_05O;P<9&>)2J10I&QD^(?'5&+=Z[]\GNC?F9H&LWBZ;8W7.[?E2,QR*
M?AJ6^TH'05P4S$@6$ZI^7NNZ78#6+NT=+ \*3@JR'U!R0AE)!!\1L#\)WVQ7
MS-^86B^6)4M]7G,+R#DO[N1@1T^TBD=NG7&E,J;\H_EYK?F\2_H* 7+0T+J)
M8U8 ]^#NK$>X%*[8I)Y]T.*QCU66\C2TG4M&S54L%V/%".1IX4KC2\00B>4-
M7DU"71HK262^@D:*2*-2Y5E)!!X5&U#OT[UIA;<_FUY>M]-76?K!:U>0Q)1&
MY,PZT1@#0=:_QVQI'&$T@_*KS)/K4GEB*S+:I @DDB#QT52JL&:3GZ8%&7]K
MJ0.NV2 >8;#Z@NKF=%L602"5C1>)Z=:4^76NW7 RMC_Z'O#>'2U@D:]$AB]%
M5)?U >)3@-^5=J9$;?\ /3RM-<&W^LLBCI(T;!&^1I7[P,-,>,,PNOR+\Y6U
MN;IM-D91QY)&R/("PJ%,2,9 U"#3C45%<G=O/'<1K-"P>-Q564U!![@C R8(
MRE2584(V(.*8I:SSUJMZ?S+\YQZ89&DTB!R J$A2L8)=^M/C;X>7@1D^31]1
M>\Z,@_*[R8^KI%Z/F34%41S.H9HED/P1K7^[8PAI/<TKTH/0%K;16L2P0*$C
M0!54=  * ?0!D&YX0[L[%F)+$U)/4G(Q^97DF/S9I,UJJ(;Q5+6[D"JL-^/+
ML&I0X06,A;*/RT\\3>3-;M]51G-NK@7$:G:2([.I6H5C0U7EMRH<$Z=K$?E[
M1+1O,<Z6TZPQI(9'7>0*.0!!^(_ZM<4@T-T'>Z,=9UB[M_*]O-=6PEE>!(HW
M=Q '/!BH!;92M:X6Q?G#Y=DLI]2^L$00/Z="I#.:5'IJ=S7Z/>@QI'&$;)^5
MOF*/4X-"-HQU"XB$RQ*Z,0A)'*1E8K'TWYD4[TP^\N>:K'S#IZZM9/\ Z,P)
M/.@*%?M!_ C^WIBD&TH\S^6KWRSJ,VD:HGIW5N0& ((W 92".H92",B.I?GM
MY?L[L6T1EN85KZD\*<D3PWVK[E?QPTQXPRNP_(_S)=6ZS2QPVEQ*0(+6ZF2"
MXFJ2/W<4A!VI^UQK^SRR8:/YGL-9L!JMA)ZUJ03558L./4<*<J^U*^&19 L0
MUW0+[0;Z72M3B,%W"P5T8C8D5&X)%"#4$&E,(--_.#RYJ=W%I]G<-)/.Q51Z
M4@H1V/)1UPTCB#(=;_*+S-H=E)JNH6?IV4*H[2B6)UXR$*C+P=N8)8;K7##S
M1^8.D>5YHX-6D>)I@2I]-V6@_P I01]'7VQI)E27>5_(>L>:4F?18!<FWXF1
M1)&' 8T!$;,'85[@$#O@_0O,]CKUE^E-.9I;8\J-P8$\>M%(J?#;%0;07F/R
MY?\ EN_DTG5HO0O(>/-.2M3DH=?B0E?LL#UR+I^=GEYHYI&>=#;U]16@>JD'
MB%.U 2=A4_.F-,>,,@F_*#S+"]G$]O'RU(5M:7,!]4<>?):2_9"[ENG3?<9S
M3R9^;-I!YAOO,&N!HUNH@D7 %@JJ11*?1U\?GDB& EO;T;S9^3FHW&BZ;Y:\
MNQK=7MC-</=CDL9DEF"4DC,K*&15BXC?E0 E?!WYWW_UW4]+U>T4M;26Z/&3
M\/+X^=#7<;$8A9% ?D_':V>D^8-&U*01W3_N" /4*_NYXF="A*O0GL=]J$YT
M/S'^>6@:+*+<,]W*/MB !@GS9BH)^5?HP4S,PQ/RC^2/F3S/;+?6\26]K(#Z
M4ERWIB0]A&*%C7H&IQ_RLF^D:O;:Q:QW]DXD@F4,K#W['P/B,BS!MA.H:?/I
MUQ+97B&*X@=HY$;JK*:,#\C@S%*'SC__ #DC#&=.LIFKZJSLJ_ZK(2W_ !$9
M*+5-ZM_SCJ'DUB\B%#&;%RP/M)%Q(]PQ&3'\I7=O*]AZBE#Z9%":[<C0U\"-
MP.W3 64>3#OS+2-/,NIB*19E^MRGDJ%!4L21Q(%"IV.W48V[MM&\\%;Q"[MH
M][\,D5 3)$%<JK;U0U'2A)&QQY+S;L-1UGR6DB\/236+!D*2"O.WF) <+V/P
MU1O#<;' NB_G'H^IZF-%*7%M=,Q11/'QJW\O4D,?<8THFB]5_*?6]-T<>8V6
M&;3J*3)!/'+Q#-P!/!C^W\)\#L<-?-WG^Q\J/%^DXYQ#,:"9(^4:G?X6(-:[
M;"F(%I,J2WREY(U+S9)+;Z.L<MQ$H?TFE2-F7N4]1E#<>^^5=_F5H=GIT&LW
M-QZ=I=5](E&JU.OP@$XTCB#=AY"UO4-4GT*TM7EU"U+B:)2IX^FW!ZM7C0-M
M6M/#"B#\[O+DNGMJ;RO'Q8J(' ]9B/Y4#'8UV-:>-,:7C";O^37F3]*_H2WM
M_K$JJKM-$U8%#+S)>?9%X[JU3]H4%=JBO(WYKZ5YPF>UM1)!<H.0CF !9?YE
MH2-NXZXD*)6I>?ORIU?R2L4]\8;BTF/%;BV<O&'%:QL2JD/05H1N.A-#22:]
MK]EH-HU_J4@B@3J3W/8 =R<#(FF,Z1I%WK%U'I^G1//=3'BD:"K$]?P&Y/8;
MG.9:U^=.EZQI5U!]5O8;>YAEA6X>(>GR=651R5CUR5-9F](3\F=8\O7T$T-W
MIMWJ=K*DK6$-R&N%X$2,&C90/@'V@"=JD5 K@?\ YQKJME?(>@EC[_Y)QDL'
M?\Y%W0N]>@N%(I):JP [ RRD ]JCVSLN1;7E>;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V)P_:?_6_@,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL\U_F%?2V?GR2\@C]
M66&>V98ZT+L$CHH^?CDQR:)<WO'DVTM[SR0EC=3&"&>&Z:24*62)5EY%W W+
M?!]D;D=!7.BZ[^8OFW3K8S/Y?:.O1A.)@NW5EB6HI[TR-,S(L7LORW\F7MPL
M$'FJ(@J23)9RP[[?"&E94W\2WT9!OR0;3;G7'U'5;JNIOS]*.04Y.Y^)PYZO
MU 7KODBUQYL@_.9M3M='CTG3[+T]"MVBY7$;%_LK2)'XF@4A@W(CXW-0>V&O
M_.07D>&$)YBM(PI=N%R5KN2/@<@;#I0GW&,2RF%+_G'SS[?+/_A>25I(6_>6
MD3<" X;G)&GJ*:<UJP%:<AXM7.A_E-?6=WY<LVL51 B!)%3M(NSU]SU^G(EG
M'D\X_,BQN['S%J$.H,[S_6)&YR !G5FY(]!L.2D&@V&1[\LO+EGJ&KZAYNCC
M0))<216H2H 524DD K0^IL>FQKA+&(ZI_P#F!YFN[?1=,\ERC_>.**YFD-.4
MAGC$\$9JO-1;I,R <R#6M!0 'NL?E_/?Z_%KB731QIQ)3N./[*]J-W_4<;28
M6;81%J'IVSVO!3S->7?)ID6Q!YL5=GFG0M5O=.\\WUQIUJ;ZX%S=@0JXCJ"Y
MJ>3 [#+3R<<<WT'YFT33+[RCI,.JWHTRV,%H_P!8:)YJOZ4G[L)%N.I-2/#Y
MYU:+SAYR('+RZ#L/^/V(;]^H_#*Z;;+"/\!^0_\ J;?^Y9<?\U9R;S'J6IWG
MGBTNM4MC:70N+4+ 7#@*&6E'78@G?;)]&L\WH&@66EZ?Y+U33M#OCJ5IZ%Y*
M\ZQ-#23@@"O&YY?94=^YIG5?SK\\3^6-+2*P;A=WC%%?J4515W7W%0!\ZY$!
MG,T\R_);R);^;M89=05GL;.(SRH&X>H:A8X?4_8YL=SUXAJ4.XY;KTOY?W.E
MRB&2X;5F^+UV$K.TG4EN1XT8_3ODHVP-/3_+4?YN:9/:SM%$VFQ+Q^K^I9QP
M>B#\5$B8 <1^T!R'N-B;?E)<W'FS3[GRU?W-R;:!!)&T3E"H&WIE@*NIY=&J
M-MAC,4F.^S%?SFME\JZY;:SI]E:0&ZC8M&ZQ3I(W+>;T6YI'R!6G$#H2*5.$
M/Y3>49O-GUS2C<-;6("//P_O'8<A&#7]D;D_YT2:8Q%LK_.#S&GE6ZTW7TAC
MN]0='%HKJ#:0QBC.T<:$<I"S[&M /%@K"<WUK+^3?EN=+:Z-U=7<P$!,8548
MK\3<>3=%7QI6FW7(\V?TL8M[E?SV\Z6S36_U"UAMQ]8"2<W,<3$D\V"U9V=4
M&VPH=Z8-\L?E'I.N:+%J.KJ]SJ5_"LKW#2N6!=05IO3;;L?#IDC)/#:1^8?S
M7U_R]JL^E:%<&PTW3[N9;>WBC2,!5<J!+Q4&4T Y>H6).Y-=\#_E5^7>K:?:
MW^C>9(T;2I2:1,58,_P_O$()(&W>FX'>N E$8]Z+_.'\R-+UK4]/USRJ9;;4
M4MP9[A"T<@<U B- HY1KL74D,K4[81_\XS<DNM11:^F4B)\*@O3\*Y*:(,B_
MYRCU&6^&D/<<3*%GJ0M&W$!HVW0-RIX;X"_YR(T>RT_4[2YM(EAFG5WE9!3D
M0PHQIMRZU/7&"S"(_P"<==;U*_TK5M*GFDFLHHD2.)R&5?528%5Y?9#4Z#;[
MSG4?SDC^M>4KTI0_#&X^0D0_JR$>;*?)Y;^4E_'8^:=.EEKQ:;TZKU!D!C#=
M#]DM7"S\C[Q+3RB+F<!(X7G=F_R5/(L<,N:('9'_ )X0'_&-[%%5R?0  W))
MACV%.OMG,-$\XZ3K-W=:OYSMKF]+R4B2,%H(0PZ4YKN0!X]*]<G7<POO>D>9
M_)VI>7+:UT'R=>6ED1!SN)6FCMKRYE5R6JS\6$2-]A0U.O(M04"6/F!?+GF-
M+ORDEREC<21J;=TW8$CE$.5:_P"2>HKUR-(ON3"Y@/G/RI<0>=9]/EU;389G
M@NDNHWE"@51I/JY:H+? 1ORV/'G\1E?YGZE:P^<(SYJMY)]'$"^@JE@ 3]IR
M 14AJ@BO2F ,Y<]V,_E7INH7/DV[?R9<QV^O_6B+C=5G>#@#'%"YW0,]2/L\
MF!'+:AE6G^1]%NM?L_,?E:6#TX2WUB*%E*T9&56X@_ ?:F_7QP6FM]F(7OYD
M:Y;Z!>>4?,,<TYG](PO<EA+!P<.0.:\F1@M.-0%[=\ZAD6UY]A'YYE$6@Z@[
M4H+6;KN/L-A#&7),_+$#7&JV<*<@TEQ$HXFC5+@;'L??.$?DGY@U;2$O1I.G
M-J*'TC(%E6/@:-39E)-=^F7Y U1-/;_SF\OZ1J][!>:SJRZ<Y$J1<[>6;FBR
M?S0\NA8]NM=\.]?\F^;?S UB%M:M38:<A*BDB/Z:[DFG.K.U *@>&U,J!IE1
M*!\N>;_*/Y<:-<R^7[T:IKLR+0O;R1IRJ./'U$V2*I;[57:G04I?Y_\ E#3M
M,M+34+2)E?F(*<F*!0AX@*31?L]J5WKB"LA2C_SC?YCU.?4+W24N!%!) ]S(
MX1?59U=!7U>/J-LS;%CW(WP;I_Y'?IZRL-6O=0G^NLD3R<QR 2@*Q)N"G$;<
MJGY8\2B-H"+\\%\NC5-!TC3[7]#7"S0PJHWY'DBSRLP;UJ@U*,./V0O%10D7
M_.0GEJQTRYM+NV5Q<77JF5WD=Z\. 7[9:E*]!B$2%,E_YQJ\U:G+%=:<60V5
MHD91$B16+.S;%D"M)RZ'FQSJ/G+RI#YS\MK!!P>8Q));ROO0T5J\J5^,;'(@
MTR(L/(_R_P#.%SY)UR+4E]55C8QW$:$J7C.SH1T]P&_: /;(%_SCAK:H]WHL
MH59!29-OB/[$@)]J+MDYAAC+/O\ G(S17DGL_,2RO/'<IZ18T* !5DAX4VXN
MCD[5%0U#DATRRM/-/GJYU1(@T&DQ+!SW'*X#$\A2@/ <EWKV/AD>C(;E)=3N
M[SROY"MM%EDX/KMR;TPBG(6\85(RZGX@)G4.A&Q"=>HP%YH\FZIK'G!-1UI$
M/ENU 8&61/3 $8Y53E7>3K4;_+#$[*1NC?+WG;1/+_D::RT:6:'S9?2A)'B0
MAQ&) 0!+39"@I1&Y%CN*;YS[\V+OR_;ZG!>^4C&LT)+2F 4C#J5*%-N!]^.V
M3@URJ]F??E38>9KVPN-$\ZM<_4+T*L4=TU9>+"1'^%SZJ+\(*<@%Y+\/?.@_
MGSHFGC1AK<D &I.\,8E4GP)(->HI7M7ID8-DAU>8_D9J%]/K<6B+.XTZ<3/-
M 6;TV*Q,>7$;!QQ6C;4IUIAO^37E[3H-"M=;-O$M])&_.8+\5 SCJ>FW6F"7
M-,1M:5_FCK=Z=7O=$%W<RZ;:W+B*"65F1>-5'%*\=MP"!T^9SG?E#S"/,.HW
M&N:WIUWK$O(K D<8>&%>O$*YXUZ?KZY*FJ)OF]!\\:"?*^GVWEG3]1LM&B,,
M3WI>23ZS<S$&OK?5XI'$*5/!#\.]=S2B&H>7M8L-?76_*NE7MI$&5S$4X]_C
M3X2PX-X=,-[)]RMH_G71M3\N2>6_.6KVUT55UMI_1GE>.JUC?DT*/R1]AONM
M5.V>DE-0"=J]LI<AX'G$/^<EBQ.FJ*\1ZY/A7]W3)Q:IO9_^<<IXHCJ98QB0
MK;[-Q#L@D)D5"=Z;#E3;H3T&=)_+.>&?RWI[VPH@MT7;^9?A?_A@<B6<>3S;
MS[#+#Y@U%+@$2B[GY5ZU+L<-/,-C?WMMZ>EW?U*XK42>FL@IX%7Q24MTFYMK
M:Y26^@^LVZGXXN90L/9UW4^]#\LXWY,\^>;/,NMIH<MY';^BSF9XX48LL9HR
M_$"-SM44I^&3( :8R)>L^:_)7E/R[Y?_ ,06MK>W7U^-([87,RJL3S1F19#Z
M2HS-'Q- :JW?)#_SD@@/E^!R:<;M*#Q^"3!!EDY('_G&FXDC\T-#&A83VDL;
M,&X\!5&Y5^:@?3@W3O-3>6O(5MJC%6FCM8Q&":@LWPH-J=/X=>^"MTW0234/
M*[^9//EWHL%1Z^HW"L>ZHLCM(VY->*!CUWIA;^2'EJUU33)M;U:..\O;N=^4
MDRASQ%%I5J]Z]/X8E$0FOYZZ^8=5C\M:8CV6E:5!#'%;JYXEBOJF9EV'J-SW
M;J:5.Y.13S_:W'Y;>9X]8T4"*SN@&,:T"&A DBXCMT;VKMA&[$[%E?D:]@_,
M_P JOY9UDF?5=/\ 4-I.Q8R ,"T=96)VY_NV78<./=0P,O\ G).9772KB+<,
M)R#[4B(QBRF@O^<9;);]]3M9">#K;\E K5>3@U]M^O;KDA_Y43HFHZ;S)E&H
M3('^L,[$ABH/V":<?:E??'B0(;,0T7\\O,FDK!:Q2Q'3X!Q%KZ,:QE2:D?NU
M5JGNW+E7>NYR'?DMK>HZ/J]UY6+ EA*J*Q9D2>*N^W16H>5.NV&6[&-AF/YX
MZ-::KH]EYP@'&6?TN7+BLCQRH70R;#F\97ARW)6A.PKAEY,\OV7D.6\U#SU)
M;&ZG8>ER(F=A\1=U2A;XCWI\\2;Y,@*YH3SUK]Q^9WU#R_Y"LKPZ781!3!P"
MJKDT4R<7:/91L[D&I;QR/_E=J<5OYW$>B\XM.NVF7TF%"4",Z5!K]DBH[TPG
MDB/-D'YBV5UJ/D%9/,3I<ZMIGI%9TE$M/4D]-T9U:C'CQYD5!9*U)J<EW_.2
MTU-.LHJ?:F9J_P"JO]N0BRFQG_G%_FOF.Y=*D"R?E0TV,L(W]LZ5Y(/+0=.)
MWK:0?\FUP%L')YGYIA$.K7L2CB$N95 /:CD4PZP)2O"'SSY:_P 2Z/<:2K"-
MYE'%B*T92&'XBF$,9"TW\H^8G\N:K;:O$@D-M('*$T##HRU[<EJ,XQ^0_FI]
M(U67R_=\U2Z)"JVWIRQUY @D4Y 4/>H&2+7 T]?_ #S\K_I+2;7S/"8G>%$]
M:1*DS13<3 _+H?3KP)-.PWIDJL&;SGY\DN0X>PT(<$%*@R,"">O4.#OX*,'(
M)YEC>HQ'R?Y M[<QL+OS/(9I&)IQ@M67TEX]_4+<P?#Q[2_\T_,$V@>7KN]M
M:B?B(T8;%2Y"<OFM:CWP!G(T&+?EAY;@\R>8['2[L@6\DA:6M=TC4RNGPD'X
MU4K4=*USF?Y;7NIZ=I*):^7/KHF#&2Y:5%,P9CUYH21VI7)%KC[GH?YCV/E[
MS!JUQ-?^95M&MV]*"S%G.\=NB!5$*&+]VH6E/@%"17J3B/Y9>2-=T[7V-U8-
M;Z7<)(LT4G%XRA^RAZ@D&E-JGY'$E$1N[\TO.^@ZMY?@MX-0_2FM6LL(BN1%
M+$X4(?5?E(OV68 \>0^+X@.N$=KY0L]5\]3:%Z12Q6>4LD9X415)H/:M.G;P
MP]$5NG/^,=0TKR%;^:9+HR:O/^YBEN/W[EA.WQ*9%HK(D9W;E2G\Q%)1^?7D
MG2-(TNWOM.MTMI1,(?W0"AE96;X@.I''; "SD*2K_G'OSMK>HZ]+9W]W)=6S
MPO+(+EFDH5H*JS$E>7+BW8@[BH4@\\V@:W^7R:GJ,<;WBVT4BR,*D,2G)@QW
M!<=< YJ>3#O+\?Z$\\G2],EE6T_2#6GP-5FB]4Q@-39OA]LWY Z1;2:&+^2&
M-IS<2%7*@L* +L3NORPR8XAL[\\?4M_,UQ8\V:.WCA1 2-E,:R4V !^)R:^^
M1FXX+^:P/$%?47MW-OU^_?!T7^)GMNX'Y.2ISJQ:O'D=E^N+3X:TIRKVZ_3D
MN_YR&@1_+@D9.31W$94UIQK4'YUZ4_IAAS9S8-^0L\J>:H(HI#&LT4Z/M7DH
MB=^)_P!DH/T9'M/TRTO?RR2YNXU:6"*8Q2% S(?6;9#2H!H <<O->B=WVHWN
ME_F8T%C(T:W&H0"5%F:-) Q3D'8-T;D>M:5Z=L+/R=_+?2O-ND7%SJJNSK.8
MDXN5X45&8J!M5JT-1TPR+"$;3G\W_/&L>1M=2VT*X2)9+>.5W$:.926DX%VD
M#EU0?9!-!UI7-^:*QZ1JFD^4]-@,NG6P286O(_O9'D;X7+5!K3N-N1QBLMMF
M_P M&FU/2-:\[ZI>B'5)Y#;F_<5>W7TP7DC6,JRLP8(O#< 44=L,_.&B:UYD
MT];%/+"6K1T$,B7,-8]ZD<5"_"?#I].!D1?1!^49_+/E74#K,'FYYI7J;B(6
M%Q^^K4LK,[;DDU#-T.^3+\FM%UC0]';3=;B,)BE8P@NC_ WQ4JA/[5>N1+*(
MIAWYTZSH^M^87U/0IOK$5Q%$TKB-HAZP7B_POOO0$GN2>O7)Q=H7A=1U*D?A
M[X&18)GG7_G'FYBAU]XG ]26V=5-=P0RL1]PR9:8<WT%_P Y&PW$FFQSK*SV
MR7@!J/AD,D/*.13UHJAAN?VL]'Y!O?/N<:_/&?6- $.HV&I7"0S2,GHAE7B2
M.55*A20*=ZT\<LCNU2V>G?DSI>E>89Y]+U'3XII(H?K"S\Y@WP.H*N%?A0AZ
M?9'0#O7!VC:+^DO)$U_K<C:A/+;S7"&Y ?TF",%],D<EZ5ZY")4#9 Z_K3:/
MYND@\NQG2X[>8V9%I+(K2*DM&+LSFI<C<;+LNVU3#?R2_+O2_-$%S=ZQ&TRQ
M,(T7DRK4BI;X2*G)F5(C&WH'YY>?]5\IZM'IF@SBV22$2R.JJ96J[J(W=@3P
M7C7CTW-:X<?FY';^1=#A\N: '@2_EDDE;D22J@!E)._Q54;=EH>IP#=9;;)7
M^3ZS^?O,DOF?S2RWWU!(?@<*H9R>$("*%3BG%F([FFS5.=)\C^7K6U\MVNG^
MDJQRVR^JH'VFD3XR?&M<B6<1L\N\X^89==UN\UAI'9I[AY$9C\07E^['4TXK
M0 #8 4&V<A\@>OY,\Y7&BPEA;23"$J]"64FL3[=Z&OTY([M8V+T[\VM=?S;Y
M3T76[T*UYQEJZ @;.(Y%8'N64-X UILV/_-/3&\C^:;7S)8K^XN)/6913[:D
M>L!7^=37YD^&(W3(44R_*BXB\^>4]0\I7[#ZY:Q 6TC,15">4*NPK\$4WCM1
MP,EWYWZC;:GHEI:6T37-U?R));*H^( +R9Z=?LFA'O[8 F983^2D$]GJ\^L-
M<"SLM-@=[J1PQ0JQ$20GC^U(["@Z[$KN,*ORH_,6+3?*MY'<K1M(!*@#=Q(6
M*"GCSJ#]&$A$94$V_-CR#-?>:K3Z@X/Z?9#&6/PI(Q"/\0Y5CW#J1^RP &V3
M'\H?+QT[0X[NX^.[U _6YG(W)D^)1] I]-<B6<1LQ?\ -S6X]2\P3V]H MAI
MP%A:*'Y@0V_[M2&[\R"_?[74]<YW^1USZOFO44"KQ=)7V'V:2K0+7_6R180Y
MLY_.#2HAY+\O7O)EECBBC"$@\A) CES3[/$J !X'$O\ G(:-)-=LXR6Y/;A3
M2M /4/Q#WZU^C&*)\VOR+N)[30]6OX_1X6<D4W&3C^\*Q3_NG[T)X\:[$U W
MKD]\U?EIH=GY8N;>"U17MK9W27B/4+HO/DS@5))&_MM@MF8[,+\N?F'K5QYF
MMM5N[R5Y);A!+5R%,;/\4?&O%8Z$@+L%[4IA1_SCA=S2Z3=0O_=1S_!T_:4%
MA3K]^,D03G_G(C3K>S\PQM;L'>:V1Y7J26</)'R)K2O%5^S0>U:YUS(MKR_.
M0_\ .2#TTNS4]#<U^Y&RR#3D>G_\X_K(VK7HA%7^H24(ZBLL(J/? WY?_EU=
MZOY?M[Q=8O[<RJQCCAD*Q1BI '"OQ;CQ&"1W6,;"*\U_F1;:3J][I_Z#TRX$
M<[QRRW,3R32,C$.YD#J%9SN>*CZ<E7Y/^5;WRO8WFFWPKQO':.3IZB%4 <#?
MK3QZ[9$LXBDC_./SEIWG#4K75M+C] -911RP4-(I$9U]-3L"H4+Q*@"A&P:H
MSGNH1R6_YHI0ABTT9 .] T(K\J#IDNC \V86LT<WY43>E P:(B.67[()-TKK
M_KT!I[?1D[_/A&;RS(50.!+$6)I\(K]H5]]OIR(+*?)@_P"3:&3S/:(KE'83
M!:5W)B<!=OYNF$_D>(3?EO,DWV1;W=-N@!D(_'#>Z!R3S\RV-K^9#R0 .ZW5
MH]&- 7X1,0378%N]<+?^<=_+MC>6=QJEU!'+<I,(T=P&*@*#\-1\/7J,,BF(
MM-O^<D=2NM/U6/0+6:2+3O065[=2RQM(SN2S"M)"*"C'I3;N22W5G'I?YFI#
MI\9B7UXSQ6@'[R(&2@Z4-3AZ,>13"*YGNOREE-S,D@2BJK4+JJ72!!6O*HY$
M#P7;8'#G\T]1_P 0>;].\KNX^IPO&TJ,&HSO\5#3K\% /"IP!9;E*_RUA_PS
MY+UCS; KC4IE-I;RHZAHD)C61U_:4\G&XWVVXUY9U#SKIEO<:!>VC1KZ2VTA
M5:4 *J66@[4(R(;)#9Y5H>H2Z??V]Y Q26&5'5EZ@@@YS3_G&5RUE?\ _&6/
M?_8G+LW-A!Z1_P Y&VBVNO6\:+Q7ZHM!_P ]9=_"OR 'MG:LH;7E.;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V)P_:?_6_@,4!V*8I=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MGGCS@##^943L*!KJS(H*U'&->GSR8Y-!YO<?*W&__+BZACH_H17/-6)2C*Z2
MU#=&HIJ%[FN>AR:;G(-[P[/+GYAVT,GFYH_+K"66::-E$9K28D<J'ILWAMEL
M7%ESV?0WY;/<CR9/<:\IAT^""YC$D@"\[>1/@1"=V+2M\'O3C7/3.J:=#J5K
M+97*\X9D9&'B&%,J<DA\_6MU+:2I<V[&.6)@Z,IH5934$'Q!SS5H5YJ_E9]0
M\FK"WUK4*0Q@M0 M5?47M\2'\!EC1RV?0OF8:9YP72_S N9(FL; *]\BQEF)
MC*-]593U)E81@G;A(&)IU]'>7=#@T*P@TRT%(H$"BG<]6/\ LB2<K;P*>!ZW
MK5WKE[-J>HR&:ZN'+R.W<GV&P Z #8#8;8K/K-E!<I82SQI=2CDD3. [#Q53
MN<5M2BTVZEMY+V.*1K:$JLDH4E%+?9#-T!:FU>N#,4H;-BKL\Z>29FA_,B<*
MQ/.[O%:HZBCG^&6GDXXYO=?/<"W/Y?6!D10;>WM)(V5OYBT;5!K4[U/A7MTS
MT7E3D/"L\[_F35?S!MW Y'U;2@)%.J_=DQR:#S>Z_EC,Q_+W5H!(L:TOF;8\
MC2"'BOT[@T[=<D'_ #DEI-Q-;6.I1+6*W>1)&'53)P*$^U5._C3QP1930G_.
M,VN6D-UJ.AW52^HPIP2@HXCY^H@Z'U.#DH!UH>],GODS\P=*\Q6*W4<J0S(G
M[Z)V"LA'VJUI\.^S=/IVP4S$GF?F_P F7_E6\-G?)5"28IEWCE6NS(WZQU!V
M(!RM(\[P:]?7UCIH66ULXUY7"M5&D>IXJ1L0!U->N)"+MK7_ "=?:!:6EUJ:
M^A->B1T@<<95C0A5D=#\2K(W()4;\21M3.9?\XU2\;G4(C6K)$U>WPEA]^^2
MDQ@]4_YR:EC?]%+'MP684)WI2$KL-@/D!O7;))_SD5I<MSHD-Y$"R6TX,E#T
M5P5Y?\%0?3@BF;'_ /G'6_AM_,;V\K!9+JUDBA!%0TG))%3_ &00@>]!WQ?\
MIOS,TR]TJ+3;R1+:ZLHE1O4(565?A#JQV^>&45C)*/S1\C7NCZE)?JIEL;^:
M1X9!N:L>1B<?:$BUIN/BZC)+I/G:+7=5ET[2PMQ96\1,URK542DCC$O9OAJ2
M:TP53(&TBU;RG-HUA%=ZF6M[NY(:&U>-@[0?$#.Q- JEUXH.K;MLH4MRO_G&
MZ18-1U"UEJLQ1**=OL,P;;Q%1DYM<'JG_.2$JW-IHMU!O;R1.ZGD6_O$@<58
MCN-QN<#_ /.0VLQ76I6L-K,CM;(X94W*LQ%0S5IT H*;8P1,V5+\@=+#V=_]
M>MF:TNC$HD:O%@@D8A5H.5#]NC^U.XZ3^;42P^3;N-CSXQQ"K;DGF@J>E3D(
M\V<^3S_\J%=O-.F"(LK?64-5-#0&IWWZC";\I;%M4\BRZ?$>,DRW4(+= S\@
M#\OBQ)W1#DGGYP7PL?/<][02"&2UDH-J\8HFH>N_\WO7(A^2?GN'RM-<^7=>
M<6R^I\#.*!9 >+H[=ATH2:"A\<LD+6)IFWY[^17\TO!YQ\L1M=QW<7.98@22
MFWIRK']L_#\,@ ^%EW J<ZCYE_,JPM%CM='GAO-2N76."*-N8JS*"S\*\0H)
M;<BN54R,NYY1H7Y?:GJ,-QJ$\+VVG6D,DLMQ*O!*HIX1JST#22/QC514\FZ8
MAKT>@^=;V;RMJJGZ[9*D@(8*:R+4F(UJ:"G*JTZ8\D&CLK:&^O>3[2W\V::_
MHP7;S6P8 ,#PX%TD5E*T:OP@[GB2/LUSE?F/RO<?E;KUE>:1*\T%RX58RW%V
M"LO*)^- 0U1O3Z,ES8$<)>J:+YHB_-K0-0L-?3T+C3(9+M9XU8QJ I/.AY,M
M./%D4T8&H%5ST<#45R#>^?L)?.J(^AZ@)!5?JLU1TZ(V$,9<D?H$DT6H6TEL
M>,ZS1E"!6C!AQ-/GG)?^<8C1=2'C]7/4>$G;KEV5C!ZW_P Y-$&]L.A(296(
M1E^(2;K4_":==NE?EG=,H;'BN<B_YR2+?HBU (X_6:D>-$;)1:IO6_\ G&64
M)YEF%#5[.10R@DH2\8Y"GMM]/T'H'D7D="L&=S(6MHFY'W4&FP'3M@+./)YI
MYAMA:ZE=6X3TQ'/(@3?X:,1QW).WS/SSE?\ SDQQ'Z-/?]^/^3>2BPF]=_YQ
MC61[G40K!558'WV^)68J>78 5KL?EG8]!M?JFGVUM2GI0QI3_54#(-@Y/%9Y
MFG=I9#5W)8D]R=SGGOSTC^0?.3:M;!@LA:X0&GQ>H"LBBG;E7M6GWY:-PXYV
M+W/R1!=?F'Y0_P -H$$D$B0^K4_NE1O4BEE![%6E0%3T&X%/B[!^4WEZ31=!
MA%R"+RZ+7$Y:O(O(:_%7N%H#[Y66Z(H/-?S0\R1:]KDTEG0:?:A;2T5351!
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MX\NM/#KWZ8T@2!1GFG\J_,GE6W6^UBR:*V8@"1621-^E6B9@M>U>O;!?F/\
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MY4ZSIVG?IF/T+RS2HF>SG2<0D=I?2)X^-=QXG#;S%^8FA>79#!J5VD<PW],
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MM$TC0-&HND<I)#Q&\DJI'261Q\+LZN2/#I]GCA?^=6CVMIYMLY8X4*W0B>5
M/MMZA#<@.[+2NV^(1+FCOR5\R7LGDK6[2.XF1].@N)86#']V'A9AZ9V*4="=
MCU:M*X;_ )W746BVUCY3TA!%:2EI988@0Q7E\*CK]IN7T@8A,MMDF_)*$ZC<
MZEYRUF4SZA8H@MKB\8O&)F5P)9F8\F]%4!Z_"-^H7'>:+QM7TA="L?+-V@"
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MNB$*V[5_9P\_/?S+9:_I6G7FGMS@>6;BQ4@GB "5Y;TK@B*3+=)?^<?=!O\
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M:!Y[USR^;EM*O)8&O5*SLIJ7WKRJ:D.*FCBC"IH=SB>I_EAY<U.<7-U8QM(
M!L64;=/A0@?AC:.$+=&\\:WHD$EIIE[/;02FKI&Y4$^.W?;KAIY=\KZ?Y<@-
MII49AA9BQ7F["I\.;-3Y# R I"Z_YBO?,%T;_4Y!+<E55I."J6XB@+\ .34Z
MLU6/<XAYE\D:/YF"#5[99_3-5-65A_LD*FGM6F&T$6BO*GG;5_*4[W>AW+6L
MLJ&-RH4@J?9@1\C2H[8$N_RR\NW<45O-8QF* 411R4"O^J14^YWQM'"%EEYS
MUJQN9K^UO;B.ZN?[V59&#OO7XWKR._CCM-_+C0=,M[BRM+41P7@"S+S<\@.V
M[$CKVIC:>$+]7\[:QK%Q;WNH7+S7%K3TI& Y+Q/(;T^(U[M7[LJP_+7R]I\D
M,UI91QRVQK&XKR!]VK5O]E7&UX0NU7S[K^K)-#J&H7,\5R094DE9D:A#+\!/
M'8@4VV[8<ZMH=CJ\8AU&".XC&X$BAJ'Q%>AP)(M*].U2[TV7ZQ8S26\P%.<3
ME&H>W)2#A+Y=_+;0/+L_UO3+58YZ$<RS.0#X<V-/HPV@1 3OS5^9'F#S7&D&
MM7CW$49!5**JU H&*H%#-3]HU/O@K7/(NBZ[<)>:E:I//&**S5Z># $!OIKC
M:F(*!T?S;JVC036FF7<UM#<%3(L3E>14U4[=Q[8+T/RYI^A1-!I<*P1NQ=E6
MM"Q[[X$@4A-4U>\U:;ZSJ,\ES-Q"\Y7+M110#DQ)H,,L4H/-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[&15JU?YOX#%#L?BEV;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V(6VG
MV]J6:WB2,N:L44+4^].N**;))ZXOBEK-BKLV*NS8J[-BKLV*NS8J[$[BWCN8
MVAG57C<496%01X$'%#:L5(930C<$9SC4?^<??+=W*)8A-;BM2L<FU/#XPQ R
M5L.!Z5I/_.1'F_3XG@>YCND9.*^O$CE6VI)RH"SBG5RP\0<-?+7Y.^7_ "_/
M];@A:6<;!IF+4^2[+^&"TB 2/S7^;'F/S7:+INKW0DM$D$HC2**,<@"H/[M%
M)V)V)IDVP,V(9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MD9\W>0+'S64&HR3^G'N(T>B5_F*T/Q4-*X06!C::^7_,]_Y>E:XTN3T9G7B7
M !:G@"1M7O3#/R]H$6A6JV-O)+)#'L@E8,5'\H( VQ2!2!OKV2^G>ZG(,LK%
MF(%*D[D[89X&2AFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)PFK/_K?P&*'8IBEV;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=B<1JS_/\ @,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[&
M1]6^?\!BAV/Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ.$;O_K?P&* [%,4NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKL3BZO_K?P&*'8IBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B<75_]
M;^ Q0[%,4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL3AZO_K?P&* [%,4NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS5%:=\5=FQ5V:M
M<5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=@34M5M-+B-Q?3)!"#3E(P45\
M*GOB@E7L;"XOYEMK.)YIG^RD:EF-!795W.V):#K]EK]JNH:9*)K=R0& (W4T
M.S $?2,5!M%:_P"7[[R]>R:9JL1@NXN/.-B"1R4.OV21NK X88I2[-BKLV*N
MS8J[-BKLV*NS8J[ UCJ=K?AFLYHYEC8HQC<-Q8=5/$FA'ABBT1=V%Q9\/K,3
MQ>JBR)S4KR1OLNM>JGL1L<$XI0^;%785^8/,^F^7H/K.J3I!'VY5)/;X5%6;
MKV!PH)I,= \O7_F"[33M*@>XN9/LH@^\D] !W)V&;R[YEL/,=J+_ $N7UK?D
M5Y<67<=11@#^&!0;7>9/+5_Y:OI-*U>+T+R'CS3DK4Y*'7XD)4U4CH<-,4I9
MFQ5V!-4U2WTNW:[O'$<*=2<4$TNCC:1@B"K'H,2T37K/6X#=:?)ZD08J30BA
M&]*,!XXH!M=- \#<)!Q;PPPQ9*>;%79L5=FQ5V;%79L5=FQ5V$=UYYT*TE,$
M]_;)*I(93,@((Z@BNWTX:8\03FS\EZY>VZWEKI]W-;.:+(D$C(3[,%H<%:1Y
METS6"RZ;=0W)0 L(G5J5Z5XG D&U#6?+>J:(4&JVEQ9F4$IZ\3Q\@.O'F!6E
M>V&6*4MPEUKSIH^B2K!J5U'!(VX5CO\ 3X8:8F0"9:-Y;U/6RZZ5:3W;1BKB
M")I"H]^ -,3L?/>AZA<)9VE]!+/)7BB."33_ #Z8TO$%;4O)NMZ7 ;O4+"ZM
MK<$ R2PNBU-:#DR@;T.'V!DD^;%787:UY@L-#@^M:G.EO%6E7-*GP ZD_+%!
M-(S2M'O=8G%IIL$MU<,"1'"C.Q ZGBH)H,C=M^<_E2XF%NE^H8F@+)(JU_UV
M0*/F33#3'B#,+O\ (KSI:6@OY-*G,1 :B<7DH?&%&,H]_AV[TR2:?YCTW4I3
M!8W,5Q(J\B(G5Z"M*GB3@96PV[TRZLU5[F&2)69E4NA4$K3D!4=5J*^%1ACB
ME"YL5=B5U<I:Q/<2FD<:EF-*[ 5/3%#8%<BODK\T=)\X7$UIIWJK+ .5)%"\
MEK3DM"=JTZT._3"0Q$K99YX_*_6?)45M/JZQA+L-3TW#\'6G.*2G1UJ*]1X$
MT-)?@9L2S8J[-BKLV*NS8J[-BKLV*NS8J[-BKL(_-7G/3/*T*7&K2F-9"50!
M68L0*D *#^.V&F)-)SY6\H:GYJN6L='B$TZ(9""Z( H(6O*1E7JP%*UQODSS
MG9>;K-M0T\2+&DC1$2 *U0 >@)VH1B12@VO\X>3[[RE??HW4N'K&-)08W#J0
MXK]H>&ZGW&U10D^P,DCS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NP#K6LVNBVDFH7[%+>( NP4M2IH-E!/4^&*":1>E:9/JMU%86@#3S,$0,R
MH"QZ#DY"CZ3D6\C_ )J6?G"_GL;*"2-($#AY* MOQ/PBM/O^C"13$2MD?G?\
MM;[R=;6=S?S02&]#D+ _J<. 0_&P'&IY_LEAM6NXR;X&;$<V*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[$X>K_ZW\!BAV*8I=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%78E=6L5W$]O.H>*0%64]"#VQ13:L4(930C<$9YF\U>6+;3O.B:+;2/':SW,
M  #$%!,5Y!3[5VRRV@C>GT+Y.U676O)-SJ4]G;S3V%M/%ZK01/S]!%,3R\UW
M**U._+C4[USJ5U^1MC;QM+HEY=V=]0\91,36O9J4-/IR-MG \WTS\XM0BDC7
M5;/3]1LD(_T>6S@51TJ4:*-&5J"E=QXJ<(?RB_,K4FU+_#&OOZK_ !K%*]2_
MJ)U1F_:V!H3OVQ(1&2??FAY TJ73?\8>5U,-H[1O-;<E*QI,!P9!7DM'^%DW
MH2./P[#M61;7D>;%79L5=FQ5V;%786>8/+.G^8;?ZIJD*SQ U -00?$$4(Q0
M1:.T;6[W1+E;[39GM[A.CH:'Y'Q'L=L\\?E!Y5M-0\T/:7\9=+19)%4FHY1N
MJKRIU KEA:8BWOWYJ><;\^2+>ZMYP&U P1SF-%6JRPM-*@VJH=J<J4Z4^R>.
M>D;O3;:\MS97,2RV[ *8V *T'38Y6W4^=[>YEMI%G@=HY4(974D,".A!&X.>
M9==\L:9:^>!HL43?4#=0(8N1Z2!"RCOQJ?G3+&@C=]*:5YVU^7R&-9:X U#Z
MM<!+DK^\98Y/3Y,]/[P+50Q-313NW7TUI^FVVFPK:V<:0PIT1  !7V&5MX%/
MFRYNI;J1IKAVDE;=F<DD_,G?!.*5+-BKLV*NS8J[-BKLV*NS8J[-BKLYK^?&
MAV-QH,VJ31J;NW,8CDI\5"X!7Y?$<D&N8>@_DAJ>H1>8[?3;*>:*"\+),D<A
M0,O!C5MZ?#U&"?R)+'RO 6Z&26@\!S/L/X_/L$IAR0WYUQ+#YKO8U8N%$ Y$
MU)I#'\5:FM>O].F=!R+-@^;%79L5=FQ5V;%79L5=A%YX\T)Y8TBXU5QR:):(
MO\SL>*#[SO[5PAC(TG/D[RO<>:=6MM%M"%EN7X\FZ*H!9W/LB L?EG&OR&\S
M3Z5JTF@7O)4NR[!2*<9E%6K7?XE'X#)%J@7K?YWZ19ZYI-MY@TIE9=.CBMB%
M8$-:D\;=Q\5/A?DK "OQ"M*9Z"R#>\+S8J[(+^<%OI\WEZ]N+F))IH(P%( +
MHS, I!ZKN:GVKA#"7)EGY527*^9M/CM)Q;F2XC#EB0K)6K(W'[08"G'OA7_S
MCUP'EL\:\OK,G*O2M%Z>U*?3ADB"<_G_ "-)YNNF/V/3@X;$'CZ24Y ]\Z=D
M6QYUFQ5V M:TFWU>TDL;L$PR#XJ&A%#4$'V(Q01:^&5H7$B&C*:C"[R9H^FZ
M59>AI$@G@+L2X97JW0@LNVU*82QB*Y*^HM<-+RNPRR,JM1@1\+ ,IH>Q4@CQ
M!KAX\J1_;8#YFF!FA<=BKL9/<1VZF29E1!U+$ #Z3BAV5;W,5R@E@=9(VZ,I
M!!^D8I;(IL>N5-=PP,B3.J-(>*!B 6/@M>IQ1;J5Q-=2MGG:S66,W*CDT88<
MP/$K6M,5M<87""4J?3)*AJ;$C<BOCN,$XI69Q/\ YR1M[9$L;CTQ]:<RKSIN
M4 &Q\:$[>&_CDXM4WK'_ #C[->27MW9QRNEDT<<DJ*0 665 AW(\6!(['PSH
M7Y6VL5OY;L! @0/"KM04JS"K,?<Y$LH\F%?F1<S7/F34Y+B1II!=S+S9N1HK
ME5'+P"@ >W3)5@9L<R!_GA;1S>5;MG4,T9B920-CZB+4?03A#"?)F_Y+736O
MFRP=6*U=U)7E6C1NI^SOWPC_ .<=+=%T>ZDH/4^MNI.W3A&>OTX9(@G/_.0-
MS]9U>QE#<D.G0!/A92 &D%&#$[U!]LZQD6QY?A+YP\TVWE?39=4NZE8Z!5'5
MF.RJ/\^F$,2:37ROY;N_,NHPZ1IX4W$Y(!8\54 %F9F[*J@D^PSDGY:^6Y_S
M!OI?,WFBEQ#&X6",GX.0-2O#IP7P/4]:[Y([-<1;U/\ ,;S/;^0+:/RCY+DD
MM96CKJ$X4"6;DJ-'^]^VNW)N*$*%8=26SL5SY:TRZMC936L+6[=8S&O'YTIU
M]\@V4'D%AJ5UI\ZWEE-)!<(:K)&Q5P>FS*01G-_)OD&7R?YSE6T4MIMU;2,C
M4/P?&I],FN_&G7P([Y(G9@!1>D>=_P SHO.?E"SM]4D9M>LKOB:@D20-&U92
M:<0_(*K"N].7<TZWD6UY=FQ5V4ZA@585!V(Q5V1/RCY4\LZ->7$N@B(72_!,
M(Y2Y0$\N++R/'<>';"6  ')DGFCS-YBUJUM&UZ:XFM0&-LTP/%@*1LR,1\?V
M:,U3OUWR,>9?S0Y>:=/T?2[B,6L;DW4A8>FW(4X<AM51_P -3PPTQ,MT]T;\
MNXU\I:AYGU5)%E/II8QJ""?C4R3L#2L7'X5;<5Y=P,Z=!>P7"&6&17C!(+*P
M(VZ[CPR+9;S_  OM/-VC7<GH6U];2RT)XI,C&@Z[!L-+83&^\MZG86ZWEY:3
MPVSD*LDD3JA)'( ,P )IO\L-(Y%E421D,K"H(W!![C J6X[%+L*]1\U:1ILO
MH7U[;P2['A)*BMO[,:XTBTTTKROJVKQO-IMG<74<?VVAB=PM!7XB@(&V"K'5
M+2_Y?4YHYN% WIN&I7I7B=JXJ#:7/$Z4Y@BHJ*BE=Z?KQNIZU8Z4@EU"XBMD
M)H&E=4!/A\1&*DTB=*T>]U><6FFP2W5P02(X49V('4\5!.V):3YDTW6.0TVZ
MAN2GVA$ZL1\^)Q6[5-8\OZCHCK%JMK/:2.*JL\;1DCQ <"N ?/Y(\OZB1N?J
MLW>G[!PA$N2)\F1K+K>GQN:*UW ">/+8R+^SW^60+_G&^'CI%TX8_%<4XGH*
M(NX^=?PPR809Q_SD1=FY\Q1\N)*6J+R4<>7QR&I%!2E>/T9U#5-:LM)C$VHS
MQ6\9- TKJ@)\!R(J<BV6\ZTK1[W5YOJNFP2W4]"WIPHSM0=3Q4$T&,TO7]/U
M8%M.N8;D+3EZ4BO2OCQ)IBMK]7T'4-%E%OJEM-:3,.02>-HV(\:. :8/Q2@,
M0O=0M[",SWDJ0Q#J\C!5'TM08HM5MK:6YD6"!&DE<A5102S$]  -R<+;[SGH
MUC:QW]Q>0+;2FD<G,$/0\3PXUY4/6G3OAI%A,+;RIJ]U=2:=!97$EY "985B
M<R(!UYH!R6GN,%:?K^GZC ;RSN(IH%KR='!5:?S'M].!-H34=,NM-F-K?0R6
M\Z@$I*A1@"*CX6 .XP'H_G71M9G:UTZ\AGF0FJ*PJ:;DK_,/<5&&D"0*-U?R
MCK&C0I<ZG97%K#+3@\T3HI)K058#<T)IX;],.\#)*,C=W^8_EVTF-M-J%NLJ
MFA',&A\"1L/?PPTQX@G]I^7_ )CO84NK72[V6"1>22);RLK+_,K!:$>^'UI>
MP7D0N+:1)8FZ.C!E/R(VP)M(Y8GB<QR JZD@@BA!'4$8 M/-6DW<KVUM>02R
MQ*6=4D5BJ@[EJ':G?#2+",O-!U"RMXKVZMIH;:?^ZE>-E1]J_ Q%&V\,#Z9Y
M[T/5+IK"QO89KA?V58&O^J>C?[&N-+Q!%:MY,UO1X%O-3L+JUMV/$230NBDG
MH*LH%3VQFK>?]!TB<6M_>PQ3\@I0M4J3TYA:\?FU,:4R"_2?(^NZQ#]:T[3[
MJXMZ,?4CA=D/'[5& H2/ ;X>PS).BRQ,'C<!E934$'H0>X.!*2,I4E6%"-B#
MG!/RIF6W\ZZK<7!$4:+<ERQ 51ZRGXFK04^>3+5'F]R_-:Y$WD/0+9 OJ$6_
M%0K*[4MP"5!5>0JPJPKO2A-:YUW3OS!T'4KM=.LKV*:Y>O%4-:T%30]#M[Y&
MFSB#R?4O)&NZ7;M>:AIUW;VZ$!I)8)$4$[ %F4 5R0X&229$M1_-CRQIT_U6
MXOXO4'7@&<#YLBLH/TX:8<095I/Y5^:-6M#J%CIES+;4!#",_$"*@H#NXI_*
M#D@&MV/U7](?6(OJG7UN:^GUI]NO'KM@96QWZA<>O]4])_K'+CZ?$\^7\O'K
M7VPJM?S"T&Z-QZ%[$XM%#S,IJJJ>_+[+?[$G#2.()EJ/DK6]-^KB^L;B!KQB
MD"/&RO(PX[(A'(_;6FV]=L%^7?-FF>8XFGTF=9XXSQ:E00?=6 (QI0;4-?\
M+6I>7K@6>KVTEK.5#A)5*DJ>A'B.WSJ.HPWP,DLS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL3BI
M5Z?S?P&*'8IBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V></S$U&.S\_?7U#R+;2VS.
ML8#,2JJ>*@]_XY,<FB7-[IY"@>?R#/I4S10F_-PT$D[>G'Q0Q\F=Q_E(:%MJ
MBAVSH.K?GK:6,#3_ *-OU(-%,T0C0GW?DU/NP4S,V(Z9^2=WJ,L<%OJFDR22
M#EZ<5XDD@_R0B5+-[+7YY#OR0TLZSKL_F"[FC,Z^HYBK\1:0_;X_RBO7QIA+
M".Y3K\XM773-*M?*-I!*+.!HV6>04Y&-61U^S]HLW-@&HO2AZX9?GC::SH4J
MZSIFH7<=G<-PDB69PL;T^'AOLK;[=C\Z !E+96_(J]T/5S_A_5M-M)[V,F6W
MFDC)+J#RFCDXFK$+\2;&@!&=)_+B[6\\OV5P)I+EGB!>25BSE_VP6/\ *U1\
ML!9QY/,_.MF]GK=];R0I;M'<2#THQQ11R- @/[-/L^V1K\N(;G4=9U34_K5U
M-IL4QAM5DG=T+"HE/'E0J#]BHZ??A+&.[(?/%U96FA:/H\5O#%J8A-Q>R)$@
M9EEH]H#+]HGT3R<"@/(<JL-C35]"U^X\P0WMO.%TY.-5#D444YJRC[1<]/;J
M1BI!MA\<UN+9D929B=CM3^N37(MB$Q*ZMTN8G@E%8Y%*L.E010],4-YYF_*O
M7U\L:Y<RFVN+IC%)"D5NG-Q216-02#0!<L+1$T^B//\ I,OFWR_IR_6[*SY^
MA<7,]U,(D:22W''[*T+?:V0;=Q0%LZY)^;]&"QZ+JQ/4UMJ?#XCXC7(TV<3S
MV/\ );E&)#Y@T%2?V3??%]/[O.4RZHFM>?X+V2&:V66Z@/I2CA(&554<A7:I
M%</1A=EG=U8OI'Y?75A#-;7CVL+*9[=C)$4EN 6"-PW;XC7I3;PSLOYJ>?&\
MH::)K=0]Y<-Z<(;H#2I<^R_K(R(%MDC3RG\M/)*>;M4^J7,I@LX(VGN'45?T
MUH.,:_M2.Q"J-^M:&E,Y?>Z1IC:;)JX\P_\ .Q\69W2Y"JS=3&%'Q4 ^$<:#
MVIDV!'5Z)I>J:M#?K$GE(R^6RR".WETXR2(AHOJB?@':1OM5=R#]D;89?ECY
MHUCSCI5YH4EW+%<VRH\=TA!DX5^P22*G;9JUWZ[8#LL3>R#_ #E\DZ9Y&U2P
MUJVMHYK:^]9GLI!(L2NG'[)5E<(?45@G+X2"*E3QR,_EXWF7S8]WIUE?RJ)$
M!FGE=V*A2>**=Z%R>QZ5Q(IA&RG7YFVN@>5[FPU6^TNV;B&]*RA C26H5O4F
M<#FR)6BAE!8]=@PR70ZEK7Y5>79QJ<B74\EQZ=G&S%@%I\3'<-P-*A>QZ]<
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M[D)(6E?A ZX2?DC^8%GI,<OEW5R+602DQ%Z@<CL\;5^RP(VKU^?4D(B:3/\
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M0W)O$5B*!Y"O,LLCC=O3>&B.17BWM3'_ )!:W^A=9NM"O>,)G %';B1+$>/
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MM'7X5G+$"M!Z$@)_'##\F%X^5;+XQ)42&HIM5V/';PP$)AR2S\VI!)YIU$K
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M:9#QF<$-(Q+,037C4]L%LA&DJ\P^<]7\Q!%U2Y>:.+[$>RQKVJL: (#XD#?
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M Q5V%JZXL\S06R/($;@S@?"#U._RPTQMV ]*T2:+ZQ+J4HF-QMNH6B@4^_\
MV\-H [VS[98M#?J8+6EO9U*MP6A;;HE  /=M_;%:MV'5M;1VL2P0*$C0!54=
M !VR+)Q))J=R<4Q2UFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=B4)JS_ .M_ 8H#L5Q2[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL!3Z@69[>U'.=!4@@T%>E>G7VPTQ
MMV M/TNZ:1I]1DYDU"  "BGJIH/X_/% '>[!LTUII47-RL49('S/V1\\4\G8
M7&NNO1"5LT8AB.LA'[(Z_!_-T-=O&CR1S;P\BB2)1'&H5%%  * #V&!DUCL4
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NR!^=?S4@T*06=B@NKG]KXJ*GS\3XBHID@&J4Z3'3-'
M:]#2,PCC4?:(K4^%,EF@:A/J-C%=W,1@ED%6C/;>G?Q&^19@V$#*H5BJGD =
MCXX88LEF;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78E#]I_\ 6_@,
M4.Q7%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[ 3:G$9?0C
M/*3D%- 2 2"=R-AL,-,;=A3)Y?O;N\DENKEC:$@I&*K0;U7K3Z2"3[9*Z15M
MDB@IUR0) B,650&( ) W('3[JY!DU@+6]8BTFV>[EJ0@V4=2?\^IR0%H)IL"
MN1O1-.F\P7 U;4E*HG'TE6H!^T2#W/$T]B?IPDULP O<NR9HBQJ$0 *!0 =!
MD&UK+Q5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%78G/<QVZ^I,RH@[L:#\<5=G/]<_.&TMW:WTR,W$@Z.WP
MH>G3]H]_#?)B+49]R,CTR1D$KD*A[GM\\*K(>:_.)<S/]3LV&W %5/R(/)JD
M>)ITK3);!&\E69K.WX^A65NY;I_P-/\ /VR4>7OROTS2F]6<?6YAT:45 ^2F
MHK[GZ,B9,Q !#S7\LH*U"J>RB@_#)CD&:&S8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKL2A/Q/_K?P&* [%<4NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NP->WZ6H ;>1@Q5>[4%=L(%H)=@>REN+PF:0>E&"0BC>H&U2
M??PH/GA(I W=@JTLHK1!'$**HH,%I IV+X$NP/?WT=C"UQ-7BHK0;D^P]\4$
MT[(EIFE7NNW'Z2O)%^JR*T?IC?97VXUJ-^.YZ]QDQ*FL"]UQ(I0#?)HJA10;
M 9!M6Y>*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NPOU;7K+2(_5OIEB7L#N3\E&Y^@80+032Y$9SQ45)R"ZC^
M;3W4OU31;9I'D'[MVJ?B/^0/ ^_T9<,?>QXNY$"SX#E*>/$T8=\03\O]:U^8
M7FMW!CH=EKOQ\.*T ^5<AQ4PX2>;:W:1(4C122*%F%3]&3+0_(^F:25EBA4W
M %#(:G?Q 8MQ^C(F38(@*#S.XHQ)&'^19*>;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%78E"*,_^M_ 8H=BN*79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=@#6M:@T>V-W=$\%*K11R8EF"@!1N=SB@FE6WMWN']., M0G
M<@;*.1W.W08 O5U/4+A%M7$&GO%R+@4FYUV%&!^'C\C7),39</2](D\O6Y"@
MH./&AKO6M:TPY2V4!.?Q,@H&/7WR+*E+%<4NS8J[ ^H7T5A ]U.>,<:EF/R_
MCX84'9L"IH,@T:7'G*]61U9-/CJ" X_RN)H":.:@[=!U]Y\FKZBNIQR?0PK"
MBQ1BB( H'@!TRMN68_%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V%6L>:-.T=>5].D9_EK5NE?LBIP@6Q,@%\<3R&
MB D^V0B^\^:IKC?5-#MW1).(]0CX@&!Y&H-%I]_\+QC'5AQ$\EXB1:\VWWV'
MB,$Z5^6#7/\ I.N3/+*PV7E4H3\7VS7=6/:HKO7(&?<@0[W&Y8;)\(I3;O\
M/)MIFBV>EIPLXDBJ "54 FGB1URLFVT"E-F+?:)/SP;@2MS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ*$49_];^ Q0'8K
MBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=E,P45)H,5=A5?WU^77]'PJ\0IS+$ FI ^$5
M%*"IW^5,+$D]&Q@BZT>VO65[N-9"!T8 BHW';]D],"D6Y6*FJD@[C;WV.#L6
M36;%79L5=C9'"*78T %2<5=D'GO[SS9)<:9;<8K6-U#,0>7'OUJI)(-!04_'
M+*IKOBV7;+0]<F.G:?#I\"VUN.*(*>Y]SXDY6S IHX)Q2UFQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V%&L>:M.TE2;F4<U
M!^!?B?85^R-_OP@6Q,@%R1ER%7J33?8?><@NL><]8\PN+;R]%(D!&\@!Y5Y;
M?&-D!%*[@CQIEHB!S:S(GDKI''&"9B>0-*#!6A?E' 0+C6&>2=MV4-4&O=FI
M6M:UH?IPG+W*,?>Y[Z0[+\*UJ ,Z%:VD5I&L$"A(U% HZ#*"6Y#DUQ7%6LV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[$H:\GK_-_ 8H#L5Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL+=5U5[,I%#&9)) >-*T
MV^6&F)-.QPLWNPC70*,C D*?A:G\*[T]L5JW8/"@&H&YP,G9>*NS8J[-BKL;
M)(L2EW("J*DGL!BKLA6NO+YAU*+38HQ)91A9G):@-:T:M"=NP]]\LCLU\RN&
MPK7?)7IFE6VF1>A9QK''6I [GQ.0)MG318MN37!F!+6;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V$FN^<=.T6JW4M91_NM?B;L
M=QVV-=Z;=,D(VQ,@%R1LYHHKD"N_,>N^;G?3[!/JT3)RJC;T(V#O_E?1X'+*
M :[,E=%CAH[4<@T*]L._+OY5VUHOJ:HYN9F'Q+4\:T*_:V;8=#M3(F;(0[VI
M[LR-\("J.@ IDXM[:*V01P(J(.RB@RML0^*XJ[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL2@-6?_6_
M@,4!V*XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%787:AK<-HH*@S2,P14CH6+'MUIM3?"Q);&%NN>67U
MX&&]<BV+1MZ8)&RD,5;B:-5A]V$&D$6J6UR]L_J14#485(!^T"IZ]Z'8]NHW
MR1 4V&19J67BKLV*NS8J[-BKLV*NR*>9-:&H&31M./J7)HLG$T* ]]Q1AX[T
M'<C+(CJUR-[!=Q( 8C8X<Z#HD6CVRVT1+D !G8U)I_#P']N0)9@4TS<B3XX9
M8$M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V%NN^8
M;31(#<7C\1V4;LQ]A_F,(%L2:7(A<\5ZYS_4O.NM>93Z'EZ%XH0=Y!]HCIOV
M7[_IRT1 YM1D3R1"110D^O4L/V1_7#30_P KHX7%S?R'U3U6,_#O3;XJ]=Z_
M@?")FR$.]2><L.'[(R=P0) BQ1*%10  .@ V&5MJEC\5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=B4)^)_];^ Q0'8KBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V-:5%(4D<CT'<XH=A?8ZHU]+/ (I(A"Q7
MFPV8^*X4 VWE:5Y=L]+CBAMDHL//@222.9Y,=_$XVH%+YIWF;G(:M0#Z *#[
M@,,\#)3S8J[-BKLV*NS8J[-BKLC7F?S++:<;335$]U+R "D$J13]FAK2M36F
MPR0#"4NY<H!ZFF"/+7EI-,!N9@KWLN[R4WW_ &>_0;$]\!*QC3F8F@WH.F'N
M!FMS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[ U_J,&GQ-
M<7+A(UW)/\,-(.S8%=AG/M4_,+4M3N?J>@0,%!*L[H2U1UV%: =]B?E3)B/>
MU&1/)$"WC1:RM1B 0!X8WR_^5<S7"7^L2^ILK&/]HM6I#G]=#OA,TB'>W)>
MH8XU"@FNU<Z/;VL5LGIP(L:#>BB@RIM0N*XJ[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[,*]\5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V)0?:?_6_@,4!V*XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V8D#<XJ[">?53>AK:QY<G5@LH%5!Z<@?8^-/$5R
M5,+OD[%M/TKTV%S<?'<%5!)WI3P_' 2D!V&6!D[-BKLV*NS8J[-BKLV*NS8J
M[";S)Y@CTN!PM6GX_"JCD16O%B/"H.$,)2IL"N%_E/RL;1FU&]/.ZD9G6M?@
M#[L!7<$U-?\ ;R<I6L8]6V:O3;)3E;-;FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=E,P458T'OBKL@.N?FBL<ZV>C0_6I'KN:C<'H!2O3Y9;"
M%\VHS[E>.WY*7<\5%.WC@73O(>I:O,;O6[B0(3S1"WQ"IJ5H"544VVZ>';$R
MI/"3S:>90 J* :4)ZUR?:=I-MIJ>E:1K&M:F@ZD^.5DLP*4B:]<%X$M9L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B</VG_P!;^ Q0[%,4NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NPFU?S5;:9(D,BN[OTX
M $5KQH34;UPTQ,J;I@I+=KQG-TO[HT"(?Q;Z:^V&Z7FU@JUM(K5/3@18T\%
M _#(I =BN*79L5=FQ5V;%79L5=FQ5V;%787:YK4&D0?6+AN()XCON>_R'?"
MQ)IL"NPR/Z!Y<N+F]GU;4W)+MQ5!]AE!JK$4W K1?8;U!PDL0+W*YI*J$ &Q
MKDQR+8LS8J[,33%78U'5Q52"/8XJ['8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NR/>8_/&GZ)RBD</=4^&)=S7MR/1?IWIDA&V$I *B0LX) V'4Y#/T?YA\WM
MPOOW%N"#2A";&FW<D$>)(R5@,-Y+^:1&L=3UR:Z!Y*T[1:/#&'GV_>,*FH%/
MA_E[_?D3*VP1 4WE9_M$G#_(LEF;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V)0_:?_ %OX#% =BN*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=C7D5 2?"N*NPEM+V^U*3B4^KQ*/BJ"2U:TX-\/SZ;9+DP!
M)=@O3] L[#>",5Z@G<BF FT@4[#' R=FQ5V;%79L5=FQ5V;%79L5=FQ5V%.O
M^9K/1('FN'7FH)$8(Y,1T'M7Q.PPTQ,J7PQ&5PB]2:?YTSE<7FFUU^^@O-1C
M>>2,,"B"B55OA6A)_F-=S4#QS)X*:^?-$36TEL"&(6M-NY#"M?EMDLN=?\T7
MC!=.LEACVW<;T#%3NY5=]J#C7OTRHQ 9[J*"*AYDUH:4_#'MIWFN]3]Y,L#%
M0**0/B!ZU6IW^GW&"PQJ16U4'85%>_A@UO*.IW"S&?4)59_L!&8!=J>(V]J>
M]:X\03PGO:5Z$; T_' :_E9#5"]PY510I0\3M2GVNE=\'$O V)2*]-^],#W?
MY1Q>@8[2ZD27F'JWV:U[ ;["M-\>)' JQWA5@S*&HO&E.U,0DT+S5HOJ-8W3
M7,04T#MS/P]/A>IJ? 5W\<-A:(=ZL<A'J+QWW*^'RZ8(T/\ ,N6*Z&F>8HA;
M3BJ^H*A2P-!534BH(-:T]@,!BD3[U2:R5E,ML2R"E0>HJ*[_ (Y/H)TG1986
M#QN 5934$'H01UR#-",I4D$4(ZC'XI:S8J[-BKLV*NQ"[OX+,!KAUC!Z<C2O
MRQ033L@.N^:=5UR)4\OQ.L9>CN".=.0&XI50?&O3KMEW"!S:S(GDJQ*@)]0]
MM@/&F#/*GY<+8$7&J,LTRL2!U&XI\7(;]?[:;9$R[DQAWNFG]0U "BE*#)SE
M;8I9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)PBC/_
M *W\!B@.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[&O(L8Y.0H
M'<FF*NPDU;4+^9C!I"KR5>3.XJ#_ "JFX%3XG;]>2 8$GHV*=\&:;HXLY'F:
M1I'DH3R-0#WX]Z'PKMB2D"FL,<BR=FQ5V;%79L5=FQ5V;%79L5=@6\U2ULJ"
MYE2,GH&8 FNVPPT@FF\CMYYX9YEMM-MVG=JU8]!OQ&RUJ._RWZ;@TP,^YP&W
M7"_6K;7IH9+FZG6"W"$E5-*4H2#05-=P-S6G:N6 A!MVW3(KY3\G+KEU*9^3
M63"A85'1JA34G?8??UR4I4QC&T2+LPA#%\+J:UV\/EG5M*\OV&DIZ5E"L:^P
MJ33<58U)IVWS';0 $.\C2'DYJ3AABR6YL5=FQ5V;%79L5=FQ5V1;S]Y6M]8T
MZ:0J!<Q(SQN!O4"M.U:TIOTR0+&05[.Y-O('ZK4<AXCOD>_)#5KBYL9[&<U6
MU=>%>P<';Y KMMWR4V,"C_,<$:3B6$U$J\C\Z_Y]\Z5E;8E.;%79L5=D.\Q?
MF);V(:+3Q]9G #<EWC4'Q8']7CURP0:Y3KDO6.O7885IY,U'S),+K77,<88,
MB BJ@_:0#?C7OO\ 1DN*N3'A)YKEF]/9.XH3XY.].TNWTZ(0VR!5  KW--A4
M]\I;0*4SO@K%+6;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V)0_:?_6_@,4.Q7%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NP
MHUSS%'I2\O3>8C[0C ^$'I6I'?\ SZ9("V)E38%?;$M+2^O6]>]JD)W$3*O@
M*5I6@K78DGWQ0++L.8H4B%(P #X>PI^H9%DUC\4NS8J[-BKLV*NS8J[-BKL(
M=5\YV&G\UY^I*FQ1 3N1RZCV^[OD@&!D V%)PN>[US6#QM@+.%DY"0'E6NZT
M) Z]Z X=@QLEVV";?R+;/,+O4&:XF)#,&/P\A]U0.U?#Z,C:>#O<&(Z9(5CB
MMDHBA$'910?<,#/DUD)^L7OFNX6:U2,65M,ZGU*_$*=:=:^%109,;-?U+RH6
MH;J1M3)G8:?!I\0M[90D:] ,B2V 4MP1@2UFQ5V;%79L5=FQ5V;%79L5=D5_
M,;S$FD:7*JL!<3J4C!]]F/M0';WR0#&7)7LH/7E5#T[_ "P+^5/E\Z5I7K2*
M4FNF]0@]0HV0?=N/GAD;1 ;*FI71N92U>04<0:4V_MR:9!FA,+M;UZUT6 W-
MXQ"UH H+$D]@!_M9*,>)B33:J6-!D,.NZCYTC,.FHUO:,W%W)'2AJK=Q7;8=
MOHR9CPM=F7)49/18AJ$C[L/O+7D2STF.LBB6=J%B=QMT V'P_.N^^1,K91C2
MUY&>@/09)L@V+,V*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[$H .3T_F_@,4!V*XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M8E-<Q0?WKJM:D5('3KBBW83O>W>H3K';H5LV+*9*]:5%?]7PH02?;"QNW896
M&FQV:!%)<J .3=33Q[=O#&V0%.P7@2[-BKLV*NS8J[-BKLV*NPCUKSA9:6*$
MF:4@D)'\1V^73QR0BQ,J; KA3^CM7UR59IK@PV3*IX(I6OB*-OOUWJ,/)A1+
MJBE*;X>67EBPM&,BQAY#3XG^+H .^W;(VS$0[#; R:RF<**L:8U:NR%:FESY
MAU6U6U8I:0#UO47=2#M0@C[5>@/;Z<M^EKYE>I 5JBI.P]O?)C;6R6Z\8P!4
MU8@4J:4J<J9@+,5Q2[-BKLV*NS8J[-BKLV*NS8J[ NIZE#IL#W5R>*("?<T%
M:#Q.$()IL"IH.^<V\N:*_G#5I=;U-"UFHXHC=*BA"BE*JI[]^_ADSLU <1M%
MR7'HPB",T->3$=>X_5G4\K;D'D.U+\Q[2.\&FV@,LK$H)!3B'V ^8J<L$+:C
M-4$+%2_884:7^7]]J5TM_KLC<EZH=^0!.U0_PCH>GRR9GW*(WS;,P"E$&Q\:
M5SH%E91V40@@'%%Z;UZY23;9R4L$8$NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ*$#D_\ K?P&* [%<4NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NSE7F/\Q-6UK6SY5\HA8Y8FI/=. P4*0'XJVWPG8]2
M3T\<E349$[!Z;Y;\@Z3H^ACS=YR,C0356SL(CPDG;<JTDE"8XR 36E2/B'97
M7UQ/._E>VDU2._AU:&%2TD,EN(FXCJR^D=Z=?M=.V.R3866EYY$\T7<6GMI\
M^@>I1%N$NS<1AR: S),@(3Q*L*=3MDK_ "\U^;S!H5KJER099U8MQ%!4,RT
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M D"".)0B+L%44 ^C S:Q^*79L5=FQ5V;%79L5=@34M6MM-C]6[D$:G85ZD^
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MH.F4-B&R\5=FQ5V$-]YOM(9%AMB)Y6<+Q0UV) )! (-"PZ?33)B+$R;H>O;
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MM/,=]\)'^CO\A^]3;#)A!,_SJF+^5=! E0@(M4%.1801_'\.W>GCN*[Y+_\
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M4:(5)I]E234^&^2#R?H6J7&JS^9]>CB@GFB6"""/XC'&"6^-Z;L3_F-@*RR
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M6;RQ5KP^M ;&HI]K:@-.G3WR-A-%:8;;M*>G\A_KC#H.J0UGFTHE5%26NU%
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M]JX:8F07I$[_ &03\AD=E_,>XOW,6AVC347ES8&GN./P[U\"?EDN%AQ7R7&
MJ*N0-^E:G\,2BM?-^J R321VJM]E!M2GC0%MR/?Y8; 7<MOZ0H$J?$G;%;?\
MK4E/+4KJ6:H'( TJ1T-37I\NN_?'C3P->N0:H /HR0V7DS2+,EH;9*ML2U7J
M/#XZ[9"TB("QI&8 $F@Z##>*%(AQC4*O@!3 S6X_%79L5=A=J^O6FDISNG .
MU%J.1J:"@)\>^$"V)--@$],A>GZWJ?G*:6"#_1K2)J%P#4K7W%&)'R&6;18
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M4ZERVU>P P<21!KUWIQ!H/;;))9^6;"T">G"I,:\ S"IH>NY_P QT&V1MD
ML))ZX9JH4<5% .PP,FLO%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M8G"*,_\ K?P&* [%,4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLA'YF>>;CRW%%!8Q\[FYY4<]$ I\5*&IWV\.I\,LA
M&VN4J3#2=/CNR[32"-(Q7I4D]AG*[3S3>)*U^\"W-T""9906.^PK4A?A)%
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MT.V*'9YZ\W_F1YL\LZQ<::;];A;9E(K!&.2D!P#1 >AH:'Y9,!J,B'O7D_\
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MB3.__*"*XT$^9O+6HQZE;0JQN(WC]"6+B Q'!G<,0M2:'H/AY89?F!^:47E
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M<O\ %VMS:C$"EJH6*W0G[,2"B[=N1JY'\S' WYL?ER?.-FC6K!+ZV),1;[+
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MJ?[, %K*5,'L+#ZWRJP0+XY++>4RQK(RE"R@E3U%1T/RP,T)CZ]QBEV<OO\
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MF(8\>0B2-G('?;WPIM/^<A+1M0EM+VREMH(PP4FK2M(IH(_25=F8[?:V\</
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M.2UJ@5VC;<)RY)(A7^5F-:=OE@#*8ZI!^1'FZS@DG\J:RBR6>HD&(2<?3]8
MKP>M-I110W+X7"D4^T ?ES_G(R&"U2'6;>1YT51ZL15N9 ZL&XT)]JXTHFC]
M4_YQHU2YN)3H<T30@L?2N"T<B#D?A/PLK<1^U45ZT&3[\LKW5-5LYM;U?G&;
MV7G# 341Q 43B.W+<GQZ]\!91WW>=^?].TO2=0&EZ/*+F.TC6*:X4U6:;=I7
M3_(4G@M.H6M36IWE7\QXO,&H2Z<L+1\ 61B:U -/B%/A/T^W7$A$9V4EN=/>
MWB29B"'\/OR98&Q"9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=G&/SZ\_0BV;R
MQ9.QGD*&X9155CJ3P)&_*H%13I\\D U3/1[#^0/D=Y;L>;KY8_JEF7%JDDB)
MZUTJUC #LOPH3RY5&X[T:G3O*%YIMWI<$FBL'L@O%" 1T-#4$ UKUJ/? 6<7
MEFMZ7=Z5>S6.HH8[J%RLBD@T;ONI(/S!ID3_ #SN],&@O:ZA)2X<AK=%%7,B
M]*#^7J"<(8S97^3,.I_XB@N-+5"L5?K#2N$C6!_W<AD8LHIQ;8>--CD*_(S\
MP5TL-H&J<HX6)D@D8-0,:<HSM0#]H'8=:]<)#&,J9;^?/E6TG9?,^F7-O*6X
MPW,<<L9:J@*DRJK<B'&S;5!'*IY'COS36Y\I^<K;S3'"98) I]N2KZ;KMT/"
MA%<1NLMBB/RPFLO-'DG4/)T]W#9WBR^M$9B$!4E&7XB=QZB4>@JH8$<OLXS\
MR?/]SYRT.5]/L9(M*AE3U;B:@):M J**]R*FN(%(E*VOR\\CV_D_S+9I>7\%
MUK$B.;>"SDY1KRC8<KB<\57X:D(O+EU8@4#2+\OKNYU?R?)H!L[B*5;.94ED
MCXQ2%RX0(U:D[CM@+(<F.?F/!:Z'YL.O6E[;7J27OUDI;R&1T(996#G@L=2Q
M('%CT]LAGY1>;M4\OBZT2ST^6ZO965UC/[L1D"CF0L-AT_5A(8Q-,[_.;RII
M6OW4/F2YUFT@TY8WA+QL)Y).+.\8@BC;XS5^+<G4+U)QWGCS#9WOGBWU!@_U
M2Q>%9I$1J QL69MAR/$FGT;8A2=T#Y$LKFU_+Z\L8+FS2]U1Y/0@EN(5=D81
M1L.,KA59@K4V#=#6O&DV_/+S%:7&@BQ@E+3W/"9(U#5:,&I8[;#_ %J8 RF6
M$?DC;F/S+:ZA+Z:6MNSAY)F145GC=(]W(!/+I2I[TVP'^65O9>;?)3^5V+)/
M&KAR5:BEI&DC<'8-O3:O;?;$[+'<4GOYJZU<>6OS"/F2T:&=1)#-&8Y%=758
MT1T:A8K6A4U /<=L(/(_F2__ "MO9=$\QP.+"9RRS*"RAM@73^92*5'483NQ
M!X4\\^Z#I?YJVD/F/RK<PIJL2+#-82ND4A45X\6<J'=>E?LLH%.)7@32ZBN/
MS6U^VNK>.2#1-.XL6F2AD;ER95'?D !UV&_L1R3]12?3KNQ_+'R]?6UP\%[K
M^LQR6_"VG21;6+AQ+2/'R D)<T45V ^(;X&_YR%U&#49;;2[)'FO+0NT@1&(
M175: FE-Z#ITIABLRB?^<<U72YKK5=3N[:STV=/JX$\Z1M)('C8E$8\OW:$F
MO3>F^].J>0?,D7F'1[>]B)Y!%24%2*2*HYC?WR);(FP\K\U^7W\O:G<:7(Z2
M>B]%>-U=70_$CAD)'Q*0?$=#0[9Q;\[=96\\S6[6:&X%G''5?3+ L'+E>FXI
M2O;)!JD=WL/Y(Z?:KY8U,W-[;6+:@SVW.6Y6-E3TB.7!F ^VU*]2*CH<E/YP
M_F5,FGVUIHA=?KREVE"LK*@_9%0""W?O0>^ !,I,3_)_R3IFIW]U=:]-;B+3
MBH$$DJ\)G8LH^,-0QH5JQ4D&JCH<C?Y7^<-)\GVQ=["]GO9MY)4A! 7LJ$MT
M\>F$A$2 R;\P?+VH>>+P27&M:+;VEJ#';P/?*M!MR;B%^T]-ZTZ!1L%R6Z3Y
M@N?S(U*[T^>":VT,V;1\95H6D+K1_#DO85/XX.3*^)BNN^7[#R#865]9:C;7
MOF(W8F5[*=98H8HA558#]MW(.^U%H.]>?V.M>9ORKNY=/$7.U9RU)$)205XB
M177<5 \?F,ES8V8O1-2TSRC^:MM%JC7<=EJOI*C(LH4HP7DRM#.1ZB*2>+1E
M:CJ=CQG_ ),O==_,"]@U/6H$M=*LI/6A0*RF24?8;XC4A 3OL/8]HG9D+DP#
MSOI>@>2;!M*T2_;4-8NU5+N6,HT"0UY-$I6OQM(J$[FBBE14@Q;SMH>J?EUY
MA/F/1D:2SG8L21R4,YK)$_&A )W4_P!,(W8D465>3M>T?\P_+:^5?,ES'9WM
MB%%O(6X%DC3A$WQ_NV9 2K)4%DW'Q#D&^=OS&U7SKH4JP:<UO8QLAN)6/*OQ
M? L=5'[76E?HQ I3*UGD_P C:7Y$U^WN+K6+6YU \_JL<$@"HX7XFNY"P$0X
MD\5K\3=30$'H'Y)WEZNCQ:;=6$UK';J>$KT"R<F+[*:-W\*>^ LX,#_-Y;>?
M7+C4H-1AU!KJ1G;TN1,?0!6;CZ3#LI1VV&X7.BY%L81G$H-7U_RIYDU;4QI\
MUUI=Q<!9/3%6V%4=!W^%M^W8G)M-T7L,>E>6O-?E71=).J6UAKUK%<E?7'&)
MD>>1_2GGW$9&[1U/[7V?C!PZU3\\[*YA-GHMK=SZA.C+$AAV#TVY#E4@'K2N
M"D\=I'H?Y-W,KM=:S?:?9Z7;LIFF%Y#(2E?B])83*3(5!X*P'([8*_)OR'<^
M4;"XNM57A>7#<F13SXHG042M6.YVKV'7$E,12G^<WGZT\W:E"-*#C3K*!8(3
M**._=G;P[ #P%=B3G/=2FNKSSU_B&TL[JYL8[B'DPMI#0*B*WP\00R]1W[X>
MC#F6?Z5#:/\ EP^@-J.GV^H,DKF)KR,,_&;U47D'9/BXD<=NU2-\GGYY7NJ_
MH6*72C2SD8?6.JNRM3@E#1J-4\AUZ>^ ,IEY[^32Z$VK2+K]0YA<6C%0T:34
MJLDM:BB $_$K+W;89R[3//\ )H]V+>70+/UTHO#T&66G85/+?W(^_+.%C;T?
M5?RVMM<TR.>?S9)+8$LW.XG66$24J24:92A))'1FW]]^C>4OSYAOKAK/7+4V
M#<"Z$<WYD?LA G*M,B8,Q)@OG3\FTT>P75M!U*'6+19!%</&$186;CPY-ZKJ
M58M3E4 =_:+>19KVR\W3Z[>Z;?16MTTQ4BWD;CZC<E+ *33Y8"P'-F'GK2;.
MY\DV>BV.K:;<7MAZ,LL8NHE)HD@9(F+*K\.?C5J;;T4G?Y]+>:Z(-,TVQO)Y
M;=R[2) YCHR] _<_1@#*6Z3?\X\2V6A7L^OZM?6MI:&$P!'F7UF)DC;:$5?B
M..Y/'V/7 _G/1[_S7Y0LA;VMREYIHC$L$L3(S@)P8H& YTI7;M[[80@[A=^7
M6L:?^7OG>Y2[NK=K&Y2:&*[@D$L:*[AXG)B9R*\ K*35>56VQ'R_YL\T:]H3
M>6].THJT<)MWN')1 H7B5HP'[SCM3E[TQ4$D4UYI\E^4] U,:[<ZXEY!+-ZZ
M6MH$GF/Q<BKR+)Z:J*_:.[#HM>CO^<?_ -*6<T]FML4LV>LTDBD%652 JG8$
M\J5Z[8E8<T'^?^I6VK7]IJ$=Y!=R-:J@^KL& 7DSCD.J'XOLMOV[5)%Y7LO,
M'D'S#/:6U@]W-.KP0M1A&P+!ED+ 'X12K"HIW(QYH%@LI\S3^6?/?EJRU"XU
M6*P>R0-<6QXF<NJ!)$AB+KS+E5*'ION00V3G\UORPU#S-:VVI6PB;6(8PDZI
M\*2#J0A<_LM7CRZCKV& %E*-L/\ RE_,VP\K7ES87ZS?H2Z?G&:\I(7%523X
M>%:QGC)QH3L1TI@33?SEU2*R_1ESI5U)KR#B$6,A&[!S^T/?:G@1V:1Q]%;4
M?R=T@WGUJP\P:>- 8>H)Y9@9U6@)C-N*.TP!V6@K3?B3QPW_ "L\CMY'TV;4
M]261[ZX ,L<:&0J 3Q5%C!8DUJU/X8DVRB*2O\U//X\\ZC;V.FHD.EV7[FS#
ME8SQ(12\KL0@Y%1X!1MD%_+BZU32O-%QJ=YIEXMM>-)S_P!'D8Q%VYJU M?8
M^QPE@.;.?S,TC2]1\I6-M;ZKIL^IZ/%&I6.XC!D3B$D5/BHS(0".[ &FYH?0
MV0;W@F<D_P"<A/+D-W86^J1DB^BE6"-5%3+ZAV04WJ*<E^G)!JF'JW_./.NR
M6NKSZ7.%.F74$DEV[K58D@1I/4;P7]AJ]0U.M,Z%Y.T!- TJVT]%"O'&OJ4[
MO0<B3WW[X"SB*>;Z[JLFKW]QJ,H >YE>4@"@'-BU .P%=AAS@9('-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[$H?M/_ *W\!B@.
MQ7%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKL1N[*"\7T[F-)4ZT=0P^XXHIL&FXP&/+
M&E#I9V__ "*3^F&T<(7&5SU8_?@^*%(4$<2A444"J* #V P)6843^2-"N)&G
MFT^U>1B2S-"A))W);X=_IPVB@G-IYTURSBCM[74+N*&'>-$GD54_U5#4'T8.
MM='LK2 V=M!%%;FM8T150UZ_"!3 FDMO;ZXOIFNKN1YIY#5I)&+,Q\2S;G$=
M(\M:;HW(Z;;16YDH&,:!2:=*TZ]<5 I$:IKVH:MP_2-S-<^F"$]:1GX@]0O(
MFG3M@5O(N@.2S:;9EFW)-O'4_P#"X;6@F%OY_P#,5O%'!!J=['%" (T6XD"H
M * ( U%H-ML-(-/M[> 6D,2);@%1&J@)0]1Q&U,"TD<TSSNTLK%Y')9F8U))
MZDD]3A1!Y T"WN?KL6GVZS;4(C6@IT*K3BI]P*X;1PA-I_.>MW%LUC-?W3VS
M;-$TSE#7Q4M0X?X&238%MM*M+61I[>&..63[;*H#-WW(%3BBES.S  DD#I[8
M*Q2MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[**@GEW&V*NR\5=FQ5V;%78V2
M-9!Q<!AX$5Q5V81*%X  +X4VQ5V.Q5V,6%%8NJ@,W4@;FGCBAV/Q2[-BKLV*
MNQK1JVY )H1OX'KBKL=BKLV*NS8J[-BKLHJ#0GMN,5=EXJ[-BKLQ4,*$5&*N
MS8J[-BKLP%-ABKLV*NS8J[-BKLV*NS8J[-BKLY#^<FE>8)-1M-3LXEN]-LP)
M/1-2HD6IYR*I!8=.^WWUD&J;TK\LO,/EJPTG4-.U5KBTU*^I"+J)5:ENW'U(
M@&^R6WY?S#X>2]Q%C^>,DD;?6=*F6<=%C<,&^DA2/N.'A7C2'4O)VG13(MCJ
MUM+;L-WE22,J?\I%638]B&/O3!FC^6]4\U:Q;^9=>MDT^.R+>A OQ2N2*<II
M-MEVXBG]K=,@+W3#4M=TGR]H]WY>\OW$FH-J1B^M7+HT406(K*B01%N1;G]J
M20#84514G.E9!FP/-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[(5^:.OZ[H]G
M')Y?@61G8B61AR],;<:)WY$]=Z?3A#"1(9)Y&LO+]U<R?XHGGAMD0E%MPO-W
M[+S<%4 Z[C?"#R[HWF+SC>VNK>:HXK:TL7,D-NBNI>0?9D8,2:+VW^CK4\F(
M!/-D&N>8?+GERRN=.\EM=RW&H((KBYN> XP;.T$0CZ\VIZC&FRT448G.J9%M
M>=YL5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MB4/VG_UOX#%#L5Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ*'[<G^M_ 8H#L5Q2[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NQ*#[4G^M_ 8H#L5Q2[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ
M*$_$_P#K?P&* [%<4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL3A%&?\ UOX#%#L4Q2[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NQ.'[3_ZW\!B@.Q3%+LV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[$XJ<G^?\!BAV*8I=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78G#U?_6_@,4.Q3%+LV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[$X?M/_ *W\!B@.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[$
MX11G_P!;^ Q0[%,4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL9%U;_6_@,4.Q^*79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V)Q=7_UOX#%#L4Q2[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ.(U
M+_ZW\!BAV*8I=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78G%]I_P#6_@,4!V*8I=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%78E"*,_\ K?P&* [%<4NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL2A
M^T_^M_ 8H#L5Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ.+J_S_ (#%#L4Q2[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NQ.'[3_ZW\!B@.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[$H?M
M/_K?P&*'8KBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B</VG_P!;^ Q0[%,4NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKL3B!Y/7^;^ Q0[%,4NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL3B^T
M_P _X#%#L4Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ.+J_^M_ 8H=BF*79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V)PCXG_ -;^ Q0[%,4NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL9&/B?
M_6_@,4.Q^*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)Q?:?_ %OX#%#L4Q2[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NQ.(@EZ?S?P&* [%,4NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL9&:EO
MG_ 8H=C\4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL3C/Q/\ /^ Q0[%,4NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKL9']I_\ 6_@,4.Q^*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)Q&K/\
MZW\!BAV*8I=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78G":L_^M_ 8H=BF*79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V)P]7_UOX#% =BF*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)PCXG_UO
MX#% =BF*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)Q?:?_6_@,4!V*8I=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%78G#]I_P#6_@,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[$X?M/_K?
MP&*'8IBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B<5.3T_F_@,4.Q3%+LV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[&1_:?_6_@,4.Q^*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)P_:?_ %OX
M#%#L4Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQD8')_G_ 8H=C\4NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKL3B^T_S_ (#%#L4Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ.+[3_/^ Q0[
M%,4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKL3B^T_^M_ 8H=BF*79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V)Q=7_UOX#%#L4Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ*$49_\ 6_@,4!V*
MXI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%78G%U?\ UOX#%#L4Q2[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NQ.'[3_ZW\!BAV*8I=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78E *,_\ K?P&* [%
M<4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKL3AZO\ ZW\!BAV*8I=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%78G#]I_];^ Q0'8IBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B</VG_UOX#%#L4Q
M2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NQD?VF^?\!BAV/Q2[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NQ.+[3_ .M_ 8H=BF*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)Q4Y/\_X#%#L4Q2[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NQD?VG^?\!BAV/Q2[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ
MD75O];^ Q0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78G"=W_UOX#%#L4Q2[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NQD7VG_UOX#%#L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B<75_
M];^ Q0[%,4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL9%]I_];^ Q0['XI=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%78G%U?Y_P&*'8IBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B<1JS_ #_@
M,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[&1?:?_ %OX#%#L?BEV;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=C(^K_ZW\!BAV/Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQD8H6^?\!BAV
M/Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NQ.,?$_S_@,4.Q3%+LV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[&1]6^?\!BKL?BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[&1]6^?\!BAV/Q2[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NQJ=6^?\!BKL=BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[&(:E
MOG_ 8H=C\4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL3A.[_ZW\!BAV*8I=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%78G$/B?Y_P&*'8IBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B<1JS_P"M
M_ 8H=BF*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V-3JWS_@,4.QV*79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V-3JWS_@,4.QV*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V-3JWS_ (#%78[%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V,3JWS_@,5=C\5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M8U.K?/\ @,5=CL5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R+[3_ .M_ 8H=C\4NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKL9'U;Y_P !BAV/Q2[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQJ"
MA;Y_P&*NQV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL:G5OG_ 8J['8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NQD8W;Y_P&*'8_%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[&IU;Y_P&*'8
M[%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[&1FI;Y_P !BAV/Q2[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NQD9J6^?\!BAV/Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQD8W;Y_P&*'8_%+LV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[&1]6^?\!BAV/Q2[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ.
M$_$_^M_ 8H=BF*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)Q4J_^M_ 8H=BF*79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V,C%"WS_ (#%#L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=B<0H
MS^Y_@,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[$XF)9P>Q_@,4.Q3%+LV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[&1]7_ -;^ Q0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R,?$_
MS_@,4.Q^*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V,C^T_\ K?P&*'8_%+LV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[$;<U:3V;^ Q0'8MBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F)IBKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[..?FQYPURP\R66BZ3=FUBN$BZ1HWQR2/'RJPJ12FU:;>.2 :I
M'=[%^5/E'0+WROJ6NZS8?7I[)Y&6L\D0XQQB3A2+^8[5/;I2E<Z+Y=T+4M.D
M9]0U*2^5EHJ/%&@4UKRJBU)[=:?A0,P"'F6M:Q:Z@$%KI]O8\2:F!IV+5_F]
M>:7I[4]\Y[JWY@Z]YLUEM&\D,L4%L2)KF105)Z?M*U%J*"@J>O3#3#B)Y/1-
M&_+_ $'RKH</F3SWZLLFH"ME8P-Q=DH#ZSN.FS A>P(K4GB+U?6_/ODNV:_U
M(VVJVO[1C0AHQ3[3<$3X???Z,=BI)#6D^7_(WGR[BTS2&N=!U"7X8UG99X)6
MK0('+*ZR/VK\)/PC<@'I/E+4Y]5TBSU"Z"K-<01R,%Z590VV LP\]\VZ1'HN
ML7VEPLSQVES- K-]HB-V0%O>@WR,>6=/\T+K<ESJDA^H_'MS!1OY>" GC3Y
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M_FO8^<:VP0V]\B\C$QJ&&U61N]#VZX"*91E:3_F'^5NI>275[EXKFSE8JEQ
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ML2<GDY+4J@))]L;I_P">.K:5JDMGYKM4@B0?$L2MS0TJO5B&##&EXSU;U?\
M*'2-1TZVG\E74U_=2M0F?A%'(!\+E P5HV1NJN3\.X;Q?K7YP>:;#AJWZ+6'
M1I6 0RAO4*UZL58<2W:JT^>-+Q%4T3\K/*%^DFCKK9G\P!6(,('U7D!]E79:
MRJM/B9#NNZK\)SK'EW7[;7M/AU6T)]"92PY;$4)# _(@C(MH-O*]:T>YT6\F
MTV^7A<0.4<5J*CP(Z@]CD!_Y6/KOF6XFC\FVD4EI;LRM<W)/%V'[,:H13Q%2
M:^V2IKXB>3.D\A:#Y8A@E\\W5REW=1I*EC8QJ9HXWW5YI)J(IV/[L58;5IN
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M@A6T,I4PAP292I;D7=_Y10"E,GF!L8CG#/\ G)8D2::1X7'_ #+R<6J;V_\
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MMN;6V,RM\05!/*'KQ[4!.WCA/^27E'R_YIM;FSU:#U;N%UD4\V7X"*;<".C
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M[=1U';)_Y#_-%?-\TN@ZQ9FUNFC8\#7C(AV848!@>)]Z[],B121*]GGWG_\
M+%?*=M;ZSI6I0ZG82R&+UH" T<RCEQ8([CINI#?0-JP1_*?FS\N-1FN- B-S
M92,*%5$G) 2561!\8(KU'T'#S:Z,6=3><O*?YCZ9:0^:KF2SU2V6132JKS8*
M6E1@C1TDXBJ-QH:T/0F2:/)YO\]W5O%KUJ+'1X9%EE"J4,I3XD4B1F8KR'8
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MY!345[T) V^C(-SRG(Y^9GEZZ\PZ!=:78\?K$WI\>1H/AD5SO\AA")"PR?\
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MS7BO&6N,?\Q^[+7SCYD(/^A1U/39O^:OZ8KQEOC'_,?NR_\ %?FBO^\<5/\
M5;_FO%>(NI'XFORRQYI\TG_CRB_X%O\ FO)4%XBZD?B<?_B3S4>EG%_P+?\
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MMZGO3<?C^L8KZG?#[YB_FJ12M+="?V@-Q]Y(_#%?4[X??&)#YL3K+$_S5?X
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M\VC_ (^HS_L$_P":<.R^IQ*^'XX\6GFSO/%_P*_TP;+ZG;>^6++S6>MS$/\
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MXD>&[ZRW@,I?RB8?\?)^[&U\-QN">P^[+7\HR!07)'T'&U\-KZP3N0/NR_\
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M<&4O6$]B:F5C="]7:61T:" R-34P/CYS=')E86T-"O_8_^X #D%D;V)E &2
M     O_; (0 !@0$!P4'"P8&"PX*" H.$0X.#@X1%A,3$Q,3%A82$A(2$A(6
M%Q86%A86%QH:&AH:&A\?'Q\?'Q\?'Q\?'Q\?'P$'"0D3#!,B$Q,B'QH:&A\?
M'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?_\  % @,Y GV! $1  (1 0,1 001 /_$ :(    ' 0$! 0$
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MW$ZA#7Z:??3#3'C"<Q?EKYGF!,>DWS &AI;2G_C7!>D?F)H&KS_5;*^ADFV
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M8N8_J\/U.U&U)+F8J1^T.7I !RI!V^+JN=4L+&*P@CM+90D,2A%4=@!09%L
MIYA//)/(TTS%Y')9F8U))W))/4G"/\P?-0\KZ-<:FM#,H"Q*W=V-%V[TZD>
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MIZ=3X^&V%C5FV2:/YTET[0=2\N-$)8=1:!PS,?W3POR+(O2KK\+=-J?+(?\
M\Y&VL3:-;7!13,+M$#T'(*R2$J&\"0,,6,V7_P#..]Q)'K5VJN1&;"=V7<JW
M !@64=>/44WKTR+?E/Y[F\J:@WE?6R([5I"JL[?W4G\M>G!ON!WPD,(RI.OS
M(\HP><M)7SKH:N]TL0>[54^&55)5YQ3<2QD?OEWJOQUV:OH'MMD&]XEG)_\
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M*9%5E,9XR\0/68,>/+BJBI-3QSI7E7RHGE/R\=.7]Y*L;O*0.7.1A5J"FX[
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M6_D]^9K>4KOZE?.RZ7<.&8J*F&4;+<(.NW1U'VD\2!A?^27YFK>6H\OZD_\
MI5NM('8T]1!T3>GQIT]Q\L,@L)=$?^=_Y<G1KH^8-.C5-.O'):./=89" VQ%
M5]*6O.,C;JM!Q!8;_P XZFFBW<9-2M[)_P 0CP290Y+?^<A"CZIIDT:",2Z3
M:/1:@;AN@-* =*#P\:YU7(MCRW/.FB/]9_,QBX" 7EP!QVW1' ^EJ;Y/HT#F
M]ZO;1+7\K6$3L[/!;O)7MSNB0.GV12@WZUST7D&]X+G"_P#G)@?'III^S/O_
M ,B\G%JF]R_YQA<"345Y=6M25/0J&DY'^4%=J$YV/RU7]%VE10^A%M_L!D2S
MCR>'O]HTWWP?*:*3['K@9+<Y;_SCE'3R]*]3\=U(=^GV4Z9*37!ZK_SDM-7S
M=);@*%M[:WC''[1' /60CJU6Z^%,@OYP?68_.T36BJUR?JS0C<U8'X0P_P!8
M?=A#"7-E7Y.QQ_X%U&2ZD=+$2W2W!55+!&@B5O3K^T5/\.^)_F!YW\S3W(T+
MS*RV%NP4S+; 'E&3]JO)B?\ 5Y#$!22O\C^4/+,-M_B7RE#-JMY&[1V\=_Q1
M(IU7FGJ*G%:D?98L5K3[)!([)^6_DO2O+FGA]*8S"Z"R&9Z<G!'P]*?".PR)
M+9$/(_/_ )YU;S??_6=9I&\(,:0(I1(M_B"H22"6W8DDD]>V OSO:GE2\'B8
MA_R53$+/DF7Y*+R\VV&]*-(W6G2)SU.0#\JO*^NZEHK3Z-J[6,33,IB]$.*@
M"I#$U%?;)%KB"67^?O-.@:=KLEOK^@IJ$T<2 R+=R0L_-5D1F]*JGBK<1U-*
M5.U,.K3RSY@T_P Z:;=ZU<MJ$+).$F"<50B-JJ47X4+"F_?Z,'1E1M 7OFSR
M[?\ D[4[#0[1=)N6N;>1X7N#*T\8+4X._%F]-CNE-A1MSR.=@R+:\GS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQJ'=OG_
M  &*NQV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL)?.XKH6H@&A^J3[_\ /-L(0>2:>5I%
MBU:RDD3U$6XB)3^8!Q5?ISF/_.-+5M;\=^<7ZFPR:X/1/^<DHU3S!%Q7B#;]
M/ ^K)6F=HR+:\GSS]^5%?\>7O(U/^E;BIK^\'CDBX\>;W3\SFK^76DT!5?4L
MOA8 ?\>LFX V(8U->N^^2O\ YR- _05N32HNTIU_DDPP9Y.3%_\ G']R-=G0
M _O+*9*CCM4KN>?:NVV^^'_Y*JR^5+'D:U$A'R,CTP2YIAR2+\VY(Y/-.HF%
M>"B8J013XE 5^GBP)]\DFL7%EI$<NN78"F"%@S_M< >7$>-3T'C@9';=C.G6
M$^I7,5A:*9)YY%CC0?M.YXJ/I)R+>;M8?6_)-QJ4<1C^LVOJ>F[4(5MZU'7X
M=QXXCFQ)L,D\MZ6^B><;73IG#26FI1Q%XAS!:.8+5 U.0)&U>W;(K_SCWI45
MSHU_#<H'AGD],U/VD*4*^(ZY9DE;& 9!^>UV4\P0215BNHK:,R  *4EYN^W'
M:M"IJ,A^J6U]^4GF5)K4--9RBJ]1ZD1/Q1D_SIV^@]Z88QXD'TEF]A>6'YK^
M6&M]0DCMM3M#4R,54)*0 L^U.,,_V)*;*]&H=AGHS3M0@U*VCO+9N<,RAE/L
M?'W\1VREN!M\_2Q-$[1N*,I((]QGG;R_+'^6/G)[:])-J0T?,;GTI*-&S=*T
MVY?33)\VD;%] >99KK\T?),>H6:@7=I*GJ1<?MRQ1LLOI$;?O%97"4K7;?X1
MGI&&5)D$D9#(PJ"-P0<@W/GS"WS-YAM_+]C)J%T12,'@A(!D>A*QI7JS=!A0
M328:%HL^M7D=A;4#2-\3M7A&O[<LA4$K'&OQ.U/A4$Y'?S+MY]7\H7?*,P3&
M%96C8@E>!61E)2H.RXA$N2>?ES>Q:1YKL)2Z2Q)=+&9!4(59O3YCU I H>0Y
M!3XT.1O_ )QSU..;2+BR%/4AGYD5WHZBAI]!PR8P9!_SD#HDNG>81/(#QN(4
M()0J 8_W++7H2. /TCYYUK(MKS/.5^1T75O/&M:W!O!"J6H->K (K4[$5B/X
M9(\FL;EZ=YWNY=-\C^7]!D/%[@SZ@\;"A"L[) _CQ=.1'8X#_P"<DE'Z-LFH
M"PG8 ]Z<#7&*)HC_ )QR91KEVLC%5:R8&@J#^^@^%O 'I^'?)U^69KY;TX_\
MNZ?JP%G'DP?S[&8_,.IH>JWMP-C7I(W?;+\^^=X/*-A]<D437#LJ0P<N+2,2
M 0NS?9!KT]NXQ M3*E;R#Y+D\W:D-/646UND;S3W+BJ0QQJ6:1]Q0=%W(W(R
M/?GK(#Y6D]1"':2&@W/$\@3N/I&^$,9\DV_)%E7S7:,Q 4)<5.W^^)?'_;\-
M\?\ D-_RC$7_ !EE_P")8E,.37YV4_Q7>4-1QM]]]_W$6^^^375&LK5?TG?!
M +17<2N 2BD?'Q/45'6G7(LBPZT6XN&%E;<W:=E41I4\VK1!Q'VC4[?/(7KO
MYB71\HKYJL(O09F0\)""1'ZW GWY+^OVR5,#+:V8:+^7'K^;&\G74RR3KZ\7
M. GCZZ0NR+5EK19@%?8=]QUR>P3Q7<2S0LLD,BAE8;AE(V(\01D6;"I8GB<Q
MR JZD@@BA!'4$9YW_.SR=:^7-0M;K1JP/=LS"-#0(Z%>+)3[-:_ADP6F0I[W
M^1WFR?6;.]MM> NK/3[8EY7!9OJS<O5BD_:D514I6I7Y4X^B+0R&%#-M(5'(
M>]-_QR#<'@.*XI=GGS\J95C\^7J4V=KH+38;/7I\ADSR:(\WNGYL1H?(&B.K
M<F468((W%;=^_M3;VV'V<]!Y!O>%XA?!#!)ZAXIP:IK2@IN:CIB@NS@O_.-\
M3-J=ZW6,0!3M7<OMO]!R<FJ'-[A_SDBZ^AI:E.#UG.Q I\,->48^%37P--J8
M%_,WR;<>1-6AU_0N45HS@KQ-!')O6/\ U''\1B#:)"D5^7'F^V\\Z+<^5O,7
M[Z_6*D4C#D[QJ*<QO\4]O]I>[I53^U7M7D7SC!YMTU=2MU*&I21#OP< %EKM
M7J-\B13:#;R#SCY4NO*NI2:7=T8I1DD7[,D;;I(OLP^[H=\Y+_SDL2UU8(5-
M!'*0?<E=OPRR#5DYO5/^<9[TVK:@1(B O:<E>FZ\I>3#O\/3;QW[9VOR]ZOZ
M-M?K']]Z$?/_ %N(K^.5-PY/$YN'-O2KPJ>->M.V#+B!+B-X9E#QR*593T((
MH0<56JQ4AE-"-P1GD^_%_P"1=3O])AJ&D1[>AWYQ2?884[D4RSFX_)]-0VUC
M^8VGZ7K=\X$=NPFN9?@4)+'Q^LHXHQXN '%3TIXYZ._+?RL?+&AVVFR4]8 O
M+3^=SR;[OL_1D"WQ%!X1^8OFYO-^OWFNL.*W,E44BA$:@)&#U^+@HK[X;>8=
M;AT.PGU.Z/[JW0N16E:#91[L=A[X$DTE.B:/<:U?0:99+RN+F18D';DQXBOM
MXG.6?EG^6-IKMB^O^:(!<7>H2-,O)FH$;<&BD;DU/RIDB6N,;YO3?S-_,F[T
M6]B\L^4KN:TT[1HQ:\H3Z9DF0D32ED^(\V]Z=^]28^=OR7T0:5<3Z/:^E?11
MEXBKMN5WI1FX[],05,=DG\J_G%K<>H01ZY?37.F22JMTLQ,E8B0K[GX_A7XE
M .S;CJ<)O^<<_,0,=SHDSGFI$T*L:_"=G"CM0T/TXR6!3K_G(30U6ZM=9ME0
MQRH;>9XE(4RQ$E69N[/$R]:?9]L[7D6UY%G#?^<F34Z8-B*7'S_W5DXM4WN7
M_.,;!6U3]X4;_1:"HXD<WK7O7^6GTYU_RN*:59[4_P!'BV_V R)9QY/$)?MM
MWW.%GYF5_P -ZC3K]7D_5B%ER3S\O^/^(]+Y[+]=MJ_+U5R$_P#.-QIH]TG<
M7-?O1<E-KQLS_P"<B)O6UZ"0,&4VB4IV DE%#[YU6[:"-/K-SQ5(:OS>E$H"
M"U3T^$D5\"<@VO,(P['@E26VH.^_3[\*/)GFI?-%FVI0)PMVE=(JD$LJGCR(
M_9)\,)" ;3'S-Y=N?+E\^EWXXW,2H9%W^%G17X&O=>5#3:O0D4.'DD:RJ8W
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M[$'%4(K%"&4T(W!&$_E+R=8^5+>6STP,L,LS3%6/+B6"KQ4]>("BE:GWPDH
MI//-_G75/-UQ%>ZU+Z]Q#"L >@!*J68<J=35C4X9ZC9F]@>W662 OMZD1 <?
MZI8,/PP)*2Q.$8,RAP.QK0_<0<Y^GY$:/'.+V.ZOEN^9?UEF D+'JQ;AU/CD
MK8<#/9?SPU^:W.GS+:26!C6$6S6L9C5%^PJ_#R^$[BK;'?KG0--LC8VZ6QED
MF],4]24\G;W9J"IR+,!@<\OK2-(%5.3$\5V J>@]ABEU:17<;07"+)$XHRN
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MI!'B/@Z8E+^9?EN(T;4K8_ZL@;M7]FN-+Q!=)^6OFB, OI%^H)H*VLHW_P"
MR112I*@DC(9& ((-00>X.!+&\#:IK-EI,?KZC/';Q$T#2N$!-*T'(]=NF*W2
M,TO1[W5IOJVG02W,Y%>$*,[4Z5XJ"<+8?/N@3R"&/4;5G)H )DW^6^&D<03#
M4/(VO:=$]Q?:=>00QT+O);R(JU-!R9E %3C6_,+RZIH=2M*UI_?)U^_&EX@K
M1_ESYFEC$T>DWS1D5#"VE((\:\,9'^9'EN2M-2M=O&51^LXTO$%3_E6/FH[_
M *'U"G_,+-_S1ASI^JVFI1^M8S1W$8-.43AQ7YJ3@3;'[RRGLI3;W4;Q2K]I
M'4JP^8.^"L4J.;%780W/GW0+65[>?4+9)8ZAE,J@@@T(._7VZX:8\03VT\B>
M8+R%+JVTV\E@EIZ<B6\C*U?Y6"T/T8+TCS-IFLU&FW45P5%2(W#$#W Z8$@V
M@=6T'4-&D$.IVTUK(>BS1M&>W9P/$89XI0&$$_Y@>7[=BDNHVJL.H]9*_KPT
MQX@GNG^1/,&I0BYL=-O)X&Z/%;R.I^3*I&"M(\U:5K+M%IMU%<N@Y,(W#4'C
MMC2@VA-9\MZGHA5=5M)[-I*\1/$\9:G6G,"M,-<#)+<V*NPOUGS!8:+'Z^I3
MI!'N:N:5IX>.*":1%AI]SJ,ZVEE$\\\AHL<:EF8^ 5:DX3#\T?+))'Z1@V .
M[>/AXX:8\03Q?RU\T/LND7Y-2*"UEZCK^QVPQTSSAHVJNL5A>V\TKUXHDBES
M05/P5Y=/;&D@V@=6\I:QHZ\]3L;FU7;>:%XQOT^VHPXP,DIS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ.(U9_];^ Q0[%,4NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKL*O-7F*'R[IL^JW.Z0(2!O\3=%78'[34%<(0328^7
M="N-?U"#2K(5GN7"+7H*]2?8#<YR;R;H]_\ FE.^M>:2?T7'\$-K&72-V'5O
MM5/'N:[G:NU,)V:@.+F]8\Y:OIWY4B+1/)K<M9/[VYU"5(VE0,I401 JWI<A
M\9I\0!'Q'MT6^_*WRS>QB*33X% % 8TX'_@DH<%MG"'GMG^9WFBSE]>'5KT/
MRYFMQ(P)\65F(;Z1D!\@^3CY.\\3Z?&&>UELF>%V-3PYI4&G@P(^X]\)-A@!
M19[Y]\\GSKY#M[^Y9%U&#4PETB*J\V>&0I/1>G)4H?%@W04P9_SD7IUK^B(+
MPQ)]8%RJA^C49&Y=.M>*]<8K,)=_SCOJ-U;Z[-;6\\L44UK*9$C^RY050R5Z
M!":ANO[(/Q'$_P L_P LO+NN^6[>[O;59+B</SD#,&J'9=J&@H!B2L8@AWG_
M /,OS7H7F6ZM[74[N)+6:D49D8IQ&ZUC8E6!!K\0->]<A%Q>S_E3YGDMM/D:
M6QJK-"S?:1P/M=N:_LFF'FP^DLQ4#\X/+?U[5(TBU:W#Q"[6,+R>%#(J405,
M;JWQ_P K_$ !\)])33QPQM-*P2-5+,QV  %23\L@WOGQ5+$ "I/09PAKVZ_.
M#7S8AGBT"S/-E4_; - 3_E/V_E6OTSY-7U%[K!:P_DOH":F55_-^H@I$9$J+
M1.(,G$,.)D4, Q_F/'=5</U=?RV\MK&(AIMKQ44!,2D_2U*D^YR-MG"'EK?F
M7YH9N9U>_+>/UJ7_ )KSE&LRW7Y0:ZC:?S?0KT\VA8U -?C"^#**4\1L:Y+F
MU_27J&CQP?G-H<L6I,B>:].0+!.**UQ'3X%FY&C5:JE]N)*'H6KU;S/HEAYP
MT60*B3K<0<X'H*U*DQLI(J.OZQD>3,BP\CT#7-0\I:K'J%HSP7EI+NM2NZGX
MHW I\)^RR]QMG&_^<<;V"VU:YL)D43RP@JS <@T9HRJ>NX-3\LORAKB=WKW_
M #D8+G5+*RUA9?5LEFD2.CLPX2JLL3!2*"H!'C0 =L./^<B?*T$20:Y!$B22
MN89W ^)B5K&?^%()^60@G($G_(7S;>07,FEO/,T$*&X@M_4(BYJP]2H[? 6;
M;N*]=\GGY.:C;WWEFT-NBQF)3$ZK_.AH2?=OM?3E99QY,/\ S9TR;3O,]_'<
M2>NTDOK+(:GDLP$J=>X5@#[@C(Q^;FEV6OZ]I/E_TXQ<W#F2:7C\8A0&B<AO
M1J/MXC"&,MRRK\G]7U3RUH>N^9K2>6."T@2&.)7XHUQ<,(TEXD,K-"/CI2O0
M5 KAKYO_ "ZAUW5M)LF@*Z1913,ZI14VX!(]M]Z;^PQ!28V4E\G?F9=^6M+U
MB:UG(UK4Y+=!.U6E"'UWN)%D-?C+< 23R^+D-UJ([^>?E/1M&T2*XL+&&&9K
MA(P\:A2 5=OV>OV>^(1(4R?\DO-_F/6M>,-WK%X;:*WFED669Y58 4IQ=B :
MFO+J*8._++\L?+VJ^7K>\OK-99[A2SL2U:AF7X:-MT[824QB"$F\_P#YI>:;
M77[JVM]5NHXK2>2*)8Y610JL: JO$-\V!)Q71?RZ/EZVUZQDB632)4#VRRD,
M21$2Q)[<6( -*[5&"T<-6A_._P"9;>8SHVL^O,/,5I$\=U.BA .,S-;F,+3X
MPK$OT&X]\AO_ #CM:))K$[R1(2EOR1R-U/(#X?F.^$L8<V7_ /.1FIM+!;0+
M=RR*;F8O"TG(<@L9#,H)"L.;;=@:9Z&DC652C@,I%"#N#D&]X9GFGR[I5K_R
ML']'K$$@2\GHG%2 %#L!0[<?X99T<<#=] :_-?WWY;-J=W>&;U+>V3CS< \9
MEC *D@,RA-S0UH3USTP!3IE;D/G_ !"^L8+Z%K:ZC66%Q1D< @CW!Q052WN)
M+:1)X':.6-@R.I(96!J&4C<$'H<\T_DKH5CJOF%[;4($EB2"1A&X!%0RKT;K
M2N6%IB+?1'YO>9=7L_+-K?VE_.));F#E-'(R%JP-(#6,@;G?Z/$9W+5/RM\N
M7\#VYL+>+F*!HHU1@?8K3(6V&(>.VWYJ>:[>9+E=6O6DC-1ZD[NOTJ[,I'L1
M3(<?)MUH_D"\TG6TCD:V$LL00DT /-6)\>53MVV/?#>[&MF3WGGI/,?YA6GF
M#1FFM)+N:U1R_'DK,J02@4J"A6HWZCL.F /^<:[:W]'4+E:?6"\:$4W"T)&_
M@QK]V,E@C_\ G(^ZO#?Z?:S.[VD=LS0\WY[M(ROOOO\  H-=\[7D6UX_G'=8
MTNTF_,ZT4QI\5L9) 5J&<+( 3[T"_=DNC4>;UW3M6NHORENX"\CQ2:LL 4M\
M*+Z:3F@\"XW'2IKW.*_GOY-TQ-*;6X8%BNXG0,\:TYJQXD24Z]J$[]L05F$%
M^1WFS5EU:#R[#.[65SSXQ%MHG5'=98JU",#UI]H5![$$_P"2_P"9HLF7R[K$
ME(R0MHQ'2O\ NMCX?RU_IA(1&2._-7R ;^)_->BPL4 +Z@%(*B0N5,\?BK-7
MF%%$:O[/3N,\4<T;1S -&P(8,*@@]0:]L@VO(@2#4;$9RK\B;.UBEU=[9$"I
M>.D;+O\ N^RJ=]NGSR1:X/3?SSN9[B30I;J226:31+221I?MEV:7D6)W)KW.
MYR-?\Y(VL,=]9S(@$LD,@9@-R 12ORJ<,43YLF_YQKNKAXKVU:9EM$N+24H6
M/$,?5Y%16@9@@!/L/ 9U'3?R\T:72(+"\LX7!AC$AXT8L *GF*-U]\C;,1%/
M(;?S5J=IJ/Z8M+F6*]]1I!*KD-5J\M_>IJ.AZ';.:?F3^6Q\E%/-'E1S:I;D
M"1.18J6/$,O/E537BRG^N2!82C7)[!^7_P":S^>@_E'STAU)+D\H)0H#JR+R
MX5CXD5"_"XJ:U#!E8TZ'^5/GP^;],]2XH+ZW(CG VJ?V7 [!OU@Y$AG$V\W_
M #.\C?X0U0VUNSR6$ZB:UE<4+1M^RU-N:&JM3PK05IDUP,V(YQC_ )R1TV 6
M=I?\%$WJM&6XCD05)H6Z[<<E%JF'KO\ SC9=W8UFZL[>5TADMN;JK\15)8J-
M3H2 2.VQ._8S_P#*^WC@\M:>L*\%-NC$#^9AR8_237 6<>3!OS)GEF\S:H\[
MF1Q>W"\F-20LC*-_8"@R48&3&\X9_P Y*VUNCZ?/Z8]=Q,I?OQ7B0I^ECDXM
M4WM/_.-MQ?BXO8K:X:.V7T'DB%:,3(%#@@BA4>XK7.J>0;=;?0-/C04'U6$^
M&Y0$Y$LX\GEGFR\:]UB^NY/MS7,SGYL[$]</\#)*<V*NP'K,$=Q93PS*'C:-
MPRD5!%#M3%!7PS/"ZRQ,4D0AE930@C<$$=",X1_SCMI]I>W=ZMU&DA6*/BK+
MR%"6Y=?A\/?)EJB+>W_\Y,5KI[<W<^I= ECW'HG:OQ?M>)'AT.+_ )T^2;7R
MW<VFNZ(#:/++P?TSQH_VE=!VJ*@TVZ8@K(4H_E+YZOM;TS4/*^L'Z]9P64DT
M23_%1(RO*/D37B/A9.Z%1PIG8_)VL-K.DVU])O)(GQFE*LOPL?I(R);(FP\9
MO(/0F>+^5B,.<#)1S8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKL3B/Q/_K?P&*'8IBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=G'/^<D]1X6%CIX!
MK-.TM?\ C&M*?\E,L@TY'K/_ #CM;F/4K[4F ]*"T],GN#-(BU![?"&K[;=*
MY./RJM([7RS81Q"@,(<[UW<EFW^9R,N;.')@WY@W\E_Y@U"XE<R$W,JAB./P
MJQ5/A[44 4R0ZE)=Q0EK"-)IOY9)#&*?ZP1_U9%D4EM%A:51<LR1?M,BAV'R
M4L@/_!#.6Z3^=.HZGJPT6+1U%Z'>-JW&R<3\?)A$=A3>F6<+5Q[O3-:_*/1=
M+TDZ\=;,EJT<;P@6E'D:0$K'Q:84(IOOTJ=Z8M_SD/R;0+8/\+&Z2H!J/L2=
MZ"OX9&+*:&_(2X%OKD\O$,RV<W&M-C5-Q7VKD8\H_G"GE7RY;V"V$\LL9=4=
MOAA8LS.?WF^XKTI].$AB)4&3^9?RKE\X>8;S4Y]5L8XWK-)&C\[F.-0%6ML*
M=N/[0%#4GMC/(WD*_P#/FHCS7KDD?U1I2_IJ>18JVT=#7B@Z;FM/G7)$ULQC
M&]T-YI\\:5Y)TZ;RIY9BG-T\?I3W$X"BDB?O'C537FX:@)V5?LU^UG4/S=NY
M+7RO?O"0K&-4)/@[JC?@<J;9<F _E=;1W'F;3EG622-+A)"L8#,?3_>4 .Q^
MSO[9"_\ G&ZVC6TO[@#]XTJ(?]55J/UG)28P93^?]Y/)J-C;RN'5+3U*"AHT
MDLA>O>IH.N=DR+:\MSE/_.1<:G1+9B:$7: #QJCY*+7-Z3^0LKQZU<M&G,_4
M9]QU3[)YCW&&_P"1=WZ_E:W6I)B>5#6NU') ^XX"F') ?G=;K!YNOP@ #&*3
M8!:EXHW+$#NQ/(]R34[YR_SG /(GGJ/4XP%MI)%N0JCHDA*3 #_@J?1D^8:S
ML7H_DF9_.WY?W.AA2;JV1H0>2U<QGZS;"AZ;*T=?Y5ZY+_SYOWU-M/\ +=B/
M4GN)/78"I("@A=AV-6^[!'9E,L(_)^WATV#5/-=Z&^KZ?;^D@ ^W+.>"J&.U
M0M>Q\>V%W_..>N*LM]I4K!6<I-&IVJ159*?\+C)$"FWY^:)Z<&DZI&696@:W
M8G<* QEAJ_[7)9&XGNJ[=#A]^6[_ .)O,>J>:)%Y01LMM:,1^RM0Q6O2H%3_
M *QP%,=S:1_F D>@^7]&\LQ.PN2CZA>H&^'U+@)Z 9:[.D(Z'IRK^UG4\BVO
M.\Y1_P Y&Q Z+;2\F#+=* H/PFJ/N5[D4V\-_')1:YO3/^<?RQUR>*BE)+.4
M/7J%#(WPG>A) 'R)&2C\HP!Y7L*&O[L_\2; 4PY,4_,,G_$>IU 4_7)]@:@?
MO&R1:V56QN#)]@1/7OMQ/L?U8$GDQ\;G/-7Y+ZOJ.D7D]QIE@^H.8@C(KA.(
M+5KN#X9DY6F)I]!_G/INE:K)#'J6J1V 2:<HS0R2AZA V\08_"13<;UZG.K3
M_F3YIMF!G\N3>F1TCF$AK_L$VR@@-G$>Y@,WY?\ E"1:6'FF%Y?":RN(5IW^
M/XOU9S?R)=W-U^8"W,T9BFDN+@R1$[H2KU4_ZN2/)@.;,_-MM9VGY>K;QE)E
M2.W]&95(YEI2S.*T*]66C;[;C/2F5M[P;*8T!.*NSRM^6$^M0:J;GR_ EU=K
M&Y='<*"A8 G=EKO3QRPN/'R?1OYBV^BW&GIIVNW$NGV8:W-O)%"9:.MO0JZ?
M#MQ/:AKXBK9T'7==\T7>O:,FMV?Z/LA=)0)()%>0[#DR';:O%3[]<BR-WNPR
MT\L>4[?RWK<VD7YU75%@B*+);-"8HA-#ZDBARX+5(!(:H6O\QSHGYE-3RYJ/
M_,-(.W<>^ -DN3 _(!IYBTPG;_3;?Q_WXOAOG//^<:D46VH./M&2('Z%;^N&
M3"#.O^<BY9SJ]I%-7@+7DE:=&EEW%.H-!TV\,[1D6UY/G*=44_\ *S;(QQD_
MZ$Q=J;4I* VWT+ODNC5_$]/L$#?E==&60(!K*&-*FKMZ(#"E*?9/+KVW[5-?
MSY8CRI=4Z%H0?^1BX RGR4O^<<EY>>M-%*U^L;'_ )AY<BWYF_EK^D-,B\QZ
M2:7,-NC2J#0.B+7FO3XUZ^X]\D"P,=K7_DY^8$&CS_H+6(TDTVZ<A690?2D<
M!*M4'E"X^&1#V^(=PQ[^2_YC'S)9G3;]R=0ME!Y-UDC[-6N[#HWT>^ AE&2%
M_./\M3Y/OQ/:T.GW+,$ ))BD4*9(6V%*%JIXI3<D'$/^<?[86]EJ4*2>I&E_
M(BMX\54<OIPS1!&_GU.+FYT2X$:Q&70[-V1!0*6,AH!UV]\B_P#SDQ47=@>7
MP^E+L!T-5WY>_ADH(FR3_G&)!(=17@KL'M6H^XH/6!^#N=QOV^G.Z:<*6T0\
M(U_4,J;0\+P%YKLH+W2KNWNZ>B\+\B>@HI/+_8]<(1+DB-/NY;*XCN;8D31.
MKH1_,#49P[_G'%YOTM<HC 1&W!<'J2& 6GWG)2:X<WMO_.2:P"*TJK+,+BX$
M?%JH(Z1EAN.M2M*=*,#7/0V0;GA6<=_YR3-=.LDJ!69C3N:)_;DHM4WK'_.-
MUPUOK]Q(JU'U0AC_ "J9H>3?=VSH/Y=MR\NZ<>G^BQ?\1& LX\F"^?@1YAU,
M$\C]=N-_']XV^2' R2'.'_\ .2]#^C=]Q]8V^B/)Q:IO:?\ G&J9X[F_"H7#
MBV6M?A!,NQ*]SW'ZLZMY(8-H6G%>GU2"G_(M<B68Y/*?,T4D.J7D<P(D6XE#
M [$$.:_CAU@9)9FQ5V!]1_WFE_U&[5[>&*"[/-OY)^:9?+TUT\5C<WXEC2HM
MDYLI5C3D!T!J<NFX\#3Z0_.CRNOFF:TA:^L]-D@DF6M]*8XW#+&Q:.0@EN'$
M*=NI&'VOVGFO\R]0@62PETW3[=JTGJM">KMR"ES38 +M]YRN0H,S<DBTUO*7
MY9Z7>H-2CU?6[V!HJ6@)C5&V]-9:%:%OB=J\J  (-RW;M$TJ/2+*&PA^S"@6
MHVJ?VF[]3OD6T"GA\LK2N9&W9C4X.Q2LS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKL3B^T_P _X#%#L4Q2[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNSF_YY>3Y]>TA;JR4-<6+-+Q[F,K^\"[==@?HR<337,6SS\F_-EGY?U=X]4)
M6ROHC;.PI2-F96CE8';BC#XNX4DC?"__ )Q[\TQ7VE-HQ/[ZS8L >Z.2PI\F
MK7Z,9A&,]$P_/ORE=Z/K?Z2N$5(=04.O$C[:*BRC;W^*O0A@<ZQD&UYGGGCR
M.KC\R+DI0CZS>!J]:?'TI[Y:>3CCZGM_GBZMV_+O3X90_JA;4QE!12U)120M
MUHG*G'O3M7)E_P Y&*3H,! J!=I7_@),A%LFQS_G'UPOF&12W!GM)U4GI6@.
M_P @"?HQ3R/Y6M?-'D.VTVY'PLLA1^ZN)'XN*>!_#$\U L(3SGYAU#RUYXO-
M3MZ)=13L2IJ5966C*P/570T/L=NV0?R!YFOORYUMO+NM BUF=0W<*S;+*A)
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M  WR+_\ .2B :E9M0?% PK4\MF[CI3?Y]<,$3YLG_P"<94<_7Y(V/[EX&,9
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M&_7^];)#@9,?SAW_ #DQUTS<_P#'QM_R+R<6J;V__G&4$RZE15JHMF]1C0J
M[5H:[5\:&GZ^K>2(Y(M#L$EH'%M$"!L!\ V^C(EG'D\?U^X2YU&ZGB9GCDFD
M96<U9@6)!8T%6/?; WGCS@OEJVB9$]:[N9DA@BW^)F._2O0?P'?$!9&D3Y;\
MMS:Z]P(F"16EM+=3.:45(U]R*EW*H -ZL,.[_4K;3HO7OI8X(J@%I&"K4]JM
M08$VEMI:37D@@MHVEE:M$12S&@J: ;],;JIK9S%=_P!T]*?ZIQ4\E'.&_P#.
M,[ 75^FU3%$:'KLS9;D:<?-[G_SDY+ZATYF Y<[K=6Y K^Y*]NM.N=]RDM[P
MS$;N]@LXS-<NL48ZLY  ^DX4$MJI8T45)[#'6]S%<QB:!UDC85#*001[$8JY
ME*FAV(Q3%+6;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R
M/[3_ #_@,4.Q^*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79S?7_ ,DK"ZNCJ6B7$NE7
MK,SEXB2"6-3\/):?00/;)6UF#T+0?SHU&UM(]'UR"WUC28D6-+>Y1:HJ@A?2
ME4<U8#8$\J#89H_)OG8)]6.O((1\(?ZNI<CQ).]?]E].-A:+D\Y>2!*9F\M.
MP;?TSJ4H0?ZM(N=.^['!/D;\HX/+5^^LW5U)>W[\QS8!%^/[1X@DEO<M3?I@
M)2(TAO._YI2>8]/AT*TLK?3]+MG5XXX^3O55*+RE<DL &/8=:FIQGGW\M-2\
MY<([G4DAMXG9TC2W/7]DL3-N0.]!\L(-*8VN_+K\Q-/\F22W(TTWES-$(B\E
MQ0*I^V$58_V]NM2*;'<X;?E_Y-O?*EK^CYKX7=HE?33T0A3D>1^(.U=R3].
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M"FH-Z;U[-6#FH7MQ<>^&'E3\JK+1KIM4OY9-2U)J?O[CXBM.Z*:\3[U)'8C
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M7E$DBLXIUJH-=L46CY] U"WLTU.:VF2RE;C'.T;"-FW^%9".).QV!['##%*
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M"7#*O)B2H*J:#PW).V,E@F7_ #D5IUG8>8TBL+:*TC-K&66% BEN3CEQ&U:
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M94/]E#V)/?,C+)KCN]._-C6-)T:WTZZN;);R>*./ZC#,6$0011\I)T%.8KQ
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M'!-A7#-&-F7_ #DCIEM8:_;"TMX;82V,<CK"BH&<R2@L57:IH-Q[9"];TE-
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M3O+BV.L:&::?J*,5C#%U4J%8-'(WQ,CJP(#?$-Z]LZQD&QY?G#_^<F.NF?\
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MI_CD^C1U>]4+?E#M2BIN*;U-_P"/;_/?MAK_ ,Y-.0FF+V)G/W>GC%E-#?\
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MD8!N(%&CB9J 590@J>VV&'_.3@_?:;1?V9M_'=-OHRS$C(A?^<:)%5-5YMQ
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M'3/)\EZ;/27:WOFC8P&[/!."N*+6$L5JY^T6VH"2=\Z?I-M<VULD-[*L\R
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MI%.^>D;&RCL84MH>7IQ@ <F9C0>+,23])R#<!3YWFE,SM*U SDL>*A14^"J
M /8"F)ZGID.IP-:W08QL03Q=D-0:BC(0PW\#BI%K[6Y:UD$T84LO0.BNOTJX
M*GZ1GG>YTZ:Y\[C06N;PVHN2J@W#E@M.9HQKM^/O7)]&BMWNEKJ*1^0FUY=.
MTMKM(0IF:Q@)J9S -J4,@ #5XTZU4]3Z+L+&.P@2V@Y>G&*#DS.?I9R6/TG(
M-X#PJYG:XE>9PH9V+$*JHM2:_"J *H\   .V+2QB161JT8$&A(._N-QBJEGF
MG\YM,C\NZR++37EBBN+='8-,[;^HW=R3U4'KE@:)"GT'^3D$>N:/^E-2M;2?
MZC=,H5;.$,T?H@R!O350]5J/C4[FM=JKZ!\JZ(='L(K:222:;@OJO)(\A9Z#
MD1S)H">PH,@6X"GA>NZL=6O);TQ10"1B1'#&L:(*[*JH%&PVKU/?#? R0&0/
M\U/S-7R9;I';H)K^>IC4_9 !W9Z$&GA3J<(%L)2IG'Y4_EF_GJ^>.6=;33[8
M*UQ,QW 8GBD8[NU#UV !)[ D.D_E1=>:HXM6\ZWD\\T@#K;(>$<:G?@13N*5
MX\3[GKAMB(WS3R\_-RT\KN]A^7]E#:0)\(O;A!-=2D4_><G!5 U-D"T&YVK0
M+>8_R:CT^UEN/*-U<Z;,$+&&.5^$I4&G*K<@3XU(]L;28]RW2_SSN-1NXSYV
ML[76;<L%:66WC$\<9/Q>DR!5VJ6"L#OW&'?Y*7TM[Y7M7G9GE5I59F))-)&Z
MDX"F'))OSMTRSTWS;?VVF*B6E8GC6,*J 211R? $HH7XMJ9.<#-@V;%79'_.
M7E%/,UO';22F(1OSJ!RKM3<5&$&F$HVK6ET]J_J)2M*;X/T+2(]#L(K!'+1P
M+3DU!7>I)Q2!2R:4RNTC=6))I[X2^2//">:IK\VRCZK:SB**0?MCCNW7^;I[
M4Q(1$VG_ )Q\EW/E7ZC'?56XO+1;IHR*&,.\BHK>_! QK0@FA&V2O S8[FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V<I_Y
MR"T33WT?]*SI6^1HXHGY$;%B2O&O$[5[5R46N8>G?\X^ZSJ%KYCCL+.5HK:Z
M247%%!JJQNRU)!*T8#<8>_DD@7RG9$=_5/\ R5? 4QY)/^=+L_F_4BX(;U@#
M44)HJBOT]:]^N3G S83FQ5V;%79L5=FQ5V;%79L5=C)9DB1I)"%1 2Q/0 ;F
MN*'9#O('G\^;;S4DB"?4[21$@9:\G!Y<F:IZ$K\- -L)%,8RMEGGCR,_E.VT
MP7?-;Z]MC<31N*"/D["-?'EP + ]":9-,#-B>;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78G%U?_6_@,4.Q3%+LV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[ >LZBNF64]
M_)4I;Q/*:=:(I;^&*"B-/L9=0N8K.W'*:=UC0$TJS'BNY]SG _\ G'N$:GKU
MUJ=Z_.[2)I!7J6E;XW^[;Z<OR[-,.;V[_G(28:9I>GZ%I\:IIJ2,@*JP-;9?
M3568_:-9'8^)-<]$90WO"<@7G#\Q_+EJTNB:\DH61#R22%^++_DFF^_0COWR
M0#69#DR[RAY \R:M&NL>7HPQAE55>.XB21)"?@^$R+(IKT-/?)#Y;\SVGF?3
MOTA9+(D#@@>JA6M.OLP^1(P,@;23S)Y>N_+M_+I6H!!<P-Q<(ZN ?]9"17VZ
MCN <X7^0^NZ=HVI73ZG<);J\06-I#Q4_%4_$V2+5$O;?SU\N:AK]OIKZ1:37
M,Z^I]8CA0R.C,D/'FD=:5XG<"FV&GYU^>+3S,UKH6A$7SB0N_I M\=.**A&S
M=6K2O;$!,C:"_)[\N]1\NB[\Q>8_4T>W6+TD:YI%R#,OJ%DD^.@% H"_$S *
M<ZC^5_EN7R]H-O9W-1.09)%_E9M^/^QZ?/(EG$4'E/GK6H=;UN\U&VKZ$TK&
M,GJ5'PJQ]V J??)7@9I%GG+SD#-^9"*: ?6[-:J:'[,>3')H/-[YY6]&V_+>
M5@TC22VMZW%ARC!]01_"..VQK6OVM\]&Y!O>!YL5=GG*)T;\S/WC!U^N$5 (
M^+C\(\?A.WA]&6]'&ZO</1"_E8S497,2[<J@K]=W;B-A4TI7?\,]&Y4Y+P_-
MBKL\Z_\ .0@+^8[?@I<K:Q_"!U_>29.+3-[Y^1EW%'Y7O;>YGCM(Y;B51-)(
M% /U?^7KML:^.>B5-0"<@W/ \O%79YI_,:Y36O/BVY/*);BVMM^E*KS'_!$Y
M<.3C2W+Z _+JS;3/(-U.Q"FYM]0N4*?;J(_JXY;=/A)V/>O?/2V4N2^?\V*N
MP%I&BVFCP?5=/B6&'DS\5\6/)C]_],4 4B+Z_GOY/7NG:63BB<F-3Q11&@_V
M*J /E@W%*'S8J[.5_GGKFO:';0WFE77U>T=O2=50<^1!8'F:FE!^R!\\D&N9
M+TS\C='\OZYJ4FFZ[8O>2,A>-A,R(O$C8HG DFO4R4[4[X,OK*]\S^2+:0WT
MMM)]5$LTBBK2A8SR1J'HW??YC$;%!W"3RZA9^4?-EZPT^"[@MKN>.*WF+LB<
M92%IO\7$"@Y\AW()SGOY(Z!J.L)<OI^HR:?;QO%ZB1(&+]3]IMEZ4[U[BF3D
MP@+>@?G=J=AH]\MIJVG+J&I21.ZW$TLB\%=VX "!UYT(9OB_FVVR4>:O,>HZ
M]YL7R=;WSZ=:Q*OJ2(0LDK<1(0K #B2#0#IWWZ9$-A.])-Y8\L6?E?RBGGV\
ML8]7N+B8Q0135,$ 5G0RSHI_><F7B%/P[C>M,7AT3S!Y3\Q:;90W\]]I-W))
M59V)*E8V)#O0_P"LO0$CIWQNT;@H>]U_RUYK\NZK>W&F6FG>8+5(#"UJS112
M*9D1^%ORX!U4_%UJ#RVIG6\@VO+,B7YG>=QY0TIKV,*UU(PCA5JT+'J33LJU
M/X80&$C3*?RV\CR^<]733$Y+"J--.Z4++$GVBH8@5)(4>Y';(KY8T#S!YET%
M=8N-6NX-1G5GB52JQ  _NZHJ5HW6M>AZ9(HJPGOF[5/+>A^8I+"PTB"?3+20
M1.));CU9.("R\I%GXJW+EQ*+Q&VS#J4?E5Y_\S^:K\6=Q=6X2VH\JM'21TKQ
M;CQ%-C\L2&,22G7YS?EWY=\IVT5YH\5ZXOB3%(TJ&!-DD"_W9=JH^U7'C5J'
M!WF;SG<>9]>G\JZ?J":7:6RD27-:/(ZD!HU)9>-*D;>!/3&DDV@=%\J6?E#R
M];><]:LCJ5Q=RTMK60E88T%>,\X )D#LM%C)52NYY5H(YYAUC5/RYU2VN[35
M7U2QN%^-)9/4-%X\A]HTJ*<6%/#'FQNF3>4[#2OS=TJ[L'TNWTS6K,AH+BQC
M]&%O5Y!(YQ1MN0 [M3[/1JGWYS>8]8@T^UU;2KXQ:9>!5$<:\7^)2]?5Z[CL
M*4P!E(L=_)'0=)U#4;G3-7TXW.HVZF6-I)&])#&Z)PD@4#F.35:K$;4X]3@3
M3=$\Z^=-%B]>\%G9"%3'N3+,1]EI&'Q?%\_>AP[!%$HF]UOR9Y)UFX":?^F[
MQ+J02>J%BM8A6C1P0T<24)8<I%"BB\5[X:?D7YXO]3>YT+5W:6>V'-'=B7(Y
M<75B34\32F A,"@?SL\G:7IOU+S!H*F.SU1"YAXT6,T1E*=@LBM7AOQ(:AI0
M!+S'YM?S-KMQH2:K'I.EV)"RRB01RS/^VB,Q%.)JIZ]*[UV:4FRB="\HKY4T
M"S\SSZ4^KZEJ/J-;PRQ,UM;QH0!+,B_WC2 UC4T7B>6^U8C<^:[O\N]6C33-
M2_2VDE>7IF82"A/Q+\)8*PZ@BF'FQNF4:;Y4L?S.TJ2*XTA=#UZ*41B:W@>&
M \OL<XSM\7V6 JX/%Q4$IB_YG>;->LI[:>/5)'L;U!=P)"!"RHQ^%&9/B;X3
MW.Y[8@+(E _ECY?T;5+2ZL6TB.#5;-?J=S<W3F9 \@E!E$3<5CD0H?&E*C>N
M'*Z'Y_N-7L];>606\\J2/"DQ"11<@?3DCVK\/6@/OCLG=+X/,GY?6_EO4-"^
MK<[V* BWNV@K-<7!_P!V))UBA5@*(U/@ZU8L"C$]Y^8_FZZLYKJYL['3U;TU
MAJA'%@F]>C,?BW!V%,>2/J*]H;'\OO)NFZJMA8W^I:PS.TEXJ7 5%_9A054<
M05#U(8.2".G$-Y=OM0\@><E\O27,MSIUU(J@2$D_O1\+[F@8-LQ[BOMA.ZC8
MJ^N6^B^?/)4WF.WL8-.UC3"JR"U011.O)01P'^0P85^*HI6F33_G(*4)Y:*D
M*6>>)5)'0[FH\#M]V"/-EDY,/_(O;S7:NP=HUCN"X3J5]&2HIM4>V&/Y(L#Y
M3LJ=O5K_ ,C7R)91Y*/YV(R>;M1#&IYH1\C&A ^@9-+J.22)T@?TY64A'(Y!
M6(V;C45H>U=\#)A,94,"X)6NX!H2/8T-/NSSIK^L^:=.\V?H^*_EOKV-T$2T
M].)BR?[Y!X#8[_?DVDW;WBPT[ROJ?D[ZX-/BTVR+4N+DGZQ<J5D0 QR%059^
MG$*%W/8DX_SCY;\[^7+===N]1FDJ:R^E,_[HM2@*[+QK\/P[8BE((1?DCS;Y
M#\Q3GRVFB06\=.-NTRAI9P.7,-.HYQS,IY+\1%1Q#?9!Z';?FHUUY,G\Q1J3
M>VZ^DX"[";X5Y4_D^(-\ML%,^+9YXWY4M%YSM_*4TZ+;74J&*8N/B@?XE(-*
M>H5'$+3^\VZ;Y%/+'D+5/-^CR>9-2U&[CU*82&WHY5 E?Y0*A7(.RT%*4!PV
MQ$;W9;YV\]:+Y*US_#FCZ-IESIE@\:SM-$L\LSA?W@,SUH5)*]-F!K\)*X8_
MDKYKU7S%IU[I,]VXO8:-%<2 2,H>HW#?;XD?M>."0I8&TK_/'RII'EW6+'5=
M-MT_1=ZH=K=&*@M&P,BBG+@KHRTXDT-:9#K#6/-DOFB?3;*]GNKV-Y8@7?A$
M*5!=HJE HZTI\L(1O;)?,6E^6/\ "-AJKV5OIMA/*DK)&#+=2 %@T,=RXY$M
MP->5%3W.V'-M^5/F>U_2,NIW[06KQ222O#*Q]=Z$_$IIMUK6GMC:\)2/7?S4
M\I_5K)]&T@2WUJZJB7D:^G%"M3Z:-"ZO*W,U#2\CU)J34E/Y.>59_,:7B6^H
M7&G"+TR5MR5Y$\N+,:CI0X25B+3W\X-?7RI?VLTNGV>K-,DO&:_5I6'Q4:,(
MLBBBU!4L":DD<37+\S:GYFT7S1%IL>H3WUU&T7I!JQQNS+0#TU;C3?XCWWK@
M0;M0T'3O+.N>4;S4VTN#3K)96CDG1S/<1A3')6-INA-515&YK0D<JX<?F!Y7
M\TZ%8GS+<ZQ*]PKJ9(HRR1IR.PC^*A :FW$8AD00A_R[\S^5->U"+RG%Y>A^
MIRJRI/*P>Y8HK,SR2A5*EU!-$("M]G;IT7RS^8,5UY53S+?@CTHSZP4"I=#Q
M;B-A\1Z#WR-,Q+9YQYG\BRZ9YHE\K6C"1S<)# S&@*RE3"7-!3X67EV&^<^T
M;4(O.JOJWF/7AIW-G6"TAN4AX)OQ+BM2:^(J0.OA+DQ&_-Z%J^@WWE#EHWEK
MR\-4$(07.H7-@]SZDPWD$')3&D._$?#4]:UH<"?EOY_U.QUE_+%W?"\@E:2*
M"X9@_%_V'5F-75J;)RZG; Q!1/YK^0=/U70(_.FDZ>VDSJD;75H(W5*,?3)5
M> "%6'6BJR_%LWVBR\USS58^;/T5#J$E]>1/Z48)XQ$NG5HE/'X>53\LF*IB
M2;1;:/Y4O_* U;]&)I=A.#++(C-<7*F*7T^,4TWV?6("T XU/Q;#)_\ EUY-
M\VZ/K4]WK-V);.0$O^\+^HW[)53]CC]&VV0);(@VP/\ ,'S?Y3UK1[.UT'3#
M87UNYY,%4#TZ4XO*&+S,30\G (WIUSJF1;7G6;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79@0:T[8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKL3B-6?_6_@,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[ 6MZ:-4L+BP8\1<1/$3X<U*_QQ043I
MU_)I]S%>P4$L$BR)7<<E/(?B,\Z_DCJ'^'O,S:?J'[J257M2#M216! -?'C0
M9?DW:8FB]Y_.G3UU_P MPZYIX,D2NMV&Y5I#..+B@J*QRT5]Z@]0,]+Y0WOG
MW.%_\Y+(JRZ=)OR*7 /AMZ?]<G%JF]N_YQMA>5=1"",CU;('G6H^.2C#[J?2
M,ZMY(B"^7[!%Z&TA_%!D2S')Y'YED>35+MY?MM<2EOF7-<X?^0>BV6JZC=0Z
MC;Q7"1P@J)5#@'GV5JC\,D6J(W>T_GWK5YI0TZ]TJZFMWG,A<PLT;56."G)E
MH2=SU/4G._:7Y>T[2:_HZUAMN5*^E&J5ITKQ KD&ZJ>)ZOK^HZU()M4NIKN5
M1Q#3R-(0/ %R33##%* S8J[/.GFOC_RLR,G;_2[3K_JQY,<F@\WOWEZ29_RO
MFC4<E$%R*(5Y >NK$L#O3Q]OH.>B\@WO <V*NSSH%CM_S-HQ^#ZV36O=DK3M
MW-*9;T<;J]R5D;\JFH660Q <=Z,%ONN^VU>H_KGHO*G)>&X67'F&UM]1AT=B
MQNIT:0!5) 5>[D;+6A KU(Q8WT14>FS26SWH"B&-@A+.JDD]D5B&>G[7$'C4
M<J5&<'_YR%D:/S';NI((M8R*=J229.+7/F]U_(:TCO?+%];2K&4>>9&Y_M<X
M  /:E#0^)ST4AJH/MD&YX!A7K?F2ST9[:.[8B2\F2")0*DLQIT\!W/;"Q)I'
M:9HUUJ8F:U3DMM$T\I) "HM 6)-.Y  ZDD ;G//GYPV,_E_S8=34$1S-%<Q$
M=.24Y#Y@BNWB,LCN&B8HO=/RD]'S%Y2DTFWX"ZB6YM).2U/&Y!:&2JC:KU6K
M;"F>CM,U*#4K:.]M'#PS*&5AW!RIR ;>!7-M):RO!.I26-BK*PH0P-""/$'!
M6*5+ &E:[9ZMZOU*3U!!(T+GB0 Z[, 6 #4\148H!M$WVFSV!1;I.#21I*H)
M%>#CDC$#IR6C"O8@]",'XI0V;%79RK_G(X5T"W/A>)_R;ER46N;U?_G&R1%\
MQSJU:O93!?"O)#\7MMAYY35I/(\*QD,YL& \*\#0'^./5>C"_/\ Q'F?4^=0
MOU^XK3K3U6R&_P#.,TR&UOXJ_&'B-/:C#)38XV>?\Y-69BUZWF4'TY+>@)-:
ML))"1[4#+MAW^9GY86?G2>2YTJ>*/5[<*LJ\MC7=/5"U93Q^R:;CV&1!IE*-
MI5^6'YJ:AY$5;>^@:XT2\+/P9:'NCO S?"=Q1P:JW&AH=\B/EKSWYB\E:O#H
M'F4E[0\4!DWXKT$D<@W91X'Y;'#5L :3[S9Y.\J^9?+]SYI\JDV]S;MSEMP"
M >3&J&*K>FP!Y*4;TR%8!13;OP-14=,@WO%\@WYQ^5U\P:#( RQRVI$Z,YHO
MP@A@3[J3]-,(82&S,?RH\YGREKD=XRR/;S*T$R0_WC(]/L?Y0<*P\:4R(?E]
M^:$NG^7H[.2QO+F\@7C"(X6*2 D^F X[ ;=/E7)$,1*F3>?ORUAN/,TQM-2T
MZ*SN)6:1Y;N)6A;K,)8F;GRY\J*H;PKX&OY.?EW>:+)/K^K!8[N\7X8EJ/35
MCS(;M4FFV]*?1@)6$:07YM_F%9:U;V'EO1&DDTS24],3RBC3NH$8D"FI5.*_
M"-NIJHZ9S?\ +;3M,O\ S)=:9YH1)FD:4*79@/6#_$ :@U;?KDR@#O9U^9-[
MJ.E^6-(UORQ<W5HB6UO'*L3T;TFC7TG=HC0+R4J1TY'?XJYUS6?RP\F:98O<
M7MG'%;6]9&;D]=ATY<N1_P!6N5VR,0'F>E?FIYUNKX1V>IWDEW=4@5/4+5+D
M !5;X5:O1A0CQR*?G?-;S>5--DTY>%F\L31+2A"F)R@I7PZX0B7)E/Y V\\'
MFV\BOVI<1P3+*QD!^/U8U>K_ !!C6N]=SW/?H_Y<%3Y<T[AT^K1_?QWP%G'D
M\[\^ CS!J88U87EQ4^)]1LY/^2D0'FW4S]E@LP"]"/WJU^'PP6TPYO3_ ,Y9
MW/D_RW$%JOU:(NZK45]! BM)_-QK\/M[86_E=I6E:MKFH:7YFA2:[D9RAD-#
MS#MZBC<?$:U^C#:QWYIA^9VHZQI/EW0]8\LW-U9V M8(YA#(ZCGZ2>FSE#0U
M^)=^XI2ISJVI^0_*>@V$][/I\/H0(97^'DU%%:+R-=_"N-MIB \QT_SMYMUN
M^M[.#5+Z2ZGD6**MU(/BD(4"I?:I.<N_/*ZM[LZ-);+Z5G);!TCXA3&C<:"@
MZ?#M2M-LD&N3T?\ (U+JR'F- ZSZA&H12']02N!."00?W@+;\OIKO0^AHJ!!
MX4&0;GA6<5_Q'>^??,,^E>7W_1]DAY7%Y!M-*(_@7XP1\)Z+[;[],GR:KL[/
M6QY8TOR%H%KKGF",:CJ]Z";6PE+"&%& 8R3*"KLU"/AJH^+N141?7/+$/EOS
MOIVGP/)*IFMG:29JLQ9]R6%,;L(JBRGRYK4OF/R%KVI7 AAH98X[:VC5(XE"
MQ..$?936E?M;5))&=0_/I2WE:<  _O(MSV^,;K[_ ,*X(\V>3D\[_(:7TO.-
MB]*_#<;?."4?=XX+_),C_"=C3_BWH:_[M? 4QY(3\YXS'YMU%6+$^HIJR\3N
MBGI^KQZY.<#-A6>?;^ #\TE5P5!GC8>Y]$$9/HTGF]S@EY_E'((V5C&W%Q7[
M(:[5J4I]JH4]>GRSL/YAHK^7=1#\:?592.72H4E?IKT]\B&R7)Y1Y&9%U_36
MDJ4%Y;\N-:T]1:TIO7Y9RC\IM=B\K>4]0U>_C+1F<!%(-)"44*HKM2O?)%K!
MH/4?SGT0>;?.UEH6B&,RM (6HX81LLL[R&4K4@HOQ,I^*G;H,-?+&B:C^9%J
M=8U^YDAT]BRQ6ENW",JII\=-S1AWW/M@Y*!Q)'YIU:P_+J[DT+RW!#<W:1Q>
MMJ%Y KS"4_&?JZ.SQQIQ('V.=>7Q&BD$G_.-,8-[?2;U$2+3MNQ[?1DIL<?-
MD/\ SDV74Z9&P4H1/(LE:LW,0D\C\]P/?WQ/1I!_RM%S$0X,TRDCX1M$U0:=
M:';WQZ,AS67L)/Y2PQR-Q*2B95>C$\IWC^"HJ@IO\)\>QSM_FAPFDWC%2X%O
M*>(ZGX#MD V2Y/%;2/U9DC#!.3 <F- M3U)\!G(/^<9G6NIKT8^@0*[T_>=L
ME)A![9_SD]"R3:8S$-\%PO)1L2KKOR[DBGX>. /S$FE'YB69>BJLEJ$*['B6
M%>7^RK]&(Y(/-9^7XB_Y5QJZHH9G:<OZH!7DB1%?3![A36O4&A'3.D?G:M?*
M5[WIZ7_)U,B&<N3"OR1D6/S?IS.P5>;@D^\;BGT],YUHU@]Y^6%TEIRED$C.
MZ@] DBLWT!!RIDNK <F?:AJ5OIOYOQW.H\+>$/$H;C\(YVRI$QKL/B9?B[==
MJ89_DQI'ECS%I0MKJSADU&V:LI=*E@2Q1N1ZBFU/;<8E,0"E/YQZQYL\L:U(
M\.I7L.GW3,UL([AD4!:*Z<(V 7@VW05V;ODRU33/*GEF^LJV$(O;J81VXBB7
MD&J/WG8*$V^+J.V1"308;::SYL\PV5\3J%Y+86T/J77JW,GI\2P55;DW%F=C
M15ZD_(YS:[Y+^:8X*"WK)]HT%#"*GMO3<>^6=&L\WHBR%/REXAR$<MR WJ1=
MK0$=AM[?U]!94Y#PS-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL3
MA-6?_6_@,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLYW^9/Y0P>:Y!J-G)]5U)!3G3X7I]CG3<$?S"IIV.V2!:Y1M
MGOY;_FQ<^45?3KF);W2)R?5@?J XXR&,_P"4FQ4U4[5&U<+M)U+\Q-")M;^Q
MBU:)1194E2-OO-*BGBE:]\=EW"=ZEH_Y9:\3=:9J5UH.]#;W%L]P* =5:-F(
MK_E.V$NN>1_.'YAW4+:_'!IMI;\N 4AVH].6RLW)J*.I48;I%$IKHOGOR=^6
MMO.OEE[G6M1N%0-+,@AMP4^)75"/4%&-:&IVIR'4]-N[?4-$TR'3M"MUN'BA
M$2L\@0*57BK$$'EOU&19&QR>/M=+?WC76I._[Z0O*R*"Q+-5R 2HKN>^<S_+
MS\O/-/DS4?KBPPW$4R<)4$@4TZCXB.QR1-L "'HWYG?F7H7G*QCMX+>YMI[5
MRT'(JR<6"*ZL.0^UQ#5WH13<';MPR#<\LS8J[$YW=$9HEYN!LM:5^G%#LX=?
M_EWYMO?,1\S"&".;UDE5#*" J455)IO\(ZTR=M5%ZO9_F-Y<B\M)Y3FCO'A,
M$@>8*G(3NWJJZ)ZM."M12O(<@*[$D9VVPDGE@5[J,13$?$BMR /LU!7[L@VA
MY5(%#$1DE*FA(H2.U14T^_-?R7,<1:SC264=%=R@/^R"/^K%2N@6-G43,RQU
M^(JH8@>RDK7[QG#F_+'S@VM'S*HMEO#,9@I<E1V"FE*BF3MJX2]<'YE>4TT.
M/RH;:^DT\1!))1Z22ERZRM(J\I%7XP:*2VVU>^39KC\Q3'S]+2PU/LCU>5?I
M?C7Z:8-F6['G;\N>)"+K9;:A+6U/?;C]V(?EQY.\P:?J-[K?F.19[N>-4C'*
MO<L1L"$4;4"^^V)*(@\RI_F#YQT/5]-T[2/+EE)8V]BT[.)&#-(THB'-G'VF
M/I[U IL%^$4R*_F'^6WFGS;J1U%H((E6-8T59N6P+'<L%WWKT';O7) @*02R
M'\N_S0T#R=IPLC'=W4DDK2RDK&BBJ! J#FQ\:DG_ &/;)9]:_,2W(A2VTZ2-
M0%#5?>@ZFL@.^1V9;L77_ K0(2-66XJI<5@9:5^(*: U Z$]? 8 T3R'YEU/
MS#;>8?-,L)2UY&.&,DA210!0-AOO6I.V-L0"3NFVJ^?O+MCY:NO*_EBSN8VO
M9(FGNKF1"\B1-S4%4%%H>@7Z2>\U\Z^1=/\ -]LMMJ(8-&>4<B&C(3UI6HH:
M;@C #3,BV)>3_.FH^4KLWNEN 74QR(PJDB'JKK45'XCL<YOHGD;SOY(=TT6:
M"\LW)I$Y( W^UP)7BWCQ;);%B(D,[\S^?_)_G*))]6T^ZM-35?BGMI$/J$ "
MDAD!9AMLQ^(=V;N>G1//'F1/JFL7%OIUD^THM@3*ZG]D,2P7Y@_?TP;)HE)H
M=>\F:(WUK3-/NM1N@HX+J,B>@CCB>9BA4&45!^%F"TZ@X>>:/*]W9^6GT;RE
M6WGC51"%;B:<JN.9_:85WKU[X%(VV2[ROYEL;SS1%K7G57OK665GNAW8LI"G
MBI7X4;B> VXCB!3;(M^3L^O:?J5WH.OR22M'$DP$DGJE"U/AYU-*C?C7WPEC
M'FF_YM7>B:N+76?+ULEK [36[A(Q$':(JP<1+L*JXW'RZC.M9%M>=9SO\V?)
MVL^;[>/3K%;>.".42^H\K<C12M. CH/M?S')!KD"6>_E%YUTOR;?RZIJ27$[
MM"8DBA"@?$RDLTC-44"[ +O7J*;G/D_RY>V>@+H.K\*I$T/.)B>2FH[J*$+3
MQP%(&U%CGG#6+;5M9N]5L%>.&YF:<))0E2YYLNVQ 8FGMG,_+?Y0^;='GEL;
M2]6ULI2HDGC8\BJFHX*-PWW=Q7)6UB)>D^:?S;\K>8I1K%[I#RZD@8I"[_N"
M[C<RLI#NBM\02@KTJ-ZR.^\F^:K#S#>>8-"D@].?TU]&=B?55(U%6IT-00-P
M?H."V5&TCM/._EV^\LV7EC7K:[:2R::2.Y@9.49E9CP6-]GC/PLPY*:C:G4K
M2^1=9\VZM:ZKYG6"VM;,GA;1,69CL?C?IQY#IX;>^-TO"3S0-IYQTOR]HM[I
M.B)-<7>I*J375PJ((T4GX(85,F[ T9V?;]E1USIV1;6#9S7\_$BFT$0-<&&9
MI5,<*[F<C;T^(W/4'V('MD@US>B_D+<2VOF:*YCMEGBCC<S3.:"UCI\=WS;X
M%,2_S;'[(^(KD'A\G?F58*BVDK<(XT5$2= H%!\/%R!5>AK]!.2L,:+*[?7_
M ,J+V2EW9W"--+(SRR"7X=B59O2G)XN3]E5V/7;?#KR_YJ\YZ!K%M:^;09+.
M]8QJ0L1HQI0AHO#N#VZ#!2;(YI-YUL/(NK:'];\GHUKJ-F%>X2620F2,G@2!
M)R!8-Q/P$;,:C^4;^:7Y-2Z_>#5]%*I<OO,CL0&*BB,G@VU#]_C@!64>Y"_E
MS^<;>6K"31]2A:YM*$0\2H*!VK*C*PXR))W#5H>G4X6Z3^4GF76GC@\V7\AT
MV/K"LI8L1]D?R_[(U/Z\-H$2>:92?FYY;T**:X\G:.+35Y20EU*0WHAAQ9HE
M)?BQ'("A %>_3#W\S?R^USS3'!8:>UK;Z?;?90NU6-.*L0(@%HO8$X 61B2Q
M_P#*KSQH_E"XFU#4H+BZNI%X*(RJJHKR:I8GER('[.WO7:0>5;#7=%T6+3F@
MM7GMD$:'UW 8 =3^Y-#[5/S& I%@,?\ ,NH:=J^L3:BDDZ07<TDTG*)"Z&1V
M;BH$@#TKUJGRR&^1/RP\S>6M9;6IY;2Y:=768%Y%8\V#,0?2(K45R1* "&=_
MF'^9OESS+H4&A:;;7=F+)E-OR9)%*HA0*XY @FM2?BIOUR_S*_)J\U?5#K.@
M-'"[K652Q5C(/VUH* D4KN-]^^(DIBH?E_\ G';Z+I#:#KUJ;^U1P8 0I"(Q
MY2QNC?"ZEJ,H/1J^U$/+_P"3NNZC-&WFZ^DFL8R&^K^JTG)E^R&Y?"!\JG]>
M"V(B3S5]8_.'1[*VD7R?I,>G:A-S4WA"^I&CBCB'C]AF&W('X17B*FJJ_F3^
M5GF'SCJ*W:M9P0PQ^G&.;DT!K\1](;FO0;#$%)B2N_*C\T?+WD>PEANK>\O+
MJZ<-+Q98XT"JRJJ4<EC\358T["@IOU+0!?BSC75EB6Z4 -Z+%E-!]KXE4BOA
MO3QR+8'ENIK:+<.-/:1[:OP&50KT_P H*S"OR/W=,XY;?DYYF\OZK)<^6[N*
M&!RP61SN$9OL.I4U(\<G;5PD/6;C\W?+6O:3;V7FC3)[FZMXT7E#(L8+1J$5
MU<?$O-11UH5[CV=K7Y':]+J%O?6NH"XF4(SW%RS%Q(IK\(HWPC;B*X\2>$MZ
M)^=6AQ:;=Z9?Z488)#(L5O9,(XS&Z*G&:1JR,_PBLOQ$^% !DE\[^0-?U?18
M= M+F.=$8/+<7#L))&!8D<50@+4U'Q;  =MT%D06,_E[YVT7R]KS^8;VT<!!
M(+>U@W1.:\*F21RQXJ2-P:D\JY(/RT\N:EY:TN/2-0]!EAY<'A9R3R8M\0=1
MX]CD2L00DWYC>9K?S/KEQK5J)42Y*MPEXEE(4+Q#)0%13X=AM2OCDMP,V-9Y
MM\\Z?>7OY@2VFEN(KUY(FB:M K")6J3_ &9,<F@C=] ^59[>V_+>.^U2W$^F
MQ--#,@^VPDF'%D-.(*L=F)V(&QH!DVUCRCYX\WQKIFM3VMIIZN!*8"Q:4"F]
M-Z_(E=^HZ8+ 9T2Q70/.7D;R;(=8T*TOK[5D6ML+_P!(0POTYGTC5RO4;#VX
MM\0EOF;\O(-2\N?X:LF$*QH@B9@#1D((+4'[7[1'C7VP6DQVIA_EKSW<Z3YB
M7S1=(+J<RR2S*Q*\_5#+)NO2H<T[>Q&V0#R9^5_FZVC.EWE[]1TLL2Z0L&=J
MG<(U*H#W-?H.2)8")9QYT_,GR;J$KZGI^ERW>KNJ*)KT\8UXB@=H8I&65@H"
MT:BGJ0>A9Y/_ "<\P:1>3W$=T+6%&/IJKFLP1JQB5D^RC?M4W]L;41*CY[_-
M?1?,6FVT'U$S:EZ9$L\P*I TBJ)?JL22T;XMU,GV:"@\%+7\IO-EMKA\RQSV
M NS*\O&LI3XZAE^Q6E#XUQM/"5>X_,WRHWEW_"BV^HO;!%42&2-6Y*_J\^/Q
M+N_[.] >M?BSM,\"W$;0R"JNI5MZ;'8Y!L>/YQ#1/R5\RZ3<W$%EJ*VEG,"/
M5B+>HP4_NU8?#Q.^Y5MM\G;5PE[1YA_.3RSK%M:7UYI3WFLV]"T<S!;4,1^]
M=55B7#, 1&R!17>O1A&N?E3YJU36(]<:6R62W:(Q*9)3M'NO)O3Y$UZFM<%K
MPE#>5?S'\J:'Y>D\N/'J$OUU)?K4P6(!6D"K^YC+L"%51U8$D5VVI+_S#\N^
M8O,VF)I-I]4B64(;AVD?[2GEQ0"/[/(#<[^V ,R"6(_EOKNA^7M3.K:L+J9K
M<-]7CA1 &9@5YR,[_#Q!J%4-5J;T&Z?Y9>2=6\MV<FDZLUK-8N'-(^98L] 0
MW(!2O'VKA)1$4L_,GS/IOF35'U32XKB%I.(83.K;(JHI6@JO3IR.075?R!UB
MPOC=>7+N-(@28RSO'(@/[/) :@#O7Z,-L>!Z/I/Y^Z/J-@MKYOL9+J:@$K((
MY(YB!02&.7B8Y#0<BC4KO3]G)CY(_*V\T6=M:UFZ_2.K>F4B]1F*1GV=^3[^
M( H*[&N ED(L,_,+\SK378!HWE_3XM)T@2<V6, 23%=D:8J #Q'1=Z$_:/7(
M[=?E3YKGU\>9VEL/K D27@&EX?" ./V*[@>.&T<)3V#\RO*J^5)/*#P7W'B_
M&<>G5G+F5&=.5  U*J"=OVJ[YVL5[Y!M>09L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=B<0HS^[?P&*'8IBEV;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=@75+6:ZMWAMIC;RN*
M"0*&*^- =JTZ5Q05\+JCJ[*' ()4UH?8TH:?(C"ORIY-L_+22_5C)+<7#!YY
MI6Y/(P[L?OZ824"-)IYB\T7>O-%]9$<<%LAB@AA0)'$A8OQ51N=V-68L[?M,
M3A]@9)1FQ5V;%79L5=FQ5V;%79L5=G/?S0_+:Z\T2VVI:;<>A>V=> 8?"=^0
M(\&!'R/MD@6N4;9U^6OYDP^4X-0TW4+);_3M4C1)H_4,;#ARX\7 .WQFNU>A
M!%-R9-5_,VS_ -%^IVUUQV]=R@+5[E4E4"G^K\\=EW3RWTW\K[VV_2-S>7]C
M,[,QL8E]4HH)HBS/$%;EL02VU:'QPZ\O>0=7NKV#6/-]XMY-;*3# B!8XW8C
MXN2\>1 %-U^G;&T@=Z1>9/.>B+82Z-Y3TYK*&=E$]U/+ZL\\:'DB$4X0@M\3
MB/[1"[T7?H.19L&S8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NR
MF) ) J? 8J[.+7'DCS#+YP'FI;)1%ZJ,8_62O$)Z9/($;]Z=/':N3VIJHW;T
M^W_,O3SY(;R=.LOKA&*2JH*AO76<(5+=#3[?VAX$;'L\3LZ*S*48@$J:5'L:
M5&0;'F&/Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL3BIR>G\W\!BAV*8I=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%78G$*,_S_ (#%#L4Q2[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLQ-,5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79@:[XJ[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[$XNK_ZW\!BAV*8I=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78G$?B?_6_@,4.Q3%+LV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[$XOM/_K?P&*'8IBEV;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C(
M_M-\_P" Q0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R/JWS_ (#%#L?BEV;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=C(CNW^M_ 8H=C\4NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLC'G^+5(
M],N+[1[Q[:XMXFD5>,;(W#XFY<XV:I6H%"!6F$,9,A\BW>E0:K;KK]H+RPDD
M5)5YR(RJWP\D,;KNM>5#UI3:N<R_+K7/.GG43/'JRV\5N4!)MXF)Y5[<1V&2
M.S6"2],_,&R\E>1[E+-M$>]N)8W:CW<T:)1V1#\/Q/\ 9_F&U.YPP\T>8O//
MDAOK%U)!J>GU%9C$(R*FG%ECIQ/@?B'ZL&Q220EF@Z3Y \YNT,27NC:DX*Q6
M\;BXA)"D\U:10[':I0LM>BM4[=)\G>:K?S3IL6J6HXB04="02CC[2'Y?B*'
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M>/>>8M2GDYU:ZF'[T4< .0H8=B *4[9R?RMJGI?F5</?-1I+BXA4M3W6-?N
M R71K'-ZKYRTY9_RQTT:6H,%L(KB7<\N3-+',?<>JX'MV[T[MK.A66M0_5=2
MA2>$,'"N*CDO0_Y_+(-Q%O%-+U:\TF876G3R6TX! DB<HP#"A')2#N,Y=^?,
M]G-Y6MGT\H;;ZTBQ^F!QH$D'PT[;=LD&N7)Z9_SCA'*?-P+!BZ02LU21_+7G
ML:@]*>.=!\A?%Y>TZO>TA_X@,!9QY,!\YA1K>H! %7ZW/0 4 'J-T';./?\
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MKUE;7L.ES2@7ER&:./>I""K';H/G2O;%%HJ'3+F:VEOHXV:W@9%D<#X5+UX
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M5#?$>=#]NG4FM>GAA'-3R5]*:7](HTN\G(UKUK3V\,._REDY^7K<;@@N-_\
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M:*6- ,Z0QH*]<BV,$SC>M0^8=5\VV>LW&ESG3;)N,489.>_^[".?$'E0TKT
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M)-(C!D@4N_0+4TKXG8?Y]LE?G;R[=R:*F@Z/;&55"5<LBBBFI[@\F/6@IO\
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M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V%FL:[%IJT
M,TY^S$F['Z!7"Q)IL9K>Q%[PNKZ%!+04!%2-O$XVH%M8/FFCMD,DI"(O4G8#
M GD[(K/;WOF*[1U=1I.SB@^)JJ59-^Y-:^ Z;Y/DP^KW-[4]\E5O;1VZ"*(!
M47H!D&QK%,5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C(NK?ZW\!BAV/Q2[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLC/F+S5);W"Z7IB>M?2>XHGN?$^WAWR8BPE+
MH%RJ#N>@P1H?E=+)Q>7;>O>GK(>WRP$VHC35<.IYA"AD.]!T'4^P]\ #)K(Q
M;&Z\R&2*_MUCLA\/%J\@U-S7:NS;;4_C+DP^IL&FXZY*(($@C6&(<40!0!V
MR#8UC\5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V,B^T_P#K?P&*'8_%
M+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLBGF/S3/ZQTK1U]2Z_;>E0E?\ C:A[[=NN61CU
M+ GH%P'<],,/+GEU--C$LH#73 <F[CQ%?XY&4K2!2W!FJ:W;::8UN&H\K<$4
M DDFOA\L%*32Y5+5(["IP+;:3<277UN\E)"%N*#[-#3B?';O[XV@!;AR%"B@
MV&!F[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[$XNK_P"M_ 8H
M=BF*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V1KS%Y@D$WZ)T\$W4BDLP'V!_S4<D URET#=.^
M+^5O+$6CQ!R*W+K^\;8FM:D5 '<Y*4[3&-.+5Q/5?,UQ'>+INFVDMQ*02\A'
M"-0-OMMLQJ1L*[9"E,NY7CM0T#3M(J\2 J5JS$^PZ #N?E@W3=/:;T[^_C"W
MI0*PV(4C^4C\-\4@=2H-2IX[CM7#7 R:S8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[$XJ<G^?\  8H=BF*79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=A!YF\VPZ&4
MC9&DE>IHH)"J.[4!.YV% <D!;"4J7I&7Z$#YFF*:-HUOI[27Y)]6Y/)JG:IW
MV^>)4"MUM<$3V5Q>RH[RO D,A8"([2#<4DY#I[?C@35MJP ((!J*;]M^HP99
M6$%C&(+9!'&NP P) IHFNYQ?%+6;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=B<75_\ 6_@,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL*?,NN?HBU,R -,W
MPQJ>A/O[#KXGH-\(#&1IM14[[9&M!L;B^NVOKY3)/Z09:FB;D,J_('MQVIXY
M8=FL"W$]ATR2V.CGUC=W0#R,J==RK LWR^&M!3($M@#6&V19.S8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[$X?M/_K?P&*'8
MIBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=C)YX[>-IIF"QH"68] !BK><YEEO?.%ZRP@K:1,0&Z*4!X]:&K$
M$FE?HIOEG)H^I<5X_3G0;.QBM%"1*!10M?8=/UY"VX"EF","79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)P_:?_6_@
M,4!V*8I=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V%VKZH]HG^CQF67P[=*]>GMUZD8L2:=D,O9+CSA/' $]**%Z\N
MM=MV(#"B'H.I]]\GR:OJ7 \>F]1DZTS3(-,@6VM5XQK4T]SU.1;@*:)KUP5@
M2UFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=B4/VG_P!;^ Q0[%<4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKL#WMT+:,O0,]#P7D%Y,!4*"=JG%!+8PITB\U/4O3
MGNX5M8&0LT?/E('Y*4%5^$CC7E\\G( (%E4F2.-G1&YT:BL 0"-]Z&AWVIA;
MYR\QFWEATVV^(RM28**GB=@@KM5Z_=X88QMC(K !0G#KRWH,6CVPBC!YM0L6
M-3[#J?LCPVR!+*(IHFNYPVP,FLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ.$;O_ *W\!BAV*8I=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V%!\P0W%Q)I]FP:ZC
MJ&#;4( /?KU[;9*F-]%Q0@ GH=Q^K'V>C@P(FH$7,H%2S 'XCN:;#85VVV&"
MUKO:.*:YJ\>DVQN9?8*-MR>V]/GC$))IK";RGHCQ2SW\LIE2=^:5 W\6.WT"
MFVU<E,L0&R:_1DIR#-K-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ*$?$_P#K?P&* [%<4NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL3N)Q AD8$T[#<GV&*'8#T749-
M0A,LL9B(=UXD[_"U-_?"0@&V\'B-5)8  GJ<#)K&S3+"C2R&B*"2? #%#LA4
MEK>^9+XRI(8]/1RH!"L"%ZD;GXF->HV'7PRP[-9%E=L,FX  H.F5MJW+Q5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=B<7VG_P!;^ Q0'8IBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V8FFYQ5V!(+Z.^B9K1Z@B@<"HWZ%:[']6%%VV138XI!;D1HLS<W4"K
M=*D=Z8%IK%\4NS8J[(+YZUB/4EDT&W+>O5.5$+ DFH7X:G;J=J=LNAMNUR/1
M>@(HW\<E^E:?'I]NL$:JE .7$4!:FY^G*68%+<%XI:S8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ.
M'[3_ .M_ 8H=BF*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V%^MZS'I-NU
MS(&<C[*)NS'P480+8DTN1>3!:@5[GIB9LY;YXI[C]V(F+<!OR!4KOO3OX85J
MUN"].TVVTZ(6]G&L40Z*HH,BD"ETDC2L9)"6=C4DFI)/<G!.*5N;%784^9M4
M?3K*26 !IZ? O<T^UW'V1OUR41;$FFP*FAVPK\C:.([<7]U$ZW<I)Y2MR;B:
M =S3;QJ??&11$-R=: @^XZ9*LBS6YL5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%787:O
MYBT_1D]34)TA'8,=S\E&Y^@8:8DTJP6TEPW"%2[> %<X]YV_-FZU2X%OY<ED
MCA78L!0L>GP[<M^V_O3,@8JYL9)_IOE^.V!FU5:(5JJ\NA\6IX>'T;'.M>47
MOGTNW;5*F[*_'R%#UVY"@WIU_P SF.60Y)!<\/4;TOL5-/EAQ@9*6;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)Q"A?_ %OX#% =BF*79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=@-KT3#C:D,X/<&@IUKTI[8:8V[%YK6*?B9D5RC<EJ*
MT;^8>^!-.Q7%+LV*NS8J[$KJYCM8VGF8+&@J2304PTAOKD1TI)M>U)=4;A)8
M<*(" 2M=Z ^.PY?/)$4P LVV=AQ/6N3/(-BW-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL#7N
MI6U@O.[E2)=]W8#I\\-(ML DT&YR"ZO^=6EVS-'8H]TR[<OL)V[D$]_Y<EP,
M#-,H?+]RP5I!Z885%>I KT'T9$;CS9YP\U2>EIRM!": ^BI%*]VDW92>WQ#+
M0 &'$2C+>/2K)"9ZSS ;4V /:GB/&M<&:;^1MW=7 N=8N1Q;XFXDL_(]JL*?
M3OX4[X?&KDD0*U_,W"'T;:-8Q2GM3^I[_('.D>7/)FF>7D"V40Y_[\>A<U_R
MNWAM3,>V8B E-W>S7;^I.Q8X>X&:AFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V)Q?:?_ %OX#%#L4Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQ-IT#^ER'J
M$$A:[[8H=@(V]U<,OK%%19 U%WJH'V?^"[X4.PQ  Z8&3LV*NS8J[-BKLQ-!
M4],5=D \^^=-->!=.CN583NJNT7[P  @T/%AU[]=LNQQ:I21$-G,]2JGX5+;
M[;>.^%NF^<H='L&MM!M9961QS,M  6^'HGCQH.E/<[891[U$JY-"+DU96H#O
M7K@XW/F[4I(Y446UO(]* *"@ %6;GO0T)'7K\L@*7U%HB(#:I:GT8@N@>;CZ
M@-P:4HM9*$@&G52:$^/A[[8;"*D[E%\.Q'CWS0_ESK7J&9K[=HE0EBQ;?CS7
M;M0=0=_QQXPO"6S.A%. !J3C[#R)KVG[6]]15)XCDQZGKQ/PUH/QR-A/"0U+
M.LG[ 'RVP-;VWG326C4N;F)10CDC$@<OVFJU3V)^7MDMBOJ"K));R\B%*,22
M*=!6G;PZY>D_G&R,(]9MC$*T]2.NU=Q5&WZ4KOU[8F#+B[U2335;_>9PYIN.
M_@?;K^&="TG6+75X%N["1986Z,OCX'N#\\K(IE=H.:%X6,<BE6'4'8X-P)69
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78G<7,5LAEG=8XUZLQ
M  ^DXH; KL,A^K?FYH>G2&%9&N'4;^D*C_@F(!^BN6"!+$S"-@T:ZF4.J41C
M2IVR*3_F7K?F6;ZEH5N88Y/@Y[LXK^US%%3CUZ?3DN #FPXB>2*;3+:S7E=2
M<G&_%3UH>GC\7CM3 VG_ ).ZMJDC7.KW C]0&H8EWWZ5H0/^&K@XT"!*J?,,
M<")':PJI0@\J#<^)ZUVR<Z!^5VCZ3'P>/ZRY-2THK]%.E/G7?Z,B96V" "6W
M>ISW3<Y&I3H!L!\ADN50HHHH!V&09H3+Q5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V)P_:?_6_@,4.Q3%+LV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL;)*L0
MY.:#%78&M;SZZK-&"J!BM6!!--CX$;]#X8:0#;L1TS18K)59JR3BM9&)));K
MN23A)0!3L,<BR=FQ5V;%783:IYLL=.!,C\V .R4/3MU _')4Q,J; KA%<>:=
M7U2,?H>V,8=00SC<5.QJ?A'3P(([X:I@9$\FZ &A-1[83:VEW465_?S1WLT=
M3#&I(8':@*T7<5%-C45RR)1[UZ#C^\H" >_],%^2/RLM].,>HZ@3)<C=4-.
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M4@L9U5(H[N9+=2D*R.$5C4A030$]R!AC'*LJAXR&4[@@U!P,D+CJCIBKLQ(
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MV7;MDS@@2!!'&**H 'R'3*VQ9BF*NS8J[*=P@+,: ;DG%79%-0_,O2K:7ZO
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M-N>D%/\ 9G'_ .'_ #($I^EP6KU^K1]*_P"?;%:/>T9[<MR]&@ITYGKA??\
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MM?Y-O^)XVGA/>TMU".L*D?ZS?UPTT/RWJ%A.LUWJ4MTB@CTV0*#7N=STP6R
MI2EE1_LH$^1)_6<D>!DI9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%78E *-)_K?P&* [%<4NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[(_>>:5>X.G
M:>OJW0[G[(H-^_T?/) ,#+H'8M8:$7*W5\2]P0"0>BFGQ #<4(V_4<;41[W8
M;Q1+$HCC 5% "@;  = ,BS=C\5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=@74M-@U.W>SNT$D$@HRGN/HP@TJZ.1HV#H:,#4
M'"*R_+/R_9EC%9I5MCR+/^#DTR7&6-!$W&K75Q3U96-*TWIUZ],/HM,M8@JI
M$BA5*J HV!-2/I(J<@FD+7!.*6LV*NS8J[-BKL!:GK%MIJ%[AP"!4*#\1^2X
ML2:=D"-]JWFW4&6T81Z=$1RC;:M/YZ5:K;[=.FU:G+:IAO)6)C$?$@^I7K7:
MG^?\<F'E[RM::&K>@H+L35R-Z5)4=^E>O?[@($VS$:4V<MUPZR+);FQ5V;%7
M9L5=D+\X>08KZ(W6EJL-\O0KMR!^UT[^^2!:Y1ODK07'IFC?$G=<#>1?.TT\
MYT'6%:.^B4!6;]N@Z-X-W'B/?J9!8RZ%5NK,)&+B,@QN2 .X_P _\^V3W(-B
M$S8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[$
MH!1G_P!;^ Q0'8KBEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=@6_U2WT]!)=.$#&BU.['P4=SA M!--@$],(;/
M4Y?-$=(D>"VJZ.25-=AQVK7>N'DPOB<13O7#;1=!MM(B$5NNX%"Q&Y^GK3 2
MR IQ-=\,L#)K-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLQ--SBKLB>K^>XXSZ&D(+RXJ/LL.
M/':IY;^- /'\;.!@9=R]$%:.>(\:87Z/Y%.HS-J.M>HSE@51VJ: U%:=/ C[
MMMR"6 C?-LRD#@M*>-.N3P"F0;E/-BKLV*NS8J[-BKLV*NS8J[.4_FC!^B-7
MLM;CHM64'_60UJ>O533IEL=PTSV-IAIRF:.2 "OPEJ?+PSJV5-R7YL5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V-WKVIOO
MWQ5V.Q5V;%79L5=FQ5V;%79L5=FQ5V4*[U^C%79>*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[$H!\4G^M_ 8H=BN*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=A-JWF6ULJPK(AN2K%4J/V=C7IT/6I&2 8DTW0T
MKVP!I&C2:M%#?:QS:=6+A#LHKV [4^@GOMAND 7S<=NG3).JA1110> R#-K+
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%78%U#4K?3XS-<N$7>E>IIV [G"!:":=D%U26^\
MZ#T;1#'9HWVBU U00&J5H0/ 5()RR@&L^I>IX&O?)/Y:\H6>@ FW'*5@ 7-=
MP"2-JG???QR)E;,1ISRL_P!HUP]R#)9FQ5V;%79L5=FQ5V;%79L5=FQ5V<I\
MV7D?F?S)::9 K/%:24D)KQ.X+[>P%*G:OMOEHV#2393"V/U>W>0D?O1Q'C_9
MG5LJ;DOS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[$XOM/\ ZW\!BAV*8I=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%78C=W<5I&T\[!(U%2Q- ,4$M]<CL_F&ZU4HNC &!V"M,
M0:@$<J\:4IVJ>^V3 IAQ7R;*TJ#L1AQ8:+!;")RBF:).'("G7=C3I5CN3D60
M#5<,,#)K-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NR-^9_-Z:3(EE !)>2@E58T V/$GI
M6K;4K]/2LQ&V$I4N5"06[#"73O*>I:Q<K?ZU(R(-_2!]Z\>NP7??N*?/)&5<
MF B3S;9A3BH^G)U!;QVZ"*%0B+L !0#*FU9BF*79L5=FQ5V;%79L5=FQ5V;%
M79L5=D$_,;SV^DHNGZ7^\OIB1\(KP%-S_K^ H<LC%@94CM,L4N"SS.$BC )K
MW)- O;KF_+3R6=+C.I7J4NYAL#^R#WIXL/I&"1M8A1N[GU2$7^[7[(]LG>09
MH?-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
M2A'Q/_K?P&* [%<4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J["[5O,%EI2%[R54IM3J:]MA_'#3$RIM5+&BBI]L((K;5]<GAN+H11
MV!#$Q_:Y FJGN"2M.NP]CMDN3#<M_#3O7QR3Z?IMOI\0@M$$<8Z 9&VP"FB:
M]<$X$M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=B=Q<1VZ^I*P1:@5)H*G88H=D!U7SM?:M,
M+7R^IXU +<#RH?V@2"H ]_I(Z9;PUS:C*^2HB ;O]&&_EKR6+207^I$2WM*5
MJ2 .H^U^T/';Y9$R91CWM,^W$?9R5Y!L69L5=FQ5V;%79L5=FQ5V;%79L5=E
M.X0%F- -R3BKL@/F'S]<7$YTK0HO4E8A#*#6A.WPA>W^43M^.2 :3/H%:.$$
M<G-!V'C3!GD[R!^B7>[U)EN+HOR1MSQ'S-"2>I]]^N&4K91A7-T\_J4"CBM!
M4#H3X_CDSR#8HYL5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V)Q?:?_6_@,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLAWF'SP4N/T7HJ?6KL\@[(>0C(\1W/S(W\=\L$>]@9
M=RJ(#Q+O\(I45[_+&:/^7D;3?7]:/UBY:A())6M-Z_S?JPF?<@1[UOJ$#B.F
M3-5" *HH!L!E38LR\5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V%^M:U#I$!N)]Z=%'4X0&
M)--Y#].NM4\VS,X8V]DAH&"]3W"\AO\ TZG)\FL7)ME"T[G)OIVGQ6$*P0B@
M4 5[FG<Y6V@4MP3BEV;%79L5=FQ5V;%79L5=FQ5V-=U0%F("CJ3L,5=D0U7\
MS]/M)1;6J/=2_P#%8VV]S_2GOE@@P,PJI 6!8D #QPOBL]=\VB1-1!L+$U 2
ME'/T'[0\:T![8+ 8[R;)2(@H>3#?VR6Z'Y:L=$C].SC"GNYW8_,_P&V1)ML
MI3=RYJQJ<-,"5N;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V)Q=7_ -;^ Q0[%,4NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[&R2I'3FP6NPJ:8J['8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLIF"BK&@\3BKL2O+?ZS!)"&*>HC+R7J*
MBE1[C%#8-,BOEG\O(]"9)8)2LH%'*J/C'ORKDS*V(C2K<W<ERW*0D[F@["OA
MDE@M98F),K,"U2#3PI3IL.^0+*E'!>*79L5=C)YT@1I9F5(U%69C0 >))Q0V
M 2:#<G$K&_M]0B%S9RI/"U>+QL&4T-#1EJ.N*J]_I]SITS6M[$\$Z;-'(I5E
MJ*[JU"-L$8I0^;%79L5=FQ5V;%79L5=FK7%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79'/,7G*#2ZQ1_',=@!O\1Z"@W)_S.61A;"4J;52V
MPPOTKRO/J;B]UL-N598FZU!4@MN1VH5\,3)B(WS;KQ.V^3"&%($$<2A$44"J
M* #V RML:Q^*6LV*NS8J[-BKLV*NS8J[ ][J$%C&9KIUCC'=C3%!V; KD6UC
M\S-/M#Z5H3<R_P"1N!7I\_EM\\L$&)F%X@:E2*#Q.V1V&Q\Q>:R)9ZV\ Y<3
M(.-0?   T(VK0GWPF@PHE<PCCV!YM^ _KDO\L>1[30E#G]]<]3(P[_Y(J:?B
M<@96S$:62R%S[=AX9),BS69L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)QCXG^8_4,4.Q3%+LV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[()^:^AB32;K5K:>>VO((JJT4SH"JFI5E4\2#\L(:Y#JRW\LM
M:^H:S:VTEM:W=O=3QQ21W-O%*"'/#X6D7DI%:CBPW K4;9SW\I]!O/.5M=2W
MNKZE&875%$5PP&XKORY5_#)'9C$6])_,KSC;^3KJWTZUT'1G2:W68M-9AF)+
MNG566@^#W\0:'*NO-7F'\K]7%AJ%P^HZ;)\8,N[,AH"58DL&6E.-:>V^-6MF
M*RU\M^7_ ,T])DO=*M8=)UZ)E1HX*K"S$? /3^RJ2] PW5@>51N>[:??1:A;
MQ7MN>4,Z+(AI2JL.0/W'(-KQ*\M);.:2UN%*31,R.IZAE-&'T'!&*5'(9YX_
M+P^9[F&Y%RT(C7B5IR%*UJNXH<(+7*%HW3]2^IJZ\%?F-B>W]1[9,D7B M2:
M"E3@;$%EXJ[-BKLC'F[SU;^7;BRL67U;F_G2)44@$*S!2Y]A7;Q.$!@94R'R
MIY(O?,D-_=6Q6.WTRU>YFD?EQHH^&,$ _&^_$&G1CVR3X&;'L+M?T7],6K6?
MUB>UY$'U+9_3D%.P:AV.*"+3'R_K'Z&OHM0]""Z](D^C<IZD35!%'2HJ-_OS
M@.MZWKOY>^9!#+?W5];1<9 DTK,)(FZ@AB0&&XKXBN3YM))!>Y6L&D?F5Y<#
MKIEAI=VTI@$UM&(N$Z+S39!R]*16 8'E3<[D#.^>7?,-GYALH]2T]^<$HV[$
M$=58=B#_ )TR#<#;PO7="O-!O9=,U.(PW4#<70TVVJ-QL00:@C8C<;9 OSNL
MY].TN37-/N[VWN$>->,,[K%0D+5DK0?1WR082V>@_D!<P7OF&#R_J%I9W=E>
M"4.+BW1W!6-I 8Y*>H&^&@'*F_2M#DS\GZ$=)L8Q)/<7,\B*9)+B9Y232NW(
ME5&_[(%>]<!91#!O,OF.37KDW4D%M:KOQBM8$A10>U$ +?-RQ]\/<#)*,V*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[,2 *GIBKLX9H$\_P";NIW9O;J:TTRV4+';0L%9E?8\VI0_9WJ#
MUH,GR:1ZGM?F.RM?RATRPBMK6VO]<OAZ\UU<1B58"E&1+93L"O,<F/4C<= A
MEYK_ "NN?*VF37_E34+N 6Z22/ TA9&7C\7$"E& KN0?HP6DQKDEOE;\SK7S
M1JD5CYYL;2^CO98(VNUCCMYT(< .\L:KR2FS@T^$;$4WZ%^7\TDWE_3I9F+N
MUK"2QJ2?@'6N LX\F#?F#:16?F/5+6W18H8KVY1$445565@JJ!T &PP_P,F/
MYL5=D2\W>?HM"U'3](C"R75].B,I-.$;'B7^=?LCOOA 8&5,D\L^2;G7-/U+
M5P62UTR 2,X3D&=F54C^T*5!9BV] NXW&$7Y[Z#;76@3ZE)ZAGM_3X4D?AO(
MJFL=>'1COQK[X0B89'^0FL36GF:VLT,217/J*[M"CN/W;D%)&4NE&H?A8>^V
M"_R+6GE6V(4*"\IV_P",C# 4PY(/\\>?^+[_ -65IW!B#.PH2?1C[>W09/\
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M*$0E$+E)%X<R" =T=3VIO41/RQJ7GSSEI%+2XAMH067ZTX*RR$'HG <0O;D
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MQ<_3%#0</4)<H1NI)W!KD5_+H76I>8-6U#ZY=2:?;3M;PQ/*7C+=7([44_8
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MXT$*!MD5>1K2OM7YXAC()Y^4VHW&LZ#>:1Y7ACT^ZMH4,S%ZO>2.'ZR%5],
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M6X#?##'P85F]-0$%*'>GWX:866;>9_*?E*/0;353;-IVGU@N7X-ZMS,9D/\
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M,$5FO_YQNNK.UM=9N;MO3$,<4C,Q^'@$FY BE>_;\,[!YSC'Z!OT.X%I,/\
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M6TL%81,D?INLG$RL_&2JN6'*H!!Z4 I3K>5MKS'.%^?ORS\R>;=6?5(K>&T
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M2/.M];ZGI*7,<J1-%,+@)0@.SHR%6;<\CR&U*"E=\CUQ^7_F;4/-(\UFWMX
MLD;")YR20BA/M(C;M3PQMC1)M-K;\P_+B>2#Y/E>_%RREBZ0Q>EZAD$P# S<
MF4%0O+KW [9*/S*_*\>=;:*X4K:ZG$M WVE(/6-V !(!Z&FV^V^(-,C&V/\
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MKD=_,?RW/YET6;2;8A9)VC')N@ =6)^@#"$2%L@_+WS;_A#7+771&9OJI9N
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MY \^LMUYAMKVQOQ&JF2 A@H4[1I\7'B*GK$#3O4;R&WC_,/S(GU6]-OI5LU
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M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C(_M/\_P"
MQ0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R,U9O8_P !BAV/Q2[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NQD9J6^?\!BAV/Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQB=6^?\!BAV/Q
M2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NQD75O];^ Q0['XI=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%78U.K?/^ Q5V.Q5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C$ZM\_P" Q0['XI=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%78R,4+?/^ Q0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R,U+
M?/\ @,4.Q^*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V-3JWS_@,4.QV*79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V,CZM\_X#%#L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C(NK?/^ Q0[
M'XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%78R/JWS_@,4.Q^*79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V-CZM\_X#%#L=BEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C(QNWS_ (#%#L?BEV;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=B</5_P#6_@,4.Q3%+LV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M&)U;Y_P&*'8_%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[&IU;Y_P&*'8[%+LV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[&1_:;Y_P !BAV/Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQD8HS?/
M^ Q0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78U#NWS_@,4.QV*79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V,C'Q/\ ZW\!BAV/Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQD?VF^?\!BA
MV/Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NQD?VF^?\  8J['XJ[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NQD?VG^?\!BAV/Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQD5>3U_F_@,4.Q^*
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V,CZM\_X#%#L?BEV;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=C$ZM\_X#%#L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C(SNWS_@,4.Q^*79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V-3JWS_@,4.QV*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V)Q#XG^?
M\!BAV*8I=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R/[3?/\ @,4.Q^*79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V,C'Q/7^;^ Q0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R/J_S_@,4
M.Q^*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V,C^T_P _X#%#L?BEV;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=C(S5G^?\  8H=C\4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL9'U;Y_P !BAV/
MQ2[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NQD?VG^?\!BAV/Q2[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NQD9J6^?\  8H=C\4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL9%U;Y_P !BAV/Q2[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NQJ=6^?\!BAV.Q2[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQD
M1W;_ %OX#%#L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C(_M/\_P" Q0['XI=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%78R(;M\_X#%#L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C$ZM\
M_P" Q0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R/JWS_ (#%#L?BEV;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=C(_M-\_X#%#L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C(^K?/^ Q0
M['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%78R/JWS_@,5=C\5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%78R/[3_/^ Q0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R/[3_ #_@,4.Q^*79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V,C'Q-\_P" Q0['XI=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M78R/[3_/^ Q0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78R/[3?/\ @,4.Q^*79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V,C^T_S_@,4.Q^*79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V,CZ
MM\_X#%78_%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V,C^T_S_@,4.Q^*79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V,CZM\_X#%#L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C4.[?/^ Q0[
M'8I=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%78U.K?/^ Q0['8I=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%78Q#NWS_@,4.Q^*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V-3JWS_@,5=CL5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%78Q!NWS_ (#%#L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C4&[
M?/\ @,5=CL5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78U*U:OC_ 8H=CL4NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKL:G5OG_ 8J['8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQJ=6^?\!BKL
M=BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[&IU;Y_P&*NQV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKL:G5OG_ 8J['8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQJ]6^?\,5=CL5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%78U.K?/^ Q5V.Q5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C4ZM\_X#
M%78[%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V-7JWS_@,5=CL5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%78U.K?/^ Q5V.Q5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C5ZM\_X8J['8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NQJ=6^?\!BAV.Q2[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQJ]6^
M?\,5=CL5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78U>K?/^&*NQV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLI>I^?\,5=EXJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NREZGY_P ,5=EXJ[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NRE.Y^?\ #%79>*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLI>
MI^?\,5=EXJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NQJ]3\_X8J['8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NQJ=6^?\!BKL=BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[&IU;Y_P&*NQV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKL9&:EO8_P&*'8_%+LV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[&IU;Y_P&*NQV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL9'7D_S_@,4.Q^*79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V,0[M\_X#%#L?BEV;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=C(^K?/^
M Q0['XI=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%78G%U?_ %OX#%#L4Q2[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NQ.(49_];^ Q0[%,4NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL3A^T_^M_ 8
MH=BF*79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V-$BD\:BOA7%78[%
M797(5I7?%79>*NQC3(K!&8!CT!.YQ0['XI=FQ5V;%79L5=FQ5V;%79L5=B%K
M]N7:GQ_\:KB@.Q?%+LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[,#7%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F)IUQ5V8,&%1N,5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V<<_YR6MXFTRRG<CU$G95'<AEJU/N%<E%JR/8_^<7+JYB\Q745J2IELG!/
M'D!^]BH2O?\ E_V62WR'Y#T*TL['5;6TC6Z-O&_J[EJL@Y'<]37$E,8A@7FC
MSSYAU22XLM4O[J:%I6YPM*_IU#5IZ5>  /0 4';(9YU\TWWF+S8ODN.Y>RTX
ML$EDBV=R8^97EX&O&GTFO3$#9!-FF=^3_*>G>7O)TOGVZBAOM1)I;6UP T**
M91;M(\761@:TK\(V.YR2ZK^2^F<?K.A/-INH(I"2PR/2M-@XJ?A_U:9%)@QK
M0_SAU2TA73=8B@U;2B[.]M=1*Q+.?CD68+ZBRT+!7Y'C7IL,WY(7VHWFEW?Z
M7EDENXKZ6)_4-2I54JOMO7;)%8*GYU:-I>EZI:'0;?ZMIUU86US"#RY,L@)Y
MMR9OB[&FVWTDTU;\N8M1UI-<>=EXLC&.G4I2E&KL#3?;!:F%FV%0Z@\4#6X"
MT:N]-]\F&!L0F;%79L5=FQ5V;%79L5=FQ5V![5PSR@=G_P"-5Q0'800^<UF\
MS/Y:C52L5KZ[.&J0_,+PIV^$UWPTB]Z9')Y/:/RTGFAI"!)>M:+$5ZA8Q(9
M_+?<\:!?]EVR3X&3',V*NS8J[-BKLV*NS8J[-BKLV*NSE7Y]QSV&GPZK975Q
M;3^NL1$<SJK!E;]@-QY#CU ^>2#7-Z7^1=Q'-JTFFW5E;7L$L$LA$]O'*4:-
M>2L'8<E&U".7'?I@#R'Y-O?,VAPZJ^M:I%=2<]A<$H"KE1\)W/3QQM$183?S
MS^8L.@ZK=Z-%H6AR6\=$5C9T;BR U$BNK FO7J.V _*_YCZWY<U\>6/-$JW$
M0<1^LP^)>0Y1MR%*JU17EO[X2$<5<VO./D/R]K7EP><?*L;V)"*9+-I/4%58
MI-Q9B7!4T;<T9-Z*?ASN&0;GCV;%79L5=FQ5V;%79L5=FQ5V;%79B:8J["'R
MGYNM_,JW4EH/W=K</;\@:A^(4\U/@:X2&(-IQYB\K7OE[ZJ-04(U[;)=1K7<
M1NS*G+P)XUIX$=]L/L#))\V*NS8J[-BKLX]YX\Y:GKWF./R7HDYLT#@3SHU&
M/PB1@I&Z\14;'<[') -4C9IZOY*\J:7H'EJ7SWKD*W\K$I96C_W7+EZ?K3BH
M+J'!'#VW^T.)S=?E=J6F1?6/+NL7RWD:_"ES*)8F\%*%:#VV-,;3PUR2V+\T
M].U%Q;:]H.F-8N_)S90_5IU%*?NY8V['XN+@ANAIL0(_);6]2U?2[J?69&EN
MTO)(VY #CQ5/@ &P /; 4P-H?\Y_+^E:)J\$6@1>GIL]E!<0L6=C(L@+>J?4
MW!;PV ITSH&!FP+-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL\_?F-;2Z
M9YXTY&NIYXY);>X"RO4(QF*T10 J@!=MLF.32=B][_+:2&[_ "]U5XK2V2Y@
MBNH&G2$>LT?I";XY#5FJVW8  4Z9Z!R#<\$S8J[&RRK$ADD(5%!))V  ZDXJ
M[.%>4_S3N+GSE(]Q.[:9>NT$4;,>";\8G5:T!8K0[?M')TTB6[V#S/Y M[;R
M="L5O&NK6 6>YD7EZC+*.;Q2 @4:$.GC0!MNISN^0;GC^;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%785^9-(DU:RDM(KF:T9MQ) P5]NW*AH/&E#[X6)"
M.T74UTN\CO7@ANA$>7I7 +1M_KJK*2/:OSVSD?\ SCMJ4]Y=ZDUS+)-(Z0L6
MD8L207%34G#)A!ZI_P Y!:;!8QZ:MM:P6:DW/P0Q*G>)A4JJD@<MN5:;[YW#
M(MKQW-BKLV*NS8J[-BKLV*NS8J[-BKLV*NPATOS?;ZEK%[H<0I+8K&6:H^(N
M"2 /\G8'W.&F(.])QJ'E>ZL-*LM;FX_5]0>=8@">7[@HKEMJ4):@W['VP^P,
MDGQDLJ0HTDC!44$DDT  [DXH;PF\F^:H?-.G+J=NI1&>1.)()^!BH)IXBA^G
M"0@&TU\T^6KKRU?MI=^ +A(X7<"OP^K&DH4U /)0]&]ZX>8&24YL5=FQ5V,F
MB$R-&25# BJFA%? CH<4.SSMY]N-5T#S&FC6^K7_ -5E](\FG8LHD:A\.G;+
M1N''E8+V[R/;:5JWEFXUNZTNR>[T\3@#BZK)Z4(D5I LG\Q^+CQ!V&U<[_H^
MEC2[9+199I^'^[)W+NW^LQRIR *>,W]X;V=[ED2,R,6X1J$1:]E4; #!N*4/
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=GG7_G
M(#3Y=/O(0;RZG2Y#RM'-)6-:,.(C50H%*GQ/OEL7'GS>^_\ ..VKP7(E@CT^
MU2YM%41W"1%IF9TEY%Y)/4IRXC8<1V WIGHE2" 1T/3*G(>!8E?7D=E!)=3'
MC'$C.Q/8**G%!7Q1/*ZQQ@L[$!5 J23T &<9\I:GJGYIW]U//>W&G:;;4].&
MT<(QYUIRDZM]FIJ"/"F2.S4/4]D\RV>F_E#':V2Z?::MJ]Q&7N9;^-I(DW'[
MN& \ *']L_$=]E#4"OYA>7?,WE'3IK[1-5N[FRH!,D[!Y4'3FDI%:5Z\>)'7
M?LA,@0W^7OF/RKYVUJVL/,VD6EI<R2*L,MF&AB8U^&&6!7X'F30/_JJ01OG6
M]&F::RMY7;DSQ(2PKN2HJ=]_OR+8.3Q@]=L&8I:S8J[-BKLV*NS8J[-BKLV*
MNS8J[&R1B12AZ,"/OQ5V0SR!Y#N/+$MQ+/<>JLVRHM:4!^VU?VOU>.2)MKC&
MD9J&H"["#@%*"E?$?V8/O?/$%OY@MO+4:>I-<1R2.P:GIA5Y+5:;\OGM@IEQ
M;TF-GY4EN-#NO,+/PAMIX;=5*G]XT@=F"MXH%!->S=?&38&219L5=FQ5V;%7
M9L5=A!Y\\R+Y;T:YU,_;C2D8\7;X4_$_=A#&1H)SY.\MR^9M7M=&@/%KF4(6
MZ\5ZN_\ L5!;Z,@7Y ^<9M3AN=+U&XDN;N-A.K2LSMP8!2H9B316_P")82&$
M"SS\_/+\5O?P:OIUC%86$ZM"$A "\XF^VRJ JET92/&A[U.=<R+:\JS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MR-ZKYTAL==L/+RJ));T2LS<Z&,(O-:K0UYT(ZCZ<-,;WIDFC>3)-3T+4_,(D
MX1Z8UNI3A7F9W*?:J*<*#L>HZ8+\P>3=)\Q<?TM;)<% 0I:H(#=:,I!&-J1:
M!\O^;-6\NN9-'O)[1G*E_1D90_"O'FH-' J=F!&Y\<X_^5UA!IGG*\L;8&.&
M&6=(TY$_"M0!6IKMX_KR1Y-4>;-_S8UJZUS3-(U/4)5N+J:W#22!0K%N3BC*
M%7<!1N.N=YR#>\RS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NSC__ #DOMH]I2O\ O3U[?8;K_#+,;3D>P?\ .+RQ
MMYDN XY-]2?@!2I8S0C:OM6OM4';.E^4Y5ET>RD045K:$CY%%R!;(\GDU];O
M;7$D$O\ >1NRMO7<&AWSE?YN?EG?F]?S1H/)YC1IHU-'5D "R14&^P^(=?"M
M=I M<X]7J?Y;?F'ILVG1^4_,_&.TC9A;S<*IQD+/+#<T8'TV<@JZ_$C;UI]D
MK\E?\Y 7=O,MIYE EA)(:=%XNG^NBBA'R /SR?AVL9ICYT_(R"5/KGECE&SA
M72UE=6616[V\]>+=-@QW'1N7PYVS1(]/,+7>DB/T;MS.SQ4H[L!R?;]HTW_'
M?*6T/(-4N;Z600:B\K2VRB!4F+$QJA-(@&W4*:_#VSB>NZ]YAL/.]KI-UJ$L
MT NH  @])&CD93Q9$V:@--ZY/HU6;>Q>6=(\M:EY'OKZ*PCAOH[9T>5W,LAE
MA",)(^1 B#EMP%KO2I&3[\X_S E\HZ<@L2HOKIBD985XJ!\;TZ&E0-_'O3(@
M,Y&F(?DS^7"^>-6:*[]0:?:)ZUP8QN17X8@3T:3>G4[&@PMO/).JZ;HDFKPZ
MO?R:K'!Z]#-SA+J.;*L7&A4[A?\ ,8;8ULK0^?-)U?5;6QNM)L+;0A,L;)''
MZ<OI$\0\EUR]9G13R)Y\6(^(4PA_+'S%YN\Y-<.-4CCBMU"D&"-FY.#Q- J[
M"A/7KA.R 24X_-CR[Y<\HM!90Z7.L\D@E]5KAN#PHQ5D7[7Q-W/[.Q%:X3Z?
MYE\V#S9)I5M??6[I7DAI,>$!H-W]%*"J]=A7%%FTSO\ 1/*\WE&#6+G3VL+6
M5A-6UY37!<221>FTTQ*I$ZK6I% U" Q^$B_S /FSR%.FI1:K)<P7#$5DH0'(
MY%1"U4"^'$;=-NZ-TFPI_EO;^5//P_15_I@L[NVCJ&M2X5H^2IZCNQ=_44L/
MM\E/L=LGWF[\QWTWRG'YBLPAGN4B],,*J&?=J@']D<N_49&F1ELP?R5^7CZU
MYL3RG?L8BLTT4S1TJ#"'Y!>7<E:"H[Y$M'\N:SKGE@^99M8U"/4'BDF5%EX1
M 1EN(,:_S*O7W[X6-;6S#S'YST+RIKUQY=M-#TR?2+>;TI&='FN&%%6;C<._
M(,&Y<>( 7\<%?E)YBO\ SGI=]IE_<SI=*4;ZU%Q1E5N@!'[7PFIX].^)3'=+
M_P WO*FG>2==M[W2K:%].DY%;:9Y'4M$:-ZGQ*W%J@@!_&NV03R%Y:GU'S3=
M:6M[<6\\)GYW$;TD8H_$U:N_+J<D6 &[-/S#UA]/\JZ;K,]C82V]V(!%9LC&
M)%:)I245/39.+&FSUW-2U2<F_P";E[KODVTLKG3]3N'!9HY#*(S4TJIH(QV!
MZUR(W9RL,1_)+1M \W:O=V.KZ9&Z-$)HDAEF3T^+*C*I:;?ERK\9;IU[9T&U
MBN=?\O6Y:YE@N;BVBD:: A6Y% Q(^$T!/@,#+F'G-PT.F:I)2!9H()G AG+$
M%58@+(8V1OGQ89SS\GO-?F+S3!J5O<7H]>)81#(\2MP)Y@GBO'E4+W/7?Q!)
M8Q)+T_\ .SREY8\LR:3-I-HZ07'K/<(DSU8#TRJ!Y?5"E>1%0#M2M<C6E><O
M.+^8IM(AO/K%\[26P]4 1*8^LHC7X5("^'WX:8V;3/6_*7E!M"M]<-G+9Z>B
M17+^@[232&;X/JWJS40T85J!\(#'C4[RSREJ/FGRE;:M=>:W:6"VB]2%I7Y!
MY#7BJ,*_"QH*=JC;K@9 D<V/><+#RGYNO-$L?(T1M;J\<P7,7"0^G5D6-GY%
M@Q4<RS*QJ!4G$_+T7F+S[IDNL3:NUDS%O0@MJ1JA!I21A\9'S./)&Y6^9KWR
MWY%U9=%M=(BU(69"W%S>22EI^05B8HXW6*(4)"$J_8FIK7?E9^9FKSZN?*_F
M K-*OJ(LHIR#QC=6ILPH#\76OCB0F,NB_P#,_P#+_0X-*B\U>5_7@LYVCK;3
M_%Q64,59)*UV*\2IY&N_*A%>R9%M>4YS3_G(+T_\.#U!5OK$7#V;XM_^!KDH
MM<V>?DB91YFA].I3T;GU #2J>B]17MVWP!^4GGG1=)\M1V]_=P0S0-*6C9@K
M_;+;*35B0>WRQ(8PE037\T?)&OZSYAN+[3]/N[FVG6 QR1PO(A'I(*"1%XFA
M''Z,@<<L_P"9/FXW6FQO':EDYN1]B)!3DW4!FIL,/)@1Q%D^O>3X?R[\G2Z?
MY@DC.HW-7BA4DDRL54JI%*K$@J[?9Y_"":Y-_.GG?4KWS7!Y/TRX:RA!59I4
M4%R77G\-1M1:4IWP -A.],>\K>0+#3_)-WYXUBW^N2LP2S@=V6*@E2)Y',+J
MY;D6 2J[ G>M5)?.NJ^8?RROX7MM1EO[*X!;T[MO4;X*!E+'<#XMBM,(W0;"
M?>1=+\N?FM;3VE]IT6DZG!P2.ZL R148/PYPLS*S<E^(UY,/VA3.G?F!YW'E
M71&U7B&F?BD2,30NPJ 2/  GZ,B S)H/+OR\\E3^<]8AT>W)17JTL@'+TXU^
MV]-NG;Q) R-^7='\QZYI"Z_<:K/!J,\;20Q(L8@537TP\90\JC>M:[CPPL0"
M=T_U_6?+.AZM)I=GHT-YI]I+Z3RW$UP+B7@>,C<X9DB3D0>-(Z#8D'"'\M_S
M+\U>:[Q;)'LJ0A'F,BNKM&"%<KP/'EOX 5]L)"B1+)/S(_+?REY/@EDD&J-+
M.)?JC(T)A#TY1++R4/3?XJ;D D9(=9\X:MK_ )A;RMY;E2VCM@&NKHJ'84(Y
M)&&JM16G3K7I3!22;-!C6D>5-+T'R\GFOS'&;J6]9X]/L@Y17XU5I[AD(<1(
MW14968@;\22(OYM\R>9ORUU&)6O3J6GS@N%N .1/1UY#XA38K0\?;KAYL23%
MDODGRUY6_,?3Y+..R;2M;A.TEJTDD+*1^[9HYGD/448!J]&!-2!VG2=074K.
M&^C%%GC60#PY"M,@V@V\<GA:"1HI!1T)4CW&QR._F=IU[>:+<-8WCV8ABDD?
M@H)=57EPY=5&QZ80QDG7D;4+6QU:WDOK.*_B9U7TIBP6I84;X2 :>#!E(ZJ<
MYC^1VB:IJ%G//IVHO8VR3T,:1H_(\14GU >U,D6$07IGYX:K!IFJ16NJ6$.H
MWQMP6N9Y)P:%G"JJ0RQ"B$-NPJ=A0 ;RG\P_S"U :O!Y1\N,([^5T$L[*&"!
MA6G$J?V?B)IL.F !E*70,=\@>1M-72+CSEYI#2:9;<DAM48HUS**+0R#[$89
M@"1OU_E();YQM_,WY?6RZU9:E+J$;,%N4NAR4%CLT8K\"5VXJ=MOH>:#83;R
M;<>5OS"O?T'JVG1Z2RQ-]3FTXL';TPS>E,)3(LK,N_J'BQ*TK\6W0/R^\XQ^
M;=*345 24,8Y4'177J![4((^> AG$V\]\Y>5+CRMJ4FF7/Q<0KQO2@>-QR1P
M-^HZBIH:CMDDP,DCSA'YO>0=0TO5/\4Z+S,;,LDA3XFCE'[87>J'O_3)@M,A
M6[V+\K?/6DW.E'ROY@2,\ ZP>JWIQ2QR-ZCPRR57@X?XXY#WVJM%P5Y%_/[G
M_H_F8*%532YC!W(Z!HU'??<?=B0D3[U'SU^1TMI.H\O+-+-*P_T*0+S0$5JL
MG*DBUV'P@_/KG7=%L+&VB>;350174AN&9.CL]"7^G(-@>6W^H7=XR"]EDE:!
M%A3U&+%$398UY?95>R]!D"?S;J_FW7;C0M#E%A9V#,MQ< *[NVX"H&4J!R^G
MO7MDJ:[)-!FX\M:9Y5T&UUS6HOKVH:JC/:6C%TBCC1PK2SM&\<C%Q_=JC =V
M)Z9%]=\Z>9?RZUD6VI7/Z2TZ6L@YJ%;B3\5"HJK+V&Z^W@:M%D,F\O>4?*OY
MAZ*ZZ5;MI7F&#BG!9'>"1B&*']\S%1(1Q^U\!H3R%:S3\T?S(D\O6=O%I"B6
M_P!1V@/4*#3X^/<_$.(I3QZ4( 92DQ#\K/($/FJYN;K4Y6@TG3(3<7;H*N4'
M["?Y34.YZ4^C"/SO8^;/+.D+KL.JRW%U"5-Q&4C](*=F*KP&RM3Z-]L0@@C=
M//(5UY2\TZ^NBZAH\-E9WI>*WDAGN3*CM_<AFDF>-B?L?W=.1!I3;#/1/S>2
M3RDWF740GUF-GA,:5 :7]A5Y$G=:$[GO\L:3Q;('S+^44]MYU/DS2O497>/A
M)+0E8V0.\C\*"B?%785ITKMA;H.E>:O.^GIK$^K/I_JN9(8K=**$Z -]ECO_
M #,V/) !*MY@U/RMY2U*;1+/24U**V#6\T]W)(LKS*Y]1X_1D]-$VHE%Y4ZM
MN<2_+?\ -+4CJK>6?-)47*DQ1R<:,T@/V6I\/Q#[)I^O$A8R[T3^9/Y;:5'I
M,/FWRAZK:;, \T3L'] .0JCEU^%ZHP:I!IN:X#\_>>?-OE_S#;V*RPR0R,KQ
M0PI3U%9RBI(SAF#&E#Q-/#" @D@HCR/Y2\I:]Y<O;F2*YBOK>,>K<2R<TAXK
MS:6*.,1\E-".#\B-J$G*\]W/GS1;1?,$]ZD40<<[>%5(B!-$W93S'2M>YQ%*
M;5O($?D#6[I?+ATVXEN)$I%>SSLC2.!R?E#$_IQ=Q'O)^SRK4G.B^2O.D6M>
M7X]=NB$X1N9Z5HICKS-/HY?(Y$AF#L\[\Y>4IO+NN7&A"LKQR!8R-RZN \1^
M;(RFF0K0_-&O?F3>3MI-P=*T>V^'FJ*\DC'H*MTVWVZ;5KAY,;,F<>9_)^C_
M )9V,%KKMLNJ>8;Q/5,+22)!;)6BU]%D:5V(8&CA13;:A>#^=[36K#S380:U
M<+=SH\!AF]-5Y)ZG[2J.H:N$,#S93Y/OM%N_*^M7NAVC6*-:W"SP&8RA']%@
MC1L]#P;PJ7K4'DM,]+9!R'S_ )L5=G/?SN\P3Z=HHT^Q^*[U*06R 'XN+?;X
MCO7[/MRR0:YEZ!^2/E^RU37OKNKMQTW2H7O[C8D%8:<5V!ZL144W%1G,/S;_
M "\7RK:V%Q95]+@(923OZH^-6-/YOB^[""PE&F;?DYYM;S-J.IC5P)+B9FNZ
M   1N?3ND4M6@X,M!O\ "I[[YW?R9KX\P:1:ZGMSFC!>G0.-G'_!5R);8FP\
M;\QZ.VBZE<Z:_(_5Y7C!9>)8 _"W'MR%#G/_ ,Y/-GF?RW)'+I\\$%C,W%&5
M TH(6K<_4JE":TXCIUP@,)$AG?Y0:)Y8UF22+5[6YNKV&-I!'ZO"!UY*N_IK
MZJLO+^:A_ EZ:OY]\R:9'K6ER16MO%$:"J%YRNS24*%5W!H-L.R+)W1-C:>0
M_+%Y-I7F*&XU"Y,P621.<4=J =XPH<22GM(2-J?!7JR'E#\RO-GF^U.DZ8L*
MZA&.4EXXHJIT'P!67U"?:E!T[XTHD2F'F[\NO*OD_4?TEJKW+Z5*Q$%E$09G
M=1R;E(W'C;CX1R_O/BIOQ+8KH'GGS'Y;\S1^7?,\Z745PR*'"@4+CX"A"K\)
M;8U'RQI02"H:_P"4/+7F;RS-YE\IVTMA/9,WJV[.\JLJE>9+R,:,JL'V/V:C
MC4<LZ%^8OG9?*6GBY4*]S,XB@5OLES^T]"#Q7O3V'?(@6SE*GG_DKRJ_F2]:
M"K+;V\3W-PR@%EAC%7X T!<_905H6(J0-\A?F*T\^:=8/KC:I&)D0R-;)$G%
M5^TRJ2K<N([G?KOXG9B;YLRT+6O(%WJ$6E2Z+,+-V]);M[M_7))HDDB*5A4?
MS*HV[%J?$IY3_,C7?-.C3?HX6RZM9D&5I@W%HRK$.BI^W4=_A^_$A1(E">:?
M(NC>4M8C_2INYM$N4=HC 8Q.'1N#1NS H2AZD#<$';<"/^0_S \X>9%N=.LI
M(Y[IN+":90JPJ:AB B_%O2E:_(X2&()*>>??)OE3RY>6=S=PW,%APDC:&!Q)
M)-)%Q(9Y9658P_,<BBL/Y1\50M9^>_,OE/S+#H_F>[%Q:R, Q5$I26O%PP0-
M17ZCL!L.F-)LCFK:AY/\M>;/*UQKGE>R.GW-F'=TDF>0L8@&E2KMQ/[IO44A
M14@KG1_S+\^)Y-TWZX$]6XE;TX8R=BU":MWXK3>GL-JUR(%LY&F _EMY#F\[
MZLNEQRK;Q*IEFE?HD:D<FIW.X &PKU(R.2:1YVFTQM9.I!+\IZJV:PKZ06G+
MTJD%N?8'QVKWPL:/--GUKR4EZ-.BTR1M+WC-Z\\ANR2QI.$4K  !3]V8C7^:
MIVB7_./LMP9-46RX+<&%#&)*\.8Y\>07?C4[TWIA*(,G_/6UCMOT.M](TT8:
M=7:,_$8@8:<6:M6*GJ:YF_,;SG!YC?2P8;JY1C%]7C3]S4BO/EM)MU)8[;XT
M$<1MNZ\D>39?+<>K1+<VEO+RE%U-(&G^!S$;=8!QBDY$'B5*MMR)"AACO-WF
MKSQY,O(+K5+J&6*YJPB1 8QQIRBKQ#"@/6OTG$ %))"IY9\O^1O.-C<V&E6-
MU;WEL% N'GY2LK'BLYA!],_%Q$B*-@1Q:N^&U_JGGKS'8MYATJ2/3[%5+QV]
M*RNJ@DL>2&O*GPBM/;Q&RV3NE.EP>0O+%P=&\PP3:M>!N$]S#*4@B:HVA",K
M2!:D.S4^)?A!&^23\G?S!NO-UG.NH!?K=HRJS(*!U8?"Q'9JJ:TV]L2&<3:1
M_FYY"M_*&H0K8&1K*[A$T8D(9D-2KQ\EIS H"&H*@C$+CS7J?FK6Y]"\O3K9
MVUCM<W/%7=FW7A$K!EI7J?;KXM(NS0=%Y:LO+.B6VOZW!];N=3]3ZE:L66(1
MQLH::=HW23XJD1JI'\Q:GPF(:YYW\T?E[JXMM3N1J-A)Q8,Z*I*[<^/ U5A[
MU'>F&K8V0R_R_P"3O*WYC:6_Z%M'TO6K<,ICCEDDB9F!:)G];F0C<>/PD%3N
MU01@O\TO/OF/0-1@FM[B--)N0'A$2J7=1Q+<RZL0=]N.U,0%D2@_RP\F^7/-
M&C75LEO+)KRI1I;B3C;Q%RZQ/&(V0D].0DY;BH!6HQWF6Z\^7U@?,T4T>GVD
M*&5+9#^\]/KRDJI5CQWH3] P;*;YK?*D'D"VO8- N[:?5KJX=(7O/4:.$2L>
M($"(4<Q5(!=_BVY!:?#A_P"2/-.K>?/+S&VN5L=2AD]*281B0, M>00D!2U=
M^M*&@\$[,@20DWGGRGI?D/S,+>ZB;4=,9!.D"S>DW%BR^E)(%8_ ZD$@ L-_
MAKMSG\FK'4]2U2[^HW[6<_IUED]))6>K?\65IOOA+"+,OS:U73[#3=,$VGQ7
M$#^HUI$TDJQP1\8B4XQ,A?D&7XJ@U6I)J<]%VD<D4*1S.9954!G( Y$#=J+L
M*]:#(-SPV1@[%E4*"20HK0>PK4_?G/?SRL+^;1);FVN_0M(5'K0A/[VK ;O6
MH \*;Y(,)LV_)Z^LK;7K:.ZLOKES-+&ELQD*B&0GX9.(V<AJ?:-!OWH04?D?
MI&HOI<-Y;WYBL_6<O:^DC T-#5R.:D^QQ*(!&_G!J4":S>V$MK#-=_NJWA:;
MU*\$8\5]3TJ?L[Q]/ ]!WFOSWJFJ:^GE'RLZP3(:W%RRJ_$ 5(56J-N]?VMM
MNN("3+>@O\I>3M*TO06\Z^:HVNK5Y/0L[)':/UY-PS22J*HBT:E-R0?DQ-YU
MUCS?^7WHWSWZZC:3.482PJ@#4J!\!Y?$ >A'3$;H-A.O(FB>4/S$:;2_T?)I
M%["IF26VF>562H1@Z7!;[')6^$BHY;BF=7\M:Y'KFGP:C$12:-690:\6*@LI
M]U.V!L!MY1JVGMIMY-8NP9H)'C+#H>)*U'L<,\"4)GG7\Z;0/YQMXX5I),D%
M?!B7*C;Z!EL>3C3YO;?RO5E\BZK.Y#JC72HO1EK;KS8-7H13X:=NIZ9Z*RIR
M7B6;%79S7\Q_/]];:E;^5O+K*FIW)4M*P#"-37;B:_%05W'V=^^T@&N4N@>@
M^0/)%G+IEUYQ\PJTNCV!X"WC?A)/*2@5.7[,?QCFP/+^4>!=YYG\V^2+:/6+
M?4?TA;*U)XYH4 !;96^  A>@V8;XC=!L)AY A\J^<KF30]2TY=.NIQRM;BTE
MF)#**M&R7$LJMR%2.AK\/4@B4Z%^8UOJ?EN3S(4)-O&[31+M21%JRBO8]CX8
M*9"6UL5U7R#=V/F-?*RNCS37$<,,A-$<2L%B<TY4!J"1N5W'49 _*5]YN\^V
MEQK5IJ@M##)(D5ND2\"U P4L>HH:5;E3#R8"R]!\\:-Y3_+;4H/+^H:.^I,$
MCEFNI+J2-W5JAO3AB*K'N#3D6V_X+#?\I/S'U;7Y;O1M7*?7[="T;E*5()5N
M:K0'BQ7[--JXD)C*TC_-[R!I.A0V6N>7'=]-U#D0C&OI[*\8J?B^-6K1NE#N
M<C&L?F9YOTKS$--N'@FEC=(_JT"?NY/4 *T=ZR [COMAI!D;9'9>0/*&J>7&
MO[**YM4E227Z]=R\V@,)'-/1A5$D1_LJWVBQV%=L%>=]9\^^64BUK4+N$0-(
M ((5!56-6]-ZI4B@I7D?GB*4V$/Y'TGR'YH<^7K2QNA=LK'Z[/-Q?B!\4BQ(
M_IAE/Q<"&'$$<J[YU[RGKZ>8-+MM50 ?6(PQ -0&Z.O^Q:HR);0;>5^9M#ET
M#4[K29SR>UF>(M0KRXD@, >S#<>QPVP)2S./^5/.FL_F#JEY!8W?Z,L[4? (
MXT=VJ2H+&13X=J?QR54T@F3U/S7Y'LOR]TC2;^]MH]3N]6B>9UG:58XE"Q,J
MQ_5Y8V9OWGQ,S$> '=+RQY^UW1O-!\K>9;A;F-VX1R^FJM5A6,_!39J[U!IX
MXTD2(-%6\V>3?+^L^55\W>5+>6TDA<+=VS2F1(Q7@2K2#D3R*$?']D]-C1OY
MP^=O-/ENX6&"2""RN>7HR1+66BTY!^=0#\751\CUQ 61(;_*7R;Y7\QVK274
M=U<:G;$&6%G"P.'8K&4,=)=MN0YKN=ML3NM2_,#6M+3S!9S0VMM''ZBQ(HYR
M*%J9"'5JU_EV'<#H<.R+/-3T1/('E^^?1]?M+G4)UE:*2=Y/2CB96*4589*L
MG=GY?ZJ^,G_)S\P+KS58SG4S&;BU9074<>2D;,R] :@UI0>V AE&5I+^</D2
MV\GZI'!8"46MQ#ZH$I#<6YNK(K@ .!0$'K0BN%%KYKUSSUKESIN@W0LM)LB5
M>=%5W<]%XEJCXF!I2GP]?#&J19*:WWE+1O)'EZTU+7+=K_6]44R0VTC/'#!$
M"#SD])TD9V4@@<E&^_V?BYQ^<%KKEE>PV.OW0O D9:"8($JK-0\@!]K;WRR+
M7*[9U^3UYHMRDVI:!:R6;\T6[MO5,B_"CM&8W>C!'/*H8D@BE2,].VB\847P
M4#\,I<@/G3&WUG'?6\EI.*Q3(T;CQ5A0_ABI7Q2M$ZR1DJZD$$=01T.>9M1@
MUO\ *W5Y([*1D@9@8W9:Q2I4E5DV Y ;&FX/3+.;1]+Z&M[C1_S6L$N;J#U;
M^-3]8BBDXW$;T7U)K:/?G$YXDJRD*2P'CG8?)?YGZ5YTA.FW:B*[DCXR024X
MOR!#>F:_$I';K^O(D4V"5O)O./Y=ZIY/D6]1O6LO4_=7<-:!A\2AZ;Q2]/A/
M>O$L!7)'Y@UNR\G:0UY*I%K:(B*B;L1LB*M3_'!S9$T$E\L^7;WS5JD.DV #
MW=TY +&@Z%F9CX* 6/MD'TNW\T^:[#_$!U'ZB\B,]I;P*I2E-O5Y EB?>M.H
MITPL-SNRG5;GR[Y6U Z,-.35%M9/3NY[AY4=Y$;C*+;T)45(]O@+JS=V_E ;
M\GOS5O\ 7;I]%UPJ]R$9XY0 A/$_$K**"OA0#8&N)"QDFOYP_EMIFBP1>8?+
MC$:9<.J>DS%RAD4RQE'ZE&0=&/)2.K UP0OG'5?.^M3Z1Y<N%L].L]Y+E5#.
MYZ44," .5?F!UQJELGD@9_*>G^3=$M-8UZ#Z[J6I@M;6;LR111"A]69H761F
M=67@@9:5JU?LY%_,/G/S)^7FNQ6%W>M?6#<9 )54LZ,2K?%3ER4UIO3IVVPU
M:+(9=Y4\B^7?S!\KW-Y86*V&LVOJ!FAEE,8*(9(BXGDD"QR <2Q8$,"1X88?
MG%YR\P^4]2B73;]A;W"%Q&\<+<2&W ^#EQITK4^YP )D2$)^1WE7RUYLL;NW
MUG3@]S:D$7"3S(2KH]*KR],%62M=JUZ&F_2?/[:A%HMS>:7<FUN;:)I@P5&#
M!!R92'4]0.U, 9EYKY$%B^M6D&J6PN[2:5(GC+NFSD+R5HV4\EK4=O$9$/RB
M\VZ[YITF[DGN8WOHYE5'EB'!5(!^Q%Z9/?OA(8Q)+,/SL\K:%Y5\P6UIIULZ
M6!M4>2-)CS9^<J$B219 #\(_9I[#(3Y:_,;SAJ>IRZ=;3"ZNY@T2U0+'#Q;>
M7B !M_E?37#3 2*?>9?(GE.TTJTUMX)K"SC2*1E,IEFNS-&'2$-M'&PH2644
M"DFE:+DP\C6GY@>A>6^HSI$5/&*2Y7U&#4W:/@15>E"U1[=<!ID+8W^8-[Y!
M-S83^6K6<PE"]W"LKQBI/PQ\YQ*0XWYE05I3B:UH6?DWYJU_S3=:@M[?DD0H
M%^!?@<D@.B4"[ &NU":5PE$22FWYX>4= \L0Z6^B63P^N97=I)6<2*!$P1OB
M_9YTJI7;WW$5T+3M3@\]-IL=^XOB\J&[9%=B!&6^R_(=!3VP]$ ;LBUF\L+[
M\OH=733XELXC&RV*O*(DD$KP&4LI61N0K]J0FK;M5=YC^9MUYL\G6L%];:M)
M/"[F.0M!".+&I4[)T/3V^G(C=D;#&_RK_P +>:+RXT_5-%@6<1F:W$-S<QAN
M%/4C^.:0D\*N/]4Y/ORVUF76=!M=0N9FN)I5)=V55^($JPXH   1M@+.)L,"
M\_Z6FE:]?6,, MH89W6.)79PJ5^#XV)9JK0U/W#ID?\ +FH:KJWF_4+<WTC:
M9IO "*D8J\B@\6XI\2K1O\H;;]<+$;E/_,.E:1IWDS2+M+,?I;4GN&:Y]20T
MBAD:.GIEN')C3MT7Q.W1\BV, S8J[.2^;KK_ !GYNM?*RG_0=/\ ])N03M(P
MXT6GMRI_LCX9(;-1W-/4?*UF?*?DN]\VNG^G:I)^CK%^\:$,;F4;_M*IC# <
ME(\&.0OS O\ RK[SRMW#2.T=UDH!MZ,GPRKQ'\IK3Y##S8G8LE\O+_C?R"^F
M4>6[L^8%2*F6+E) 59C0@Q,T9&QVVST9&ZR*'4U5A4'V.0;WA.<K\^^?=0F\
MQ6WE#1Y&MFD91/.H#-\8J%4,#0 ?$3U^62 :I'>GI'D_R/:Q>5K_ ,ZZI$ET
ML#"&VMI#(J,Q>-7D=HGC8@!Z*JMUK78;E?Y@MKGY<QPW^F:G<W-M,QCD6\(F
M(>A8%25V%!B-U-A-_(UKI'YGW4^E76E6]C>+$LL$M@S0@*C!71TE>1&Y\A\5
M.7SPRBO?.ESY=EUK](VJ 0?68C'#R=E"EV1N5$4[?RMOX8[+O5I)9VWE&TU^
MWTRZL+YT6X-O<I/=(H#<_3J/3A#43<D<Q4[5IN8-Y4\V^=O,]O=Z9ID[2R%?
M6:5CQ=1T].-Q14+]AMWI3#LQ!)9[YG\G^1O*VH6NHZK \=MZC0"UA=I$=D;_
M 'HE]1C(T:@@,$/Q&@ILP:9/YYU_R-Y:CE\Q!)]4FE,=NCL"W +]J4K]KB>M
M/$5.^"K960&+1>1?+WGSS7-:^4GDL]$@A:>XED4D#@:,8%)Y!7JO!9"&Z^ 7
M*\Q>3]?M=(;6UUZY-]%&)9$Y\82 M2J*M!7K0D;^&*"#2#\M>>O+SWBZ3=^7
M[1]*FEXJ09?K2\CQ5C/ZA+$#[2KP4G[/'!?Y4_FM)K%A=+K;@W-@AE:0"G.(
M"M33;D#L: =O?$A,9*?YO?EM#Y;O[9]&23ZG?F18XI#R=)4?BT8[E:,C(6W(
M;>I%2&T.XUK\QH6U2?4FTK3?4988;4\9*K_OR78]QL-CX+CR4$E%:U+HOY:7
M;:/#I\.K:O"JBXN+X,UN&=:LD%N.%0 121S6M2H IA%Y1_,?7-"UX>6];N!=
M0M+Z EDW*L=HW#5!*L:5Y'[L-,1(IKYH\AZ!YD\M'S5Y4MWM+B&/UI[92[I1
M2!.*N25,9JP(-"G[(.!?,7G'S?I/FA-,:Z^MS12)Z42H(HI/54'BP6A*BO[3
M&G6N-*2;1NA^5O)VL>4GU(6IL0$=;BZ>8W$L30LI7BE(TY3<E6G$?:IMU(K\
MPAYW\N>EKM[J>S2<!';U$:$@E04*\7'NU3\\12380_Y?7WDG6UD\O1Z,/4,2
MR?6+F<F64Q?$_!EX^BQ%:*E0U*,,,K"/SG^8>E)?PWR:=!QXHL7)6F=*JSLZ
MT*J3V!I_DX[!=R@GN/*'Y::Q+876G-KUS%)5GN'5(XE901&L0$B3. WQL]!R
M'P@?:P9^1/GZ^UGU]%U:3UIK9 \;L29&7EQ?FV_+B2M#UW[X"$P*A^>?D32]
M)^J^8?+T;QV.H%^:<:11O1701]" Z-RXGI0\3391OFGS;J&N^8/\(Z%<"S2!
M2]W<@@MQH*I'_*PKXUKX4W0%)LTE/EWRSIVB^76\XZ_#]<]>5K:QM"S(KN :
MSS,A5S$A4CBA^)AQ) W$8\YZEY@_+>YM;BRU*74-/GHS+<L)"67[2\C\04@U
M'$C"-T&PROR7%Y9_,^.ZL-1T^#2]9"CZO-8K)'$%) !>+DZ?"_VJT+*VQ!6N
M&/YJ>;M732+/7M'O_0L[RBB*- ''-.6\E3NI!!I2F !9$I-^4?E/3+G6+_0_
M,&G_ %N[ME8@F:1%C:*01R K'0MRY=SM3IOLS3--\[^<-'BN3?"PMUA4PB,M
MZLQ44#R2*>0Y==CO_+AV7<JT^K^2O(^K2Q1:>VMW$<[K*;@\((@#0QPQ?$9"
MM2I:3:J_"-^6"_R8\]ZAYDM;K1+^5_K<$=8[G8O0_#4\A0LAIN:U[X"$Q-[*
M'YT>2=-\M7MGK.DHAL=0+/\ 5&)*H8^#%.:/RX2!QT8%=P#TR!V^@7EOY[&E
M+?2->"6IO&%'WBYGX6Y#IL!DNC"MV:WNL1W7Y=_I?ZE;Q6"JL:Z>I?T25N%0
M2LR,LP8_%R+258C<FM,]&:-8W-E;B"\N6NY03^\=54T["B #;*V\/ =2NX[N
M=IX8([6-J4BB+E%H*;&5Y'WZ[L=^FVV<<\G%5_,&] X[W$]./2O$D]:[^/OD
MSR:1]3-/.!9O+6B\N=1;M]L"M!/,%H=JK3I6N=QR#>P'-BKLV*NS8J[-BKLV
M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J
M[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKL
MV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[.2?\Y).PT2U
M4=#=J3]"/DHM<WL/_.+R1MYBN_5 VT^;B20.)]2(5!-:;$[@&GRKG3=" &GV
MP7H(8Z;4_9';MD60Y/'R:FIP!I7FJ._U>_T3CPEL/1-:_;65 ]0/\D['Z,*@
M[IQJOE:XT[3+#67='M]1$W *?B5H7X.KCL=U8>S83>=ORGTCS.KS^F+>_;<3
MQ[$G_+'1AX[5]\04&-IGY._,S5_*Y$-O)Z]CN&M9JM$0>O$=8VJ:\DH:^/3(
M)_SCMJ-U%<7VCRD^A%\? _LORXM2O2O<99,->,LK_/L0W4NG:O&*R7ML',AI
MR=*(8^?'X2R*W#EU-!7I@;\Q_A_,;2R0*%[3PW/J$8@;*>:<?EQZ;_EKKD:L
MPN!)(=N7V?3B)K^SO0@]_'MDK_YR \NP:CHBZC))Z<UBU4KT;U"JLOSZ$?+(
M!G,,8_(7S?=>7_,"V\$)N8;]##+&*UH/C$@H13TZ5)_EY=.H#:9Y_P!7O="7
M2TTR\&KM L2.T1$3$T3U?4/38\C7&D<6U(?6_(NBZ;JBW":I:W&A-,U3!+RN
M%C7XO3]$CD78? C@%"U"S*M:'WY3_EV?)MBXN7$E[=%6F*_9'&O%5^534^.
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M-U>O; FJ0V\:R,/V:,TS*OOLU/?KE_EA^6H\G132W4BW%_<-5Y0"*+UX"O\
ME5-=J_1@)M,8TCOS+_,4^<9K9+:W%CIUC$(K>W#<PH  +<N*DE@JCZ,BOGK\
MF;X:D=>\J2^C.[F1HPW$JYZO&Q/<]5/T> (+$Q[F1^4_SFMH](_P[YKLAJ-H
MB".)ZT8(OV4;N>'[#*0R]-Q2C[#R-YR\R/';>;;P#3%8-)"G -(!^P3$!L>]
M3^.&PM$\U*;\P/*6BQ//Y4TAXM5*\8KFYE,@A/>6-#4>H/V&_9(#>(,C_,O\
MK8_-L,+V;I;7=L"JL4JK)_OMJ;@#MUIOMOD$SC:1?EM^8[>3I9EGA-W97"CE
M")#&5D4@I,C4:CKN.FX-#D*T;R?^8EK"FD177U:RIPY%D8HO^2PJ_P OX9,D
M(HLCU#SKY#O+AM3NM'FFNRYD94F,,<I/^_%'(+ON>&U>V3^/\K=/7RVWE@DE
M9!R::@Y&78^K3QJ!]&Q/?(VRX=J8B/S$U%/,*^:8^*W$<G)(C4Q+'NOU=5)V
MBX$IQ!%%V%,B7E#R]YP\A%M.MX8=0TYF9QQ8J02 -B?LU[BA[TP\V L,@_,;
MSCY:\[R?I=(;K3]5(C1UJDT3JM5ZT1^:IQ4'H0H%!]K#KRA^6MV-7?S7YFD2
M;4W^Q'&#PBV"C?:K*OP_C4G?$ED(]2@_,_YD0OHD?D_RY$]MHZ-ZDSRFLUQ)
M4$O)Q/%%J%HBU^R#R.%'G?R1Y@UOS+;Z[;VT?HV1BX R@%PCF0[]MS3IB"@@
MDHKR;^8>FZ)Y8U#R]<+.UQJ'J?O$52L=4"J*%@6Y'[1_9VH"<E?YE:7JNO:/
M)I.G6Z%KE5YL\@'#BP:E*?$32F ,I66,>0]:L]#UJVU345D>"V?U"L5.3$ \
M14D4W_VL*_RS\FZCI6CS>7=<MXQ:2J]61_B;U/A96 _R?VJ^&2)ZHB$P\]^=
M4UOS WF33&E@G+QN@:E4,2H$9"#XKTIMXG(CI7Y;^;O(^HO)Y<D2XM9"!1^(
M5UZCU%+ @CIR4_KR?$"M$,M\T_FIY=\[VL7^(-/EBU"-36>WD ^(BK< RGX'
M?XBC5XU/%MR2CYE_+;SEYBU*/4K_ - S@*5*L%CC"L6";?$:'>N_7KD+8$$K
M="_,GRQHEA/H]G:W8M)TE1V9T::0R(8R[$CTU'$T"!=J DL<[CIGUOZLGZ0]
M/ZU3X_2Y<*_Y/+XOOR#<'D\_I^HWHU,=3QY=:=JT[X6^<)-86Q:/R_&CW;[!
MI&XJE?VO<^'OUPA$KZ(W0OT=]<C.L^M]2!)D$ 7U#0;*O,A14[%MZ#>AZ9'?
MR?\ +&H^6-.DT[4X%1S(91(CAN7(#9@.A%,)8Q%)]^:7FVT\UZP=4L!+' T4
M4:PRT_="-0G!"&-4VY#IN3MW,YNI'CB9HD]1P"0M0*GPJ=AD6;$<X5I'Y9^9
M]$UI==TRUAB19786XF%/38[QEC7JO?MD[#4(EZSJ'YF:'K.AG0]7%Y-.8H@+
MLK&2LL?V7]/FO*BUCJ6Y%:DFIR1_FGY7U[SE!:PV]DD3P<G<M*K$%@!Q1MMO
MYJCL, 3($L>_++SE8>4[RXNKL3RQRH(U2/BH8<PQ:0$]0%^$#N=S38R;3+;5
MK/RXFFBT_P!-CM_0 ]1.)(3CSY5Z?17 G>F,ZK<VU[J<UPI=;6:=GKQ',(S5
M^SRIR /3E2O?OD7_ ">\E:YY2N+A=0@4PW02KK(IXE.5/A'6O+"2B((9?^:_
MGW3?-IMOT9#) ML9MG JPD(:I;DV^W3\<+_.'D3S!K/F6+7[>S58H6A8*9E#
M-Z9K\1J:$]-L(*"#:OY._,.PT/RW=Z#+ZWKWOKAF6-&51)&L8I5U)^S4_@*B
MN3GS[Y#C\[Z;'#<_Z->1_'&VS<&(^)33[2G^A]LB#3,BV.^0//5SY-U#Z];H
M)H9$,4\+$@2(>W(;JP-"K#H1X5!YOI'E#\Q- B%CILP2!":"L3+OX<]P/HR6
MS6 0S/4?//D35KF6_P!1T>9YIR"Q2=HSL*$\5^ L>[=R*D;G)MHWD_4="TF[
MN2#?^8-14^L[.%4,5(5=]N$=>W7V%*-VRX:#$O-7FRT\P7=K:0Q-8:%9?NX8
M4_>.B,U99#R(#S/U.XZ*M:"N$_Y.^2=:\HW%P+^!6CNO3!<.M4*!CT_:4\NV
M,C:( A-OS6_,:Q\X1V<5A!);K9M/0.5(99"A4_"!1OAHW7M3 'YD>0?,7F;6
MH]7LH%A%NB)'RD0L2CLX;KMUZ;X00$2!)5_(7YDZ=Y?T*[T&^@FG%ZTG,JP"
MJKQB/8=2W4]J&G7?)5^8GY>OY[T^ N!9ZA 21SHXH1\2$J>A-#7VZ;X :9RC
M82C\L?S&E\C7TET(C<6\\?!XA)Z9J#6.16XM1D/3X3L2.^$7E^Q_,2SMDTDB
MV2!4$:S2<6:-0.(X\'^(CW!P;(%HO5-1\DW,\M^MO?\ J.Y<0))&L9)8&G(Q
MED7[6PY'I0]\ _EG^7WFCRI=RW:16YBD4*ZRN0[ ,31.%55C_E;8241!"/\
MS(_,;2/.-E"ABN8;RV9O2 *F((ZQ@HU?C/'A137W/7+TCR1YEL?-<GF>2T1H
MY9)28Q,E0K"B[^(^62)%4H!M!ZQYXTN\\I6OEB%9Q-:E90[!>)D+2-(OVMD^
M/;J216@J<-OSA\FZSYP%M;Z?;JJ6Y=C(\B@GD **/HP1("9@E1_*?SS8^3KN
MYOKZ.6<RQ")(T"\2>:N6<LP^SQ^&G<]L.H++68?*ITHVBB]6V^K*HF!%.'#U
M"U/IXBOSR(3O3'[V]L;C6FO"9#927!E;X 'XLW)@$YD5[#XLCGY/>1];\HW<
MRWUNOU>Z1 T@E4\3'RI\(K4&N2D;1$$,H_-+\Q+7SE'!Z"O$;:6<HA1=TE*M
M5G#5Y KTI]. _./Y+7T&I'6O*<@B=GY^D#Q*-W9&)IQ)_9/CX9$%!CW)AH'Y
MQ6SZ/'H'F>S^O0P+Z<;\J$QC94?N#'^Q(IY  +3N'P^3O._F<IIWF>Z]/2ZA
MI0HC#.%/V/W>^_7?;OUIC86B>:G%YZ\IZ 7U'RWIDBZL!2W>XE]6*!C_ +M6
M-E^*1/V.6P/Q=L5_-;\O]=\T7L(T^");.S3A'\8#-7K\@*  8@K($H?\KOS
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M$Z JSC]XK!RM58UZ=L-H,3>R-\L>=/*VM^64\N>;I;BTDLP?3DA4OZH5F:,
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M>"QMF5D<R,#0+P"\ E% !/[1V Z=,069%I9^57Y@:;Y2U&?6]5%Q>74\;QE
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M-$L )[@'U!V/MDOP,V/9L5=FQ5V;%79S'\Q?RLU'6=33S!H-Y]7OD41T<D
M5W5UJ1UZ4^G) M<HV]'_ "\_,S3-'TF?RQYCL3>Z3<3?6"8VXR+)Q4=]B/@'
M0J15MS6F)Z7I7YCH3!<WEH%1>"R,H:I/[>RJ:J/'KW!ZX[(J2CKVI_E\SK-I
M5AJ7QR%WB>XCC5%"[1QOPF9@6W);< ;9)/+GD(V-[^F]8NGU'5>/!974(D:]
M"(HEV6O?^%346R$>J4>9?/":A:?H?1[.+3-*]02F%&,DDC@$*TT[_$_&K<0
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M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLY?^8VB^<+K5(Y-"NY$LV4<$C(4)(/\
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MS<G_ (U&-+XCOJ7^4,<GYQR!1SLZMW(DH/Q4_K.-)\1WU+_*&8?G')WL^_\
MOSM_P/\ GX8TCQ'?4O\ *&7)^<CG[%G3YR5_XU&-)\1WU+_*&4GYQ2 _'9U%
M.TE/G^R<:7Q&OJ?^4,?_ ,KC/_+$?^1O_-F-+XCOJ?\ E#*?\XV(HEE0^\E?
M^-!C2^([ZI_E#,/SADH*V53W_>?\V_Q.-(\1KZH/YAF'YP2U-;/;M\9_YIW_
M  QI/&[ZJ/YAF3\X)!3G9U\:24_XU.-+XCOJH_F&/_Y7$>]D?^1O_-F-+XCO
MJH_F&;_E<8_Y8C_R,_YLQI?$=]4/B,W_ "N+_ER/_(W_ )LQI?$=]5_RACO^
M5P;;61K_ ,9/^;,:7Q&OJW^4,K_E<!_Y8C_R-_Z]XTOB.^K?Y0RW_.$#[-FQ
M^<E/^-#C2^(Y;4GJPQJ_G'7_ (\C_P C?^;,:7Q&VM*?M#+_ .5PG_EA/_(W
M_FS&E\1KZL/YAE?\K@;_ )83_P C?^;,:7Q&_JP_G&8_G"1_QXG_ )&_\V8T
MOB.^JC^<97_*XC_RPM_R-_YLQI?$;^J#^<9?_*XF_P"6 _\ (W_FS&E\1WU5
M?YQF'YPMWL3_ ,C?^;,:7Q&OJH_G&;_E<)Z?43_R-_YLQI?$=]5%*\AE_P#*
MX#_RPM_R,_YLQI?$:^K?Y0Q\GYO**<+-CMO62F__  )V]\:7Q&A;_P"4,9_R
MN$_\L+?\C/\ FS&D>(N^J_Y0RO\ E<1_Y86_Y&?\V8TOB.^JC^<97_*XF[6#
M?\C?^;,:3XC8M%[N,K_E<3][!O\ D;_U[QI?$;^IKVD&._Y7$?\ EA;_ )&?
M\V8TOB-?5!_.N7_RN _\L+?\C/\ FS&E\1;]6'\PQW_*WU_Y8G_X/_FS&E\1
MKZL?YE^_*_Y6^W_+"W_(S_FS&E\1OZN/YACU_-RHWLF_Y&?\V8TOB+3!_E#*
M'YMMWL6_Y&?\V8TO&WZ _F&6/S;8_P#'BW_(S_FS&E\1HPC^89O^5LO_ ,L+
M?\C/^;,:7C=Z(_F&7_RMB3_E@;_D9_S9C2\;O1'\PR_^5LL.MB__ ",_YLQI
M>-KTA_,,O_E;!_Y8G_X/_FS&EXW>E_E#+;\UF%"+)SX_'^KX-QC2\;O2_P H
M8W_E;#5I]1?_ (/_ )LQI>-WI#^89C^;##_CQ?\ X/\ YLQI>-WI?Y0QX_-A
M*;V<E?\ 6_LP(\1WH^X^_*;\V$%:6<GM\7Z]ML5\1WH_Y0^_,GYLH?M6<@V_
MF'7[NGOAI?$;,'^4OWY:_FPIZV<@/^M_S;@7Q&O1_P H??E'\UC7:R?CX\_X
M<<-)XW>E_E#+7\U>O*RD![4;]?PXTO&[TO<??F/YJD?\>,G_  7_ #;C2\;A
M%_E#+3\U00>5E*#VH:_P%,:7C=Z7^4/OQS?FBU?@L9"OB6I_QJ<"/$:]/W&-
M/YI/_P L$G_!_P#-N*^(WZ8_F&4?S1E'_'A)3_7_ .;,*^([TQ_,,W_*UJ=;
M*3W^+_FW OB.]'_*7[\:OYKFOQ6,@'^M_P VXKXC?H?Y2_?F_P"5L'_EAD_X
M+_FW#2^([T/\I?OQQ_-5OV;"4_[+_FW OB.]$?S+]^4/S3E[Z?)_P?\ S9BO
MB.]$?S+EG\TI:;:?)_P?_-F*^(UZ0_F&5_RM*;_JW2?\&?\ FC"OB-^B/YAF
M'YIS'_I7R?\ !G_JGC2>-WHC^88[_E9\YZ:?)_P9_P":,:7C:],?S#+_ .5G
M3?\ 5OD_X,_\T8TGC:],>(QW_*S)NVGR?\$?^:,:7C=P]QE_\K+E_P"6"3_@
MO^;,"/$:X>XS#\RY>]A)_P %_P V8KXCN'N,L_F7(/\ CPE_X+_FW%?$=P]Q
MCA^9J\:FRFY>&U/OQ7Q&^'N,9_RLR0]+"2G^M_S;AI/&UP]QE?\ *RY_^K?)
M_P $?^:,:7C;X>XQW_*R9QUT^3_@C_S1@1XC7#W&6OYFFHYV,P'L:_P&*^(W
MZ?N,W_*STY$&SFXUV/M[BF*^([T_<??E2?F@E?W5G,VW>@_KBOB.]/W&-/YG
M-7_>&6E/'O\ \#T]\5\1WI^XRQ^9DA_X\)?^"_YMQ7Q&N'N,W_*RYJ[:?)3_
M %O^;,5\1OA[C*_Y67,>FGR5[_$?^:,5\1W#W&5_RLRXI_QSI*_ZW_-F&D\;
MO3'\PS'\S)^VGR?\$?\ FC&EXW>F/$8X?F5,?^/"2O\ K?\ -F*\;13W&-_Y
M69/_ -6^3_@S_P T8HXV^ \1F/YFR[4T^6O?XOU?#OBGC=Z8_F&;_E9\G?3Y
M?^"_YMQI'&WZ8_F&4?S/FVII\E>_Q?\ -F!?$=Z0_F&6/S/D(_W@EK_K?\VX
MKXCO3'\PQO\ RM";OI\G_!_\V8KXCO2'\PS?\K2?_E@DK_K?\V8H\1WI?Y0^
M_*/YIO\ \L$G_!?\V8KXCO2_RACQ^:0Y4^I2T^>_W4Q3XCC%_E#+7\SG8C_0
M):'_ "O^;<-)XVC'[C''\R'5CQLI&4[C??IX4.*.-H+[C,/S+D[V,G_!?\VX
MTO&[C[C*/YF2;<;"4^/Q?\VXIXV^'N,K_E9LO_+!)_P7_-F!'B.X>XQX_,U:
M?%9R\O8[?>0,5\1KA[C*;\SOA^"RE+=P33\:'%?$;X>XQI_,]P*FPE'^R_YM
MQ7Q'>G[C'_\ *STKO9S4I[=?Z>^*^([T_<9?_*SXJ_[R3\?';]6*^([T_<8T
M?F>"0#92\>YK_"F*^([T_<97_*SP">5E*%[;[GZ*;8KXCO3]QC3^:/\ +92G
MZ?[,5\1WI_Y0Q\?YH(:>I9S*.]*'^F*^([T_<??B@_,^WWK:S^VP_KBOB.X>
MXR_^5G6]?]YIZ5\!T^_K[8KXC7#W&)Q?F>A/[VSF4>U#_3%?$;]/W&/7\S[>
MGQVTP-.P!W^\;>^*^(UP]QEM^:-F#M;W'TJO_-6*^(WZ?N/OS?\ *T;*FT%Q
M7N.*_P#-6*^([T_<90_-.R[V]Q2O\J_\U8KXC?I>X^_*7\U++]NWN!X453_Q
ML,:7Q'>C[C[\MOS4L:?#!<$^ZK_S4<5\0.]'W'WY7_*T[/B3]7N.78<5I]_+
M%?$=Z7^4/ORD_-6SXU>WG#> "D??4?JQ7Q'>C[C[\=_RM2PXU]"XY>'%?U\L
M5\0.]+?J/OS?\K3L?^6>XK_JK_S5BOB!WI>X^_+'YIV%/B@N ?9%_P":L5\0
M.]'W'WY7_*U+"H_<7-/]5?\ FO%?$#O1_P I?OS'\U=/[07'_ K_ ,UXKX@=
MZ/N/OR_^5JZ;_OFX_P" 7_FO)4OB!WHGQ'WY7_*U=//2"X_X%?\ FK&E\0.,
M1\1]^._Y6EI]-H;BO^HO_->13X@:]+W&5_RM33P/BAN ?#BO_->*/$#?I>X^
M_,?S5TZO]S<4[_ O_->*^('>B?$??F'YJZ=7^YN*?ZJ_\UXKX@=Z1\1]^7_R
MM/3J;0W%?]1?^:\E2^(&O3/B,P_-+3CUAN*_ZB_\UX*3X@=Z?N/OQJ?FC9&O
M*"X!KM10:C_@A3Y8$>([T_<??F/YI6?:WN/^!'_-6*^(WZ7N/OQZ_FA8DT,%
MP/\ 8K_S5AI?$#1CIW&5_P K3T__ 'Q<_P# +_S7AI?$#O2]QE'\T[#]F"Y)
M_P!1?^:\BGQ WZ7N/ORD_-.QI5X+@&O0*I_XV&*/$:]+W&6?S5TW_?-Q_P
MO_->2I?$#8B/B/OS'\U-/VI!<T_U%_YKQI?$#O2]Q]^7_P K3T[_ 'S<_P#
M+_S7C2^('>E[C[\W_*T]-_WS<?\  +_S7C2^(&O3/B,W_*U=-_WS<?\  +_S
M7C2^('>D?$??E#\T]/\ ]\7/_ +_ ,UXTOB!OTO<??E_\K3T[_?-S_P"_P#-
M>-)\0->G[C[\O_E:%B>EO<_\ O\ S7C2/$#O3]QE?\K1LA]JWN0/]1?^:L:7
MQ'>E[C[\I_S3L*?!!<%NP*J/^-CC2^('>E[C[\M?S1L*?%!<@^'!?^:\:7Q
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M?2H@N#_L%_YKQI?$#O2]Q]^9OS2L:?!;W)/NJC_C8XTOB!WI>X^_'#\T=/\
M]\W/_ +_ ,UX*3X@:,?N/ORO^5HV/^^+C_@%_P":L"/$#O3]Q]^6?S1L.T%P
M?]BO_->*?$#O3]QF/YH6-:>A<4_U%_YJR5(\0.]/W'WYO^5HZ?U$-S_P"_\
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M_P  O_->-+X@=P]QF_Y6AI_>&Y'^P7_FO&E\0-F/W'WYO^5HZ=_OJX_X!?\
MFK#2\8:X'V^_&_\ *U--K3TKC_@%_P":\:7C#?I'K4??E_\ *T=._P!\W'_
M+_S7C2\8=Z?N,O\ Y6AI_P#OFX_X!?\ FO&EXPUP]QF_Y6AI_P#OFY_X!?\
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MZN/^ 7_FO&EXPX1'VS#\U=,/6*X'^P7_ )KQI'B!OT3XC[\K_E:VF_[YN/\
M@%_YKPTOB!WHGQ'WY7_*U]-_WS<?\ O_ #7C2^('>B?$??F'YKZ:?]TW/_ +
M_P UXTOB!LP'Q'WY?_*U=.IM!<U_U%_YKQI?$#7H^X^_+_Y6IIW>&Y'^P7_F
MO&D^('>E[C[\;_RM;3?]\W'_  "_\UX\*\8=Z)\1]^6/S5TW_?5Q_P  O_->
M/"O&'>D?$??EC\T]./2&Y_X!?^:\:1X@:]+W'WY?_*T;#O!<C_8+_P UX*7Q
M [T_<91_-/3AUAN?^ 7_ )KPTGQ X1^X^_*_Y6KIM:>C<?\  +_S7C2/$#?I
M'Q'WY?\ RM33/]]7'_ +_P UY%/B!KTC[??C_P#E:&F4#<)M^HXBH_X;]6*^
M(&O3-:8P_FIIH_W5<?\  K_S7DN%>,-^F?$9O^5J:9_OJX_X!?\ FO&EXP[T
MS[??E_\ *TM.[0W!_P!@O_->"E\0.]/W&;_E:>F_[YN/^ 7_ )KQI?$#O3/B
M/ORO^5J:;_OJX_X!?^:\:7Q [TCXC[\MOS3TU?\ =5P?]@O_ #7C2^('",GP
M^_*_Y6GIW^^;C_@%_P":\-(\0.]/W'WYA^:>F_[YN/\ @%_YKP4GQ [TCXC[
M\H_FKIO^^;C_ (!?^:\/"O&&_2/B/OS'\U=,'^ZKC_@%_P":\>%>,->D?$??
MF_Y6MIG^^KC_ (!?^:\%+QAOT3XC[\Q_-;3/]]W'_ +_ ,UXTO&'>BWM]^8?
MFMI9_P!US_\  +_S7AX5XP[T6]OOS'\UM,_WU<'_ &"_\U8TO&'>D?;[\W_*
MU],_WU<?\ O_ #7C2/$#O1/B/ORO^5KZ9_OJX_X!?^:\:7Q [T#XC[\W_*U]
M,_WU<?\  +_S7C2^('>B?$??E_\ *U],_P!]7'_ +_S7@I?$#O1/M]^6/S5T
MW_?5Q_P*_P#->&E\0->D?$9O^5J:;WBN*_ZB_P#->"E\0.](^(^_*'YJZ;WA
MN/\ @%_YKPTOB!OTCXC[\P_-;3#_ +JN/^ 7_FO&E\0.,)'<??E_\K5TS_?5
MQ_P"_P#->"D^(&O2/B/OS?\ *T]-I417'_ +_P UXTCQ [TSXC[\W_*U-,IO
M'.#X<%_YKP)\0.](^WWYA^:NE_R3_P# #_FK%?$#?HM[??E#\U]*Z%)Q\U7_
M )JQ7Q [T&RS^:VE#HDY^2K_ ,U8H\0.]!N^9?S5TL_[KG'^P7_FK&D^(&O2
M;+/YJ:7QKPGKX<!_S53\<:7Q WZ+?YG&?\K7TO\ WU<?\"O_ #7DJ1X@=Z)]
MLO\ Y6MI?^^Y_P#@5_YKQI?$#O1;,?S7TH?[KG_X%?\ FO(I\0.$#91_-C2A
M^Q/_ ,"O_->-+X@;%N^6/S8TGNDX_P!@/^:L5\0.^KOX?CF_Y6QI7\D__ +_
M ,U8H\0.^KOX?CE_\K7TG^6;_@1_S5C2?$#7U=_#,/S6TD_LS#_8#_FK%?$#
MOJ[^'XC+_P"5JZ3X3?\  #_FK%?$#OJ[^'XY7_*U=)_EF_X$?\U8KX@=Z#^&
M.'YJ:3X2_P# #_FK&E\0.]!_#&K^:NE'JLP_V(_YJQI?$#O0;PQ1/S1TENOJ
MCYIU^XG%?$#7HMX9G_-'25Z>JV_9/QW(Q7Q [T6QJ_FEI34^&85_R1_S5BOB
M!QB8=L</S0TDC_=O_ ?VXKX@=Z3>&5_RM+2:5I+7PXC_ )JQ7Q [T6\,9_RM
M72?Y9O\ @1_S5BOB!OT'\,<?S3TD&E)3[\1_S5BOB!WH/X90_-32=JB45_R1
MM_PWZJXKX@=Z#^&/;\T=( )!E)'8)U_&F*^('>@_AEG\T-'!IRD/OPQ7Q [T
M'\,;)^:6CJ:*9&]PG]2,5\0.^KOX?CE_\K1T>E>4G_ '%?$#?U=_#\<3_P"5
MK:16A$U/'@/^:L5\0.^K2>'XX]/S3T=FXDR**TY%-OPJ?PQ7Q [ZM)X?B,IO
MS3T@$@>J:=#PZ_+?]>*^('?5W\,L_FEI'$-64DBO'AN/QI]QQ7Q U]7?PRO^
M5J:3X2_\"/\ FK%?$#O0?PS?\K4TFG27_@!_S5BOB!WH/X9;?FEHZBM9"3V"
M;CY[XKX@=]7?PRYOS2T= "K2/7LJ=/OI^&*^(&_J[^&,_P"5JZ1QY?O:^'#<
M?C3\<5\0.^K2>'XC+/YJZ.*;R[_Y'3\<5\0.^K2>&4?S5T?_ (M/^P_MQ7Q
M[ZM)X?C@E?S*T1@"9B">H*-M]P_5BO&&O0?PQ_\ RL?0_P#EH[5^P_\ S3BG
MC#OJ[^&!1^:6CDTK)3QX?VXH\0.^KOX8L_YF:*H)$K,=M@C=_F!BO&'?5W\,
MN/\ ,K1&&\Q7YHW\ <5XP[T'\,1?\T='5N(:0C^8)M^-#BOB!WH/X8]_S.T9
M:T=VH*[(=_;>GXXKQAWU=_#'Q_F1I$A"AW%:=4/?%>,-&)AU&&UKYAL[O^X<
MM_L2/UX&7$%F&/+:N%D["V]\NV=[O,@.&V)C;L"+Y*TX?[K'W8VC@#>/'D_3
MQ_NL?=@7@#6.'E&P'^ZQ]V*\ =F_PEI_^^Q]V*\(=ECRI8?[['W#%>$.S?X3
ML/\ ?8^[%>$.R_\ "EA_OL?=BO"'98\K:>/]U#[L5X0['?X9L/\ ?0^[%/"'
M9?\ AJQ_WT/NQ7A#LH^6K _[J&*\(=E'RQ8'_=0Q7A#LK_"NG_[Z&*\(=F'E
M;3Q_NH8KPAV.'EFP&WI+]V*\(=E_X9L/]]+]V*\(=E?X9L/]]#%>$.RD\KV"
M?[J'6O3#:\(=B@\O6(Z1+]V-KPAV._0-E_OI<"\(=E'R_9'K$OW8;7A#LP\O
MV(_W4OW8VO"'9?Z!LO\ ?2_=@7A#LWZ LO\ ?2_=BO"'9OT#9?[Z7[L5X0[,
M=!LC_NI?NPKPAV5^@++_ 'TN!>$.R_T!9?[Z7[L5X79AH-D.D2_=BO"'8[]"
M6?\ OI<5X0[,=%LS_NI<5X0[*_0=E_OI<5X0[+_0EGT])?NQ7A#LWZ$LO]]+
M]V*\(=EC1[0=(E^[%>$.R_T3:?[Z7[L4T[+_ $5:_P"^U^[%:#LPTNU'^ZE^
M[%:=CAIUN/\ =:_=BM.R_J$'^^U^[%:=E?H^W_WVOW8K3LWZ.MA_NM?NQ6G9
M?U"#_?:_=BM.S?48/]]K]V*T[-]0@_WVOW8K3LK]'6W^^U^[%:=F_1UO_OM?
MN&*T[-^CK?\ WVOW8K3LO]'V_P#OM?N&*T[+%G"/V%^X8K3LOZI#_(OW#%:=
MF^J0_P B_<,5IV;ZI#_(OW#%:=E_5HOY%^X8K3LWU>/^1?N&*T[-]6B_D7[A
MBM.RC:Q']A?N&*T[,;6(_L+]PQ6G9OJL/\B_<,5IV7]6B_D7[ABM.S?5X_Y%
M^X8K3LOT(_Y1]V*79OJ\?\J_<,44[-Z$?\J_<,5IV7Z*?RC[L4NS>BG\H^[%
M79O23^4?=BAV;TD_E'W8J[-Z:^ ^[%+LWHI_*/NQ5V5Z$?\ */NQ5V7Z2#]D
M?=BKLWIKX#[L5=E^FO@/NQ5V5Z*?RC[L5=E?5X_Y5^X8HIV5]7C_ )5^X8K3
MLOT(_P"4?=BEV7Z2#]D?=BKLWIKX#[L5=F]-? ?=BKLWIKX#[L5=F]-? ?=B
MKLWI)_*/NQ0[-Z2^ ^[%+LWIKX#[L5=F])/Y1]V*'9O13^4?=BEV;T4_E'W8
MJ[-Z*?RC[L5=E>A'_*/NQ5V;T(_Y5^X8HIV;T(_Y5^X8K3LOT4_E'W8I=C5M
MHT)*J 6-3MBBG8[TD_E'W8J[-Z2> ^[%+LWHI_*/NQ5V5]7C_E7[ABBG9O0C
M_E'W8I=F]%/Y1]V*NS?5X_Y5^X8HIV;ZO'_*OW#%:=F]"/\ E7[ABM.S>A'_
M "K]PQ6G9OJ\?\J_<,5IV;ZO'_*OW#%:=E?5HOY%^X8K3LOZO'_*OW#%:=F^
MKQ_RK]PQ6G97U:+^1?N&*T[*^JP_R+]PQ6G9OJD/\B_\",5IV;ZK#_(OW#%:
M=F^IP_[[7_@1BM.S?4X?]]K_ ,",5IV;ZG#_ +[7_@1BM.S?4X?]]K_P(Q6G
M97U.#_?:?\",5IV7]3A_WVO_  (Q6G9OJ<)_W6O_  (Q6G9OJ<'^^T_X$8K3
MLHV4!_W6O_ C%:=E?4+?_?:?\",5IV6+& ?[K7[ABM.S?4H/]]K]PQ6G91L+
M<_[K3_@1BM.S?4+?_?:?\",5IV;ZA;_[[3[ABM.S"Q@'^ZT_X$8K3LOZE!_O
MM?N&*T[+%G"/]UK]PQ6G9OJD/\B_<,5IV;ZG#_(OW#%:=F^IP?[[3_@1BM.S
M?4X?]]K_ ,",5IV5]2@_WVOW#%:=E?H^W_WVG_ C%:=EBR@'^ZU^X8K3LQL8
M#_NM?N&*T[*^H6_^^T_X$8K3LWU&#_?:_<,5IV7]3@_WVO\ P(Q6G9OJ4'^^
MT_X$8K3LOZI#_(OW#%:=E_58OY%^X8K3LKZI#_(OW#%:=F^J0_R+]PQ6G9OJ
ML/\ (OW#%:=E?4X?]]K_ ,",5IV7]3@_WVG_  (Q6G9OJ</^^U_X$8K3LWU.
M#_?:?\",5IV;ZI#_ +[7_@1BM.S?58?Y%^X8K3LWU2'^1?N&*T[,;.$_L+]P
MQ6G97U*#_?:_<,5IV;ZG!_OM/^!&*T[+^J0_R+]PQ6G9OJL/\B_<,5IV;ZK#
M_(OW#%:=F^JP_P B_<,5IV7]6B_D7[ABM.ROJL7\B_<,5IV4ME"I)$:U)J=A
M\OU#%:=E_5(?Y%^X8K3LPLX1TC7[ABM.R_JL7\B_<,5IV5]4A_D7[ABM.ROJ
M<'^^T_X$8K3LKZA;G_=2?\",5IV;ZA;_ .^T_P"!&*T[+^I0?[[3_@1BM.S?
M4X/]]I_P(Q6G9OJ4'^^T_P"!&*T[-]3@_P!]I_P(Q6G9?U.#_?:?\",5IV5]
M1@_WVG_ C%:=E?4;?_?:?\",5IV7]2@_WVG_  (Q6G9?U.'_ 'VO_ C%:=F^
MJ0_[[7_@1BM.S?4X/]]I_P ",5IV;ZG!_OM/^!&*T[-]3@_WVG_ C%:=F^IP
M_P"^U_X$8K3LWU.'_?:_\",5IV;ZG#_OM?\ @1BM.S?5(?Y%_P"!&*T[-]5A
M_D7[ABM.R_JL7\B_<,5IV;ZM%_(OW#%:=F^K1?R+]PQ6G9OJ\?\ (OW#%:=F
M^KQ_R+]PQ6G9?U>/^5?N&*T[-]7C_E7[ABM.S>A'_*/NQ2[*^KQ_R+]PQ13L
MWU:+^1?N&*T[-]6B_D7[ABM.R_J\?\J_<,5IV5]6B_D7[ABM.R_0C_E7[ABM
M.QIM83U1?N&*T[,+6$=$7[ABM.R_JT7\B_<,5IV;ZM%_(OW#%:=F^JQ?R+]P
MQ6G9OJT7\B_<,5IV5]4A/["_<,5IV4+* 'D(UK\ABM.QWU6+^1?N&*T[-]6B
M_D7[ABM.S?5HOY%^X8K3LKZI#_(OW#%:=F^IP?[[3_@1BM.S?5(?Y%_X$8K3
MLWU2$_L+_P ",5IV5]2@_P!]I_P(Q6G9?U.'_?:_\",5IV;ZI#_(O_ C%:=F
M^JP_R+]PQ6G9OJ<'^^T_X$8K3LWU2'^1?N&*T[,;2$]47[ABM.ROJ-O_ +[3
M_@1BM.S?4H/]]I_P(Q6G9OJ<'^^T_P"!&*T[+^IP?[[3_@1BM.ROJ<'^^T_X
M$8K3LOZG!_OM/^!&*T[,+2$=$7[ABM.S&TA/^ZU_X$8K3LWU.#_?:?\  C%:
M=E?4H/\ ?:?\",5IV7]4A_D7[ABM.R_JT7\B_<,5IV5]5A_D7[ABM.S?4X/]
M]I_P(Q6G97U&W_WVG_ C%:=E?4+?_?2?\",5IV7]3@_WVG_ C%:=F^HP?[[3
M_@1BM.R_J<'^^T_X$8K3LKZG!_OM/^!&*T[*^HV_^^T_X$8K3LPL+<?[K3_@
M1BM.R_J<'^^T_P"!&*T[-]3@_P!]I_P(Q6G9OJ4'^^T_X$8K3LKZA;_[Z3_@
M1BM.ROT?;?[Z3_@1BM.RCIEJ>L2?\",5IV;]%VO^^D_X$8K0=F_1=K_OI/\
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MS#>E8M/)7,[*.J^H2*K=!E%_KS*A;IV!K/D>A-L#>W9L)+A^I!*0/V[5/6H
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M),O;OL53V])W>.LU.$K;53HH]O"NKU7'$&OSVMG>>%OC$;Z\!F12%809TF@
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M7USJ#$[P6]>1I*U9U*E6,QZ(^-C74N'H5IZQ9!EI=K?9XUM;'M01*)1QFN%
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M.8K>Y_\.>)P3[JW4^ZL*CG5HX?>!=:0#0M)G0=*/T/D@I9'2LY;93PJZ/\E
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M&AYR+?'.I,3+%B'B+%^[,[]>GXG.9XBU2.+Z[-UT0 T4WL''/\#$7;U3#<)
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M:TS1**T^&1]<K?1.VSHT:ENU1=/B+-8L_37&&ZQ[G P#42M30W*'6K^_.:M
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MU"HH,.;JDU:M:T-BL%=M?"N;+S@1.37SD204[:I6QO#QK^*7HOBS8C[B5UP
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MHB<_-6W;O,C6.+/Y\\( 2$[X8188)YI6%-C1$UE*'=5U4M+'K6SV/YH/D1:
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MA[0/U^Y5'-6'U?<(E89\/\Y2RQC^+2F]8B7Z+GXG*]T8&4^0@D%GF?YYC<7
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M2J:2I(9*7V+=JXY\YV-W="]3T#J% VZ;0^2(E36O<#XR1^7/<&4ETP%D/:[
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MGXBTM(X+F-]PX_FXK.B0[.80@ME:EL>Q [P3AZ&K]]P(P_26??YSD/V)_:(
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M#,P(:(XE/?1]:NH1>8>9>P^(8,KQ5:CC%0A59S#US I 89IRP-$!#TN2ICU
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M+3^O!"@:$F("%+4T 8D".2#=EC E 47YR<&I)='Z 2YN^B&I%26Q=G8  08
M904?[PT*96YD<W1R96%M#65N9&]B:@TW-B P(&]B:@T\/"]!<G1";WA;," P
M(#8Q,B W.3)=+T)L965D0F]X6S @," V,3(@-SDR72]#;VYT96YT<R W-R P
M(%(O0W)O<$)O>%LP(# @-C$R(#<Y,ETO365D:6%";WA;," P(#8Q,B W.3)=
M+U!A<F5N=" Q,#0P(# @4B]297-O=7)C97,@-SDY(# @4B]2;W1A=&4@,"]4
M<FEM0F]X6S @," V,3(@-SDR72]4>7!E+U!A9V4^/@UE;F1O8FH--S<@,"!O
M8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" R,S@V/CYS=')E86T-
M"FC>K%C;;N/($7WW5_1# I"!Q>&=(O9I9C8(-@B01:P@ 59Y:%$MBQF:K>TF
MY5%^(_G@U*6;(CWR>@TL#%ABJR]5=4Y5G>:'/STDXM'>?=K<?=AL<I&(S>$N
M244,?_"1Q7$4QW$IJB1*BG4A-D]W'S[;M6@L3+5-?Q>+38/_GN^"I!+AYM]W
M552O:3U]J5+<(!%Y'=4);P #:8K+?@K^_K#Z_J^?'[;;)*VK.@_+(,[640&?
M(OS7YL]W2>PWXV])2=MEHHK7T;J&$=AO!4/9&C<,MD'[=1NB%>#-VGD3Y6F)
M'FV^9VL#X29\XVZRKG'[?+$]CM#N45)6!7KZ4] I:=51AT6T#KIPE41EL!=M
M3\^#,LK"MR08\",-_ ^"5EG!RPPN@Q_MN'/;9%$>T Q:+&2_%UW;J)Y'4AZ!
MZ<M!BM.JC,"T%8*$;C)F:'*<9#F;_&AD/RBT4@Q');39M[TT%]'HT5AX/HC=
M:-M>64OG])H!J*.J3G*.7H1 \JYYPKL.L!\X?%"F[1]Q;]E?Q%.XAH#(<!5E
M&(U6=@)"<E+-()[AISQHAZ.SV^^_,)VBC:BF:W<*&$S64:301# 7!RD4-,C1
MT"%&]COQ!GO*HHCR.7OJ*XNWP0T&)47V/@+-3XCBLG;A^DL+R&&8#O*L#7K1
MC';03V$% >/ &W56_:B$' <D&/(DA8"U0!QI6HMAEO!5\!J)+,J# <*,N[U&
M!N9OG&6>O_)9#%I8U8Q,1B5.\O)$X*A^F!F&(V(_TOG#40Y@1%C"P;# N)]/
M0W>!Y>U>Z!YX)7;JH&%#Q&<O!_IR8<LV?Z!PQP[6G6K<%@JX4N(YZFWL8OA2
MUZ7'+D\7V+6_1?K/S^ 1"E^:EW,8P=NVMR/D54/1:)3:6XHI)0/ZST%%]\J@
M#Q$H#.T!,@_6[&?+;P$'WJ%S>.#)* Q4$K00J"08^6%"9 (C^75@^, G%/B:
M B^V<(H^MWNPB[:U8W-<PE;/O5=?!TJ]/,"CX%#DTT@#L,YYQH_ T6 6(2XO
M R[ :J'!)(._GF!V%B@S7-!P::T:[#9\DQ!%#M6FKHO7"'&#$33]78R8'S)C
M1.83VPYR& <-]12]@^@^0?@QRTS[>!RP7G$F@4\K?3C0+';<MLB0MI/&SX7T
MAM"\ELKD792N\XQ/WJN3MJT_ AI"(^V16P4QD3)W7G%VLO]B[]WI;C4:#I -
M+3C1ZIXQ\MA?RWZ<N/JQ,_J+,O)1 9<-EWO[)E!Y#26ZKO,)J.P%4#>0JJMU
M\CZDYJ?,D*)L1M.QPU).]@-$X3^ZQUR%]C28MB'?[QT.@-/J63*@,Y!4WV#Z
M!3M,9TI>^RI6+FRE+[O ":.@&R+9B><M5O$J  P@ZW878@QRWQ7Z7^S55+BY
M85LM.LV-809:7$U]=&JC%['7E'P(6D8]NG(]ND-SH'(8.O,LNQ%/7DPT7]0@
M=VW78HIB!P8;*DAMHSJ)VN)$SZ1LLD#3PRG$&> K/;W-D3Q!X94M==V5(^<;
M%$FS=R;S_! <*5QYKQU,V^#C-A3_"&LLN-"%QP$*Y FTAD2"H.=8MW[H]VH'
M7A,"+;#"& P!(#02J!BR/.BISC6='"W4V@*+[6ML8::F259Z,\Z8$E.DH4U"
MOD+S:+T9/RI#O!PP^&0/31M0,H!AO :KKP563TWK,Q8(WZ9HCM @*ODKN4C?
M;)BC:)T3RLF(W,O@$YU/@@XM8"T!9ACGL%BX,+>>!3%S ?A530+3@Y%[,"8W
M"8S)41=XL+$.[BE'M\$G.,D5/:1;X4/-)]R(=9*NDQ=5%%*NT7VOJ!:(9U2J
MRY1E$7]/_E 7Y4H ">I18?I<32)5O(ACZ1,S=E#+QT>C'K$_RR<] F>X/X(3
MH(K45^R;XG?9?4P#<7P/*P5V_IX&H/=B?8+B_[9\RLH8N9],";8LPC?RJRSB
M=XK?^1FS$ES-Y8/5G8**H_G& )3$Y$B#(\92*&D 7"I24#.Q:'EX< 0U+P"&
M]?*3-D8_H_8U;UV$BMQ=A$AS' 3N]C#N;+MOH=RJ)?(45@<_Q[.*TCASK8CW
MZ)17W7@%0M%L,/N;(_!#2,!3.4RP!*"@<F1T.\UEGL]X.)][,(I]3_O,T?YC
M\_,(;8%81C>A"F^$@JG#-R[B#RV9D0CX0Y.)1(?V#$I,&;XV0>D'CA:_!Y+.
MZ9E.]%Q/.8ATO[)T\A,M!LEH)!<>M(W$YS*-4&JH07_W!C?3.D.1]4KM/[>_
M1>V?G3&[V"=9^BTYN4:Q^<)H?I8=MNW93=]?\GU(N NN@Y&NHG:4W $F.'VQ
M?$'7O%@40"2%U]M_TQ<Z=0-JPTJ.*%07KG!.5=.#Y3Y10+]5FC7F#ST-#*KK
M (L1"MF/1M,0-.:"Q?:.U]!- %4'ZL@";QH0W\#=5':NH%XO!?$RRVK/F8*L
M#@ZR(9V !0DP>1WS/(ZR8CV!GK_ _!O0TRBIR^J=H,\.X6.=L<E4D_B5"B?J
MSQ"G]G!!.46@51@8 HT@."@#8A>C^Q:?DSPJ?LFW&\[E2,Y?XUR:E,ZY%Z=D
M7&[SI,J]<UA;Z1:*';T/5_BF"0H>#_<AOKYJ^,>1?S0&?\O]DCV/7E?PHUNC
M^1&RG9_=\,"3W1H_"6HJ#T!EQ;P*ZX!NDA98?8]/1OE]GH&M,*"=+2YCZD7E
M=)<(O"K[_F(4WZ^1RJYP+:0:*026VTX2\:3A<D*%8AO3[O@]&8L8T-2K/,97
MBU FAZ/1X^/R7NS:6U)[V<:T%7*GS]"0_:WZWMW6H77,/$9WGR5[V&$+,>K4
MR48]8=M ^X0]@C:'*[OH6KYIM<A$?T/T-A13_EW%_E6TN$L+2*@=ISW[CW/4
MUQ9Z#L2*#D-6\TI0M.T)$'""!(,40KFJL47##LN8SDW)?"G(BLR_Y\']R6F*
M _D,%I"WT\N0;2"IOSOIG(&L.5)@L@!ZUDXIO#SM1ZY&%$;WRJIR+1:K7@\9
M-5/9/CHO.EJPUP KMD?PTJ"@BRC/,K%*K]PJ"H?H?UWI+ET5N%&0_R>>E*1[
M\T782P_&#&V#38,FGJ2!1P@G7Z[!4_<*Q#6!6Y3&\UT"3]NX%F/IQ<YX@8N)
M!9XYD<HO6/U+E8/X^,^'55S<\V?%GTGJ/G-$^H-730LB@SHI9DII>CL#(FG
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M=W3B1',URP7C_4J43-$Q-4RD^<JA>QJ&"3N:H3&FQM!>9)Z-R!_4!QJW-FY
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M/G-T<F5A;0T*:-Y\6-MRVS@2??=7X)'<DACQH@MKGQQ[,\E4=L8;:VH?XGV
M2$A"AB(T &F-\QF;_,/^YIYN@+2<*%.NDD6( )JG3Y\^X*N?[E.Q<U>OUU>O
MUNM"I&*]O4HS,<,?_N6S63*;S19BF2;I?#47Z\/5JQNW$I7#K:YJKV9B7=''
MZ2I*2Q&O/UTMDW+%\_G+,J,%4E&429GZ!3"0933M8_3;_?3VUYO[AX<T*Y=E
M$2^B6;Y*YO@OXO^L?SZ+)"T*6B@7R]DJ6958&2M-,52DM!2^%>6"PO@8?;E3
M-IXNDC0ZQ%@LTEVG:O%O::UL.[&V,I[.,=S&21DY677:M%_%0<G6"=D^B4HV
M#4V?1\(<Z<>).(6YQ@JK=_M.=/X&0TN(8V^KO73*ASQ=B"F!)=:W'%^^H/@0
M7A[">XBPC.LWKL.2^E$U3T+]T>M'V2AL42N+KQB/%TD1*=%A8Q\D!C($3<,/
M<3Q-@)%5#6YM=Z(SXL8<#J85]YVI?A>\A^GV"CNIJK>ZT\K%\V09<%W_S6-7
M^-A6\]S'AEE':X[*=D]B:YK&G&AU"73L#FNI1^51\$M7^SB= 0;9[I0P6X'!
MYS (H56$8!YBP%J_PJQ*NCU"TRT&7L21EQQ'GL]]&)RAG-.WC$S/L'3*^FN-
M9\^C%BG=/ &!K;*JK11!0/L?K:XX&-=7^Y?1Y"$:9QJ>^]I8:T[*[V7I7_D2
MGI"Z=%&4/JXQ:Z#($V="5*8%O@BA0QY/NMLSAYXI,8^>=[(4E_190_AW]$1E
MH.=KT];BK:IWZF4(*Y^AM%CZ$-8C'PC%6D@G")85809^/(F-$M*/J+;&PH1V
M51E;2T*)(L2/621TYP1AZOY.*7_4=&^WEQT2]"= PFW$-UP3J@'\5>1BE-7D
M/,1LD?K(@$2M*2['@54&9 %6'GE'CZXD4L)YH1H+U77&<$1JE:AZUQF?:FF)
MAE;(G57*#P%H-Z9W",,K@Y>!=!9(U#W%E-@C?ZHX1W8G_)TP"WR"1(%/,V83
M@-H94XNMI"PB:_3@&R-M3?O%)="HM5559ZP;V/Z<6 2)1SZ$)9%211#RUE:9
M+6+/OZF]0;=F,V971* ]1$]$T+^"Z&1ZHB]P:J1S>JL5DP 512J"NM6MZVQ_
MH$K]/O>LT"&">3EJ]\?HI^OKN^2\!B!CV9F,%5D(-YMESS+K6#KQ<) JFKR(
M!A75( -(U<MF0@6G6%>L5H3>7A\GXBAMUZIP\<EHA$OJTELUP?." Y/O]10J
M6@2V]:UN\61'8[F6C-W)5G^67J\!C*ETN!CNXHM&#ST!DQHM-[HAS)"Y(Z*>
M,'BZZ_W-7N5>E.-\2%H:6(:0:0'D?P?"VQ85C0K!:/(7,"9I7HXH-ESTUT1Q
M#V' L^TN0$ND^^&,L:^M(B@FXR)'JMXTQI&8WV+\$K*A VQ4=U*J)6;['NKY
M3>2\WB$F I?7<](CB5VI5?J+T%I1M18EG.:(1'3:-\L7MY-:^V'\FI[_2O-9
MQ.AK\7*<!&T"_80(=_3-_VCB:8% :]2"7S)(>NW'+W2\J3<U0\OC/)\TY-KU
MQV/#TU>\<T9I\)V, E]%]>6TYJF7Z=FS!^&&DE)P.?Y]\@^@**1Y5'7A.=]K
M_P6>(HP@JWXB!(_WIM&O?IH@<F$13P1(<X5&+5'DU\ZI3MP-3>?:RR7?2QD;
MJ7#1H!0A]GE9!$2VXI\22XEL/A$H]VQ":CBXIGKX=H"D GQ0:E1!8LG/\O-G
M<;>7@P63E4(Y0<V<N'M_,V'NA'1NM\HGN2(?U"K'9'T6]7R(Z+37"$<[4I(Q
MQ?ALJ')#UR$1:,]7EWR+Q3VA>S'7$%(;'H#E%.E7?QZUUX>A5DYH 50K,$(:
M':$'[RS] *K.J.F?,VJV\C&^A9Y-[RO3==,/IM:M$=<D#:1DXAT%G84RI6X[
MU"UWL^NJHXW3<KD N[#%]PH<^!H:W,BQ?M/H"JY!-E#V]_+D1A^+WO&!^H%5
M@<;,WM [<>=@'6,*8_=LG@S,S-D4^*S+.@S:!"%;!6]4PQPVYHBYGG15HUM*
M.Y.B->UT'%"PNKW$SEGD=1;;UCU D$?"!G<@*>PV\'2J==P2#K+MMVB!?#%2
M)%UE ?ZPAI?_5C9/3CLP7Z,7ZDW0<UP=L1XR"Z$_H"ETH2N  72!/1<AI-YA
MFSU";_CN/]#'(/.3%XXCN,-R<*T.#AX=1FZ4GW2TQB-I0B,: $!(^+1JA^C@
MH*.!?##?!FSQDR1GS/Z.PK8_S"1UVMKVN\GW5@B!#3UFHTUC=F#*Z-P'Q,F,
M5TT/T[* ?E+09!),WW&C]%9FZ*G<U*$LM0Z' #1-ON6(XFN[4#N^ZGTX,V9,
M$2A3EJ%UP]&IG>'Z\F$X]CR;3_!6Q$3\VC<>$E]Y,;D2XN<;A4M ]P8^;2)N
M^<&)7C?&44%QA45!OJ$Y7%D/49:>AS,2>/!?\\$P_I;<)S>)^!].O:D [$[]
MD?C#BV^[+ZKM7ME'.OW@/ )KY3="<Q_7R,[7(%\!F GA$>#SA*W&IA1"\3:E
M&-#W5A*/=H8-#\".P\H'HA51W^Q8ZH-Y?7-[+= EUKJ#_P(*XQ&MYA/2@.:'
M2VM>XE,>2IW/'5 8U"L0D9OF/"['X7P3R2_\$_9Z%_R58OH&+!^B+[^\>_LU
M8,T[_V-]5:P@]&A.V3)+%M@Z2Y-<)/.2SOY676WIG<7S^X'A/4.V0$[(V1[.
M:G2V+(<S2AT<\P +<O9C6%@=^Q@?X=F(;CQ8BUVOV59/N ZH,H]\H_:#]+/B
M^VNBR2*Z>%@9;60H2P,\<5)'JW/]BSSZO@F4&*)P_![J+X9.2\MY&$PHC:,H
M27Y[\,V_ /B!=RF'8,J@I5_^17+'.-W@R.YMZ'+P'<&:T?$\3?WI'*@-'N"_
MCN>(O<(I1?N^U\8I48J.(CT)UUFM7W8D\^"FTH%O*#">BR2UG36-MTF#$2A]
MS9?<8-E\T\EG*_W@H^%S-[M7FE-&24QFZJ(]SX,76EQ$0ER_NA/7!XJ$.ZU7
MFH *SLL+;X"7'$A^"9L1@Z-\XH1=!&"V' XY)']T-$,'[3!'!_>UC+9DF_.H
M\\9$I*L9"JF6YZ]M:%RWCX8$:LOOG&"BPO2*G9#'-(227'0=\Z&7!*)^^: J
MI1_E)B8+U2CGV9%Z=J"?4!73R?7%8X?TH1[>^=/ID"B,W,)SA.NAM4U^ $OV
M+5-OX(([U8@[":LV$?>P[VCD]/"_0JQW0]$V"G?Y4WM%#:SCYEPI58]=U-]R
M?@<5VGL>C:?+;R7Q^V/$5MSP1/&!WA#ZRB<\!D"&UQH1=FG0^!V=B[?=":7*
M+V]PTE)^TJ:'12$S;%5E8O+'MG9Q06>IX=41]X."7BUT)N&OHVS^7X ! ,&C
M9"4-"F5N9'-T<F5A;0UE;F1O8FH-.#0@,"!O8FH-/#PO1FEL=&5R+T9L871E
M1&5C;V1E+T9I<G-T(#8O3&5N9W1H(#DV+TX@,2]4>7!E+T]B:E-T;3X^<W1R
M96%M#0IHWK(P,%0P4+"QT7?.S\DO"BY(3$X%<8HM% P-+,R!4D%V=OJN%27N
MP26))2 I]V!#D)0%5,HM/Z\$*!H28@(4M32!B@84Y2<'IY9$ZP>XN.F'I%:4
MQ-K9 008 /$L'1T-"F5N9'-T<F5A;0UE;F1O8FH-.#4@,"!O8FH-/#PO07)T
M0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R(#<Y,ETO0V]N=&5N
M=',@.#8@,"!2+T-R;W!";WA;," P(#8Q,B W.3)=+TUE9&EA0F]X6S @," V
M,3(@-SDR72]087)E;G0@,3 T," P(%(O4F5S;W5R8V5S(#@P,B P(%(O4F]T
M871E(# O5')I;4)O>%LP(# @-C$R(#<Y,ETO5'EP92]086=E/CX-96YD;V)J
M#3@V(# @;V)J#3P\+T9I;'1E<B]&;&%T941E8V]D92],96YG=&@@,C0T-SX^
M<W1R96%M#0IHWGQ8VY+;N!%]GZ_ 2ZK(E$23(G5AWF;M=38I)_9FM$_K/$ D
M),&A2"U CCS[&8D_>$]W@QI)5J5<Y9% L-&7TZ</].:O3YG:^8<?U@]OUNM"
M96J]?<AF*L4__,G3-$G3=*&669+-5W.U/CR\>>M7JO+8ZJOV(57KBOX[/42S
M5,7K+P_+I%SQ^_QA.2,#F2K*I,S$ !9F,WKMU^B7I^F[CV^?/G_.9N6R+.)%
ME.:K9(Z_*O[W^N\7GF1%089RM4Q7R:J$9;&4KLC2-$EGBQEY\6OTOW^9VASB
M55)$Q]YVK7K;M;6E3SZ>)[/HFY*'1K=^HDZVWRMG_-%46%U&O>H[I=L7==0O
M85_;JVZK*NWWRK9A+R^QB].%FE)RU/H=^\.1)5E>+,2=?F_4T=FVLD?=*'V(
ME\DJZ@8Q2@=],DX6;=^;FKQ]-JZWF\;$68;SU3NSZ2?*Z][ZK:XXI&X+UV:1
M,KK:DQTZ9-LU37>R[4[\6O^9LD*I#_FA3)%#YAD1^;^HSY'^'*NV@_VM'AKX
MX]2/SR':<<WO==,H')9'YJOUO D9H$<XTYFMZPZ3>#I/YA&"J6%T Z.;#DFU
MAX.IK>Y-\W+V2,!$"4K+4MS9F&WG#+^L>T6G]?; T1FO]+8W3OFAHAI)56?1
M,4X6$:5AHN(%OO_0.=>=C/NO5S\/NK%;2VFD<HGW&T-1-L9[^*S;*V?F8W:R
M3-S)YNF?QHQV0^][.$8YO2KA*LG.):2-3UB91Z8:X*3ZN&GL3C/>U+$9/.^X
M<>SQS:=+-Z0=4O'@\1"7 2*); +"9K<(H]IF^1GQ.]3&N&]JK^4\010@3KX3
M8.5PX/?)"(2 K65RE8MEL%LLYE=V'06#UEE&K?\6<GH02"";>NCW\M3%:(0\
MLK]+\*@.XU<?CTXV/.L&JXVM3,O?O<'7(\&?C-D>WRJ"_M96@ T9N&VP5T0G
M65F$DKE7+UNV[WM$_9TQ(-=\-928N1"#I_)AU7H_(#>;%V['78?V:V4;FH$*
M3A$ZVU_#N! OLEEHJ\\1 -(,#!8$%&ED(W+_,>2+XAQ(^!;M#0<%(;#>FI.J
MW<![&O)5HL#^>@#-./,:1<AJ<"(5!Q:KX  ;(;\7?#8RWP[$%X,C#W"F!C#]
M7G90FU_FC?MO/#-DD)RP%;N/A\[8PV9PWIP-X) 9\=-E5H3]9K,\0/,B\$9O
M3'.5#$H^P&J=(@JPNU:9WP:+)S .%D&S@A# #<[\QLP]Q/C/4H]M^4U>I,?>
M:%?M)_S]U9ULF0<@U^"\ICN&IFC!IO*1\S0[Y\D ,MTA[(JGQ"V,Z5546;2O
MX'JB:LJ:W0SR[<I2J#?8NN^<WL$@\MOZ8^?Z\/(5-X<1$=(\N<#>ZCOL7>4_
M1#%X(4Z/E!&81R94GZ22/E'J+H7DXY!:OG;ZT&@X_:(>F1\P)6E *NKPFHXL
M(QN3C:@-H'DV,@S.+YH69:G,@; E<^I.!P,;Y6P,NZN,J5$U-#]P0:UXV1P8
MSMJUX3'_V8'%,20=(@?\:%S;O@$<QM7WG1-75;'*R9ZWP?5&DW&>W-)VWPV!
M)%WEH1[=QAOW//9;1X,.$Z0';U&2GVW7!$:<1^WY;#0JB!&5CPL<"/C0L;\/
MO(N0-?)NGLYY[6S1*3'5QSFR2V=Y*R.&O;['.:O@Z,F19F@9M4,;*(*9KH+K
M8%E()2B:VE3.P(5 =%PU-)H3TJ-Q\1Z#=!F]>Z1G0UL;[DOU:0!C5)>0+>9A
M:O]D=(,9_T&?D"':^\^__40O:_(%[(<9#>9WH!QS1K4T5=0B-5ET#6[;,O=*
MJB\@]07DY6O+F<.PFA8I90Y_.8/WD+V26A9%>49V"/4#8BRX,/ !(?I+(<C:
M QZ(]L":1 7P+*-]U]!VJKT\[&*D%;S$:N)"+_CA<%\3YN/$3D._A1?T;H=@
M,9Z0]*.V]:U0+*]4QMJ,Z/[0D<M8:R\URAVU,%N4^74>0AG0QCU'A IR'C@Q
M*-F-)C[+8:A43]BJH#()R2#4EY"C>Q&'EBKR$# A%.!O]$F4'B3$UI!N+$'.
M3E/?@"$-S[UGR@$M-1U::L+V9QGZDV\#<D 6[ >"'P<(+@Z3.(NX3@O,BRQJ
MP,?<K2@ZTLH<@WZEG>,$;@C$YRO'=#SJ'(\,6B JI)(\15]'K"HJ-"]"H"YP
M!A;I$Q<$RV$,NQIK;FA(S_(@97@+N>P&6]-4-)Z24434O*BE;BN1+ 2\R1T.
MR,M1/W\9ZAW7KR7]1(S (N/+T%;A#&E_KRX5"G$Z4PRY6-YP.DQ:J@"* ?51
M&X9*8**4\U)(H?.B#/4=6QGQ8W)3F 0-3C6,R/!C?KB=)7)W.,L0OE0 EAN
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M";A0!=&8@6TVME,UA#XD);@@E?:K#JD#EI/'A,BAZ<TA!D=63I;9LAB16JQ
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M/G-T<F5A;0T*:-[,5]N.VS80??=7S$,+4(6M%259DONVE[1 T;1!U@4*K/M
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M&A)B A2U- &) CEF((X9E ,RRA*F/J H/SDXM21:/\#%33\DM:(DULX.(,
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M$*;!)KO$"VUX4YQ43K.ZEA*CF$%\JN((F<]AIR[?LB;?2;A;RBW;9A7$$?'
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M#0(_-\HRS<93_A(X5L38CT"X RM=)L6'<Y>**KRE,",SUA,J XOYRPR?@\N
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MZ5BUHA48AE$7U%(.C/*MG1Q-NPD"$_*/D[7Y:0@GE.$T]->&%="+4%T?:2[
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M:7Q!+W9B]MF4I^F%'$%R)*Z8_KS#*I"@T>4?I/*<S/ML,E,\DZP0Y<CBAD'
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M<MLX$GWW5^ 1G+(9WB_[)MO*UNS%3DF:R<-H'B 2DIB120U!RM%^QG[QG@9
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M]V!#D)0%5,HM/Z\$*!H28@(4M30!B0(Y9B".&90#,LH2ICZ@*#\Y.+4D6C_
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MA-.M!04FT:7A[7)PS%=5&1LZ?"3!QW 0('Q5A5^#?=REE[WKWE@;\7<7@<1
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M>0)_97['3-26JBPL,&VZGT["<LX85WCU'+-3\D4U+<I46-4*Y!1L 8*X+W:
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M-&X9EU40K7*O6-&EU-8AE)JV.!@DB8X:M?@&G_>*-4N@::(S;;'*/1>P4GE
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M. KOQC6[24JZNW^O]._MZ>;"'UR-WKIC%_QP!C<0J5"UE(AVITUY*7)3CR"
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MT+6'SA2]:1O5;M5]@*FF4;3JH; ]EI$5>EV],9L/$*D9>4ZMWY.1.#B9Z[[
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MP^97\,A9DO8]Y04Q1A; L';[)ORB)9%]>EU5'B;Q'-&_(BMI.H^_3U8N=G*
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ML#6N_G]DQ,'%^CN(I.].@4,<3,OUTB_="P32SU9^-IX&JN,^C5";<^21;*A
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MROZX"S@'KV>SPGN]5JH5 2.>-- ]MN*>)=80/]_?_V.$C)5JYP0,+4!D&G4
ME[ 3<MUQ_E'+VAC7&J< 'FI7[*.-PYSE?5,DZ:!$[#;L \/K;QR1$92</#(Q
M_EG/"4@"$P?A75;?]IT+7($$4J]VG[VIF1BGYX"3Q9G\GZ/R!@,G'Q-PT9<C
MQ^SX<[3;ZE:Y(S84TVO*/:'FFG:+OKN"T9YRB6QKW94A&\2SX+J&.C1.B.%Z
MUKWF54^I"T"OIT[&[25_TI&G@HW]5/05FTW#T#DQZA\BTP%A#KE27S DD>,M
MTD]/I']F3CB?12?Z] /CS)O4%,DU:?JN[)1CQVIF5S18%EFT.:,1)_K'=_$X
M(VQ:R>!%K[]<$ER2]6P+M%C5[4S+P=1ZL\?'$SJ0JU*%;P9%NR 5B>]P/GM?
MJ1WJ0;WSCDMA<Q9J<'Y\MU\CJ0S:?>LD9:%3C2<W',V<%"<)J@YF"I/GQ(1X
M"J#FY@7B[D'U;O2>XH9P[4=+2J-E/A@M88ZD1&=$1JW<*+^@/+^Y?OC4-IS@
M.V[@^6=Q$\!#_%;_$P4%E1C83\1)7A"W_%%(XY]E2,]Z2 .(C>HZ"C^//I12
M&0E#QO2;HV)S!CG[9 KP:5$_FH',OT')@/:8$2MB1%$VIE.7+,(PYBUU/*,]
M3!6>(DWKMNC^"V2'BC[T]6PTH_#!MU9)THSC]-WO*V9HHFWU6COQ^%^PK?H.
MMNVSE2R6?Y9V?[=&MZKS_U&4))!*P$JW-:\LTS;XS_P6X((02$01N>@#:] <
M&I3PS6_/VW;\6<89#!XI7^_+-CXENZ];_:YN'Q0M/5<L"3.KI\8=07T!Q;!S
MQ#:_4Z;<E^:<-.@)9DQ0:.UE*FD]9>K1;5CUXGRV/#4*'0/B5\)K:,D:FJ0?
MJ-?LH&=[Z0D7WX[]&$FF-!"1MM&M6\DL#!D;F(RLR,#34_8HN^"L"0^PH3*$
M-.O8(Z_ZLJA2 AVFK&PH/P>(\IZ,MZ:IP$VL_ZG0?KC!)O#Z@BY\<J;\-8S;
M$$]<1!S2P*'\@O?&WC/?7YM]0X-H!]%K*IH@-!JABBEDBH\%O^WCW?#%!(H_
MQ4OGK-?H(36+29B_G \_<O(P<5! .,>8N;X@>'S/\G"O?()2MM#_V$Z^/+Z5
M6XG;!P?,>*$K51)U'5D.EX"-@59O3U=&N"[W;FMPS-$[$Y0C*T16_D,'DE-2
M."L1U&?GM-OSQ8 Z#L0WZDVU'#+UP]E/%7S\S)#X8&QMOG-LS7C/UW^J3MF#
MJG[Q!L<W+,+8]CN-+3SOSH/6.".!RK+>=Q"S'5&P^>89D=][@##.:],TGK:0
M1&U)]UESP//]_>D2OT5:7-^?Q-I(RZ*TTJ X9VS0;D/Z&/'MJ2>13K_Q9P>:
M32,B_?F)]*_HN+YH@EG?!//DG1L7D@W0?55-0Z_K?;51Q!)F1SHS17-9KW9W
MD+*^?_W]])P\W?(87="%'#?@B %TNQLY\=% IUGUVUYU;C"3/K.-]UWG?[/J
MVTY?=\*DR#YJA!27G/QJ --O+CU$0YT3U%G@GH?[*.GZ$[L%I#P!1KK2TAZ9
M[WYMS6NCD+ !/;S2#T0WN?PT0H+)]V=BY1YWX7B\0,-!M#B^>IZ/U9UH-"?+
M>/GRY:?[!_$W+#&702[0G;1 KV GYOI!LU@^EV*>A88T[4CPCW88MCD$DI)5
MD Y(&?W<1SF#V+U(:6L:0\>RB+#J,L'S23Y$6@AVWM_%0?QDL62+&?F'"X%W
MCWQA[RO^,K@OK95ZTX:+UU8UV'B@2H36HMZ<P;^+%)\Z/NU_F-E*NU%D[&":
M [6Q[U/3XEK>R#T%$N8QKC.5UX:EU7X7'L2\>KG:/ E:_G%U]Q\!!@#[Z5#&
M#0IE;F1S=')E86T-96YD;V)J#3$V-2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$
M96-O9&4O1FER<W0@-B],96YG=&@@,3$P+TX@,2]4>7!E+T]B:E-T;3X^<W1R
M96%M#0IHWC2,00J (!!%K^(-3 D:(=Q4NI5T%RTBW$6&S:+C-P.U?._Q/V@0
MC>A[.92CU'AM>V:X0:@&.DJSM7)ZT$?<D)./BA-\R943R::D-&EM6!.U!*;]
M@+_,/PBU[#'C(L/H9,H/KM:^ @P $)(BT0T*96YD<W1R96%M#65N9&]B:@TQ
M-C8@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @
M-C$R(#<Y,ETO0V]N=&5N=',@,38W(# @4B]#<F]P0F]X6S @," V,3(@-SDR
M72]-961I84)O>%LP(# @-C$R(#<Y,ETO4&%R96YT(#$P-#,@,"!2+U)E<V]U
M<F-E<R X,CD@,"!2+U)O=&%T92 P+U1R:6U";WA;," P(#8Q,B W.3)=+U1Y
M<&4O4&%G93X^#65N9&]B:@TQ-C<@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C
M;V1E+TQE;F=T:" R-C,Q/CYS=')E86T-"FC>G%C+<N/($;SK*_H(.$@L7B2(
M]<4:S<R&'6-[8T6?5CZT@":)'1#-[0:DH3_#]@<[J[H! M+:!X<B*#SZ45V5
ME96%[WYX3,31WGW8WWVWW^<B$?O#79**&'_XE\5Q%,?Q5A1)E&QV&[$_WWWW
M8'>BLAAJJ^XN%ON*?E[O@KP0X?Z7NR(J=SR?+XJ4%DA$7D9EXA; @S2E:3\'
M?WM<?_SKP^/34Y*619F'VR#.=M$&_T7X]_V?9I:,ZQ3Q+MJ56-@M%.>T$&PK
M$[+A9\Q;)[L\CC;!!VV,?E5&V)-L6]'I7CP%KTU_TD,O^I,2E>ZLZGJA#^+^
M&&ZB,L#=2MBA.DWO:%:OQ;,20V>4M+J3S^W5&9=&Z4:LR3%B_Q'&I+O<V4";
MG%1;"VU$K5IY5?53N!)G^54)V5U%=9+=48FF$TUO891\"H6L*CUT?=,=Q46W
M3=4H2].-NFCCGAI9]4VE[,KMOO_=W1I[YJ7;4WVKU*47TF+*KT-C5"V>K^*'
M^_L?:9FGX!E['!I;R59<E32\N+__=9"F5P8+#UVKK!5O/'>2+VK:DWS.P8OB
MA*) >\-)S:'!CO='\AG.]6H:-IH\@5O\F/X**[(89M3R:FF0K%]D5RGRO_,Y
MNR42>\1F9FJXWD:[8&' E@S Z>/$>QQ+O#%:=7!_AZ@"2A]5I<[A+DJ#9[S/
MDL@MMG8!3'T :;T\<4=;P*G,-P'9I+ZI:NAQS =]OK0-V_Z@#)V]DKU:(;:U
MH+T_-V$9%4&'$0T.\=CC;;C> )-DQ2; #6SI^EFL',8 EN9%T?UO (SLRQCN
M"7R?^9-?!F,'V3%*JU8.%K@)DSB) \;5RH6>_E5P/;W9!&3G4P!,>E]A9P;[
M2R.%6I]A?!K(,,J"IJ5E9W#SZ99MR]1M?VC\*>UXR)P/N>5#YG3(/YSZ8Q55
MVCUF2 B)!+M<:?%6'64['U($[$?X/<?UN1YZ(\?WX7J'+#TO+,IV'@S@)^\2
MHU^:6M4KX$X"C@<<BBPKV+(21UM'"9VML9S?\D4V+=):44[ $34AEQ'YN5G$
MD*;OB"3LY"IZ(#F<M_46_LK886FR&XW3UC;8BXQ3UUL #O*;@X'+(=E_CQ!M
M-Y0O>9&M2Z 0 .M[O&QT)^X=78@_RTX>E?E^D1ZC1^(L<YO>?[/LVYRC@B
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MW7$5N")B@#<;5A0B,JU*F; RRAL?+1\W44A'BTT+Y/]3H[&F)5EVHYI)Y43
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M X%OR1#]W=!Z';W::2% [BH4$"WI>2-L77B:*@Z FA_4^ 8 Y\4>LS.=@[^
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MQ(]ISB+5DVE2S^T&6&=^G_L)YEUD^ESR*#0PF@>)Y,1.<O*9BMSY/XC".!.
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M+3^O!"@:$F("%+4$F14$Y(!T6\*4!!3E)P>GED3K![BXZ8>D5I3$VMD!!!@
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M86T-"FC>I%C)DMO($;WW5]1!!\!!0E@)<'R2U+)'$Q.RPLTY3?M0!(MD>=
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MLFNJ8E;UE:%L:K/]<+"L"8DU?[[V(/#J@*>UA4*OG,$@?RG$!S=S#B[^G%H
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M0Y"4!53*+3^O!"@:$F)H!!0VL@0) WDF0(ZE"90#,LL2IB&@*#\Y.+4D6C_
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M)*GYJM%;(P*NFZ\7GQ[MX=R4NSTF]$Y0*DLUZ(?YR120.'!?U<F2'>R45CR
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M8!TD',B82LXEWGPN )55=YOI&P;SX@5 JZJ$&&\O+E^&(),A]N73ZN[_ @P
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MM[4VI17V1F&7_\>S*%*E+:WP$3@?\HT 'L4$1ZP8_^$LB$'8.8M*4E)^$*X
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M@^Y@YTW[^ C'W@]M\8G,(%!OVZYK7W0GU""4<!,O=?J=ZC3"415:Z-_VJB:
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M!N\4C@C0GKG+-3X/!U509XH>J1C,-@CE=-\Z(U<L+%E<$Z'G1VL+B^$-,'#
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M5W]Y0NI.\"E@O,4A >ZLG#EJ6]_E)O-&Q$DN1E"_ZIQ4*<*G*=E)< ]7OD[
M2.[P&BX+"@^C%G:65 -T'P'XVC2/R9(QF8R8%&30+DGP1D.(-V4FMDK12(6=
M!7=ZX'-KZRY-EQ9^-9*7_YPLH>*C =#&BDL#AVZ[!VH6ROS.)69<9:5^#:.)
M,"KP1"#GM5I;TU_9F(J-R0AV!B[ >B1R0"+)F%G#/@%;[CZV&XEMRK$%I7!P
M7VT/:UZT;1CKV,P.?H/1 LIDG(\YS3VP:/LOCX]LOJ0)]=U8*9E&ORX(Z\VI
MILJG>]E;VM^9QNC>+-2^:VJ@=YG$T3KH#47*7VDL0EK#F\6;?<A'H8+'AGJ#
M,[JQ?Z!0CUV[N/:LMOVQPR<RQAW"<4$=M2/*8I3<!F_LHF+O_/B5')^.;1J^
M$*D=@9(3.@0L6*BCZXC$>9>J.U!64=SM<V-NSB%$PJ!YO[K"0L)8*'^ !2XN
M-B-@C 'Y"DD^87,J:-JF[08 #QGHL1*Q'LH4\3QKA)E80OA3N@K5M?&J*RI6
MT#JX+5#^RJC'HM1?F9N2I3XBCY(1E,A/Z@/Z?M5TZ#$X77U!:C@"7@:TE5A9
M0XUX@'B%H^G2J&J6ZXNLB4?'5_F%NF_5QT(BJ@CO:^D1^5T98S7%U;MJGM6Q
MN50O'L-)X2JX;[2PK"P\&*Q7<H2QG>L.ZK)"%4HM;T,M*<''7 PNN&[.Q$H>
MSH)^.) '7 )4&D2$7<N;'Q!8U6M(,5\OM'B/TV1LOF\5PT)XQ2E/F]?8I-)%
M&^AIN15:0G)J.RF85>#($:SO\%#WRNR.#=\B@209J_5PH ZHA3ATW[7ZB25=
M(_(3LI;XQ'GZ<6,M87,VJ#]5>RQ39](]IYF?EEQ/?'!6AJ)(Y75CT*08/%AY
M/XJC.N@S%1!E)>?.OPYJHXR5KC:HX^F)-0*Z&[N_$?=3* IG7\(2+=LK,DD,
M/4/A.S;:8SE)L.?32;J_;5E%.UA*"P "Y#1525@&]XE$"/,QAN-$H321,N5'
MP"FQ@9ELH6.S]&B,=!/-W>0L]<>=$D39@F*3&.Q9X<:VUD[5^MQ_?XL?\]SS
M(_;&":\8(@8CTI%:C:T8YJ.!(]^J*S9%VKG$Y#9^EIS!<[KOS>'IKDF^&8VD
M2,;ZKZ^<^[<A[KKB,C&"@J2.C-L&RAOWP]J:AY]22K(,GEN-1-)$49/LEP<Y
MOM! #%=^'F)M%6#W,U7$"R^9UM*]LRDLYWZUO,QA$$+EQ!G>)A@_B]:6ICK"
MNZEYP.*D(BD+7[14>R%UZJ"=",[SGM0+9Y2J^:UI<"+OV'>K*QZ$%SF/)/D=
M&7IRX3M(/ 1"\CY&K"F>0[H&CZPT^$M'D%J%,PP9>&#Z/XMY40:"F;B(#$M]
M=:Y&<H<N2-=E&7RPCC3Y5=SHF'!9!F.CMJ2M%4;L$O9TD.NHA]V.2\M6G!R:
MI;5,$[Q\"E/\G_'O)&&S2^3(KJP<4;?RJ!MD0-J'RTS4*D^E'_T7,HB^E33
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M!53*+3^O!"@:$F("%+4T 8D".2#=EC E 47YR<&I)='Z 2YN^B&I%26Q=G8
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M(%_?U\;0;\\_43"697<&O\C6M;$EDK88$EA8L;]%"\R -V5->[#[1?F'  ,
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MH-X1A.S6QY&NT?NND<G*CGU\V>^P%\0-E(_S+B\BY[K$L;T6W'<C58!^]&%
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M^L681HD# ?ZG(/H$Y*[NBZHJ\GZ?5>2^;79%VQ_(O,K*K0<1TRFT21^R$^^
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MN3<H1YBLQ_U"/1R6R+:+TCP0)%Y'%P'1'XKQ1*2VOQ+!H%C8%-TZL":S]S)
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M!!P-1'9P8 BBY.&[Q9ED=*M5-:CG]@H GO-O9AJ&SGFIFI9B)/N<N;S4N\3
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MN>6]HM&"R/?>2XI97+><C4_"=V5O)E$>W]/,#A]$<9Y>U+/M='/Q2)7MH:B
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MXV5#(T67,:EMVWOC1XK-O"AKZ%.R.%?!I=#$BR*VI@DV?VUN46S%U.@N)XD
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M^N1GN-WZ,6%^('=MX64UX66-M/2J/5@G7SS3E/7(H<V<6">Y0RS"P_:@DFF
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MB&<.#\/1P<EB^X@ %GL;)]?D@[21H[]*;K*PMBTO"G/7\B:;M&CM_>:O2!_
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M]8(O$_9Z]/HV.G/O>[J=L,B;ZKU&E*PRWY(1U=L,-'/\M6ZH9L;6^9JQYP.
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M/Z\$*!H28@(4M30!B0(Y9B".&51)0%%^<G!J2;1^@(N;?DAJ14FLG1U @ $
M8.(?XPT*96YD<W1R96%M#65N9&]B:@TR-C@@,"!O8FH-/#PO07)T0F]X6S @
M," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R(#<Y,ETO0V]N=&5N=',@,C8Y
M(# @4B]#<F]P0F]X6S @," V,3(@-SDR72]-961I84)O>%LP(# @-C$R(#<Y
M,ETO4&%R96YT(#$P-#8@,"!2+U)E<V]U<F-E<R X-C,@,"!2+U)O=&%T92 P
M+U1R:6U";WA;," P(#8Q,B W.3)=+U1Y<&4O4&%G93X^#65N9&]B:@TR-CD@
M,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" R,C,U/CYS=')E
M86T-"FC>K%C;DMNX$7V?K\ CF9)HD11%,7Z:]:@V3GF]KAVY7*E5'C D),&K
M(10"G$M^(_G@G&Z $C4S\4,JY:H1"()].=U]NN%W/]^F8F>O?EI?O5NOYR(5
MZ^U5FHD9_N&GS)+9;):*<CY/EE55B?7]U;L/=BEJBZ.V;J]F8EW3G\>K2,3K
M[UA.BWF296)]$W8J%E:=9:5)7BT7)(HV<A+P>_1M=;O>;+)JD6=Y.ELD65SB
M\[^O_WI5)M621?!BD#*ODBI=%D$*Z2,I7V^G-[]^N-ULTJPJJWF\B&;Y,BGP
MZV7!Q\5+'],B2TJRHYPMD[*$#LB<DI8%"<4BK<B_WZ/KFYO5YYNOOXA<.",^
M_7K]65Q_OA&WJP]??_NX_INX_OFWU>J7>%I&J\_KD\( :ID492&F69+."1N2
MOR3YT[!B!3O5.B';1GQ2;:,ZL5;=?;Q,YI&-DRSX,%TF.<LI@IRT/,=@$\E-
M3*A#\3)XFJ0I/,59CI4/RBC8"*Q_/?7(>IORP::5K/>#.7O5J;MGH;M./9A:
MWAV>A3P>C6Z=%7]17=T?E!4?Y%$[>9B(CVV=$%"R=L*T0N.0=V AING9_ !S
MEN8!YCNUEX>MD%:XO1(>$]+<LPV$CE_1V[A,\LA@U8E/1K;BQM0](99%*IXF
MRX@LVX0#;H\#_!%9L?X3E.?YPNO\)KM.MFX30WY<)&74"-F[O>GT/Y7%1AJ-
MC(%/3OZAA.WK/0Q HL)%;5H[N#EX %-Q5CT!&FW]^9%RCW4R*Y?!B*-Y5)TE
MQV6G1*,.:B>=:BA[2>5)/T) #XZ2(TV1&U-D"$-DML(P,+2<X"M\NU/L_:-V
M^U<6S,HA!;/4V^ ]80B0<W";G+@TK%/2AB.4 KP0NJUUH_PNHN]M<";Q;UGE
MBZP=)^W=&TF[*'Z<M7EX3V[,/9+%&SDK=YU"5@) C6?D1M3&@$MOGT>(:A^W
M6AYA[QP@:/=,[C)>FXC1YS?JK13.\MSK54^.I+7& 21-NN[ZSJJ&(O:3Z3J"
MD0&E8)C>B0,?TDZW.[;&W!TT8HX(",/ZMG%.L3U]#$L:<XY@-EN67K4UFWB"
M/*Q-U[ T0Q[%"]0 ;+%'A;@^*$\H(-)(?##W]]KY!S+ZJ'"XC+H:#W*GJ&SN
M)-G>'XTO&V<HL./L&0AR&9('+ED'_\B 0%V9U\0KC43-(Q=/R:I0I2A0%!WP
M5]NM\D1!NAHD/JT?]QH1")'#><1N@=CIVH.D$2+3[_;NPBQ?5UDV%/= %SA]
MW2!)F_[>EVT^$=O.A >*B]Q)W5JBX&?_?#@@1O).'P!.18%2=C**$AX.QEK:
M' Q@[@Q!::27+6-D2XY*Q+FC:N7!RPFL,1'?^V;G3Q(>$Z2=II_:6/I13_@&
M.JBT&VTYI<ZGA=FRN7\ I L4JA"<+-#JXUXZ:]2#9T(G"-""3,-?>.N==MIO
M*W"8T/='0QD0IR62T+03JO(>Y,\)#6LD7.\<H,$'9_"XK" %#L<^N2CB132V
M+@\((?"D]E$^(TL/TH74)=F=MG$ZAY>T1\7"C,9!I)(.=K9NPA*  A>0;P5L
MDB'MHYY04$\H\-,.G>@%"69%L.I5Q_@65W"'L$*%A$9!-D)Q$Z3G/AJU:9VZ
M/QZ(N -*G=HJ!@V.$2O"YX&DL1P;$FCLQ"=OV<')-#:"2Q./=FA"<3H#<5\8
M$AKWH#9$CY*<OSD;D<ZK@ %U.#;4>([0+GAT9DU?5S@"-Z"N55X8=YI13+:F
M4SL,";OW8KU7E OI12[,BL#>51%ZT!#?U&.J6Q_WVZ# [JDN;=\]$*6!F9E)
MQ%$^GSX:=--08$^E[-&4_I3I(9L2XH4UZ6DJ8U:+(!9M3IU'D(1[T8]FL/I_
MGL%(+<^R23ZKQD,A,/@(*#Z"7!]TTX.(,6=QGTH$P2J^H$-3SV".!.NB,A_X
MD<IG-$OQGGM[$@L#29&'/GJ>NCSD>\EX8Y()Q*8\L8E.@X/M>59@@.VHK9XZ
M*@]L\M2<K4\4CLLX",NALP1+AO-0X =BJL4%>.LT7 UFT4O%+X6DZ"["[$P-
M=X=6X@3L4]RCSYG,D]HP4I$$\2^O\=\75F4A->:AL3 J$]0!YE[KO7@D6\#8
MZ+F69Z.,9J/&1R)&RF11S27I8]41@&C1O8\+RR%#N'J?7) )T-#U+(U>_^AU
M1[T#3'SH&W5A7G[*W%##BN8@GF&^<'/G<($\+!41\D.35J+I*9DI[3!L\Z[B
M;CTD0 BEIOSCU^Q,&G$JUN=4'$UZ\S='O>;_,NJEBRK$8/6$:\=1.C\O=<_\
M([YTYD%;HL/$;W"->/=&N=QBG.JI&0N,8<1UY\[^=H4,5[9L40PC7ZV.E$KF
M''<?RF= [(C\P(:!ZRG-=#MN5.,[RY"WH"4 22T'01_-B32U.@[9$B&COZ^;
MQS2LF,&A!@ZK3AZH^$9LS) P)4]"MRY9)IEP @@5\F>O8'%!=?ZN/813OPQG
M4LU_%,VD*$;!+(+-Q>QT]T.^WGVG29!NCN"&+=BNUK+CEA6(8DG(H+=IU)&/
MWP2EL9-=XPMQZVOX<:_.Q#)[@^JF84Z")]S*U5;V!S?TQM5#:"0W87^/"C%U
MF( XEK[?Z[;G[D:>0DEQAFMZ*LL37OIU_F?9CP#+EB^OYTE>!K@XB=GT'A$>
M[J6\H6V-"Q@RF: +;1Z.G?B2#OU78)#@\Z#B4I"_"=),RFGO7S+;#R=>M@)[
M9L.W9IW9</GU\PK*\-7($F:.4^RK:%PV3&H\TO%4.[K3V?%,/HIX%3P+9'IY
M1T>(&VS69 )J;4Y7)7!G%CUV_IH6K/'MP;X71V*:AJ20^M>W^W28O]V(@' M
M]R6&A:-1>VP+8HAM-9K/^'\ ('XRT#!]=XQ3]'9_55R@D<RCU\T@F2V&7LX0
M'L,'6]^7,0)9A0;F)SSINP/U5)K[+__#P]^"F$?"_4';-WLCKX: =I01H9!'
M02.VX5Z$8<67VQ'%7/.8=9"/[SE[6/AJ??4? 08 ";7O)@T*96YD<W1R96%M
M#65N9&]B:@TR-S @,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I<G-T
M(#8O3&5N9W1H(#$P."].(#$O5'EP92]/8FI3=&T^/G-T<F5A;0T*:-ZR,#-6
M,%"PL=%WSL_)+PHN2$Q.!7&*+10,#2S,@5)!=G;ZKA4E[L$EB24@*?=@0Y"4
M!53*+3^O!"@:$F("%+4T 8D".68@CAF4 S+*$J8^H"@_.3BU)%H_P,5-/R2U
MHB36S@X@P #R6B*G#0IE;F1S=')E86T-96YD;V)J#3(W,2 P(&]B:@T\/"]!
M<G1";WA;," P(#8Q,B W.3)=+T)L965D0F]X6S @," V,3(@-SDR72]#;VYT
M96YT<R R-S(@,"!2+T-R;W!";WA;," P(#8Q,B W.3)=+TUE9&EA0F]X6S @
M," V,3(@-SDR72]087)E;G0@,3 T-R P(%(O4F5S;W5R8V5S(#@V-" P(%(O
M4F]T871E(# O5')I;4)O>%LP(# @-C$R(#<Y,ETO5'EP92]086=E/CX-96YD
M;V)J#3(W,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O3&5N9W1H(#(Q
M-34^/G-T<F5A;0T*:-Y\6-N2V[@1?9^OP".9TM"\B+H\>NVM5%*N2BI6GG;R
M )&0!KL<4@N ,YY\?4YW@Q(U4EQVC4B ;/3E].EN?OKK]T(=_<,ONX=/N]U2
M%6IW>"A*E>,??JJ\RO(\7ZEUD17UIE:[EX=/7_Q&-1Z/^J9_R-6NH3]O#TFI
MTMWO#^MLN^'7^6)=TON%6FZS;2'O8Z$LZ:W?DG]_?_SZCR_?GYZ*<KO>+M-5
MDE>;K,:O2O^S^_M,D6*3DZ!*K?--MME"LDC*UR0IR^MJ33K\ECPEUMJGU/QH
MS"DH[97Y<7+&^^Y=>1/487#A63T;9]*BR*K$]DKWK<)/>#9JP!^GO@VZ5U^'
M9GQ)-]DR,>ECMDKZX!=1J:Q6C^0.M?OZ\"CF00=<U74M2CSK5P.Y[ZH=P[L*
M@VJM;[K!F[3.-LF"CZ3S/A]-'Y1_UEVG^B&HO5&=U?O.D)[\Q$';;G1&3M[]
MA4U>LLEEL2GDM(O\= GQT+=(%CAIF; .MH>P%QWLT,NB,QWNY.:8T@HDT&&_
M#+SFW/ &-\0;2(/Y+&DX*!O\E2ZK:'J^VHHRGP\'"QN"\1 )":M$!V6]:H87
M<F>9C+UML T'#+RM8.FP#]KV6-N_RQJ=]D_C_- C:N[5]L>X[M,ZN5*@FA3(
M-]$;9[]"\$SKF6(<]'?5Z)-N;'C/(+N*4A^7%-TR1A=BB_4%X$^)>4H)XTB5
M34R5K"B 4#S+B9"HN#UE$K JVV>LDJ[KB)/=#0:@RCKY" 125C=ID=.>A'&-
MH.D_^(+PN4YZ,I<PA&43G]@C^$$A(YY2]6:!>S%Q=07?,M]>'-<,O9]<%Q@3
MSOPY&A_(BW3[S?0MXH('TA6P1@GV$<A[TUD#_,/+QV%H"<(X6O;N1ZX2!6!T
M;QKDJG;O"S7202R\L8YR$7R2^#1/@N[Q$*E(N0[38O+J/51OS!3OX0WGN\%[
M"#UV]BA[[DJ%<T#RR!YOMNL.8Z<(JB 'POXZ\?!*.S8A$Z^R@.H"$GZ_GJ/D
M<(.2GT"DO."#/9(5U6;[_^#!R !W@203?T*P[(01_+]A'>T;XRBSSG;/8T\G
MEM$!2U L'VG[/T?K*'AX7Y!#$GU XE (0"]]6*@W[9SN<0H$.T,$BV6F&"5/
M:7)=F;0, SR$O_ BPLO/,!C#L_5WHU%.-/KYZ(R14,SS^9:DJRD)H%H$141S
MP(N>(,$)#V_8@VT W1JT9!:D.PH"4Q!+O:79O%ZN1)M6#F-56F#\%46DY5(B
M4!7&GMTQ95T;3OML_/0PW8C.I/3Y>-3:&9V=C",*Q]DZ@GC8$RWJ"/?(<N#;
M54)6OYI><[W2T8&)>&&R,ACWXC_F0BWFYMOH? *]):7]A\(I 0U7EVIHFM$Y
M,U.H-0<]=NS;7U\Y? ?U%6&JD<:\L[@-/BZ6U;F.O\8PONK.0A5P@J%2UAB]
M!Y/S_>% CH5XL(9*BV6"TY P(XH)+[%7 +-K)"UF./J9"ZXP5C#&MLE'($X^
MI@=(M.U]<"-3Q>UK[468+#PEDY4>Z>,/6G "O2^*G1'(&)[",HL*PO ] FQ)
M0DWGS1O $ \O$B2TA&LQ(> 9EB'#(>U@W0ORH#'V%.;G4B(6$80V1 OG[115
M!NNXD!,KM3"YCL8B.>0N;DN)D*4^9.I?2!\&+RH4$URF(M'),9JET!'=^^)>
M4N;;<G))>RX["LP-O4YN"/"&X:Z._-D?%\)3\,@J.3@0(M:8(!L$; 2/"B)@
MV-"-Y,?%Q'B1[V9.N9!F7L>X3+S"E"+Q)Q9<RKO#">>12"&;!=&X;9A\N+0N
MIJI+6H(Z%FJ/&%^R]:1/'W"Z%2=LIYYW!BQV,(4W4.E_1GGN!QRDJ9/B.$EM
MYMX+G=3>S $1,T?:TT'JR=Z8_EZBEMN8J-X>J7.##K$,<!O'(4<D3FR DTI!
M%S86+]POILK=:,^TT5#' ]H*IC/-<.(<BC78<.-'BMTF;+&J8L+2BS]8PEQ[
M[FAN56(/S/3R .'?[K82TD;<PK!8ES%!KEN,61=!^I?G#F)Q03E72!S?I%N
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MZHOJ*].H&KI>]=L.*N3MX-K4M=EU$TLM]N<1GQ3$!\6YKV?AJ%-'G3KJE#B
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M0H=E79?'M'YEB.F!<2,\75AA/,TEZCB.RVG&#,<YPC2?4\;[-/^Y-^N$Y%N
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M_K+;;PZ[AV^11[@<YHRP0)O[S (OO?D**9Y?##_,YH;(E)(BU*@A7^(CVRK
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MZI&]+[JRFP8OM0=^@=$K$ 2(F7GXRC%\PY1N0S9\ RF.9O)L:(_Q>7B/2TV
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MEGR".[#ZG-7<H#CWV9MFC3IV/$G;_X!E^8>QEI=J#V#GI0W](VL7RZM_"S
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M!Y[M_@F!7KW^##^&]'+$']EM:JHI$1[H5H4O/^2\GUS8 OOK_V]XI.]? 08
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MM=6XG*#<2E@N2G97Y?6+9)GXR;[MFFVMI5XYZ+5_C*)-*Z!)R-VP!Q42*$@
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M!+(.U3.Z>$ZU#.*@ ;[1@(P!G0I%*!P!@ 4T!V] 7VT42DUS=5G;6(6207]
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M>*2"[!G5R2K%5#O9ANY-[U>J%Z&YGD$.Z&%![D$P0#X=W)G.:7:U/8R[7=V
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M**(@<*(H26C-/A8-$UJ4MDO(FF_6Y/=?;ZYN[/[0":VI^,WNATYB]>V^AX]
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M5,HM/Z\$*!H28@(4M30!B0(Y9B".&51)0%%^<G!J2;1^@(N;?DAJ14FLG1U
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M4S1:;1GS-7Y),U17"2MQJ'I54%8RZOE\ :5#14"W6VHYV8O^;G>%Z;UR/$O
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MB!-  T><:.K/85C4?P%3G>@N*"O8%EKOYVROIWX1.@MC2V=X@.)!07[(HS0
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M'PESM[D*XW60+E6<S"$0&#P-YI$*X@41=VVN=I1ROL7P<9P&BS#M$\8T*,[
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MR >.WZ&_LG"T<+"B'OF;'?(T7X,Z79$CY?*;:' !26J?0"?FVOE]YK@(O[Z
M<IT+' +'^BFL^H$S":54,NW$LJ11Z)W9EQ]-Q@ 7_#^R/XI)%&(.E[\_,9"4
MB#1# "?C^C0,$ NSN>!P9*-QU G]CK4;-2Y(?X3XV1\"G&H%<%]<=X"6!BT=
MM30ZZ_LOQPBQ-+MT:G6TI6-'KD;YB*I#,5EPF):&5S**J;J_#JI,&I87EE:F
M%CB(M$J]1DU,*87+M^RY$GLFGON+ZUV <D ;JR7^2R8@A6[]]"65Z<M;-<,
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MNOQ2=T?Q1>8>S9R]W<RGJ0H *Y-1E2P1VJMZKTO[J^8Q@,P-GGB"5$GJ!'&
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M$7W?KYC'08H+$S<"R-M&6L=*V9)KETD>Q#R X) <"P1H#+"K_0W;'YR^S(
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M\D4T6_J_E_B)_'?1PCO=OJDVJOW-NXW]7!K1JF.KC*J[ I<R0M?LZ_T2HKX
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ME"\,0X>#TW^<.E]'):OA,+^@K*_EUI! L.-*6E)%F$=PHH"R#"":LEI@+ ,
MZC0<#<BYJ1QPCNA+@$J<=3E;YQ[= Y:PZF4V5R=S"2,18'![^'DLV@[=(73
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M1-63_B0-@=M1V1"/@Y^%^$FU.[#TGJYLFZIJGO'%Y[TN]^?T,FV],.!]B6F
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MU5-1]47GU.R8M:&,6'&T$!2J;+Q@B9"FVWAS3Q-0",0:9&SW2K-^00IK53
M*%#6#8,UL,*U'>F>\G!:63.1=*"K_&__RE3^:5^9+"+>E26F/R8_*Y^FA=R9
MYHW&$(K?B].C?$;:OO"'ZVA<]/EK6PATJ1F_D&6WW*Y-\@A2)!@)G1BSX;5$
MRG,_C/@C^:0. G8H@1_4A>*&:M>S?.5B?XO-[J&O)L.'O?U&61@G$ZJ1)%;;
M+34QX T@^TK^3FO:Y?Y8>?[@4)1C$POV 0)#/20@Q^RWLX!]^J\  P"5IA,B
M#0IE;F1S=')E86T-96YD;V)J#3,V-B P(&]B:@T\/"]&:6QT97(O1FQA=&5$
M96-O9&4O1FER<W0@-B],96YG=&@@,3$S+TX@,2]4>7!E+T]B:E-T;3X^<W1R
M96%M#0IHWC3,30J (!"&X:MX Q7,%,1-?UM)=]$BPEUDV"P\?@[8\OE>9I3N
M""/&T"%=*?OG."/B580SU=>T6DNG HN' S MGF-2+<WIAKJ&P%F=-<.Y2B!$
M@T3(!GRL_VN7T^DC;-2-,PVQP&[M)\  R"@ED T*96YD<W1R96%M#65N9&]B
M:@TS-C<@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP
M(# @-C$R(#<Y,ETO0V]N=&5N=',@,S8X(# @4B]#<F]P0F]X6S @," V,3(@
M-SDR72]-961I84)O>%LP(# @-C$R(#<Y,ETO4&%R96YT(#$P-3$@,"!2+U)E
M<V]U<F-E<R X.38@,"!2+U)O=&%T92 P+U1R:6U";WA;," P(#8Q,B W.3)=
M+U1Y<&4O4&%G93X^#65N9&]B:@TS-C@@,"!O8FH-/#PO1FEL=&5R+T9L871E
M1&5C;V1E+TQE;F=T:" S,CDY/CYS=')E86T-"FC>K%I-<]M&$KWK5\P1V!)A
M@B1 XJB5E2UO9>TJBZD]1'L8@D,2,00P U"R_T:2'[RONV< $*3M5"655$B!
M0$]_OG[=R)M_/<9JW]S\<WWS9KU>J%BM=S?Q3$WQ#SZ6LV@ZG<9J&4>KY2I5
MZ^>;-_?-2N4-[FSRZF:JUCG]Y_4F4.'ZEYMEE*WX8?[B'U]D41:O$GH<%V8S
M>NCGX*?'R=L/]X]/3_$L6V:+, VF\U64X%.%_UO_^R:>>F'R+9ZN2!RTFF;1
M,L,5D1<G)"]X"K9/(>D 0U;.D"A.LP4$K-^*IJ)D;VFT2+-,?B?12[K'?7F%
MAN]K]7BH;:L>=1DF41R8<!+-@R92X21.5_/@O]I:7;6'NMP:JPZZ457=*HU_
MJR_A9!DE@6J+YW 9K0*CZDK55AUM@?^VM6H/1CWL=B9OBQ>CWNK6B-D/:P0@
MA9&P-E5I$L&"*)F3O=;<["A48\]X/Z?9,HKGXIB? U/M]=YL55&1.JIA2QI=
MFH;T,+^>BA?\$:91%E2M@GU)T,*:1D.CNFKH.=+QOGX6"VJQJ%*/;9U_BI0Z
MMU[OK8'H]J#9 VS+5$T0@\4R\1[.O(<3\; N2W@HG"11&CR'\%((+S=J9_FP
M.5]3]/,BT-56Z5V+DZYXCGX4_[(=&[.KK>$;S>=C8359Q%9KF+((;%F0'&-)
M/HXGL]P].]5"Q#PX(,0PNFB&EB2S[&NYXIQQJPHX^4!V42I(#%P(7$9\)1"(
MP87[.>F@R2R0.-2=\UDI)'(JB3R/9LO5DG1$0K.W)Y(2HF3LW/WX<+]^]^&]
MBL/)"C;B8P8;(R\LGHJT-)K&TVQ0-X,*[XMG#L%)TE</QS98?[Q[__C#P\?'
MB&^?9)"5+H::T;VI]]Y*%$.,Y],91?SQM/D%D:4*R6M*O&5P)#7CH"QT12Y,
M@]RHUZ*EM,C8._A1Z>.Q+'*]*8W:F:T),\BRNN3,:%K*D<;D)UNT!=Q>RK,Z
MA%;!:W.+3$&@[_:6KL/9?-T\4TS8-Y/>OW$R]T:LO!&I2V;*4 3>%OM#VT@F
M'HPUIXKK@Q*2 KPSEM2\=7F-.+^BA SE0A'2\54X#]116R03S#S4IY8OJ_R@
M+9+)88<''1R I'T*S.?<')V^ZW]PU+U^,]%O1\#C-%"M_FR:IU"=CDBJYF2!
M W%@0[C;L+I4".04+H8[JFUVQ]'61V,)#1<!)S3TP@.U;03EML"%!YT?(/\3
M&0V7.$594"?U*CHL1,_NM%NU^4*"BFHOWH0!)(W^;ED%KE*HC')ZAD=S% Z>
M:Y0.5_B5XC% )1]D+_SU8"I1GHUO!"N'Y3[_&FYM2EU]NG6%OC%J2S*WJC+[
MNBTDNF3Z&92P!BYNC+H^>$Z3<_6<[(,&Q&T,?F[JJ[%U/I,80 4ZEGU5P U=
MM*W):[LU#)(CSP%7X*PX.#J$F@6_(3YH+&FPJ>M/C;?2 2MD&E33%J%QX?^N
M/.4+HX;]=FC%!0X@MQH"OZW1)469\G_L&-VP'_6FJ<L3=4W.C->J+P9*='<Z
MR,3Q9(]U(SW"/2O'G&F2>$TR[]"V:$O8B7(SGXW-BT8:"JJ;!"\%>68!W&S-
MT1I*O,XMRV"D-<IB?>@!H"NO<;PWC@4X^!X52#IJ.J.P>C!$QE#D% =&.EK_
MT[U'U=Y#C &090H R,9?)7@")3CX1U;=(VABXO2=TM3FN$T50&4ZRUOHZ -B
M(0]?%A80LVV!%="? L> SC2#4J91#Y\/Q0;=]-V[=X WDO7[V@M_CS)C*W+S
MQU/HH1051ED/BE7EQ1'@7^]V4*N16J2X:Z>_XV15Z]'44Z\9FE"<JB1>11FH
M88HV O:UH#K['OM*B+&!R'I:.JK0^UJJP56'E$M?(]ZA_,FTZ RIA>%(_= =
M^_K%V$IDP0S8*MT!O*$[@.36<DXC.=*<@,P]TX-TY.5/R/2R=X*KAS&_N:^'
MGJ.6'/39P+GS@L/Y@+,HY>96C7)('OH2(F)*+NIP#ISL*#,AC-2:V1<-:!II
M/RQP5\9R;:CU2D8+!@#XT)4^"#OI0F "*E!Q_X#R*$!\(9$%D\,SEE::O1$H
M700N1]!=X#;[Y<*@GMEYWG?6WQ:N?./9J"%;XGZ6D$G51^K]:5 1"?6YD->G
MJB%67))N.+XR3 X%%N%(2L#@"W-)-)RF*?;DW(#Q! 9Q9:;$0?IL0D<]Y^U7
M^]V8VGBX<H^B'GN(7;CD/:*/$JMB#5V@W"4>0 K@HV5_FJ9U;@<!J1D,)>T[
M@?"D)7KL?I#D6P0\B62!I\&J:)H3<N,;?9&AK:\R('E(H6*BPY#N%$6($04-
MO #-1%-Y"C1UH5U1"2OX:/:G4D8$UN@M:;[#5R#]F3]O 3],)^J7@HTE>&;Z
M(<4W3M8A?^Q.+ZC>':C]KO,<!5"TK B*K!7Q]@_U517?N@'A@K9>8?-N@H!.
M?V9DF/VM(\-2RO4_[Q[O'W[\\>[]PX>?'J-P0O:Y-C@<'Q;=7+-P$[^^,O%/
ML_FW)OYD#A.] G&7+K%8>SY6NJ8-SOM2-)QY13@-B)]T[3ND5KDGD$T#ZN3
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M1*VV3S8:(MQ"W2')S#WP1"]LG%+W.W_(_=E?F3$[RD3&:_5-/K@Y>%$UG&A
M3);F#CT?!.S9VM@=P]!OF\6]60P_!"$/@K2\BS=9@-T4*_:\)_R,K^Q/<(#/
MB&G'IQM.R9Y]UBG+OH,(GO%HG_$A>Z*77U4C^A9TJFO@+H"/*3EU0! 3#I'$
M5!X_)/+"+,\HU6E1I$.NH[WHS)WEW*5:A'KE5KT@&%C(RF1$::]L7AH5D;EO
MN7+D_%2!Q/*NJBWI,L<C> R)(N>J82W (@!N/<\<T3:*0B+G4V8XH-+**(4B
M(FVKCK.RTPXRME,96_)+9LU@DZ._F$&*4Y&&J1>D(@$8H?"2B*1/J[,EB?9K
M&ID&B1=&13IH9&XDU^B&N%-BI6HJB*VL*TH\$N,2.^]E3;&PVFP:FR72F1$'
MHUD-"D>Z: @@*;'DA0!/8\/SOJ-"7_"DRJH,Z8.LH&0C6T+JV$GKWY%KS,V]
M&_MG:K6N90E5O'L2TBK0AA5H@Q5'LB++4JU[%M1#>0F+P5,+H'7%.$(>'OBQ
M=\'JP>.J*E=@_0,4VM1G65,3Z:D83&@]0.*2LMI&!1Y"7O#TPH%%Z$:%W9MF
MH;3Q.'8J7D/=ZGCQ]X3E!$2F:@T90:\U<$(F,N>E6+P7*G'(7Y <5N+]LTH$
M;8OX>^48P]B^'//!Z=0X?0,U*U4',;CX1ND1LC/MX;'JK(<+984.5U75C(82
MBAW1\.X1%/F0LXVYNS"@C<"1WS?(R(AZ7<>"?EAZ29)Z12BBR$OB/UMZ29QX
M!6/T<-R9<JN0:_)<UN19R6V?$A$X4DO3&3NEM_!\-[%TS)Y];P2AH,=4-*71
MXWXE>X&RHUA,[=C&C8*J)3?NU*'+5-DOU>&.+;%Q<:TT*7X Q>\!,+/OM+)A
MBYNG5MV:1-U2VBVPK=O<_4;7;%-B4])%W?6P0YE":+LJ15=^U%4/*3$U;VZ\
M7(4[+ /C*+8O% <*-^'!2FX5;*+=,-WKH><2I 3 ?07M)N!K'.Q41JM2X1R!
MKJD4J2NRSDM=5W"X7=(\)*D#*TUC5WW4 7=-I# ^6>-/ R*[W@]9QR720B(L
MT7-9D0MSYPZVK6+ =:(A)&OH!'0=^5Q6^H&"5+7Z-A**&JEN00'1:]ETIOE4
M'0L@4K.495>YX]2Q-^HC>7A6:=72/'6QT;M9K&FU+1RD:=-5#1$1\X#NAM8&
MW*IUQ44# PAH="))<,5*&RUOU+>>+1G]LFM@="%MS8Z,(LV=<@!D"2CW]SLW
MY(G%1H):6C*CY):\YKP?@ <-T+:K55U/Z29D2J4-\.)!5BA"-X@!LU;]1C>&
M"1 :JPJ4'9JZY#W)C5K+RA31W%G 0>K[+[>U9Y200S:-PPL%JU5OIT]A9CVP
MWHV!R+ 4OK3W3?4'N0T^-=7]JD=A(T-*0R10=-72KD6F$2T@8(@9N/TCS:DA
MI4M*8&\0V(6]??JB\/I<3:7:4WTI#12M ($/%KFC$B;+H+M<++0;A)1J4FO6
MA-/:B(;:&,I"2'?(..Z9-Y/N[>[%T \'Y<51X.?FM2N.^,TP&J1WR(-5BROJ
MKSE"YR$-K1\NN(10ZOQ"3E"/ !4T_6_,$@S ]8(6:?MLB$.>I (WHSACE,:'
M,(560=]?_'S^^?IB*LXYC(D[CL#<VZO9Y'I$S[NZ.?>.R!-E1UV0C":V=U_S
ML/$.]&,RZ_X!!A2Z6>30X']@I,AV#@VAVW?126\GC;?L44XEBJ8&YA 5E.L[
M2V&>\VF)M"KS!O,1\XM4-3G\;M/S4DVXY(X\FC:RP>74/B[V7:HJ7[S'^TP0
M MG*C?"_[L&6R=:,; VOV:!%3S=5KT04F$W\_P5PQD.GHH/(\O%6UJV8P"Y@
MA=R=,T0,-V;"(HZPXV6$PJ'I158#+TDR'Z"4;T5*) V<Q/SX+CP?(]OF=%R8
MWP"CS0$(D7V'F$&:UV;%JFW, 9E,?+L]S,U!,8Y\^R#?&!J_0JZ37(*K.2,:
M *?>OH]R-J$E9;OFSC.WTR<;1D_.4SMHC0_'P]#&;@H6M<=C4%_U&^0#63<S
MU-Q]NY^*P,\HA QC< L*/#L57IR=S$7'U9G[9A"-?-\+L0W%.;8]W.0RMD5S
M/9FY](WA_>2C^(OX93+[Z>IFRFF]OL:-PKE]I62&< )K* %D'S&)X,6WH8I'
M!VC!0ZH89?0'[7G:8Y3IN1J9?YB T7M"F'NMIM(=^:RN3V4C+M%^2_K^,1+G
M$W:VB(,@V%%C;+\(E4.EV')$);Z7%7GEB'_)NO^#',L<OB#I\T+S2@E\C[BQ
MI>; 7R)N5%@>CRWQ?,RFSR/\,87C8# 4V1)(QGF>_8C".^0.&J)58O-!B!HU
M*S'U]G.3*$RNF.1?T-P@?)7$DW]./WV\$#-H[^3V@GOI9ZJ+R)GQR16=Q,[Y
M="2>R:_!P!_2E+R@FD0CJC,4'G]T<6D\$9?FK"$22%;*04 /YZT]U:VO>)-G
MN6IU7T-I^QT;@Y3WI5YLWBWX(,P"+R0="+*4WL/XTZ=Y[>I7]$IU6G,AK8MY
M0XB.:#8P:,7@B4'-$9=U2Z\%,#(NO-3'TXZ+*S@9 &[4(]#,'?$K__ 7/<V2
M_94.1]SUQ8WYH/E(@/S:ZJ^O@7WPZ7A'G>]WLO^#^@W5&&;_B_H%$5Z5HV/U
M"W^L?@'FS#S"*_20B2$NV^7?74_$[=7MQ<_TY.OK6\3P>4IC\)_4HB1@1GUH
M5PT?7'KB)]4T:O$D;K\^/@U-EFX%H7\D3\\ F:[ 2_+C?577W4C<?!!^YF?Y
M#H?_"C  Q )FA@T*96YD<W1R96%M#65N9&]B:@TS-S(@,"!O8FH-/#PO1FEL
M=&5R+T9L871E1&5C;V1E+T9I<G-T(#8O3&5N9W1H(#$P,B].(#$O5'EP92]/
M8FI3=&T^/G-T<F5A;0T*:-ZRL#17,%"PL=%WSL_)+PHN2$Q.!7&*+10,#2Q
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MR!A*YL1[,7Z0*N!-KDA\WY2EJQQ/T)R"!"++@A6(DY!E_XLX<"2(UX8XD\[
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M4"@ H,D#'#'GBAM;.Q(*A:UP\'#TL+<PP_G["X-#;*@PC&F3_EHW(R9ONU4
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MK]%W+BX.,=6;$C;W5N,4YI1";<.:^SH8#PK,%6FS>:.D*9'0WH6.NE)O<_X
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M'WDH4A'Y"6'+C,9F!?\)/WJ<S6)NQUEFY4PJ)F@J3,7IL<3JV4UF@^S()G^
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M5,HM/Z\$*!H28@(4M30!B0(Y9B".&51)0%%^<G!J2;1^@(N;?DAJ14FLG1U
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M  >X:XI)Y,/=MBZM#S?5BVF[X1 MJ^Y$D_FK5*?)H&I?FGIGFHZA9B=PO\%
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M079V^JX5)>[!)8DE("GW8$.0E 54RBT_KP0H&A)B A2U- &) CEF((X95$E
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M@0!'@S!(K+*-^+I^F5^NV[-D=H*$M0=4^-&?BIB8I-I^@."$P1WL)?H1J(V
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M8/W\RV1"4OJE,^'2NR7MQ]:$?]PM;[_<W,V7N.K=W[/JDU=O3$_\-(O)4R
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M&R.4ZCL%_ZC<7C+E!AZ&*]#A_51L5P(3+!I.MW)1IJI*]PXQKY1W@?'Y-,V
M\S)J3U3-44Q\(5%CJCO"$11\$;%,Q-M$RDFO^)XWWK-,AS)$#=^G/&X-7"AF
M]2[V>;.G>QM*(DGQ948KSIG;8,[%TCH?:\,FHA[SO1@DF!=6M)(=],O1Y 1<
M&1/AOBW%I8?@S:;BP=BC=BCE\L05.1?X_9B$7A$N\,1C\#,)Y&U[X72KWW&M
MH&,$C?7))'V!K!7?% OJNNX-"8M)$4N*9I+<^WM2CZ-BZJ<BWUQ!%3="N>;(
MHG*:@V:- ,%Z54_YEC9"0H?H\\@<&)17]^U$\K<3KOENL$66'C@VMF?GWBA0
MFZA(IHORO>>$(I7CU?1)@*=;^/M=GP?W&^9*I!FVT7R)JX>^L*:I3\]=HBJ@
M*.SV41,@QJ']RW)=3-]R[WO@A";#X9,;LH_&H Q+M(0_3D(^(F\YXPDXSRZF
MHJ(K*Z6[(DX1A-2JUVEP]\WNTVX1;R*,!R(J$'SW'1.Y$^;\;8R_8\9I&>:S
M#9L0W)YON/O0.7Y[CK9IF&0%?^<,HTWI/3[+[]H9XXP?SLZ9]"&;.,UG?</U
M"UJ=AH7;P$*?,C!V3E45GH?B;V^V,V1F/M;G9Z-KV58\@]9FV*.^MX;"X<JR
M[BGX'PQZVC]4C9*Y8R9& 29!.96F+]0,<N^-._(+V]%C_VWG%5>4-S.+OR)P
MI5)<=1#SCI+S+DORARR!P;//JCZ0_Q-@ #3]8I@-"F5N9'-T<F5A;0UE;F1O
M8FH--# U(# @;V)J#3P\+T9I;'1E<B]&;&%T941E8V]D92]&:7)S=" V+TQE
M;F=T:" Q,#@O3B Q+U1Y<&4O3V)J4W1M/CYS=')E86T-"FC>+,JQ"H @%(7A
M5_$-M! S$)=*UTBW:!!QBPR[@X^?%QR_\Y^92<*(4G3)=R[N#3$A/DD&)J>6
M#JWI5L$Z"(#)N@&3[,GD!]KJ_=C6><2U@2-XAT"(_M]+CB[!2??54)\J7%K_
M @P \$PBFPT*96YD<W1R96%M#65N9&]B:@TT,#8@,"!O8FH-/#PO07)T0F]X
M6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R(#<Y,ETO0V]N=&5N=',@
M-# W(# @4B]#<F]P0F]X6S @," V,3(@-SDR72]-961I84)O>%LP(# @-C$R
M(#<Y,ETO4&%R96YT(#$P-3(@,"!2+U)E<V]U<F-E<R Y,#D@,"!2+U)O=&%T
M92 P+U1R:6U";WA;," P(#8Q,B W.3)=+U1Y<&4O4&%G93X^#65N9&]B:@TT
M,#<@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" R,S4Q/CYS
M=')E86T-"FC>?%C;;MM($GW75_3#+$ NI ZOHHAY\MB9V0P&2! KV(?Q/E!D
M2^H)36K9I!WM;\0?O*>JF[K8G""()3;[4G7JU*EJO?OM/A0[,_ME/7NW7B<B
M%.OM+(Q$@'_XR"(9!$$HLB21JSS/Q?IQ]N[6K$1I,-64S2P0ZY+^/,\\X:__
MFH6YC%*Q2!,9K5*QOIMY2Q['[DN[>\Z;Y^>]0QF%-/<1^\@\C^,4$P/Q=6;?
M8_\_O7^_OU\_/$3Y,H[B,%C*R%_*%4[\S_KWV?OU+(.IL0QC[)I*/,@DHJ6=
MFFVO7<MDON+S^<MH0I++W)EP[=V"WL?6A"_WB[N/M_?^ DN]AP<^^NS5*],3
MF2YC\A0(8(]X9?<(HSS+$S^32P]CTH>Q7L@[R=4J7JV$S):KU,+_=9;**%M%
M=A.LY678@#_S).#/<9=TM,<Y>NT'=DK3I=V)(V:#!>2FS@W30*8)H9*FN4A"
MF2="QBG%GQ$=WZ]DF%V]C^S[5UB$P0KQ$&DH4T"21#)\$Z SXT(PC3'/L J4
M6TT'Q0(JPQ"V@WM_>M]OV\.QT[M]+_[0I6J,>A&//K;P5-$8431'\=SIOE>-
M*':=4NZ=OP T7N.#@UXO=EW1]+K9\72[6=^":9$G!J-XE&%>+,4BE"'SFZQ)
M$K8FR/.EM>9L3-N)\T.G=MKT7='KMIF+IGT6[7.C*IJT5YTJMKWJ1%'^=] =
M1C='\4O;=>TS!MO.7RQEX@G=B.>]+O?6D/4_[?F<)4S6G%/QM([.V+=U92;/
ML+CH!D/*])(Y =<BYYI,XN0-O,;BFA!V (; ]9,X!16+NA;E:=H<=JH>'$T\
MG.M<5YWU=FC.SW/859-WJ5?YBT2&WC3(061-.0R=&1 GA$;T>R7JXAG>;?G[
MET;W..&^+RBPJ=?[V"+U%$^X(;OQT"%A<D_;(\MBSB!@2:]HCTZUVSG9B!7T
MHJ4Q^#4T?7>4UK0+C&!9&(X8=:TQBSNUY=,3;ZA[\5EML653*O%Q4^L=A_Y%
M[ O#]I)%2\O"&% R]8S1.R(%W#,# @V0[#2*/2V:1L<%JE);#1!P"CGP_9-B
MXD2>C1DE0 5"-D^JZ_6F5N).;7KY0@8LO3?.R6"9CP2X4X?6Z%[<E-8Y1L21
M@5W F/,;Z>19:GVOW*JBM//G+W"0_+(S]Y@I>DMMVB+VND>AC6 O8*GUV,+S
M-WY;PG^YO:4XTHJR'BK'['*ORJ\,JCU^+DSQA&=S'D"@2\)BJTLB #!S)K_)
M!I:=E!,]"O-TA*5]]'-P%OFC2W$_;(RN=-$="1@>+QH(R(C'^3T.WB'@_X.3
M0U.!8:^I/"TT3O62V!Y_YGM_P7&$H]-_0VS>FN"^(R7294^K;MMZ>-SH@N$X
MD_ZOH=.FPAQBTZ7>6/6]3,IGW>\=/:=M6EF;Y 3'.(%*+I/)B.H 9FKD"V/'
MZ?.K<HJ>C:I-TO-3ELYAQ9SG.67<*K@84H[O>;A@8AFQ4<K&0AP*7=EO3D/^
M4(T=(!*&7F?$@1^1/"05K7UX&Q-"(+,QR<=*Y+:\K<$B4.\.,%AJFCTIY$:!
M85Q^8@\P;8>Z/@I5=%P'&J[E-N\KBAMDLN@J'JV5 9S\=>O'-(V.P<KZ:%==
M1BAR!''B$9/<@1=-,2H#PF7$S5@)84K33\8F.)66=)2Y]Z@=_5%\<&6#-2"C
ML" @4'TP 6:;@P*W(+]HRP@28A7$R%#A([O+XJ#[HA:F;\NO<T2DZQN\WNO#
M%,IY[I@!?M;:'L<LJW6Q 4]@3MG:X8-/(;\H:U;, 5%(Y2""K\1M99TPJ@3)
M>ZVX0+I!*LK6E'$/YO&([T7+RX&R;KVMGB=N1%F2C=A]_G!_ \"X*2$<WH-:
M,=0YQM]#W1[!W<^J1VT>PX(/& ZTR4$>$O=D-(DFP@IS;VP2AWF6S$E=)UF:
MGC+6*5?QR#N#^%2"B9]D#O@VU$P2I$#7VCE#C;JE*BLBK%:3=7!L@\+@U#6\
M_\9J7,%&UMO1\P=//_BGHD#-567;+-/6"OD PFQQ$&AQ[%HD#<7FD>&AU'=]
M6^;]2"2#=&S&-JI!.<$Q$*B+"H4^<$?IA2QSHU8[R23T3=Q?J&^ELH[3_V;1
MJ&\8?VY/AKDZ=L1^)1)T3IZQ:\UQ]/E:.9U:Q#$SPL-T+EA0BKG8MK8,%$^M
MK@H2/2I'[;#IK927A=G/^2\S]:FH%954YC<+-B)V0#&C9&CZ@BLHD7+L$BTN
M2>(8P.'4#:QUD@7G%-7$$:2*+3*MJ%MN3.96F$:_(""'6E4[G$+TH2 28/5@
M]),+(J>7FJX=4>"2 B9OJ;\EQ;8";Q4; +C*#QC:4_>$2HJR9+MT,$1=K;0-
MCJVH95W )B+;$T)"H?FFGS@V%7VGKZ[67C1-;&K A$K.C(IMU)+84>JBM8H]
M)[ XV;*RP@T$%Y 7=Y!F0M@ W8R,[_=%CR[P"<$6FZ+F8%]S[F.CQ+_@"'7,
M%T:=;3KW_$[KU_MV,'3F'9A9=.3X3R%J(V9@%FQP!?J"]SWSJM<7?6CB273A
MWE2")V'Z.J^O&AZ7V@4Q"N=\0)CV%S,H AOW[F:@>Q#4N\$$[L?'6:_NU5/W
MTSB269I>W&:M&,_=[PR3-V 9)6[%#Z^^:9RAZ0U%%&4RQGTWPMT6)5 N@]-U
M]3P%P<[.4^A^G$_<:,<?&:(PP7UZE4]?:$_AC&U'"X%F]I0 3!7(NE];).NN
MN6HAM^<+(EI>O&69MO=&XB9Z%GY94/<I)J/V\QMRD4(X1D%/GG3% EA %\ ?
M-L5E#9)6[5I*1$@2:1_WEHL,QTZ<1+>.RN88A,,@E<U68P;W"U<"D3O]=B5_
M["7X/N0OO?*24TQAZ/ K"AL?&3E>"*S19",!4:.9\UC.D'!BRE"4?_/CZS4E
M#;4_=0W#!G0QGYSPRO&WKLC]DA:@^+\AJK@FZFMJX@Z<(A37I=6UR&'R@Q0\
M0VP[Y=3"D7K7>7G._TX]J69@B;22^=O-S:<'WU)GLKB&R_2D@(3[6RNHE:I:
M95C.G)9M41!(J4N4%YR5_N,LO:A4J/FZ8N;"'M^5=VI6+RV[:F[MCS_1B:?6
M[*M\X-!#:*U=/MT7K'$_.UDF)4(%':C(\NOQ:I2B7:7.U%\0@KB.*VQC'Z@)
MM*/U^/X$P/A3Y/\%& #&= AZ#0IE;F1S=')E86T-96YD;V)J#30P." P(&]B
M:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O1FER<W0@-B],96YG=&@@,3 X+TX@
M,2]4>7!E+T]B:E-T;3X^<W1R96%M#0IHWBS*L0J (!2%X5?Q#;004PB72E=)
MMV@(<8L,NX./GQ<<O_,?Q11A9)[IDN]<_'O%A/@D&9B<6MJUIEL%Z^$"3-8/
MF&1/)C_0UA#&MJH1UP:.X!T"(?K?E1Q]@H.ZU="0*IQ:_P(, /#.(IP-"F5N
M9'-T<F5A;0UE;F1O8FH--# Y(# @;V)J#3P\+T%R=$)O>%LP(# @-C$R(#<Y
M,ETO0FQE961";WA;," P(#8Q,B W.3)=+T-O;G1E;G1S(#0Q," P(%(O0W)O
M<$)O>%LP(# @-C$R(#<Y,ETO365D:6%";WA;," P(#8Q,B W.3)=+U!A<F5N
M=" Q,#4R(# @4B]297-O=7)C97,@.3$P(# @4B]2;W1A=&4@,"]4<FEM0F]X
M6S @," V,3(@-SDR72]4>7!E+U!A9V4^/@UE;F1O8FH--#$P(# @;V)J#3P\
M+T9I;'1E<B]&;&%T941E8V]D92],96YG=&@@,C@S-#X^<W1R96%M#0IHWGQ9
MVW+;1A)]YU?,RU8!6^0$@SLV3XQD.]Y:EUT2DTU5M \@,"1A4P"#BQ1]A_T/
M^<T]W3, 29%QJ8JXS?2]3W>/?GAWK\2VF_VTFOVP6H5"B=5FIGSAX0^7Q)>>
MYRF1A*%,LRP3J\?9#S==*HH.2[NBGGEB5=#/\\P1[NKS3&72C\0B"J6?1F)U
M.W,2?@_JL:&>,?'L2%M)7]':1]"1618$$19ZXLO,? ?]WYW_OKE?/3SX61SX
M@?)BZ;NQ3,'Q?ZM_S]ZL9@E$#:0*0#62>)"A3UM;/=N<JY;(+&7^?#.*$&8R
MLR*<:[>@[X$1X9?[Q>W'FWMW@:W.PP.S/FKU2O101G% FL("H!&DAH;RLR0+
MW43&#MY)%\(ZBBG)- W25,@D3B-C_B^S2/I)ZALBV,O;0("O6>CQ=:02C?)8
M1<_U *4HB@TE]IAQ%BQWC:^*/!F%9)4HRD2H9!8*&43D?[;H^#V5*CG[[IOO
MKVRAO!3^$)&2$4P2^E)=..A*Q&$3(BZ]] E]3T@'.,=7 87>[\[]L.ZJLLK;
M2G>PAW)$V>A.U$TO])]LH$+K4FRJ)RT.NBUTW8L')_K'@RL:_KQQ _R*?N>F
M<*\615-WS;XJ\Q[;>K.FS_<B[SK==Z+9B)^:MFV>=2ORNA05WK$'/+%04D76
MT)>B.>2NV$9N+!:^74Q:158KCGK:^O7M[?*;>(1(RM'N H+E[B+"I>X@J1:_
MR'LIWC9-R3+<ML-6+$NSO((^OE-77=_F?=74HB%!7\ \<D0W%(7NNH:?6E*:
M;G2K^T::%2S>ZI^S*?ZE[X?)42KQCKA^R.MADQ?]T%;U5GQJ<5N!,(E,2:)S
M*V=^.(!LX.Q=TM>IBGR]UW#^'T/5:KO672BGAA5)$^:^B(^FG)! ^C%"CL7H
M>BS-V[(3\(C8-&V_$U7-_,@D<[;'G.G=-!W9+7*(5\*FC!R(*I9XCIP"O"$=
M101TNUE^0U2,3JT>#WMMM]4]J7EJFHQE@HE\(U.KM\.>[=V!&&1"].7DD,@!
MF3E)*0Z[O#6O<B-4H0?(DN\[L=;,0/EX.W0(/.CS";Q#9^<J)^^T\,F/@>CZ
MH40X&>V*YI'HQ7!@42%$3P7TK>^0XBR@89X ._.)[1R^\1WA*W$C^?:MO)/B
M4]Y"?5]YS,-7_$49RY@-K=[KIQR)1/&P'9 K=:&1=_RU& P;\JLTGF6#N(LC
M<%L90Y8Q5*&->F.R"X.=2 R[@$GHB$\[,HJ:N\JCI#H31)LU?=7O=6F6?[UY
M]^$3T[0;S>M1F!'M4<O>UT^ZZZLM^Q(VI5CJOIT7LFO0F4D/=>2(LZ8R/KAV
MYU5PE@25O(4$B&Q(1;Q3BN\"=:J @2)"[2,\IGL9LT4-3H^?@="^_4PHGE[!
M784*S]I'@/4XRZ+KP!M:B(KB\ 0,_I,_<]*G)N7S_9Y2?D]YSA9&LG<N.@BG
M!P X>3_T%+OML.?+,6?F8DKJ.3M2[ZN:UEP%A,18*LQL#3@ KPMD!0=LTY:Z
M-;=W(\ZD2'+*_83#$1 .N04G8>*4[B+$9[.HHB@UZ E0+.>,_H "_LAXP*1J
MU(8YX@P!56AB*:JN&W"W?KD$T&-P_>Z0S0P>4_(R_AU<4,Q;!L9M\Z3;VN)B
MS55GZ'=-6_4O\FKAB$V6PQ2C4S2TQ[Z?=;X'+-[DK08\-]N6P0BY.WI,495@
MIQ7-?J^!WT]<G_3^96X*U<:2^J!+^!-T(/B%.Q9'K%%>9,%PW(D-<&NO+8FJ
MY$<3 _?$DM!2*3^=\^_27'XREQO:KM(D(7\1MM\W%R!G*H,716,SH(N!C"66
M!6$Z>@\JE#=2_/674('OY8MD/M[DT]UZNBNFNQT'$/K*J*X?W#D+<,IYK-A!
M?*[RZN[]S?+NS:@HA ".CD((Y25*H&9U^@])5+FZ$.FB>JKVXBT03HN;?5Z9
M4MZQ'E!?I7$ 4H$:29T!E[*RA)ZU_U\B2/SLE%'15H]<\2K"M WS*9@/O>PF
MOX")EEL),Z0GIO/3Q)@#O$9CC$%%^\7;-A_*22C/>"4)K5=N6+D[+J:QJ0NA
M0U5L4B]+XS/UH$#JG5GJY_>?EH@/A 2*#[=FIQ47KQL(U;JO"HR)#Q6/!>;N
MV'@D1I#@%!'Z7=Z+$@N*?O_"65U/3R8U6?6=R2W.":P8T&F]S,5A,DCB="XU
MHJ Z">-[F<7-8XXGKW*<+#)JA\8SI@IE>!&K^1E?<-N@D>,:==3_;,EEI?7B
MS(;K 34>D'E $>^.5B5;[JH#P/.16^D&/<DKID\5H2O@>B"8UZ:/Q'-)_6:U
M'OJ&GAZG]I"@^,(CE#>>[2DIK@Y@K5D2>B(3'UI(5Z.)ZW+ (KUM=65LMA[:
M3C]BN6F(R<IG#NFM>]DJG6Z?J#&%GXH].B<H]#J3;3'QQF@=X1"=L^%[0(-)
M&]NKU>14YH90-7:HPZ8-D(R ?BR(4,3-R%QZ#1<C)]'=;'%??)F0]:QW0]&P
M(9.7GQ%D)VT5*E0_%T-=TA!R),]UU4I]3 [C6M*\83DG,$:$10[/#G<LDLUI
M4P(?7Z=SE%F/G>$J063<+E+;.).^!O(Y0,:4YS W>I_D2>S,7<\YUI<<B9%O
M-?N\XQ#0IZ-5.%4]6V_4F%)''UW(%CTO@GS"K&$-4XVU\=[$QF6M$'X4K\<]
MORXOQKNI\#+F6F@9"^_]<."F 64]<8 ;]\5.E_ +X=L14T6J_)A&T';TXF2X
M<4KPCVTOS9X5-4A<F(O)AI<IOK!W)!%H\YAXJRG;N4<SHQ8%YJ\:#0Y5_^5F
M0QYW*NJ9MJW6O)#":_*GG1G;J3WA!9,C4\"=YWRG/R&AQG']ZULPZL72:*CK
M<KSI4?<:3IM;6,',OCY)'-'( D$_%GVSAJ54.!<^YG]Y+662,#WC\[[FF82:
M.3Q]K.&0-W_VNB;@Q'!H!YJ*$P5]:NQ\$]V.NEB;;'F-:.RKCL ,:\SX _/I
MO-B-?<G5%G7L_/PXL@T"8*5Y)OWT$X_$!'C_0E0@.D7=B%)O\F'?\Z%$X+24
MY>@\W[B$<4^N64\<;^VZ;L<+2=9=;BF:B4LT!;J@ED>?P&$WKOE8 QDR0( ?
M^=6#@Q"_-"'Y*K9MA*ZXII".2T[7WUP?O_<+=#\?*N1HW]3<%?**W_ ^.7D/
MJ308:\!HL:OT$XH:(4O@F",)I#?M;":_GL&-F9X"Q:Z.)(]"KT)K%%?%H\<;
ME.J\Z[\=G=>-P/QY[#9I!#R>WW2"!HTG;8SE&V/E"/>##1ONZ)=;LOV%FT\$
MA4KG$^+K@S!Y.NC9:JQLICJC!6Q@$Z5K,U\LLS":#A;'WC=+CNF^UE!/FV99
MP^$E\HQ2['5V???$T,= '?Z]L#^.74 I=C B;#<W?=/WIE7,H1A3513*),N$
M'R*84C.P1G9@'5<$?+)XNB(Q*\Z%#/U8)K[B#:DY6XQC,^-:BB&-QNG)"E3-
M]&S%*Q^EP!NLQB\$2 .)XGNZ^NI9I:(CT C=\=^?54HO'<?4*>X>\Q>Q:1O3
M28B>A\[$>=1<H>VPJ<5PH#-(>ZQE0EL\(R5%3E%LGG-;;. 2$ZNT>MU@CIZZ
MSU>%RP)E.)X+F0877=L(9Z.4U..M*6_&OH$.1J=$4'QP?A(F$UT+'J!F\J:J
M^3BMU7F'9I7:%/2*1:LI'X_!-)].],,LE&$,V\+%OG7MV>'&=4\H#/'6$R>=
M?Q38IF4SM!;,<I2V"F*AW!5?ZN9YK\LM-=P4PV>VKJ@'L<UDA0I'QW)-/1>V
MQZ?FN+$TD5AH! O=]CG4/?G?! 99&4*)P)>)4<(>??]?@ $  D/]R0T*96YD
M<W1R96%M#65N9&]B:@TT,3$@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E
M+T9I<G-T(#8O3&5N9W1H(#$P,R].(#$O5'EP92]/8FI3=&T^/G-T<F5A;0T*
M:-XLBKT*@" 0@%_%-U!!RB!NJ6R-=(L&";?(L!M\_.[ \?L9M!)*C*.<\IV+
M?^.5&#XKM+(]I1U +A57CQ$YK5YSLBVY_"#9$ S9P; EZ!BZMFPE7S[A(;?9
MR9 JG@"_  , 7B$?W0T*96YD<W1R96%M#65N9&]B:@TT,3(@,"!O8FH-/#PO
M07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R(#<Y,ETO0V]N
M=&5N=',@-#$S(# @4B]#<F]P0F]X6S @," V,3(@-SDR72]-961I84)O>%LP
M(# @-C$R(#<Y,ETO4&%R96YT(#$P-3(@,"!2+U)E<V]U<F-E<R Y,3$@,"!2
M+U)O=&%T92 P+U1R:6U";WA;," P(#8Q,B W.3)=+U1Y<&4O4&%G93X^#65N
M9&]B:@TT,3,@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" S
M,C,Y/CYS=')E86T-"FC>C%E-<^,V$KW[5^"0 [4E80A^L_8T,\XDNY544F6E
MLE7Q'B@2LCF12"U)V='?R.0'[^L&0%(:V4ZE,I9(H-'=K_MU-_3NNSLE'OJ;
M#^N;=^MU))18;V]4('S\AS]I('W?5R*-(IGE>2[6^YMW'_M,E#V6]F5SXXMU
M2?\\WWABL?Y\HW(9Q&(51S+(8K&^O?$R?@[IB9&>L_!\DJUDH&CM'G)DGH=A
MC(6^^/W&O(?\W[Q?O[U;W]\'>1(&H?(3&2P2F>'$_Z[_??/M^B:%JJ%4(:3&
M$E]D%-#63M]LSTU+99[Q^?S!J1#E,K<JG%NWHO>A4>&7N]7M3Q_O%BML]>[O
M^>C)J@O5(QDG(5D*#T!&F!D9*LC3/%JD,O'P3"Z@K*=8DLRR,,N$3),L-N[_
M_2:609H%1@CV\C8(X+]YY/-?)R5V^EA#S^V I#A.C"1&S( %SUT[5\6^C"/R
M2ASG(E(RCX0,8\*?/>K>9U*E9^\#\_["%\K/@(>(E8SADBB0ZBN KD0<-B'B
MLJ\QH?<1V4#@0 V$WF]>T??'_2+S#@L9>4/=-KTH-NUQ$!<P73,7;DQ&I/S
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MQV*W,\JL_S$%L501<H.5V9#2=(P'K8=6X'MQ1$PAH-M],=0E!)SXNS@>*OX
M:RM2QSSM]%.-3['7&P'L NNZ ^)1T[K LTXB2Z&;K@^#P,>99HIS0#+SD6)8
MU3XT-:45N03'Z.9($KJ6; 8/7R"X6%$F^.E2+!2=6 "2PV$'"Q"S2[$YL5)]
M87:3QZ!50;L"SSQKC_ SN;^V:P#YF?-R&UFA2PF2:# O=L+AZE*S*(<C'N_8
MG[DW1LH_!9/H@9]2YN9>^U17% [;8\?P#H_%<(XD:11[QP46XQM0 AH,A$M
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M =,*(\&N>+G[Q2!&*Y1*N/FE>G)^I@)=LTIFP85"$69M8@7W]G(W7,?-N%M
M!?=<G_\+, !<[(%!#0IE;F1S=')E86T-96YD;V)J#30Q-" P(&]B:@T\/"]&
M:6QT97(O1FQA=&5$96-O9&4O1FER<W0@-B],96YG=&@@,3 S+TX@,2]4>7!E
M+T]B:E-T;3X^<W1R96%M#0IHWBR*O0J (!" 7\4WN 0I [FE'U=)MV@0<8N,
MNL''SX/&[V>44G3"&)C*61Y_QY097BUDIX>6-D18*EE/D3A9+SGI/ZWEHF9#
M4,V.BFV#GJ'_%_>4Y#/MX.850JYT('X"# !>EA_>#0IE;F1S=')E86T-96YD
M;V)J#30Q-2 P(&]B:@T\/"]!<G1";WA;," P(#8Q,B W.3)=+T)L965D0F]X
M6S @," V,3(@-SDR72]#;VYT96YT<R T,38@,"!2+T-R;W!";WA;," P(#8Q
M,B W.3)=+TUE9&EA0F]X6S @," V,3(@-SDR72]087)E;G0@,3 U,B P(%(O
M4F5S;W5R8V5S(#DQ,B P(%(O4F]T871E(# O5')I;4)O>%LP(# @-C$R(#<Y
M,ETO5'EP92]086=E/CX-96YD;V)J#30Q-B P(&]B:@T\/"]&:6QT97(O1FQA
M=&5$96-O9&4O3&5N9W1H(#(T,34^/G-T<F5A;0T*:-Z46-N2VD@2?><KZF$?
MQ ;(Z"Z%GWS=\(0GUF&8F ?W/!2B@)H6$J,23;.?L?8'[\FLDH!NVA,;,^Z&
MNF3EY>3)S'[UKWD@-F;T=C%ZM5C$(A"+]2@(Q0S_X5<6^K/9+!!9'/MY411B
ML1N]>F=R41H<-64]FHE%23^.(T^,%W^.@L(/$S%-8C_,$[%X/_(*7H?TU$HO
M6'AQEAWX84!G=Y#C%T44)3@X$_<CNP_YW[S?/\P7=W=AD49A%,Q2/QRG?HX7
M_UC\,OJP&&50-?*#"%(3'U_\.*2KK1JMKTW+_"+G]_E#KT)<^(53X=JZ*>U'
M5H7?YM/W_WXW'T]QU;N[XZ?/5CU1/?:3-")+X0'(B'(K(PB+K(C'F9]Z6//'
M4-8+6)*?YU&>"S]+\\2Z_WZ4^&&6AU8([O(U".#?13SCW[V4I-?'&7IM!R0E
M26HE<<1LL."Y6^\&R<Q/8O)*DA0B#OPB%GZ44/S9H_U^[@?9U7YH]Y_X(ICE
MB(=( C^!2^+0#VX%*'T1>[B>98@6HD,K*>GOSP*(!.J^>?M6UZ7>RTI(>"+U
M=N-IX,=><Z@[T:Q%MU5BH=J=^-S(6KQ9/<BZ5$9H(]1?!USJ&M&T8M,JV:D6
MIW%HKA^[D_BH'Y3X55>5;FJ@K;A&6Q#XD8C3W"<5_11ZQ8,USVU(B\2?%6<;
M&-53]PFI\[ZI*MD:<>?](TTF6*9_%*%;X<E]B!N@9>%)LH+$.N2CKF'7NZHQ
MNMZ(][ +<J41*[76M5H)7;-3OK3-GZKLQ&>]@=\B;SL.@*-.O($OU$[5W4\1
M%:9^')RU" <:^.;=C?UQ=O;6381EJ1_%<$OL![&( K@WOW;C<"+T<>O6B2<H
M0U#2 AD1BF 6T]47@Q* S-AO:0JR*HKL>=X/.(-?P[2P=GW_5)NF>E UPZP<
M3\% )W)CJ=0*KN;E'V,PGR=VXQR_%,Y$GJR-D/5)[.U)/D:169X(>=+>D[HV
M'1_[HEK3U.)0KQB/O*NL-Z>I +:#I ]]#Z-XYD+_6ZT[1'C>(>A&O)7U?7O8
M=^5)O&M6:L+/X84&X6_%\KR+=7VV+?"P5,GC!(ME=2#3A#1&;^H=*"?S  UC
M]5G\D]5(;$;&A=-BW;2,L*6J 3G.PK*%B[H&TA.O-1-1-N2AP-L#I!T2#$OJ
ML5.UT3B2>U@0&]QN956=Q%%W6Z'QZ%,I>&=OOU#.)U[OW\2SX4@\@W#TF0MM
M.4TBJZ51ZIY,:U73;F2M_R-)D8F0;2OKC;+ZJ7&(.-8=OV7]9K3=TLA87*ZT
M6OOV 40G=-&AA^+(^B7+TP% G:HJ)!T1#X"S5VUW^B%VBB%25>2IMTW;-D?5
M_M<@:/M3JS?;SKP6BU:N ">B>GH>J&KOL?P%@48X7H^GJ=_GW"5*2(\HLWH@
M&5B-S[J$HQ5N=R14& 6_=H11T%SL$4$ "!R5UP!RX<GQS#/WXMCPDQ<*ROV^
MTB7[#5<C>)N4("^I-6-M!0=I8P[*3/C &3;!K$>+BSMCH"&/UNHH*V/%-.O7
M+.;BT4W3K(Z@9<)D4VI)@&>$,+0MX>-UM6D0W<E5Z&T9!N7$[NVNV2@.*@NX
M>,2ZG8H#E"=Q8B\-4+!OE8%O6*?UH3NT"MY:HP)M.#@A!R?GQ"?8D#Z70:<P
MA==PC ?^GF56J1X8_ A9XRRV,;ZRFWU$NM]&(,IM3Q#QSR HYJH\M!H?!O+_
M@?1!XEAHDA)_<_&GR(L2EW-6/%Q4$(N(%1N!TD1A(_,"KD(1^,Z6KW$!\G,U
M;*FZHU*V=O618A=!7 S)BK)46F6-=(\ N6(G3V+=-N-I3LES Q!31V*,".TB
M2+'OM W8$%2*,!1!IW$9;##U:@+@&J)=? +GY-ZN6>FUAGD]<1RU@6('I,PU
M5.#7U0L$$EJX]IF"X#W@D1T;3!!+ 3'2$&5'G%<#KC@H^7=CS@E+P_8<< .6
M.8)9S5;O<>A,\:9KRGL@7+:=VYZ\$-7>:6'OM,HYC8M/I>525X0)2_*YMT=,
M0X]4T3"6_&0N^=1"2"L#?0$$+D87E7 "+9?.E H]'()LFSB<)$?F?Y=/I=SK
M#F:73=VU>GD@NJ+H7A1;O'GGD8<BKNN9Y]Y[4_YUT#;O;)UZ'JBA!:,&+^P#
M]46\05-*3=U)?&4N<30_L50#)^RI^7)J#$P_L41/A;8@BI\XAI_<;@#"H?=S
M+YMFW1UEBUI_S>U4D2\6'+\-%9YRH_"HSD.9,_<=ZCV_KBYKPD3<U\UQ>FX
M M<?;1NT# 8_I_C'F4DD@>H N610CD(R)234H!"(H8*']QN[I^P>\J@YR8K@
M,.D[)L/">EQA1TC;*B%9U1-*):_DKMX14$FQU4%QJR!/<EGQ1U HZ MFV2ZK
M::^C,@Y#ST7F:4&Y3N?K6Q<JV,R=Y7WJ,E%WS55+!?.ORPQ7O[)Y(%[KT(&-
M ^K(CRXC,*Y04JU=$W==C[#HRM&E%N?1(+!J]+7*XHM='G!W8Q>  \#:,ZCK
M(/A6NXYHI:L##YOVZX-N*MXYY[#>[:5N>ZDSKT;>)U['5; OY!.*XH0MD>56
ME-*HR96VKEA0G\_*7CNH67;2\8)[DZH#'CE7I7U?E?@6CG(&<B>.-'PQU5PW
M-;GMNIE#=Y^'_T>&N;$*/SKC\Y=+]HB?E^FHC]/W3ZTV6S$_+(U>:9#(#QI8
MWSP:9M3,#19B 3_(O0*C87+YK"V!V1.:*Y$D#MYSM8H\\ISM= ?@$[1O<OQ3
M%O4P#W"9_H2.%W'T^>\'3^M5X!)O-DQ,7^>V,B7>T$A<SRC45K0TKWY5(!@D
MP5RU#VA0?7%=J-E%&#G[G/[^"[*13!A:"CN8V.<R^]S:5@CT,0RY.>\,/@7E
M6R3QT(__/SQ2;D*W6RX)8V?4.2AW8^?ABRI7*6YIP%?J$86-AY#.%?R5>*8T
MUW]'84"W@>Q.@F=Y[G'$LP,;=- ?<BV+7(\S]B\(:'P^/&[U$N/6Q]O!<<U$
M&O6MH)L#AOGC,CF$V^SKS_G[,(BDGFTYD#K]+B7!2X,J=+3>KOJSZSZ[F=]<
M8W!;=U=@\R0;=%>U#77$R9!YT@Y'-8T@UAB[V]!"V]DBOI$;F+!2U):!V-L#
M<VBE5K2\/>U)P[*? ]W(RT_  PRF\Q#S+&.L>[.BGRYM8SSI^YMS\X-1MRX/
M)#CUEN/ :UGUV$-+,Q&5>L =#)7,KN56MAMV%1F$<14Y?=SRR )=//'05(>Z
MDZVN3L/?6_XGP   93@R#0IE;F1S=')E86T-96YD;V)J#30Q-R P(&]B:@T\
M/"]&:6QT97(O1FQA=&5$96-O9&4O1FER<W0@-B],96YG=&@@,3 T+TX@,2]4
M>7!E+T]B:E-T;3X^<W1R96%M#0IHWK(T-%(P4+"QT7?.S\DO"BY(3$X%<8HM
M% P-+,R!4D%V=OJN%27NP26))2 I]V!#D)0%5,HM/Z\$*!H28@(4M30!B0(Y
M9B".&51)0%%^<G!J2;1^@(N;?DAJ14FLG1U @ $ 7PL?WPT*96YD<W1R96%M
M#65N9&]B:@TT,3@@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E
M9$)O>%LP(# @-C$R(#<Y,ETO0V]N=&5N=',@-#$Y(# @4B]#<F]P0F]X6S @
M," V,3(@-SDR72]-961I84)O>%LP(# @-C$R(#<Y,ETO4&%R96YT(#$P-3(@
M,"!2+U)E<V]U<F-E<R Y,3,@,"!2+U)O=&%T92 P+U1R:6U";WA;," P(#8Q
M,B W.3)=+U1Y<&4O4&%G93X^#65N9&]B:@TT,3D@,"!O8FH-/#PO1FEL=&5R
M+T9L871E1&5C;V1E+TQE;F=T:" R.#<P/CYS=')E86T-"FC>C%C;<N/&$7WG
M5\Q#'L 4">-.('E:2^LX+KF\M:++#U8>1N"0&@L"&%PD:S\C]@?G=/< )"78
M26VM2 (S/7T]?7J^^L=MJ [=XNOMXJOM-E&AVNX78:0"_,/')O*#( C5)DG\
MO"@*M7U:?'75Y:KLL+0KZT6@MB7]>5EX:KG]91$6:ITF?I2G:GN]\,* GT)V
M)K(+%EV<)(=^%-+B)TCQBR*.4RP,U.-"WD/ZS]Y/'V^W=W=1D<51' :9'RTS
M/\=Y_]I^M_BX76R@:.R',:2F/G[X241;6[/87QJV\8N<S^<OHPI)X1=.A4O;
MUO0^%A5^O%U?_W!UNUQCJW=WQT>?K'JC>N*G64R6P@60$><B(XR*39$L-W[F
MX9F_A+)>R)+\/(_S7/F;+$_%^8^+U(\V>21"L)>W00!_%DG GZ.4=-3'&7II
M!R2E:2:2.%X2*GAN[MPP#?PT(:^D::&2T"\2Y<<I19\].K[/_7!S\3Z2]V]\
M$08YXJ'2T$_ADB3RPW<!FLDW;$*^Y?,Q23@M_"".8TJ\GSU;ET/;FIUJ6J5;
MV]GZH.Y?57,TK>YM4ZMFKRK]0J^;_L&T+[8S*Z4/VM9=KW3]JHXM+>Y?5_RK
M;.J=I8VZ4IVN#&UD#P=J'?HAIS8I$G+>LTC5VQX+6].;FH_4A]:8)_P@D3L6
M6QG=&65KA0VJUOW0&M),J\Y ?]N_XEUO6M/U/@<H4^OH[#1)(W)0)&;_=M/H
M^G?UM,R1DV:Y]D-/+]<I/NIEZ,=>QP=]V#V/3TO3N=6:5^^,&NH=*?]@._6!
M-19A-:E %F__BA.C*#T[45TWY4"6=3C;Z+I[LSVG[2O>'6[\,,P323VR(=J(
M#90Z+)%5A/>?EJA"SW9=T[ZJNNFAZ9UG]\CNV"/GW2U78LW5MZ+8.HI%]D5$
MD&DD/RR*3.1_&/J'IK5?. ^<B+)LAKI75TW=MTVU7&>H)%&?_)1Y9$3BN1_U
M$@;UG6S]KK'LK_^Y6%>5^O'J2GUC:UV7R,?ENO C;_(IQ]/Y(@J<=V][W9\"
MX([\B1TC\6I;3?E$CS]59G<P;V)&K[ \]HSZ)S*IJDS9#\CA3RZ[U>V8:._W
MF4O=)-?"!.@@?H2\TA[5M6W)5,2X[$]NB."&V 5^2G>IBQTERS*,G%'*_ H=
M>M0JZ@!U5D,.E<N+[1]8"U;1[(#P\^Z*@F(C*OUP7]D#Q[6C J7-/1S4Z5*>
M07IO)//%TF.EZ6!H9>ZITKD^9 '*_'SE^'0LEL![57LD*:J<T@7+<%9S^G56
M@>K^TI,"5MQ*7,KS22EO2N&3G=FMU%.SLWM+W[KA>*S,Y9)>H(V0@2SPE7K3
M?^9P7- CFRHC=7ID8[K]]KVN>JUNA_O.[JQN7W]75,:_=@VLDW<W_<Z'HU0I
M,6^6I-21@]L>=,WF%]X7Y%PH/BN\W9(JEF!%?DM@@+Z=),K4M<,D46F"+A:I
MN,@837WJ,KEK,_PZFWTWVS/2./$WFX+[^)SC/4 MJ?+9' =D3DG0RU;Z8S<$
M=4ACI#$X3!AEU+7\#+L3.93?1GXTO;M4:(X^P0:A$&E0^$%1S' ,/TCB8HI'
M^VB 2_IH>UTYS!)\SSP"6LY9ZA@(P Z90-]WZ#@M+=EXEA.P/H,Z .MN0*%B
MW9VG[Y8..K-+T"0%N+&,H,G]:1"A]ZAA;&^&'LF'MHC6VCUHI"(]O6J>GE"\
MMSTE0NPUY:,2YU90T'9EU712Z211Y#5H3:&'MMN:$IFM]K8BF1!V436B49*X
M#O]UT[;-"U29<.+'VE)9,&9V([!9?/WX:_F@:V C*8>&PLVXNS! O-@-Y8.X
M\?SDL;F.KCU5> H'!W"OU*8T>4#=G7</QY)*9"Z)/[:VY-B,6O^G.WF*?'3G
MD=3(@Q[_'AJN[EI]737-$[Q].&N\<>'@]\;_Y$/*41^XK!*/J0[2 $:4[A'U
M3EY!RH"(-*P"2>4$8M$DA[9:9SXO1]6CXRK]K&VE[RLC).C"*<49TREABFE+
MBQ[W>MJDNF9H2W.WG.<N+L7R))^2'<Z%#/6!M=L]FQ;DZ.-^;TH!"N049@-/
M\C_G_ <2/8W;M-MA:$>OAF-3_XTH R5Y3L!#$;D?$!#3H7!F$W]D"U'N6LK$
M&+'#44*D%)5=9WKN,GMIZ%# D43&/J&84Y)26EBLGZ"5\K+7CX8S49^[-DR=
M0UX>FLK\G8Z $6S%.DR<&?H>18*N?7X&P@OU]DTKJ20T1'$&O)XW4G7>)E&)
M&NRGW<$&([5TT6*S$3+''LM-E?"E\+HE=3<'HB<>N*3&A[(@OH*9!" @B'^F
M\X<#'Q(AG,$F.I'!,'+'A9$K.@($WB]&X1SJCRV<UW 2*%.S*'"<3782E,23
MWHD(@E]@(#>J/8>BM8<'?$@:Q)A@\CAZ@X*9HZ9.!#?<T;P=19#]!>0[4L)1
M^Y_W\A1$ZW#AJJF(>;1(FH:X(ZQ$+=]80\2E?L>]WC6NR_V"Z[9IG7>YCEG8
MN\IS(LBJ- GG"B_V#DMJTD(&F6M(P:52<-(U$ ^J*-!-QP)O0,\(#F/\!8IW
M9T0T%1(XHB)OU+TJ44H8M][7H8-<-C@:P1<=A*7*$(6T8FK)8+USZ/V=K@=P
M%A4&*X5] 0U\5'?WIG\Q*+2+8ORTMU],NP(K+OT_']UC8'N6GE(KV(PY6KA6
M1 +_<&@/_7':.;L86;DKD-GA'+/Y=%$P^<&Y 5XL_P^F%T*[Z5"<1^ AC":-
M C_/0A4'X$; X%@8C1N]3V]IE'KW%JXH\M/>A.(3_L$2$3"SY.W-2 $.P#MR
M/\*.".0MO]@PR^VB(O2+E*^?YAPPW=/X4/8,N3#W_$*U>D/%[U*4\DC7R-^-
M1[U[]Z<W)R&6;5QX8*0K(?CW--^X5%V-N8I))QMQ;.R7F#.U3&(C^9VS M 8
M%8%/%RWPHA\E%WZAMSGAWNS;>:]M<A19,4<ZPY%T:IHI#UQC,L'$@'+U(C/2
MJ8@<VW!@.O8U,A93*6$C.$1K_CU8PD*"1AK$]E1RQK(3;+U^Q.S\AS<I8^KS
MY"EW.JK4W<-*L&Z$VRWUHHPZ'7>@[^D2A7#P&LB $"S748*^,77K\5I'/>MJ
M@&;HJ:D':&J:1WHMHF@78(NX-T6V=X\;X1^M.>-C[D:2-68X0)I!C2WPYGM;
M540)KPFL6T+.OP":L(/^8SU$.QZL#\@4] I#<]P,57)S;A&]0^S/C-@R9QX&
M] 2Z++FQTFH1A?$^AE%;N!#?.YU63-=C-,WRU'IJ/^_8D5RS19O4E=2S;:KI
M/NV3#%'?NE$5@Q2Z$*:\E?K&[+A7?6OXX16&!52B\.CFT%Z,OVX+8;04B\;T
M:TLFE">W9X4;6<M&MAVI:>F6EWV6M+N8F.&AE"@)*7KC#GQ9,7]KG0CE'M=T
MW52O6\P'Y!<W3*5$=Q)O)9-OZA'7(PN$][-<X@=B%!V7>*S%='[J%+B@5X6+
M[%A\]NG( U)K*AF@-!=@;Y_Y>H%B]]D<;-<[4DJLHBZK@8>8LNG$P/&^8ZJ_
M<?B.O7-_@JCFES<J0IN(\;@ G[ERPZZ49-M<NG)#KCSI\<WU!_<B]UXZ#N5\
M!E#LGSC@<KNR$D+9JAJ38-=1,W]/@XC3N3J 1^;"O'L]"^5%BI+_WDQP.!K=
MC$^=+GF[\Z2;<SO=/4[VKC!4])(*%^J./)XFJ<K*I:*0<IY3^V;%_''7ZA?B
M<7M2FJY'O2- "O"THH$8(Q5]/C>E&^*[ 6RS[OC[)#2&T&/3]CR@UM,@VAG[
M97#C@"#Y7/8%Q>A/YZ$)XS_)9<'*3;5V@H^FX^A#-%]$T%T[3]%U32T-ZIIZ
M(&BAT0;T>*CZT?NT=34UO?\*, !OEDM^#0IE;F1S=')E86T-96YD;V)J#30R
M," P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O1FER<W0@-B],96YG=&@@
M,3 T+TX@,2]4>7!E+T]B:E-T;3X^<W1R96%M#0IHWK(T-%8P4+"QT7?.S\DO
M"BY(3$X%<8HM% P-+,R!4D%V=OJN%27NP26))2 I]V!#D)0%5,HM/Z\$*!H2
M8@(4M30!B0(Y9B".&51)0%%^<G!J2;1^@(N;?DAJ14FLG1U @ $ 7X ?X T*
M96YD<W1R96%M#65N9&]B:@TT,C$@,"!O8FH-/#PO07)T0F]X6S @," V,3(@
M-SDR72]";&5E9$)O>%LP(# @-C$R(#<Y,ETO0V]N=&5N=',@-#(R(# @4B]#
M<F]P0F]X6S @," V,3(@-SDR72]-961I84)O>%LP(# @-C$R(#<Y,ETO4&%R
M96YT(#$P-3,@,"!2+U)E<V]U<F-E<R Y,30@,"!2+U)O=&%T92 P+U1R:6U"
M;WA;," P(#8Q,B W.3)=+U1Y<&4O4&%G93X^#65N9&]B:@TT,C(@,"!O8FH-
M/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" R-#(W/CYS=')E86T-"FC>
MA%C;<MO($7WG5\S#;A60$F$,;@3RIHN=5,J6G15=>;#R (-#$C$$,!C E/8S
M8G]P3G<#!$EQDW+)!&<P/=VG3]_XYB\/6FWL[&8Y>[-<1DJKY7JF ^7C'SX6
M@>?[OE:+*/+2+,O4\FGVYM:FJK!XU1;US%?+@O[;SQSE+O\UTYF:QY$7I+%:
MWLT<K7D5LA.1G;'H;)*LO4#3RT^0XF59&,9XT5??9K(/Z5^<?[Q]6#X^!ED2
M!J'V$R]P$R_%??]<_FWV=CE;0-'0TR&DQAZ^>%% 1ULS6Y\:MO"RE._GAU&%
M*/.R0853V^:T'XH*GQ_F=Q]O']PYCCJ/CWSU9-69ZI$7)R%9"@@@(TQ%A@ZR
M11:Y"R]QL.:Y4-;1+,E+TS!-E;=(TEC _S:+O6"1!B($9_D8!/!G%OG\.4J)
M1WT&0T_M@*0X3D02^TM<!>0NW:MCWXLC0B6.,Q5I+XN4%\;D?49TW$\]O3C9
M#V3_# OMI_"'BK47 Y(H\/0K!UW@&PZ!;^EEGT3L$SR%\8*8]\6QO=V9VI9-
MK9I65>63FWJA4W9YQTMKE=<OZC>S*6W7NO,$>[D[!VZT;:_4?EL6VRM5UJK;
M&E7DUM 9>EXWK=DT9;U1197WUECUZ)2/+N2MZ F/5T)#7\VUIYGTK*(>5/3]
MF(/#/!?&K-0OP166Z ^WK<KOY:K/J^J%M!YNSS<;7)EWYHH6'YVO?-N+^H"E
MMLPK=;WZ;EIH^':]-D7G*<7.3-0\.+I?:.L%\(0@] /G^[;L7MP(=JNWH$WH
M/ .$T.D$.=FX;: 6PX+OVOFIGD"TT#%Y3:;C>>&4;H 5J.5F3K?E8P9X1PXM
MW" T%T[#JVTKGWL<TW@GQ+%6Y86<*<WWX2RMRW4D8<FJ):S:A\/J_2 #*,-M
M@OD\.05=<YQY?AS&8O2GMEGU10?/?S=U3TZ%=H&C\DY5)K>=2OQ?V=/N/,/Z
MEJ2GCE'+Y(.Z-YWZQ-<$OI>&47 (9_(H7Q/)+6>7E'51]2OX>G#H.U"HH,N(
M,Z+W*/%$>_$8/A,FC+"+)=PT0')O6E4W7;DN04):O=Z8NJ-+]G K,12&E)TE
M,D!^E"8+T9AD!^DH7(O.:F5LV1K5-<H\=\;5A OT(\%+TSZI]TU>JY$SZ@[D
M@ULR9S* +SCE_"GEOS@2C?NRVT++=?G=@$$Q;+KI;4E1&#FUBVN-M;C@Q8XQ
MA]?;%="J2R)ZWKZ,&^_*%C!>/YEZ10&>. 3 ;=58LIY4]$2]LUC0"S8^#J/T
M$ O/2!%D3R\?;+.K?7IDRZ]EO>GKCD* =Q #K@ZAL%7+;6N,^FM?KUHX^D-9
M591G[IJJREM[F9P3/-'HX%]"207T]^AZKP*93B7BN# ;R/:#>7E&N=\HSY&>
M*<&94TK+&4X8$3F4/59 AQ96IB-+Z;V2(ZSF%'G%^+;TS,?.#3C17P\<>G3R
M@:!-W]D.]"8_Y)#.N(U>8VA3P=6EU$L9+*\+HG$S)+AE. 3<J6&O_3E!HOWP
M@,A>W;7]1EWO=E59L$$P/'%^PD)</,!"5*,LEBO9-;R[5RLZFN]X[?0\@DL^
MR8S/==G!UP^H*<:ZL4.EX:*GM3\4I;SOMDU;_DX"N4K79+"4)BD_[3?8G*N=
M6$U.PWN:@G-=UI)!@)AVN"Z(<5\KHZI\;SF;H%#T%>LKWVW_=:Q\I"MKM_S3
MU$G-AR>P#YIP2-U=>Y?J!TJUO!^-WOYQW]3SN](6B+>^I?2#$$ H=L*[A92(
M3JKKU@4@#M)L8=HNAQGW>"5V+DF0L_5P4'U].<J39R$4#8G7'Q'^:KJ],34E
M2#H>.Y(F20!GQROF_6H(ANM^TR-_:'VE A\9;.R9 NF9@A IXJA).FIJI\8*
MG92\(AMSC8*8GD(7C8G\0-"/[ZYO?ZIR0&<!=,AD]=E[\-2=V>5M)UXS3 J)
MG&6+ M4C]WU<KTLY5G $4SDI-\A0UIK.4KWNVJ;R#LYF[TG&TT&X.%)!O4?[
M8W^JO$5O42!7H7U BJU>)/H?=J8HN1FY0VW8U(S</;,KKX1?-U53?#-_Y!TQ
M.Y7TAN*+Y$W$I%LEVRO)VL3]R"EK(@:$P>.LW:YO;9_#>E#S[;,I>E).?81G
M*1.OX-?[QE,Z#(+H2B6)>F=6L)K=CL[.0\/JHQ\]@B'PLS%1/9@=.J4@)L_[
M6OJW-TW+C54#XZEGM)*Q#&IM2T!1[9*]UJ!M+ O"8S1*:)MS"CU8<FS!L3O\
M@*G$ETE.;/O*O YA;#(2N/A8U*3D40XX1@C8V/\1Q9Z?'2K?)W@54M^7!9H^
M<Q*Z= VU$G@!3>A1:+J8!-!R;5KHPQD>+[;E9MMQ:2=TP)S)Z).ZH=/!!W2H
MK)'5I2.OI>=&\ALT0G0@39AG(&]J8GH[[>537J?WT.E3I>%^7:0<@SV5J>'B
MT13.^#$W'<BHQTW57FV;:L4.!\HF7W>$=?'O'AV2X (7&V+!I8(49MD)N(BP
M)P&TJM!F D]J";BZB#G-FEM[AM B$%M"L)'J26XV77.818:J<S'@0HFX($X'
M[TIMXE3WA%FAR'FL(*-3,IHJV<2E@FITB]@G-5VM 4PK ])104'GVK2DF!7-
M2'5:QQD)R^/A)WI=/8)D],+D0LN5<P3F'!,I Q,R7!#_'SR7#(<@Y_)H%AQ*
M83K%Y3$FEV-I'#K][!!,IETWG)]"YPE10F6=H 9];QM0G>+W6M@ ,ZAOM$#
MKO-B'$L-AB%NN&C\D'FSJIH]1UG'GNE*D6SLGY'L4IZ&+I)!.OQ@$89CTJ/Q
M863Y?RR:>6XW;O,=YN)J:$NX[5<RG%KUL<:P<=;,HDW58Y,JC>K1\'L:>2.P
MP=BL'F+L*9<D:=7?,>_2#+."(G:KV-\)S0$ID5/EA&8"-$/PD;M(S#P@BR4"
MYC1%K#&.[$Q;$&LP3OB_0@O)JG(43="33*,GJR>*'BKTX,GC_G778H K=QBT
M\Z>S-E:X*;6:VED2O2#=%T<][=A5Z*FM"*9!+#YT%E_0;-*O29'3V[-?;Q"I
M<3R=B9)1W6&N8GW.@+Q^ V'.)P0 *4VS!+-$IUX*6:<-BHB+QB[JP./$&0LT
M:';"XIN?0^WFQ'9PZQ%'>=->J/"O7'ZY>3C\I#-V38APXH.@?8$)AM+GBXR5
M$Q_2>.+#P(1P9 */*>X\0MKJY'>$"RZ?KCONGH>6YA45AF%Q\/VYZY%4M7[E
MR'$8I.9R5_7VM,'47IH='SFTO,D?^%[R,#-@\O[XR^A_!1@ @E(-!@T*96YD
M<W1R96%M#65N9&]B:@TT,C,@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E
M+T9I<G-T(#8O3&5N9W1H(#$Q,B].(#$O5'EP92]/8FI3=&T^/G-T<F5A;0T*
M:-XLR[T*@" 8A>%;\0Y,$5,0E_Y62;=H$'&+C/H&+S\_<'S.R]%,D($80Z=R
ME=<_,67$IP@;U-C2;BU=*FP>(F#:/,.D>EK+#6T-@?$V<XUS$T+S#H$0'1(A
M^]N])?D,!W7S2D.N<%K["S  PJ<E@ T*96YD<W1R96%M#65N9&]B:@TT,C0@
M,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R
M(#<Y,ETO0V]N=&5N=',@-#(U(# @4B]#<F]P0F]X6S @," V,3(@-SDR72]-
M961I84)O>%LP(# @-C$R(#<Y,ETO4&%R96YT(#$P-3,@,"!2+U)E<V]U<F-E
M<R Y,34@,"!2+U)O=&%T92 P+U1R:6U";WA;," P(#8Q,B W.3)=+U1Y<&4O
M4&%G93X^#65N9&]B:@TT,C4@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E
M+TQE;F=T:" R-S(Y/CYS=')E86T-"FC>K%C;CMO($7W75_1+ #(8T;Q?[">O
M[00;.(F1T2(/JSQ09&O4:XK4LLE1]!W)!^=4=5.B-!H;!@(#'HID5W55G7.J
MFF_^_!B()[WX:;5XLUK%(A"K[2((A8]_^).%GN_[@<CBV,N+HA"K_>+-!YV+
M2N-57;4+7ZPJ^N^X<(2[^FT1%&*9Q%Z8)V+U<>' !MV%[=38+MAT<;$<>&%
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MWWN2L]R1&%,&.L)MY);4BFI?;DG^].@6SHVBM)WX*+?EV P$U4\H(WT "9'
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M/BU-XS?N!?8MY,J\87LJV]+V+UG ?7[]\E 8FSTP>"]7= A.;9.ETV^O=^I
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M\6\NAA#BPB]<"..]S>E^9$/XY\/\[I?;A^D<KWK+I7%]W-59Z+&?I!'M%!#
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M+7FL8<LW;S*\'2MA&!<NCS0J#.]49X;L%)'2G?XNQ:_2X^8Q+;X1^@JUA_&
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M]^Y)QM;8.=!,@A>!3:7+VWB,)"+7@VK(QM+;V CB!8U!_L&8TRPP!]R7H?]
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ML.%-,HGRE) :SN??L1I>WV'"GFJ8\FN299<#4F#YU-;#-4*H,&AT 9&VW^.
MNU5A9LHP*BR+J;UH37/1U(02Z8]LQP$#T1!EZ=>MV RU2P= #H+6*&TJ3$%K
MF!PY>CB1)4UM#YB F^JQ4B_-5<ZSD]NV'FN)*JOT,8[#Z\PAV.A'!!U&0W*I
MNMZ2YJM>V6. $YT97/0+]!J@$V,Y+-VI ?"DOJ\QC$7Q2EW8_/XI\?4/_P'&
MV-''K*QE5Z)]3HW-3P"UY7(4O+4C/S;E:((1RI-PRLUD2[HG34XV^K.1^4G?
M2RMUH F:NDXVK@'U1X8A-''> FI0T%@4W)Z]7M]EEK_284>1TRS_)RBA9P<8
M/;3"'&W0XGJQD25#.4K3Y>[WJ$GCOSO#FP-HF!86)R=,7[16FNA4@Q37YC@T
MN!#C=#AP,L"1)GW[H2BWC:K5YO@PGCH!K4J@,:O]_%RK)?2G^=G7EL4GT^QH
M7\2V>,Z2*1)Z---=8JI8$K3H7*':_G+PI^%;CXNWA_D8/&#>=02:B4D7P7H\
MS?9?S\-]I70IF!)@/X7)"?AD*->@/=6./0E0)5 H8@=&$^3?I,\P";U(G]!O
MH_)=3@272J+LLCQM R^N&SC&H3<\"%,OF7H077CP+M/DI1:+\B ;+S<FE8'J
MTJ,-B'XZ!.WYT:+5GO%P-C8O), 2.L.NN[AHN5=B\3B.);;$J.$*NKR@\8%(
M3F-9M&CI9U"&FJ9SA^@,VJ?7(0/-"0\:0K^+V1:3C\\*,O\EJHVX<S"U:5S2
MZ8R71BC9H:41D9*TG*21<,PA%?L#I)EKDT*G;>F0HW?K\_PH@F!=EN AS<'C
MO9-$K8YXZ5S4_9LH#^B:-<EGMR>O\L;U6Q%&/XCMJ6@=D_1T[V0YU\3-#F&%
MR3Y1(5KUH,F0P&_B_&M#5W&BTG0Y/?R5-1_&8]XM0,RNFL:C/-.P4.N/.A7?
M/U0$443X/KLQKZ(;H4H3_P<'J4L=L8U4;*F/5Y4N>7#7?4+M#/6>V='PW4V.
M!#U"A#.CR+LA/,VTYK[0L5,%L:@W7CO_7X ! !OWGI -"F5N9'-T<F5A;0UE
M;F1O8FH--#,X(# @;V)J#3P\+T9I;'1E<B]&;&%T941E8V]D92]&:7)S=" V
M+TQE;F=T:" Q,#@O3B Q+U1Y<&4O3V)J4W1M/CYS=')E86T-"FC>LC2T5#!0
ML+'1=\[/R2\*+DA,3@5QBBT4# TLS(%2079V^JX5)>[!)8DE("GW8$.0E 54
MRBT_KP0H&A)B A2U- &) CEF((X9E ,RRA*F/J H/SDXM21:/\#%33\DM:(D
MULX.(,  \ULBJ0T*96YD<W1R96%M#65N9&]B:@TT,SD@,"!O8FH-/#PO07)T
M0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R(#<Y,ETO0V]N=&5N
M=',@-#0P(# @4B]#<F]P0F]X6S @," V,3(@-SDR72]-961I84)O>%LP(# @
M-C$R(#<Y,ETO4&%R96YT(#$P-3,@,"!2+U)E<V]U<F-E<R Y,C @,"!2+U)O
M=&%T92 P+U1R:6U";WA;," P(#8Q,B W.3)=+U1Y<&4O4&%G93X^#65N9&]B
M:@TT-# @,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" R,S,P
M/CYS=')E86T-"FC>K%C;;MM($GW75_0CM; 9-N^</&428S"+ #M8:S /XWV@
MR9;,A"857FSK-W;G@_=455,F;64$ X$!\UY==>K4J6J]^^5:JUV_^GFS>K?9
MA$JKS7:E?>7A#X?$=SW/TRH)0S?-LDQM[E?O/O:I*GJ\VA?-RE.;@OX]KARU
MWGQ9Z4Q=1J'KIY':?%HY.N&[L!V+[8Q-9\^6M>MK>OD>5MPL"X((+WKJZTJ>
MP_J?SA]7UYN;&S^+ S_07NSZZ]A-L=Y_-O]<76U6"1P-7!W :N3BP@U]^K0S
MJ^TRL,3-4EZ?3R87PLS-K O+V"[I>2 N_'Y]^>E?'Z_7E_C4N;GAI9^C>N%Z
MZ$9Q0)$" M@(4K&A_2S)PG7BQ@[NN6LXZVBVY*9ID*;*3>(T$O"_KB+73U)?
MC.!;_@P&^)B%'A\G*]'DCPUT&0<L15$LECA?DBH@=VI='7EN%!(J492I4+M9
MJ-P@HNPSHM/SU-7)XKDOSU]@H;T4^5"1=B- $OJN?I6@9[YI\(PQ3_ 5")>>
M3DI@D_*_WTQWO\[<P*F&P93J<V6:_B\EMTS>]#\I(8GVILS+F8Y]62=. ]?+
MLH36(<LAI\JY<:J;M25N*I"Z61"&KS \530ZS<AX^,JXT)G/(JJ8/YW/R%[D
M5&L?_^&ZJAJUS1_:3K5;]6%GFD'A?+@SZK-I2M/U[\_&$R6N/X\G?JY/!/4J
M*E2?ER1O#.OE&LNH',Z",D]5/U3-3K4-1_"Q;GNZ_)0/1CW>5<6=RCNCRJHO
M\ 3)0^S7Q9TIQ]HH_9$B)3GY;J"!=L.Y$]$RT!.1AJF7O3'2%XN P!*J[\4V
M@1SKEK*4/YG^0FT-_<_[WJPO(["P[^_7*2H4E[AJAAX9I2>9HUK TJE=^V"Z
MYAZYSFM5W.7VZ<[0FZHV#Q49Y*Q?QFX2J4OM:A97#ILIA212J9!#IF*K33NH
M@QE4:>JJ^39:)MT:RD!!*X1.VPRF'P3X7=N68!Z^5;<'E>_W7;OOJC46C!S*
M%ZX+8TI\W8LKFW_0HJ&E<5G5%;&U/JBB;<JQ@-GW]-%#59KR OG/9<UA#>]#
M1_W<=EW[:!!K[*C[O$+P%7"T;Y5K[9AO(RW<F=YT#\""HC*$,^@T><  L!2X
M7%ODRF3YOST6:;]R2>4%AYPX;5?F30'Z4:"_?/CPV]EZBN*0N!X?&9 N:/9P
M@F5^[+^-9:?70#^+%B3K33%VG+\ZKXA4J<,4*8U< #S7=YH2-[=H#AK SNX/
MIJORFC+J.R ;*-H-50^)O+"O&7"OJ8KO<,T%]ZTW1=YU%;3H0CVB@._:<:*Z
M)3ILUWE3U@ ;&6U*R_.Z^FH4]+IO*=%=Q6)0B3;@U:K).V+/V/6&U&^1XTDW
MCS[,LGP[PI+I92E+6?(D<O8L*Y3K=AQ @J$"=X -O:'Z$0*T)Q!,_X*J _NT
MSP]4E M'_-22+;#$9U;"VZK_3L5UAIH1)0'_*L()*8+<^PXMD-_61$:Y+6[N
M39/7P^%"A!^^D""$E!^J7FM@1V5&U2O7AM[PG?*Y-$6+21C0J=G399$35K-"
MGY6X;4B7X \5NPCUO/SO\@?# )GMUA0# 9I22<_7]H\=P9?5]YUY "*4<OH4
M=;R%4(T=I5[U.5!81PYP9.#ADNF& U)T^X56P"/&>6C?GZG6,,Y(K\.E7D_5
M>J)8=12\K59?K2 PZS"-YK4J_&:F[=2V:XD$*,@O8[DC4J%V2E-T1C0^'X:\
MN)-7Z"%515%UQ2BW^C5J:R#=ZL^T 48\XV@E;V7+M 19T(J'$5G.&W7UP-S<
MJD]FFX_UH C;D<:+<STW]#,:R@(9UBVHU8^0P+GE13S:"X^5!MK4=?M()&*4
M4:RM,/%IH)"DZKF'1$YI_D9<)LWX2>1"H2N%?#RE?(&V+I0&BE(-HC3[VI34
MHQDX]=AV7UF-BI:\B)T]M3#I9@U.^YS$YP)OF_M]W8JRH..-'>7U0O5M 75>
M:(UPU_6B-)/E1?]1%\^:VE>BN56=BP1#9O/'7L2CE8XAQ8J*VDZ#AWR3RT!2
M6/%F6*J20)51DVR0RG00SGXIQZ%XYH>)>';CB#O0JT9FH3OJW)."DF7H-6&-
MJ>,1FGS?-N9PLUZZ66%9:=/D(%Q;4V0DA9/SL6TR@20Y@?=TC!V6D86+OI2E
MGEKHA!<9B=E(2*AA)&JI8UKS4.4Y6-PK>6#X>W!>QC\S=6I4.>(F$'% ,YR^
MCU _Y"CB%E1N;S%P,:=>K#Z7G]UR=5D\L606WE[]^]?K#[2(:1ZJKFV$O#*+
MLBEQ 3PUPV&M-8^M'?4-@S<8NXO76;QO.&VO$\("90?5!<B<#V)D/#$RYH5>
MI.TY8V<'M\!+2*B74G5"J^(LB]ZF53/+%(\.CWN"<-X",&M<?1NK_3W!YCMV
M'NC;[4!CTW-PF'U-7://H5MH9P2LQP8(5'SG*-Y(*&?GW%[ 2]#4!.*QPU '
MR1-E;&E,0%LWAXDF(I6-W3ASWVF;QLBDQ$-RD>\K(D-M8&<V@_Z*--]BRN?)
M:R%;\3'1R3'1:&1VATY+U#E&1F4W::I=DRQLUR$-$79#;U^>+_(7,GXFY9AU
M@$9ZS(S4VRS[)]*?):E^6_I?K?*R]4Y8 JG.1CP#E1NLCZ9B63<A)2:T+0Z"
M_GH4D;NE!K:^#"AU^2 G*!$?APDB>Y.!>B\7Y[#RH3JS*%[L:YY^1%.?KV$+
MGS0Y3NRHQ)RZ:S%QIDY-&\/8(;CX&ML5T^-,.P,=H*;VP<1$^:RCSWR:YF^M
MF0 TXC?X8^Z5=54@(\;:H3MX?7GS]);'\V*I*!W8TMZA7UL:GQDM>)VFE2QD
M;I+I\/A[H*U3'=H]Z\ B@)&XLWNBO#DHD6+2Q-!NWF@SO*>!^%':%S@B?D_V
M%ZZG$Z?\]'F"8N\8*7+1#MP,!=\4-%K:JW1G%58GH9M%:7IZV'[Z </V? 77
MBS,]U]?Y3V7%V \8O.@740&>MQLCQMUQ(((13WP AKW>L3?F.%7R32Z_2D!S
MNN/6\P09[.8OF#9_&+6FQB=DE$TC)\?V<^L8;Y#*D=>?-G4QSRW[SC[>TX\G
M^[PJJ7'P3S7HCC*[E;0]P\EA(;13'[TUA35AN']B'3/E[FJS^K\  P!@;V'?
M#0IE;F1S=')E86T-96YD;V)J#30T,2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$
M96-O9&4O1FER<W0@-B],96YG=&@@,3 X+TX@,2]4>7!E+T]B:E-T;3X^<W1R
M96%M#0IHWK(T,E P4+"QT7?.S\DO"BY(3$X%<8HM% P-+,R!4D%V=OJN%27N
MP26))2 I]V!#D)0%5,HM/Z\$*!H28@(4M30!B0(Y9B".&90#,LH2ICZ@*#\Y
M.+4D6C_ Q4T_)+6B)-;.#B#  .],(J$-"F5N9'-T<F5A;0UE;F1O8FH--#0R
M(# @;V)J#3P\+T%R=$)O>%LP(# @-C$R(#<Y,ETO0FQE961";WA;," P(#8Q
M,B W.3)=+T-O;G1E;G1S(#0T,R P(%(O0W)O<$)O>%LP(# @-C$R(#<Y,ETO
M365D:6%";WA;," P(#8Q,B W.3)=+U!A<F5N=" Q,#4S(# @4B]297-O=7)C
M97,@.3(Q(# @4B]2;W1A=&4@,"]4<FEM0F]X6S @," V,3(@-SDR72]4>7!E
M+U!A9V4^/@UE;F1O8FH--#0S(# @;V)J#3P\+T9I;'1E<B]&;&%T941E8V]D
M92],96YG=&@@,C4Y-SX^<W1R96%M#0IHWJQ9VX[CQA%]UU?T@PV0P8C+^P5^
MVK6-P$& &!D%#A#E@:):&GHTI-Q-SJSR&\D'YU15DY)F-9XL$!A8#<GNZKJ<
M.E75_O#'^TCM[>+3:O%AM4I5I%:[112K$/_AIXB#, PC5:1I4%95I59/BP_?
MVU(U%DMMTRU"M6KHGY>%I_S5KXNH4LLL#>(R4ZL?%EY4\EO(SD5VQ:*KL^0H
MB"-:_ 0I054E28:%H7I<R'=(_X?WRX_WJ_4ZKO(D3J(P#V(_#TJ<]\_5GQ8_
MKA8%%$V"*('4+,!#D,:TU>C%[MJP(JA*/I__F%1(JZ!R*ES;MJ3OB:CPM_OE
M#W_Y_MY?8JNW7O/19ZM>J9X&69Z0I7 !9"2ER(CBJJA2OPAR#^\"'\IZ$4L*
MRC(I2Q44>9F)\Q\761 792Q"L)>W00#_5FG(OY.4;-+'&7IM!R1E62Z2.%X2
M*GCNUKE1%@992E[)LDJE45"E*D@RBCY[=/I>!E%Q]3V6[Z]\$84EXJ&R*,C@
MDC0.HB\"%(537.2O*(_%\P7V G;E[=! *MFR]CZW:]^AK'0(Q@EY_(7%MR >
ME14=EEX=1F\X:$$8TS$OB,"?6]U9U7>J[2R<'GNC#Q":NFNT.IH>KTJOT7IK
ME=7-R(^F[?AW3RO5\("%]>G)AT,\W0VJWZE=VY& +0D=11:'<ID'1::641!E
M#D1A1OK [A0IQ@H=C299D=?Z2_P[RH/%.?6@:L-:R;OC<#CAZ'9+ZO=&;?2N
MQW=D4>R15MMZT*3>"5\:MT=#:.6I[:C5&D?US^T6:K)L.S8/HN;J#XLY1SA;
MJDM?Z<^#)@<D'AT,%88>>_D%!#B+Y=$G4SU667Q8=UO5]0-MJ;N3ZJ&=H:]'
M7J_-<")#:FOU8-?^=TKT>1-)>98%J0ON&3O"6P2@&PC*JRK[.@1='B)O&$%)
M%8E7[% /X]";$UL'1S\A'(?Z19EV_S  6SN&!O S+/O=CE>)X;9%4+SV4)MI
M;6W)-6]AA:T#":>)G+S5Q]ZVTQ&QIYK:/K!\PJIIAU9;!$3MZF=X%;C<U-VC
MO7.GN]VD.((VM#"B[3N)T04,(C$W)#7HT(WI'[6I]QHH-P2JW+/O!RK$'U65
MSX%*7@7J1J2JHHR^,E(7IUQ$BM^0ZKJVE%N4I?#"O_JN[?:@*SN8MF';[UP<
M$*?E2RT!O0B2[AI*1V_C(YZ<UO;-6#FWY8ES&S!A='U@L#/.(;8 QR,&2,#-
MB1%#V#>M);40-LKAWFS!)0A1TX_&:@[B:)E^VDY;L%*O#CW6U_8J=XLI=QW-
M,0UL>TX^"EKBU6""PANT:>O#@=0!DQ@^\[D^C'3RU4+SJ(=ZTQY:2M$=UG&%
MTC#J )K9JB,_&\KXQ.OYX>C3"MC*3^]B)$/MX>QT&)'Z>L;(\PV(Q,E7)O/E
M(3/]HAQ4+DQK[^/:5[_X%1'P\-"/ [CR>&B;F@!"EA-O_=1M]096<P1:H,(8
M<@$B-')0R66IUS'/-8=ZM*#=C'CW+;0(4N,HR2<UGBDE9D^CLB!?45;:28V?
MM6%<#N1\UH>7#?XR]J"8[$$T/ M4ST7N>R(((8=NSVM4OSFT\B>;R']9/YT[
M,0<H5S?3PCGJR.=CK6@@E1%J&&>PNC+A4GM>Z;  ?!5S0S4%(YV",9O)P9@-
M=8Z'CI5WQSFZ]C[A)$=Z!+=L<K6<<,/745Q&KU@4*=?T7:>9"]0+PO\J90]$
M(' GV<,%59@ "3I%1>!S5@DBZ^[*C_E<5%VHZ_W>Z#V5ZOJI'X$9J8\P(O=0
M:ZENJF^2NY!?A.$==BKJ!#I^@>I+_ 3RU^\F6)H7A/UD3K!K$KZ17WF&;5^5
M7Y=G7%!P<=E V/Z@P3A]Q[D$2%)RQ-X#^5+IVB"X3%+@3"*M*3STIB9$;S7Q
MY:?>F/X%> -1O956N9R>I:GS=<?D1=+NQXUMMRWH5E]'GMWJPB_^+((X3**I
M92<9!PTT<D5MNX%[/D/9WSP 'ZI&/+6+"5$ ]58.C$[2K".B,&4\SI<:#'7J
M"?:)@_W'YK<198%1QLUGX1&N!#K\*/CA+1<@ G[X*X-HUSZC$].FT2)A $:S
M;P'22WC&,SS+.0<)[F>4SG:2QN@>32W$0[IQ,WJ=1M1JZ*'_[CULAB$U6?$;
MY/_<_C_(__*0,Z=%41)_"4]A*3% F5Z>ZP,5;F$P   XE9EA=HK4P=(-$7:L
MI0;, 9WH\KUI()E:[K_V)SYTA7;#UN)2T(M0G&NK^<%*H<A0<'4O3>9/';\8
M].& 8(Q@LI]YH,FH,F?2;6]D#T\%U'90(YG1Z '_>FZ(V3A&_6) J":P9*RM
MMZL;;A"(B>C2X*U@)VE!75DT=X.O8OU%L#%>5GGQ=<&^/.1JFHEF,D(F@,\E
M0W^#?]K=B?HHCA5="$BLV/4[;=#EDE?? 7(21T'\>[;=,"X%8_Y/QL51[HQ[
M=4HB/)M&13H91Z1:4F2IE'?^,J&ZKMSKS@>YTWR6,ECYHS'T+9VV;.7M>8<\
MNCV]/"+-Y=F]'F2QVS,M IG*"U JI9-?>3Q$6J#YCIZ,GN2\ *5XT3M=7*)4
M5Y3II@<:FJ?"8K2,W 1AQUA7/1JW!M)GNUY(%@VG([4FMC'M1@MU<?>"9GJ9
MAH@8=3##@^G'_1GZ<UB#<!K:)]BJ>M,_HQ)/D_6=&]M1,RXL)G-?:K'P0+7#
MZ..A;O03U0O23]D'-.48V]6AE1&K)21.HV'([DC/_LCF1#RW^^>VQ8TM:*(V
MDO?B"%JC/[>H.G :GTKPEIWH:=LC0N%:$O*6#[JJJ$A#PK5S+W2:54HF;D@R
M-ZQN-)W#7F#'L!.@"9L_7YBLO9HKO6NB$S0X#^RIQ$/UVFA-8]1V%%IBO[J[
ME\(56Z*_#BEVT6]/(7M5V[QMCSA3H82UAEJ[@!,O4<OX;$F6N1#_VU%X[FCA
M!C/_1SWIFB?HD[*G#LH,;4/%@Q<>:X-'N%7&;%CJ+D-<,;B%<3K?9?0LQI4:
MRU<^XPDCB@7P7+MJCZ#Z^7IEIS[^_7X99G?R6\AO%+O?E"+^8>J?KI"-/B6[
MZ)GF>QJT2P.-HW)%,Z71W(N]D/\OFS.C&XV^PZKQN#-]QRA"6H_=-';K[1M!
MJM(IM1">PX@Q>'_'[K+CYM<+(P$'GJYR3PKLT1<>RBE25,=RCW(.>?VRJ1M9
M^7BG*.=[GKAYP*?*/(_X&[FR(V22G)CK8^[-]P17/=-\#]3I02Y@Y-JP<M>&
M5(P''AT&]4TD#3PW\2 ;M/</=4=7*?U\!02SKI!" &=Q3WY"N==AS::6B3+S
M+JYJHB2MYKL&4L;6!VUO@(!L0@/Y&@KB&@'$''2Q_W="?Q$\U$ Y?XZ^C#]7
M<\TTTA1!]BW)($6Y96)M99RCKDN2#7V-#]Y2%R!@I--<+M2(9F5@/]U=X2B9
M9LFDG!C1\? T):H]HCSH[:VQCSL=SO=J'CVO\MW/Z6)$=K2659&56.C&F^E_
M8_Q7@ $ W"KV.@T*96YD<W1R96%M#65N9&]B:@TT-#0@,"!O8FH-/#PO1FEL
M=&5R+T9L871E1&5C;V1E+T9I<G-T(#8O3&5N9W1H(#$P."].(#$O5'EP92]/
M8FI3=&T^/G-T<F5A;0T*:-ZR-#)4,%"PL=%WSL_)+PHN2$Q.!7&*+10,#2S,
M@5)!=G;ZKA4E[L$EB24@*?=@0Y"4!53*+3^O!"@:$F("%+4T 8D".68@CAF4
M S+*$J8^H"@_.3BU)%H_P,5-/R2UHB36S@X@P #OSB*B#0IE;F1S=')E86T-
M96YD;V)J#30T-2 P(&]B:@T\/"]!<G1";WA;," P(#8Q,B W.3)=+T)L965D
M0F]X6S @," V,3(@-SDR72]#;VYT96YT<R T-#8@,"!2+T-R;W!";WA;," P
M(#8Q,B W.3)=+TUE9&EA0F]X6S @," V,3(@-SDR72]087)E;G0@,3 U,R P
M(%(O4F5S;W5R8V5S(#DR,B P(%(O4F]T871E(# O5')I;4)O>%LP(# @-C$R
M(#<Y,ETO5'EP92]086=E/CX-96YD;V)J#30T-B P(&]B:@T\/"]&:6QT97(O
M1FQA=&5$96-O9&4O3&5N9W1H(#(V-# ^/G-T<F5A;0T*:-ZL6<F.XT82O>LK
M\N #.9#87"5R?.H-,S8,3,,EHP\M'R@J)=%%D1HF5=7ZCID/GA<124I4J]Q3
M@-% B;E%QO)BRW[SCX= [<SDW7+R9KF,5:"6VTD0*A__\+,(/=_W [6(8R_-
MLDPM#Y,W[TVJ"H.MIJ@GOEH6].=YXBAW^<<DR-0LB;TP3=3RP\3!D&9!>RZT
M,R:=72@'7AC0Y@.H>%D610DV^NIQ(NN@_L7Y_/%AN5J%V3P*H\"?>Z$[]U+<
M]_ORY\G'Y60!1B,OB$ U\3#PXI".MGJR'0NV\+*4[^>/GH4X\S++PEBV&:U'
MPL)O#[,/_WK_X,YPU%FM^.J+5#>LQUXRCTA2J  THE1H!&&VR&)WX<T=S'DN
MF'4"IN2E:92FREO,TT24_SA)O'"1AD($9_D8"/!O%OO\VU-)>GZLH&,Y0"E)
MYD*)[26F@N;NW1LDOI?$I)4DR50<>%FLO"@AZ[-&^_74"Q:C]5#6;W01^"GL
MH9+ 2Z"2./2";PQT!V\X!+RE]VT".A#""T/Z>(9RND9U>PUZYJB+KGS2ZJ>Z
MTU6%P2FOU*>V.>JV.ZNU+NN=VI9U7A=ZH]9G94[%7FWSHJS*[KQR55YOU'/9
M[56NCJ>VV.=&MX(S7\T"+V!4$P\Q0Y.XC1G\)N]* T)=TYX5^'F[TW7G*<6:
MGJM9>'4V6MBSD)CY_\\GW1[<%,@JNPZ,+=N\-EO=FO^J@\;GWXD.,1'X/8+E
M*YB'@M%Y''EQEBU(832SN+CERBE7KG7"5. !D\&"MWBX%P""-!,9KR]@^6,Z
MR!XR%R%,7FFCFBUT_Z3=60(/K5D;9<W6:=H-%(]QT9Q:HVGG^F3*VNXU9OI=
M(0-@/LOF5LA@).,W0B*PA*\5\NJ"*Z#!62W05LY;@*0J"UT;"$MH,:4[FWN1
M0_9;.&65MRIO8;^=EAF(A]6ZDUU&;9N6U7$R+'CDB,KNP96U@6.+Y(*]P;A>
MX <+X:JL.0B +/]J-V:R/&C="'\W_%WB&ZSP=\Z;VK.<+'@D)TY7YPR^@S'!
M+4NEUE=[99?E0C;+E/P%7WE'5J\VRIW1:=G9N/C3D=>>JHY0DJM*[Z" CN#/
M1[?,!5P0.NK*KM(#$Y$(K$5)R[]-AE@-P\5)))JQEMJH8Z]3YB5OM:J;>J:_
M%A4@^$3@5 >70GONDJH=BA7JL@SF;' !PG$KF3 'K'7;EHSQGHN9C0CB&DDB
M;%CJH5!/;ZGGAB(&$<,R@K4C-->G3C5U=;;KF](4K=:=V@$X\ S8:]?FQWU9
M0&60"+N:4V?*#;O6M6K 2A"&EJD@3(6IW]Q91CX*8B'=B=\8*:6SOW1)A-^-
M75</?&LZ;,C)EJ/]-#2\/26TR+DM78/C;WE?"C^979-O>?IR?6'G<_NK^H6>
M3]5?N+<3/:7AQI[DAI+UA7(M0R&<#+O./=W^YI[,Z8:<H?/I<-V/EJQB/20#
M?X.^5HX]^(X5%SH(4#+QL@@Y"IO86;ND0027ICX@BTR5&R0.X'N0[. &OE/E
M1Z.G8PNG$A:RU ;D@K)<52$Q-?64X'5 _*4!Q:TW%'Q"0F:AC9%IP":OSZ1Q
M6CH<<IPI :[WS>%("S]]$O<I$:I+"5XU6 U8(!KM>70#O%C86E"\)K8(J4V=
MK^',?Q 64N>TV9%N8X>DE:D>PN^:MFV>=3N%OZI*UAHX?^@@P+9*%TW=',@#
M9 G.<FR1A#$#^E,$G<-!MP6$J$8^&D2A1/8PLY%]HTW9BN"Y2S8 >W"Z0\Z"
M CW=\$7! M%[>ZJL&@A;Y-9*YZ@FBIPL0TE/UO:\IL%+O3D5=O*2_8RYE973
MRDB%\[[6L)8M$88>3FM*/0D %X+?,F]YI"FH(E[DC[JFP)&KYWU3]5!Y,;7&
M:4#I/;Z?6N_DUL0/%Z]+KM=7< 4A)@B2/E@CP!T;4Q(462?/35O/$-*FJED;
MR-!QF#:G]HBXJ3[^^U0>*<7&#E!#7IA(-)J3>K=V7,JXI1\XWH&GDW[\2*AA
M][-G SK[4MH-^K ><MGF/.7527^WNI&ZACJC%W6/&AK%;M3K/ATI_^E;W<=0
MY2MU/[["EU 1A7$X*J#UUXYT":0:9-M31]7R4(M.E:U28UNE_E(BMS)8QPMN
M,C1G=[08#])]<:A2-!V.<@2$CYGOXM1'O*16P^HJ806LG#M:"N;9*\N_&^+^
M?&SP+XZ5,[0*^+4YYQ5JBJ74*PX%GH9J&TJ#OO/=>C9:S,DC!F&B:\,_E7^%
MX6^N\!,K4NC;TH3,SH[GDE^(]_6)P(H;6''?-S!7VY44&C_H-1]@G\D@*NW_
MI][L-#H?5"ERCL#TYT4L6KAPJ)'@2H!>K5F-M@V[L!%9-MXACMJK6/&B=0H-
M-QL_NQF^X?$4 +"3*\>.:^!1U7CI9&)AY8KL%(=BAS@;8CM%U2/?9.]!.:A/
M]09)2C9_Q^AAY/E9%O1&#\=&OV/U13A/7VGU\1V7R-5+:!L04EIG_9N,_CZW
M7<I>RG$J6A=2M"+5UU+A2?%+50!R<D>5];Y<EYWTTT28*@T^:&RN>PD"T6T+
MR8D0="V$J!XG"-F.20KO7QH4WA^:XF37I5Y'Z.!(]/]$XS^W3YARH_N2>;ZQ
M3RAU_JOL,[Y# .CYBZSWR3[DDD9)JIS UB 8?U,FD'] N*$@V% =@,YTY8BV
M7E*];6S]Q0 (:-7Z3V)Q/41G+^$N-B$MK]P?R>1/:#,V@H.5DZ_<E?/5#:C.
M07O,;RJ=.%SFB"#4<=VQ#>]HQ81&7S^TQ#VK0?_0$B4#2(;*B52P<NCAAJ.%
M[=%0(5.%B*1&ZKEHDR?41^J[-FY E;9&F-Y<-'>>7I@W'-^VZ&81QW#X]A'H
M&L"AWY<P#?M$63\U%35V5]?W0?5^J\^V%!V!Q7P'!]BA_";+$\J;$]R *%_'
M+5L59I=',+24&F;Y@5-0XOM3[!*29[5%^X@;S[RF\Y:\:N6L>=@;[:((M4>4
M@^\AM)%3D>;4STU)4>Z%V&F[RC[Z2U%&[R-$6,"X8:_E)4-1U.Q1EZNA'^"N
MN-6HZUH))OR&-KV4PR_Z;)"F0'B:W:^@OOX5B?3F"DFD7I#VW;1]%1BP1M8V
M1D/0??Y$=52.FK2D=P!*C)24 /Q'=/-216)[+2FXLUL:E^I4+0\-+[EQ.%:_
M\\.5T<G7+D"Z00$ X$E9&HW?)N,^5\39_/(X26DA<*Z#PV=^Y.HH!4M)7;OD
M[)(U[;,EWXCK*CJ>H.<Y2BOZ;,\"@6VYVW>JDPT-D1C>77NAQ^^ND45]',W[
M)SEN"M:F \GR20-&!"&HE1 (O.(3\]Q8:S$0,^E2 U#S-#7FE*=:3<TRA=F&
M>MX#JHJ'KBD>%=\A%C:Z.+6HDK21E[/KAY_8!O*T[VAP:GAXVC95U3P+$M"3
M<O?Z9+.;D"[0*?I0 [T=]CWAP 9I"#F@>)1'ZC?4N.?(T\ WAXQK/NRS9=1'
MS%RZ<WF/Y%"RT9W$>GH4Y/=)\;A6 [RZ+KCWI?N/;5DP,^S&(VXBRPU:,SYK
M\Y+<Q:UT=ODOFO\), ")J.^[#0IE;F1S=')E86T-96YD;V)J#30T-R P(&]B
M:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O1FER<W0@-B],96YG=&@@,3 X+TX@
M,2]4>7!E+T]B:E-T;3X^<W1R96%M#0IHWK(T,E(P4+"QT7?.S\DO"BY(3$X%
M<8HM% P-+,R!4D%V=OJN%27NP26))2 I]V!#D)0%5,HM/Z\$*!H28@(4M30!
MB0(Y9B".&90#,LH2ICZ@*#\Y.+4D6C_ Q4T_)+6B)-;.#B#  /!0(J,-"F5N
M9'-T<F5A;0UE;F1O8FH--#0X(# @;V)J#3P\+T%R=$)O>%LP(# @-C$R(#<Y
M,ETO0FQE961";WA;," P(#8Q,B W.3)=+T-O;G1E;G1S(#0T.2 P(%(O0W)O
M<$)O>%LP(# @-C$R(#<Y,ETO365D:6%";WA;," P(#8Q,B W.3)=+U!A<F5N
M=" Q,#4S(# @4B]297-O=7)C97,@.3(S(# @4B]2;W1A=&4@,"]4<FEM0F]X
M6S @," V,3(@-SDR72]4>7!E+U!A9V4^/@UE;F1O8FH--#0Y(# @;V)J#3P\
M+T9I;'1E<B]&;&%T941E8V]D92],96YG=&@@,C<Y.#X^<W1R96%M#0IHWH18
MVY+;-A)]UU?@D=R2:-Y%[CY-9G)QRDEF/4KM0V8?(!*2F%"$0I SGGS&.O^P
MO[FG&R!'LN5LN6HLXM+H/GT[P)MO'R*Q-XNO-HLWFTTJ(K'9+:)8A/B'_]9Q
M$(9A)-9I&A1E68K-<?'FUA2B,EAJJFX1BDU%?YX7GO WORZB4JRR-(B+3&SN
M%EX<\BADYU9VR:++5\E1$$>T^ @I05DF28:%H?AM8><A_1?O7U\_;!X?XS)/
MXB0*\R#V\Z# >?_>?+_X>K-80]$DB!)(S0)\!&E,6WNUV%T:M@[*@L_G'Y,*
M:1F43H5+VU8TGU@5?GY8W?UT^^"OL-5[?.2C7ZWZ1/4TR/*$+ 4$D)$45D84
ME^LR]==![F$L\*&L%[&DH"B2HA#!.B\R"_YOBRR(UT5LA6 O;X, _K],0_Y_
MDI)-^CA#+^V I"S+K23VEW45D+MV;I2%0982*EE6BC0*RE0$24;>9T2G^2*(
MUA?SL9W_!(LH+. /D45!!DC2.(@^<]"5>,,FQ%MQW2=)3D8$49Z6%'B_>&;<
MFD%V0R/;]@6QD7JBTETU]KWJAO9%/#?#0<CN19S&OCI(HX2?>=L7\97N>_VL
M>J%W0D*=5@ZJ%O>J/_JEUPST\97N:O&=JO?*AELH5E$0<7"O9M<&892NK2J;
M7G9&5D.C.YQ8"VG$T8<QGO170>R]B*T2THZHKL8!#=95E>YKV56*-<5D[(EF
M,&* )N8?XM3KIX;6#@<YB$?OPZ./G[ S]O ]'!0O9)G&#R)O:57=_(U4C//(
M:@9$ZH;T,JQ8I9]4!\S\51XDGB$(E*P.PHSX4P%(H4]LQ7!N4:]$-9I!TVEK
M3_8O8J=[(?>]4G8(@+,L%C.I,><1](G"S.HSO"!T$^_$?Y6?(*^6_)LPJQ6;
M1,G6^*'76:#V6M=B)\F;\!X9OM6RK^D\OP0:==.K:M ]:T#3KPZ&DC#YZ$3"
MM8H@Y*-[I7?0/?'.80O3R"D<AAQE'H'VZ+T ^[^$Z%F/;4U>KEII3+-K% >!
M[(3Z?6R&%]AAAGX\ J@KON?$=!H@^Z;:^HOW[<W-?>"O,FAOU<S%*CX+1*28
M53<.8[OC(^+8Z.Y/CK\4"&-S#BL,9T*#8$!0C;)="J-;14%VZAM%Z!V:TU*<
M9#]TRGW\JANHBX 9QEXM82]BP$79*G_-B"!,4Q=M8]=TL.RD>\XIW>]EU_PA
M":(E\#"Z:MS'M(H_VH:TS> A;&H;N6U:P@R>.T'K)8/7#*-=K.'B_L)IJ#K.
M:9&+,JA, N#_/0*^[Y#9R!",!G\!(_62&<66D_^&0MQ"Z/#LABO04M!]<0=]
M9%[G(T\'43,N<@[5VU:;IMN+.XQ?0S:Q^FS5\*Q41Y%-F1MY-KXI.&_VT(G
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M#N163G3U >ZD14" IJ@\*WIX6+I7!!L+6PC=HG:#;1X1*G EKD]3N_N?  ,
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MQ.C +!' D95% !I+JCP@!0*JA*4KA3P-KUR=O5K9L@)5IZ#"=9BY:F'K1N[
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MJC'S%]+E#V;*#?MWT=2&G0@X0CO)'%CECS)GY(5:I3*PM+CLHN]SF6D7?5L
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M=<B[NGG1.EHPRE!W^R<=E<1,/U%D^NF1G?+G&S4QH++1"&>2(.\ZC#LT:E$
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MS@]4DT]$C)*"H9PI1*9]A2GV./440-3 YO[9 @1O=L=B.T-+R0:%N34'\1\
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M/7$[II]5592Y<62-27<+V^45*.?1CCAT9)0>C^F%=YQZS-)]%\'0\[;K^^Y
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MD5W.$ 6P7D3LKY&0;.Y#6SF;"S+?%MQB_P"+QZ>L'>&B>>^<D9O9,@9KSN8
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M&8\P:$8@"OB@$#I2<!LO<15$VZ/[_ E<I<@M52'EN&]L](URJE^MVSV$JG?
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M^3'?!A+YG-=/1?26S1V'NX X#/*6F+JXY"Y@IZ/SO1(.&8@CZGM_8*S']RG
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M1,I'FT ^(S_U(D@%M#@Q7MBPT DZ0>X_Y"5I$O -L/AYO9@8X,.;1,P(EJW
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MHHK[*++.>%SJ#85&Z!N/Y [T8N1'JZFNBS99]D 9Q(>02WAT6\.C_ZN&BSC
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MF+7*AI.5J#Y74A^RBM8ME47);DL]B>8&6YW+&O,!O5! LDZ'B=BW"@5XQK?
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M*%\V58#<W+Y"!UR'B(K6*0L%3T/&E<;L$Z+]>L)%/%F7=OT$"Q$DD ^F!=<
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M_[BB>J'(4J^?A+:I^33UT@O7()S!B-8!@EN<>G)[I&'R&JL8%UE^FC2@L6E
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M*!H28@(4M30!B0(Y9B".&90#,LH2ICZ@*#\Y.+4D6C_ Q4T_)+6B)-;.#B#
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M\C2DP;E4Q< MA^\(R.?+F*KZ3?7[ZF >2*$/]/R]-C*-XHNFS43/5NZ/334
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M6R=J+O(8[_(YB!0?;8!ZU UV1#K( Y8'01OZL>4AUI+,>92.S?P2-<U[7C*
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M2=D"81Q9$TBS7Z<?3% H\=1V+XVJ*&B/\TYX>D;L!# 9S$"08(D770]U>T*
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M63?Y04_QWA[SLD3=]:U67<WYIUP7>8/JW'&8IT  FG-3\3;-"9!%W10F+R7
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M46[=L^,1]*IM!Q!KHJV80Y-.JM'=;#^N?[,$NVD[RW5KR7D]74JA3OY'@ $
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M+J]T>*V.LIXOR3R.(^*>X/.Y&GHCQ_>K30Z6GA<6V1[/S22?FLE55ZI:V[Z
M1J(V9%G&EA5P;8-. ]]0YXC?\BIU#5HKX@0"41%R&9&?]2*'M#VG(M%-H:('
MDM-Y.V\1+ZZ)I+1&X]JNT[B+C$-=FQ)PD%\M#"R'9/\=4K1-B2])%F\*H!
MZU'\>XTB?&_+A?A1-O*HS'<+>HP1">+87GK_M>/8)IP5) %P-O*B!O C]U!5
MP/T_-N62%Z&_?<,+?$J";")&%) X]?[<]I13 ,!&CDKKH34.\<<6S]:B:LOA
MK/XGY+G BT=5DH,=E&*X1/!_HP1["Q$:NPA;I'/1.^##98!FC;P;2_H3/X!J
M4,8FL%OA.YJ<4:@C3QZO(;KWG D4; 8#NW!#@#14P<MZJ.QQ%96T6Q:2Q#'D
M#. 8(HAH<:IYT1U5-^@6RP2ZZ?'3 PP]R]=E0%2-6)BV076IT7.(%<!RU]Z6
MK+^%M2 :N_X$KDJILXTXU_*]4LWL'J=F*A8\J-TG#6^G<JK.8 ?<A?9IGFFA
M46]K0C3B+> 4>".*?5:!L1]G,SC-YI8,\\1"18:4718Q;P5DZ&??T(^H0]93
M2P,K(0GB!0J/^%D?3WT'O?"F-5QLWE$";';18XWJN%6XRKPBY(+Q^LJ?G,"T
MS 2PWNE+,B5S7*-0?F&)AJ -4!M&_X.:ML4*$82:/IC<\MD&Z@9?[965DP'N
M?L ,9<*NP_[N CQPJA[:NB98H3"-.^VB>5J"?%0&TKG;* :1_28Y3,\D@RXD
M-KAY[?F8KB>MT5%C!EG"@$.PMW:TS_R<[>0'S8ILY>U&E<ZIJIND,S^@X,M;
M90Q<41R!.BDK1)K%W]9S%@T7('+VV@T'U<"ZL6G-&3'8#QU\@W"!M#/=[\6M
M 8R#:E(D?HPB%J>QGV8\#6V%3Z-5_JUA*, JDCG8XF\+T@+GF\#UHTE6GX"J
M*XT&C \PLVYAE:0V(#Y=G;;\J YRJ'L>6=JR'(QQJMI."=!) Y=(+C)L<,#(
M2B9=O1UYG2PRBI[32%LL)Z;7VKWI+=\;$M"&-!:*&9F)/R\409!@+K)\JY30
M!2#+*OX"!=?R!ZNBUBM:0'R9V3A5X;$ML!.64'"?&*3F*I+ :XB6K"LP'G-+
MCCVE>EL.[5?")NDG2^F8:9EYC459BQFM)';-1=]4>#'JNRCAA@H.#L %6[5O
MY]AM;I EM*)V(Q<--Q_KM+6'=[Z+MT]QFG?<P@V7L2OZB"&%#Z/55#3F=6%*
M%W7SGGK!*DP\0.@-$5@L6B)HS'WF2FVDYRFP(T@MZ.ZD:U3<AA!+ZNI*/8?N
M)VJE%-V0B,OAS:P>Y0=OXDN#<+:0UK@7;QK %3T/0JW#B,CJ%ULG$L[CDEJY
MF(Q#M^ZZ@1PZ'"C2X,JB1/B8QMWL!>\6T"9=-4U@N+SP: SCH!S0D3A9RQ)H
M:TQ0%*XNCT[\L[N9VH(%8T9WV(\R=\$LI'EDI3G;$GM";2>.!KY.DX[D%>H;
M4 @GEY<Y)]]@9PS1U0\\<Z+I_LMFVO8P.I<NLR^[?P,:*$+>-$DIX7 A&QZ=
M#P(9?_ _^S_[3CSQSH;_+BQS\B ;Q]0H16F/-RAW(4\#&,_HC]:DMO8\)$O;
M(0E")20KL>4,"RN7&YK;*5ZEOO 3&CF77=+^[I%OW_=&QB?*Q&5%,P-WMI8O
MF[+CP#("@-?UHYQ9Y9ZM<$<J,>Y27F((S2A5R\2DH]?N_C4UC^5AJ(T8\4Q)
M;)D[,K>Z/:RY:)NVMC^(C !./(NM=W,RCZFN%1/=<LN_B/E'LVWD'BOWN"?>
M08]2<-TO >-O'K.?/!8R*O[_9)3M*V&0N9+Q>3"D[\0] F]HO.W&MO ]]^26
M6L!"2AWL[W:PMG>-1['$GKX<H%3:%P(JAW,,T.+'N7#2 ?2S ?4IFA&L'NMZ
M.W;S-\S8UAZG78E_]@$):HQ':+\\Q#&V^,(U0\I-J336C7-<Q"I^O<B7'6Z3
M(AJ;&2Z&1<#_T2++084WEC,-UE$A'%]A:>BMG5+I;G"1Q\5^F,D#P?MZN7&?
MR(1QZ CMT('87JCBE7",@4_8/*%:4* N1K=L[B@9QY!_T8BI4_DSZ?B$;KW_
MU3%O5$K_$6  XM82NPT*96YD<W1R96%M#65N9&]B:@TU,S<@,"!O8FH-/#PO
M1FEL=&5R+T9L871E1&5C;V1E+T9I<G-T(#8O3&5N9W1H(#$Q-B].(#$O5'EP
M92]/8FI3=&T^/G-T<F5A;0T*:-ZR-#52,%"PL=%WSL_)+PHN2$Q.!7&*+10,
M#2S,@5)!=G;ZKA4E[L$EB24@*?=@0Y"4!53*+3^O!"@:$F)H!!0VL@0) WDF
M0(ZE"91C!N*803D@@RUAN@.*\I.#4TNB]0-<W/1#4BM*8NWL  (, ,75)8X-
M"F5N9'-T<F5A;0UE;F1O8FH--3,X(# @;V)J#3P\+T%R=$)O>%LP(# @-C$R
M(#<Y,ETO0FQE961";WA;," P(#8Q,B W.3)=+T-O;G1E;G1S(#4S.2 P(%(O
M0W)O<$)O>%LP(# @-C$R(#<Y,ETO365D:6%";WA;," P(#8Q,B W.3)=+U!A
M<F5N=" Q,#4V(# @4B]297-O=7)C97,@.34S(# @4B]2;W1A=&4@,"]4<FEM
M0F]X6S @," V,3(@-SDR72]4>7!E+U!A9V4^/@UE;F1O8FH--3,Y(# @;V)J
M#3P\+T9I;'1E<B]&;&%T941E8V]D92],96YG=&@@,C<W-#X^<W1R96%M#0IH
MWHQ9VX[;R!%]UU?T(QE(-*\2B3RMQXO$P2)K9+3(PTX>.&1+8JPAM;QXK'Q&
MD@_.J:IN7B0M$!@8D6QV=5U/G:(__.DY4,=N]7&_^K#?QRI0^\,J")6/?_C9
MA9[O^X':Q;&79EFF]F^K#T]=JHH.KW9%O?+5OJ _[RM'N?M_KH),;9+8"]-$
M[3^MG,3GIY"]%=D9B\XFR8$7!O3R&Z1X619%"5[TU=>5K$/ZK\[??WS>O[R$
MV38*H\#?>J&[]5*<]X_]7U8_[E<[*!IY002IB8<;+PYI:ZM7AZ5A.R]+^7R^
ML"K$F9<9%9:V;6@]$A5^>=Y\^OGIV=U@J_/RPD=/5MVH'GO)-B)+X0+(B%*1
M$839+HO=G;=U\,QSH:P3L"0O3:,T5=YNFR;B_*^KQ MW:2A"L)>W00#_9K'/
MOU9*8O4QAB[M@*0DV8HDCI>$"IY[=&Z0^%X2DU>2)%-QX&6Q\J*$HL\>M>NI
M%^P6ZZ&LW_@B\%/$0R6!E\ E<>@%=P&:\BWP(R_Q?<03NY!PZ7U0*"8[,H*B
M$U#B_>I\T>V;FWJ14_6]+M5/E:Z[%U<UK6K8/;V["?!STNU[U6FEOU6EKGFE
MT.J'HZ[[?W>JK8ZGOE-X25>UN%6ICTW;-N^Z51T>!,[)Q=/\?%:'MI$355_)
MA59](QGI*YP6)";X?D+*>GX ![.RLB' ADO;%$.K55Y?555W?3N\096.]"ZQ
M8EZC)WFGY"YW-PD2\*I>-=R7=TV=OYZON/QMT!W9_GH5@]:06HH^^S](U+T@
MIDQD'?*O.);L&-H>%JN\Z*NF5OTI[W$2I59./HOEI%H7NNOR]KHFW?@E/N3V
MU7N-UJ-7H 5Y8VM"%Y.#2)6+;@^ZZ%E=.*2G:ZBD?D*-ATY%HE,XH5/'-J>8
M;1TRDZ($4W,W<;"OEUM/J<^URLNR(F/$ P<HW W%25V&]M)TNEMH$TMLPM@H
MT]1GV#@&W9XR]*>FK?Z%S3_ X-0YNC"7[(=Q^KLNAE[S8:4^5]^P#YY\U:?\
M?%#-89(V#P@='EI7;$U0&G6HSEK4/2#<;'Z(GSJOBZH^JJ[/>_W&*G!:O#A5
M79R'DM;R&CE4PD'CKB*?8DH>/52/Y:BB@=)+QZ3BF&ULDO8_E"QYUVE*3QR2
M.BU%)G0XBQ!#Q)T?YV>*(A[T5[[_K[M!R!9^J!"CHFC:,I<MJ,'WJC^I9RU)
MF&T2! 8[H#2E>^(L5#/UM+-N^^7IZ<5=PXCS&5:U.>M9'>NI?-:J;OH**4QO
MU7W;X)5CJ_7\C0Y1;*O^>KO"46NX1N9*!%)086P02.IU!W3@361/,XC;29>\
MISIO#BQV\H2N6# <8D&HSHT4\B[0I>%5$K-8"=FC]P$+,ALPJ4_@1BX7L"+O
M>Q.Z6E\WE3A_(^(.  "N%:N;-\>^$P>YE=V]K=92DSTI:800WR2WA>C0.,@*
M@XU]U9\9+<FL)S:J(5R=XL=Y#/BU7B% ER)'>N1'7LP),3G[@/Z"S@U0HCCG
M!I"E**[WN<.-(Q:UJAI':A)44@VP6JRJ2WE'QL,GXDM) E13K4R_">;]!@Z3
MHR*%ZA/XGY&CG1<;(I0:DH6F+"W9L13)TB]OEUCN$&>BY^>ZU*\XJP8.WX<&
MZ:T*@&^OUVX04<$ %X9V394P"$9KP>BU.@XY@+37FBQ[I;_@-*;"-ML'K0ON
MBK8FBJT>VQ"Z$#+S7 'M3?W"CQ=&[X;]/E=YK1BY<>)E<AV_]3R\=E59H;>X
M&=5&U]#^LEG/_7W70#P_V6T7O3\TL?@L/6)V--^3L9=67W(4N+QA%)2.XI)O
M\#[?43ZG3L=]6!HE])0&V;DQ[%;OIPH07<FYU%4(\9>]-HSBF\PGA&Y>S]71
MP'(S*73K+/V]T!>IQQ<G!Y.A2@%T48K2WIO:#RQ8;^^3!9E 3>JW@;#-@%RE
M!=9(ZH4K)Q>XN;+4(*.>--%7:50D/Q+Y;UP.!U7DW8D;CN),T(/<8.70BK]0
MS.:5'-E!KTF>V2,>$*6(J",? X-KTQ(XO[@O3EY8PS>O\ U<:.!:N%'MH@ L
MG]#3JN@,&E"<<D3LK0$*/L@L!.[&B_.D -_H7-]AZ45^J7I8> ;KP7/8!^'=
MD LOJ- &X&#@U>5RK@HN$U*&].B*DRZ'LR83"I@PT\+$TC=*3!9LV8+7ZTW5
MD$V@ 1#"4+8IW" F0)4ME]O<4LA$)HGLS)F8!ZQH.R,F),<F,I- G,F''NXD
M5>AB!)\Q!6&VB?4K2+$':CUH\$FT,Z1L4EDB?*((SX]D!04OYD^)^+ V<T5$
M^1*ZHSGR'IX)'G'4L4M<EO,%-:(!VMOQHC7-&I%N0:5*RO-WJC-T(.+CG']'
M5\B!F2SLI!#."L#$/K L_:]-3XD/ME8;BG?M3W1A>B>3&7:Y4 3@A3XV>&'-
MMU5'R5@0[U@3[F)9*(1Y>#>M;$8EJ''[IO5,F-4IL7I).Z]2@3O$1*:7@[)=
ME7@95\JL:(%M@/2CIBOD WR_GBL2C]Z(#<7*QMYC:W>-5E-J3B0BXHP0,YW6
M#)SD@?Q;4Y76VK(97FDLXM&D@@0U21R1Z69V,Y P8L(M)-$A1A?J!"[U$@/0
M-WW)I>\&3^R'OI*N T#XA I0PZ41C%$=W-P=!#I-VSHH'OE2Y_'<$HQZR= #
M;8A%E39%NKXIO@('*_$!,Z[F#=BGGFF% @1.#SY&WF2(!"O-6PQP/>M/LP12
MNY:>9578S'0($N,;["S(UT3CC ]>G/>3MA3W_=2<M2&TE[S%3!Z3A90?4SJA
M7&KH0Y<TN.E^TQP.J%4*+Q0#TMQ-4%[@IR95"TZ.V9G4H=8+BRDYSN?FG7-7
MF1E(.'![)$K^C;W /:N5X=,P$4Y;?CZCX.30N\ 08TH,=HYG$\OB\T7:K!4S
M-9&1B>)A<G>>"YP&*+0IS(QM[\UP+A\UCVP!6UOB6I!J\IXE&=5GB$%/OTP;
M*(?&=+69.F.;C0O*WX'*#RY-Y(^R,TE-(\^G1FS;\ +\$?2/"$1,8T#L&)BV
M-3S.[:PRX-R.B=CP1V6_>]&W(^+.4>BEEE<+\29(KDI=+CDV2')R]T%L$VV]
M"-S[ 03 &/OIA#R/@L(D?>$:I8E76G0H &CR#CD[H[#\Q-"D!4/BC"*:1 P)
MF2X^I@\1Q,[OL]U/3;WEE,;4;"24?V,8HG0&#(4"0T\V7\#W6IM2YL,"=2/N
M5):V-Z:5&S274,G<R&/6/,]LF@>V0])'K8PH4'[HS=>RU!F85EN1&0F\CUC@
M>TF03&0SFF:FWP^=>9\T"(T&XZ<L"M#:XI_^WC-M0B1F5#H_8LA'3\/56S-@
MW;#2V,/<^G ",CAK2"\9Q(2.H)MJ@8;%B9WS+8,':,H- >4^.2^VX/>*[<5!
MJS2P>%]=P2ZSU55?IY:VK+)QNKV=SSC07PS"/S[^]FO5UI)"P\HFY48*8"K
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MO/1E5S>N9V%>I+130  ;:2DVXJ1:5ME\&18!WH5S.!O$;"DLR[0L5;@LRES
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MM!M#UP^LAPB8K&>89$];N:'9$'BSBJ-M(!!$7UPMR6<XJ%LV&O('IS&_  ,
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M%,#YI$S3];-S*W=N-0P0/@7Y+ 5P''/2#?=\AGM.N'>.T)1*=;G49J^>>!,
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M5[N*N*QR WLW\5>?(V5_;OLF3&WS9Q#^ZL*@V +Q\Z]WJXJ^&5C>RL!V0=Z
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M+W%PS7/AK"/9DI=E898)+TVR6"?_815[09H%V@CNY=M@@#_SR.=/:R6V_IA
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MP6Z?7.J(1]?Z*S:JZU\%M41TTY*DYE&1KLC78U/SLV[4KJGWXOVCJO?XUUO
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MR]7\XNNGJ]D<KP;7U_SI@U<GIL>A231Y"@BPAL[<&E+E:1[/TC )<"V<P=A
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M*!H28@(4M30!B0(Y9B".&90#,LH2ICZ@*#\Y.+4D6C_ Q4T_)+6B)-;.#B#
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M/0R(IK, RX_6FR)RWE6/O:E! 1ZP/P849J"LO9TQ:?BJ]3BG',M7^XQ($?&
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MF-^H!/Y%6'W2[/8O=!IG16:$38TV$_Q57:%HU*%%OL$GJ/7QE0,PI](9.ZS
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M&.74BF4MT8(4\)Y"!QZ@*=<EL[TWYW/;HPM/S5K#KB]4S92,5H_]AC44'R[
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M/I]_#"ID95AZ%:YM6])Z*BK\X^OR\]\^?9TOL378;/CHBU4WJF=AODK)4K@
M,M)"9,1)N2ZS^3I<!7@7SJ%L$+.DL"C2HE#A>E7DXOR761XFZR(1(=C+VR"
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M#L#"-P3P,$ ^P/YA1-E&[GU1U=$?[62,21X;074+*1X L5=X_$<YZK-JHLS
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M"W!3>*07 K,=]RN(":(BN6[H-^E&'#ASR^GU&+ D[XU@2'2S@D&<\];282.
M,=NVXZV_/O>T_K,T.JP?#XB!'?98XM6P9U?XN+35!@=/6YF*:^*?_F1-^W0"
M'\BK"Y[QZ/T%)\F@WER6QM/0,;$([@7) N*&X\GOR-!W/RWOA"K,W<YA(W+S
M\A!\Q4,"05._3LN%G*G9:1[- 99:?79QN-.!@C1W*^UQT$B/1L:77]3G9JA/
MN].!:@J8/>N76B[ CND%SI+)@@'9G_9/T@\96H7L(O1>.O.61/K1_6DJ#NV<
M2] 3U$6,NN4W*.*IWO$,R?W1/L(\N],H]A_G8\[T$FC./B2;4)]YKU_GD$V9
M>P%JX>B@MKS!F@7+!+KE''(.&<L)%TL!B47$/01$L5NWQUO&BFPK8<:B@.)P
M=Q< 3#U4DQ.3[/C=B$<Z:4+O3Q*2YC0P2)P=[LVR+=AZZUK=SC9RWJ)LNT/=
M7F841U430<8AMHG96AX[T5'EZLPQFM)_;/5Q6C/X#>8T@U+/7U[>6<?QG5V=
M%%A.:-JN/BSM[L4=9 =,UZ8E\!]EHN8HSCJ1(Z#;<1T,\*XV3\'T_YS_"3
MFGBMR@T*96YD<W1R96%M#65N9&]B:@TV,#,@,"!O8FH-/#PO1FEL=&5R+T9L
M871E1&5C;V1E+T9I<G-T(#8O3&5N9W1H(#$P.2].(#$O5'EP92]/8FI3=&T^
M/G-T<F5A;0T*:-ZR-#=1,%"PL=%WSL_)+PHN2$Q.!7&*+10,#2S,@5)!=G;Z
MKA4E[L$EB24@*?=@0Y"4!53*+3^O!"@:$F("%+4$F14$Y)B!.&90#L@H2YCZ
M@*+\Y.#4DFC] !<W_9#4BI)8.SN   , \^,BJ@T*96YD<W1R96%M#65N9&]B
M:@TV,#0@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP
M(# @-C$R(#<Y,ETO0V]N=&5N=',@-C U(# @4B]#<F]P0F]X6S @," V,3(@
M-SDR72]-961I84)O>%LP(# @-C$R(#<Y,ETO4&%R96YT(#$P-C @,"!2+U)E
M<V]U<F-E<R Y-S4@,"!2+U)O=&%T92 P+U1R:6U";WA;," P(#8Q,B W.3)=
M+U1Y<&4O4&%G93X^#65N9&]B:@TV,#4@,"!O8FH-/#PO1FEL=&5R+T9L871E
M1&5C;V1E+TQE;F=T:" R-C(Q/CYS=')E86T-"FC>G%C+KMO($=WK*QJS"1E(
MM/B22'CEUQ@)/+:1*V,6HRPHJB5U+B^IL"G+RF?$_N"<JFI2KYL$, Q?262S
MZU35J5/5?/'^(51;.WJ]&+U8+!(5JL5F%$9JBG_XF$?!=#H-U3Q)@BS/<[5X
M&KUX8S-56BRU93V:JD5)?XXC3_F+?XS"7$W2)(BR5"W>CKQYQ%>Q]TSVSGGK
M_+QS&$0A+7["+D&>QW&*A5/U.)+[V/T/[_=W#XOE,LIG<12'TUD0^;,@@[V_
M+_XZ>K<8P<@\#L(8NZ8!?@1)1(^V>K2Y=FP>Y!G;YR\]A"0/<@?AVK<)W8\%
MPI>'R=M/;Q[\"1[UEDLV??;J!GH2I+.8/$4(L$><R1YAE,_SQ)\',P_7 A]@
MO9!W"K(LSC(5S&=9*L%_'*5!-,\BV03/\F/8@#_S9,J?_2YIC\<Y>NT'=DK3
MF>S$^9)4(7+/V0W3:9 F%)4TS542!GFB@CBE['-$^_M9$,ZO[D=R_R86X31#
M/E0:!BE"DD1!>)>@,]^0PR"EF,_Q% B7W2?%"\,@G#E29>)N! ?%/:^GFPM$
M,$^'-$P3\CV8SI,9\?4/[TUSJ#O=[HNVLX%2BYVQZM6VU?K)SSQ==ZJHU_A_
M4H5<6+OK=JR.A?FJ6WPIF]K2)=6TPL?)3$V ,.V-IF043(K33*S:PWY?D8D@
MY,W43K>Z:Y1<*?P)"'92*ZWT-UT>.KU6IF84]4&6K'2KF@TLG]&/&>KJI-9F
ML\%VP$[7C;8":O'G41!2^1( 9P^[6HU51:=O]M)%N2,+QYW!E^-.8V6CUKHB
MGX''[HJJ(H1KW?M!<3J;ZLNF+R"RVK1F:^JB&JO5 9'%!H.%2^MN<[ Z\RBV
MG>D0 WZFJ36[V>VTLD@)5:+V*=@>G+%=>W#7ZBX0++&:1"X5%SI%!)K_%($B
M)E 8@NKLT\>&2-.N)Y\A2#,/^$_JM:[UQI2F:!%]L IKV)E]VWPUUL E<IQ\
M^- @9F^;DF%GXDKD$2.*5C]'IB1S=@W"5:_U>HR=(T_5#7^VZF@D+X;#B2QC
MB4*JV?9:$T?+5E/"B4\=0]\SZM6 ^J20J-T%H2\3&H33W.63=FC@1CNLW_"N
MCZ8>&/L9)=+4;EFW@[NOMLC.6-PG%UK+*7W=M&USU*T_F4'-+CB;)*&8.]25
MMF#'7I<&0,&14^_66@P<C=5<2Z;F<@"/OY5Z#Z[9BP5VB 86,-,N?,Q$(-+$
MQ7G(&6<0V_#GQH^I^]RD$"I'*00-*(-])O;PD)/3@/KLJFTJ78FDX(FFWCX3
M$SP1>E?(HJ&<&)K7UT$?.!"->/O?"9_]%.'[@/2$)ZCE"<88,_O#8B&X.?H0
MH8(TE'A'",%$<=7Z0>SQ(ZCKM>FX%)Z3S%",3F-GU.I.;9JV@R:!0.LU;'&\
M9YZ*5=%U   .B*H!VNO&SSV)BBK*Q[HY5GJ]U4(TAF9OL,T(6WH=\' (^'P(
M^ 7N9S$]!^=_9R7_J:RD4HI9DDJ /A]6%6JW.['<0"6=P/0MP E^C8KFJMTH
M XJVFHJI@Z:[U@/VII#/)^HOS[:RK(_)S#70U<&:&F7I@OMJLS&5@;P(Y47*
MT2M-MY/*.?CXTS$VT02'\-^H22-+(&*MZ2!O%&TI.Q][$=N6GK0+UR$NDN4"
MDL>NP]5-1\5WJ"%V$*!BA8(C%#M=K4G7T,J*DUXO_;':2^S^Q>)X@$ LO6+I
MWT \_<FGR%A5%T.HA@$4&*8N,&GH*+N$1)?586U0WH5:H15L8-26K=D3?_H$
MM<#!?-J9/12!Q. ^;X2R:K8- =R=("B5J1^OW)>Y)HSZN0:YM@=JX4"=>)T_
MB;RK8!^'?N.ME#6='M,DP(L+/_%H(JA.;""<!]%L%I^IE_>FG"P3J*[AZ&PU
MQ6O,WZD!'!&IV&NE04M*01*Y+4^X>Q#&_>5OC8&*?W<2G+%C8P_FBI-NIHM=
M*11KC"@=-+O>CDGH:6)K:!>GOO2[(,?;1]U1=H8+T )35#3158;85AE+LY#P
MXYRINP=N^F3N@"#)5&1'+1$&K;K&18AS_,M0M.JWPFWUR])_B84KQ[]:QDZR
M9:DT45'@38,B*ZEOXKMDF6EZW\:2*)N[-N;XA*30OL]8YGI]R1%:>B5^I1Y
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M]V!#D)0%5,HM/Z\$*!H28@(4M30!B0(Y9B".&90#,LH2ICZ@*#\Y.+4D6C_
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M-B],96YG=&@@,3 R+TX@,2]4>7!E+T]B:E-T;3X^<W1R96%M#0IHWBR*/0J
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MU]C=:M/+S)1T8TJ%!6DPK EZ^GNHLL[6'\Q>'LU>ML$2,L-\1K81-ZK63!J
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M\H(YE-C(L&*O]B\,0Q1N"?JD+!^D%8[MF'XA[TTAL[(%84:^24 8&QX8(\=
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M]V!#D)0%5,HM/Z\$*!H28@(4M30!B0(Y9B".&90#,LH2ICZ@*#\Y.+4D6C_
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M0R1*@%P5PLMF<FA;NVG"*K0$2IXJ='&X#8M<D1TG&V;([1F1-?7EYKT$E8V
M3U8:*AD"8]39-3?PB&36'<'U^\;/;[T2-ZW]B(V,V*!N@_I%BI)<..4YV>&?
M=I!T.9A7'I"1KS<!4>MPS5L8JZ4GU_?.=;'U,4G=G' >ENU^>6JKKVQD#2-0
M3MU0,YMF"?LA8Q?O[K!:,^(Q%=K:DYQU+$DSQ0YX&"5*KPR>/3[]WSD3HQOG
MX_N<4B362+K%C$OLL853:<:!K-.U?J6$.[30_$98L@PV="0<*&W/\*$C.GED
M8MF61RJV.EP!=13$GB!+OP.J&&;H_BQK*_'I!I-FDK'RS@)CR/BJ9?(&909F
M-M8]8_A@"P-G)2D->T3+>.":OC^93KNK\5#JM 2]I&&9FO+#TQ.7M&!*$*I)
M"=.[H\*3M)5AW*=\:E0.%D_U&1K6\!74B88^#(9EUS%]9R1VK\S0X20+JF/9
M'9!GQDZ7]G"*T9*.$M\G6=Z13*A%7AI!5K_RN#P.L3. I"G%A3N].=A#SF$!
M*9Z!9/KKVPC@+T1,Y<3E#CDGIL3%XM9%Y%&R6GGW,G]%\Q,[]-=VH"3M!Q0/
MGXJ:"_#''U8,Z&C;T;&!H_5INY$=$$/P8V"P(+P9I,XHIG?ZB1O%4G=VEYCM
MZT\7,T4\3J&NVETG0$NA]QO-N,=$IN?M8.JGZS?9]?]"_%>  0"*4S9/#0IE
M;F1S=')E86T-96YD;V)J#38S," P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O
M9&4O1FER<W0@-B],96YG=&@@,3 X+TX@,2]4>7!E+T]B:E-T;3X^<W1R96%M
M#0IHWK*T,%8P4+"QT7?.S\DO"BY(3$X%<8HM% P-+,R!4D%V=OJN%27NP26)
M)2 I]V!#D)0%5,HM/Z\$*!H28@(4M30!B0(Y9B".&90#,LH2ICZ@*#\Y.+4D
M6C_ Q4T_)+6B)-;.#B#  //D(JH-"F5N9'-T<F5A;0UE;F1O8FH--C,Q(# @
M;V)J#3P\+T%R=$)O>%LP(# @-C$R(#<Y,ETO0FQE961";WA;," P(#8Q,B W
M.3)=+T-O;G1E;G1S(#8S,B P(%(O0W)O<$)O>%LP(# @-C$R(#<Y,ETO365D
M:6%";WA;," P(#8Q,B W.3)=+U!A<F5N=" Q,#8Q(# @4B]297-O=7)C97,@
M.3@T(# @4B]2;W1A=&4@,"]4<FEM0F]X6S @," V,3(@-SDR72]4>7!E+U!A
M9V4^/@UE;F1O8FH--C,R(# @;V)J#3P\+T9I;'1E<B]&;&%T941E8V]D92],
M96YG=&@@,C,S,SX^<W1R96%M#0IHWJ18R8[CR!&]ZROR2!HE-G>1OO4&HXTQ
M/)B2,8>1#Q29E'*:(F4NJJ[?\!?[1412$JOD!3 *4)'*S%A?O(C4AS\]!^HP
MK#YM5Q^VVU@%:ENO@E#Y^,._3>CYOA^H31Q[69[G:GM:??@\9*H<L'4HVY6O
MMB5]O*P<Y6Y_7P6Y6B>Q%V:)VGY9.5G WT)V*K)S%IW?) =>&-#F$Z1X>1Y%
M"3;ZZOM*UB']-^?7K\_;W2[,TRB, C_U0C?U,NC[^_;/JZ_;U0:&1EX006KB
MX<6+0SK:ZU6]=&SCY1GKYX?9A#CW<FO"TK<UK4=BPM^>UU_^^OG97>.HL]NQ
MZIM7;TR/O22-R%.$ #*B3&0$8;[)8W?CI0Z^\UP8ZP0LR<NR*,N4MTFS1(+_
M?95XX28+10C.\C$(X/]Y[//_64HRVV,=7?H!24F2BB3.EZ0*D7ND-TA\+XDI
M*DF2JSCP\EAY44+9YXC.ZYD7;!;KH:R_B47@9\B'2@(O04CBT O>)>B&MSSV
MTLQ'.G$(>,L>YR0F'^@AC0AXOSGGXO7D9HB';D?5U>KE:,JC>NFFQEVG7NQ4
MZMP4I5;C42O35EHVMV[@&-E0N[%C-+85"&?D].,K]JE"-7K %[$SJ+JX='VQ
M;[1J]:B*>M3]>EO\4.=N,*/I6@&CK]:!%S#T85_DYV+?>"S:F_+6U**K'TE[
MXKRRJ94Z%A>M]EJWI-S4 /G&X6.D:)CVOVMWG6!_Z:YATZC&[NI- F_6L0>'
M:E,6;%#15NI@+J8]B&W;/TCP0HJ>%Z7(%QO7FT&3J&%"S'I=3RU94JFV&\68
M2E=3.>KJ2;V8\7C4L+3K50?#^A<Z:\B V$$DV+[4J5RJ3M)/QM\KCU*;NBA)
M1#LY@%/.R<TI(9 C'B R#GG!J<T=WB/KXT#JBZKBN!>-*N;SW=1BD8QT<VR$
M,\-9E^/5.0HC>Z8ONA??SH6I/.6N(XK=,D[,/9Z?9A9DVZ,9U#/DD5F9&HY%
MT]@@J;)KA[&?D%7HZO4_)M-K!.!56?<\,E"R!/HPDO;:); X,Q9>Z>RI^(Z#
ME\(TC#4#?]['S_,WL4T>N=3K<>K;0>T<B@N4<FJ@NNYZ2<A)$-'K!@_  P$'
MDG%8#\A1,>(5:=84Q(&<J4V%4C)%LW-I\]LTQM%<@?YFD48 EOR,R,\-,OE*
MVL2YA6T_ZW[H6D^$(@J)6H>WNO&36U/)/=L_,F$V;Q._([(;#X/(9)6MS&RP
MB$<@ZEM;]KH8$.[/W3 .]J1ES'1Y-'P39T^I;S4[4**6#YKIX7QN %7*4U.\
M6$!PF0)SM/4779JS(4Y"#.D+";@XS0JO;('N%:>B"FGD&#%I[)R/2,$W&UUD
MTI('2WK"\B<LB]A*#V5O]EB$;6533(,F3!A#.3SVW70XTNL%KZ!(2SU'80V6
M'B\+($HD!MS*R;!*UZ85LH. KS_*9JIF4[C:=XY _;,;X1-Z/G=M:PL&P>\
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M>F^S)%(,=YO[O?:BE,PQQZS\M8 ;//?_<UC4H*T_1/W<=Q<S\)?WXRB-''?
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M3;H ZP1L2699E&5"II,LL?3_'"4R3+/0&L%=O@8#_)W'/G_OK21[/'V@QW'
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M#K'C%75^L'T2SPU+5' 'M!^W1;[Y+6@A$70M!'$%31BII&D2?B<]$W+%);M
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M"MDW]0R>V#<M+PC:]>N"5K]9T&KU_Q*T"$C;R"=$%S=1UZ51D([P]N9.TXX
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M93@V,G0"Q-?H")+80;(M<4<=^EE9=?-\:65!1;U >#7]9B[;XP<#XI!Q<ZP
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MWSARHU2,H9&#SM$,['YXBP/?Y.SKY[M/M],OL[F8S>\7M]>WL^D"QX=PCOW
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MJ^56TQ8R]G2+@#V6RV\KIA>@T[%J<T 9AK1 "LR@Z),)7?M4U0;!2NSJZJ5
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M1.JS7BT;GIT1D'55M6A!C!AHS(> WXYB"TB[4G7(>C)V6-3-C2"R13V<]#@
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MY9S\=J.X3%+IA."L/08!]JJCP%X'*6JPIX_4:2P@2:G82;)Q<?Y_6%S5*U3
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M (/-QQDR71Q_]TA&4VRV74L226NW+9J5U7%XZ\]B<!AC?S>M%7)*R!+D%J0
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MQ"GOFJQJU]A+_BCGC_*02&HMY B2T!B H^ZI*J_WY0H:L]:=J'S\9$M[7Q[
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MN.4G7Y#[=Y_?LX?%G,V_W,\?WC_</3U\F-O%NX\?'^A3/O(^/=PML'@%OL/
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MFC9$6 I93Y$X62\YJ9;6?%.U(?35ZIYMA8%A:(M[\^D3[>#F%4(J="#^ @P
M97D?[0T*96YD<W1R96%M#65N9&]B:@TV-S8@,"!O8FH-/#PO07)T0F]X6S @
M," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R(#<Y,ETO0V]N=&5N=',@-C<W
M(# @4B]#<F]P0F]X6S @," V,3(@-SDR72]-961I84)O>%LP(# @-C$R(#<Y
M,ETO4&%R96YT(#$P-C(@,"!2+U)E<V]U<F-E<R Y.3D@,"!2+U)O=&%T92 P
M+U1R:6U";WA;," P(#8Q,B W.3)=+U1Y<&4O4&%G93X^#65N9&]B:@TV-S<@
M,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" S-3DX/CYS=')E
M86T-"FC>W%IMC]O&$?Y^OV(_. !96&ON*Y=HT>!LUX&+V$EC%6CA"P+ECKIC
MHI,NHNX<]V?T0W]OG]GE\DVDSFF+%*V#G"CM<'8Y._/,,[-\]L4[P:[KL^?+
MLV?+I6:"+==G0K(,_^$CESS+,L%RK;DKBH(M;\^>O:@=NZPA6E]NSS*VO*0_
M'\X2EBY_P.7"6)XYPY8OFY]R7CBOT%]$E;K@A2"QV[,%_:)(T?ODS^\6+[]Z
M\2Y=0#BYN$B_7?Z15F;#RC+&BT(I@V\9^_%,<V-5@4O,!1W*!1U"%GFATYS;
M!+_QU/ \$5X3=TXYQWANG0D/^>.9X3)W,BC!O?XV*/"?A<[\9]1BXGH:2PUM
M 4W&V*#)VR4\_Q^6D_,*DW&CR0[&%$P+7FC&E2$K[\NS=3ONN,@'XS*,CVPA
M,L>U9$9P Y-HR;%]^(%,[<6QPQ/[*@J>3>YK6'K?\@O!A>UVM3-"&-+-)F22
MGIRVE'Z"6[PK+P_5;HO=EY!DKZKM:GM9K3;LQ>ZAQ/6ACE;*);,.YG!,6,<5
MXV0,URZ_6\SQ@]@\YR8O<GJ0L4MRG?L5%G&%WDV2;B&-WT+$>VWGCDE<HA=Q
M7+(HX^<0A@O8'Q.]3[XI?[JO]N45.[\\W)-.83"&!0AE19:\WC+O.E)SJ<UH
M+M$M^,7N]FY385WEYWVKY/!TVDZXD,Y;FW0C&O8B/?U1N &&1._F+--']VO+
MBZ!9PM$;S\LSKGM#I+D;U9GB&>F=&[>"*ST_WJZK-ZY[XW-0! %-.ZTH8,-.
MD_5R2]9K+F@GWJ0+[%12I0O8?4M 8ILOM_?XD/AZRU[0#[A:I8LBJ<,=-T&6
MQ1C'I'X-R]_T7**YH(GZCGV1K"[2"YHG!TQ<I"E]!$VXG6XR,2PR[S');LT.
M-R7[<K?:^IT>S!*<X?QZ7Y:W9>-^G5'($177)OJS;B-.A)5]L2]7AW*/":!\
MMV?P3;CD8>=GK.]O4Y<PS.^7UT1OY]5A[B?C\!^ #3<!Y1)AGF(!]+^/M F8
MTZVLSOJR<R#:R<>GCOL =&VA/LM]?-YM[NNA,L%MWDFIUN@JX $9X$\P1K6N
M$*LGT%DJ9#$$@<P(CX##?3"*@\+QPHX'Q[CL9%"D>78D.P!ED9-6K-1F\!X%
MS4>H/.&'R8M5?</.GWT] NSIO<A,SX:BM8X(_G:[N]\>?LON]KN'Z@KV@?\<
MV/?E=;7=5MOK:"Z)1\FQ2,MS(#40&'EW8)UFW%"^B./6^^F)AS:%XDZ$AQZD
M$;JB>-GZS3O_R[L%(NA-M2GKPVY;LI?P]*=PZLL;\NRXQJ 62B5WEDGDQM$B
M6P$!0)X2F%FERWC66^78P>J;U68#D['KN1 <+3 OR"V$U?1M:H' /:VG!&86
M:"V7HC"C1/A$MH$:_:2)*C,(*]V&U<B=0#_R1J[+69WK#.-JX)*]A[68C';#
M(($,7*(54 #Y*8&9I- ]MI'$>\QQR+0)/PO8> [TXSHA3T\7ML5[$"$%-FI!
M<]O$'#C ^Q:'5!-9QO4XWN^ 1:O?#S (.CJ+CG#_?<*^9>D"1-$D?RWK,+GB
MH&R3,#S%380/C>3M+N:-'M?$M^3ML_/AW@T)N';(<C(KX,L:6J.K#$ KT2-4
M;2VN$3#(PX6/!#$)4BWK';-U/[' G8:00_L]UJ)UZ*&6AIS ]Z?(#48-F+.#
MW8B[%';(77IC=&<W',G+O$##7F8%(GT9".B>P)!H-ZS%H(+ DYJ(&SI4*E^7
M^_5N3_F8*!_\L>,,/5!I6>C)?07=Y(IN,=*16:?VM>=99BYA<T.%5).R2:@7
M;AJ>ZL,-$*\*%"288EP.C,)/#M+Y7"T$HRKI5YY1,>1=0UF*F;"K<1Q6SB?&
MQSF73 &; ZM5<>QH 4PBK9C8+%##>3!IV5:FIWC@]R!_!# C@A7JX7^'\6G@
M88L!NLO=A;\3W/,B9<]W^_WN0[G_>\W>K/8_E@= \5UU "[_;>776/Y\6997
M]1A6.B#_"BGU>;79D/#+W6:SVM?L(GDB8O:@_S'1:GN%GRN:,\).G)O=KJKM
M ?_7XXQ0;=GHT8M@0;!PPTU"R&P\,K/M[L VA,\F05C@;UV'5+JNUH>/[*[<
M7Y*5+A*3?88U1%LW>B,/;NDND7$BW*11@>CCN9.2[>X/]0%/0MSF;E^A&+Q#
MCO:+44FXRR^FKUJW[*LI-QH>ORSW0?EMV.#SJP<*Z?JHFA# %SOBL6'S'R.S
MKMURUY%9NF$A &KJ:#<'W&XB.0>ZYS6TV:\8Y+ZPKE\S 4[FO[BK_Z&\1Q?@
M<'HJ[]E/044SGQP-M]9/(:$W3#&3'"?YN4^N K<#YSH<['I"G8 O@GM .-T4
MBBE7.\?M%!0>Y5Q*:XJFGDZZ&CS+%EW2'63=WF#,F:.T>T*BR;OS$C'Q#B1T
M7V(R\VH-MQ*%^L3,FXW<L$N^S\?U:"-Z7(;_MQ+#5-GT2U!YDF?V'VAUF]J&
M.P>$+B,LERG*E*0"L.KD^@8(O8:D:WYX*%O 'K";KF\1U%\DSC1HWB WVQ$8
MZV2=4MO&_SH-VOU.BVV7;=ME4W_'+[N#Z_ C69WF<,DVI2DB;A_!MJ8V8C:S
MUPF; N]"?A)XVP'X_<O@#3?XWP7OOLBS\U[KDZ(=]6P/CUS;TL:P<LH/$Q[9
MH@]&O1'?("Z&2#0WW,#0S'#$H,&P;H<G 4CE@K!7?CKU'P'/BU\3>$9P,W1I
MD'YU=+RAN,M'Y#1R)-%T2EL06EU2K.7)354^P'V6]@U["Y+Z]7YW=7]Y8-_@
MU^U]>;3*R!6;I\PC\P+HB(2M"(A6]8'9[+,VOD>:!Z9M0B2T[<.,P)'-/;6\
MJM!F>K7;EY?0^30U";M*B84JP,/!GP:%:^R=;R976QJ^&K+$,3W'9JS83_>K
M_:'<;SZR[U=U5?>#-[9S_\^B5X$'Y6H^>D%<I8G12W_'(P4<=W!7$]S=C2$\
MVWMI'+0J"D@EZ6BJKZ%%@%D=)&&R3L+DW(UT1)B8UP$)UYL%:) /5+10TE>A
M^RIF)/I*)@_U5":IK]-V -LFDIQ,,2ZXQNNZK1[9Y>[6'V#<I8BOS4=*M1^J
MPTT7:=1X;0",T*L]ROL\U$",^=-2^-AW^,?"O[>[[]IODP$N.]^#%P7AT<K#
M\_3@3;!_L-?;0[G9E.'<#0$/K@$"TCFA5-IW:L@U9-/D+4[83V985@XG\LV-
M7_JO-R_<B(BJT'H\:5>C6-IN6H"_B$L0+D,!$)8PV9H3&3%YOW!_E:,>H&0C
MX&=Q[8/# M%L,_MJ"_PY@. 0YT%!3!!&N)?2@?LZ?/<0^'H;?COX(U*;O*FV
MU2THF:<@^+XLX0C4?:<O-ZN:/NY6=5V"^<GD"E4[L/DBJ7C):6BU#NWP,.QI
M7%A"P^5(I$<O\35 >1 GOA:\)MC6GZI@3Q5U[ZGME34U@#<$S%"$^L@BUEU3
MQ:ANS\?6BV:WALS>GBV&ZAP74@;K#4M[0'AHZV.QU-G'DO?T-_;^0V/9\$+9
M?NN\B$IU[%) Z2O?UWA5/93!UK$#$W10:]BYG@X7=80.8=NG,:9KTERDO.>-
MPB*B@0K*4!/>0W%KCQDG-'0,Y<9GZB<:A_VN88\(CZWM",)(OP:N!?W';;9H
M^HA/A$XI2'BR3P$;,/4'JCED_,J0C<&XDWOR8)7 ->O5H:K7'U'<?/1;LRV#
M4WDEA%[^(GS=A;OVC9* :6F1 -8PB4JV*S\7^) _Q(=392Z/KXR0VO.G]+=3
M&I;8ZD,9A+M;H&R444E)4I^\HL'-,1JFMJ*) FP@O5L2@@0Q$1$H#EM?ZA\-
MCQ"'G,<45$3'<'L\D#3R?C&UM5WAU[SPP$<'33.^" S/3?3%XY[VJ<;-3-=F
MSBN5H!>"9KQ2CIAMS(*T2QK[C*P7=PK E9/C^ ]*F1OOAX#>X$74M,MC4+=6
MZ74O"977+10[HI\$Q;T9[< O+/P$$RT]B)8IODT!M!<#2E_1UP#/<+BB>^UA
M^L1? L9L(3H(TDU<>ESWQ7XH:1_W2FRER>>]4H&1YI_FE<K2$50C*KL,J\&B
M<BTZ799ZKCX)F,=]%Y3<JBX)Q)-.V7#H?@/")ZUAO@JI<=^T@0D:CM+%*%>D
MU/M>I0N=M ?&&'A7_1P3PIM1/[Z?!Z4(!!L\-W?#=MVI9\P<[-4]HW+CXNHB
M(2HGDB?6T(5+GF;A,\OB]_@#RDLO2IUSZQLI"Q2*R14[^;(<<HNUO9/G<621
M*3?$-2]7&U^^EMNK$$Q[UH3;;@M."D!7Y+XD#]$F[%I16+(INZ)8/.XUN53=
M]/$MHO9(XD#[A;M]Z.&ARC"K\[/67CLCJ%8!JC5R\.Y#(WOM5U.N?'VZWU3E
MOO$/'W*G TW A$H7O2HO .7/ISK335PFU>FCN+SW]H<,I]O- <Y,Q!J*!4O^
MDOO^,9S,CLJX3B0$XX3(1.3"'57AJR(GAV^M">T[UE'"\-%+:R>\NL"FY'-)
M1T0'DWGG8$=ODV"#"#$?V2*J#U0^Y[L)G8[-[18\R *MQKO[])$S5-$CD-J$
MJ@Z>=/H=+9?E_6[-QU,>U*F7H9"O3ON2,5G1W3/&2'A5 X7>POFC%IXT%:!-
MNSYSCD$JFPSICR%#&O-'D3[JUFLJ#WVCYB%=4*>FW%*?NHU DD*9^ /$V)?5
M]4U'I20J9RO)CXCLR/#:9.=Z<1@>.CDL;+S53(Z%^X[&%.I\J46\5]"+4'9:
M(FB8D#AZZ4S1FVD%T CI3S@Z(NFG/XG Z<:[&'L\.]+!DW'A_:<I5QH<6[P/
MC43/#GPW\51" ,$3TH[PB5R)!W9QDEE(YC35V$R#'<MQGPG6R";'_BG  /8
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M>!,CAEC=X%#&G7?$=D?@TXXO^LVGSQ_4IS?JW:>W'U_//JO;GS_/9A^<FP1
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M<W1R96%M#0IHWBR*/0J (!2 K^(-?)*80;A4MDJZ14.(6V38&SQ^/FC\?@1
MQX"-(Y_RE8M_SI@(7LT$Z+ZES1B^5%P]GDAI]8*2_I/--S8;@FQVD&0;* +U
M+Z[DZ!/NW,V6AU3Q,.838 !QU" '#0IE;F1S=')E86T-96YD;V)J#38Y,2 P
M(&]B:@T\/"]!<G1";WA;," P(#8Q,B W.3)=+T)L965D0F]X6S @," V,3(@
M-SDR72]#;VYT96YT<R V.3(@,"!2+T-R;W!";WA;," P(#8Q,B W.3)=+TUE
M9&EA0F]X6S @," V,3(@-SDR72]087)E;G0@,3 V,R P(%(O4F5S;W5R8V5S
M(#$P,#0@,"!2+U)O=&%T92 P+U1R:6U";WA;," P(#8Q,B W.3)=+U1Y<&4O
M4&%G93X^#65N9&]B:@TV.3(@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E
M+TQE;F=T:" S-#0^/G-T<F5A;0T*:-YLDDUOPC ,AN_Y%3ZVAYHXC9ODRH<8
MNTP:F30).+$R:8@=J+3]_3D)90*A2HWK.&_LY^UDN2;X'-0TJDF,%@CB09$!
M+8\LSJ#6FL!9BSZ$ /&D)K/!PWZ0TF'_K33$?7K]J@KJ^"5APQUJSQ#GEY3#
MX+-@#D9)&S!0*CNI)F7:)+2IWM;-_&6VKALIKK;;>A>?4V==Z4P#AM"V+%\:
MCLHB=VV04.X2C=87#3+!!5L[["K)8<WH*LI*Z'WK/:#K/)<ACXK1.&^*B)S-
MQT0@K\'JO(XJ//9S(77+0I28NZ*4N93Y%_'AO<0:V28.S $L8;" +2?*YUX=
MKOL>R=WLF[)_QX*T1VN "5F06(-BGR02ZEQ>'.[N'3;.(EG-X,BC8'M@<;;'
MI'DDD/:3UXOWI]5T%6&9)_P'@L30R-TV,6B*T]<?9//:#_WYI__ W0CF3X !
M #W*ARL-"F5N9'-T<F5A;0UE;F1O8FH--CDS(# @;V)J#3P\+T9I;'1E<B]&
M;&%T941E8V]D92]&:7)S=" W+TQE;F=T:" Q,#4O3B Q+U1Y<&4O3V)J4W1M
M/CYS=')E86T-"FC>,C0P,%$P4+"QT7?.S\DO"BY(3$X%<8HM% P-+,R!4D%V
M=OJN%27NP26))2 I]V!#D)0%5,HM/Z\$*!H28@(4M029%03DF($X9E E 47Y
MR<&I)='Z 2YN^B&I%26Q=G8  08 <DD@" T*96YD<W1R96%M#65N9&]B:@TV
M.30@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @
M-C$R(#<Y,ETO0V]N=&5N=',@-CDU(# @4B]#<F]P0F]X6S @," V,3(@-SDR
M72]-961I84)O>%LP(# @-C$R(#<Y,ETO4&%R96YT(#$P-C,@,"!2+U)E<V]U
M<F-E<R Q,# U(# @4B]2;W1A=&4@,"]4<FEM0F]X6S @," V,3(@-SDR72]4
M>7!E+U!A9V4^/@UE;F1O8FH--CDU(# @;V)J#3P\+T9I;'1E<B]&;&%T941E
M8V]D92],96YG=&@@,3@R,3X^<W1R96%M#0IHWI17W7+;.@Z^]U/@DMJQ5)$2
M]7/N'-L]\4X:=VQE9GN:,SN*3"?:RE)&/\W)/L9V'W@!4K+EU.ULVVDMD> '
MX ,(0.]^WW)X;"97R>1=DOC (=E/N  7_^)/*!S7=3F$ON]$<1Q#<IB\FS<1
M9 V*-EDY<2')Z+^7"0,K^1<^VC)PW$A"LNB70B>.-*!^&"#]V(DYB1TF-JUX
M!/29W6WMQ7J^M6P49O?WUI_)W\FRP%CF@A/'GB?QS84O$]^1@1?C(^I"#"\R
M&%S$8>Q;H1,P7',LZ82,:R0GBKPH B<,(FF<_#*1C@@C84#PK#Z& /HW]EW]
M.Z#(P9Z>J7,N$$G*P"!I7HS_R^2B7BY=1_K$@Y0Q^-R)?7 \22S7:K(_[D<.
M#\_VA=E_PP5W(\<7(+DCD1)?.!@^7""JM;B)</ VPB+T'>Z[$D(>.4C;A1#K
M\ CR!Q_0?(KU\A_7JZM5 M?:0SMR7"'!1J4Z[J> ]@\OR.QL?@V+)1V:W277
MZ\W*LB7&^ \K0&)GR6I]"[/?-\OE!\NFE>5M F_81C48J*,633&IXH&VZ5K5
M65>H!N;I<]ZFQ1169>; D);<X8'L,\489X^L\UT7KE-2S=G!HN3+B[;"H'NL
MA-E7579J"MLN;Q5XW-7KQCR#' [ X@@L#/#'M*A@AEA3F".N8#-+8$8!Q+Z'
ML=$8GG;J9%UHJ)-^;]Q&_09P4Z4EI.4.MBKKZKQ]A=ECK=3!BM 65;:P2UM%
MN\^M.CRH&H2<@G"%"_>L?5+P[5S\O_<6/+QJP)$?)QMD[XAP8V-$2D<YJ\I'
MF/W55.9-6392!<F3JM-GU;5YUAC:IY#"0A7I2UHKR"H4#EG]7-5IFU?D!C(H
MV0Y4FCU!M8>\;9#=AR;?Y6F=8PSO6=I<)-C7W'#7Y\:LG=KG)?J-+M8J+]&K
MBA[Q'>E:_I45W8Y8^0[[^W/W+"]W^==\UZ5%\1-F3'2$H')#%F154:BLS;_J
M$J&*UZE^@&]755U7+ZI&JJ<:[G*&XEX#Z2.%\)Y]FU?Z].$Y+5\I1G2.PJ=-
M2?YVXL#NG\B$0I4[53?PG-:8%]JEMD*THVED%:XCM,\P%6Z,O(55G9$2#6Z;
M-#PR'?1:?!D8+:L2(UF6!(@Q?,G;)VU9^E!]55AD]JBUS)#2/M$X-PDB44EI
M8<ZW4RT_T )D)J5@USY5=?YOY(6VYSJU!","+@?@Y'YH#$-?\S)O<[P &->'
MO 4D4X=Z7]445W21H)]5G5>[/$.>7E$)&1>0:3[#]-MU"CJB18L.ET7?+(H!
MHA!,K=*F*M.' LO!."2!2<N@#\BNRKK^AI1T*ZNNM:N]_5QE7U0+A7I,"]@K
M-)"@LZI!_7F)E5 RO-LU'GC 4 7LE6A#6\B(RAAV,X2ZJYLNQ75=I8++U<C4
M8!['/5';/G84&D'W;N0JU3S48_ID'+IX[YTP<CFV+2'=D(/CQF$@0NHU'G8F
M.6ITHP'@O'<X@]BIAZ U_!BV<3[\!]G(,O)&L X=H]N8Z9KVH(KJ!2MY,I*F
M4AWU7MMH4!S+'Z4)[R_JFT3;J>>JR=NJ?D5539NWG>:F3/O4X*S7C!3W::6Y
M]ADT'98M,K;3[R:%G&,(CL5\3,[0AX8K1I9)WC=)W@?H\^H]O%_1],/9S7(!
M'^^N;OK7^<VG*<SF\S5Y[K,[[(^KV_=KHY2'CA_T5!.P?]Y]V6:YF,T3!'R_
MWL!V.;_;K))/B+[YN-XNMW]>FM-P[O%I3G.YX]'0,0QJ\DAKG^N+)8)8-B7[
M*EEOD#@7(_@);LENB?T.-SXLC=6 NW'@<4S8J\WL=GYM9(P3."B% A4B$L?D
M\R/Z=QQ@1EM^$)'^LVV<>API^/@XI< ;!"^,':\'%SA.F W/Q4D$&\IHEPZ=
M! ;P,P%_)(#3U67Z/)IWY8B^J _,4"GF& @B@7+9%D$H<-!CVV26]&,06(9$
M+7*[@#]6'XEKI'*^7BR-T)@^+T2CO,L<T3;-W>&)@. - Z?M@8'@#05C"7\L
M\6,.<!H-0[KUA]$P:8_2/L%<V.J!4++DW>Q*NRN822'![NA^?;A:8F[%-&Y@
M$H6Q*W"0H?N -\',;7![9^0_$!)F&!**!Y>;,W[0?C]^PX]_XD=@\@X)$CLB
M^FY'>)X>Q4?GCNR=#FOV3N<]%[-?\#.0<]U'?L<8_ACC!Q)C$ S!]Q]O'MZ(
M.#;TFQ5=AJ779V#RE#=#$\;IX24O"D0[I'F)=1'V';YB&\V4[E5JO\<> DT%
M!4V"%O%.XPOVZI1Z2,@JK-VX@&/?N*-:6!2P&5[L4L&QG_>#QG%2%=21:(3_
M26']YR_\&;[',)QXU>ABXB]22%]=\B<4"ND[_>?O,7_9/1MZ$4U0Y\7]R+/=
M/Z&A5Z^_P:]9>MGCS^PV-=7TH#].J57ARR^!]Y,+6V!__?\/#O3]3X ! .'C
M$D,-"F5N9'-T<F5A;0UE;F1O8FH--CDV(# @;V)J#3P\+T9I;'1E<B]&;&%T
M941E8V]D92]&:7)S=" W+TQE;F=T:" Q,#0O3B Q+U1Y<&4O3V)J4W1M/CYS
M=')E86T-"FC>+(J]"H @$(!?Q3<X!2L#<:ETC72+A@BWZ*)NZ/'SP/'[45(V
M0@IK8< 3GWCO1V9XC5#2="4MSL'T48BT$Z<0%2=3D\>+BDU)%]MKM@5:AK8N
M\X-'S+3"/'I(^:/-N5^  0!ROB )#0IE;F1S=')E86T-96YD;V)J#38Y-R P
M(&]B:@T\/"]!<G1";WA;," P(#8Q,B W.3)=+T)L965D0F]X6S @," V,3(@
M-SDR72]#;VYT96YT<R V.3@@,"!2+T-R;W!";WA;," P(#8Q,B W.3)=+TUE
M9&EA0F]X6S @," V,3(@-SDR72]087)E;G0@,3 V,R P(%(O4F5S;W5R8V5S
M(#$P,#8@,"!2+U)O=&%T92 P+U1R:6U";WA;," P(#8Q,B W.3)=+U1Y<&4O
M4&%G93X^#65N9&]B:@TV.3@@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E
M+TQE;F=T:" S-#8^/G-T<F5A;0T*:-YLDDUOPC ,AN_Y%3ZVAYHDC1/GRH<V
M=IDT,FD2<&)ETA [4&G\_3D)((&F2HWKCS?VXTZ>5@:^1C5-:I*2 P-IKXP%
M+8\<P:+6VD!P#CG&".FH)K.183=*ZKC[41K2+K_.JH$V?8O9D4?-!&E^<06,
M7 2+<95T$:/):4?594^?A=;-^ZJ;O\Y6;2?)S6;3;M-+[LS7SC1@C'U/\J7A
MH!R2[Z.8<I=H]%PUC(TANC:@;\2'+6%H3%%"YIX9,'BF.N1!$=K MHI(;2D3
M@7)&I\MY5:%K/Q=2]RQ$B<A7I<*ESK](_]YK2".YS($H@C,8'6!/F?)I4/M;
MG-&$N[BM\0<61C,Z"V20!(FS*.L31T9=TNN&_>.&;?#H6!,$PRC8_EEQ64_,
M\UR,LW!:?#POI\L$R[;S2#+H/1BI<02==.$RC:[N_/:KK-^&<3C]#I^XO2+Z
M$V  B4")3@T*96YD<W1R96%M#65N9&]B:@TV.3D@,"!O8FH-/#PO1FEL=&5R
M+T9L871E1&5C;V1E+T9I<G-T(#<O3&5N9W1H(#$P,R].(#$O5'EP92]/8FI3
M=&T^/G-T<F5A;0T*:-XLBKL*@" 40'_%/U!!S$!<>KA*ND6#B%MDV!W\_+S@
M>!Z<,4D8T9HNY2[5OS%EA$\1SM34TV$,W1I8#Q$P6<\QJ9'V\D"W(8AN9X&V
M@T208W&U))_AI&[=:<@-+F-^ 08 <S,@"@T*96YD<W1R96%M#65N9&]B:@TW
M,# @,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @
M-C$R(#<Y,ETO0V]N=&5N=',@-S Q(# @4B]#<F]P0F]X6S @," V,3(@-SDR
M72]-961I84)O>%LP(# @-C$R(#<Y,ETO4&%R96YT(#$P-C,@,"!2+U)E<V]U
M<F-E<R Q,# W(# @4B]2;W1A=&4@,"]4<FEM0F]X6S @," V,3(@-SDR72]4
M>7!E+U!A9V4^/@UE;F1O8FH--S Q(# @;V)J#3P\+T9I;'1E<B]&;&%T941E
M8V]D92],96YG=&@@,C S-3X^<W1R96%M#0IHWI18VW*;R!9]UU?T8W-*(EP%
MS)LLRS.><IR43>I,531U"J.6Q02!BD9V]!WQ!\_:W2V$L%)GQJY(&+IWK[WV
MVA?RX=='ESW+T54Z^I"F 7-9NAZY'G/PBZ_(LQW'<5D4!':<) E+MZ,/<QFS
M7&*IS*N1P]*</EY'G%GI7[B<A%/;B4.67IM;D9W$RJ"Z.)H,$CMQ:=EV-*$[
M/AGZRK\\3JX_S1^M"1;SY=+Z,_V=D$TU,H?92>+[(?YRV+=18(=3/\$ESH(-
M/]8V7"^)DL"*["G'/=L*[8B[RI(=QWX<,SN:QJ%V\MLHM+TH]K01[%7;8$!]
M)X&COH]6PB,>P]0Y%[ 4AE-M2?&B_5^D%\]U0\<. ^(A#!,6N'82,-L/B>5&
MC-;=\]AVH[/GGGX^X,)U8COP6.C:(2@)/!OAPPVB6BW7$9X.(^Q%/JT*6>3&
M-FB[$&(*#Q#"'XI30K'^RA=__'9[=6M-IG;(4_:[-0D1KXDU\?#E,D73)+:C
MD.&.J\1 9H*I,>-/M9F;3P\?V:<;]L5^M%DZ^X/-/WW\?'<[NY\OV'SQD-Z2
M88_?6"Z_G<_2A;$<V9XWL.P- "[Y3=TP_!/%<\7N1+42C63I)FO93,6T$>R^
M;MGGK&DK/-H4.TG+-90;@>59R6ZKO-X*EF;?V>=]LZNED$N+O/8X&V@!:&+M
M;M"!"C0HR$F#>A!KT8@J%ZR0;(/+IP/;6K'M\XP<C?A*L+9F[4:PNSJK6%:M
MV*/(]TW1'MCLN1&"EDVYWB/TGLK"1\M662M6+).L7K/_F1^Z&!O.?#9Q3X21
M4!4DSZ%U2XZ-V9986HV9W.]VI;(>JZ,\+BHR#G9J8&M>"RG8MEX5Q$3,UP6>
MK9MZRUISQVRR)KA6#A5;,59N_8!?!O;)H=XI>O^;VKFT-/3T/YI-5[/I(H44
M=)!'!&7;NGIFL^]210KPLIW8MT4NQQ0^>\PR=BW*[#5#Q/,:06RRMJ@UN2++
M-T18T4KVN'^2Q:K(FD)(3<CQ=%2(Q-5GKL2ZJ.!N49VBU/D1*C]"\@/8%558
MA16+[WFY![47SKADL#O727Q]K#J"C$^-\24G^115MFYQ2%Z7I<C;XD64!Z0[
M1-; )(A750NG*.JOZJ:I7T7SMK1T,*1X42I_RJIO4O&A,?=9]R/%NNO'1C"
MFU5Y@6U%)=NBW1.9DK0!9$5+CADM$-Z$"R, *U%_[)!OM*8O\\Z[A+R#;R=_
MK)"7%@F7'\;G:C"YE00&5]_MH\<F[97#Y-YOBX?YE[O%(YO//M^FLSLHY'ZN
M%/(Q:W0Q.UCX*&EQ3RMC"@]IY(P9U6YPY8>QAI!GNRRG5*5D6I%#,2\(O<>K
M0K9DZT6P[)F<U">4);*60J!O6JZ+O%[7C<X*.E*4:Y;I*H@=BC)R2M]I2$2
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MO>MKA+$@.[1*PF4OOVQ[W%7Z6<.A-K_A(8]7YN5&@8*<5H.%FARZ\3X_.U*
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M#$L[:KQKQTF'?]#+3J?Z2B4,4XVT_\KM\\/RK_+4CY'44OHL\7L+JU]O @P
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MZ%'MTT25NBU7AS]]]2)5<X9$&=V/QE93(M5;J&&I1B\JS][K+ES]\D 32)N
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MT>:[HQPM)\Z/4S^ZU('C;C(C7!J,!*J!X-E+NV;?7%6&\9M"SIDE8%KAU:O
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M86T-"FC>O%K;<N/&$7W75\PC6"5A,3< 4WY::^7$*6?7M:*3!RL/$ B*\)(
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M%6]G1#JVTZMEOY;[NL89BXX6JJ.5T6C"H7",'9I-CTSVR*3=;X_-;03_(\
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M>U$HO BP8NT!;4L\%0[&T/=#;0S\Q-PH$QB#R9W:R'<.UO'6:9J=^QC/]"E
M<08_)-K'U[-M]-Q<YB@O2%++FW$?JU1[\[>RV]>G3AS*8]GE75E7HMX*Y%?D
MY-6+>&KJKV5+W^X+-_&DTQ3U=B%^RYLF=V\39&&%^P^;HA'YKBF*5G3[O,,?
M93LZ.80',]]#!JO(]Q)$U/8'F]/4BU/+K#) ?RT1^Z*)D]0+DRPYST.IH;VC
M QV+JA,;A-VIW=L E8$C5G4G\'79'0J<M!C1)".:KA:$_VO=E94;(K-VR"_4
M55/N]ETKZD;4N+7I_Y[C7]%V]?H/<[]5?W$"/X4BC)&MZ10<6ZE56-9)IKP*
M/8Z\5([037- Z C0^_KXI*-7U@R%XTF6XEO1K$NJ NFTA4#AH"QP%UW-%_$3
MR)XYA?[FZ=2L]SDN!E1R4NH0X+;HQ+9NNKUY1EGIH ].YU(+)XTHCD/"$*K,
MRX(I5+8J+PPLZ]4<&)I1'$I/1I=)<-:,DO^_&=V:LN''!X&IGW?WY(# N7_W
M27^@;@3OH?7H#Q_N],][8:[$WZEM?5R:*^__[1DG3OI2'/K4E,?&U'N#C>CT
M23QCI-YC[I0QBBJ^M.I;9ZQO[$Q!X(59%O_=G6D(7*0]N^H3V50F>^U%M/O\
M<!#'O*PZ_(>J:XI=V78-6>KGLMIQ!53YL4!2;T2^V31%VPI3&9.>%$CR $C/
MR\)IPFFS[\E9Z[6Z!#6F2CMG2,(OCCYCT10;8?H#GV=2+\(D 7>CO@_]V8JR
M*KLR/_1(%E1VYE*4YE/=%HRN/:WW@R\65'Q3%8"3H<G$7AI?MB!P51C.6J]
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MXBS,"T'F*?\RO$%(*_FI^0T(04:![.MR(L$"EF!G2I40[?,--2(33R)S.^C
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M2/RNDDMVZU"C7LQ0J0^#BY2(T?[UP9VDDB!JO815C48P7XJFJ%\,68_&8"A
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MD/N4A%L">\A+[:J<'$1("G5*B[WUFA;Y@5W^@AW*RY.5#@^81)_""V*J,KX
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M;3X^<W1R96%M#0IHWBS,30J (!"&X:MX \<(,Q W_;B-=!<M)-Q%ALW"X^>
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MJ0@-:0$:0X\90IA*4M*3);C,9[ ^H)@"LTPGI>>"HN*8P$)YZ-9=5O\-#$-
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M0N/M.3_''X;VJ9F<-$_@ Q0H![VC6?__E84I&IH!4M]A8HK0>%I\+C$D9EV
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MN/"N*O,N\RG\C5L4S0%!1@93[R.+$$.EQA99,:@M/Q++WS<8/4CJ+K2$])^
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M^:NUWJ6I*BNF_M11>U7%%J)@^)O&;RS+*ZC#B$1P4U8 27J!@N"AZO6%CW)
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MWQ6H]!J>#?"Z/XV'[_LD33H25'R5< 39'W5O^W?EJ^N$Q[WQ&;D>] KCU[)
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MNAEX#1@+5-/^:RZ_Y/\#?:@]^J<TEQVJGMNF_%<T_A_1G+;'7O^_H[9MZ?(
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M0\.\0<;,Y^F@JS-YL7Z5](T@TG=5A@2^"?G5[;X>6+], 'ER$O*P)ZDP$2N
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M/$%DTK;@O3OE4PWR+[#F^=^WYOHSC-K^)5:Z_WVQ7TX5_Y:?&+50;B5T_OM
M?Z2'(9TE/X'\?L(7();JCOQTQ,@U,?^+L%^'42NQ3I=K:83@72W$N2MIH+&8
MYHM=-,S\CJ8;IER(=5=TO]E2+D=>*]6&,4S^I.NB/]@?G^;A(5 \:7ZR0?.3
M#0XO#P!\9(?B(W?;.; RP$_N_ASH^7"09:<_>("?69JGM3GG+#LTOP[&ZG;N
M\XQY=*#G,S=64D\UQQIK:63N,3I0<Y\=>NPVU%HX4/.@UD6OART'(A$X+M?K
M,:MR@;&VU./">(RB,L.1 7%&?JGY_A1['NL);->\J7[&8:]B_8WW8$-GR#VZ
M?=6F+5.ZGLI'6976_*GW.VFPXL&HB[7'F(-SB_DTWY6KS7UXMYF>@Q^WS:A-
MG8Q]<IMN^P#\&)M_HXMLJ]HR?;"77>0%8R_**J@Z3Z,-Q7^6S8/-NY8U);^J
MS9=MWO?#9VQ#RZP9\J#UFCQHS*&1YAKT\[G<#/Z*6,F*3SE-]<D3*1&8##P!
M)  M[><.P'*@C5WF'Y4S#E$UUU:Y^\]@K8?_5X1&*;A:P6=8_1#T1)D#-,/U
M&OSA*; CN3$3;7E1)K_\22'/<:0_"<!<@;$^!%9E2M 8K&/X,=9YM--(;E P
MWT&?EQZ"1ZBANS#H$/"QFEX,XAOYNX(KF;IF'YLSKK\;GQI;=JAQ_M.Q.G#&
MFWO,:EP.G/'I>\6 &F=V/'3,EP)CSHX'Q@U^7$,1TTS"NPJP4R7U=\=9AI=&
M8VZ[&[$4:5;1=X_W:GU/\I[K6[G)["B7N=K(0^8L6=HU0<XQY\A)VO8=IS*N
MJWAOR&7N-O(S<[@^K]JCSXT"W]2UKZ>@[D]:4^4.HQYL=C\:)3Y$W_?D%V*+
M?Y?V1<^P$-BPND::^N8&?I7?54:>9^WA'W9E>0-WK.$[QZC8!#IA#WUMSH:.
M_YIVF]>HE3D!Z=VP0W>DSWQ3+G>5E2NM4.ID/BE]QB/2YTI#_BF:9BZBL\;'
M\DOXO6U1OI7Y*56U)M-1^!NC,;>;S"G4U<Q$NZ_2 >L]:F)NH##K*:0S4>8B
M=32KTM-F&M(O4ZHQ1FZPFM!4:R!9Y@4:;XVD/FPAJ\'\+(XET RZ1;/92IK+
M3E(OXP7V#6+/QK"M'L-#382?*HH+]+A1C!J)&"HN[L#/+89W3:F%N"<]3,H/
MS1O2(^Y2<\1A+<1/L,?'$7O?0[VO*<;(1PW8$?\D<9Y:\(LRO[BCON_**/#;
M4(R5?3#/%9'7 /%Z(_,T\NZ@K</R%I]"T9B[!D8E6<G(3['F"YCS-8CW8^ [
M7J?MKE$4KV 5HU:NJ]3 =9T:N/. GJ)&(8P::'\^VUTD=9?(OG^U#^MR4M^7
MS_+O%;?]DT)B9+0[#OV_#OU55 X-GG_7H>)F4^R;NH@#ZM$@?:]?X2!=X']
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MW:P;7TFMI&ZC;J5/<"H(WG@G=IH8C0G$:=*PAL5J,&Z3P%Z[\7,0NQG!S-5
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M>/2AL(551?5Z?YO)+MHINSN*IE-$K9U&8*EQ2VQ.WBC#1'N-V%@CQ5]U7?3
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MH<$ED.)O&#D-=7MG7YRZO3EQ'_4X15 F,_Y,D?/RH4? H7. :TX Y.L"SIH
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M\Z9VM;KZ5,GW1B()!FDWN6P*"XO#WA4/J:2%^*(]<.#^Y^_;4&/W.(QA@UU
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M9[6Z0AJ*\REG<OKB,89CCC$D8UHC9@RT 3U4<N"KI;U1*Q0*._0,Y]0T\#=
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M(50^QM>(H#.-J'?'4=J+RG:AZV?!#'^40VD.U;X!_8[P->7H7QLZVH%*<^
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M[I\8R4VSL[@=[?ULU]AP;F(FEV%G<CDVMW=';F0D-\*.%TK9D=S,\/38/MQ
M_ADCN=FAL?&92$M[1]/:QF#_V-[<S#6Y [V3>X<F0NVS0^BZO^X47\:B0I8O
MQ2\_Q,Y.#XWD]@Y-[V$G=WY\Q_^-%86$1UE9_']1%BWHF1VH=6N1E(.K5$=!
M<:RHC1"J-\NW'#\/RWX7:L,XWYZ_[AY_RZO^5U0B3Q< D/\._"?(@H>1#2>
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MUR&9F'",J#"I1"VST"GL#>& (9E,1#4U30^-?D@2E2A1)$SICX2T,,WZ5?1
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L+'\-"F5N9'-T<F5A;0UE;F1O8FH-<W1A<G1X<F5F#0HQ,38-"B4E14]&#0H!

end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>axsm-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PERIODIC REPORT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">I, Herriot Tabuteau, M.D., certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.&#x2003;I have reviewed this quarterly report on Form 10-Q of Axsome Therapeutics, Inc.;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.&#x2003;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.&#x2003;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4.&#x2003;The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">a)&#x2003;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">b)&#x2003;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">c)&#x2003;Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">d)&#x2003;Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">5.&#x2003;The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">a)&#x2003;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">b)&#x2003;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Date: May 2, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.750pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Herriot Tabuteau, M.D.</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Herriot Tabuteau, M.D.</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Executive Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:27.0pt;line-height:1.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>axsm-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PERIODIC REPORT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">I, Nick Pizzie, certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.&#x2003;I have reviewed this quarterly report on Form 10-Q of Axsome Therapeutics, Inc.;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.&#x2003;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.&#x2003;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4.&#x2003;The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">a)&#x2003;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">b)&#x2003;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">c)&#x2003;Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">d)&#x2003;Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">5.&#x2003;The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">a)&#x2003;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">b)&#x2003;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Date: May 2, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Nick Pizzie</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Nick Pizzie</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:27.0pt;line-height:1.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>axsm-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">STATEMENT OF PRINCIPAL EXECUTIVE OFFICER OF<br>AXSOME THERAPEUTICS, INC.<br>PURSUANT TO 18 U.S.C. SECTION 1350,<br>AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the quarterly report of Axsome Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the quarter ended March 31, 2022 as filed with the Securities and Exchange Commission (the &#x201c;Report&#x201d;), I, Herriot Tabuteau, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1)   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Date: May 2, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Herriot Tabuteau, M.D.</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Herriot Tabuteau, M.D.<br>Chief Executive Officer<br>(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:27.0pt;line-height:1.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>axsm-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">STATEMENT OF PRINCIPAL FINANCIAL OFFICER OF<br>AXSOME THERAPEUTICS, INC.<br>PURSUANT TO 18 U.S.C. SECTION 1350,<br>AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the quarterly report of Axsome Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the quarter ended March 31, 2022 as filed with the Securities and Exchange Commission (the &#x201c;Report&#x201d;), I, Nick Pizzie, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1)   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Date: May 2, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.625pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Nick Pizzie</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Nick Pizzie<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:27.0pt;line-height:1.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>axsm-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-02T16:59:20.3575+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockFairValue" xlink:label="axsm_CommonStockFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ThresholdDaysToAchieveSecondMilestone" xlink:label="axsm_ThresholdDaysToAchieveSecondMilestone"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockSalesAgreementAuthorizedAmount" xlink:label="axsm_CommonStockSalesAgreementAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentsMaturityMonthAndYear" xlink:label="axsm_DebtInstrumentsMaturityMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheOneMember" xlink:label="axsm_TermLoan2020TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfLateStageProductCandidates" xlink:label="axsm_NumberOfLateStageProductCandidates"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheTwoMember" xlink:label="axsm_TermLoan2020TrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentThresholdCashPayInterestRate" xlink:label="axsm_DebtInstrumentThresholdCashPayInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheTwoSubTrancheOneMember" xlink:label="axsm_TrancheTwoSubTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_UnregisteredCommonStockValue" xlink:label="axsm_UnregisteredCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ExtinguishmentOfDebtFeeAmount" xlink:label="axsm_ExtinguishmentOfDebtFeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CollaborationArrangementFuturePotentialPayments" xlink:label="axsm_CollaborationArrangementFuturePotentialPayments"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_FairValueOfWarrants" xlink:label="axsm_FairValueOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_RevenueMilestones" xlink:label="axsm_RevenueMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember" xlink:label="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs02Member" xlink:label="axsm_Axs02Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccruedGeneralAndAdministrativeCurrent" xlink:label="axsm_AccruedGeneralAndAdministrativeCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheThreeSubTrancheOneMember" xlink:label="axsm_TrancheThreeSubTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice" xlink:label="axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LeerinkPartnersLimitedLiabilityCompanyMember" xlink:label="axsm_LeerinkPartnersLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockSalesAgreementCommissionPercentage" xlink:label="axsm_CommonStockSalesAgreementCommissionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementsDisclosureTextBlock" xlink:label="axsm_LicenseAgreementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:label="axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfFinancialInstitutionsHoldingDeposits" xlink:label="axsm_NumberOfFinancialInstitutionsHoldingDeposits"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodValueFinancing" xlink:label="axsm_StockIssuedDuringPeriodValueFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_PfizerIncMember" xlink:label="axsm_PfizerIncMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfAsianMarkets" xlink:label="axsm_NumberOfAsianMarkets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccruedResearchAndDevelopmentCurrent" xlink:label="axsm_AccruedResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockSalesAgreementSharesUnsoldAmount" xlink:label="axsm_CommonStockSalesAgreementSharesUnsoldAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt" xlink:label="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccountingPoliciesTable" xlink:label="axsm_AccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DevelopmentMilestones" xlink:label="axsm_DevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TwoThousandNineteenShelfRegistrationMember" xlink:label="axsm_TwoThousandNineteenShelfRegistrationMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsExercisedInPeriod" xlink:label="axsm_WarrantsExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent" xlink:label="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccountingPoliciesLineItems" xlink:label="axsm_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TwoThousandFifteenEquityCompensationPlanMember" xlink:label="axsm_TwoThousandFifteenEquityCompensationPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs05Member" xlink:label="axsm_Axs05Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheThreeSubTrancheTwoMember" xlink:label="axsm_TrancheThreeSubTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DecemberTwoThousandNineteenSalesAgreementMember" xlink:label="axsm_DecemberTwoThousandNineteenSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_JazzPharmaceuticalsPlcMember" xlink:label="axsm_JazzPharmaceuticalsPlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentCashPayInterestMultiplier" xlink:label="axsm_DebtInstrumentCashPayInterestMultiplier"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate" xlink:label="axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee" xlink:label="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="axsm_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SharePriceFairValue" xlink:label="axsm_SharePriceFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodValueNewIssuesNet" xlink:label="axsm_StockIssuedDuringPeriodValueNewIssuesNet"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward" xlink:label="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheTwoSubTrancheTwoMember" xlink:label="axsm_TrancheTwoSubTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentAggregateAmountPercentage" xlink:label="axsm_DebtInstrumentAggregateAmountPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding" xlink:label="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent" xlink:label="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward" xlink:label="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_EquityInstrumentVotingRightsPerShare" xlink:label="axsm_EquityInstrumentVotingRightsPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheOneMember" xlink:label="axsm_TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount" xlink:label="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_InitialCashPaymentPerCollaborationAgreement" xlink:label="axsm_InitialCashPaymentPerCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties" xlink:label="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ClassOfWarrantOrRightTerm" xlink:label="axsm_ClassOfWarrantOrRightTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" xlink:label="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentInterestPaymentPeriod" xlink:label="axsm_DebtInstrumentInterestPaymentPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheThreeMember" xlink:label="axsm_TermLoan2020TrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember" xlink:label="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SecondAmendmentToLoanAndSecurityAgreementMember" xlink:label="axsm_SecondAmendmentToLoanAndSecurityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020Member" xlink:label="axsm_TermLoan2020Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfLicenseAgreements" xlink:label="axsm_NumberOfLicenseAgreements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ThresholdDaysToAchieveFirstMilestone" xlink:label="axsm_ThresholdDaysToAchieveFirstMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales" xlink:label="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodSharesFinancing" xlink:label="axsm_StockIssuedDuringPeriodSharesFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs04Member" xlink:label="axsm_Axs04Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs05AndAxs07Member" xlink:label="axsm_Axs05AndAxs07Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays" xlink:label="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SunosiMember" xlink:label="axsm_SunosiMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_UnderwrittenPublicOfferingMember" xlink:label="axsm_UnderwrittenPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_UpfrontPayment" xlink:label="axsm_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ChangeInOperatingLeaseLiability" xlink:label="axsm_ChangeInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheFiveMember" xlink:label="axsm_TermLoan2020TrancheFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsIssuedDuringPeriodDebtFinancing" xlink:label="axsm_WarrantsIssuedDuringPeriodDebtFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202010Member" xlink:label="us-gaap_AccountingStandardsUpdate202010Member"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsIssuedInPeriod" xlink:label="axsm_WarrantsIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ConsecutiveTradingDays" xlink:label="axsm_ConsecutiveTradingDays"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementTerm" xlink:label="axsm_LicenseAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_HerculesCapitalIncMember" xlink:label="axsm_HerculesCapitalIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheFourMember" xlink:label="axsm_TermLoan2020TrancheFourMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_MarchTwoThousandTwentyTwoSalesAgreementMember" xlink:label="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentPenaltyPercentage" xlink:label="axsm_DebtInstrumentPrepaymentPenaltyPercentage"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoanMember" xlink:label="axsm_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheTwoSubTrancheThreeMember" xlink:label="axsm_TrancheTwoSubTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2019Member" xlink:label="axsm_TermLoan2019Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment Occurs Prior to First Anniversary of First Amendment Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Occurring Prior To First Anniversary Of First Amendment Closing Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment occurring prior to first anniversary of first amendment closing date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Debt and Unamortized Debt Discount Balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value per share (150,000,000 shares authorized, 38,883,445 and 37,816,794 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Value of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of RSU Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ThresholdDaysToAchieveSecondMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period to achieve second milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ThresholdDaysToAchieveSecondMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Days To Achieve Second Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ThresholdDaysToAchieveSecondMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days to achieve second milestone following such date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockSalesAgreementAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock sales agreement, authorized amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockSalesAgreementAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Sales Agreement Authorized Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockSalesAgreementAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The authorized amount under a common stock sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of tax withholdings on stock award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentsMaturityMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity, month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentsMaturityMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instruments Maturity Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentsMaturityMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instruments maturity, month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan 2020 tranche one</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan2020 Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents about term loan tranche one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Warrant Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining credit facility to be drawn</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average contractual term, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfLateStageProductCandidates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of late-stage candidates in Company's product candidate portfolio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfLateStageProductCandidates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Late Stage Product Candidates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfLateStageProductCandidates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of late-stage candidates included in the Company's product candidate portfolio.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Occurs On Or After Second Anniversary And Prior To Third Anniversary Of First Amendment Closing Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment occurs on or after second anniversary and prior to third anniversary of first amendment closing date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment Occurs on or After Second Anniversary and Prior to Third Anniversary of First Amendment Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan 2020 tranche two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan2020 Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents about term loan tranche two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentThresholdCashPayInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash pay interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentThresholdCashPayInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Threshold Cash Pay Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentThresholdCashPayInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective cash pay interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheTwoSubTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two Sub-Tranche One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheTwoSubTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two Sub Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheTwoSubTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche two sub tranche one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_UnregisteredCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unregistered common stock value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_UnregisteredCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unregistered common stock value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ExtinguishmentOfDebtFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final payment fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ExtinguishmentOfDebtFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment Of Debt Fee Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ExtinguishmentOfDebtFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The final payment fee at extinguishment of debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CollaborationArrangementFuturePotentialPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CollaborationArrangementFuturePotentialPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangement Future Potential Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CollaborationArrangementFuturePotentialPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of future payments payable under the collaboration arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum amount of market capital to be maintained</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Additional Drawn Covenant Minimum Market Capitalization Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum amount of market capital to be maintained under debt instruments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments or royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antecip</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliated Entity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The fair value of outstanding warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_RevenueMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_RevenueMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_RevenueMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of unpaid invoices amount maintain as security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Additional Drawn Covenant Additional Security Unpaid Invoices Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The period of unpaid invoices after threshold period respective amount should be keep as a security under the debt instruments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment Occurs Prior to First Anniversary of Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Occurring Prior To First Anniversary Of Closing Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the prepayment of debt occurring prior to first anniversary of closing date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subject to FDA Approval of AXS-05 and AXS-07</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subject To FDA Approval Of AXS Zero Five And AXS Zero Seven [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subject to FDA approval of AXS zero five and AXS zero seven.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs02Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AXS-02</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs02Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Axs02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs02Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to AXS-02.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset - operating lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks and Uncertainties [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccruedGeneralAndAdministrativeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued general and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccruedGeneralAndAdministrativeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued General And Administrative Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccruedGeneralAndAdministrativeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued general and administrative current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019-12</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheThreeSubTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Three Sub Tranche One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheThreeSubTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Three Sub Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheThreeSubTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche three sub tranche one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average price at which warrants were issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum loan amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LeerinkPartnersLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SVB Leerink</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LeerinkPartnersLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leerink Partners Limited Liability Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LeerinkPartnersLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SVB Leerink limited liability company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Antidilutive securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockSalesAgreementCommissionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock sales agreement, commission percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockSalesAgreementCommissionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Sales Agreement Commission Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockSalesAgreementCommissionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The commission percentage paid under a common stock sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for license agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options expired in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfFinancialInstitutionsHoldingDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of financial institutions that hold the Company's cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfFinancialInstitutionsHoldingDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Financial Institutions Holding Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfFinancialInstitutionsHoldingDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of financial institutions holding the Company's cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodValueFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodValueFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodValueFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock issued pursuant to a financing arrangement during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, operating lease, existence of option to extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line Of Credit Facility [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information pertaining to Pfizer, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfAsianMarkets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Asian markets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfAsianMarkets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Asian Markets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfAsianMarkets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Asian markets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccruedResearchAndDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockSalesAgreementSharesUnsoldAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock sales agreement, shares unsold amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockSalesAgreementSharesUnsoldAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Sales Agreement Shares Unsold Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_CommonStockSalesAgreementSharesUnsoldAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock sales agreement shares unsold amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding at March 31, 2022 and December 31, 2021, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average contractual term, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First advance used to repay previous debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From First Advance Used To Repay Previous Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of proceeds from first advance used to repay previous debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding principle and advances under the loans agreement exceeds 65 million</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Advances Under Loan Agreement Equals Or Exceeds Sixty Five Million [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information if the outstanding principle and advances under loan agreement exceeds fifty five million.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TwoThousandNineteenShelfRegistrationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Shelf Registration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TwoThousandNineteenShelfRegistrationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Shelf Registration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TwoThousandNineteenShelfRegistrationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen shelf registration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants (or share units) exercised during the current period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments of Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of warrants (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TwoThousandFifteenEquityCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TwoThousandFifteenEquityCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Equity Compensation Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TwoThousandFifteenEquityCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the 2015 Equity Compensation Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs05Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AXS-05</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs05Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Axs05 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs05Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to AXS-05.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheThreeSubTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Three Sub Tranche Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheThreeSubTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Three Sub Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheThreeSubTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche three sub tranche two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DecemberTwoThousandNineteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2019 Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DecemberTwoThousandNineteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December Two Thousand Nineteen Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DecemberTwoThousandNineteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">December two thousand nineteen sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_JazzPharmaceuticalsPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jazz Pharmaceuticals Plc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_JazzPharmaceuticalsPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jazz Pharmaceuticals Plc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_JazzPharmaceuticalsPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jazz pharmaceuticals Plc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentCashPayInterestMultiplier_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash pay interest multiplier</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentCashPayInterestMultiplier_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Cash Pay Interest Multiplier</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentCashPayInterestMultiplier_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the multiplier used for the cash pay interest under the debt instrument.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share price not less than three day volume weighted average share price discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share price not less than three day volume weighted average share price discount rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Add: accreted liability of final payment fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Accreted Liability Of Final Payment Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of accreted liability of final payment fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock issued as a result of the exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SharePriceFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SharePriceFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SharePriceFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value price of a single share of a number of saleable stocks of a company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodValueNewIssuesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodValueNewIssuesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodValueNewIssuesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting of RSUs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Vested During Period Value Restricted Common Stock Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock vested during period value restricted common stock award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheTwoSubTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two Sub-Tranche Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheTwoSubTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two Sub Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheTwoSubTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche two sub tranche two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentAggregateAmountPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate amount of loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentAggregateAmountPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Aggregate Amount Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentAggregateAmountPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate amount of loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of final payment fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Final Payment Fee Threshold Percentage Of Debt Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The final payment fee to be paid under the debt arrangement as a percentage of aggregate amount of all term loan advances minus the aggregate amount of repayments made.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum product revenue percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Additional Drawn Minimum Revenue Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum percentage of revenue should be achieved under the debt instrument.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loan payable, long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan payable, long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt, Excluding Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon vesting of RSUs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Vested During Period Shares Restricted Common Stock Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock vested during period shares restricted common stock award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_EquityInstrumentVotingRightsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting right per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_EquityInstrumentVotingRightsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Instrument Voting Rights Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_EquityInstrumentVotingRightsPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of votes per share each holder of shares is entitled to.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of cash to be maintained as a security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Additional Drawn Covenant Minimum Cash To Be Maintained As Security Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum percentage of cash to be maintained under debt instruments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of warrants outstanding beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of warrants outstanding ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of long-term debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Current Net Of Noncurrent Debt Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount, after noncurrent portion of unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_InitialCashPaymentPerCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_InitialCashPaymentPerCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Cash Payment Per Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_InitialCashPaymentPerCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Cash Payment Per Collaboration Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement royalty, maximum reduction percent as a result of required third party payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Royalty Due Maximum Reduction Percentage As Result Of Required Payments To Third Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum reduction percentage of the royalty due as a result of required payments to third parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average price at which warrants were exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of warrants (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period during which warrants are active, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total principal payments outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Outstanding Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares tendered for withholding taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to Additional paid-in capital Shares tendered for withholding taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset obtained in exchange for operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentInterestPaymentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest payment period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentInterestPaymentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Payment Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentInterestPaymentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, interest payment period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan 2020 tranche three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan2020 Tranche Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents about term loan tranche three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Line of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Line of Credit, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2019 and March 2022 Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December Two Thousand Nineteen and March Two Thousand Twenty Two Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">December two thousand nineteen and march two thousand twenty two sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Occurs On Or After First Anniversary And Prior To Second Anniversary Of First Amendment Closing Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment occurs on or after first anniversary and prior to second anniversary of first amendment closing date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment Occurs on or After First Anniversary and Prior to Second Anniversary of First Amendment Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SecondAmendmentToLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amendment To Loan and Security Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SecondAmendmentToLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment To Loan and Security Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SecondAmendmentToLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second amendment to loan and security agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Principal Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan2020 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents about term loan two thousand twenty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unamortized debt discount, long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, operating lease, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Net Loss per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of exclusive license agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_NumberOfLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of license agreements the Company has entered into.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ThresholdDaysToAchieveFirstMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period to achieve first milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ThresholdDaysToAchieveFirstMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Days To Achieve First Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ThresholdDaysToAchieveFirstMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days to achieve first milestone following such date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement royalty as a percent of net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Royalty Due Percentage Of Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of net sales of products containing the licensed products, due to licensor as a royalty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodSharesFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon financing (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodSharesFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodSharesFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of stock issued during the period pursuant to a financing arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average contractual term, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs04Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AXS-04</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs04Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Axs04 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs04Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to AXS-04.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs05AndAxs07Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AXS-05 and AXS-07</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs05AndAxs07Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Axs05 And Axs07 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_Axs05AndAxs07Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information pertaining to AXS-05 and AXS-07.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock to be issued if warrants are exercised (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrants Or Rights Weighted Average Price Trading Days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold period of specified consecutive trading days within which the volume weighted average price of company's common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SunosiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sunosi</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SunosiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sunosi [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SunosiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sunosi.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-vested options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of cash to be maintained as a security following market capitalization condition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Additional Drawn Covenant Minimum Cash To Be Maintained As Security With Market Capitalization Covenant Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum percentage of cash to be maintained as security following the market capitalization conditions under the debt instruments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected vesting period for non-vested share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding principle and advances under the loans agreement exceeds 55 million</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Advances Under Loan Agreement Equals Or Exceeds Fifty Five Million [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information if the outstanding principle and advances under loan agreement exceeds fifty five million.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">An underwritten sale of stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted net loss per common share:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average grant date fair value, Outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average grant date fair value, Outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment Occurs on or After First Anniversary and Prior to Second Anniversary of the Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Occurs On Or After First Anniversary And Prior To Second Anniversary Of Closing Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the prepayment of debt occurring on or after the first anniversary and prior to the second anniversary of the Closing Date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ChangeInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ChangeInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ChangeInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in operating lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan 2020 tranche five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan2020 Tranche Five [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents about term loan tranche five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Risks And Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Risks And Uncertainties Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for significant risks and uncertainties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon exercise of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsIssuedDuringPeriodDebtFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued During Period Debt Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsIssuedDuringPeriodDebtFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued during period debt financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsIssuedDuringPeriodDebtFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants upon debt financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202010Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020-10</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202010Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2020-10 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_WarrantsIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants (or share units) issued during the current period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of operating lease right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior trading days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consecutive Trading Days</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_ConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the consecutive number of trading days to determine the weighted average price per share of ordinary shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement term, from first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LicenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of time, after the first commercial sale of the applicable product, the license agreement is valid, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_HerculesCapitalIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules Capital Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_HerculesCapitalIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules Capital Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_HerculesCapitalIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules Capital Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment Occurs on or After Second Anniversary and Prior to Third Anniversary of Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Occurs On Or After Second Anniversary And Prior To Third Anniversary Of Closing Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the prepayment of debt occurring after the second anniversary and prior to the third anniversary of the Closing Date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan 2020 tranche four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan2020 Tranche Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2020TrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents about term loan tranche four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 2022 Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">March Two Thousand Twenty Two Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">March Two Thousand Twenty Two Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentPenaltyPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayment penalty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentPenaltyPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Penalty Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_DebtInstrumentPrepaymentPenaltyPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the prepayment penalty percentage on principal amount of debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum cash to be maintain as a first priority security interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Additional Drawn Covenant Minimum Cash As Security Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum amount of cash should be maintained as first priority security interest under the terms of debt instrument.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheTwoSubTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two Sub-Tranche Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheTwoSubTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two Sub Tranche Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TrancheTwoSubTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche two sub tranche three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2019Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2019Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan2019 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_TermLoan2019Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">This member stands for Term Loan 2019.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to non-vested stock options expected to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of stock issued as a result of the exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line Of Credit Facility [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost not yet recognized related to unvested RSUs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon financing, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember" xlink:to="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_CommonStockFairValue" xlink:to="axsm_CommonStockFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_ThresholdDaysToAchieveSecondMilestone" xlink:to="axsm_ThresholdDaysToAchieveSecondMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_CommonStockSalesAgreementAuthorizedAmount" xlink:to="axsm_CommonStockSalesAgreementAuthorizedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentsMaturityMonthAndYear" xlink:to="axsm_DebtInstrumentsMaturityMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TermLoan2020TrancheOneMember" xlink:to="axsm_TermLoan2020TrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_NumberOfLateStageProductCandidates" xlink:to="axsm_NumberOfLateStageProductCandidates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TermLoan2020TrancheTwoMember" xlink:to="axsm_TermLoan2020TrancheTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentThresholdCashPayInterestRate" xlink:to="axsm_DebtInstrumentThresholdCashPayInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TrancheTwoSubTrancheOneMember" xlink:to="axsm_TrancheTwoSubTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_UnregisteredCommonStockValue" xlink:to="axsm_UnregisteredCommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_ExtinguishmentOfDebtFeeAmount" xlink:to="axsm_ExtinguishmentOfDebtFeeAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_CollaborationArrangementFuturePotentialPayments" xlink:to="axsm_CollaborationArrangementFuturePotentialPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_FairValueOfWarrants" xlink:to="axsm_FairValueOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_RevenueMilestones" xlink:to="axsm_RevenueMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember" xlink:to="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember" xlink:to="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_Axs02Member" xlink:to="axsm_Axs02Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_AccruedGeneralAndAdministrativeCurrent" xlink:to="axsm_AccruedGeneralAndAdministrativeCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TrancheThreeSubTrancheOneMember" xlink:to="axsm_TrancheThreeSubTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice" xlink:to="axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LeerinkPartnersLimitedLiabilityCompanyMember" xlink:to="axsm_LeerinkPartnersLimitedLiabilityCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_CommonStockSalesAgreementCommissionPercentage" xlink:to="axsm_CommonStockSalesAgreementCommissionPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LicenseAgreementsDisclosureTextBlock" xlink:to="axsm_LicenseAgreementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:to="axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_NumberOfFinancialInstitutionsHoldingDeposits" xlink:to="axsm_NumberOfFinancialInstitutionsHoldingDeposits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_StockIssuedDuringPeriodValueFinancing" xlink:to="axsm_StockIssuedDuringPeriodValueFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_PfizerIncMember" xlink:to="axsm_PfizerIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_NumberOfAsianMarkets" xlink:to="axsm_NumberOfAsianMarkets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_AccruedResearchAndDevelopmentCurrent" xlink:to="axsm_AccruedResearchAndDevelopmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_CommonStockSalesAgreementSharesUnsoldAmount" xlink:to="axsm_CommonStockSalesAgreementSharesUnsoldAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt" xlink:to="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_AccountingPoliciesTable" xlink:to="axsm_AccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember" xlink:to="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DevelopmentMilestones" xlink:to="axsm_DevelopmentMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TwoThousandNineteenShelfRegistrationMember" xlink:to="axsm_TwoThousandNineteenShelfRegistrationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_WarrantsExercisedInPeriod" xlink:to="axsm_WarrantsExercisedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent" xlink:to="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="axsm_AccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TwoThousandFifteenEquityCompensationPlanMember" xlink:to="axsm_TwoThousandFifteenEquityCompensationPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_Axs05Member" xlink:to="axsm_Axs05Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TrancheThreeSubTrancheTwoMember" xlink:to="axsm_TrancheThreeSubTrancheTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DecemberTwoThousandNineteenSalesAgreementMember" xlink:to="axsm_DecemberTwoThousandNineteenSalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_JazzPharmaceuticalsPlcMember" xlink:to="axsm_JazzPharmaceuticalsPlcMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentCashPayInterestMultiplier" xlink:to="axsm_DebtInstrumentCashPayInterestMultiplier_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate" xlink:to="axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee" xlink:to="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="axsm_StockIssuedDuringPeriodValueWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_SharePriceFairValue" xlink:to="axsm_SharePriceFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_StockIssuedDuringPeriodValueNewIssuesNet" xlink:to="axsm_StockIssuedDuringPeriodValueNewIssuesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward" xlink:to="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TrancheTwoSubTrancheTwoMember" xlink:to="axsm_TrancheTwoSubTrancheTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentAggregateAmountPercentage" xlink:to="axsm_DebtInstrumentAggregateAmountPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding" xlink:to="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent" xlink:to="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward" xlink:to="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_EquityInstrumentVotingRightsPerShare" xlink:to="axsm_EquityInstrumentVotingRightsPerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TrancheOneMember" xlink:to="axsm_TrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount" xlink:to="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_InitialCashPaymentPerCollaborationAgreement" xlink:to="axsm_InitialCashPaymentPerCollaborationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties" xlink:to="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_ClassOfWarrantOrRightTerm" xlink:to="axsm_ClassOfWarrantOrRightTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" xlink:to="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentInterestPaymentPeriod" xlink:to="axsm_DebtInstrumentInterestPaymentPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TermLoan2020TrancheThreeMember" xlink:to="axsm_TermLoan2020TrancheThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember" xlink:to="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_SecondAmendmentToLoanAndSecurityAgreementMember" xlink:to="axsm_SecondAmendmentToLoanAndSecurityAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TermLoan2020Member" xlink:to="axsm_TermLoan2020Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_NumberOfLicenseAgreements" xlink:to="axsm_NumberOfLicenseAgreements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_ThresholdDaysToAchieveFirstMilestone" xlink:to="axsm_ThresholdDaysToAchieveFirstMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales" xlink:to="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_StockIssuedDuringPeriodSharesFinancing" xlink:to="axsm_StockIssuedDuringPeriodSharesFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_Axs04Member" xlink:to="axsm_Axs04Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_Axs05AndAxs07Member" xlink:to="axsm_Axs05AndAxs07Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays" xlink:to="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_SunosiMember" xlink:to="axsm_SunosiMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember" xlink:to="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_UnderwrittenPublicOfferingMember" xlink:to="axsm_UnderwrittenPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_UpfrontPayment" xlink:to="axsm_UpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_ChangeInOperatingLeaseLiability" xlink:to="axsm_ChangeInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TermLoan2020TrancheFiveMember" xlink:to="axsm_TermLoan2020TrancheFiveMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_WarrantsIssuedDuringPeriodDebtFinancing" xlink:to="axsm_WarrantsIssuedDuringPeriodDebtFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202010Member" xlink:to="us-gaap_AccountingStandardsUpdate202010Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_WarrantsIssuedInPeriod" xlink:to="axsm_WarrantsIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_ConsecutiveTradingDays" xlink:to="axsm_ConsecutiveTradingDays_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LicenseAgreementTerm" xlink:to="axsm_LicenseAgreementTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_HerculesCapitalIncMember" xlink:to="axsm_HerculesCapitalIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TermLoan2020TrancheFourMember" xlink:to="axsm_TermLoan2020TrancheFourMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember" xlink:to="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_DebtInstrumentPrepaymentPenaltyPercentage" xlink:to="axsm_DebtInstrumentPrepaymentPenaltyPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TermLoanMember" xlink:to="axsm_TermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TrancheTwoSubTrancheThreeMember" xlink:to="axsm_TrancheTwoSubTrancheThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_TermLoan2019Member" xlink:to="axsm_TermLoan2019Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>axsm-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-02T16:59:20.7917+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="axsm-20220331.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails2" xlink:href="axsm-20220331.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="axsm-20220331.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="axsm-20220331.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="axsm_ChangeInOperatingLeaseLiability" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="13" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ChangeInOperatingLeaseLiability" xlink:label="axsm_ChangeInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent" xlink:label="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="axsm_AccruedResearchAndDevelopmentCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="axsm_AccruedGeneralAndAdministrativeCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccruedResearchAndDevelopmentCurrent" xlink:label="axsm_AccruedResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccruedGeneralAndAdministrativeCurrent" xlink:label="axsm_AccruedGeneralAndAdministrativeCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee" xlink:label="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount" xlink:label="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>axsm-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-02T16:59:20.5377+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="axsm-20220331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="axsm-20220331.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="axsm-20220331.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="axsm-20220331.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="axsm-20220331.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="axsm-20220331.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="axsm-20220331.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="axsm-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="axsm-20220331.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreement" xlink:href="axsm-20220331.xsd#Role_DisclosureLoanAndSecurityAgreement" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShare" xlink:href="axsm-20220331.xsd#Role_DisclosureNetLossPerCommonShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="axsm-20220331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="axsm-20220331.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:href="axsm-20220331.xsd#Role_DisclosureLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/DisclosureSubsequentEvent" xlink:href="axsm-20220331.xsd#DisclosureSubsequentEvent" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="axsm-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="axsm-20220331.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementTables" xlink:href="axsm-20220331.xsd#Role_DisclosureLoanAndSecurityAgreementTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables" xlink:href="axsm-20220331.xsd#Role_DisclosureNetLossPerCommonShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="axsm-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="axsm-20220331.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="axsm_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsIssuedDuringPeriodDebtFinancing" xlink:label="axsm_WarrantsIssuedDuringPeriodDebtFinancing"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward" xlink:label="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward" xlink:label="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodValueFinancing" xlink:label="axsm_StockIssuedDuringPeriodValueFinancing"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodSharesFinancing" xlink:label="axsm_StockIssuedDuringPeriodSharesFinancing"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" xlink:label="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_14"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_15"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockIssuedDuringPeriodValueWarrantsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_WarrantsIssuedDuringPeriodDebtFinancing" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockIssuedDuringPeriodValueFinancing" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockIssuedDuringPeriodSharesFinancing" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent" xlink:label="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ChangeInOperatingLeaseLiability" xlink:label="axsm_ChangeInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="axsm_ChangeInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementsDisclosureTextBlock" xlink:label="axsm_LicenseAgreementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="axsm_LicenseAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_HerculesCapitalIncMember" xlink:label="axsm_HerculesCapitalIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoanMember" xlink:label="axsm_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SecondAmendmentToLoanAndSecurityAgreementMember" xlink:label="axsm_SecondAmendmentToLoanAndSecurityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfLateStageProductCandidates" xlink:label="axsm_NumberOfLateStageProductCandidates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheOneMember" xlink:label="axsm_TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SunosiMember" xlink:label="axsm_SunosiMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_JazzPharmaceuticalsPlcMember" xlink:label="axsm_JazzPharmaceuticalsPlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheOneMember" xlink:label="axsm_TermLoan2020TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_UpfrontPayment" xlink:label="axsm_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheTwoSubTrancheOneMember" xlink:label="axsm_TrancheTwoSubTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfAsianMarkets" xlink:label="axsm_NumberOfAsianMarkets"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheTwoSubTrancheTwoMember" xlink:label="axsm_TrancheTwoSubTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_RevenueMilestones" xlink:label="axsm_RevenueMilestones"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheTwoSubTrancheThreeMember" xlink:label="axsm_TrancheTwoSubTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DevelopmentMilestones" xlink:label="axsm_DevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheThreeMember" xlink:label="axsm_TermLoan2020TrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheThreeSubTrancheOneMember" xlink:label="axsm_TrancheThreeSubTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheThreeSubTrancheTwoMember" xlink:label="axsm_TrancheThreeSubTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_UnregisteredCommonStockValue" xlink:label="axsm_UnregisteredCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheFourMember" xlink:label="axsm_TermLoan2020TrancheFourMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate" xlink:label="axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheFiveMember" xlink:label="axsm_TermLoan2020TrancheFiveMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="axsm_HerculesCapitalIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="axsm_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="axsm_SecondAmendmentToLoanAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_NumberOfLateStageProductCandidates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="axsm_SunosiMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="axsm_JazzPharmaceuticalsPlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_UpfrontPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheTwoSubTrancheOneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_NumberOfAsianMarkets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheTwoSubTrancheTwoMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_RevenueMilestones" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheTwoSubTrancheThreeMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_DevelopmentMilestones" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheThreeMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheThreeSubTrancheOneMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheThreeSubTrancheTwoMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_UnregisteredCommonStockValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheFourMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheFiveMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccountingPoliciesTable" xlink:label="axsm_AccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccountingPoliciesLineItems" xlink:label="axsm_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfFinancialInstitutionsHoldingDeposits" xlink:label="axsm_NumberOfFinancialInstitutionsHoldingDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202010Member" xlink:label="us-gaap_AccountingStandardsUpdate202010Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="axsm_AccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axsm_AccountingPoliciesTable" xlink:to="srt_StatementScenarioAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="axsm_NumberOfFinancialInstitutionsHoldingDeposits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axsm_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202010Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValueAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axsm_AccountingPoliciesTable" xlink:to="axsm_AccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_RisksAndUncertaintiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccruedResearchAndDevelopmentCurrent" xlink:label="axsm_AccruedResearchAndDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccruedGeneralAndAdministrativeCurrent" xlink:label="axsm_AccruedGeneralAndAdministrativeCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="axsm_AccruedResearchAndDevelopmentCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="axsm_AccruedGeneralAndAdministrativeCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020Member" xlink:label="axsm_TermLoan2020Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs05AndAxs07Member" xlink:label="axsm_Axs05AndAxs07Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember" xlink:label="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheOneMember" xlink:label="axsm_TermLoan2020TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheTwoMember" xlink:label="axsm_TermLoan2020TrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheThreeMember" xlink:label="axsm_TermLoan2020TrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ThresholdDaysToAchieveFirstMilestone" xlink:label="axsm_ThresholdDaysToAchieveFirstMilestone"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheFourMember" xlink:label="axsm_TermLoan2020TrancheFourMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ThresholdDaysToAchieveSecondMilestone" xlink:label="axsm_ThresholdDaysToAchieveSecondMilestone"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheFiveMember" xlink:label="axsm_TermLoan2020TrancheFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt" xlink:label="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2019Member" xlink:label="axsm_TermLoan2019Member"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentsMaturityMonthAndYear" xlink:label="axsm_DebtInstrumentsMaturityMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentInterestPaymentPeriod" xlink:label="axsm_DebtInstrumentInterestPaymentPeriod"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentThresholdCashPayInterestRate" xlink:label="axsm_DebtInstrumentThresholdCashPayInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentCashPayInterestMultiplier" xlink:label="axsm_DebtInstrumentCashPayInterestMultiplier"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent" xlink:label="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ExtinguishmentOfDebtFeeAmount" xlink:label="axsm_ExtinguishmentOfDebtFeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding" xlink:label="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentPenaltyPercentage" xlink:label="axsm_DebtInstrumentPrepaymentPenaltyPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentAggregateAmountPercentage" xlink:label="axsm_DebtInstrumentAggregateAmountPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="axsm_Axs05AndAxs07Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheOneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_StatementScenarioAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheTwoMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_VariableRateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheThreeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_ThresholdDaysToAchieveFirstMilestone" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheFourMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_ProductOrServiceAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_ThresholdDaysToAchieveSecondMilestone" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheFiveMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2019Member" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentsMaturityMonthAndYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentInterestPaymentPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentThresholdCashPayInterestRate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentCashPayInterestMultiplier" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_ExtinguishmentOfDebtFeeAmount" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentPrepaymentPenaltyPercentage" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentAggregateAmountPercentage" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee" xlink:label="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount" xlink:label="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LeerinkPartnersLimitedLiabilityCompanyMember" xlink:label="axsm_LeerinkPartnersLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DecemberTwoThousandNineteenSalesAgreementMember" xlink:label="axsm_DecemberTwoThousandNineteenSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_UnderwrittenPublicOfferingMember" xlink:label="axsm_UnderwrittenPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TwoThousandFifteenEquityCompensationPlanMember" xlink:label="axsm_TwoThousandFifteenEquityCompensationPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheOneMember" xlink:label="axsm_TermLoan2020TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockSalesAgreementAuthorizedAmount" xlink:label="axsm_CommonStockSalesAgreementAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_MarchTwoThousandTwentyTwoSalesAgreementMember" xlink:label="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TwoThousandNineteenShelfRegistrationMember" xlink:label="axsm_TwoThousandNineteenShelfRegistrationMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockSalesAgreementCommissionPercentage" xlink:label="axsm_CommonStockSalesAgreementCommissionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember" xlink:label="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockSalesAgreementSharesUnsoldAmount" xlink:label="axsm_CommonStockSalesAgreementSharesUnsoldAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodValueNewIssuesNet" xlink:label="axsm_StockIssuedDuringPeriodValueNewIssuesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_EquityInstrumentVotingRightsPerShare" xlink:label="axsm_EquityInstrumentVotingRightsPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays" xlink:label="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ClassOfWarrantOrRightTerm" xlink:label="axsm_ClassOfWarrantOrRightTerm"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_FairValueOfWarrants" xlink:label="axsm_FairValueOfWarrants"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="axsm_LeerinkPartnersLimitedLiabilityCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="axsm_DecemberTwoThousandNineteenSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="axsm_UnderwrittenPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="axsm_TwoThousandFifteenEquityCompensationPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_CommonStockSalesAgreementAuthorizedAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="axsm_TwoThousandNineteenShelfRegistrationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_CommonStockSalesAgreementCommissionPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_CommonStockSalesAgreementSharesUnsoldAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_StockIssuedDuringPeriodValueNewIssuesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_EquityInstrumentVotingRightsPerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_ClassOfWarrantOrRightTerm" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_FairValueOfWarrants" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:label="axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsIssuedInPeriod" xlink:label="axsm_WarrantsIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsExercisedInPeriod" xlink:label="axsm_WarrantsExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice" xlink:label="axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="axsm_WarrantsIssuedInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="axsm_WarrantsExercisedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_PfizerIncMember" xlink:label="axsm_PfizerIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs02Member" xlink:label="axsm_Axs02Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs05Member" xlink:label="axsm_Axs05Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs04Member" xlink:label="axsm_Axs04Member"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ConsecutiveTradingDays" xlink:label="axsm_ConsecutiveTradingDays"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_InitialCashPaymentPerCollaborationAgreement" xlink:label="axsm_InitialCashPaymentPerCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SharePriceFairValue" xlink:label="axsm_SharePriceFairValue"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockFairValue" xlink:label="axsm_CommonStockFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CollaborationArrangementFuturePotentialPayments" xlink:label="axsm_CollaborationArrangementFuturePotentialPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfLicenseAgreements" xlink:label="axsm_NumberOfLicenseAgreements"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales" xlink:label="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties" xlink:label="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementTerm" xlink:label="axsm_LicenseAgreementTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="axsm_PfizerIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="axsm_Axs02Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="axsm_Axs05Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="axsm_Axs04Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_ConsecutiveTradingDays" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_SharePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_InitialCashPaymentPerCollaborationAgreement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_SharePriceFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_CommonStockFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_CollaborationArrangementFuturePotentialPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_NumberOfLicenseAgreements" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_LicenseAgreementTerm" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>axsm-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-02T16:59:20.6583+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="axsm-20220331.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="axsm-20220331.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="axsm_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_WarrantsIssuedDuringPeriodDebtFinancing" xlink:label="axsm_WarrantsIssuedDuringPeriodDebtFinancing"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward" xlink:label="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward" xlink:label="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodValueFinancing" xlink:label="axsm_StockIssuedDuringPeriodValueFinancing"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodSharesFinancing" xlink:label="axsm_StockIssuedDuringPeriodSharesFinancing"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" xlink:label="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockIssuedDuringPeriodValueWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_WarrantsIssuedDuringPeriodDebtFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockIssuedDuringPeriodValueFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_StockIssuedDuringPeriodSharesFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_HerculesCapitalIncMember" xlink:label="axsm_HerculesCapitalIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoanMember" xlink:label="axsm_TermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SecondAmendmentToLoanAndSecurityAgreementMember" xlink:label="axsm_SecondAmendmentToLoanAndSecurityAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfLateStageProductCandidates" xlink:label="axsm_NumberOfLateStageProductCandidates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheOneMember" xlink:label="axsm_TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SunosiMember" xlink:label="axsm_SunosiMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_JazzPharmaceuticalsPlcMember" xlink:label="axsm_JazzPharmaceuticalsPlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheOneMember" xlink:label="axsm_TermLoan2020TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_UpfrontPayment" xlink:label="axsm_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheTwoSubTrancheOneMember" xlink:label="axsm_TrancheTwoSubTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfAsianMarkets" xlink:label="axsm_NumberOfAsianMarkets"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheTwoSubTrancheTwoMember" xlink:label="axsm_TrancheTwoSubTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_RevenueMilestones" xlink:label="axsm_RevenueMilestones"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheTwoSubTrancheThreeMember" xlink:label="axsm_TrancheTwoSubTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DevelopmentMilestones" xlink:label="axsm_DevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheThreeMember" xlink:label="axsm_TermLoan2020TrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheThreeSubTrancheOneMember" xlink:label="axsm_TrancheThreeSubTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TrancheThreeSubTrancheTwoMember" xlink:label="axsm_TrancheThreeSubTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_UnregisteredCommonStockValue" xlink:label="axsm_UnregisteredCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheFourMember" xlink:label="axsm_TermLoan2020TrancheFourMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate" xlink:label="axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheFiveMember" xlink:label="axsm_TermLoan2020TrancheFiveMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="axsm_HerculesCapitalIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="axsm_TermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="axsm_SecondAmendmentToLoanAndSecurityAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_NumberOfLateStageProductCandidates" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="axsm_SunosiMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="axsm_JazzPharmaceuticalsPlcMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_UpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheTwoSubTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_NumberOfAsianMarkets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheTwoSubTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_RevenueMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheTwoSubTrancheThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_DevelopmentMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheThreeSubTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TrancheThreeSubTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_UnregisteredCommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheFourMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheFiveMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccountingPoliciesLineItems" xlink:label="axsm_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_AccountingPoliciesTable" xlink:label="axsm_AccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfFinancialInstitutionsHoldingDeposits" xlink:label="axsm_NumberOfFinancialInstitutionsHoldingDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202010Member" xlink:label="us-gaap_AccountingStandardsUpdate202010Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="axsm_AccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="axsm_AccountingPoliciesTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="axsm_NumberOfFinancialInstitutionsHoldingDeposits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="axsm_AccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202010Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValueAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_RisksAndUncertaintiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="axsm_AccountingPoliciesLineItems" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020Member" xlink:label="axsm_TermLoan2020Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs05AndAxs07Member" xlink:label="axsm_Axs05AndAxs07Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember" xlink:label="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheOneMember" xlink:label="axsm_TermLoan2020TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheTwoMember" xlink:label="axsm_TermLoan2020TrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheThreeMember" xlink:label="axsm_TermLoan2020TrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember" xlink:label="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ThresholdDaysToAchieveFirstMilestone" xlink:label="axsm_ThresholdDaysToAchieveFirstMilestone"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheFourMember" xlink:label="axsm_TermLoan2020TrancheFourMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ThresholdDaysToAchieveSecondMilestone" xlink:label="axsm_ThresholdDaysToAchieveSecondMilestone"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheFiveMember" xlink:label="axsm_TermLoan2020TrancheFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt" xlink:label="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2019Member" xlink:label="axsm_TermLoan2019Member"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentsMaturityMonthAndYear" xlink:label="axsm_DebtInstrumentsMaturityMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentInterestPaymentPeriod" xlink:label="axsm_DebtInstrumentInterestPaymentPeriod"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember" xlink:label="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentThresholdCashPayInterestRate" xlink:label="axsm_DebtInstrumentThresholdCashPayInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentCashPayInterestMultiplier" xlink:label="axsm_DebtInstrumentCashPayInterestMultiplier"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent" xlink:label="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent" xlink:label="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ExtinguishmentOfDebtFeeAmount" xlink:label="axsm_ExtinguishmentOfDebtFeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding" xlink:label="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentPrepaymentPenaltyPercentage" xlink:label="axsm_DebtInstrumentPrepaymentPenaltyPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DebtInstrumentAggregateAmountPercentage" xlink:label="axsm_DebtInstrumentAggregateAmountPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="axsm_Axs05AndAxs07Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_ThresholdDaysToAchieveFirstMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheFourMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_ThresholdDaysToAchieveSecondMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheFiveMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2019Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentsMaturityMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentInterestPaymentPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentThresholdCashPayInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentCashPayInterestMultiplier" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_ExtinguishmentOfDebtFeeAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentPrepaymentPenaltyPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="axsm_DebtInstrumentAggregateAmountPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LeerinkPartnersLimitedLiabilityCompanyMember" xlink:label="axsm_LeerinkPartnersLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DecemberTwoThousandNineteenSalesAgreementMember" xlink:label="axsm_DecemberTwoThousandNineteenSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_UnderwrittenPublicOfferingMember" xlink:label="axsm_UnderwrittenPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TwoThousandFifteenEquityCompensationPlanMember" xlink:label="axsm_TwoThousandFifteenEquityCompensationPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TermLoan2020TrancheOneMember" xlink:label="axsm_TermLoan2020TrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockSalesAgreementAuthorizedAmount" xlink:label="axsm_CommonStockSalesAgreementAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_MarchTwoThousandTwentyTwoSalesAgreementMember" xlink:label="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_TwoThousandNineteenShelfRegistrationMember" xlink:label="axsm_TwoThousandNineteenShelfRegistrationMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockSalesAgreementCommissionPercentage" xlink:label="axsm_CommonStockSalesAgreementCommissionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember" xlink:label="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockSalesAgreementSharesUnsoldAmount" xlink:label="axsm_CommonStockSalesAgreementSharesUnsoldAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_StockIssuedDuringPeriodValueNewIssuesNet" xlink:label="axsm_StockIssuedDuringPeriodValueNewIssuesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_EquityInstrumentVotingRightsPerShare" xlink:label="axsm_EquityInstrumentVotingRightsPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays" xlink:label="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ClassOfWarrantOrRightTerm" xlink:label="axsm_ClassOfWarrantOrRightTerm"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_FairValueOfWarrants" xlink:label="axsm_FairValueOfWarrants"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="axsm_LeerinkPartnersLimitedLiabilityCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="axsm_DecemberTwoThousandNineteenSalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="axsm_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="axsm_TwoThousandFifteenEquityCompensationPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="axsm_TermLoan2020TrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_CommonStockSalesAgreementAuthorizedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="axsm_TwoThousandNineteenShelfRegistrationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_CommonStockSalesAgreementCommissionPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_CommonStockSalesAgreementSharesUnsoldAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_StockIssuedDuringPeriodValueNewIssuesNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_EquityInstrumentVotingRightsPerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_ClassOfWarrantOrRightTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="axsm_FairValueOfWarrants" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_PfizerIncMember" xlink:label="axsm_PfizerIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs02Member" xlink:label="axsm_Axs02Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs05Member" xlink:label="axsm_Axs05Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_Axs04Member" xlink:label="axsm_Axs04Member"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_ConsecutiveTradingDays" xlink:label="axsm_ConsecutiveTradingDays"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_InitialCashPaymentPerCollaborationAgreement" xlink:label="axsm_InitialCashPaymentPerCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_SharePriceFairValue" xlink:label="axsm_SharePriceFairValue"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CommonStockFairValue" xlink:label="axsm_CommonStockFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_CollaborationArrangementFuturePotentialPayments" xlink:label="axsm_CollaborationArrangementFuturePotentialPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_NumberOfLicenseAgreements" xlink:label="axsm_NumberOfLicenseAgreements"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales" xlink:label="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties" xlink:label="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties"/>
    <link:loc xlink:type="locator" xlink:href="axsm-20220331.xsd#axsm_LicenseAgreementTerm" xlink:label="axsm_LicenseAgreementTerm"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="axsm_PfizerIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="axsm_Axs02Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="axsm_Axs05Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="axsm_Axs04Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_ConsecutiveTradingDays" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_InitialCashPaymentPerCollaborationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_SharePriceFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_CommonStockFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_CollaborationArrangementFuturePotentialPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_NumberOfLicenseAgreements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="axsm_LicenseAgreementTerm" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>axsm-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-02T16:59:18.2958+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://axsome.com/20220331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:axsm="http://axsome.com/20220331" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axsm-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axsm-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axsm-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axsm-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails2" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments of Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100040 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100070 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100090 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreement" id="Role_DisclosureLoanAndSecurityAgreement">
        <link:definition>100100 - Disclosure - Loan and Security Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShare" id="Role_DisclosureNetLossPerCommonShare">
        <link:definition>100110 - Disclosure - Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100130 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreements" id="Role_DisclosureLicenseAgreements">
        <link:definition>100140 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/DisclosureSubsequentEvent" id="DisclosureSubsequentEvent">
        <link:definition>100150 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100160 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100170 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementTables" id="Role_DisclosureLoanAndSecurityAgreementTables">
        <link:definition>100180 - Disclosure - Loan and Security Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables" id="Role_DisclosureNetLossPerCommonShareTables">
        <link:definition>100190 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100200 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100210 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100220 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100230 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails">
        <link:definition>100240 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails" id="Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails">
        <link:definition>100250 - Disclosure - Loan and Security Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails" id="Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails">
        <link:definition>100260 - Disclosure - Loan and Security Agreement - Schedule of Outstanding Debt and Unamortized Debt Discount Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails" id="Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails">
        <link:definition>100270 - Disclosure - Loan and Security Agreement - Schedule of Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails" id="Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails">
        <link:definition>100280 - Disclosure - Net Loss per Common Share - Computation of Basic and Diluted Net Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails" id="Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails">
        <link:definition>100290 - Disclosure - Net Loss per Common Share - Potentially Dilutive Securities Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails">
        <link:definition>100300 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails">
        <link:definition>100310 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
        <link:definition>100340 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails" id="Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails">
        <link:definition>100350 - Disclosure - Stockholders' Equity - Schedule of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails" id="Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails">
        <link:definition>100360 - Disclosure - Stockholders' Equity - Schedule of Stock-Based Compensation Expense Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails" id="Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails">
        <link:definition>100370 - Disclosure - Stockholders' Equity - Schedule of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="axsm_AccruedGeneralAndAdministrativeCurrent" name="AccruedGeneralAndAdministrativeCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" name="AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_ChangeInOperatingLeaseLiability" name="ChangeInOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="axsm_ClassOfWarrantOrRightTerm" name="ClassOfWarrantOrRightTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays" name="ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_CollaborationArrangementFuturePotentialPayments" name="CollaborationArrangementFuturePotentialPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_CommonStockFairValue" name="CommonStockFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_CommonStockSalesAgreementAuthorizedAmount" name="CommonStockSalesAgreementAuthorizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_CommonStockSalesAgreementCommissionPercentage" name="CommonStockSalesAgreementCommissionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="axsm_CommonStockSalesAgreementSharesUnsoldAmount" name="CommonStockSalesAgreementSharesUnsoldAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_ConsecutiveTradingDays" name="ConsecutiveTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee" name="DebtInstrumentAccretedLiabilityOfFinalPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_DebtInstrumentAggregateAmountPercentage" name="DebtInstrumentAggregateAmountPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_DebtInstrumentCashPayInterestMultiplier" name="DebtInstrumentCashPayInterestMultiplier" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding" name="DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_DebtInstrumentInterestPaymentPeriod" name="DebtInstrumentInterestPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_DebtInstrumentPrepaymentPenaltyPercentage" name="DebtInstrumentPrepaymentPenaltyPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_DebtInstrumentsMaturityMonthAndYear" name="DebtInstrumentsMaturityMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_DebtInstrumentThresholdCashPayInterestRate" name="DebtInstrumentThresholdCashPayInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_DevelopmentMilestones" name="DevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_EquityInstrumentVotingRightsPerShare" name="EquityInstrumentVotingRightsPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_ExtinguishmentOfDebtFeeAmount" name="ExtinguishmentOfDebtFeeAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="axsm_FairValueOfWarrants" name="FairValueOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent" name="IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_InitialCashPaymentPerCollaborationAgreement" name="InitialCashPaymentPerCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties" name="LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales" name="LicenseAgreementRoyaltyDuePercentageOfNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_LicenseAgreementTerm" name="LicenseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod" name="LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest" name="LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent" name="LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent" name="LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount" name="LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent" name="LongTermDebtAdditionalDrawnMinimumRevenuePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount" name="LongTermDebtCurrentNetOfNoncurrentDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_NumberOfAsianMarkets" name="NumberOfAsianMarkets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_NumberOfFinancialInstitutionsHoldingDeposits" name="NumberOfFinancialInstitutionsHoldingDeposits" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="axsm_NumberOfLateStageProductCandidates" name="NumberOfLateStageProductCandidates" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="axsm_NumberOfLicenseAgreements" name="NumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt" name="ProceedsFromFirstAdvanceUsedToRepayPreviousDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_RevenueMilestones" name="RevenueMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_SharePriceFairValue" name="SharePriceFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate" name="SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="axsm_StockIssuedDuringPeriodSharesFinancing" name="StockIssuedDuringPeriodSharesFinancing" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised" name="StockIssuedDuringPeriodSharesStockWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_StockIssuedDuringPeriodValueFinancing" name="StockIssuedDuringPeriodValueFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_StockIssuedDuringPeriodValueNewIssuesNet" name="StockIssuedDuringPeriodValueNewIssuesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward" name="StockVestedDuringPeriodSharesRestrictedCommonStockAward" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward" name="StockVestedDuringPeriodValueRestrictedCommonStockAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_ThresholdDaysToAchieveFirstMilestone" name="ThresholdDaysToAchieveFirstMilestone" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_ThresholdDaysToAchieveSecondMilestone" name="ThresholdDaysToAchieveSecondMilestone" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_UnregisteredCommonStockValue" name="UnregisteredCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_WarrantsExercisedInPeriod" name="WarrantsExercisedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice" name="WarrantsExercisedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_WarrantsIssuedDuringPeriodDebtFinancing" name="WarrantsIssuedDuringPeriodDebtFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="axsm_WarrantsIssuedInPeriod" name="WarrantsIssuedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice" name="WarrantsIssuedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_Axs02Member" name="Axs02Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_Axs04Member" name="Axs04Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_Axs05AndAxs07Member" name="Axs05AndAxs07Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_Axs05Member" name="Axs05Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember" name="DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember" name="DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember" name="DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember" name="DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember" name="DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember" name="DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember" name="DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_DecemberTwoThousandNineteenSalesAgreementMember" name="DecemberTwoThousandNineteenSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_HerculesCapitalIncMember" name="HerculesCapitalIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_JazzPharmaceuticalsPlcMember" name="JazzPharmaceuticalsPlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_LeerinkPartnersLimitedLiabilityCompanyMember" name="LeerinkPartnersLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_MarchTwoThousandTwentyTwoSalesAgreementMember" name="MarchTwoThousandTwentyTwoSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember" name="OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember" name="OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_PfizerIncMember" name="PfizerIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_SecondAmendmentToLoanAndSecurityAgreementMember" name="SecondAmendmentToLoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember" name="SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_SunosiMember" name="SunosiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TermLoan2019Member" name="TermLoan2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TermLoan2020Member" name="TermLoan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TermLoan2020TrancheFiveMember" name="TermLoan2020TrancheFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TermLoan2020TrancheFourMember" name="TermLoan2020TrancheFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TermLoan2020TrancheOneMember" name="TermLoan2020TrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TermLoan2020TrancheThreeMember" name="TermLoan2020TrancheThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TermLoan2020TrancheTwoMember" name="TermLoan2020TrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TrancheOneMember" name="TrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TrancheThreeSubTrancheOneMember" name="TrancheThreeSubTrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TrancheThreeSubTrancheTwoMember" name="TrancheThreeSubTrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TrancheTwoSubTrancheOneMember" name="TrancheTwoSubTrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TrancheTwoSubTrancheThreeMember" name="TrancheTwoSubTrancheThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TrancheTwoSubTrancheTwoMember" name="TrancheTwoSubTrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TwoThousandFifteenEquityCompensationPlanMember" name="TwoThousandFifteenEquityCompensationPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_TwoThousandNineteenShelfRegistrationMember" name="TwoThousandNineteenShelfRegistrationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" name="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="axsm_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="axsm_LicenseAgreementsDisclosureTextBlock" name="LicenseAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855740501624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AXSOME THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4241907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">22 Cortlandt Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">16th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">332-3241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AXSM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,913,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001579428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855744232888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 84,707,782<span></span>
</td>
<td class="nump">$ 86,472,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,122,144<span></span>
</td>
<td class="nump">45,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">86,829,926<span></span>
</td>
<td class="nump">86,518,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
<td class="nump">460,946<span></span>
</td>
<td class="nump">283,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset - operating lease</a></td>
<td class="nump">946,479<span></span>
</td>
<td class="nump">660,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">322,910<span></span>
</td>
<td class="nump">322,910<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">88,560,261<span></span>
</td>
<td class="nump">87,785,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,595,112<span></span>
</td>
<td class="nump">13,149,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,987,222<span></span>
</td>
<td class="nump">9,295,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">967,248<span></span>
</td>
<td class="nump">620,675<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,549,582<span></span>
</td>
<td class="nump">23,065,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Loan payable, long-term</a></td>
<td class="nump">49,312,665<span></span>
</td>
<td class="nump">49,089,522<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">73,862,247<span></span>
</td>
<td class="nump">72,154,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share (150,000,000 shares authorized, 38,883,445 and 37,816,794 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively)</a></td>
<td class="nump">3,888<span></span>
</td>
<td class="nump">3,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">463,525,522<span></span>
</td>
<td class="nump">424,825,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(448,831,396)<span></span>
</td>
<td class="num">(409,199,085)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">14,698,014<span></span>
</td>
<td class="nump">15,630,352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 88,560,261<span></span>
</td>
<td class="nump">$ 87,785,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855740351224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">38,883,445<span></span>
</td>
<td class="nump">37,816,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">38,883,445<span></span>
</td>
<td class="nump">37,816,794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855744188600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 12,585,141<span></span>
</td>
<td class="nump">$ 16,595,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">25,703,731<span></span>
</td>
<td class="nump">11,248,372<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">38,288,872<span></span>
</td>
<td class="nump">27,844,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(38,288,872)<span></span>
</td>
<td class="num">(27,844,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income (expense)</a></td>
<td class="num">(1,343,439)<span></span>
</td>
<td class="num">(1,415,909)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (39,632,311)<span></span>
</td>
<td class="num">$ (29,259,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted</a></td>
<td class="num">$ (1.03)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">38,323,167<span></span>
</td>
<td class="nump">37,429,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855737427304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 113,792,909<span></span>
</td>
<td class="nump">$ 3,737<span></span>
</td>
<td class="nump">$ 392,585,265<span></span>
</td>
<td class="num">$ (278,796,093)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,374,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,731,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,731,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">1,913,299<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">1,913,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward', window );">Issuance of common stock upon vesting of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward', window );">Issuance of common stock upon vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_StockIssuedDuringPeriodValueFinancing', window );">Issuance of common stock upon financing</a></td>
<td class="nump">6,115,864<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">6,115,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_StockIssuedDuringPeriodSharesFinancing', window );">Issuance of common stock upon financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,259,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,259,970)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">96,293,199<span></span>
</td>
<td class="nump">$ 3,756<span></span>
</td>
<td class="nump">404,345,506<span></span>
</td>
<td class="num">(308,056,063)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,563,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 15,630,352<span></span>
</td>
<td class="nump">$ 3,782<span></span>
</td>
<td class="nump">424,825,655<span></span>
</td>
<td class="num">(409,199,085)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">37,816,794<span></span>
</td>
<td class="nump">37,816,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 7,598,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,598,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 181,637<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">181,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">18,015<span></span>
</td>
<td class="nump">18,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward', window );">Issuance of common stock upon vesting of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward', window );">Issuance of common stock upon vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_StockIssuedDuringPeriodValueFinancing', window );">Issuance of common stock upon financing</a></td>
<td class="nump">$ 31,008,601<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">31,008,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_StockIssuedDuringPeriodSharesFinancing', window );">Issuance of common stock upon financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes', window );">Shares tendered for withholding taxes</a></td>
<td class="num">(88,594)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(88,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,632,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,632,311)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 14,698,014<span></span>
</td>
<td class="nump">$ 3,888<span></span>
</td>
<td class="nump">$ 463,525,522<span></span>
</td>
<td class="num">$ (448,831,396)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">38,883,445<span></span>
</td>
<td class="nump">38,883,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional paid-in capital Shares tendered for withholding taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_StockIssuedDuringPeriodSharesFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to a financing arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_StockIssuedDuringPeriodSharesFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_StockIssuedDuringPeriodValueFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to a financing arrangement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_StockIssuedDuringPeriodValueFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock vested during period shares restricted common stock award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock vested during period value restricted common stock award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855737300888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (39,632,311)<span></span>
</td>
<td class="num">$ (29,259,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,598,329<span></span>
</td>
<td class="nump">3,731,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">223,143<span></span>
</td>
<td class="nump">276,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">36,636<span></span>
</td>
<td class="nump">8,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use asset</a></td>
<td class="nump">275,063<span></span>
</td>
<td class="nump">262,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_ChangeInOperatingLeaseLiability', window );">Change in operating lease liability</a></td>
<td class="num">(214,807)<span></span>
</td>
<td class="num">(275,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,076,858)<span></span>
</td>
<td class="num">(226,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(554,217)<span></span>
</td>
<td class="nump">1,117,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,692,042<span></span>
</td>
<td class="num">(2,848,723)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(32,652,980)<span></span>
</td>
<td class="num">(27,215,489)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(213,736)<span></span>
</td>
<td class="num">(29,995)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(213,736)<span></span>
</td>
<td class="num">(29,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon financing, net</a></td>
<td class="nump">31,008,601<span></span>
</td>
<td class="nump">6,115,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of options</a></td>
<td class="nump">181,637<span></span>
</td>
<td class="nump">1,913,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of tax withholdings on stock award</a></td>
<td class="num">(88,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="nump">31,101,644<span></span>
</td>
<td class="nump">8,029,163<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash</a></td>
<td class="num">(1,765,072)<span></span>
</td>
<td class="num">(19,216,321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">86,472,854<span></span>
</td>
<td class="nump">183,876,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">84,707,782<span></span>
</td>
<td class="nump">164,660,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,118,750<span></span>
</td>
<td class="nump">$ 1,143,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">$ 561,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_ChangeInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_ChangeInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855739359800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 1. Nature of Business and Basis of Presentation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Axsome Therapeutics, Inc. (&#8220;Axsome&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing novel therapies for central nervous system (&#8220;CNS&#8221;) disorders for which there are limited treatment options. By focusing on this therapeutic area, the Company is addressing significant and growing markets where current treatment options are limited or inadequate. The Company&#8217;s core CNS portfolio includes </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> product candidates, AXS-05, AXS-07, AXS-12, and AXS-14, which are being developed for multiple indications. The Company aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with CNS disorders. The Company was incorporated on January 12, 2012 in the State of Delaware.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited interim consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, which are normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the operating results for the full fiscal year or any future period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Acquisition of Assets of Jazz Pharmaceuticals</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On March 25, 2022, the Company entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Jazz Pharmaceuticals plc ("Jazz Pharmaceuticals"), pursuant to which the Company will acquire Sunosi&#174; from Jazz Pharmaceuticals ("the Acquisition"), a dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients living with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, which was approved by the U.S. Food and Drug Administration, or the FDA, in 2019 and by the European Medicines Agency (the &#8220;EMA&#8221;) in 2020.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Asset Purchase Agreement, the Company will receive from Jazz Pharmaceuticals worldwide commercial, development, manufacturing, and intellectual property rights to Sunosi, except for certain Asian markets. Jazz Pharmaceuticals will receive from the Company a total upfront payment of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, a high single-digit royalty on the Company's U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on the Company's U.S. net sales of Sunosi in future indications. The Company will also assume the commitments of Jazz Pharmaceuticals to SK Biopharmaceuticals (&#8220;SK)&#8221; and Aerial Biopharma (&#8220;Aerial&#8221;). SK is the originator of Sunosi and retains rights in </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Asian markets, including China, Korea, and Japan. In 2014, Jazz Pharmaceuticals acquired from Aerial worldwide rights to Sunosi excluding those Asian markets. The assumed commitments to SK and Aerial include single-digit tiered royalties based on the Company's sales of Sunosi, and up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">165</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in revenue milestones and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in development milestones. The Company expects to finance the transaction via its existing $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">300</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million term loan facility with Hercules Capital, Inc. (see below).<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Purchase Agreement also provides for customary conditions to closing, including the receipt of antitrust approval from the Federal Trade Commission pursuant to the Hart-Scott-Rodino Act, and the receipt of certain required financial statements from Jazz required by Regulation S-X of the Securities Exchange Act of 1934, as amended. The Company expects the closing to occur in the second quarter of 2022 and therefore, purchase accounting is not reflected in these consolidated financial statements.<br/><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment to the Loan and Security Agreement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On March 27, 2022, in connection with the Acquisition (as described above), the Company entered into a Second Amendment to the Loan and Security Agreement (the &#8220;Second Amendment&#8221;) with Hercules Capital, Inc. The Second Amendment amends the terms of that certain Loan and Security Agreement, dated as of September 25, 2020 (as amended by the First Amendment to the Loan and Security Agreement, dated of October 14, 2021) (the &#8220;Loan Agreement&#8221;). The changes in the Term Loan Advances (as defined in the Loan Agreement) amounts and dates are as follows: (i) increasing the Tranche 1 (as defined in the Loan Agreement) from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">95.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, whereby $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">45.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million is available upon the Second Amendment closing date (ii) changing the Tranche 2 Advances (as defined in the Loan Agreement) from two sub-tranches of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million each to three sub-tranches of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, (iii) changing the Tranche 3 Advance (as defined in the Loan Agreement) from one tranche of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million to two sub-tranches of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, (iv) decreasing the Tranche 4 Advance (as defined in the Loan Agreement) from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">55.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, and (v) decreasing the Tranche 5 Advance (as defined in the Loan Agreement) from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">75.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million. In connection with the Second Amendment, the parties also clarified certain terms of the Warrant Agreement previously issued to Hercules. The Second Amendment shall only be effective upon the closing of the Acquisition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Conditioned upon the closing of the Second Amendment, Hercules will also purchase between $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s unregistered common stock, at a share price equal to the lesser of (a) the three-day volume weighted average price as of the date of the Second Amendment, or (b) the three-day volume weighted average price as of the Second Amendment Effective Date, pursuant to a stock purchase agreement to be agreed upon by the parties; provided, that, in no case shall the share price be less than a </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% discount to the three-day volume weighted average price of the Company&#8217;s common stock at the time of the purchase.</span></p><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred operating losses since its inception and expects to continue to incur operating losses for the foreseeable future and may never become profitable. As of March 31, 2022, the Company had an accumulated deficit of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">448.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s primary sources of cash have been proceeds from the issuance and sale of its common stock in public offerings and the issuance of debt. The Company has not yet commercialized any of its product candidates and cannot be sure if it will ever be able to do so. The Company&#8217;s ability to achieve profitability depends on a number of factors, including its ability to obtain regulatory approval for its product candidates, successfully complete any post-approval regulatory obligations and successfully commercialize its product candidates alone or in partnership. The Company may continue to incur substantial operating losses even if it begins to generate revenues from its product candidates.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company believes its existing cash will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing. The actual amount of cash that the Company will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for its product candidates. The Company may use a combination of public and private equity offerings, debt financings, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements if market conditions are favorable or as a result of other strategic considerations to finance its future cash needs.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s common stock is listed on</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">the Nasdaq Global Market</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">and trades under the symbol &#8220;AXSM&#8221;.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Impact of COVID-19</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People&#8217;s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency in the United States on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a global pandemic. The full impact of the ongoing COVID-19 pandemic is still unknown and rapidly evolving. While the potential economic impact brought by and over the duration of the COVID-19 pandemic may be difficult to assess or predict, the COVID-19 pandemic has resulted in significant disruption of global financial markets, which could in the future negatively affect the Company&#8217;s liquidity. In addition, a recession or market volatility resulting from the COVID-19 pandemic could affect the Company&#8217;s business. Given the nature and type of the Company&#8217;s short-term investments, the Company does not believe the COVID-19 pandemic has had or will have a material impact on the Company&#8217;s current investment liquidity.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855739386056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Significant Risks and Uncertainties</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company&#8217;s product candidates; the Company&#8217;s ability to obtain regulatory approval to market its products, if approved; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company&#8217;s products, if approved; the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, if approved; and the Company&#8217;s ability to raise additional financing. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve and maintain profitability.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock&#8209;based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; and the recoverability of the Company&#8217;s net deferred tax assets and related valuation allowance.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency Translation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Expenses denominated in foreign currency are translated into U.S. dollars at the exchange rate on the date the expense is incurred. Assets and liabilities of foreign operations are translated at period-end exchange rates. The effect of exchange rate fluctuations on translating foreign currency into U.S. dollars is included in the Statements of Operations and is not material to the Company&#8217;s financial statements.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Segment and Geographic Information</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> operating segment, which is the business of developing novel therapies for the management of CNS disorders.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Cash Equivalents</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company&#8217;s cash and cash equivalents includes holdings in checking and overnight sweep accounts. The Company&#8217;s cash equivalents, which are money market funds held in a sweep account, are measured at fair value on a recurring basis. As of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the balance of cash and cash equivalents was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">84.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, which approximates fair value and was determined based upon Level 1 inputs. The sweep account is valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level 1.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the majority of the Company&#8217;s cash was held by </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three&#8209;level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Inputs that are unobservable for the asset or liability.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments are cash, accounts payable, accrued liabilities, and current and long-term debt. The carrying values for cash, accounts payable and accrued liabilities reported in the accompanying consolidated financial statements approximate their respective fair values due to their short-term maturities. The carrying value of debt on the Company&#8217;s balance sheet (see Note 6 &#8211; Loan and Security Agreement), is estimated to approximate its fair value as the interest rate approximates the market rate for loans with similar terms and risk characteristics.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Debt Issuance Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs consist of costs incurred in obtaining long-term financing. These costs are classified on the consolidated balance sheet as a direct deduction from the carrying amount of the related debt liability. These expenses are deferred and amortized as part of interest expense in the consolidated statement of operations using the effective interest rate method over the term of the debt agreement.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Equipment</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Equipment consists primarily of computer equipment and is recorded at cost. Equipment is depreciated on a straight&#8209;line basis over its estimated useful life, which the Company estimates to be </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is included in operating expenses.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related expenses including salaries, benefits, travel, and stock&#8209;based compensation expense, contract services, costs incurred to third-party service providers for the conduct of research, preclinical and clinical studies, laboratory supplies, product license fees, consulting and other related expenses. We estimate research, preclinical and clinical study expenses based on services performed, pursuant to contracts with third-party research and development organizations that conduct and manage research, preclinical and clinical activities on our behalf. We estimate these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments associated with licensing agreements to acquire licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternative future use are expensed as incurred. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates an annual effective tax rate of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% for the year ending </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and has </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">t recorded an income tax benefit for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021 since it determined that a full valuation allowance is required against the Company&#8217;s deferred tax assets.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position as well as consideration of the available facts and circumstances. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. As of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company does not believe any material uncertain tax positions are present. In the event the Company determines that accrual of interest or penalties are necessary in the future, the amount will be presented as a component of income tax expense.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For stock options issued, the Company estimates the grant date fair value of each option using the Black&#8209;Scholes option pricing model. The Black-Scholes model takes into account the expected volatility of the Company&#8217;s common stock, the risk-free interest rate, the estimated life of the option, the closing market price of the Company&#8217;s common stock and the exercise price. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management&#8217;s judgment. In addition, the Company recognizes expense for equity award forfeitures as they occur.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For restricted stock units (&#8220;RSUs&#8221;), the Company issues them in the form of Company common stock. The fair market value of these awards is based on the market closing price per share on the grant date.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense using the accelerated attribution method when it is probable that the performance condition will be achieved. The expense related to the stock-based compensation is recorded within the same financial statement line item as the grantee&#8217;s cash compensation.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s policy upon exercise of stock options and RSUs is that shares will be issued as new shares drawing on the Company&#8217;s 2015 Omnibus Incentive Compensation Plan share pool that was adopted by the stockholders in November 2015.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Basic and Diluted Net Loss per Common Share</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options, and RSUs, which would result in the issuance of incremental shares of common stock. As the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted net loss per share of common stock for the three months ended March 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. When evaluating whether a contract contains a lease, the Company considers whether (1) the contract explicitly or implicitly identifies assets that are contractually defined and (2) the Company obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s lease agreement contains lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. The Company has applied the practical expedient to combine fixed payments for non-lease components with lease payments and account for them together as a single lease component, which increases the amount of lease assets and corresponding liabilities. Payments under the Company&#8217;s lease arrangement are primarily fixed, however variable payments, are expensed as incurred and not included in the operating lease asset and liability.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses the implicit interest rate when readily determinable and uses the Company&#8217;s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s operating leases are reflected in the right-of-use operating asset; operating lease liability, current portion; and operating lease liability, long-term portion in the Company&#8217;s consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, and do not include an option to extend the term or purchase the underlying asset that the Company is reasonably certain to exercise, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</span></p></div><div style="font-size:9.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-08, Business Combinations (Topic 805) . This update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 606. This differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The amendments in this update should be applied prospectively, and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855739319768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 3. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022 and December 31, 2021 accrued expenses and other current liabilities consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.688%;"/>
        <td style="width:1.531%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.807%;"/>
        <td style="width:0.91%;"/>
        <td style="width:1.553%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.817%;"/>
        <td style="width:0.932%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,726,847</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,416,897</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,013,040</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,050,236</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued general and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,856,779</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,442,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued Interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">390,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">385,347</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10,987,222</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9,295,180</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855739450840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Loan and Security Agreement</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 4. Loan and Security Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hercules Capital, Inc.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, the Company entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender (in such capacity, the &#8220;Agent&#8221; or &#8220;Hercules&#8221;) and the other financial institutions that from time to time become parties to the Loan Agreement as lenders (collectively, the &#8220;Lenders&#8221;). The Loan Agreement provides for term loans in an aggregate principal amount of up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">225.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million under multiple tranches (the &#8220;2020 Term Loan&#8221;). The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million was funded to the Company on the Closing Date (the &#8220;First Advance&#8221;), and of which the remaining $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million was available at the Company&#8217;s option at any time through September 15, 2021; (ii) subject to the approval of the Company&#8217;s AXS-05 product candidate for the treatment of major depressive disorder (the &#8220;First Milestone&#8221;), a second tranche consisting of additional term loans in an aggregate principal amount of up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, available at the Company&#8217;s option beginning on the date that the First Milestone is achieved through the earlier of (A) </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">181</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> days following such date and (B) June 30, 2022; (iii) subject to the approval of the Company&#8217;s AXS-07 product candidate for the treatment of migraine (the &#8220;Second Milestone&#8221;), a third tranche consisting of additional term loans in an aggregate principal amount of up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, available at the Company&#8217;s option beginning on the date that the Second Milestone is achieved through the earlier of (A) </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">181</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> days following such date and (B) June 30, 2022; (iv) subject to the achievement of either the First Milestone or the Second Milestone and so long as the Company is in compliance with a required ratio of Lender indebtedness to net product revenue, a fourth tranche consisting of additional term loans in an aggregate principal amount of up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, available at the Company&#8217;s option beginning on January 1, 2022 and continuing through March 31, 2023; and (v) subject to approval by the Lenders&#8217; in their discretion, a fifth tranche of additional term loans in an aggregate principal amount of up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, available through December 31, 2023. The remaining $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million on the first tranche was not utilized and such tranche and future tranches were amended upon the execution of the First Amendment to the Loan and Security Agreement. See "First Amendment to the Loan and Security Agreement" below for further information. The Company intends to use the proceeds of the Term Loan Advances for working capital and general corporate purposes. In addition, approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">21.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of the proceeds from the First Advance was used to satisfy in full and retire the Company&#8217;s indebtedness under the 2019 Term Loan (as defined below), as amended.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The outstanding principal balance of the term loans bears interest at an annual rate equal to the greater of either (i) the prime rate as reported in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">plus </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">5.90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% or (ii) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">9.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">%, subject to an ability by the Company, during certain periods (each, a &#8220;PIK Deferral Period&#8221;), to request a reduction of the then-effective cash-pay interest rate by up to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% per annum (the &#8220;Cash Interest Reduction Amount&#8221;). Accrued interest is payable monthly following the funding of each term loan. During each PIK Deferral Period, the term loans will bear cash-pay interest, at the reduced amount, and will accrue paid-in-kind interest at a rate equal to the Cash Interest Reduction Amount multiplied by </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, which amount will be capitalized and added to the outstanding principal balance of the term loans on each monthly interest payment date during the PIK Deferral Period.&#8204;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to repay the term loans in equal installments of principal and interest commencing on May 1, 2023 through October 1, 2025 (the &#8220;Maturity Date&#8221;). However, if either the First Milestone or the Second Milestone are achieved prior to May 1, 2023, and no default exists, the amortization commencement date will be automatically extended to November 1, 2023; if both the First Milestone and the Second Milestone are achieved prior to November 1, 2023, and no default exists, the amortization commencement date will be further automatically extended to May 1, 2024 and if any term loans are funded under the fourth tranche noted above prior to May 1, 2024, and no default exists, the amortization commencement date will be further automatically extended to November 1, 2024. On the Maturity Date, all unpaid term loans will be due and payable.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">As collateral for the obligations, the Company has granted to Hercules a senior security interest in all of Company&#8217;s right, title, and interest in, to and under all of Company&#8217;s property, inclusive of intellectual property, which includes one of the Company&#8217;s existing license agreements (the &#8220;License Agreement&#8221;) with Antecip Bioventures II LLC (&#8220;Antecip&#8221;), an entity owned by Axsome&#8217;s Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., subject to limited exceptions</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> Antecip consented to the collateral assignment of the License Agreement, among other things, under a direct agreement (the &#8220;Direct Agreement&#8221;) with the Company and Hercules.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement contains customary representations, warranties and covenants, including covenants by the Company limiting additional indebtedness, liens (including a negative pledge on intellectual property and other assets), guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates and fundamental changes. At the initial closing, there were no applicable financial covenants contained in the Loan Agreement. Only after additional amounts are drawn down by the Company in the future, if the Company decides to do so, under the terms set forth in the Loan Agreement, there will be certain limited financial covenants that will apply, including:</span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Effective upon the date the outstanding principal amount of the advances under the Loan Agreement equals or exceeds $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">55.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, which has not yet occurred, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest, in an aggregate amount greater than or equal to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, plus the amount of the Company&#8217;s accounts payable under U.S. GAAP not paid after the </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">180</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">th day following the invoice for such account payable (such amount, the &#8220;Qualified Cash A/P Amount&#8221;).</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Effective upon the later of (i) the last calendar month of the calendar quarter that is twelve months following the earlier of (x) the date that the First Milestone is achieved and (y) the date that the Second Milestone is achieved, or (ii) the date on which the outstanding principal amount of the term loan advances under the Loan Agreement is equal to or greater than $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">65.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, neither of which have occurred yet, the Company is required to (A) ensure that at all times its market capitalization exceeds $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> billion, and that it maintains cash in an account which Hercules has a first priority security interest in an amount not less than </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the sum of the outstanding principal amount of the term loan advances </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> the Qualified Cash A/P Amount, (B) ensure that at all times that it maintains cash in an account which Hercules has a first priority security interest in an amount not less than </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the sum of the outstanding principal amount of the term loan advances </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">plus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> the Qualified Cash A/P Amount, or (C) achieve at least </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the net product revenue per the board of directors approved forecast solely from the sale of AXS-05 and AXS-07 (which may include royalty, profit sharing, or sales-based milestone revenue recognized in accordance with GAAP, but will not include any upfront or non-sales-based milestone payments under business development or licensing transactions), measured on a trailing six-month basis as of the date of the Company&#8217;s most recent quarterly financial statement, determined on a quarterly basis.</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on the Company&#8217;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions.</span></div></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s obligations under the Loan Agreement are subject to acceleration upon the occurrence of specified events of default, including payment default, insolvency and a material adverse change in the Borrower&#8217;s business, operations or financial or other condition.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company is required to pay a final payment fee equal to the greater of (A) $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2,910,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and (B) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4.85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate amount of all term loan advances minus the aggregate amount of repayments made. The final payment fee is being accreted and amortized into interest expense using the effective interest rate method over the term of the loan.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company may, at its option prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs prior to the first anniversary of the Closing Date, (ii) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs on or after the first anniversary and prior to the second anniversary of the Closing Date, and (iii) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs on or after the second anniversary and prior to the third anniversary of the Closing Date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">First Amendment to the Loan Agreement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On October 14, 2021 ("First Amendment Closing Date"), the Company entered into the first amendment to the Loan Agreement (the &#8220;First Amendment to the Loan Agreement&#8221;).</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the First Amendment to the Loan Agreement, the First Amendment amended the terms of that certain Loan and Security Agreement, dated as of September 25, 2020, by and among the Company, Hercules and the Lenders (the &#8220;Loan Agreement&#8221;) to, among other things, (i) increase the aggregate principal amount of the loan, available at the Company&#8217;s option, from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">225,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">300,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, (ii) change the draw amounts and dates available in Tranche 2 through Tranche 5 including increasing the amount available under Tranche 2 subject to FDA approval of the Company&#8217;s AXS-05 product candidate for the treatment of major depressive disorder from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">35,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">100,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, maintaining the amount available under Tranche 3 subject to FDA approval of the Company&#8217;s AXS-07 product candidate for the acute treatment of migraine of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">20,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, reducing the amount under Tranche 4 available upon achievement of certain combined sales and outstanding debt criteria from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">60,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">55,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, and increasing the amount available under Tranche 5 to support future strategic initiatives, including further pipeline advancement or expansion from $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">50,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">75,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> subject to the approval from Hercules, (iii) extend the maturity date of the facility from the original </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">October 2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">October 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, and optionally to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">October 2027</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, subject to certain conditions, (iv) reset and extend the interest only period from the initial </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">30 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> from the original loan closing to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">48 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> from the First Amendment and extendable up to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">60 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> subject to FDA approval of the Company&#8217;s AXS-05 product candidate for the treatment of major depressive disorder and subject to FDA approval of AXS-07 in the acute treatment of migraine, and (v) decrease the interest rate from </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">9.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% (floating rate based on the greater of (a) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">9.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% or (b) US WSJ Prime + </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">5.90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">%) to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">8.95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% (floating rate based on the greater of (a) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">8.95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% or (b) US WSJ Prime + </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">5.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">%).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company is required to pay a final payment fee equal to (A) $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2,910,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> plus (B) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate amount of all term future loan advances. The final payment fee is being accreted and amortized into interest expense using the effective interest rate method over the term of the loan.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company may, at its option prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs prior to the first anniversary of the First Amendment Closing Date, (ii) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs on or after the first anniversary and prior to the second anniversary of the First Amendment Closing Date, and (iii) </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount prepaid if the prepayment occurs on or after the second anniversary and prior to the third anniversary of the First Amendment Closing Date. These percentages are unchanged from the Loan Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Second Amendment to the Loan Agreement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On March 27, 2022, the Company entered into the Second Amendment to the Loan Agreement subject to the closing of the Sunosi&#174; Acquisition. See</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Note 1 - Nature of Business and Basis of Presentation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">for more detail.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loan Interest Expense and Amortization</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company incurred interest expense of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,123,958</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,143,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively. In addition, amortization of the final payment fee was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">97,860</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">143,589</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Amortization of the debt discount in relation to warrants and debt issuance costs was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">125,497</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">132,508</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2021, respectively.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The outstanding debt and unamortized debt discount balances are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.074%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.076%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.076%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total Outstanding Debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Add: accreted liability of final payment fee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">804,053</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">706,407</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less: unamortized debt discount, long-term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,491,388</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,616,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less: current portion of long-term debt</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loan payable, long-term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">49,312,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">49,089,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the entry into the Hercules Term Loan, the Company issued to Hercules a warrant to purchase a number of shares of the Company&#8217;s common stock equal to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate amount of the Term Loan Advances that are funded. Further information on warrants issued related to this loan and prior debt financings and amendments are disclosed in Note 7 - Stockholders&#8217; Equity under the &#8220;Warrants&#8221; section.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Scheduled Principal Payments on Outstanding Debt, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022, are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.137%;"/>
        <td style="width:1.814%;"/>
        <td style="width:1.376%;"/>
        <td style="width:15.714%;"/>
        <td style="width:0.96%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8,026,818</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">41,973,182</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total principal payments outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50,000,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company was in compliance with all covenants and requirements of its financing arrangements as of and during the three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855739441160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 5. Net Loss per Common Share</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per common share:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.056%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.085%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.085%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per common share:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">39,632,311</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29,259,970</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted average common shares outstanding&#8212;basic<br/>&#160;&#160;&#160;and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">38,323,167</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">37,429,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss per common share&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.03</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.78</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive securities outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.927%;"/>
        <td style="width:1.627%;"/>
        <td style="width:1.006%;"/>
        <td style="width:12.897%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.627%;"/>
        <td style="width:1.006%;"/>
        <td style="width:12.897%;"/>
        <td style="width:1.006%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,219,030</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,385,598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">667,366</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">303,983</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,541</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,541</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,901,937</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,705,122</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855739342968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 6. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Operating Leases</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021, the Company had the following operating lease expense:</span></p><p style="text-indent:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.459%;"/>
        <td style="width:1.692%;"/>
        <td style="width:30.534%;"/>
        <td style="width:1.692%;"/>
        <td style="width:1.371%;"/>
        <td style="width:14.052%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.692%;"/>
        <td style="width:1.371%;"/>
        <td style="width:14.052%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.692%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Statement of Operations Location</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">290,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">286,923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">290,769</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">286,923</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments of the Company&#8217;s operating leases as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022 were as follows:</span></p><p style="text-indent:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.809%;"/>
        <td style="width:1.934%;"/>
        <td style="width:1.371%;"/>
        <td style="width:15.972%;"/>
        <td style="width:0.914%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">885,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">105,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">990,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22,752</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">967,248</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In January 2022, the Company entered into an agreement to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">extend</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> the lease of 22 Cortlandt Street for a term of</span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> six months</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> from August 1, 2022 through January 31, 2023.</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> As of  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the remaining lease term for our operating lease was </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0.8</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> years with a discount rate of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">6.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">%. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855739433480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 7. Stockholders&#8217; Equity</span></p><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Capital Structure</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the Company entered into the December 2019 Sales Agreement with SVB Leerink, pursuant to which the Company may sell up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company&#8217;s common stock from time to time through SVB Leerink, acting as the Company&#8217;s sales agent, in one or more at-the-market offerings utilizing the 2019 Shelf Registration Statement. SVB Leerink is entitled to receive a commission of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds for any shares sold under the December 2019 Sales Agreement. The December 2019 Sales Agreement was replaced by the March 2022 Sales Agreement (see below).</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, the Company entered into the March 2022 Sales Agreement with SVB Leerink, pursuant to which the Company may sell up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">200</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company&#8217;s common stock from time to time through SVB Leerink, acting as the Company&#8217;s sales agent, in one or more at-the-market offerings utilizing the 2019 Shelf Registration Statement. SVB Leerink is entitled to receive a commission of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds for any shares sold under the March 2022 Sales Agreement. The March 2022 Sales Agreement supersedes the December 2019 Sales Agreement, dated December 5, 2019, by and between the Company and SVB Leerink LLC.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the December 2019 Sales Agreement and March 2022 Sales Agreement, for the three months ended March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company received approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">32.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in gross proceeds through the sale of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1,044,081</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> shares, of which net proceeds were approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">31.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The holders of shares of common stock are entitled to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. The holders of shares of common stock are entitled to receive dividends, if and when declared by the board of directors.</span></p><p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Shelf Registration Statement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">On December 5, 2019, the Company filed an automatic shelf registration statement (&#8220;2019 Shelf Registration&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) for the issuance of common stock, preferred stock, warrants, rights, debt securities and units. It became effective upon filing with the SEC and is currently the Company&#8217;s only active shelf registration. Through the date of this report, the Company has issued common stock of approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">261.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million pursuant to such shelf registration statement.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under SEC rules, the 2019 Shelf Registration Statement allows for the potential future offer and sale by the Company, from time to time, in one or more public offerings, of an indeterminate amount of the Company&#8217;s common stock, preferred stock, debt securities, and units at indeterminate prices. At the time any of the securities covered by the 2019 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">2,187,058</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> shares available for the issuance of stock options or stock-based awards under the Company&#8217;s 2015 Omnibus Incentive Compensation Plan at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock Options</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the stock option activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.963%;"/>
        <td style="width:1.049%;"/>
        <td style="width:0.835%;"/>
        <td style="width:9.037%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.381%;"/>
        <td style="width:9.016%;"/>
        <td style="width:0.846%;"/>
        <td style="width:1.049%;"/>
        <td style="width:0.857%;"/>
        <td style="width:9.027%;"/>
        <td style="width:0.846%;"/>
        <td style="width:1.049%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.868%;"/>
        <td style="width:0.846%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;Number<br/>of shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;Weighted<br/>average<br/>exercise price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted<br/>average<br/>contractual<br/>term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;Aggregate<br/>intrinsic<br/>value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,090,377</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">28.89</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,223,019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30.05</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,015</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10.08</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">67,139</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">43.83</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9,212</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">53.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,219,030</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">28.98</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">106,188,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Vested and expected to vest at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,219,030</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">28.98</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">106,188,389</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exercisable at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,932,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15.85</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5.7</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">82,434,018</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method as described in the SEC&#8217;s Staff Accounting Bulletin No. 107 relating to stock-based compensation. The simplified method was chosen because the Company has limited historical option exercise experience due to its short operating history. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for a period approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. Expected volatility is based on historical volatilities of similar entities within the Company&#8217;s industry which were commensurate with the Company&#8217;s expected term assumption.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The weighted average grant date fair value of options granted was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">21.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> per option for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022. As of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, there was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">91.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million of total unrecognized compensation cost related to non-vested stock options which is expected to be recognized over a weighted average period of </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> years. These amounts do not include </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">6,169</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> options outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022, which are performance-based and vest upon the achievement of certain corporate milestones. Stock&#8209;based compensation will be measured and recorded if and when it is probable that the milestone will occur.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In 2020, the Company began granting RSUs covering an equal number of its shares of common stock to employees. The fair value of RSUs is determined on the date of the grant based on the market price of its shares of common stock as of that date. The fair value of the RSUs is recognized as an expense ratably over the vesting period of </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, total compensation cost not yet recognized related to unvested RSUs was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">19.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the RSU activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"/>
        <td style="width:1.595%;"/>
        <td style="width:0.985%;"/>
        <td style="width:12.857%;"/>
        <td style="width:0.985%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.857%;"/>
        <td style="width:0.985%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Number<br/>of shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted<br/>average<br/>grant date<br/>fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">302,764</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">429,902</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">23.27</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">41.49</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,719</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">48.73</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">667,366</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021 was allocated as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.149%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.243%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.243%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,809,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,534,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,788,852</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,196,702</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7,598,329</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,731,097</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes warrant activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"/>
        <td style="width:1.595%;"/>
        <td style="width:0.985%;"/>
        <td style="width:12.857%;"/>
        <td style="width:0.985%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.857%;"/>
        <td style="width:0.985%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">exercise price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,541</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">80.43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,541</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">80.43</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Outstanding Warrants</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the first advance of the 2020 Term Loan, Hercules Capital Inc. received warrants to purchase an aggregate </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">15,541</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock at an exercise price of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">80.43</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> per share, which was the volume weighted average price of the Company&#8217;s common stock over the </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ten</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">-day trading period immediately preceding the initial closing, subject to certain limited adjustments as specified in the warrant. The warrants are exercisable for </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">seven years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> from the date of issuance. The warrants were classified as a component of stockholders&#8217; equity. The relative fair value of the warrants of approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the debt. The discount on the debt is being amortized to interest expense over the term of the debt utilizing the effective interest rate method.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855739446120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LicenseAgreementsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Note 8. License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive License Agreement with Pfizer</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In January 2020, the Company entered into an exclusive license agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) for Pfizer&#8217;s clinical and nonclinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which the Company is developing for the treatment of narcolepsy. The agreement also provides the Company exclusive rights to develop and commercialize esreboxetine, a new late-stage product candidate referred to as AXS-14, in the U.S. for the treatment of fibromyalgia.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the agreement, Pfizer received </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">82,019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock having a stated value of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, based on the average closing price of the Company&#8217;s common stock for the </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_94398959-42ea-49ba-9af0-943b9d4f9861;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ten</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> prior trading days of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">97.54</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, in consideration for the license and rights and also received an upfront cash payment of $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company determined that the fair value of each share of common stock granted to Pfizer on the closing date of January 9, 2020 was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">87.24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, based on the closing price of the Company&#8217;s stock on that date. As a result, the fair value of the stock issued was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">7.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million and therefore, the total research and development expense recognized was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">10.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million related to the Pfizer license agreement during the year ended 2020.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Pfizer can also receive up to $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">323</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million in regulatory and sales milestones, and tiered mid-single to low double-digit royalties on future sales related to the licensed products. Pfizer will also have a right of first negotiation on any potential future strategic transactions involving AXS-12 and AXS-14. During the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> milestone payments or royalties were paid to Pfizer by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive License Agreements with Antecip</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In 2012, the Company entered into </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> exclusive license agreements with Antecip, in which it was granted exclusive licenses to develop, manufacture, and commercialize Antecip&#8217;s patents and applications related to the development of AXS-02, AXS-05, and AXS-04, anywhere in the world for human therapeutic, veterinary, and diagnostic use. Pursuant to the agreements, the Company is required to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize AXS-02, AXS-05, and AXS-04. Under the terms of the agreements, the Company is required to pay to Antecip a royalty equal to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% for AXS-02, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% for AXS-05, and </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% for AXS-04, of net sales of products containing the licensed technology by the Company, its affiliates, or permitted sublicensees. These royalty payments are subject to reduction by an amount up to </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% of any required payments to third parties. Unless earlier terminated by a party for cause or by the Company for convenience, the agreements shall remain in effect on a product-by-product and country-by-country basis until the later to occur of (i) the applicable product is no longer covered by a valid claim in that country or (ii) </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> from the first commercial sale of the applicable product in that country. Upon expiration of the agreements with respect to a product in a country, the Company&#8217;s license grant for that product in that country will become a fully paid-up, royalty-free, perpetual non-exclusive license. If Antecip terminates any of the agreements for cause, or if the Company exercises its right to terminate any of the agreements for convenience, the rights granted to the Company under such terminated agreement will revert to Antecip. To date, the Company has not been required to make any payments to Antecip under any of the license agreements.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the 2020 Term Loan, the Company entered into a Direct Agreement with Antecip pursuant to which Antecip consented to the collateral assignment of the License Agreement to Hercules, among other things.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_LicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_LicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855744246536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock', window );">Significant Risks And Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Significant Risks and Uncertainties</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company&#8217;s product candidates; the Company&#8217;s ability to obtain regulatory approval to market its products, if approved; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company&#8217;s products, if approved; the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, if approved; and the Company&#8217;s ability to raise additional financing. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve and maintain profitability.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock&#8209;based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; and the recoverability of the Company&#8217;s net deferred tax assets and related valuation allowance.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency Translation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Expenses denominated in foreign currency are translated into U.S. dollars at the exchange rate on the date the expense is incurred. Assets and liabilities of foreign operations are translated at period-end exchange rates. The effect of exchange rate fluctuations on translating foreign currency into U.S. dollars is included in the Statements of Operations and is not material to the Company&#8217;s financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Segment and Geographic Information</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> operating segment, which is the business of developing novel therapies for the management of CNS disorders.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Cash Equivalents</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company&#8217;s cash and cash equivalents includes holdings in checking and overnight sweep accounts. The Company&#8217;s cash equivalents, which are money market funds held in a sweep account, are measured at fair value on a recurring basis. As of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the balance of cash and cash equivalents was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">84.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> million, which approximates fair value and was determined based upon Level 1 inputs. The sweep account is valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level 1.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the majority of the Company&#8217;s cash was held by </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three&#8209;level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Inputs that are unobservable for the asset or liability.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments are cash, accounts payable, accrued liabilities, and current and long-term debt. The carrying values for cash, accounts payable and accrued liabilities reported in the accompanying consolidated financial statements approximate their respective fair values due to their short-term maturities. The carrying value of debt on the Company&#8217;s balance sheet (see Note 6 &#8211; Loan and Security Agreement), is estimated to approximate its fair value as the interest rate approximates the market rate for loans with similar terms and risk characteristics.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Debt Issuance Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs consist of costs incurred in obtaining long-term financing. These costs are classified on the consolidated balance sheet as a direct deduction from the carrying amount of the related debt liability. These expenses are deferred and amortized as part of interest expense in the consolidated statement of operations using the effective interest rate method over the term of the debt agreement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Equipment</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Equipment consists primarily of computer equipment and is recorded at cost. Equipment is depreciated on a straight&#8209;line basis over its estimated useful life, which the Company estimates to be </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is included in operating expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related expenses including salaries, benefits, travel, and stock&#8209;based compensation expense, contract services, costs incurred to third-party service providers for the conduct of research, preclinical and clinical studies, laboratory supplies, product license fees, consulting and other related expenses. We estimate research, preclinical and clinical study expenses based on services performed, pursuant to contracts with third-party research and development organizations that conduct and manage research, preclinical and clinical activities on our behalf. We estimate these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments associated with licensing agreements to acquire licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternative future use are expensed as incurred. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates an annual effective tax rate of </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">% for the year ending </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> and has </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">t recorded an income tax benefit for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021 since it determined that a full valuation allowance is required against the Company&#8217;s deferred tax assets.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position as well as consideration of the available facts and circumstances. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. As of March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company does not believe any material uncertain tax positions are present. In the event the Company determines that accrual of interest or penalties are necessary in the future, the amount will be presented as a component of income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For stock options issued, the Company estimates the grant date fair value of each option using the Black&#8209;Scholes option pricing model. The Black-Scholes model takes into account the expected volatility of the Company&#8217;s common stock, the risk-free interest rate, the estimated life of the option, the closing market price of the Company&#8217;s common stock and the exercise price. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management&#8217;s judgment. In addition, the Company recognizes expense for equity award forfeitures as they occur.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For restricted stock units (&#8220;RSUs&#8221;), the Company issues them in the form of Company common stock. The fair market value of these awards is based on the market closing price per share on the grant date.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense using the accelerated attribution method when it is probable that the performance condition will be achieved. The expense related to the stock-based compensation is recorded within the same financial statement line item as the grantee&#8217;s cash compensation.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s policy upon exercise of stock options and RSUs is that shares will be issued as new shares drawing on the Company&#8217;s 2015 Omnibus Incentive Compensation Plan share pool that was adopted by the stockholders in November 2015.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Basic and Diluted Net Loss per Common Share</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options, and RSUs, which would result in the issuance of incremental shares of common stock. As the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted net loss per share of common stock for the three months ended March 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company&#8217;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. When evaluating whether a contract contains a lease, the Company considers whether (1) the contract explicitly or implicitly identifies assets that are contractually defined and (2) the Company obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s lease agreement contains lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. The Company has applied the practical expedient to combine fixed payments for non-lease components with lease payments and account for them together as a single lease component, which increases the amount of lease assets and corresponding liabilities. Payments under the Company&#8217;s lease arrangement are primarily fixed, however variable payments, are expensed as incurred and not included in the operating lease asset and liability.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses the implicit interest rate when readily determinable and uses the Company&#8217;s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s operating leases are reflected in the right-of-use operating asset; operating lease liability, current portion; and operating lease liability, long-term portion in the Company&#8217;s consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, and do not include an option to extend the term or purchase the underlying asset that the Company is reasonably certain to exercise, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">In October 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-08, Business Combinations (Topic 805) . This update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 606. This differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The amendments in this update should be applied prospectively, and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for significant risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855739411032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022 and December 31, 2021 accrued expenses and other current liabilities consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.688%;"/>
        <td style="width:1.531%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.807%;"/>
        <td style="width:0.91%;"/>
        <td style="width:1.553%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.817%;"/>
        <td style="width:0.932%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,726,847</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,416,897</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,013,040</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,050,236</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued general and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,856,779</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,442,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued Interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">390,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">385,347</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10,987,222</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9,295,180</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855738693560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Outstanding Debt and Unamortized Debt Discount Balances</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The outstanding debt and unamortized debt discount balances are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.074%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.076%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.076%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,<br/>2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total Outstanding Debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Add: accreted liability of final payment fee</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">804,053</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">706,407</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less: unamortized debt discount, long-term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,491,388</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,616,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less: current portion of long-term debt</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loan payable, long-term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">49,312,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">49,089,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Principal Payments</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Scheduled Principal Payments on Outstanding Debt, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022, are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.137%;"/>
        <td style="width:1.814%;"/>
        <td style="width:1.376%;"/>
        <td style="width:15.714%;"/>
        <td style="width:0.96%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8,026,818</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">41,973,182</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total principal payments outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50,000,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855743640024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss per Common Share</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per common share:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.056%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.085%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.085%;"/>
        <td style="width:0.921%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per common share:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">39,632,311</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29,259,970</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted average common shares outstanding&#8212;basic<br/>&#160;&#160;&#160;and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">38,323,167</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">37,429,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss per common share&#8212;basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.03</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.78</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive securities outstanding at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.927%;"/>
        <td style="width:1.627%;"/>
        <td style="width:1.006%;"/>
        <td style="width:12.897%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.627%;"/>
        <td style="width:1.006%;"/>
        <td style="width:12.897%;"/>
        <td style="width:1.006%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,219,030</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,385,598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">667,366</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">303,983</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,541</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,541</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,901,937</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,705,122</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855739337880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Expense</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">For the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021, the Company had the following operating lease expense:</span></p><p style="text-indent:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:30.459%;"/>
        <td style="width:1.692%;"/>
        <td style="width:30.534%;"/>
        <td style="width:1.692%;"/>
        <td style="width:1.371%;"/>
        <td style="width:14.052%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.692%;"/>
        <td style="width:1.371%;"/>
        <td style="width:14.052%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.692%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Statement of Operations Location</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">290,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">286,923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating lease expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">290,769</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">286,923</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments of Operating Leases</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments of the Company&#8217;s operating leases as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2022 were as follows:</span></p><p style="text-indent:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.809%;"/>
        <td style="width:1.934%;"/>
        <td style="width:1.371%;"/>
        <td style="width:15.972%;"/>
        <td style="width:0.914%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">885,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">105,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">990,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22,752</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">967,248</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855744353960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the stock option activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.963%;"/>
        <td style="width:1.049%;"/>
        <td style="width:0.835%;"/>
        <td style="width:9.037%;"/>
        <td style="width:0.921%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.381%;"/>
        <td style="width:9.016%;"/>
        <td style="width:0.846%;"/>
        <td style="width:1.049%;"/>
        <td style="width:0.857%;"/>
        <td style="width:9.027%;"/>
        <td style="width:0.846%;"/>
        <td style="width:1.049%;"/>
        <td style="width:1.381%;"/>
        <td style="width:10.868%;"/>
        <td style="width:0.846%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;Number<br/>of shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;Weighted<br/>average<br/>exercise price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted<br/>average<br/>contractual<br/>term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;Aggregate<br/>intrinsic<br/>value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,090,377</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">28.89</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,223,019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30.05</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,015</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10.08</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">67,139</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">43.83</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Expired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9,212</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">53.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,219,030</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">28.98</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">106,188,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Vested and expected to vest at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,219,030</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">28.98</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">106,188,389</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exercisable at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,932,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15.85</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5.7</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">82,434,018</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the RSU activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"/>
        <td style="width:1.595%;"/>
        <td style="width:0.985%;"/>
        <td style="width:12.857%;"/>
        <td style="width:0.985%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.857%;"/>
        <td style="width:0.985%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Number<br/>of shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted<br/>average<br/>grant date<br/>fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">302,764</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">429,902</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">23.27</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">61,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">41.49</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,719</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">48.73</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at March 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">667,366</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30.36</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense Recognized</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022 and 2021 was allocated as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.149%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.243%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.243%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#8203;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,809,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,534,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,788,852</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,196,702</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7,598,329</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,731,097</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes warrant activity for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">three months ended March 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.759%;"/>
        <td style="width:1.595%;"/>
        <td style="width:0.985%;"/>
        <td style="width:12.857%;"/>
        <td style="width:0.985%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.381%;"/>
        <td style="width:12.857%;"/>
        <td style="width:0.985%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">exercise price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,541</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">80.43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Outstanding at March 31, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,541</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">80.43</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855734530856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 25, 2022 </div>
<div>USD ($) </div>
<div>Market</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>Product</div>
</th>
<th class="th">
<div>Mar. 27, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 14, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_NumberOfLateStageProductCandidates', window );">Number of late-stage candidates in Company's product candidate portfolio | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 448,831,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,199,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate', window );">Share price not less than three day volume weighted average share price discount rate | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_UnregisteredCommonStockValue', window );">Unregistered common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_UnregisteredCommonStockValue', window );">Unregistered common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=axsm_TermLoanMember', window );">Term Loan | Hercules Capital Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheOneMember', window );">Term loan 2020 tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheOneMember', window );">Term loan 2020 tranche one | Second Amendment To Loan and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TrancheTwoSubTrancheOneMember', window );">Tranche Two Sub-Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TrancheTwoSubTrancheTwoMember', window );">Tranche Two Sub-Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TrancheTwoSubTrancheThreeMember', window );">Tranche Two Sub-Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheThreeMember', window );">Term loan 2020 tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TrancheThreeSubTrancheOneMember', window );">Tranche Three Sub Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TrancheThreeSubTrancheTwoMember', window );">Tranche Three Sub Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFourMember', window );">Term loan 2020 tranche four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000.0<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFiveMember', window );">Term loan 2020 tranche five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=axsm_SunosiMember', window );">Sunosi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_RevenueMilestones', window );">Revenue milestones</a></td>
<td class="nump">165,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=axsm_JazzPharmaceuticalsPlcMember', window );">Jazz Pharmaceuticals Plc | Sunosi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 53,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_NumberOfAsianMarkets', window );">Number of Asian markets | Market</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_DevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_DevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_NumberOfAsianMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Asian markets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_NumberOfAsianMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_NumberOfLateStageProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of late-stage candidates included in the Company's product candidate portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_NumberOfLateStageProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_RevenueMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_RevenueMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price not less than three day volume weighted average share price discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_UnregisteredCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unregistered common stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_UnregisteredCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=axsm_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=axsm_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=axsm_HerculesCapitalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=axsm_HerculesCapitalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=axsm_SecondAmendmentToLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=axsm_SecondAmendmentToLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TrancheTwoSubTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TrancheTwoSubTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TrancheTwoSubTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TrancheTwoSubTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TrancheTwoSubTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TrancheTwoSubTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TrancheThreeSubTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TrancheThreeSubTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TrancheThreeSubTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TrancheThreeSubTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=axsm_SunosiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=axsm_SunosiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=axsm_JazzPharmaceuticalsPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=axsm_JazzPharmaceuticalsPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855738239688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>Institution </div>
<div>Segment</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment and Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentration of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_NumberOfFinancialInstitutionsHoldingDeposits', window );">Number of financial institutions that hold the Company's cash | Institution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_NumberOfFinancialInstitutionsHoldingDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of financial institutions holding the Company's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_NumberOfFinancialInstitutionsHoldingDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855734501464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 2,726,847<span></span>
</td>
<td class="nump">$ 2,416,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">2,013,040<span></span>
</td>
<td class="nump">4,050,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_AccruedGeneralAndAdministrativeCurrent', window );">Accrued general and administrative</a></td>
<td class="nump">5,856,779<span></span>
</td>
<td class="nump">2,442,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued Interest</a></td>
<td class="nump">390,556<span></span>
</td>
<td class="nump">385,347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 10,987,222<span></span>
</td>
<td class="nump">$ 9,295,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_AccruedGeneralAndAdministrativeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_AccruedGeneralAndAdministrativeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855733385896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreement - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 14, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,123,958<span></span>
</td>
<td class="nump">$ 1,143,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,860<span></span>
</td>
<td class="nump">143,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,143<span></span>
</td>
<td class="nump">276,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentAggregateAmountPercentage', window );">Percentage of aggregate amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,497<span></span>
</td>
<td class="nump">$ 132,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt', window );">First advance used to repay previous debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentsMaturityMonthAndYear', window );">Debt instrument maturity, month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentInterestPaymentPeriod', window );">Debt instrument, interest payment period</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Base interest rate</a></td>
<td class="nump">8.95%<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentThresholdCashPayInterestRate', window );">Cash pay interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentCashPayInterestMultiplier', window );">Cash pay interest multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_ExtinguishmentOfDebtFeeAmount', window );">Final payment fee</a></td>
<td class="nump">$ 2,910,000<span></span>
</td>
<td class="nump">$ 2,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding', window );">Percentage of final payment fee</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentsMaturityMonthAndYear', window );">Debt instrument maturity, month and year</a></td>
<td class="text">2026-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentsMaturityMonthAndYear', window );">Debt instrument maturity, month and year</a></td>
<td class="text">2027-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate basis</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Subject to FDA Approval of AXS-05 and AXS-07 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentInterestPaymentPeriod', window );">Debt instrument, interest payment period</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Prepayment Occurs Prior to First Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentPrepaymentPenaltyPercentage', window );">Percentage of prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Outstanding principle and advances under the loans agreement exceeds 55 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest', window );">Minimum cash to be maintain as a first priority security interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod', window );">Period of unpaid invoices amount maintain as security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Outstanding principle and advances under the loans agreement exceeds 55 million | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Outstanding principle and advances under the loans agreement exceeds 65 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount', window );">Minimum amount of market capital to be maintained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent', window );">Minimum percentage of cash to be maintained as a security following market capitalization condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent', window );">Minimum percentage of cash to be maintained as a security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Outstanding principle and advances under the loans agreement exceeds 65 million | AXS-05 and AXS-07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent', window );">Minimum product revenue percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Outstanding principle and advances under the loans agreement exceeds 65 million | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Prepayment Occurs on or After First Anniversary and Prior to Second Anniversary of the Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentPrepaymentPenaltyPercentage', window );">Percentage of prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Prepayment Occurs on or After Second Anniversary and Prior to Third Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentPrepaymentPenaltyPercentage', window );">Percentage of prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Prepayment Occurs Prior to First Anniversary of First Amendment Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentPrepaymentPenaltyPercentage', window );">Percentage of prepayment penalty</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Prepayment Occurs on or After First Anniversary and Prior to Second Anniversary of First Amendment Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentPrepaymentPenaltyPercentage', window );">Percentage of prepayment penalty</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member', window );">Term Loan 2020 | Prepayment Occurs on or After Second Anniversary and Prior to Third Anniversary of First Amendment Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentPrepaymentPenaltyPercentage', window );">Percentage of prepayment penalty</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheOneMember', window );">Term loan 2020 tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining credit facility to be drawn</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheTwoMember', window );">Term loan 2020 tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_ThresholdDaysToAchieveFirstMilestone', window );">Period to achieve first milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheThreeMember', window );">Term loan 2020 tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_ThresholdDaysToAchieveSecondMilestone', window );">Period to achieve second milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFourMember', window );">Term loan 2020 tranche four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="nump">55,000,000.0<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFiveMember', window );">Term loan 2020 tranche five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan amount</a></td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_DebtInstrumentAggregateAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate amount of loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_DebtInstrumentAggregateAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_DebtInstrumentCashPayInterestMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the multiplier used for the cash pay interest under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_DebtInstrumentCashPayInterestMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The final payment fee to be paid under the debt arrangement as a percentage of aggregate amount of all term loan advances minus the aggregate amount of repayments made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_DebtInstrumentInterestPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, interest payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_DebtInstrumentInterestPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_DebtInstrumentPrepaymentPenaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the prepayment penalty percentage on principal amount of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_DebtInstrumentPrepaymentPenaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_DebtInstrumentThresholdCashPayInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective cash pay interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_DebtInstrumentThresholdCashPayInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_DebtInstrumentsMaturityMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instruments maturity, month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_DebtInstrumentsMaturityMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_ExtinguishmentOfDebtFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The final payment fee at extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_ExtinguishmentOfDebtFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of unpaid invoices after threshold period respective amount should be keep as a security under the debt instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of cash should be maintained as first priority security interest under the terms of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of cash to be maintained under debt instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of cash to be maintained as security following the market capitalization conditions under the debt instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of market capital to be maintained under debt instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of revenue should be achieved under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from first advance used to repay previous debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_ThresholdDaysToAchieveFirstMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days to achieve first milestone following such date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_ThresholdDaysToAchieveFirstMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_ThresholdDaysToAchieveSecondMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days to achieve second milestone following such date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_ThresholdDaysToAchieveSecondMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=axsm_Axs05AndAxs07Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=axsm_Axs05AndAxs07Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855737334952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan and Security Agreement - Schedule of Outstanding Debt and Unamortized Debt Discount Balances (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total Outstanding Debt</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee', window );">Add: accreted liability of final payment fee</a></td>
<td class="nump">804,053<span></span>
</td>
<td class="nump">706,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent', window );">Less: unamortized debt discount, long-term</a></td>
<td class="num">(1,491,388)<span></span>
</td>
<td class="num">(1,616,885)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Loan payable, long-term</a></td>
<td class="nump">$ 49,312,665<span></span>
</td>
<td class="nump">$ 49,089,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accreted liability of final payment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855740348472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan and Security Agreement - Schedule of Principal Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">$ 8,026,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">41,973,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal payments outstanding</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855744198344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Computation of Basic and Diluted Net Loss per Common Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (39,632,311)<span></span>
</td>
<td class="num">$ (29,259,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">38,323,167<span></span>
</td>
<td class="nump">37,429,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted</a></td>
<td class="num">$ (1.03)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855738404392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Potentially Dilutive Securities Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">6,901,937<span></span>
</td>
<td class="nump">4,705,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">6,219,030<span></span>
</td>
<td class="nump">4,385,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">667,366<span></span>
</td>
<td class="nump">303,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">15,541<span></span>
</td>
<td class="nump">15,541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855744390600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Operating Lease Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total operating lease expense</a></td>
<td class="nump">$ 290,769<span></span>
</td>
<td class="nump">$ 286,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total operating lease expense</a></td>
<td class="nump">$ 290,769<span></span>
</td>
<td class="nump">$ 286,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855744386840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments of Operating Leases (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 885,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">990,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(22,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 967,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855733328104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lessee, operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In January 2022, the Company entered into an agreement to extend the lease of 22 Cortlandt Street for a term of six months from August 1, 2022 through January 31, 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, operating lease, existence of option to extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">extend the lease of 22 Cortlandt Street for a term of six months from August 1, 2022 through January 31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855735234088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 05, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_EquityInstrumentVotingRightsPerShare', window );">Common stock, voting right per share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to non-vested stock options expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected vesting period for non-vested share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.43<span></span>
</td>
<td class="nump">$ 80.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Term loan 2020 tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock to be issued if warrants are exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays', window );">Trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_ClassOfWarrantOrRightTerm', window );">Term of warrants (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_FairValueOfWarrants', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Compensation cost not yet recognized related to unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axsm_TwoThousandFifteenEquityCompensationPlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,187,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=axsm_TwoThousandNineteenShelfRegistrationMember', window );">2019 Shelf Registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="nump">$ 261,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=axsm_LeerinkPartnersLimitedLiabilityCompanyMember', window );">SVB Leerink | December 2019 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_CommonStockSalesAgreementCommissionPercentage', window );">Common stock sales agreement, commission percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=axsm_LeerinkPartnersLimitedLiabilityCompanyMember', window );">SVB Leerink | March 2022 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_CommonStockSalesAgreementCommissionPercentage', window );">Common stock sales agreement, commission percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=axsm_LeerinkPartnersLimitedLiabilityCompanyMember', window );">SVB Leerink | December 2019 and March 2022 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_StockIssuedDuringPeriodValueNewIssuesNet', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | SVB Leerink | December 2019 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_CommonStockSalesAgreementAuthorizedAmount', window );">Common stock sales agreement, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | SVB Leerink | March 2022 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_CommonStockSalesAgreementAuthorizedAmount', window );">Common stock sales agreement, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period during which warrants are active, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which the volume weighted average price of company's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_CommonStockSalesAgreementAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The authorized amount under a common stock sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_CommonStockSalesAgreementAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_CommonStockSalesAgreementCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The commission percentage paid under a common stock sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_CommonStockSalesAgreementCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_EquityInstrumentVotingRightsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes per share each holder of shares is entitled to.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_EquityInstrumentVotingRightsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of outstanding warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_StockIssuedDuringPeriodValueNewIssuesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_StockIssuedDuringPeriodValueNewIssuesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axsm_TermLoan2020TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axsm_TwoThousandFifteenEquityCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axsm_TwoThousandFifteenEquityCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=axsm_TwoThousandNineteenShelfRegistrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=axsm_TwoThousandNineteenShelfRegistrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=axsm_LeerinkPartnersLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=axsm_LeerinkPartnersLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=axsm_DecemberTwoThousandNineteenSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=axsm_DecemberTwoThousandNineteenSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=axsm_MarchTwoThousandTwentyTwoSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=axsm_MarchTwoThousandTwentyTwoSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855737365688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding, beginning balance | shares</a></td>
<td class="nump">5,090,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="nump">1,223,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised | shares</a></td>
<td class="num">(18,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited | shares</a></td>
<td class="num">(67,139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod', window );">Number of shares, Expired | shares</a></td>
<td class="num">(9,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding, ending balance | shares</a></td>
<td class="nump">6,219,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Vested and expected to vest | shares</a></td>
<td class="nump">6,219,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable | shares</a></td>
<td class="nump">2,932,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding, beginning balance | $ / shares</a></td>
<td class="nump">$ 28.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted | $ / shares</a></td>
<td class="nump">30.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised | $ / shares</a></td>
<td class="nump">10.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited | $ / shares</a></td>
<td class="nump">43.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired | $ / shares</a></td>
<td class="nump">53.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding, ending balance | $ / shares</a></td>
<td class="nump">28.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest | $ / shares</a></td>
<td class="nump">28.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable | $ / shares</a></td>
<td class="nump">$ 15.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average contractual term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term, Outstanding</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term, Vested and expected to vest</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual term, Exercisable</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding | $</a></td>
<td class="nump">$ 106,188,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest | $</a></td>
<td class="nump">106,188,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Exercisable | $</a></td>
<td class="nump">$ 82,434,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options expired in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855734439192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of RSU Activity (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding, beginning balance | shares</a></td>
<td class="nump">302,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted | shares</a></td>
<td class="nump">429,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested | shares</a></td>
<td class="num">(61,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited | shares</a></td>
<td class="num">(3,719)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding, ending balance | shares</a></td>
<td class="nump">667,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding, beginning balance | $ / shares</a></td>
<td class="nump">$ 42.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted | $ / shares</a></td>
<td class="nump">23.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Vested | $ / shares</a></td>
<td class="nump">41.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Forfeited | $ / shares</a></td>
<td class="nump">48.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding, ending balance | $ / shares</a></td>
<td class="nump">$ 30.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855738404248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock-Based Compensation Expense Recognized (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,598,329<span></span>
</td>
<td class="nump">$ 3,731,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,809,477<span></span>
</td>
<td class="nump">1,534,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,788,852<span></span>
</td>
<td class="nump">$ 2,196,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855734515240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding beginning balance | shares</a></td>
<td class="nump">15,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_WarrantsIssuedInPeriod', window );">Number of warrants issued | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_WarrantsExercisedInPeriod', window );">Number of warrants exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding ending balance | shares</a></td>
<td class="nump">15,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price, Beginning balance | $ / shares</a></td>
<td class="nump">$ 80.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice', window );">Issued (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price, Ending balance | $ / shares</a></td>
<td class="nump">$ 80.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_WarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_WarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrants were exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_WarrantsIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants (or share units) issued during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_WarrantsIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrants were issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139855735308280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>Item</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of common shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,883,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,816,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,585,141<span></span>
</td>
<td class="nump">$ 16,595,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Antecip</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_NumberOfLicenseAgreements', window );">Number of exclusive license agreements | Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties', window );">License agreement royalty, maximum reduction percent as a result of required third party payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LicenseAgreementTerm', window );">License agreement term, from first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Antecip | AXS-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales', window );">License agreement royalty as a percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Antecip | AXS-05</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales', window );">License agreement royalty as a percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Antecip | AXS-04</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales', window );">License agreement royalty as a percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=axsm_PfizerIncMember', window );">Pfizer Inc | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Number of common shares | shares</a></td>
<td class="nump">82,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of common stock</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_ConsecutiveTradingDays', window );">Prior trading days</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 97.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_InitialCashPaymentPerCollaborationAgreement', window );">Upfront cash payment</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_SharePriceFairValue', window );">Fair value share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_CommonStockFairValue', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_axsm_CollaborationArrangementFuturePotentialPayments', window );">Future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Milestone payments or royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_CollaborationArrangementFuturePotentialPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future payments payable under the collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_CollaborationArrangementFuturePotentialPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_CommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_CommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_ConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the consecutive number of trading days to determine the weighted average price per share of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_ConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_InitialCashPaymentPerCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Cash Payment Per Collaboration Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_InitialCashPaymentPerCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum reduction percentage of the royalty due as a result of required payments to third parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net sales of products containing the licensed products, due to licensor as a royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_LicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time, after the first commercial sale of the applicable product, the license agreement is valid, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_LicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of license agreements the Company has entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axsm_SharePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value price of a single share of a number of saleable stocks of a company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axsm_SharePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axsm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=axsm_Axs02Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=axsm_Axs02Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=axsm_Axs05Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=axsm_Axs05Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=axsm_Axs04Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=axsm_Axs04Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=axsm_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=axsm_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>axsm-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:axsm="http://axsome.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="axsm-20220331.xsd" xlink:type="simple"/>
    <context id="C_cc7591c2-a315-4ba0-8ba7-30d3937ab8ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d518ab07-50e1-4f22-8ead-a8eb4564ed95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_6854c542-e5e2-4d67-b182-044dbba449bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-14</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="C_fda19f6a-c507-42ec-b932-514114edee24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_2357bd34-be20-473a-9a97-21a5de4d2722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_43574450-92b4-4988-81e4-50b6b102e732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-14</instant>
        </period>
    </context>
    <context id="C_0d2b4eb6-939a-4140-adcf-dc65291830f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_8499400d-f664-4e71-b17e-d1301c2cb375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6c8df518-2cca-4db3-a63e-69a63815b2f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_fa561b4e-b6ea-4fd4-8d9a-70f77c8de67f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-14</instant>
        </period>
    </context>
    <context id="C_ae13ec89-1fa4-4e02-b9fc-58d4fca0deaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_8e3cc36d-423a-457f-931c-9109e9833261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_ee66dee5-84e1-46c5-b128-680ea4f73cbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_58506d7a-5c75-4b99-8279-0688e8c43429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_21a3ddfb-93a7-4cbb-82fd-5e3bc5f0961b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_a7171c32-68b1-44fb-bc72-6ca42e63f926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2dda7b7d-4eb5-4947-be5a-64886b352ff5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_133a145c-e960-4fc8-b6d5-388d2e167e6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_9f1dee24-d9e9-4cd0-809c-31fbba3bb1c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_df3f324f-9e88-4cd0-becb-e386dfb62dde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-14</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="C_044ac2dd-a43b-4bf0-a117-1190f9ff7f2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">axsm:LeerinkPartnersLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axsm:MarchTwoThousandTwentyTwoSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_a94eb90c-f0d3-4b2c-9a0c-9754a3a9a0a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_1f6dcc9c-a3d6-4cf1-8464-0d285bc4d9a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_80117ee7-80d8-4a57-96a2-e2ea5118fefe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_52720a6e-acc3-4746-a598-7a3115ffa670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_e6b4b679-0646-4f99-b733-4c1487965f80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_73c76e5f-6946-415b-ac4a-5f14307e04c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_525e81c7-d46e-4ea7-9684-74def5e30aac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_93fc45bb-69f6-4b6b-ba71-8a6735312525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:SunosiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">axsm:JazzPharmaceuticalsPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="C_bb885263-2c35-4cf7-8ae9-82fc64c0f7a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-14</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="C_d3c1be52-c032-4a53-856d-c71d3887807f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-14</instant>
        </period>
    </context>
    <context id="C_b4dbaf2a-a0d5-4d55-b135-ec0dd9346cc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_4c1d2970-ecdc-417a-8c38-beb830e327cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_d9bc5005-9c34-42dc-a103-770e8beb2d78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_ad457fe7-35cb-4f1c-adfe-9364d3096822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_b4a98684-d57a-4c5f-b5a6-c9b492ff4e17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_303637a5-8b91-4570-a728-6f97f2270ef4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">axsm:Axs05AndAxs07Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_b4195b45-d05d-44d6-967c-803d41a1847f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">axsm:LeerinkPartnersLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axsm:DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_3c83df33-9153-49e3-a55c-f2a68eb4045a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_3922af5a-d586-4a59-a748-dca027a9e1b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_7dd348d4-cefb-4639-92c0-78e13450f2b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_5d352228-7b5b-4785-b9bd-1cfc63c353da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">axsm:Axs02Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="C_8ec01d46-909a-44bc-befd-1d1a23e4ab9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_203ed062-9609-4a15-a548-eb77d8ad1188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_bf72b4a0-6c33-4db5-9316-0eaa208085c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c4afe19c-11d0-445b-b47f-99cea4fdcb9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="C_008bb3dd-4868-4984-8e42-390d9ffd5c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7fa0e148-2225-4c34-bcbe-ec944991768c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_78a1f202-d9b2-477b-b649-06874c29753a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheTwoSubTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-14</instant>
        </period>
    </context>
    <context id="C_56c3f743-f85c-4b20-9622-f711609bcf18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_e79659be-62a0-4d7f-8919-a6af22ec548f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_a8eda348-341b-4541-93f2-83c532439893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-14</instant>
        </period>
    </context>
    <context id="C_99cf65ea-42df-4c36-87cb-c410c3027f8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_cb2f9874-656b-41a0-87d5-d87935757fb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a5109b34-436f-4349-abc0-b0c0dca35cfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_46bc8e64-2627-43a1-9043-0b5495dccc01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-14</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="C_c6555893-bd98-4700-a5a7-8076bf2d8d0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_6dacb844-4b15-4c03-acb3-09a6b640217c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">axsm:SecondAmendmentToLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_bdddd48e-24d8-466b-85d6-b30c067ffe9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">axsm:LeerinkPartnersLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axsm:DecemberTwoThousandNineteenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_d123927e-7029-4dd1-878a-36b68f4a9e6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="C_c3170278-1391-4a56-9d86-0add7cd33446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_4b988683-b18d-41ce-bc31-605656e6a4f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_13dea1cb-aa1f-4a8f-94bb-ccbf522d6b7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_47fac860-11d6-4b0d-8e1c-85902d5c680c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-14</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="C_b2abbcf3-4402-4301-9f22-3638b33916cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_4616eca2-d061-41e6-b773-9b50623ea068">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_e07b08d9-2bba-42e4-bf1e-6aa9c55ce68c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">axsm:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">axsm:HerculesCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-25</instant>
        </period>
    </context>
    <context id="C_838ee7b0-8654-4765-abd6-662f63a4c8c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_e7fe0f8e-7fa9-4070-979d-a3234fed3fa1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-14</instant>
        </period>
    </context>
    <context id="C_3c22e247-ede4-4b63-a5a8-09b68eef26a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_b8689f73-8b90-434a-8cae-7e991d869064">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_75b98a95-0d49-477b-bc05-e21aa024dc87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_c4d05faf-ec2b-48f5-8a76-5f0bc4fe39a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_e5af5223-2fe5-4213-acad-7c31eefaf440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3f4ab0e3-713f-4c51-8c3a-4b2e440fc6c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
        </entity>
        <period>
            <instant>2022-04-26</instant>
        </period>
    </context>
    <context id="C_1882e4f2-eb93-4210-b724-5c9bb20bebf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_d91b4b62-4ebe-490a-a88e-6f69afcf5a05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_3c74abd6-a2c2-4c0f-9355-8d60eb862eb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheTwoSubTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-14</instant>
        </period>
    </context>
    <context id="C_234c04e9-be43-4c65-8294-bca64c8b14d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_2038d698-c757-4fc1-8d54-847b886c8572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_7beabbcc-8b62-4676-8c90-7970bd0c23b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">axsm:LeerinkPartnersLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axsm:DecemberTwoThousandNineteenSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_d9fad345-924e-408f-93e8-d534f64b717a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">axsm:Axs04Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="C_3c213636-da72-4c96-a325-3f0b156f4462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axsm:TwoThousandFifteenEquityCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_ed7f64ac-9d3d-4975-a4ad-4adbcbe2e765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_d49b89d1-f1b7-475f-9685-738cdbff9497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="C_aac9dd6a-0f39-4dca-9c62-e17e1926a68c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_39b63eb4-ca27-40bd-82f5-858e406e3701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheTwoSubTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_766126cd-3c63-4018-b6f6-3bc6d4b038fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheThreeSubTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_81597194-9eed-48c4-a703-a29a052262b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_70fafa52-2071-4fb1-b999-e133e767989d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">axsm:Axs05Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="C_27e2a477-b3de-4e25-a8a8-015812de985a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-14</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="C_c6e03d77-74bc-438d-ac62-681542cd683c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_bb6e9275-c30c-46d5-9e05-d49f1beb2c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_bc41918b-50a0-4e0c-ae3a-cc2fea3bfbfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_87baa8d3-aef8-4d44-b758-b03bb30059dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_965ed3a9-df64-4456-ade2-24619ff19b45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-14</instant>
        </period>
    </context>
    <context id="C_bd3b09d8-962f-4a8d-95b5-a2380be0bb5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="C_ebcc446a-08e2-4b02-a7fc-b6339311af4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">axsm:LeerinkPartnersLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">axsm:MarchTwoThousandTwentyTwoSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_21a8a9ca-0b07-4cdd-ac95-7ef4b8971c9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">axsm:DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-14</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="C_3d7b6b8c-7fba-4794-bad1-9528cd8b0a02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_839cd5d9-6625-4c96-98f0-b8b61c6a4475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_2d6af9b1-56a3-4f2a-b2f7-a25d457c6cbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheTwoSubTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_724babf7-6fd0-424b-9476-154cb4318da6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-14</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="C_6ba10b02-2ba9-41b3-b76d-552fff659baa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TermLoan2020TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_7ba32c09-ff41-4912-b05b-767b2f5e43d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_148374f5-3d5c-4b2e-ade2-fb6cd32a789e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_144b60f0-d4f4-4610-977c-bd99ba58cc09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_6a6da949-18b2-470e-9fe3-f0d2c926ef8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">axsm:SunosiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="C_9f1904ba-152a-46e9-9e57-e92380cbcce6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_caa50054-de64-4723-b525-0cfcc3b7185f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheTwoSubTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_a6291cbc-4212-426f-966c-f9d236bef96a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_e075509a-46d1-46e0-8bb0-6f2bbee2ca82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axsm:TrancheThreeSubTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-27</instant>
        </period>
    </context>
    <context id="C_41c6af09-fd7f-47cc-bdbe-fdeca00ab829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">axsm:TwoThousandNineteenShelfRegistrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-05</startDate>
            <endDate>2019-12-05</endDate>
        </period>
    </context>
    <context id="C_b7fb4e8a-2ebf-48fc-8a1b-f5d6d9833933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001579428</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_Product">
        <measure>axsm:Product</measure>
    </unit>
    <unit id="U_Segment">
        <measure>axsm:Segment</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Item">
        <measure>axsm:Item</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_D">
        <measure>utr:D</measure>
    </unit>
    <unit id="U_Institution">
        <measure>axsm:Institution</measure>
    </unit>
    <unit id="U_Market">
        <measure>axsm:Market</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Vote">
        <measure>axsm:Vote</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_532497aa-4ade-4d72-8db1-44a2373f74cb">0001579428</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_3564befc-c2f1-49a8-b9cb-3fe71364b65b">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_50964fc1-b913-49d5-9e79-a77051394e37">false</dei:AmendmentFlag>
    <axsm:ConsecutiveTradingDays
      contextRef="C_d123927e-7029-4dd1-878a-36b68f4a9e6e"
      id="F_94398959-42ea-49ba-9af0-943b9d4f9861">P10D</axsm:ConsecutiveTradingDays>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_f4629aff-5441-4573-b028-ad83f8f53b51">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_0d64b852-52d9-4fc6-81b2-f4db7e5c398b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_579615d3-9f61-4c33-b0dc-c1daf4f1e6ff">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_b4a061a5-f298-4362-836f-86c63821d957">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_e6d284a3-fd66-446a-b67f-85712c7a67fc">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_d7290102-7876-46fb-92ac-39332cd2d110">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_28cb7ceb-0db7-4c33-baa0-f95acd0353cd">001-37635</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_92c27eab-1d3c-4034-998b-f7776ac4aed4">AXSOME THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_369ebb12-42e2-4f7e-b51d-78dd42bf6020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_37788250-8c36-4a43-b2ab-4f02f1d2c2fd">45-4241907</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_7755d9e2-5e27-4dc6-b4e2-a0fba9d9f5b1">22 Cortlandt Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_17b8897e-785f-46f8-9964-560a7716ceb9">16th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_6fe6ba23-6990-46c2-8f39-e137d26ea236">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_13da5860-90d1-4865-bb43-7c867b9f0ff8">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_de6b4972-b3f4-4828-99ad-a93c1bf8fddb">10007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_809be6bb-6789-4572-9ce4-710e4e01fc0d">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_f06cf604-493e-470b-af83-55b517103dac">332-3241</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_5fedfe08-bee7-4eb8-9df3-24435820406e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_3bfdbe36-d5ac-4794-93b3-da8aafa16e59">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_0ddc8662-a01b-4a3a-bf55-49097d135a16">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_44e09ddb-9639-4593-8ea1-a52697daa49b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_fce7f4b5-f115-4fe6-a758-40bb7c6285da">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_cbc40848-28e1-4833-96cd-02ccb2b87ab5">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_fde2c811-e271-4d39-9f22-303da4b2abbf">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_a7ba5c7d-b15e-4794-b1c9-182a5ddb52c7">AXSM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_6cac6772-62ad-4e54-b618-3650835ed0ae">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_3f4ab0e3-713f-4c51-8c3a-4b2e440fc6c3"
      decimals="INF"
      id="F_b828ced4-b96a-4ee0-aee7-a7ed0eb0307d"
      unitRef="U_shares">38913550</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_d2b02986-1752-46d8-8dfc-d844f04b9266"
      unitRef="U_USD">84707782</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_5f8467d7-ca13-4cd7-a845-8b95880bff9a"
      unitRef="U_USD">86472854</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_653bc318-6f66-404c-aa79-4b19e3df9db3"
      unitRef="U_USD">2122144</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_da4b34cb-66ef-4feb-817f-88c566f1a33a"
      unitRef="U_USD">45286</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_32c49e73-c17d-43fb-a217-350d79c7f474"
      unitRef="U_USD">86829926</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_09757e7e-08d7-46cb-b59a-25c1c731c28e"
      unitRef="U_USD">86518140</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_02d2ecd5-28bd-473e-9dda-b8564bd1c238"
      unitRef="U_USD">460946</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_7eedf5fc-7d09-4cb7-b2a1-4703479dcfc1"
      unitRef="U_USD">283846</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_7622794d-3df6-48d9-a98e-baa39facaa10"
      unitRef="U_USD">946479</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_6ebac1f7-e2c8-4f0f-b5fb-975474b1127e"
      unitRef="U_USD">660162</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_7a5f5553-5fd2-4e95-9e61-37e7657116c0"
      unitRef="U_USD">322910</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_b9b27b81-c69a-4aac-a7b0-e3e53d8c4043"
      unitRef="U_USD">322910</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_2f010700-67e4-44ce-b5ab-22f5304bdd57"
      unitRef="U_USD">88560261</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_df0618ee-499a-415a-87bb-ce80aa7590d7"
      unitRef="U_USD">87785058</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_0ba99af9-1eec-43ab-a34b-e18a6853f007"
      unitRef="U_USD">12595112</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_cb3a77a0-6002-4032-bfdf-eac1e616f9c3"
      unitRef="U_USD">13149329</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_791c1c42-be33-4687-89bb-ce0d5bb3e732"
      unitRef="U_USD">10987222</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_b4051252-0333-4689-8396-86c30df9ccd9"
      unitRef="U_USD">9295180</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_267c01c6-5928-4241-9005-83a360671734"
      unitRef="U_USD">967248</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_1eeefb48-27a8-4f4f-90c7-5693f62c1564"
      unitRef="U_USD">620675</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_4e1ecf29-cafe-4662-b4e1-d3a86d1119ad"
      unitRef="U_USD">24549582</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_76df5e3c-8d68-4c22-ada7-165af8d30cbc"
      unitRef="U_USD">23065184</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_b46a49af-ab0b-4be3-83ce-497ad2a16437"
      unitRef="U_USD">49312665</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_e937a59a-7b9f-4e08-837b-548fa8aeba66"
      unitRef="U_USD">49089522</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_6be2ab6a-5dde-47d0-b7cc-6e1b4f2a5458"
      unitRef="U_USD">73862247</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_9c55a634-0241-46bc-a3f1-cb071fd2e927"
      unitRef="U_USD">72154706</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_12c1c503-a081-4041-ad16-5f3fd0bd7074"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="INF"
      id="F_3001dbab-516c-4c02-8583-da3c623e9ab3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_c7cbaf19-ad1b-44d8-b40e-3be7918667fa"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="INF"
      id="F_2549e8bf-5252-4b82-b05c-f8b46e3a8e0c"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_a0551316-e183-41f2-a3e3-aca940e4d854"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="INF"
      id="F_b5788e5d-d8a3-4c2b-b8c2-dc4d824f431b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_4768a764-a059-4d48-aadc-23fc623116d3"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="INF"
      id="F_b6a3ffae-610b-42a6-a6ec-2ddfa31eccbe"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_1f6def08-6324-47c1-8f03-a96077b94776"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="INF"
      id="F_14bb5fc4-018f-47dd-a0b4-5a708228ad88"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_3ed74f32-efa9-4ef3-92ee-bb7b1347e937"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="INF"
      id="F_a53be23b-df3a-48da-ab94-53c3d899b03e"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_e26f66bf-32c1-44ca-a551-018774797e80"
      unitRef="U_shares">38883445</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_f5410c3b-49b8-49ab-9a46-628005cde7ca"
      unitRef="U_shares">38883445</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="INF"
      id="F_89ed3514-82af-49cc-aec1-33d53ddd463e"
      unitRef="U_shares">37816794</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="INF"
      id="F_ba16560b-8d61-4517-a237-b813057eaf03"
      unitRef="U_shares">37816794</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_686c62d1-bcd0-44ce-8b23-a2d5aee4e414"
      unitRef="U_USD">3888</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_b256abab-87ff-465e-a941-42527c413318"
      unitRef="U_USD">3782</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_9a291dad-4d1d-4a19-a0f3-a2a7db9b2e7e"
      unitRef="U_USD">463525522</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_18b6f865-fa29-4835-9dda-00d7d88e5972"
      unitRef="U_USD">424825655</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_b0a44387-b512-45d0-8a43-263304048766"
      unitRef="U_USD">-448831396</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_f8087c42-d499-451e-8826-f06f978f7920"
      unitRef="U_USD">-409199085</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_98c922eb-1250-4e4e-b555-01f69aa28678"
      unitRef="U_USD">14698014</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_7245243b-f084-4c37-9a97-f4ec3cc1876c"
      unitRef="U_USD">15630352</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_0dea413e-4947-4e39-91d6-d0288f648acc"
      unitRef="U_USD">88560261</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_10f340b4-110b-497d-b025-5c35da5fe3fb"
      unitRef="U_USD">87785058</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_34ca7351-727c-4e1a-b2cf-f0082e97857a"
      unitRef="U_USD">12585141</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_0f4cce61-a359-4946-a38a-5827456a9898"
      unitRef="U_USD">16595689</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_988bc06a-6269-4542-8032-1dfb62a5abaf"
      unitRef="U_USD">25703731</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_7dd606d5-32b8-4321-ac49-617d0d20e6fb"
      unitRef="U_USD">11248372</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_d0a50230-88f8-4cfb-bfe1-43f0bbdd5d85"
      unitRef="U_USD">38288872</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_59e13c4c-824d-4cba-a145-0bd8c3a335e7"
      unitRef="U_USD">27844061</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_7ef8ecb3-0cda-47d3-8ff2-d42d28eefca2"
      unitRef="U_USD">-38288872</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_61f02343-40cc-48ff-8609-990fe970805a"
      unitRef="U_USD">-27844061</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_0749d5ab-afa7-4d32-b17f-262a771eecc3"
      unitRef="U_USD">-1343439</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_b9be52d1-8fa9-40b6-bcbf-5b5f99fccc44"
      unitRef="U_USD">-1415909</us-gaap:InvestmentIncomeNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_31bce4d2-f40b-4404-9101-c7ad03908177"
      unitRef="U_USD">-39632311</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_5162048b-5f04-43be-8e42-dfe8b4756baa"
      unitRef="U_USD">-29259970</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="2"
      id="F_4f63c11d-a6da-494d-89fa-5d253b6909ba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="2"
      id="F_506d74a0-9fc5-400c-a61b-084057a5e039"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.78</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_b29f1e04-0185-4641-a987-d428ccbecfc6"
      unitRef="U_shares">38323167</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_ed4b6f13-53d5-415d-a1ce-95013ea6ebe3"
      unitRef="U_shares">37429450</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a7171c32-68b1-44fb-bc72-6ca42e63f926"
      decimals="INF"
      id="F_941473b7-45ca-421a-ac13-ae90592702c5"
      unitRef="U_shares">37374088</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_a7171c32-68b1-44fb-bc72-6ca42e63f926"
      decimals="0"
      id="F_859fa57e-150a-4bf6-9c2a-67a2c92ce440"
      unitRef="U_USD">3737</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8ec01d46-909a-44bc-befd-1d1a23e4ab9f"
      decimals="0"
      id="F_42f13969-b1d8-4233-bb11-9f95c27c6f65"
      unitRef="U_USD">392585265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b8689f73-8b90-434a-8cae-7e991d869064"
      decimals="0"
      id="F_a7750a75-96c2-41fa-be12-590d0886785a"
      unitRef="U_USD">-278796093</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b4a98684-d57a-4c5f-b5a6-c9b492ff4e17"
      decimals="0"
      id="F_d1df4558-c005-46c1-9169-8a7c528c0c23"
      unitRef="U_USD">113792909</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a5109b34-436f-4349-abc0-b0c0dca35cfc"
      decimals="0"
      id="F_0ca8dd8d-1a56-4db5-891a-6e4ee47867db"
      unitRef="U_USD">3731097</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_77677036-9cab-42e0-bbd7-00359b52f127"
      unitRef="U_USD">3731097</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a"
      decimals="INF"
      id="F_51d7ab5e-4f6c-4c6a-ade4-f80507bef421"
      unitRef="U_shares">94000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a"
      decimals="0"
      id="F_77f06d08-3062-411d-9157-c8a6f0e24dd6"
      unitRef="U_USD">10</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a5109b34-436f-4349-abc0-b0c0dca35cfc"
      decimals="0"
      id="F_831cda4a-74ef-402d-bedd-28927926785d"
      unitRef="U_USD">1913289</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_f52314b6-f420-4b11-a378-1a7f8d89d74c"
      unitRef="U_USD">1913299</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <axsm:StockVestedDuringPeriodSharesRestrictedCommonStockAward
      contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a"
      decimals="INF"
      id="F_167b6210-cba9-4158-b40e-11d4e5cd0c1f"
      unitRef="U_shares">1917</axsm:StockVestedDuringPeriodSharesRestrictedCommonStockAward>
    <axsm:StockVestedDuringPeriodValueRestrictedCommonStockAward
      contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a"
      decimals="0"
      id="F_d40612e9-4228-45af-a80a-de197ed45eb3"
      unitRef="U_USD">0</axsm:StockVestedDuringPeriodValueRestrictedCommonStockAward>
    <axsm:StockIssuedDuringPeriodSharesFinancing
      contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a"
      decimals="INF"
      id="F_9e35940b-dd82-4671-b368-723d5993329b"
      unitRef="U_shares">93877</axsm:StockIssuedDuringPeriodSharesFinancing>
    <axsm:StockIssuedDuringPeriodValueFinancing
      contextRef="C_3c83df33-9153-49e3-a55c-f2a68eb4045a"
      decimals="0"
      id="F_3296c7b9-458a-4ae5-b03b-b5399bac89c3"
      unitRef="U_USD">9</axsm:StockIssuedDuringPeriodValueFinancing>
    <axsm:StockIssuedDuringPeriodValueFinancing
      contextRef="C_a5109b34-436f-4349-abc0-b0c0dca35cfc"
      decimals="0"
      id="F_e0a2551a-4811-428b-a865-d9f148d71132"
      unitRef="U_USD">6115855</axsm:StockIssuedDuringPeriodValueFinancing>
    <axsm:StockIssuedDuringPeriodValueFinancing
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_8e1a6640-fa92-4702-8079-a1c1bd04fa86"
      unitRef="U_USD">6115864</axsm:StockIssuedDuringPeriodValueFinancing>
    <us-gaap:NetIncomeLoss
      contextRef="C_73c76e5f-6946-415b-ac4a-5f14307e04c8"
      decimals="0"
      id="F_f55832fb-f393-481a-89eb-0ba5d9dc5086"
      unitRef="U_USD">-29259970</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_fbbba2ec-2069-485b-9d41-f6d91887c1cf"
      unitRef="U_USD">-29259970</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_525e81c7-d46e-4ea7-9684-74def5e30aac"
      decimals="INF"
      id="F_00560f85-08a6-4038-b5e0-4d864d19dad0"
      unitRef="U_shares">37563882</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_525e81c7-d46e-4ea7-9684-74def5e30aac"
      decimals="0"
      id="F_aeb54b8e-0917-4065-9888-b7fb973f67c1"
      unitRef="U_USD">3756</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_144b60f0-d4f4-4610-977c-bd99ba58cc09"
      decimals="0"
      id="F_9cb7d24c-22f8-4e80-a14d-8d2ed3a121c5"
      unitRef="U_USD">404345506</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2038d698-c757-4fc1-8d54-847b886c8572"
      decimals="0"
      id="F_b4230731-2385-4b89-a62f-859df8182b71"
      unitRef="U_USD">-308056063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ee66dee5-84e1-46c5-b128-680ea4f73cbe"
      decimals="0"
      id="F_e88e179f-f487-4eec-8269-685ea2863442"
      unitRef="U_USD">96293199</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_bf72b4a0-6c33-4db5-9316-0eaa208085c8"
      decimals="INF"
      id="F_d6c0d4fd-f6de-4d7d-af73-d26e4041a202"
      unitRef="U_shares">37816794</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_bf72b4a0-6c33-4db5-9316-0eaa208085c8"
      decimals="0"
      id="F_60754ea9-25b2-4859-b59e-e4e4445b2d5d"
      unitRef="U_USD">3782</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_008bb3dd-4868-4984-8e42-390d9ffd5c65"
      decimals="0"
      id="F_547bb82d-e530-4829-97a3-cd00a8b67e0d"
      unitRef="U_USD">424825655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cb2f9874-656b-41a0-87d5-d87935757fb7"
      decimals="0"
      id="F_fcf03b86-77e1-49a7-b9c3-627334e82fe9"
      unitRef="U_USD">-409199085</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_876780cc-a7e0-4394-ab6c-fca3474990e7"
      unitRef="U_USD">15630352</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1882e4f2-eb93-4210-b724-5c9bb20bebf2"
      decimals="0"
      id="F_6cc6907f-57a1-4cad-8fd7-13389764ca18"
      unitRef="U_USD">7598329</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_c1cff78a-2c86-4881-a6ab-1a0d2cc59660"
      unitRef="U_USD">7598329</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5"
      decimals="INF"
      id="F_71caafcd-a88c-46ff-9802-37517069774d"
      unitRef="U_shares">18015</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5"
      decimals="0"
      id="F_b9e41308-f1fb-4a3c-9090-9d3b3971d24a"
      unitRef="U_USD">2</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1882e4f2-eb93-4210-b724-5c9bb20bebf2"
      decimals="0"
      id="F_2d827e6e-7e92-4c96-903b-df7303aa12e4"
      unitRef="U_USD">181635</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_79c8af0a-a99b-4153-b420-a42d4a95004c"
      unitRef="U_USD">181637</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <axsm:StockVestedDuringPeriodSharesRestrictedCommonStockAward
      contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5"
      decimals="INF"
      id="F_3d76ead8-db6e-4555-bf28-ac1eeef827d4"
      unitRef="U_shares">4555</axsm:StockVestedDuringPeriodSharesRestrictedCommonStockAward>
    <axsm:StockVestedDuringPeriodValueRestrictedCommonStockAward
      contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5"
      decimals="0"
      id="F_1272ce5d-973e-486c-aff8-33343ddfed29"
      unitRef="U_USD">0</axsm:StockVestedDuringPeriodValueRestrictedCommonStockAward>
    <axsm:StockIssuedDuringPeriodSharesFinancing
      contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5"
      decimals="INF"
      id="F_34022d61-09a5-4ddf-801e-c5a6d2d3be0b"
      unitRef="U_shares">1044081</axsm:StockIssuedDuringPeriodSharesFinancing>
    <axsm:StockIssuedDuringPeriodValueFinancing
      contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5"
      decimals="0"
      id="F_af064529-3638-4fd1-a46c-edce809b9711"
      unitRef="U_USD">104</axsm:StockIssuedDuringPeriodValueFinancing>
    <axsm:StockIssuedDuringPeriodValueFinancing
      contextRef="C_1882e4f2-eb93-4210-b724-5c9bb20bebf2"
      decimals="0"
      id="F_0a434dfa-1b06-49cc-9d5e-f9755cdd90c9"
      unitRef="U_USD">31008497</axsm:StockIssuedDuringPeriodValueFinancing>
    <axsm:StockIssuedDuringPeriodValueFinancing
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_a1e14c03-fd4e-4ef5-91df-36b9adb01086"
      unitRef="U_USD">31008601</axsm:StockIssuedDuringPeriodValueFinancing>
    <axsm:AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
      contextRef="C_54b14ada-417a-43c4-9fad-af0d01f2c8e5"
      decimals="0"
      id="F_6d963f6d-c9b1-409f-b85d-9d7fc5055b48"
      unitRef="U_USD">0</axsm:AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes>
    <axsm:AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
      contextRef="C_1882e4f2-eb93-4210-b724-5c9bb20bebf2"
      decimals="0"
      id="F_4295b678-06bc-4c1f-867f-b3510d9f6102"
      unitRef="U_USD">88594</axsm:AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes>
    <axsm:AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_9128eed4-8592-44e6-9deb-304e09e124a1"
      unitRef="U_USD">88594</axsm:AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes>
    <us-gaap:NetIncomeLoss
      contextRef="C_e6b4b679-0646-4f99-b733-4c1487965f80"
      decimals="0"
      id="F_16358588-b85a-45f9-b473-c56f1851c4c7"
      unitRef="U_USD">-39632311</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_d05f6802-b66d-40b1-8c32-6f03cb1377db"
      unitRef="U_USD">-39632311</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a94eb90c-f0d3-4b2c-9a0c-9754a3a9a0a0"
      decimals="INF"
      id="F_3b842ff7-5379-421a-b4ec-aac17991d5f9"
      unitRef="U_shares">38883445</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_a94eb90c-f0d3-4b2c-9a0c-9754a3a9a0a0"
      decimals="0"
      id="F_45442568-c8d9-4829-8e03-7b8a7b79ef53"
      unitRef="U_USD">3888</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_148374f5-3d5c-4b2e-ade2-fb6cd32a789e"
      decimals="0"
      id="F_94c8a500-ae2c-4eef-8d64-41ffd5c22db0"
      unitRef="U_USD">463525522</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_81597194-9eed-48c4-a703-a29a052262b3"
      decimals="0"
      id="F_6b9407c1-e7d8-46b8-b53c-0bbdf4fe4807"
      unitRef="U_USD">-448831396</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_3632a038-37db-4439-a615-092301d09047"
      unitRef="U_USD">14698014</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_ca832e99-1a74-4405-9925-e6e9f1805bcb"
      unitRef="U_USD">-39632311</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_24ea9e7b-8624-49c2-927c-12ef81837d93"
      unitRef="U_USD">-29259970</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_d7e42545-313f-4b66-b05b-5d82e1ed6d10"
      unitRef="U_USD">7598329</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_c000d895-0159-4f58-bc3b-af1312e77f12"
      unitRef="U_USD">3731097</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_258efade-5964-4237-9b8b-7a50743f4118"
      unitRef="U_USD">223143</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_28c676ce-e92f-4d5e-808f-2a7594c27687"
      unitRef="U_USD">276095</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:Depreciation
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_a64c3360-f086-4cdf-85fe-d169f0950f9a"
      unitRef="U_USD">36636</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_92a14575-0fe9-4ce0-baf2-b220249fc228"
      unitRef="U_USD">8326</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_855fe9e6-08e1-4502-9495-ce0d509bf2d0"
      unitRef="U_USD">275063</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_2b7b5845-23c8-4b4d-8310-12fcd5c90095"
      unitRef="U_USD">262764</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <axsm:ChangeInOperatingLeaseLiability
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_387818a4-a1a7-4891-a573-fcfc07aa1821"
      unitRef="U_USD">-214807</axsm:ChangeInOperatingLeaseLiability>
    <axsm:ChangeInOperatingLeaseLiability
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_78390498-6cd1-4db7-81e2-c3cdb660f078"
      unitRef="U_USD">-275840</axsm:ChangeInOperatingLeaseLiability>
    <axsm:IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_c1ca69b6-5309-4732-a13c-29d18c1c8f2e"
      unitRef="U_USD">2076858</axsm:IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent>
    <axsm:IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_7b2a61a6-8508-4559-867a-89d2b9a04259"
      unitRef="U_USD">226933</axsm:IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_62a32120-fbf5-4ad9-a2d0-d92bcccee798"
      unitRef="U_USD">-554217</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_ad549146-08b2-485e-85d7-81bccbb0ec1b"
      unitRef="U_USD">1117695</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_a0ecad13-839b-4312-a944-bdc78d5e37b7"
      unitRef="U_USD">1692042</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_531039a2-e14f-40c4-a6de-0f8df32f8e02"
      unitRef="U_USD">-2848723</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_7537d89c-84bc-4eb7-9619-3938c9d1b666"
      unitRef="U_USD">-32652980</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_37d625cc-aef2-4143-8062-e5a6f6ccd335"
      unitRef="U_USD">-27215489</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_18cc1e5b-8cac-4e9f-8f08-cd9b4be6d033"
      unitRef="U_USD">213736</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_73cb96ca-314c-4773-af62-aefc58f7dbae"
      unitRef="U_USD">29995</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_8660a982-e982-47ee-ada8-aaacd35edf44"
      unitRef="U_USD">-213736</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_ef525d78-9e74-435a-834b-ff4b5c1da8ab"
      unitRef="U_USD">-29995</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_99f62563-0c2c-4e53-965a-86d2ab3b7ff4"
      unitRef="U_USD">31008601</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_873ed22a-1eba-493b-9956-305c8053883b"
      unitRef="U_USD">6115864</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_8003afba-f12f-40f8-b548-33952f3b07a1"
      unitRef="U_USD">181637</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_f51f3276-0ef2-4d63-88b3-7acdadcbcf9e"
      unitRef="U_USD">1913299</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_e2c81213-3aa8-4eee-b2ab-f7f81253db3c"
      unitRef="U_USD">88594</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_7e877b6a-218e-448f-9147-6c5094f91cb8"
      unitRef="U_USD">31101644</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_122c10d0-6c20-45d2-9b7b-6504a34064c0"
      unitRef="U_USD">8029163</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_5d31f9f5-f9a0-48a6-97a9-ee84f4099994"
      unitRef="U_USD">-1765072</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_2280aa31-a302-41a4-bab0-7447ceca8c54"
      unitRef="U_USD">-19216321</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_e1a8d37b-ef4b-4c12-a6a0-74fd34674ddd"
      unitRef="U_USD">86472854</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b4a98684-d57a-4c5f-b5a6-c9b492ff4e17"
      decimals="0"
      id="F_049b209c-13a2-4715-a745-51dd72ed2645"
      unitRef="U_USD">183876453</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_290cf371-bcdc-45d9-87fd-55b5f32d1306"
      unitRef="U_USD">84707782</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ee66dee5-84e1-46c5-b128-680ea4f73cbe"
      decimals="0"
      id="F_cfdbb2f8-cea8-4cb5-a114-e3c994448eb6"
      unitRef="U_USD">164660132</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_27b90ac9-f33e-42f5-b2fd-aa9034172746"
      unitRef="U_USD">1118750</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_c7178ade-7c23-42d8-be53-2cf8dbda00a4"
      unitRef="U_USD">1143750</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_3def91f7-82e8-49b1-89bd-1c8a25b61638"
      unitRef="U_USD">561380</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_02254cf0-fe86-450c-bf45-11d46c64810d">&lt;p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 1. Nature of Business and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Axsome Therapeutics, Inc. (&#x201c;Axsome&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company developing novel therapies for central nervous system (&#x201c;CNS&#x201d;) disorders for which there are limited treatment options. By focusing on this therapeutic area, the Company is addressing significant and growing markets where current treatment options are limited or inadequate. The Company&#x2019;s core CNS portfolio includes &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; product candidates, AXS-05, AXS-07, AXS-12, and AXS-14, which are being developed for multiple indications. The Company aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with CNS disorders. The Company was incorporated on January 12, 2012 in the State of Delaware.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying unaudited interim consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, which are normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the operating results for the full fiscal year or any future period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Acquisition of Assets of Jazz Pharmaceuticals&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 25, 2022, the Company entered into an Asset Purchase Agreement (the &#x201c;Asset Purchase Agreement&#x201d;) with Jazz Pharmaceuticals plc ("Jazz Pharmaceuticals"), pursuant to which the Company will acquire Sunosi&#xae; from Jazz Pharmaceuticals ("the Acquisition"), a dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients living with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, which was approved by the U.S. Food and Drug Administration, or the FDA, in 2019 and by the European Medicines Agency (the &#x201c;EMA&#x201d;) in 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Asset Purchase Agreement, the Company will receive from Jazz Pharmaceuticals worldwide commercial, development, manufacturing, and intellectual property rights to Sunosi, except for certain Asian markets. Jazz Pharmaceuticals will receive from the Company a total upfront payment of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, a high single-digit royalty on the Company's U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on the Company's U.S. net sales of Sunosi in future indications. The Company will also assume the commitments of Jazz Pharmaceuticals to SK Biopharmaceuticals (&#x201c;SK)&#x201d; and Aerial Biopharma (&#x201c;Aerial&#x201d;). SK is the originator of Sunosi and retains rights in &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; Asian markets, including China, Korea, and Japan. In 2014, Jazz Pharmaceuticals acquired from Aerial worldwide rights to Sunosi excluding those Asian markets. The assumed commitments to SK and Aerial include single-digit tiered royalties based on the Company's sales of Sunosi, and up to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in revenue milestones and $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in development milestones. The Company expects to finance the transaction via its existing $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;300&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million term loan facility with Hercules Capital, Inc. (see below).&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Purchase Agreement also provides for customary conditions to closing, including the receipt of antitrust approval from the Federal Trade Commission pursuant to the Hart-Scott-Rodino Act, and the receipt of certain required financial statements from Jazz required by Regulation S-X of the Securities Exchange Act of 1934, as amended. The Company expects the closing to occur in the second quarter of 2022 and therefore, purchase accounting is not reflected in these consolidated financial statements.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Second Amendment to the Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 27, 2022, in connection with the Acquisition (as described above), the Company entered into a Second Amendment to the Loan and Security Agreement (the &#x201c;Second Amendment&#x201d;) with Hercules Capital, Inc. The Second Amendment amends the terms of that certain Loan and Security Agreement, dated as of September 25, 2020 (as amended by the First Amendment to the Loan and Security Agreement, dated of October 14, 2021) (the &#x201c;Loan Agreement&#x201d;). The changes in the Term Loan Advances (as defined in the Loan Agreement) amounts and dates are as follows: (i) increasing the Tranche 1 (as defined in the Loan Agreement) from $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;95.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, whereby $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;45.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is available upon the Second Amendment closing date (ii) changing the Tranche 2 Advances (as defined in the Loan Agreement) from two sub-tranches of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million each to three sub-tranches of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, (iii) changing the Tranche 3 Advance (as defined in the Loan Agreement) from one tranche of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to two sub-tranches of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, (iv) decreasing the Tranche 4 Advance (as defined in the Loan Agreement) from $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and (v) decreasing the Tranche 5 Advance (as defined in the Loan Agreement) from $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In connection with the Second Amendment, the parties also clarified certain terms of the Warrant Agreement previously issued to Hercules. The Second Amendment shall only be effective upon the closing of the Acquisition.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Conditioned upon the closing of the Second Amendment, Hercules will also purchase between $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s unregistered common stock, at a share price equal to the lesser of (a) the three-day volume weighted average price as of the date of the Second Amendment, or (b) the three-day volume weighted average price as of the Second Amendment Effective Date, pursuant to a stock purchase agreement to be agreed upon by the parties; provided, that, in no case shall the share price be less than a &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% discount to the three-day volume weighted average price of the Company&#x2019;s common stock at the time of the purchase.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has incurred operating losses since its inception and expects to continue to incur operating losses for the foreseeable future and may never become profitable. As of March 31, 2022, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;448.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s primary sources of cash have been proceeds from the issuance and sale of its common stock in public offerings and the issuance of debt. The Company has not yet commercialized any of its product candidates and cannot be sure if it will ever be able to do so. The Company&#x2019;s ability to achieve profitability depends on a number of factors, including its ability to obtain regulatory approval for its product candidates, successfully complete any post-approval regulatory obligations and successfully commercialize its product candidates alone or in partnership. The Company may continue to incur substantial operating losses even if it begins to generate revenues from its product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company believes its existing cash will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing. The actual amount of cash that the Company will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for its product candidates. The Company may use a combination of public and private equity offerings, debt financings, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements if market conditions are favorable or as a result of other strategic considerations to finance its future cash needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s common stock is listed on&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Nasdaq Global Market&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;and trades under the symbol &#x201c;AXSM&#x201d;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Impact of COVID-19&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2019, a novel (new) coronavirus known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People&#x2019;s Republic of China, causing outbreaks of the coronavirus disease, known as COVID-19, that has now spread globally. On January 30, 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency. The Secretary of Health and Human Services declared a public health emergency in the United States on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to the COVID-19 outbreak. On March 11, 2020, the WHO declared COVID-19 a global pandemic. The full impact of the ongoing COVID-19 pandemic is still unknown and rapidly evolving. While the potential economic impact brought by and over the duration of the COVID-19 pandemic may be difficult to assess or predict, the COVID-19 pandemic has resulted in significant disruption of global financial markets, which could in the future negatively affect the Company&#x2019;s liquidity. In addition, a recession or market volatility resulting from the COVID-19 pandemic could affect the Company&#x2019;s business. Given the nature and type of the Company&#x2019;s short-term investments, the Company does not believe the COVID-19 pandemic has had or will have a material impact on the Company&#x2019;s current investment liquidity.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <axsm:NumberOfLateStageProductCandidates
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_f43abe17-77f0-491d-a421-70c13dbb668d"
      unitRef="U_Product">4</axsm:NumberOfLateStageProductCandidates>
    <axsm:UpfrontPayment
      contextRef="C_93fc45bb-69f6-4b6b-ba71-8a6735312525"
      decimals="-6"
      id="F_e970f475-1e38-4195-b725-8c8ecf8bee1c"
      unitRef="U_USD">53000000</axsm:UpfrontPayment>
    <axsm:NumberOfAsianMarkets
      contextRef="C_93fc45bb-69f6-4b6b-ba71-8a6735312525"
      decimals="INF"
      id="F_470231b6-b8c4-40c3-a48a-4c00ee469ba2"
      unitRef="U_Market">12</axsm:NumberOfAsianMarkets>
    <axsm:RevenueMilestones
      contextRef="C_6a6da949-18b2-470e-9fe3-f0d2c926ef8b"
      decimals="-6"
      id="F_e8db2567-a450-428d-a4ca-e97bb3ca606d"
      unitRef="U_USD">165000000</axsm:RevenueMilestones>
    <axsm:DevelopmentMilestones
      contextRef="C_6a6da949-18b2-470e-9fe3-f0d2c926ef8b"
      decimals="-6"
      id="F_d8a5e90f-74bb-4769-af92-44b30943c2c7"
      unitRef="U_USD">1000000</axsm:DevelopmentMilestones>
    <us-gaap:LineOfCredit
      contextRef="C_e07b08d9-2bba-42e4-bf1e-6aa9c55ce68c"
      decimals="-6"
      id="F_5266dd43-eb11-4550-b178-8ec81c99a8d2"
      unitRef="U_USD">300000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_8e3cc36d-423a-457f-931c-9109e9833261"
      decimals="INF"
      id="F_fb0dce63-d148-4946-b106-6b32b5245979"
      unitRef="U_USD">60000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_6ba10b02-2ba9-41b3-b76d-552fff659baa"
      decimals="INF"
      id="F_af95082e-7a49-4921-8350-d9eb93c726c5"
      unitRef="U_USD">95000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_6dacb844-4b15-4c03-acb3-09a6b640217c"
      decimals="INF"
      id="F_d7178071-2915-4cda-a05c-13a48e701f13"
      unitRef="U_USD">45000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_3c74abd6-a2c2-4c0f-9355-8d60eb862eb8"
      decimals="INF"
      id="F_4d2030f3-eb20-4cd8-99c8-f1cca69fdb7c"
      unitRef="U_USD">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_78a1f202-d9b2-477b-b649-06874c29753a"
      decimals="INF"
      id="F_67c3f579-16c6-4e84-aa28-4d074f545080"
      unitRef="U_USD">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_caa50054-de64-4723-b525-0cfcc3b7185f"
      decimals="INF"
      id="F_e26c8990-5a14-4ecd-abbc-a1f41649e04e"
      unitRef="U_USD">35000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_2d6af9b1-56a3-4f2a-b2f7-a25d457c6cbf"
      decimals="INF"
      id="F_68c83b8a-08e9-44f3-8dd2-1f6126578579"
      unitRef="U_USD">35000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_39b63eb4-ca27-40bd-82f5-858e406e3701"
      decimals="INF"
      id="F_2c8bfa16-2aee-4a2c-a716-53e2625d39a8"
      unitRef="U_USD">30000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_e7fe0f8e-7fa9-4070-979d-a3234fed3fa1"
      decimals="INF"
      id="F_2ec7e8da-6e4a-4aa4-88a2-0591e8817a85"
      unitRef="U_USD">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_e075509a-46d1-46e0-8bb0-6f2bbee2ca82"
      decimals="INF"
      id="F_f150f3b7-3efb-4746-8c17-67cc4e51f36b"
      unitRef="U_USD">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_766126cd-3c63-4018-b6f6-3bc6d4b038fc"
      decimals="INF"
      id="F_178dbfcb-4312-4d65-9fec-c4e10a63ff58"
      unitRef="U_USD">5000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_d3c1be52-c032-4a53-856d-c71d3887807f"
      decimals="INF"
      id="F_399aaf4f-cf0d-4eb0-84ab-35188a52f773"
      unitRef="U_USD">55000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_839cd5d9-6625-4c96-98f0-b8b61c6a4475"
      decimals="INF"
      id="F_180e1eac-cced-45a8-8f08-4812b7f0da15"
      unitRef="U_USD">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_fa561b4e-b6ea-4fd4-8d9a-70f77c8de67f"
      decimals="INF"
      id="F_8f087ff1-a274-43dd-a070-c122a1f21217"
      unitRef="U_USD">75000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_d91b4b62-4ebe-490a-a88e-6f69afcf5a05"
      decimals="INF"
      id="F_03086db4-e760-4e05-8353-ef81cc1d247f"
      unitRef="U_USD">35000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <axsm:UnregisteredCommonStockValue
      contextRef="C_b4dbaf2a-a0d5-4d55-b135-ec0dd9346cc6"
      decimals="-5"
      id="F_7f9ca1f9-fb94-485a-89c4-bde1c9c51c0b"
      unitRef="U_USD">5000000.0</axsm:UnregisteredCommonStockValue>
    <axsm:UnregisteredCommonStockValue
      contextRef="C_75b98a95-0d49-477b-bc05-e21aa024dc87"
      decimals="-5"
      id="F_0fced09e-2761-41d2-bfeb-2d773653eeaf"
      unitRef="U_USD">8000000.0</axsm:UnregisteredCommonStockValue>
    <axsm:SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate
      contextRef="C_c4d05faf-ec2b-48f5-8a76-5f0bc4fe39a0"
      decimals="0"
      id="F_188847fd-ca39-4adf-8e79-b77b519b8d89"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20</axsm:SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="-5"
      id="F_d10c2ee1-3190-4d8f-b394-e19d56a52244"
      unitRef="U_USD">-448800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_d8a5b580-3531-437c-ab5e-bce7271655a5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company&#x2019;s product candidates; the Company&#x2019;s ability to obtain regulatory approval to market its products, if approved; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company&#x2019;s products, if approved; the Company&#x2019;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, if approved; and the Company&#x2019;s ability to raise additional financing. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve and maintain profitability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock&#x2011;based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; and the recoverability of the Company&#x2019;s net deferred tax assets and related valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expenses denominated in foreign currency are translated into U.S. dollars at the exchange rate on the date the expense is incurred. Assets and liabilities of foreign operations are translated at period-end exchange rates. The effect of exchange rate fluctuations on translating foreign currency into U.S. dollars is included in the Statements of Operations and is not material to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Segment and Geographic Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment, which is the business of developing novel therapies for the management of CNS disorders.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company&#x2019;s cash and cash equivalents includes holdings in checking and overnight sweep accounts. The Company&#x2019;s cash equivalents, which are money market funds held in a sweep account, are measured at fair value on a recurring basis. As of March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the balance of cash and cash equivalents was $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;84.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which approximates fair value and was determined based upon Level 1 inputs. The sweep account is valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level 1.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the majority of the Company&#x2019;s cash was held by &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three&#x2011;level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Inputs that are unobservable for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments are cash, accounts payable, accrued liabilities, and current and long-term debt. The carrying values for cash, accounts payable and accrued liabilities reported in the accompanying consolidated financial statements approximate their respective fair values due to their short-term maturities. The carrying value of debt on the Company&#x2019;s balance sheet (see Note 6 &#x2013; Loan and Security Agreement), is estimated to approximate its fair value as the interest rate approximates the market rate for loans with similar terms and risk characteristics.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt issuance costs consist of costs incurred in obtaining long-term financing. These costs are classified on the consolidated balance sheet as a direct deduction from the carrying amount of the related debt liability. These expenses are deferred and amortized as part of interest expense in the consolidated statement of operations using the effective interest rate method over the term of the debt agreement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equipment consists primarily of computer equipment and is recorded at cost. Equipment is depreciated on a straight&#x2011;line basis over its estimated useful life, which the Company estimates to be &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is included in operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related expenses including salaries, benefits, travel, and stock&#x2011;based compensation expense, contract services, costs incurred to third-party service providers for the conduct of research, preclinical and clinical studies, laboratory supplies, product license fees, consulting and other related expenses. We estimate research, preclinical and clinical study expenses based on services performed, pursuant to contracts with third-party research and development organizations that conduct and manage research, preclinical and clinical activities on our behalf. We estimate these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments associated with licensing agreements to acquire licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternative future use are expensed as incurred. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimates an annual effective tax rate of &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for the year ending &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and has &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recorded an income tax benefit for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022 and 2021 since it determined that a full valuation allowance is required against the Company&#x2019;s deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position as well as consideration of the available facts and circumstances. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. As of March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company does not believe any material uncertain tax positions are present. In the event the Company determines that accrual of interest or penalties are necessary in the future, the amount will be presented as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;For stock options issued, the Company estimates the grant date fair value of each option using the Black&#x2011;Scholes option pricing model. The Black-Scholes model takes into account the expected volatility of the Company&#x2019;s common stock, the risk-free interest rate, the estimated life of the option, the closing market price of the Company&#x2019;s common stock and the exercise price. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management&#x2019;s judgment. In addition, the Company recognizes expense for equity award forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;For restricted stock units (&#x201c;RSUs&#x201d;), the Company issues them in the form of Company common stock. The fair market value of these awards is based on the market closing price per share on the grant date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense using the accelerated attribution method when it is probable that the performance condition will be achieved. The expense related to the stock-based compensation is recorded within the same financial statement line item as the grantee&#x2019;s cash compensation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s policy upon exercise of stock options and RSUs is that shares will be issued as new shares drawing on the Company&#x2019;s 2015 Omnibus Incentive Compensation Plan share pool that was adopted by the stockholders in November 2015.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and Diluted Net Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options, and RSUs, which would result in the issuance of incremental shares of common stock. As the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted net loss per share of common stock for the three months ended March 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company&#x2019;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. When evaluating whether a contract contains a lease, the Company considers whether (1) the contract explicitly or implicitly identifies assets that are contractually defined and (2) the Company obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s lease agreement contains lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. The Company has applied the practical expedient to combine fixed payments for non-lease components with lease payments and account for them together as a single lease component, which increases the amount of lease assets and corresponding liabilities. Payments under the Company&#x2019;s lease arrangement are primarily fixed, however variable payments, are expensed as incurred and not included in the operating lease asset and liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses the implicit interest rate when readily determinable and uses the Company&#x2019;s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s operating leases are reflected in the right-of-use operating asset; operating lease liability, current portion; and operating lease liability, long-term portion in the Company&#x2019;s consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, and do not include an option to extend the term or purchase the underlying asset that the Company is reasonably certain to exercise, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2021-08, Business Combinations (Topic 805) . This update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 606. This differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The amendments in this update should be applied prospectively, and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <axsm:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_97fc6110-6d65-4eb6-b5f8-327eadffb6d6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company&#x2019;s product candidates; the Company&#x2019;s ability to obtain regulatory approval to market its products, if approved; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, the Company&#x2019;s products, if approved; the Company&#x2019;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, if approved; and the Company&#x2019;s ability to raise additional financing. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve and maintain profitability.&lt;/span&gt;&lt;/p&gt;</axsm:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_df055793-4bba-4b12-bcb3-42342a3f6fe5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock&#x2011;based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; and the recoverability of the Company&#x2019;s net deferred tax assets and related valuation allowance.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_4ecfb8c5-f839-4a32-96b8-baaf23060a33">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expenses denominated in foreign currency are translated into U.S. dollars at the exchange rate on the date the expense is incurred. Assets and liabilities of foreign operations are translated at period-end exchange rates. The effect of exchange rate fluctuations on translating foreign currency into U.S. dollars is included in the Statements of Operations and is not material to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_14e61e1a-117c-4bd1-951f-3b6e15a94978">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Segment and Geographic Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment, which is the business of developing novel therapies for the management of CNS disorders.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="INF"
      id="F_3c601263-e079-4ab2-ad4f-553de694d119"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_688868f7-a7ca-4a4c-abb0-cfb9a34ad11f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. The Company&#x2019;s cash and cash equivalents includes holdings in checking and overnight sweep accounts. The Company&#x2019;s cash equivalents, which are money market funds held in a sweep account, are measured at fair value on a recurring basis. As of March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the balance of cash and cash equivalents was $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;84.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which approximates fair value and was determined based upon Level 1 inputs. The sweep account is valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level 1.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="-5"
      id="F_f45b18a8-7e97-4091-99b4-82cb44ec24d1"
      unitRef="U_USD">84700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_f4cd6e39-3795-4ed2-963d-139f4b6b8c4e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the majority of the Company&#x2019;s cash was held by &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <axsm:NumberOfFinancialInstitutionsHoldingDeposits
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_8d95e50a-9ca4-47c1-bd47-cee92f86c7dd"
      unitRef="U_Institution">1</axsm:NumberOfFinancialInstitutionsHoldingDeposits>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_4d10e179-797e-4076-88f6-d732afc8f219">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three&#x2011;level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Inputs that are unobservable for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments are cash, accounts payable, accrued liabilities, and current and long-term debt. The carrying values for cash, accounts payable and accrued liabilities reported in the accompanying consolidated financial statements approximate their respective fair values due to their short-term maturities. The carrying value of debt on the Company&#x2019;s balance sheet (see Note 6 &#x2013; Loan and Security Agreement), is estimated to approximate its fair value as the interest rate approximates the market rate for loans with similar terms and risk characteristics.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DebtPolicyTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_8c9afe01-eb07-483c-bd4f-10e6880919af">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt issuance costs consist of costs incurred in obtaining long-term financing. These costs are classified on the consolidated balance sheet as a direct deduction from the carrying amount of the related debt liability. These expenses are deferred and amortized as part of interest expense in the consolidated statement of operations using the effective interest rate method over the term of the debt agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_c972473e-df08-4395-bb93-5b0d409c670e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equipment consists primarily of computer equipment and is recorded at cost. Equipment is depreciated on a straight&#x2011;line basis over its estimated useful life, which the Company estimates to be &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. When equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is included in operating expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_a0acdc90-ebf5-4632-b9e2-542c9ba25186">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_1c685d02-9ced-449a-9b9e-a5f2ca6fe7b3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related expenses including salaries, benefits, travel, and stock&#x2011;based compensation expense, contract services, costs incurred to third-party service providers for the conduct of research, preclinical and clinical studies, laboratory supplies, product license fees, consulting and other related expenses. We estimate research, preclinical and clinical study expenses based on services performed, pursuant to contracts with third-party research and development organizations that conduct and manage research, preclinical and clinical activities on our behalf. We estimate these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments associated with licensing agreements to acquire licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternative future use are expensed as incurred. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_4ae5947b-52aa-40cb-9def-d62985bb640b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company estimates an annual effective tax rate of &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for the year ending &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and has &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recorded an income tax benefit for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022 and 2021 since it determined that a full valuation allowance is required against the Company&#x2019;s deferred tax assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position as well as consideration of the available facts and circumstances. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. As of March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company does not believe any material uncertain tax positions are present. In the event the Company determines that accrual of interest or penalties are necessary in the future, the amount will be presented as a component of income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_b7fb4e8a-2ebf-48fc-8a1b-f5d6d9833933"
      decimals="INF"
      id="F_065449c7-0759-48c3-965a-352f327cf6b4"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="INF"
      id="F_8f023759-6f4c-4727-840c-8c1b45597f9e"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="INF"
      id="F_e339eb52-33d2-4b6c-8edf-36f1483de4e5"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_e52cc4f2-4637-4b5c-b2cb-6e19b5359ff2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;For stock options issued, the Company estimates the grant date fair value of each option using the Black&#x2011;Scholes option pricing model. The Black-Scholes model takes into account the expected volatility of the Company&#x2019;s common stock, the risk-free interest rate, the estimated life of the option, the closing market price of the Company&#x2019;s common stock and the exercise price. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management&#x2019;s judgment. In addition, the Company recognizes expense for equity award forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;For restricted stock units (&#x201c;RSUs&#x201d;), the Company issues them in the form of Company common stock. The fair market value of these awards is based on the market closing price per share on the grant date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;For awards subject to service-based vesting conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense using the accelerated attribution method when it is probable that the performance condition will be achieved. The expense related to the stock-based compensation is recorded within the same financial statement line item as the grantee&#x2019;s cash compensation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s policy upon exercise of stock options and RSUs is that shares will be issued as new shares drawing on the Company&#x2019;s 2015 Omnibus Incentive Compensation Plan share pool that was adopted by the stockholders in November 2015.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_267e4b37-420c-49bb-b22c-71f8da5e0713">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and Diluted Net Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options, and RSUs, which would result in the issuance of incremental shares of common stock. As the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted net loss per share of common stock for the three months ended March 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_5ac3b4e9-9e03-4220-bd54-c7bc495560b1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company&#x2019;s right to use an underlying asset for the lease term and operating lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. When evaluating whether a contract contains a lease, the Company considers whether (1) the contract explicitly or implicitly identifies assets that are contractually defined and (2) the Company obtains substantially all of the economic benefits from the use of that underlying asset and directs how and for what purpose the asset is used during the term of the contract.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s lease agreement contains lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. The Company has applied the practical expedient to combine fixed payments for non-lease components with lease payments and account for them together as a single lease component, which increases the amount of lease assets and corresponding liabilities. Payments under the Company&#x2019;s lease arrangement are primarily fixed, however variable payments, are expensed as incurred and not included in the operating lease asset and liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses the implicit interest rate when readily determinable and uses the Company&#x2019;s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s operating leases are reflected in the right-of-use operating asset; operating lease liability, current portion; and operating lease liability, long-term portion in the Company&#x2019;s consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, and do not include an option to extend the term or purchase the underlying asset that the Company is reasonably certain to exercise, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_3475eac0-069a-493e-ad5f-9266c8d7e19e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2021-08, Business Combinations (Topic 805) . This update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 606. This differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The amendments in this update should be applied prospectively, and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_cea657a0-caf3-495c-bb6f-abf58e1d53f5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 3. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;At &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022 and December 31, 2021 accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.688%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.807%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:1.553%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.817%;"/&gt;
        &lt;td style="width:0.932%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,726,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,416,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,013,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,050,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,856,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,442,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;390,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;385,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,987,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,295,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_b3616852-ac79-4c96-8181-2e3edba0ae37">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;At &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022 and December 31, 2021 accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.688%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.807%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:1.553%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.817%;"/&gt;
        &lt;td style="width:0.932%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,726,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,416,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,013,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,050,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,856,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,442,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;390,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;385,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,987,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,295,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <axsm:AccruedResearchAndDevelopmentCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_3ca1a91a-4705-4f40-bb63-2a21e8c9ee0f"
      unitRef="U_USD">2726847</axsm:AccruedResearchAndDevelopmentCurrent>
    <axsm:AccruedResearchAndDevelopmentCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_def4ac24-72f1-4cc9-9e65-1e1fb416eee6"
      unitRef="U_USD">2416897</axsm:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_bc562137-af52-4a3e-a413-c8436fdcb0a2"
      unitRef="U_USD">2013040</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_d07d3b62-0d01-4e22-a4fc-98dde35ac45d"
      unitRef="U_USD">4050236</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <axsm:AccruedGeneralAndAdministrativeCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_7d5e5e00-273a-4a3a-b71f-ce562434b7cf"
      unitRef="U_USD">5856779</axsm:AccruedGeneralAndAdministrativeCurrent>
    <axsm:AccruedGeneralAndAdministrativeCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_7bf1a5c9-1be2-48c7-b0e3-8369a538f46f"
      unitRef="U_USD">2442700</axsm:AccruedGeneralAndAdministrativeCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_da4c9e4a-d543-4636-8221-eaa78784b056"
      unitRef="U_USD">390556</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_fb9d9148-95bc-4e35-9b40-601c83f948f9"
      unitRef="U_USD">385347</us-gaap:InterestPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_34e9c0f0-67f8-481d-b56b-db86d861c35e"
      unitRef="U_USD">10987222</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_6d176cab-3ef1-41e3-b425-31bf70ad46b8"
      unitRef="U_USD">9295180</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_0c56b5f0-7ecb-4b8b-b9cc-70dc90efb469">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 4. Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Hercules Capital, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2020, the Company entered into a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent and as a lender (in such capacity, the &#x201c;Agent&#x201d; or &#x201c;Hercules&#x201d;) and the other financial institutions that from time to time become parties to the Loan Agreement as lenders (collectively, the &#x201c;Lenders&#x201d;). The Loan Agreement provides for term loans in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under multiple tranches (the &#x201c;2020 Term Loan&#x201d;). The tranches consist of (i) a first tranche consisting of term loans in an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was funded to the Company on the Closing Date (the &#x201c;First Advance&#x201d;), and of which the remaining $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was available at the Company&#x2019;s option at any time through September 15, 2021; (ii) subject to the approval of the Company&#x2019;s AXS-05 product candidate for the treatment of major depressive disorder (the &#x201c;First Milestone&#x201d;), a second tranche consisting of additional term loans in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, available at the Company&#x2019;s option beginning on the date that the First Milestone is achieved through the earlier of (A) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; days following such date and (B) June 30, 2022; (iii) subject to the approval of the Company&#x2019;s AXS-07 product candidate for the treatment of migraine (the &#x201c;Second Milestone&#x201d;), a third tranche consisting of additional term loans in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, available at the Company&#x2019;s option beginning on the date that the Second Milestone is achieved through the earlier of (A) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; days following such date and (B) June 30, 2022; (iv) subject to the achievement of either the First Milestone or the Second Milestone and so long as the Company is in compliance with a required ratio of Lender indebtedness to net product revenue, a fourth tranche consisting of additional term loans in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, available at the Company&#x2019;s option beginning on January 1, 2022 and continuing through March 31, 2023; and (v) subject to approval by the Lenders&#x2019; in their discretion, a fifth tranche of additional term loans in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, available through December 31, 2023. The remaining $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the first tranche was not utilized and such tranche and future tranches were amended upon the execution of the First Amendment to the Loan and Security Agreement. See "First Amendment to the Loan and Security Agreement" below for further information. The Company intends to use the proceeds of the Term Loan Advances for working capital and general corporate purposes. In addition, approximately $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;21.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the proceeds from the First Advance was used to satisfy in full and retire the Company&#x2019;s indebtedness under the 2019 Term Loan (as defined below), as amended.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The outstanding principal balance of the term loans bears interest at an annual rate equal to the greater of either (i) the prime rate as reported in &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;The Wall Street Journal &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;plus &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% or (ii) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, subject to an ability by the Company, during certain periods (each, a &#x201c;PIK Deferral Period&#x201d;), to request a reduction of the then-effective cash-pay interest rate by up to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum (the &#x201c;Cash Interest Reduction Amount&#x201d;). Accrued interest is payable monthly following the funding of each term loan. During each PIK Deferral Period, the term loans will bear cash-pay interest, at the reduced amount, and will accrue paid-in-kind interest at a rate equal to the Cash Interest Reduction Amount multiplied by &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which amount will be capitalized and added to the outstanding principal balance of the term loans on each monthly interest payment date during the PIK Deferral Period.&#x200c;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to repay the term loans in equal installments of principal and interest commencing on May 1, 2023 through October 1, 2025 (the &#x201c;Maturity Date&#x201d;). However, if either the First Milestone or the Second Milestone are achieved prior to May 1, 2023, and no default exists, the amortization commencement date will be automatically extended to November 1, 2023; if both the First Milestone and the Second Milestone are achieved prior to November 1, 2023, and no default exists, the amortization commencement date will be further automatically extended to May 1, 2024 and if any term loans are funded under the fourth tranche noted above prior to May 1, 2024, and no default exists, the amortization commencement date will be further automatically extended to November 1, 2024. On the Maturity Date, all unpaid term loans will be due and payable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As collateral for the obligations, the Company has granted to Hercules a senior security interest in all of Company&#x2019;s right, title, and interest in, to and under all of Company&#x2019;s property, inclusive of intellectual property, which includes one of the Company&#x2019;s existing license agreements (the &#x201c;License Agreement&#x201d;) with Antecip Bioventures II LLC (&#x201c;Antecip&#x201d;), an entity owned by Axsome&#x2019;s Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., subject to limited exceptions&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; Antecip consented to the collateral assignment of the License Agreement, among other things, under a direct agreement (the &#x201c;Direct Agreement&#x201d;) with the Company and Hercules.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Loan Agreement contains customary representations, warranties and covenants, including covenants by the Company limiting additional indebtedness, liens (including a negative pledge on intellectual property and other assets), guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates and fundamental changes. At the initial closing, there were no applicable financial covenants contained in the Loan Agreement. Only after additional amounts are drawn down by the Company in the future, if the Company decides to do so, under the terms set forth in the Loan Agreement, there will be certain limited financial covenants that will apply, including:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective upon the date the outstanding principal amount of the advances under the Loan Agreement equals or exceeds $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which has not yet occurred, the Company at all times thereafter must maintain cash in an account or accounts in which Hercules has a first priority security interest, in an aggregate amount greater than or equal to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, plus the amount of the Company&#x2019;s accounts payable under U.S. GAAP not paid after the &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;th day following the invoice for such account payable (such amount, the &#x201c;Qualified Cash A/P Amount&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective upon the later of (i) the last calendar month of the calendar quarter that is twelve months following the earlier of (x) the date that the First Milestone is achieved and (y) the date that the Second Milestone is achieved, or (ii) the date on which the outstanding principal amount of the term loan advances under the Loan Agreement is equal to or greater than $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;65.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, neither of which have occurred yet, the Company is required to (A) ensure that at all times its market capitalization exceeds $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion, and that it maintains cash in an account which Hercules has a first priority security interest in an amount not less than &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the sum of the outstanding principal amount of the term loan advances &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;plus&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; the Qualified Cash A/P Amount, (B) ensure that at all times that it maintains cash in an account which Hercules has a first priority security interest in an amount not less than &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the sum of the outstanding principal amount of the term loan advances &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;plus&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; the Qualified Cash A/P Amount, or (C) achieve at least &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the net product revenue per the board of directors approved forecast solely from the sale of AXS-05 and AXS-07 (which may include royalty, profit sharing, or sales-based milestone revenue recognized in accordance with GAAP, but will not include any upfront or non-sales-based milestone payments under business development or licensing transactions), measured on a trailing six-month basis as of the date of the Company&#x2019;s most recent quarterly financial statement, determined on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restrictions on the Company&#x2019;s ability to incur additional indebtedness, pay dividends, encumber its intellectual property, or engage in certain fundamental business transactions, such as mergers or acquisitions of other businesses, with certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s obligations under the Loan Agreement are subject to acceleration upon the occurrence of specified events of default, including payment default, insolvency and a material adverse change in the Borrower&#x2019;s business, operations or financial or other condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, the Company is required to pay a final payment fee equal to the greater of (A) $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,910,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and (B) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the aggregate amount of all term loan advances minus the aggregate amount of repayments made. The final payment fee is being accreted and amortized into interest expense using the effective interest rate method over the term of the loan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company may, at its option prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the principal amount prepaid if the prepayment occurs prior to the first anniversary of the Closing Date, (ii) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the principal amount prepaid if the prepayment occurs on or after the first anniversary and prior to the second anniversary of the Closing Date, and (iii) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the principal amount prepaid if the prepayment occurs on or after the second anniversary and prior to the third anniversary of the Closing Date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;First Amendment to the Loan Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 14, 2021 ("First Amendment Closing Date"), the Company entered into the first amendment to the Loan Agreement (the &#x201c;First Amendment to the Loan Agreement&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the First Amendment to the Loan Agreement, the First Amendment amended the terms of that certain Loan and Security Agreement, dated as of September 25, 2020, by and among the Company, Hercules and the Lenders (the &#x201c;Loan Agreement&#x201d;) to, among other things, (i) increase the aggregate principal amount of the loan, available at the Company&#x2019;s option, from $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;225,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;300,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, (ii) change the draw amounts and dates available in Tranche 2 through Tranche 5 including increasing the amount available under Tranche 2 subject to FDA approval of the Company&#x2019;s AXS-05 product candidate for the treatment of major depressive disorder from $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;35,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;100,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, maintaining the amount available under Tranche 3 subject to FDA approval of the Company&#x2019;s AXS-07 product candidate for the acute treatment of migraine of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;20,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, reducing the amount under Tranche 4 available upon achievement of certain combined sales and outstanding debt criteria from $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;60,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and increasing the amount available under Tranche 5 to support future strategic initiatives, including further pipeline advancement or expansion from $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;75,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; subject to the approval from Hercules, (iii) extend the maturity date of the facility from the original &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and optionally to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, subject to certain conditions, (iv) reset and extend the interest only period from the initial &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the original loan closing to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;48 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the First Amendment and extendable up to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;60 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; subject to FDA approval of the Company&#x2019;s AXS-05 product candidate for the treatment of major depressive disorder and subject to FDA approval of AXS-07 in the acute treatment of migraine, and (v) decrease the interest rate from &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% (floating rate based on the greater of (a) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% or (b) US WSJ Prime + &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%) to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% (floating rate based on the greater of (a) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% or (b) US WSJ Prime + &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, the Company is required to pay a final payment fee equal to (A) $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,910,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; plus (B) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the aggregate amount of all term future loan advances. The final payment fee is being accreted and amortized into interest expense using the effective interest rate method over the term of the loan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company may, at its option prepay the term loans in full or in part, subject to a prepayment penalty equal to (i) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the principal amount prepaid if the prepayment occurs prior to the first anniversary of the First Amendment Closing Date, (ii) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the principal amount prepaid if the prepayment occurs on or after the first anniversary and prior to the second anniversary of the First Amendment Closing Date, and (iii) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the principal amount prepaid if the prepayment occurs on or after the second anniversary and prior to the third anniversary of the First Amendment Closing Date. These percentages are unchanged from the Loan Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Second Amendment to the Loan Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 27, 2022, the Company entered into the Second Amendment to the Loan Agreement subject to the closing of the Sunosi&#xae; Acquisition. See&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Note 1 - Nature of Business and Basis of Presentation &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;for more detail.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Loan Interest Expense and Amortization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company incurred interest expense of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,123,958&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,143,750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. In addition, amortization of the final payment fee was $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;97,860&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;143,589&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. Amortization of the debt discount in relation to warrants and debt issuance costs was $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;125,497&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;132,508&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The outstanding debt and unamortized debt discount balances are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.074%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.076%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.076%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total Outstanding Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Add: accreted liability of final payment fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;804,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;706,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Less: unamortized debt discount, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,491,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,616,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Less: current portion of long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Loan payable, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;49,312,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;49,089,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the entry into the Hercules Term Loan, the Company issued to Hercules a warrant to purchase a number of shares of the Company&#x2019;s common stock equal to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the aggregate amount of the Term Loan Advances that are funded. Further information on warrants issued related to this loan and prior debt financings and amendments are disclosed in Note 7 - Stockholders&#x2019; Equity under the &#x201c;Warrants&#x201d; section.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Scheduled Principal Payments on Outstanding Debt, as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.137%;"/&gt;
        &lt;td style="width:1.814%;"/&gt;
        &lt;td style="width:1.376%;"/&gt;
        &lt;td style="width:15.714%;"/&gt;
        &lt;td style="width:0.96%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,026,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;41,973,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total principal payments outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company was in compliance with all covenants and requirements of its financing arrangements as of and during the three months ended March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_52720a6e-acc3-4746-a598-7a3115ffa670"
      decimals="-5"
      id="F_de06861a-6b32-4c40-b2f5-08363e1c52a1"
      unitRef="U_USD">225000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_8e3cc36d-423a-457f-931c-9109e9833261"
      decimals="-5"
      id="F_f47e68ea-7172-4464-b41f-2a3a64fbc701"
      unitRef="U_USD">60000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_e79659be-62a0-4d7f-8919-a6af22ec548f"
      decimals="-5"
      id="F_5aa059f5-3488-4e93-8d94-f52dd6db3d79"
      unitRef="U_USD">50000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_8e3cc36d-423a-457f-931c-9109e9833261"
      decimals="-5"
      id="F_98c80e22-784a-4128-b53e-cec6a22d319d"
      unitRef="U_USD">10000000.0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_7dd348d4-cefb-4639-92c0-78e13450f2b6"
      decimals="-5"
      id="F_81bb4f75-2c8f-45e0-82f3-f3984189f8cd"
      unitRef="U_USD">35000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <axsm:ThresholdDaysToAchieveFirstMilestone
      contextRef="C_aac9dd6a-0f39-4dca-9c62-e17e1926a68c"
      id="F_1a5aaa31-7435-4e93-b999-eebb1355860f">P181D</axsm:ThresholdDaysToAchieveFirstMilestone>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_21a3ddfb-93a7-4cbb-82fd-5e3bc5f0961b"
      decimals="-5"
      id="F_2c4a7e88-ccaf-467b-b12c-4a2338cc4988"
      unitRef="U_USD">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <axsm:ThresholdDaysToAchieveSecondMilestone
      contextRef="C_4c1d2970-ecdc-417a-8c38-beb830e327cb"
      id="F_c7cc4a03-0ac4-4a54-96cc-f1f2776fb01a">P181D</axsm:ThresholdDaysToAchieveSecondMilestone>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_c6555893-bd98-4700-a5a7-8076bf2d8d0c"
      decimals="-5"
      id="F_e23f9336-dbf8-4b58-868c-e3e212095c19"
      unitRef="U_USD">60000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0d2b4eb6-939a-4140-adcf-dc65291830f9"
      decimals="-5"
      id="F_6c5ef56d-2206-4285-bd6e-b1b95f4c46cf"
      unitRef="U_USD">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_a8eda348-341b-4541-93f2-83c532439893"
      decimals="-5"
      id="F_828f85b3-3a0e-49ae-85d9-71353b33f6db"
      unitRef="U_USD">10000000.0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <axsm:ProceedsFromFirstAdvanceUsedToRepayPreviousDebt
      contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd"
      decimals="-5"
      id="F_c6436bfa-f721-4b78-a2b4-5b2f3448fbac"
      unitRef="U_USD">21700000</axsm:ProceedsFromFirstAdvanceUsedToRepayPreviousDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_d518ab07-50e1-4f22-8ead-a8eb4564ed95"
      decimals="4"
      id="F_1eaf80e0-eb07-43b1-9508-69fbd433b444"
      unitRef="U_pure">0.0590</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_56c3f743-f85c-4b20-9622-f711609bcf18"
      decimals="INF"
      id="F_d88cb128-4469-4d52-a310-ca0d751e4838"
      unitRef="U_pure">0.0915</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <axsm:DebtInstrumentThresholdCashPayInterestRate
      contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd"
      decimals="4"
      id="F_f3369d18-d037-4f56-bdd3-5a776dc54886"
      unitRef="U_pure">0.0100</axsm:DebtInstrumentThresholdCashPayInterestRate>
    <axsm:DebtInstrumentCashPayInterestMultiplier
      contextRef="C_56c3f743-f85c-4b20-9622-f711609bcf18"
      decimals="2"
      id="F_6d9f5a9c-aa1b-4982-9de4-3845dcb06c86"
      unitRef="U_pure">1.15</axsm:DebtInstrumentCashPayInterestMultiplier>
    <us-gaap:LongTermDebt
      contextRef="C_9f1dee24-d9e9-4cd0-809c-31fbba3bb1c1"
      decimals="-5"
      id="F_6068f956-86af-4813-a245-91f1b28eefe6"
      unitRef="U_USD">55000000.0</us-gaap:LongTermDebt>
    <axsm:LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest
      contextRef="C_4b988683-b18d-41ce-bc31-605656e6a4f0"
      decimals="-5"
      id="F_14443ee4-e176-4955-9337-7c59fc81e20d"
      unitRef="U_USD">15000000.0</axsm:LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest>
    <axsm:LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod
      contextRef="C_80117ee7-80d8-4a57-96a2-e2ea5118fefe"
      id="F_f216811e-0f7d-495e-a4ed-16db121c4628">P180D</axsm:LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod>
    <us-gaap:LongTermDebt
      contextRef="C_bc41918b-50a0-4e0c-ae3a-cc2fea3bfbfd"
      decimals="-5"
      id="F_ffcf2601-8748-4624-ae39-22247deebe89"
      unitRef="U_USD">65000000.0</us-gaap:LongTermDebt>
    <axsm:LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount
      contextRef="C_58506d7a-5c75-4b99-8279-0688e8c43429"
      decimals="-8"
      id="F_63235dfd-3410-4dc7-84a0-123926a3e949"
      unitRef="U_USD">2000000000.0</axsm:LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount>
    <axsm:LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent
      contextRef="C_58506d7a-5c75-4b99-8279-0688e8c43429"
      decimals="2"
      id="F_ed98b35e-4445-43ca-86ea-4ac1cdbc3986"
      unitRef="U_pure">0.65</axsm:LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent>
    <axsm:LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent
      contextRef="C_58506d7a-5c75-4b99-8279-0688e8c43429"
      decimals="2"
      id="F_d9c55a52-123d-4fb6-8b8b-06a2af9ff586"
      unitRef="U_pure">1</axsm:LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent>
    <axsm:LongTermDebtAdditionalDrawnMinimumRevenuePercent
      contextRef="C_303637a5-8b91-4570-a728-6f97f2270ef4"
      decimals="2"
      id="F_0b479239-913d-4c2c-82a7-bb7db3461eb7"
      unitRef="U_pure">0.60</axsm:LongTermDebtAdditionalDrawnMinimumRevenuePercent>
    <axsm:ExtinguishmentOfDebtFeeAmount
      contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd"
      decimals="0"
      id="F_bcd6a63b-a830-4b8b-9808-6487a36579eb"
      unitRef="U_USD">2910000</axsm:ExtinguishmentOfDebtFeeAmount>
    <axsm:DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding
      contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd"
      decimals="4"
      id="F_6d37f594-d29b-420a-a688-ae33d4116bd1"
      unitRef="U_pure">0.0485</axsm:DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding>
    <axsm:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_133a145c-e960-4fc8-b6d5-388d2e167e6b"
      decimals="3"
      id="F_02b788e5-de03-41c5-bcfc-da5c81b62092"
      unitRef="U_pure">0.020</axsm:DebtInstrumentPrepaymentPenaltyPercentage>
    <axsm:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_ae13ec89-1fa4-4e02-b9fc-58d4fca0deaf"
      decimals="3"
      id="F_01ba3617-4485-4ef1-b19b-5bec824f1fb5"
      unitRef="U_pure">0.015</axsm:DebtInstrumentPrepaymentPenaltyPercentage>
    <axsm:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_3922af5a-d586-4a59-a748-dca027a9e1b9"
      decimals="3"
      id="F_60b01954-24ef-4c6f-9837-25a885f663a3"
      unitRef="U_pure">0.010</axsm:DebtInstrumentPrepaymentPenaltyPercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_52720a6e-acc3-4746-a598-7a3115ffa670"
      decimals="INF"
      id="F_1a4a6836-e2f5-458d-920a-7a6795e21530"
      unitRef="U_USD">225000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_43574450-92b4-4988-81e4-50b6b102e732"
      decimals="INF"
      id="F_39655eee-2523-4a89-a519-cdaab1146547"
      unitRef="U_USD">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_7dd348d4-cefb-4639-92c0-78e13450f2b6"
      decimals="INF"
      id="F_7d7759cc-808a-4bd6-a4fc-ea5099b2ed8f"
      unitRef="U_USD">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_965ed3a9-df64-4456-ade2-24619ff19b45"
      decimals="INF"
      id="F_ebf8d965-910d-4571-9209-92c512c9be4d"
      unitRef="U_USD">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_e7fe0f8e-7fa9-4070-979d-a3234fed3fa1"
      decimals="INF"
      id="F_b96db4fd-192e-4d9b-a644-5c6f4a306441"
      unitRef="U_USD">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_c6555893-bd98-4700-a5a7-8076bf2d8d0c"
      decimals="INF"
      id="F_94ee447b-ee61-440d-a17d-55b0c020d45c"
      unitRef="U_USD">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_d3c1be52-c032-4a53-856d-c71d3887807f"
      decimals="INF"
      id="F_15093f34-4435-4021-9af3-5053c613494f"
      unitRef="U_USD">55000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0d2b4eb6-939a-4140-adcf-dc65291830f9"
      decimals="INF"
      id="F_76bc364b-62ba-45a4-b6a2-20a05329bcbd"
      unitRef="U_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_fa561b4e-b6ea-4fd4-8d9a-70f77c8de67f"
      decimals="INF"
      id="F_97b9068f-42f8-4d3b-85d1-885209c59084"
      unitRef="U_USD">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <axsm:DebtInstrumentsMaturityMonthAndYear
      contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd"
      id="F_cd409dc7-2134-4153-9529-b365729b55de">2025-10</axsm:DebtInstrumentsMaturityMonthAndYear>
    <axsm:DebtInstrumentsMaturityMonthAndYear
      contextRef="C_27e2a477-b3de-4e25-a8a8-015812de985a"
      id="F_17a77bb4-2dfd-4fc1-9ef7-7190332763c8">2026-10</axsm:DebtInstrumentsMaturityMonthAndYear>
    <axsm:DebtInstrumentsMaturityMonthAndYear
      contextRef="C_46bc8e64-2627-43a1-9043-0b5495dccc01"
      id="F_cc49c851-9f5a-4074-ab4e-3d60eb31bf7c">2027-10</axsm:DebtInstrumentsMaturityMonthAndYear>
    <axsm:DebtInstrumentInterestPaymentPeriod
      contextRef="C_87baa8d3-aef8-4d44-b758-b03bb30059dd"
      id="F_6a2f7f88-236f-4b35-93cb-3bc06b9bd698">P30M</axsm:DebtInstrumentInterestPaymentPeriod>
    <axsm:DebtInstrumentInterestPaymentPeriod
      contextRef="C_df3f324f-9e88-4cd0-becb-e386dfb62dde"
      id="F_6f12ad36-a39b-4f9a-b01f-11f671044366">P48M</axsm:DebtInstrumentInterestPaymentPeriod>
    <axsm:DebtInstrumentInterestPaymentPeriod
      contextRef="C_47fac860-11d6-4b0d-8e1c-85902d5c680c"
      id="F_37791d25-283b-4c27-a8d3-6bf1ffab3ef1">P60M</axsm:DebtInstrumentInterestPaymentPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_56c3f743-f85c-4b20-9622-f711609bcf18"
      decimals="INF"
      id="F_7bdde9c9-9cf4-424c-811e-678110d3211f"
      unitRef="U_pure">0.0915</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_56c3f743-f85c-4b20-9622-f711609bcf18"
      decimals="INF"
      id="F_a42bc292-5ba2-4fc5-ba11-93764d0b8aeb"
      unitRef="U_pure">0.0915</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_d518ab07-50e1-4f22-8ead-a8eb4564ed95"
      decimals="4"
      id="F_5071d811-bbed-475f-b035-f8aeda15ae72"
      unitRef="U_pure">0.0590</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_43574450-92b4-4988-81e4-50b6b102e732"
      decimals="INF"
      id="F_d36cb077-4da9-4970-a3c4-845b3c138d4c"
      unitRef="U_pure">0.0895</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_43574450-92b4-4988-81e4-50b6b102e732"
      decimals="INF"
      id="F_3031eef2-fc5d-4f9d-b1fa-44753e50586f"
      unitRef="U_pure">0.0895</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_724babf7-6fd0-424b-9476-154cb4318da6"
      decimals="4"
      id="F_f70806ec-fbe9-47d7-bd45-38abf48ec6fd"
      unitRef="U_pure">0.0570</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <axsm:ExtinguishmentOfDebtFeeAmount
      contextRef="C_df3f324f-9e88-4cd0-becb-e386dfb62dde"
      decimals="0"
      id="F_c7e4087d-951c-4945-a838-45ea7642d00d"
      unitRef="U_USD">2910000</axsm:ExtinguishmentOfDebtFeeAmount>
    <axsm:DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding
      contextRef="C_df3f324f-9e88-4cd0-becb-e386dfb62dde"
      decimals="3"
      id="F_cf04d0a0-7d98-43c1-87f5-f76f4377d426"
      unitRef="U_pure">0.045</axsm:DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding>
    <axsm:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_21a8a9ca-0b07-4cdd-ac95-7ef4b8971c9a"
      decimals="3"
      id="F_17e5796d-babe-47c0-9768-92803349b73b"
      unitRef="U_pure">0.020</axsm:DebtInstrumentPrepaymentPenaltyPercentage>
    <axsm:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_bb885263-2c35-4cf7-8ae9-82fc64c0f7a0"
      decimals="3"
      id="F_5ba49847-860a-430a-a272-233d3efd11a0"
      unitRef="U_pure">0.015</axsm:DebtInstrumentPrepaymentPenaltyPercentage>
    <axsm:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_6854c542-e5e2-4d67-b182-044dbba449bd"
      decimals="3"
      id="F_66fa5912-a6ae-4685-b8a1-77a0199b3888"
      unitRef="U_pure">0.010</axsm:DebtInstrumentPrepaymentPenaltyPercentage>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_59dda81e-7070-4a94-8fcd-a904d264677a"
      unitRef="U_USD">1123958</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_d4f082c4-6729-495b-b038-5e103a73213f"
      unitRef="U_USD">1143750</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_71f71f16-68f2-4619-bf62-9ad066994990"
      unitRef="U_USD">97860</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_8fe3fd97-d60d-40fc-9c39-7b69430c2076"
      unitRef="U_USD">143589</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_99cf65ea-42df-4c36-87cb-c410c3027f8e"
      decimals="0"
      id="F_7fbfc270-6fa9-48d5-b6c6-7e2a96b5d07c"
      unitRef="U_USD">125497</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_c3170278-1391-4a56-9d86-0add7cd33446"
      decimals="0"
      id="F_ce0eafec-d9e4-46a3-8669-ab93c7db4e56"
      unitRef="U_USD">132508</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_225caa5b-fd2a-4cee-8729-715f78af3321">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The outstanding debt and unamortized debt discount balances are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.074%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.076%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.076%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total Outstanding Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Add: accreted liability of final payment fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;804,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;706,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Less: unamortized debt discount, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,491,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,616,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Less: current portion of long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Loan payable, long-term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;49,312,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;49,089,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_73bbb74a-601f-4948-886b-aee13701b617"
      unitRef="U_USD">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_dfb8580e-48e2-41ea-a62e-6e2f1a6963bc"
      unitRef="U_USD">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <axsm:DebtInstrumentAccretedLiabilityOfFinalPaymentFee
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_7e5a66e9-7da7-47bf-b6eb-b94d92532943"
      unitRef="U_USD">804053</axsm:DebtInstrumentAccretedLiabilityOfFinalPaymentFee>
    <axsm:DebtInstrumentAccretedLiabilityOfFinalPaymentFee
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_8c9a28f4-afd3-4d34-9d1e-f5e1cd71b419"
      unitRef="U_USD">706407</axsm:DebtInstrumentAccretedLiabilityOfFinalPaymentFee>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_46906c3c-646c-46db-9260-d88e82abaade"
      unitRef="U_USD">1491388</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_c62c9669-4b69-41c0-a64c-14b4b740cf89"
      unitRef="U_USD">1616885</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_56c0ccd2-34bd-4d7b-bf19-3329560c9994"
      unitRef="U_USD">49312665</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="0"
      id="F_44bd4d78-e3da-43a5-b4d6-2d77b33bb067"
      unitRef="U_USD">49089522</us-gaap:LongTermDebtNoncurrent>
    <axsm:DebtInstrumentAggregateAmountPercentage
      contextRef="C_99cf65ea-42df-4c36-87cb-c410c3027f8e"
      decimals="3"
      id="F_2bd04210-18b7-4086-973b-d73e6437a46f"
      unitRef="U_pure">0.025</axsm:DebtInstrumentAggregateAmountPercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_c4838814-aef4-4da3-99f5-6a51b1faae65">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Scheduled Principal Payments on Outstanding Debt, as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.137%;"/&gt;
        &lt;td style="width:1.814%;"/&gt;
        &lt;td style="width:1.376%;"/&gt;
        &lt;td style="width:15.714%;"/&gt;
        &lt;td style="width:0.96%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,026,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;41,973,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total principal payments outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_e7fe1fa8-1fe7-4e4a-a1d2-3e883018e6f8"
      unitRef="U_USD">8026818</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_e3db0be5-f5ae-47c4-85d8-06b45d68bd4b"
      unitRef="U_USD">41973182</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_ac76876a-3a25-4c46-bae3-6a7e0ccbdcc2"
      unitRef="U_USD">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_51631803-923f-42d2-97c1-9f11432bb7e9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 5. Net Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per common share:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.056%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.085%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.085%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted net loss per common share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;39,632,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;29,259,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted average common shares outstanding&#x2014;basic&lt;br/&gt;&#160;&#160;&#160;and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;38,323,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;37,429,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss per common share&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following potentially dilutive securities outstanding at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.927%;"/&gt;
        &lt;td style="width:1.627%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:12.897%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.627%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:12.897%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,219,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,385,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;667,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;303,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,901,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,705,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_f449e1b5-28c8-4fea-a279-dad434262756">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per common share:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.056%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.085%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.085%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted net loss per common share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;39,632,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;29,259,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted average common shares outstanding&#x2014;basic&lt;br/&gt;&#160;&#160;&#160;and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;38,323,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;37,429,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss per common share&#x2014;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_40557c49-68d9-4e0d-ac24-e8e18e914188"
      unitRef="U_USD">-39632311</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_83f1ab48-e7fc-4ced-8c16-6b9bb77dd7f1"
      unitRef="U_USD">-29259970</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_6bd50fa6-ea6a-46da-92ff-930e6e42a663"
      unitRef="U_shares">38323167</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_cd224ff2-5d2d-47b0-8e89-a5b7444d7888"
      unitRef="U_shares">37429450</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="2"
      id="F_bee25b21-b5da-4840-b8d0-3413b142b684"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="2"
      id="F_09685e11-7908-419e-8ae6-9266b4c262cd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.78</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_092a4d31-23dc-47e1-83c6-e637145d6d7c">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following potentially dilutive securities outstanding at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.927%;"/&gt;
        &lt;td style="width:1.627%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:12.897%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.627%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:12.897%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,219,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,385,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;667,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;303,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,901,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,705,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1f6dcc9c-a3d6-4cf1-8464-0d285bc4d9a6"
      decimals="0"
      id="F_3cd1bf61-c0d6-4a05-8501-f8ef643d15f3"
      unitRef="U_shares">6219030</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a6291cbc-4212-426f-966c-f9d236bef96a"
      decimals="0"
      id="F_50c0390e-967f-44ab-b9c6-5e10019ef1cd"
      unitRef="U_shares">4385598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3c22e247-ede4-4b63-a5a8-09b68eef26a4"
      decimals="0"
      id="F_d441581b-e811-401c-8496-50272c451505"
      unitRef="U_shares">667366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4616eca2-d061-41e6-b773-9b50623ea068"
      decimals="0"
      id="F_9152783c-7640-402d-bc09-93832956b0cc"
      unitRef="U_shares">303983</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b2abbcf3-4402-4301-9f22-3638b33916cb"
      decimals="0"
      id="F_11c25c99-acba-4d68-b491-4d4d7ba5472f"
      unitRef="U_shares">15541</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ad457fe7-35cb-4f1c-adfe-9364d3096822"
      decimals="0"
      id="F_17c5840a-cee6-4ae1-9949-b09c9a5b62b3"
      unitRef="U_shares">15541</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_89d13552-03e9-4c1d-8d8a-5da94eafa3fc"
      unitRef="U_shares">6901937</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_1e89daab-ce9f-40ff-a475-773c1b0ed6b4"
      unitRef="U_shares">4705122</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_cad6ede2-da7a-4638-89b0-736772a8cd32">&lt;p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 6. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022 and 2021, the Company had the following operating lease expense:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.459%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:30.534%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:14.052%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:14.052%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Statement of Operations Location&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;290,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;286,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;290,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;286,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments of the Company&#x2019;s operating leases as of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.809%;"/&gt;
        &lt;td style="width:1.934%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:15.972%;"/&gt;
        &lt;td style="width:0.914%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;885,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;105,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;990,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;22,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;967,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2022, the Company entered into an agreement to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; the lease of 22 Cortlandt Street for a term of&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; six months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; from August 1, 2022 through January 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; As of  &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the remaining lease term for our operating lease was &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; years with a discount rate of &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses its incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_dc25ae0e-afde-441f-8a28-1819b7eb3bf9">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022 and 2021, the Company had the following operating lease expense:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:30.459%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:30.534%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:14.052%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:14.052%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.692%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Statement of Operations Location&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;290,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;286,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total operating lease expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;290,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;286,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_7ba32c09-ff41-4912-b05b-767b2f5e43d0"
      decimals="0"
      id="F_e7b8001e-6af5-4ac6-a881-705869481b2f"
      unitRef="U_USD">290769</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_fda19f6a-c507-42ec-b932-514114edee24"
      decimals="0"
      id="F_09500908-2491-40c4-aaf5-18f9987289a2"
      unitRef="U_USD">286923</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_1ad80ec0-49e9-455e-bc7b-f904ed91cb03"
      unitRef="U_USD">290769</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_60a7456a-3615-40cf-8010-c7de51b17ffa"
      unitRef="U_USD">286923</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_4c2531ac-3451-44dc-a983-93f09472fc8d">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments of the Company&#x2019;s operating leases as of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.809%;"/&gt;
        &lt;td style="width:1.934%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:15.972%;"/&gt;
        &lt;td style="width:0.914%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;885,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;105,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;990,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;22,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;967,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_a032c9d4-b1da-49b3-ac91-ef0b818cf893"
      unitRef="U_USD">885000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_93e1341a-39c0-4cfc-9133-ca757eed58c6"
      unitRef="U_USD">105000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_5ea95d2c-3b5e-445b-a930-7b7dcdfcb51a"
      unitRef="U_USD">990000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_409849f0-9471-4c92-b71f-1bb0c8076c11"
      unitRef="U_USD">22752</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_214e91e4-f534-4748-a5d3-935450aa10d2"
      unitRef="U_USD">967248</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_eb204685-e6ea-4773-a87b-6b3afd596a2d">In January 2022, the Company entered into an agreement to extend the lease of 22 Cortlandt Street for a term of six months from August 1, 2022 through January 31, 2023.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_e28be1eb-3744-4d7c-90a3-4bcbdc142b35">extend the lease of 22 Cortlandt Street for a term of six months from August 1, 2022 through January 31, 2023.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_ed7f64ac-9d3d-4975-a4ad-4adbcbe2e765"
      id="F_167175b9-678a-4d3d-9612-304f110a6030">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_2dda7b7d-4eb5-4947-be5a-64886b352ff5"
      id="F_91e739cf-c1d4-4e60-b1c0-deef6fb83ece">P6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      id="F_2ea0e1f9-2cb7-40b9-99bd-dbbf3cc30775">P0Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="3"
      id="F_77ea11ac-ab99-44a7-bb4e-9ca61543fe46"
      unitRef="U_pure">0.060</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_2d5cf7da-0b39-4a99-ab35-13790f335cfd">&lt;p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 7. Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Capital Structure&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2019, the Company entered into the December 2019 Sales Agreement with SVB Leerink, pursuant to which the Company may sell up to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in shares of the Company&#x2019;s common stock from time to time through SVB Leerink, acting as the Company&#x2019;s sales agent, in one or more at-the-market offerings utilizing the 2019 Shelf Registration Statement. SVB Leerink is entitled to receive a commission of &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the gross proceeds for any shares sold under the December 2019 Sales Agreement. The December 2019 Sales Agreement was replaced by the March 2022 Sales Agreement (see below).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2022, the Company entered into the March 2022 Sales Agreement with SVB Leerink, pursuant to which the Company may sell up to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in shares of the Company&#x2019;s common stock from time to time through SVB Leerink, acting as the Company&#x2019;s sales agent, in one or more at-the-market offerings utilizing the 2019 Shelf Registration Statement. SVB Leerink is entitled to receive a commission of &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the gross proceeds for any shares sold under the March 2022 Sales Agreement. The March 2022 Sales Agreement supersedes the December 2019 Sales Agreement, dated December 5, 2019, by and between the Company and SVB Leerink LLC.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the December 2019 Sales Agreement and March 2022 Sales Agreement, for the three months ended March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company received approximately $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;32.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in gross proceeds through the sale of &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,044,081&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, of which net proceeds were approximately $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;31.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The holders of shares of common stock are entitled to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. The holders of shares of common stock are entitled to receive dividends, if and when declared by the board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-6.383%;padding-left:6.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Shelf Registration Statement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 5, 2019, the Company filed an automatic shelf registration statement (&#x201c;2019 Shelf Registration&#x201d;) with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for the issuance of common stock, preferred stock, warrants, rights, debt securities and units. It became effective upon filing with the SEC and is currently the Company&#x2019;s only active shelf registration. Through the date of this report, the Company has issued common stock of approximately $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;261.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million pursuant to such shelf registration statement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under SEC rules, the 2019 Shelf Registration Statement allows for the potential future offer and sale by the Company, from time to time, in one or more public offerings, of an indeterminate amount of the Company&#x2019;s common stock, preferred stock, debt securities, and units at indeterminate prices. At the time any of the securities covered by the 2019 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,187,058&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for the issuance of stock options or stock-based awards under the Company&#x2019;s 2015 Omnibus Incentive Compensation Plan at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.8pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the stock option activity for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.963%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:0.835%;"/&gt;
        &lt;td style="width:9.037%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:9.016%;"/&gt;
        &lt;td style="width:0.846%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:0.857%;"/&gt;
        &lt;td style="width:9.027%;"/&gt;
        &lt;td style="width:0.846%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.868%;"/&gt;
        &lt;td style="width:0.846%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;contractual&lt;br/&gt;term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,090,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;28.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,223,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;67,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;43.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;53.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,219,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;28.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;106,188,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Vested and expected to vest at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,219,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;28.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;106,188,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,932,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,434,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method as described in the SEC&#x2019;s Staff Accounting Bulletin No. 107 relating to stock-based compensation. The simplified method was chosen because the Company has limited historical option exercise experience due to its short operating history. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for a period approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. Expected volatility is based on historical volatilities of similar entities within the Company&#x2019;s industry which were commensurate with the Company&#x2019;s expected term assumption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted average grant date fair value of options granted was $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per option for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022. As of March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;91.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of total unrecognized compensation cost related to non-vested stock options which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. These amounts do not include &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,169&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; options outstanding as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022, which are performance-based and vest upon the achievement of certain corporate milestones. Stock&#x2011;based compensation will be measured and recorded if and when it is probable that the milestone will occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2020, the Company began granting RSUs covering an equal number of its shares of common stock to employees. The fair value of RSUs is determined on the date of the grant based on the market price of its shares of common stock as of that date. The fair value of the RSUs is recognized as an expense ratably over the vesting period of &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, total compensation cost not yet recognized related to unvested RSUs was $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the RSU activity for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.759%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
        &lt;td style="width:12.857%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.857%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;302,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;42.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;429,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;23.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;41.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;48.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;667,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022 and 2021 was allocated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.149%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.243%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.243%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,809,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,534,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,788,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,196,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7,598,329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,731,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes warrant activity for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.759%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
        &lt;td style="width:12.857%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.857%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;80.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;80.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Outstanding Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the first advance of the 2020 Term Loan, Hercules Capital Inc. received warrants to purchase an aggregate &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,541&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;80.43&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, which was the volume weighted average price of the Company&#x2019;s common stock over the &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;-day trading period immediately preceding the initial closing, subject to certain limited adjustments as specified in the warrant. The warrants are exercisable for &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of issuance. The warrants were classified as a component of stockholders&#x2019; equity. The relative fair value of the warrants of approximately $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the debt. The discount on the debt is being amortized to interest expense over the term of the debt utilizing the effective interest rate method.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <axsm:CommonStockSalesAgreementAuthorizedAmount
      contextRef="C_bdddd48e-24d8-466b-85d6-b30c067ffe9b"
      decimals="INF"
      id="F_9dc75894-e29c-4343-8146-621e06f9f2d0"
      unitRef="U_USD">80000000</axsm:CommonStockSalesAgreementAuthorizedAmount>
    <axsm:CommonStockSalesAgreementCommissionPercentage
      contextRef="C_7beabbcc-8b62-4676-8c90-7970bd0c23b7"
      decimals="3"
      id="F_fde932fb-91e0-455f-8e36-380bbbd20480"
      unitRef="U_pure">0.030</axsm:CommonStockSalesAgreementCommissionPercentage>
    <axsm:CommonStockSalesAgreementAuthorizedAmount
      contextRef="C_ebcc446a-08e2-4b02-a7fc-b6339311af4e"
      decimals="-6"
      id="F_6d8874c8-f24d-44ac-b2c5-1025745bb40b"
      unitRef="U_USD">200000000</axsm:CommonStockSalesAgreementAuthorizedAmount>
    <axsm:CommonStockSalesAgreementCommissionPercentage
      contextRef="C_044ac2dd-a43b-4bf0-a117-1190f9ff7f2e"
      decimals="3"
      id="F_c64b361c-262e-430a-8794-8460f002fbfb"
      unitRef="U_pure">0.030</axsm:CommonStockSalesAgreementCommissionPercentage>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b4195b45-d05d-44d6-967c-803d41a1847f"
      decimals="-5"
      id="F_52d40f98-6e64-4244-a1cf-b0247d05dbd3"
      unitRef="U_USD">32000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b4195b45-d05d-44d6-967c-803d41a1847f"
      decimals="INF"
      id="F_918406ab-a3b6-41a4-845c-2e1d1b9f147c"
      unitRef="U_shares">1044081</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <axsm:StockIssuedDuringPeriodValueNewIssuesNet
      contextRef="C_b4195b45-d05d-44d6-967c-803d41a1847f"
      decimals="-5"
      id="F_ea5cad97-7745-444a-a30b-017d23e24843"
      unitRef="U_USD">31000000.0</axsm:StockIssuedDuringPeriodValueNewIssuesNet>
    <axsm:EquityInstrumentVotingRightsPerShare
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="INF"
      id="F_3753dc59-939a-415d-8656-d0c4b30831ce"
      unitRef="U_Vote">1</axsm:EquityInstrumentVotingRightsPerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_41c6af09-fd7f-47cc-bdbe-fdeca00ab829"
      decimals="-5"
      id="F_e822c528-9fee-4add-813f-3db10df67b01"
      unitRef="U_USD">261200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_3c213636-da72-4c96-a325-3f0b156f4462"
      decimals="INF"
      id="F_642e9f95-59ca-4614-a56d-15806cb6ac17"
      unitRef="U_shares">2187058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_fb55cefa-86d3-46fa-8470-987b8c7092d1">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the stock option activity for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.963%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:0.835%;"/&gt;
        &lt;td style="width:9.037%;"/&gt;
        &lt;td style="width:0.921%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:9.016%;"/&gt;
        &lt;td style="width:0.846%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:0.857%;"/&gt;
        &lt;td style="width:9.027%;"/&gt;
        &lt;td style="width:0.846%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:10.868%;"/&gt;
        &lt;td style="width:0.846%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;contractual&lt;br/&gt;term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,090,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;28.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,223,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;18,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;67,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;43.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;53.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,219,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;28.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;106,188,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Vested and expected to vest at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,219,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;28.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;106,188,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,932,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,434,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="INF"
      id="F_72619c62-777e-4eb1-966b-d02df1f7822d"
      unitRef="U_shares">5090377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="2"
      id="F_e29174f1-688b-48c7-93fc-79b0d0e25160"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="INF"
      id="F_f7f5becc-e990-4e49-88fa-459fb5fa64a2"
      unitRef="U_shares">1223019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="2"
      id="F_2840b311-ed29-4e6c-b2f7-5f8aaccbc286"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">30.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="INF"
      id="F_e81fc71f-eed9-4f86-b569-df382ba7b75d"
      unitRef="U_shares">18015</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="2"
      id="F_a0b73d34-3083-4baa-99ba-ee6041814ffb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="INF"
      id="F_ffee1ffd-2e30-46f0-a32f-9aca09fc95a8"
      unitRef="U_shares">67139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="2"
      id="F_259eaad2-3df8-4fb6-b0c3-a31cf58b38c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">43.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <axsm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="INF"
      id="F_17629ea4-e34c-4d8c-a379-fac135e57e0d"
      unitRef="U_shares">9212</axsm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="2"
      id="F_66937464-1495-4c04-ae6c-9eae9c296caa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">53.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_3c8df0d0-6e5b-4377-b552-7071b966e75f"
      unitRef="U_shares">6219030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="2"
      id="F_8ef018ed-2140-495e-8c0b-2058272d76f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_cfd1b48d-f580-4713-b4e5-f6d9e9a66a9d">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_42b8ceb9-105b-49b2-9454-dab63e1abb71"
      unitRef="U_USD">106188389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_2398fb3c-3338-4055-a867-0ca508d75ec4"
      unitRef="U_shares">6219030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="2"
      id="F_7ba1e5ed-6930-4931-ae7c-09a7914f2ead"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_3bbb7169-00ad-4451-84fa-a262839259d9">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_206bb63f-f030-4794-a242-41cc436484f7"
      unitRef="U_USD">106188389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_0fd6f754-b4b8-46ce-86a6-a681bab37616"
      unitRef="U_shares">2932835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="2"
      id="F_e8c6d4f2-9f32-4742-97b8-5e4977d07771"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_a7407870-be2a-41eb-a0e4-36a4adbee7ce">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="0"
      id="F_c0cfb877-4829-4716-b652-2d229f9c5924"
      unitRef="U_USD">82434018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="2"
      id="F_f7912a89-c4f0-4a2c-80b9-0bb6edeb1b6b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="-5"
      id="F_00bb7d06-3567-4081-a9db-b048349ea6fe"
      unitRef="U_USD">91000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_cab74e76-cd4a-41fb-b619-79ff2a5d63a9">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_74f3931c-7d51-4c02-b4d9-da6b42618366"
      unitRef="U_shares">6169</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188"
      id="F_302a6813-a6e8-47d9-826a-2b3c68c73ba8">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_7fa0e148-2225-4c34-bcbe-ec944991768c"
      decimals="-5"
      id="F_2578175b-3c42-49a2-b0aa-a17544e0e73f"
      unitRef="U_USD">19500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188"
      id="F_ca8a50eb-4058-4c1c-b961-515bd082dc61">P3Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_dc43d87a-d786-44dd-bfcd-4b6316749c1e">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the RSU activity for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.759%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
        &lt;td style="width:12.857%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.857%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;302,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;42.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;429,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;23.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;61,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;41.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;48.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;667,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;30.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_e5af5223-2fe5-4213-acad-7c31eefaf440"
      decimals="INF"
      id="F_0ef6e2a0-c96a-4274-ad62-1866fe58aeea"
      unitRef="U_shares">302764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_e5af5223-2fe5-4213-acad-7c31eefaf440"
      decimals="2"
      id="F_fa1071a8-5ea3-45e1-b965-d679b60071aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">42.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188"
      decimals="INF"
      id="F_6fa5f770-78fa-485c-b769-90d7c67604a1"
      unitRef="U_shares">429902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188"
      decimals="2"
      id="F_e2206770-d29c-4240-9a5b-58192a77b976"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188"
      decimals="INF"
      id="F_a852e80f-d1bb-41ac-a8ff-1340a03efa93"
      unitRef="U_shares">61581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188"
      decimals="2"
      id="F_e93b792c-4c2f-4a88-91e5-afab9866e23e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">41.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188"
      decimals="INF"
      id="F_db1d7a56-977d-43f1-9e43-1f068ca65143"
      unitRef="U_shares">3719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_203ed062-9609-4a15-a548-eb77d8ad1188"
      decimals="2"
      id="F_15e0d61d-8ca3-48a1-a38f-ea82740f9889"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">48.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_7fa0e148-2225-4c34-bcbe-ec944991768c"
      decimals="INF"
      id="F_c7238d0e-fdf5-41f8-af4e-697346685f55"
      unitRef="U_shares">667366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_7fa0e148-2225-4c34-bcbe-ec944991768c"
      decimals="2"
      id="F_3181b95a-e38c-460c-82f5-0a724ae1d13e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">30.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_454b127d-633b-454d-8f5b-f4dcfa8b02eb">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022 and 2021 was allocated as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.149%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.243%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.243%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,809,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,534,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,788,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,196,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7,598,329&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,731,097&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bb6e9275-c30c-46d5-9e05-d49f1beb2c70"
      decimals="0"
      id="F_87b32e65-b884-48c0-8392-a133d8baea15"
      unitRef="U_USD">1809477</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d9bc5005-9c34-42dc-a103-770e8beb2d78"
      decimals="0"
      id="F_2dbc80c4-6fbc-4953-8231-61ce2b36818b"
      unitRef="U_USD">1534395</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7ba32c09-ff41-4912-b05b-767b2f5e43d0"
      decimals="0"
      id="F_d3a1c46d-da39-4a7c-a135-3b40e82ade6d"
      unitRef="U_USD">5788852</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fda19f6a-c507-42ec-b932-514114edee24"
      decimals="0"
      id="F_7d73f20e-a4ba-4ccf-a80c-bb1e61fcce7e"
      unitRef="U_USD">2196702</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_2741d067-206d-4cf4-a007-16df2ade74b5"
      unitRef="U_USD">7598329</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2357bd34-be20-473a-9a97-21a5de4d2722"
      decimals="0"
      id="F_28073dc2-5ffe-47fa-b31e-aa3ac0fed1a1"
      unitRef="U_USD">3731097</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_694f84c8-5c9b-40b7-8e42-a2c9e39e7f24">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes warrant activity for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.759%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
        &lt;td style="width:12.857%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:12.857%;"/&gt;
        &lt;td style="width:0.985%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;exercise price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;80.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;15,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;80.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="INF"
      id="F_9628b6ce-da64-4ea3-a7ae-93f2287a37b9"
      unitRef="U_shares">15541</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_8499400d-f664-4e71-b17e-d1301c2cb375"
      decimals="2"
      id="F_6a20dc6d-b0c0-4fb8-be3e-71508febbc6e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">80.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <axsm:WarrantsIssuedInPeriod
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="INF"
      id="F_84997054-e05a-4e2e-96bf-e2847d116015"
      unitRef="U_shares">0</axsm:WarrantsIssuedInPeriod>
    <axsm:WarrantsIssuedInPeriodWeightedAverageExercisePrice
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_181b5d71-6a1d-45e6-a008-b69501b9a243"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</axsm:WarrantsIssuedInPeriodWeightedAverageExercisePrice>
    <axsm:WarrantsExercisedInPeriod
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="INF"
      id="F_0e5e8f79-77cd-4baf-bf36-eec64b106c87"
      unitRef="U_shares">0</axsm:WarrantsExercisedInPeriod>
    <axsm:WarrantsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      decimals="0"
      id="F_74580b84-6e5e-4cea-9312-50390c09a5b2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</axsm:WarrantsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="INF"
      id="F_a7963d98-b87c-4238-9090-ab2b5c4e1a2a"
      unitRef="U_shares">15541</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_9f1904ba-152a-46e9-9e57-e92380cbcce6"
      decimals="2"
      id="F_bdebcb4a-9945-4a54-b7d7-2d81b1e201ec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">80.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_3d7b6b8c-7fba-4794-bad1-9528cd8b0a02"
      decimals="INF"
      id="F_851ddb8b-9871-4b7e-ab9f-1864d806e016"
      unitRef="U_shares">15541</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3d7b6b8c-7fba-4794-bad1-9528cd8b0a02"
      decimals="2"
      id="F_3dfb15e3-a7f0-402d-9f0f-20a946012944"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">80.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <axsm:ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays
      contextRef="C_234c04e9-be43-4c65-8294-bca64c8b14d4"
      decimals="INF"
      id="F_8e6c9850-4a9e-4883-9dbc-ad0f1b420de7"
      unitRef="U_D">10</axsm:ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays>
    <axsm:ClassOfWarrantOrRightTerm
      contextRef="C_234c04e9-be43-4c65-8294-bca64c8b14d4"
      id="F_ccd646e7-2bcb-498d-816b-2a0023531fb1">P7Y</axsm:ClassOfWarrantOrRightTerm>
    <axsm:FairValueOfWarrants
      contextRef="C_3d7b6b8c-7fba-4794-bad1-9528cd8b0a02"
      decimals="-5"
      id="F_755a5911-d3e0-4721-ae40-fa112a229e7f"
      unitRef="U_USD">900000</axsm:FairValueOfWarrants>
    <axsm:LicenseAgreementsDisclosureTextBlock
      contextRef="C_c6e03d77-74bc-438d-ac62-681542cd683c"
      id="F_c8569c9c-b8b2-46b2-bc9c-ae781562a911">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 8. License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Exclusive License Agreement with Pfizer&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2020, the Company entered into an exclusive license agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;) for Pfizer&#x2019;s clinical and nonclinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which the Company is developing for the treatment of narcolepsy. The agreement also provides the Company exclusive rights to develop and commercialize esreboxetine, a new late-stage product candidate referred to as AXS-14, in the U.S. for the treatment of fibromyalgia.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the agreement, Pfizer received &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;82,019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock having a stated value of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, based on the average closing price of the Company&#x2019;s common stock for the &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_94398959-42ea-49ba-9af0-943b9d4f9861;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; prior trading days of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;97.54&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, in consideration for the license and rights and also received an upfront cash payment of $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company determined that the fair value of each share of common stock granted to Pfizer on the closing date of January 9, 2020 was $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;87.24&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, based on the closing price of the Company&#x2019;s stock on that date. As a result, the fair value of the stock issued was $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and therefore, the total research and development expense recognized was $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to the Pfizer license agreement during the year ended 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pfizer can also receive up to $&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;323&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in regulatory and sales milestones, and tiered mid-single to low double-digit royalties on future sales related to the licensed products. Pfizer will also have a right of first negotiation on any potential future strategic transactions involving AXS-12 and AXS-14. During the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended March 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; milestone payments or royalties were paid to Pfizer by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Exclusive License Agreements with Antecip&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2012, the Company entered into &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; exclusive license agreements with Antecip, in which it was granted exclusive licenses to develop, manufacture, and commercialize Antecip&#x2019;s patents and applications related to the development of AXS-02, AXS-05, and AXS-04, anywhere in the world for human therapeutic, veterinary, and diagnostic use. Pursuant to the agreements, the Company is required to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize AXS-02, AXS-05, and AXS-04. Under the terms of the agreements, the Company is required to pay to Antecip a royalty equal to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for AXS-02, &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for AXS-05, and &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for AXS-04, of net sales of products containing the licensed technology by the Company, its affiliates, or permitted sublicensees. These royalty payments are subject to reduction by an amount up to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of any required payments to third parties. Unless earlier terminated by a party for cause or by the Company for convenience, the agreements shall remain in effect on a product-by-product and country-by-country basis until the later to occur of (i) the applicable product is no longer covered by a valid claim in that country or (ii) &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the first commercial sale of the applicable product in that country. Upon expiration of the agreements with respect to a product in a country, the Company&#x2019;s license grant for that product in that country will become a fully paid-up, royalty-free, perpetual non-exclusive license. If Antecip terminates any of the agreements for cause, or if the Company exercises its right to terminate any of the agreements for convenience, the rights granted to the Company under such terminated agreement will revert to Antecip. To date, the Company has not been required to make any payments to Antecip under any of the license agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the 2020 Term Loan, the Company entered into a Direct Agreement with Antecip pursuant to which Antecip consented to the collateral assignment of the License Agreement to Hercules, among other things.&lt;/span&gt;&lt;/p&gt;</axsm:LicenseAgreementsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_bd3b09d8-962f-4a8d-95b5-a2380be0bb5b"
      decimals="INF"
      id="F_2e51140f-1d37-466a-8c7f-484e6cfe0cf8"
      unitRef="U_shares">82019</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_bd3b09d8-962f-4a8d-95b5-a2380be0bb5b"
      decimals="-5"
      id="F_dc317c00-69c3-41a6-b078-6227c0108b0d"
      unitRef="U_USD">8000000.0</us-gaap:CommonStockValue>
    <us-gaap:SharePrice
      contextRef="C_bd3b09d8-962f-4a8d-95b5-a2380be0bb5b"
      decimals="2"
      id="F_a39794dd-6e82-45d8-ae5d-ca876bd7edb9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">97.54</us-gaap:SharePrice>
    <axsm:InitialCashPaymentPerCollaborationAgreement
      contextRef="C_d123927e-7029-4dd1-878a-36b68f4a9e6e"
      decimals="-5"
      id="F_318d20da-c3d4-4f5b-bc0b-2f49d6ae2fc7"
      unitRef="U_USD">3000000.0</axsm:InitialCashPaymentPerCollaborationAgreement>
    <axsm:SharePriceFairValue
      contextRef="C_c4afe19c-11d0-445b-b47f-99cea4fdcb9b"
      decimals="2"
      id="F_aeff018b-40f5-4041-a95d-c2205a27ad2e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">87.24</axsm:SharePriceFairValue>
    <axsm:CommonStockFairValue
      contextRef="C_c4afe19c-11d0-445b-b47f-99cea4fdcb9b"
      decimals="-5"
      id="F_9ef376c9-40f3-4371-ba9f-c8647abeaeca"
      unitRef="U_USD">7200000</axsm:CommonStockFairValue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cc7591c2-a315-4ba0-8ba7-30d3937ab8ef"
      decimals="-5"
      id="F_ead86fa5-b053-4f48-b252-b82fc722ea31"
      unitRef="U_USD">10200000</us-gaap:ResearchAndDevelopmentExpense>
    <axsm:CollaborationArrangementFuturePotentialPayments
      contextRef="C_13dea1cb-aa1f-4a8f-94bb-ccbf522d6b7d"
      decimals="-6"
      id="F_35e0bece-3702-4a3c-93c6-66ef1642e29f"
      unitRef="U_USD">323000000</axsm:CollaborationArrangementFuturePotentialPayments>
    <us-gaap:RoyaltyExpense
      contextRef="C_6c8df518-2cca-4db3-a63e-69a63815b2f7"
      decimals="0"
      id="F_d8166d53-413b-4784-8c72-99e168790feb"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_838ee7b0-8654-4765-abd6-662f63a4c8c8"
      decimals="0"
      id="F_967b5f93-9495-479a-a8e9-201fd1a74b04"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <axsm:NumberOfLicenseAgreements
      contextRef="C_d49b89d1-f1b7-475f-9685-738cdbff9497"
      decimals="INF"
      id="F_cad06444-bf4c-49a4-bf2a-55f593ea8d5d"
      unitRef="U_Item">3</axsm:NumberOfLicenseAgreements>
    <axsm:LicenseAgreementRoyaltyDuePercentageOfNetSales
      contextRef="C_5d352228-7b5b-4785-b9bd-1cfc63c353da"
      decimals="3"
      id="F_7177e4a0-2023-4e34-a80c-5379304f4e9d"
      unitRef="U_pure">0.045</axsm:LicenseAgreementRoyaltyDuePercentageOfNetSales>
    <axsm:LicenseAgreementRoyaltyDuePercentageOfNetSales
      contextRef="C_70fafa52-2071-4fb1-b999-e133e767989d"
      decimals="3"
      id="F_a46274e0-54ea-4e33-85fa-caf355787ef9"
      unitRef="U_pure">0.030</axsm:LicenseAgreementRoyaltyDuePercentageOfNetSales>
    <axsm:LicenseAgreementRoyaltyDuePercentageOfNetSales
      contextRef="C_d9fad345-924e-408f-93e8-d534f64b717a"
      decimals="3"
      id="F_2f74793d-3232-41eb-ae03-0b3137414679"
      unitRef="U_pure">0.015</axsm:LicenseAgreementRoyaltyDuePercentageOfNetSales>
    <axsm:LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties
      contextRef="C_d49b89d1-f1b7-475f-9685-738cdbff9497"
      decimals="INF"
      id="F_d44b336e-0b0f-444d-803c-61cabbe582b9"
      unitRef="U_pure">0.500</axsm:LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties>
    <axsm:LicenseAgreementTerm
      contextRef="C_d49b89d1-f1b7-475f-9685-738cdbff9497"
      id="F_36f41e30-a446-40f3-9dcf-5146d0803034">P10Y</axsm:LicenseAgreementTerm>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  2)HE0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  $B:)4?5<O#NX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2@,Q$(9?17+?G6Q**X1M+HHG!<&"XBTDTS:XV81D9+=O[VYLMX@^@,?,_/GF
M&YC61&E"PN<4(B9RF&]&W_59FKAE1Z(H ;(YHM>YGA+]U-R'Y#5-SW2 J,V'
M/B (SC?@D;35I&$&5G$A,M5:(TU"32&=\=8L^/B9N@*S!K!#CSUE:.H&F)HG
MQM/8M7 %S##"Y/-W >U"+-4_L:4#[)P<LUM2PS#4PZKDIAT:>'MZ?"GK5J[/
MI'N#TZ_L))TB;MEE\NOJ[G[WP)3@0E1\77&Q$XWDMW*]>9]=?_A=A7VP;N_^
ML?%%4+7PZR[4%U!+ P04    "  $B:)4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M  2)HE2<)(M<604  "$6   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9A=<^(V%(:OM[]"P_2BG0FQ+?.1[!!F'$)VF2:$!';;M-,+80OL6=NBLAS"
MO^^1#39AS+&GO0%_G=>/CZ3W2!ILA?R1^)PK\AZ%<7+3\I7:?#:,Q/5YQ))+
ML>$QW%D)&3$%IW)M)!O)F9<%1:%!3;-G1"R(6\-!=FTFAP.1JC"(^4R2)(TB
M)G>W/!3;FY;5.EQX"=:^TA>,X6##UGS.U;?-3,*94:AX0<3C)! QD7QUTW*L
MSR/;U@'9$]\#ODV.CHG^E*40/_3)Q+MIF9J(A]Q56H+!WQL?\3#42L#QSUZT
M5;Q3!QX?']3OLX^'CUFRA(]$^'O@*?^F==4B'E^Q-%0O8ON5[S^HJ_5<$2;9
M+]GFSW8Z+>*FB1+1/A@(HB#._]G[/A'' ?1, -T'T), Z]P;['U ECDC)\L^
MZXXI-AQ(L252/PUJ^B#+318-7Q/$NAGG2L+= .+4\$ZX*;2*(BSVR#A6@=J1
M29QW#YWF-DE\)GDR,!2\3<<8[E[Y-E>F9Y1M\BABY2>@ZG'O8[P!E 4J/:#>
M4E3PD<E+8EL7A)J45O",\'!G ^&T5Q7^ <<N,F=G>O89O9%XXY+\Y2P3):$S
M_HU(=@K)3B;9J6N,Q6[#JS*.AUMF^QFAZ!84W684SRF3BLMP1U[X1DA5181+
M*9ERA*A7$/4:YD4R,)"L8YY'PK56+$PPIG[!U&_&-.,R$'KL> 1&8&6SX4J'
M?OW3IT\U7?.J8+M"%??C^#X(.9FFT9++*BI<PS2MMMWOV5V$Y[K@N6["\\+7
M@1XLD+0IBRHSA>LX?\R?'L=D\77\XLS&WQ:3T?R"3*:C2X31,DLG-)M03F)7
M2.A;F?]=D+F"1B5"DI%(8R5W\.]5HM>HWXTQR".[MII +M@[F7C0_8)5X.9.
M?;ZA:R0[W7:'=JQKLX\1TI*0-B%T/ _*1G)Q." /\!QYBJMSATM2"EF7*H0:
MI:!!)!0[#+5T<,O^[ZB+K:A$Q26MGO+)?2B$Q C+@F#AEGY*.-)GT!D78AM7
MTN%R4YA6O<*T"F,KRX2%F_LI6S%29E*\!;%;W=*XYO050ROKA86;_"G:3"2*
MA>3/8'-^^.**EFGBXZ.L&Q9N]UD3.C#E/H^""U +JQ%6620LW.$?A LYF?DB
MQJI$C8AMT[8-[H$1E67"POU]$2BH6&)%+/K+\E<RYVXJ(5N56+C22$01>.)<
M"?<'-#^3Y#L+4TY^-B^A(2U=M,E<3VRQ>6E9.2CN[3 M\8)X3>:[:"G"*MP:
M 2ALCQA)61XH[N6'E)'QN^NS>,W/5MH:H:DSOW.PV20M"P)M5!!&J91ZOI1/
MW+)T@6&DE2N+&L77T_7(1[+2_VDC_Y_$,,O-UY-Z"L<.J)5DN&(-6>G[M)'O
MZQD<S#S 5]="5HZ#&IT')J$/.*X+ZV:8T7 OE\082_^GC?Q_'K$P)+=I K>3
MZM;$=>IFY+2T?=K(]L<1EVO=P;Z  I1C,(,-BZO3]_\6"[1T?8J;]B%9/H=D
M84"X3"U0Z?ZTT1KAHU%FEIB0IU1!O8RUIU6NLW/E;J:L]XG>AO;5M65WN^;
M>*NB*BL K?'MO4G<!XDN3J\<G!M;6=7(M=L6E">L.-FER=LU$_C#@N^8[1XN
M5O;Y&K&Z/8C2\&W<IT^I]JO1\URXW#.:J]+R[6:6#V 2H":QQ]_);[RRQ]=(
MZ7+=[5]WZ!5&=K1I@QNT \GR\H2%K*IWW]8(G!V!QM$FG#:@;&\R(:Y>-N;[
M<<758O_3R7;]C/+Q?//TD6G_2DC(5Q!J7O9AJ,E\/S(_46*3;>DMA5(BR@Y]
MSCPN]0-P?R6$.ISH%Q2[PL-_ 5!+ P04    "  $B:)47;U.(/8$  !B$0
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M)902QHXPC^T8IU+$ ?,>,)\%_)?UJGP#2#Z:7 I)LXR*(Y0Q0TXD83@.5/1
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M4(QF=Z#?77B[[<[$-];#";L;;K2"!((!/+^UUC]?A&-V_[?*^C]02P,$%
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M1GP;5Y1_OH2*Q3$JUA+T 2%V/'Z+QQ_%4U?<5'6AU$E8(5LSCU4IV9;#MV&
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M5,>=V^.)8+MZ:_*)"<&*^G!+8_E.*0-Y?\.8>#M1NYWM_OG\/U!+ P04
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M5+IC=IVAAO*?![&WVNYD9J@P4'1 $_O5WFF8)*-;L],B/"U&@T6]S$H#?2A
M(]!=AA/0.['"R9O6<R-*!GW3:]>3=(I"IA7E7LF4\^RT;;0^P#S<+B[T1P5(
MI;8M$SKLX;$%\<%V;"[BR% _H 7R:.3U&TZ'981Q2,<TDG1*0_#_%A%_XBH5
MFM<-@6T-G/NAF?%%A:(X\OM5UF678&@51_*;=&I&+J@9>VZ/7X8]P5G0['8R
MSV QX-LI)G9D*G,&X% I2L-DC.Q.I,BT2+4I]J[)L?=HK^2C@!,=6C^_8MLV
M^(;R!&<4#T=!T*=X:$D]DN!H1 )()V3D\D'J7<939?NI]Q!*_63KAHW0"=LA
M2""JH1?WI<MIF1" 3? (\$Z[R+1V5;6"&;3F6U&6EFS8)"!?0KKWPE"&(.MB
M0L,!UT-+3'T*?6PXQG8G6&3Z)'8"S6VW, EW>*ZB0>S%,1UP/+2$#11![?')
M"-Q.]D@\68\?#OM]7MV L+PZ?<'1]:!J%4Q/M1JV2GU]!G5DJHDEG8*1:07[
M4AH.LQAD6UDG.T,!@KZ.PIFD3PX=G/ Q' K/#5]B[*2*3!^L_KIXD$)R;1AX
M51K,G]+Z$ -4O>T4T^ X#R&,L$_[$2S.+KT*KK;57:!&53==WR:U7]O[QMOJ
MEJWW_0Y?K>I;PVZ8^A+S*U.0:QI0;V!([V,,"Z#J>\'ZQ<A]=;6VEL;(HGK<
M<99Q90W@_QLIS>G%3M#>SB[_ U!+ P04    "  $B:)4;4ZLH%L0   8+
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M!L0ZG7TIZ3VSO6X-]0JG]F</,HK<P12MA_"0/OY.%DN5*3G>TXP)RP$70@8
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M@%:73.3[+32[,1N>?6%.<9%2X+RA<1ICV8"G=438+9N\,W6-J9FD679 GI.
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M;O)-=.?PKZ0S@=$7'<3TL:Y7J%[=(+.M47D2A?@4^:A$5RB!J>B.;%Q$OMC
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M7K:% FU/+A?[&C\L&D="$ 7G2 9A+58HR.I.$@"X7!U8FG.VY!L-G+,8HI9
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M_J:Y>].8+?_Z8&F:QE3\<J,DH$(#\'QE3-.]H07ZGZ,\_P]02P,$%     @
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M_+.5 ET)?6$:U#' C1BU4-CFO-C%,B$H.4QG,&>/"/W\(E>D+XZ'K+ $O\;
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M3.$9R41^(F'E:!6''/66>61[?GS*FIR;K:2.:IL!9_]$BOP#JL/0WRLQ#M?
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M_?1$/&3\T+LM_T[7PO6]V_"?:PH#3(<%]/W2N3Y^P 'IE]M>_1]02P,$%
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M=5,V$#"@J9-ZF'CFTGA?;B28[X2);PCFNT%ZCWO,B7U+O<2-V8\HAD1ED:$
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MH._6-]+,_,Y+R6IH%!,-DK"<>%?!Y32U]L[@)X.=ZHV1S60AQ+V=?"DG'K9
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M5,=W>[-"JZ+@[%DR5<)U]?>'SQ:N4ZE^&8R:+*[&GCMIC^UJ!+IPC_TC'=J
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MQX8)33BLD1(U8**JZJ+5Q,C2-:)7:;"MN6&.'QY0M@#?KZ4TAXG=H/F4)?\
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M=9&KA>5,PKTF9B$$U;_'P-5J%/6BS<8#F]?6;<1%WM Y3,$^-O<:5W%@J9@
M:9B21,-L%%WV+B9#9^\-OC%8F:TY<9$\*?7L%C?5*$J<(.!06L= <5C"!#AW
M1"CC5\<9!9<.N#W?L'_TL6,L3]3 1/'OK++U*#J+2 4SNN#V0:T^0Q?/J>,K
M%3?^2U:=;1*1<F&L$AT8%0@FVY&NNSQL 9!G-R#M .EK0'\/(.L F0^T5>;#
MNJ*6%KE6*Z*=-;*YB<^-1V,T3+HJ3JW&4X8X6TR4$,QB6:PA5%9DHJ1E<@ZR
M9&#(!S+%:U,M.! U(U\:T-2=DEO S)'K-=XE'(^NP%+&S3':/TZOR-&[XSRV
M*,ZYB,M.R+@5DNX1DI$[=%T;<BTKJ%[B8PPJ1)9N(ANG!PGOJ#XA6>\]29,T
MW:%G\G9X[X"<+"0Z\WS9'KY;9<RK[/ZX11MR8T&8GP<\](.'OO?0W^/AJ[*4
M$Q6*Q'V1H"W2KH*T= -/YU[[LDC/D^'@/(^7VWG:878V.$^S8/9"[6E0>WI0
M[2>0*)3[2W=9X<UFQCKA2SB0BD$@'_RG9 ^#A^&_3?;P;<G>8;8KV?'6BQ>@
MY[X1&E*JA;3M$PF[H==>^A;S:G^,/;AMF7]IV@:.#V#.I,'(9DB9G RQGKIM
MBNW"JL;WE2=EL4OY:8W_$=#. ,]G2MG-PCD(?Z;B#U!+ P04    "  $B:)4
M1J$ER84"   8!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R%E5UO
MVC 4AO^*%>VBDV@3 B&T"I%:4+5)K8;*NEU,NS#D %;]D=DGT/[[VDZ(4!O8
M#;%CO^=YCW..R?9*OY@M ))7P:69!%O$\B8,S6H+@IHK58*T*VNE!44[U9O0
ME!IHX46"AW$4C4)!F0SRS+^;ZSQ3%7(F8:Z)J82@^NT.N-I/@GYP>/'$-EMT
M+\(\*^D&%H#/Y5S;6=A&*9@ :9B21,-Z$MSV;^Y2M]]O^,5@;X[&Q&6R5.K%
M3;X7DR!RAH##"ET$:A\[F +G+I"U\:^)&;1()SP>'Z+?^]QM+DMJ8*KX;U;@
M=A*, U+ FE8<G]3^&S3Y)"[>2G'C?\F^V1L%9%495*(16P>"R?I)7YMS.!+$
M_1."N!'$WG<-\BYG%&F>:;4GVNVVT=S I^K5UAR3[J,L4-M59G683Y40#.TI
MHR%4%F2J)#*Y ;EB8,@E6=@J*"H.1*W)?865!O+()!.5( ]@3X/,Z5NMMAM^
ME*"ID]=KAES, "GCYFL6HC7KD.&J,797&XM/&'ND^HH,^CT21W'\O)B1BR\?
MHH0VU3;?N,TW]F$')\(^@#$ O8]6>^2!T27C#-]ZAY1Z9%8!^7.[-*AM\?P]
M0Q^T](&G#T_072Y=1U&K1E[EVFB7C\=)%$59N.N@#5O:\'^T01>M5B5'M'YT
MFI:TM.0L[:="R@GW15$V1=%%3S[1KZ^CD_112Q^=I;OO2I@H*X2",(F@P6 7
M?O0)?QG':1)WX],6GY[%SRW.)DQVE%>^5U1;7_6)\*:\;%=UN4H_%<#U*(V'
MXP^NPJ-&=W>F;9(-D\8RUE887:4V+UW?0_4$5>E[?ZG0WB1^N+57-VBWP:ZO
ME<+#Q%TG[9]!_@Y02P,$%     @ !(FB5 Z5V$H1 P  @0D  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&ULQ59=;],P%/TK5Y&00!I-FVQ=.[65N@[$
M$!/3)N!AVH.;W"86L5ULAW;_GFLG#65JC=@++VWLW'/NN5]V)ANEOYL2T<)6
M5-),H]+:]44<FZQ$P4Q/K5'2FY72@EE:ZB(V:XTL]R!1Q4F_/XP%XS*:3?S>
MK9Y-5&TK+O%6@ZF%8/KI$BNUF4:#:+=QQXO2NHUX-EFS N_1?EG?:EK%'4O.
M!4K#E02-JVDT'UPLQL[>&WSEN#%[S^ B62KUW2VN\VG4=X*PPLPZ!D9_/W&!
M5>6(2,:/EC/J7#K@_O.._;V/G6)9,H,+57WCN2VGT2B"'%>LKNR=VGS -IXS
MQY>IROA?V#2V0S+.:F.5:,&D0'#9_+-MFX<] /$<!B0M('D&&/6/ -(6D/I
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M<UUE@C +]/R$<[7J& =-W=K_ U!+ P04    "  $B:)4T88-,O,"  #U"
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M4_\EP+6!VE\R)@\3?4#]IS/X!U!+ P04    "  $B:)4]U.F!ND"  #F"
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M++]8<?+A7TFV_U4.!7LU=N?5L8N\> TBT^,7F61'J3'J3IV=HVWO8.NM ;Q
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M9)4H9)4H9)4H9)4H9)7_2=8/K9=__7NV79-:E<W!GW7_P&=?4$L! A0#%
M  @ !(FB5 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  $B:)4?5<O#NX    K @  $0
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M=#(N>&UL4$L! A0#%     @ !(FB5$UIV]K" @  2PD  !@
M ("!R!(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (  2)
MHE1^%\OW5P,  .T)   8              " @< 5  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    "  $B:)45!Y&D#@%  !+%P  &
M        @(%-&0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ !(FB5%M,H)'?!0  J14  !@              ("!NQX  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  2)HE1M3JR@6Q   !@L   8
M              " @= D  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    "  $B:)4_\YG@,87   T1@  &               @(%A-0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ !(FB5*[WD'O- @
M2 8  !@              ("!74T  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    (  2)HE3B(>L+/1,  -4_   9              " @6!0
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ !(FB5"7I
M_UI0 P  6@<  !D              ("!U&,  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    "  $B:)4-7B,[E@$  #2"0  &0
M    @(%;9P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M  2)HE0=K+#L/@P  )HB   9              " @>IK  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ !(FB5.\6.[CD!P  I!,  !D
M             ("!7W@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    "  $B:)4\E0>0;T8  #%30  &0              @(%Z@   >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  2)HE1;*KUJV (
M  @&   9              " @6Z9  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ !(FB5'MU,5]+ P  F0<  !D              ("!
M?9P  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  $B:)4
M" 0U!'T#   !"   &0              @('_GP  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    (  2)HE0Q<+O</ ,  ,P'   9
M      " @;.C  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ !(FB5&N^U'YU!   T0L  !D              ("!)J<  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  $B:)4FT^A9_\%  !9'0
M&0              @('2JP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    (  2)HE0W:#JQ; ,  +@*   9              " @0BR  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ !(FB5+%,'R"W
M @  3@<  !D              ("!J[4  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    "  $B:)40[)6>1@)  "9-0  &0
M@(&9N   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  2)
MHE0<,BAGM@(  -(&   9              " @>C!  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ !(FB5 ]?F]Q) @  <@4  !D
M         ("!U<0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    "  $B:)4M(JS!9H"  #6!@  &0              @(%5QP  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  2)HE2UO>Z__P(  "H*
M   9              " @2;*  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ !(FB5"D@7QU_ @  I08  !D              ("!7,T
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  $B:)41J$E
MR84"   8!@  &0              @($2T   >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    (  2)HE0.E=A*$0,  ($)   9
M  " @<[2  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M!(FB5&/1MT@A!@  B1P  !D              ("!%M8  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    "  $B:)4X3&]#&<$  !!$P  &0
M            @(%NW   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    (  2)HE0"J0?N)P,  ,,*   9              " @0SA  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ !(FB5-&&#3+S @
M]0@  !D              ("!:N0  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    "  $B:)4]U.F!ND"  #F"   &0              @(&4
MYP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  2)HE2*
M51'Q?04  (88   9              " @;3J  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ !(FB5*8?U?(0 P  ,A$   T
M     ( !:/   'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  $B:)4EXJ[',
M   3 @  "P              @ &C\P  7W)E;',O+G)E;'-02P$"% ,4
M"  $B:)4VTVH#GD#  !^&0  #P              @ &,]   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ !(FB5)D^HH1\ 0  EA8  !H
M ( !,O@  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M!(FB5*IG%&&8 0  "Q<  !,              ( !YOD  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     "T +0 R#   K_L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>115</ContextCount>
  <ElementCount>250</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Loan and Security Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreement</Role>
      <ShortName>Loan and Security Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Loan and Security Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementTables</Role>
      <ShortName>Loan and Security Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreement</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Loan and Security Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails</Role>
      <ShortName>Loan and Security Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Loan and Security Agreement - Schedule of Outstanding Debt and Unamortized Debt Discount Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails</Role>
      <ShortName>Loan and Security Agreement - Schedule of Outstanding Debt and Unamortized Debt Discount Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Loan and Security Agreement - Schedule of Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails</Role>
      <ShortName>Loan and Security Agreement - Schedule of Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Loss per Common Share - Computation of Basic and Diluted Net Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss per Common Share - Computation of Basic and Diluted Net Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Net Loss per Common Share - Potentially Dilutive Securities Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails</Role>
      <ShortName>Net Loss per Common Share - Potentially Dilutive Securities Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Operating Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stockholders' Equity - Schedule of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Stockholders' Equity - Schedule of Stock-Based Compensation Expense Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock-Based Compensation Expense Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stockholders' Equity - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="axsm-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="axsm-20220331.htm">axsm-20220331.htm</File>
    <File>axsm-20220331.xsd</File>
    <File>axsm-20220331_cal.xml</File>
    <File>axsm-20220331_def.xml</File>
    <File>axsm-20220331_lab.xml</File>
    <File>axsm-20220331_pre.xml</File>
    <File>axsm-ex10_1.htm</File>
    <File>axsm-ex31_1.htm</File>
    <File>axsm-ex31_2.htm</File>
    <File>axsm-ex32_1.htm</File>
    <File>axsm-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="333">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "axsm-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "contextCount": 115,
   "dts": {
    "calculationLink": {
     "local": [
      "axsm-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "axsm-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "axsm-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "axsm-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "axsm-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "axsm-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 425,
   "entityCount": 1,
   "hidden": {
    "http://axsome.com/20220331": 1,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 5
   },
   "keyCustom": 58,
   "keyStandard": 192,
   "memberCustom": 36,
   "memberStandard": 14,
   "nsprefix": "axsm",
   "nsuri": "http://axsome.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Loan and Security Agreement",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreement",
     "shortName": "Loan and Security Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Net Loss per Common Share",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShare",
     "shortName": "Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Stockholders' Equity",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "axsm:LicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - License Agreements",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "axsm:LicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "axsm:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "axsm:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Loan and Security Agreement (Tables)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementTables",
     "shortName": "Loan and Security Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Net Loss per Common Share (Tables)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables",
     "shortName": "Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "axsm:NumberOfLateStageProductCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of Business and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "axsm:NumberOfLateStageProductCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Product",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "axsm:AccruedResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "axsm:AccruedResearchAndDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Loan and Security Agreement - Additional Information (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
     "shortName": "Loan and Security Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Loan and Security Agreement - Schedule of Outstanding Debt and Unamortized Debt Discount Balances (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails",
     "shortName": "Loan and Security Agreement - Schedule of Outstanding Debt and Unamortized Debt Discount Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "0",
      "lang": null,
      "name": "axsm:DebtInstrumentAccretedLiabilityOfFinalPaymentFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Loan and Security Agreement - Schedule of Principal Payments (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails",
     "shortName": "Loan and Security Agreement - Schedule of Principal Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Net Loss per Common Share - Computation of Basic and Diluted Net Loss per Common Share (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
     "shortName": "Net Loss per Common Share - Computation of Basic and Diluted Net Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Net Loss per Common Share - Potentially Dilutive Securities Outstanding (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails",
     "shortName": "Net Loss per Common Share - Potentially Dilutive Securities Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Expense (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails",
     "shortName": "Commitments and Contingencies - Schedule of Operating Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments of Operating Leases (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Payments of Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "axsm:EquityInstrumentVotingRightsPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Vote",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "axsm:EquityInstrumentVotingRightsPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Vote",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_8499400d-f664-4e71-b17e-d1301c2cb375",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_8499400d-f664-4e71-b17e-d1301c2cb375",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_e5af5223-2fe5-4213-acad-7c31eefaf440",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Stockholders' Equity - Schedule of RSU Activity (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails",
     "shortName": "Stockholders' Equity - Schedule of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_e5af5223-2fe5-4213-acad-7c31eefaf440",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Stockholders' Equity - Schedule of Stock-Based Compensation Expense Recognized (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails",
     "shortName": "Stockholders' Equity - Schedule of Stock-Based Compensation Expense Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_8499400d-f664-4e71-b17e-d1301c2cb375",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Stockholders' Equity - Schedule of Warrant Activity (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails",
     "shortName": "Stockholders' Equity - Schedule of Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_8499400d-f664-4e71-b17e-d1301c2cb375",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_9f1904ba-152a-46e9-9e57-e92380cbcce6",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - License Agreements - Additional Information (Details)",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
     "shortName": "License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "axsm:LicenseAgreementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_d49b89d1-f1b7-475f-9685-738cdbff9497",
      "decimals": "INF",
      "lang": null,
      "name": "axsm:NumberOfLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Item",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Operations",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_b4a98684-d57a-4c5f-b5a6-c9b492ff4e17",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_b4a98684-d57a-4c5f-b5a6-c9b492ff4e17",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Nature of Business and Basis of Presentation",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axsm-20220331.htm",
      "contextRef": "C_c6e03d77-74bc-438d-ac62-681542cd683c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "axsm_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "axsm_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Table]",
        "terseLabel": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "axsm_AccruedGeneralAndAdministrativeCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued general and administrative current.",
        "label": "Accrued General And Administrative Current",
        "terseLabel": "Accrued general and administrative"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeCurrent",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional paid-in capital Shares tendered for withholding taxes.",
        "label": "Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes",
        "negatedLabel": "Shares tendered for withholding taxes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_Axs02Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AXS-02.",
        "label": "Axs02 [Member]",
        "terseLabel": "AXS-02"
       }
      }
     },
     "localname": "Axs02Member",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_Axs04Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AXS-04.",
        "label": "Axs04 [Member]",
        "terseLabel": "AXS-04"
       }
      }
     },
     "localname": "Axs04Member",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_Axs05AndAxs07Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to AXS-05 and AXS-07.",
        "label": "Axs05 And Axs07 [Member]",
        "terseLabel": "AXS-05 and AXS-07"
       }
      }
     },
     "localname": "Axs05AndAxs07Member",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_Axs05Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AXS-05.",
        "label": "Axs05 [Member]",
        "terseLabel": "AXS-05"
       }
      }
     },
     "localname": "Axs05Member",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_ChangeInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in operating lease liability.",
        "label": "Change In Operating Lease Liability",
        "terseLabel": "Change in operating lease liability"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseLiability",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_ClassOfWarrantOrRightTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period during which warrants are active, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Class Of Warrant Or Right Term",
        "terseLabel": "Term of warrants (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTerm",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axsm_ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which the volume weighted average price of company's common stock.",
        "label": "Class Of Warrants Or Rights Weighted Average Price Trading Days",
        "terseLabel": "Trading days"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsWeightedAveragePriceTradingDays",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axsm_CollaborationArrangementFuturePotentialPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of future payments payable under the collaboration arrangement.",
        "label": "Collaboration Arrangement Future Potential Payments",
        "terseLabel": "Future milestone payments"
       }
      }
     },
     "localname": "CollaborationArrangementFuturePotentialPayments",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_CommonStockFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Fair Value",
        "terseLabel": "Fair value of common stock"
       }
      }
     },
     "localname": "CommonStockFairValue",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_CommonStockSalesAgreementAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The authorized amount under a common stock sales agreement.",
        "label": "Common Stock Sales Agreement Authorized Amount",
        "terseLabel": "Common stock sales agreement, authorized amount"
       }
      }
     },
     "localname": "CommonStockSalesAgreementAuthorizedAmount",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_CommonStockSalesAgreementCommissionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The commission percentage paid under a common stock sales agreement.",
        "label": "Common Stock Sales Agreement Commission Percentage",
        "terseLabel": "Common stock sales agreement, commission percentage"
       }
      }
     },
     "localname": "CommonStockSalesAgreementCommissionPercentage",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axsm_CommonStockSalesAgreementSharesUnsoldAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock sales agreement shares unsold amount.",
        "label": "Common Stock Sales Agreement Shares Unsold Amount",
        "terseLabel": "Common stock sales agreement, shares unsold amount"
       }
      }
     },
     "localname": "CommonStockSalesAgreementSharesUnsoldAmount",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_ConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the consecutive number of trading days to determine the weighted average price per share of ordinary shares.",
        "label": "Consecutive Trading Days",
        "terseLabel": "Prior trading days"
       }
      }
     },
     "localname": "ConsecutiveTradingDays",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axsm_DebtInstrumentAccretedLiabilityOfFinalPaymentFee": {
     "auth_ref": [],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accreted liability of final payment fee.",
        "label": "Debt Instrument Accreted Liability Of Final Payment Fee",
        "terseLabel": "Add: accreted liability of final payment fee"
       }
      }
     },
     "localname": "DebtInstrumentAccretedLiabilityOfFinalPaymentFee",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_DebtInstrumentAggregateAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate amount of loan.",
        "label": "Debt Instrument Aggregate Amount Percentage",
        "terseLabel": "Percentage of aggregate amount of loan"
       }
      }
     },
     "localname": "DebtInstrumentAggregateAmountPercentage",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axsm_DebtInstrumentCashPayInterestMultiplier": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the multiplier used for the cash pay interest under the debt instrument.",
        "label": "Debt Instrument Cash Pay Interest Multiplier",
        "terseLabel": "Cash pay interest multiplier"
       }
      }
     },
     "localname": "DebtInstrumentCashPayInterestMultiplier",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "axsm_DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The final payment fee to be paid under the debt arrangement as a percentage of aggregate amount of all term loan advances minus the aggregate amount of repayments made.",
        "label": "Debt Instrument Final Payment Fee Threshold Percentage Of Debt Outstanding",
        "terseLabel": "Percentage of final payment fee"
       }
      }
     },
     "localname": "DebtInstrumentFinalPaymentFeeThresholdPercentageOfDebtOutstanding",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axsm_DebtInstrumentInterestPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, interest payment period.",
        "label": "Debt Instrument Interest Payment Period",
        "terseLabel": "Debt instrument, interest payment period"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentPeriod",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the prepayment of debt occurring prior to first anniversary of closing date.",
        "label": "Debt Instrument Prepayment Occurring Prior To First Anniversary Of Closing Date [Member]",
        "terseLabel": "Prepayment Occurs Prior to First Anniversary of Closing Date"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfClosingDateMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment occurring prior to first anniversary of first amendment closing date.",
        "label": "Debt Instrument Prepayment Occurring Prior To First Anniversary Of First Amendment Closing Date [Member]",
        "terseLabel": "Prepayment Occurs Prior to First Anniversary of First Amendment Closing Date"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentOccurringPriorToFirstAnniversaryOfFirstAmendmentClosingDateMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the prepayment of debt occurring on or after the first anniversary and prior to the second anniversary of the Closing Date.",
        "label": "Debt Instrument Prepayment Occurs On Or After First Anniversary And Prior To Second Anniversary Of Closing Date [Member]",
        "terseLabel": "Prepayment Occurs on or After First Anniversary and Prior to Second Anniversary of the Closing Date"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfClosingDateMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment occurs on or after first anniversary and prior to second anniversary of first amendment closing date.",
        "label": "Debt Instrument Prepayment Occurs On Or After First Anniversary And Prior To Second Anniversary Of First Amendment Closing Date [Member]",
        "terseLabel": "Prepayment Occurs on or After First Anniversary and Prior to Second Anniversary of First Amendment Closing Date"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentOccursOnOrAfterFirstAnniversaryAndPriorToSecondAnniversaryOfFirstAmendmentClosingDateMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the prepayment of debt occurring after the second anniversary and prior to the third anniversary of the Closing Date.",
        "label": "Debt Instrument Prepayment Occurs On Or After Second Anniversary And Prior To Third Anniversary Of Closing Date [Member]",
        "terseLabel": "Prepayment Occurs on or After Second Anniversary and Prior to Third Anniversary of Closing Date"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfClosingDateMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment occurs on or after second anniversary and prior to third anniversary of first amendment closing date.",
        "label": "Debt Instrument Prepayment Occurs On Or After Second Anniversary And Prior To Third Anniversary Of First Amendment Closing Date [Member]",
        "terseLabel": "Prepayment Occurs on or After Second Anniversary and Prior to Third Anniversary of First Amendment Closing Date"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentOccursOnOrAfterSecondAnniversaryAndPriorToThirdAnniversaryOfFirstAmendmentClosingDateMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_DebtInstrumentPrepaymentPenaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the prepayment penalty percentage on principal amount of debt.",
        "label": "Debt Instrument Prepayment Penalty Percentage",
        "terseLabel": "Percentage of prepayment penalty"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPercentage",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axsm_DebtInstrumentThresholdCashPayInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective cash pay interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument Threshold Cash Pay Interest Rate",
        "terseLabel": "Cash pay interest rate"
       }
      }
     },
     "localname": "DebtInstrumentThresholdCashPayInterestRate",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axsm_DebtInstrumentsMaturityMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instruments maturity, month and year.",
        "label": "Debt Instruments Maturity Month And Year",
        "terseLabel": "Debt instrument maturity, month and year"
       }
      }
     },
     "localname": "DebtInstrumentsMaturityMonthAndYear",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "axsm_DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December two thousand nineteen and march two thousand twenty two sales agreement.",
        "label": "December Two Thousand Nineteen and March Two Thousand Twenty Two Sales Agreement [Member]",
        "terseLabel": "December 2019 and March 2022 Sales Agreement"
       }
      }
     },
     "localname": "DecemberTwoThousandNineteenAndMarchTwoThousandTwentyTwoSalesAgreementMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_DecemberTwoThousandNineteenSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December two thousand nineteen sales agreement.",
        "label": "December Two Thousand Nineteen Sales Agreement [Member]",
        "terseLabel": "December 2019 Sales Agreement"
       }
      }
     },
     "localname": "DecemberTwoThousandNineteenSalesAgreementMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_DevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones.",
        "label": "Development Milestones",
        "terseLabel": "Development milestones"
       }
      }
     },
     "localname": "DevelopmentMilestones",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_EquityInstrumentVotingRightsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes per share each holder of shares is entitled to.",
        "label": "Equity Instrument Voting Rights Per Share",
        "terseLabel": "Common stock, voting right per share"
       }
      }
     },
     "localname": "EquityInstrumentVotingRightsPerShare",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axsm_ExtinguishmentOfDebtFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The final payment fee at extinguishment of debt.",
        "label": "Extinguishment Of Debt Fee Amount",
        "terseLabel": "Final payment fee"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtFeeAmount",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_FairValueOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of outstanding warrants.",
        "label": "Fair Value Of Warrants",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "FairValueOfWarrants",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_HerculesCapitalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Capital Inc.",
        "label": "Hercules Capital Inc [Member]",
        "terseLabel": "Hercules Capital Inc"
       }
      }
     },
     "localname": "HerculesCapitalIncMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.",
        "label": "Increase Decrease In Prepaid Expense And Other Assets Current",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_InitialCashPaymentPerCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Cash Payment Per Collaboration Agreement.",
        "label": "Initial Cash Payment Per Collaboration Agreement",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "InitialCashPaymentPerCollaborationAgreement",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_JazzPharmaceuticalsPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jazz pharmaceuticals Plc.",
        "label": "Jazz Pharmaceuticals Plc [Member]",
        "terseLabel": "Jazz Pharmaceuticals Plc"
       }
      }
     },
     "localname": "JazzPharmaceuticalsPlcMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_LeerinkPartnersLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SVB Leerink limited liability company.",
        "label": "Leerink Partners Limited Liability Company [Member]",
        "terseLabel": "SVB Leerink"
       }
      }
     },
     "localname": "LeerinkPartnersLimitedLiabilityCompanyMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum reduction percentage of the royalty due as a result of required payments to third parties.",
        "label": "License Agreement Royalty Due Maximum Reduction Percentage As Result Of Required Payments To Third Parties",
        "terseLabel": "License agreement royalty, maximum reduction percent as a result of required third party payments"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyDueMaximumReductionPercentageAsResultOfRequiredPaymentsToThirdParties",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axsm_LicenseAgreementRoyaltyDuePercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net sales of products containing the licensed products, due to licensor as a royalty.",
        "label": "License Agreement Royalty Due Percentage Of Net Sales",
        "terseLabel": "License agreement royalty as a percent of net sales"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyDuePercentageOfNetSales",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axsm_LicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time, after the first commercial sale of the applicable product, the license agreement is valid, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "License Agreement Term",
        "terseLabel": "License agreement term, from first commercial sale"
       }
      }
     },
     "localname": "LicenseAgreementTerm",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axsm_LicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for license agreements.",
        "label": "License Agreements Disclosure [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "axsm_LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of unpaid invoices after threshold period respective amount should be keep as a security under the debt instruments.",
        "label": "Long Term Debt Additional Drawn Covenant Additional Security Unpaid Invoices Period",
        "terseLabel": "Period of unpaid invoices amount maintain as security"
       }
      }
     },
     "localname": "LongTermDebtAdditionalDrawnCovenantAdditionalSecurityUnpaidInvoicesPeriod",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of cash should be maintained as first priority security interest under the terms of debt instrument.",
        "label": "Long Term Debt Additional Drawn Covenant Minimum Cash As Security Interest",
        "terseLabel": "Minimum cash to be maintain as a first priority security interest"
       }
      }
     },
     "localname": "LongTermDebtAdditionalDrawnCovenantMinimumCashAsSecurityInterest",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum percentage of cash to be maintained under debt instruments.",
        "label": "Long Term Debt Additional Drawn Covenant Minimum Cash To Be Maintained As Security Percent",
        "terseLabel": "Minimum percentage of cash to be maintained as a security"
       }
      }
     },
     "localname": "LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityPercent",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axsm_LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum percentage of cash to be maintained as security following the market capitalization conditions under the debt instruments.",
        "label": "Long Term Debt Additional Drawn Covenant Minimum Cash To Be Maintained As Security With Market Capitalization Covenant Percent",
        "terseLabel": "Minimum percentage of cash to be maintained as a security following market capitalization condition"
       }
      }
     },
     "localname": "LongTermDebtAdditionalDrawnCovenantMinimumCashToBeMaintainedAsSecurityWithMarketCapitalizationCovenantPercent",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axsm_LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of market capital to be maintained under debt instruments.",
        "label": "Long Term Debt Additional Drawn Covenant Minimum Market Capitalization Amount",
        "terseLabel": "Minimum amount of market capital to be maintained"
       }
      }
     },
     "localname": "LongTermDebtAdditionalDrawnCovenantMinimumMarketCapitalizationAmount",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_LongTermDebtAdditionalDrawnMinimumRevenuePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum percentage of revenue should be achieved under the debt instrument.",
        "label": "Long Term Debt Additional Drawn Minimum Revenue Percent",
        "terseLabel": "Minimum product revenue percent"
       }
      }
     },
     "localname": "LongTermDebtAdditionalDrawnMinimumRevenuePercent",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axsm_LongTermDebtCurrentNetOfNoncurrentDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after noncurrent portion of unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Current Net Of Noncurrent Debt Discount",
        "negatedLabel": "Less: current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrentNetOfNoncurrentDebtDiscount",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_MarchTwoThousandTwentyTwoSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March Two Thousand Twenty Two Sales Agreement [Member]",
        "label": "March Two Thousand Twenty Two Sales Agreement [Member]",
        "terseLabel": "March 2022 Sales Agreement"
       }
      }
     },
     "localname": "MarchTwoThousandTwentyTwoSalesAgreementMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_NumberOfAsianMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Asian markets.",
        "label": "Number of Asian Markets",
        "terseLabel": "Number of Asian markets"
       }
      }
     },
     "localname": "NumberOfAsianMarkets",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axsm_NumberOfFinancialInstitutionsHoldingDeposits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of financial institutions holding the Company's cash.",
        "label": "Number Of Financial Institutions Holding Deposits",
        "terseLabel": "Number of financial institutions that hold the Company's cash"
       }
      }
     },
     "localname": "NumberOfFinancialInstitutionsHoldingDeposits",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axsm_NumberOfLateStageProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of late-stage candidates included in the Company's product candidate portfolio.",
        "label": "Number Of Late Stage Product Candidates",
        "terseLabel": "Number of late-stage candidates in Company's product candidate portfolio"
       }
      }
     },
     "localname": "NumberOfLateStageProductCandidates",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axsm_NumberOfLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of license agreements the Company has entered into.",
        "label": "Number Of License Agreements",
        "terseLabel": "Number of exclusive license agreements"
       }
      }
     },
     "localname": "NumberOfLicenseAgreements",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information if the outstanding principle and advances under loan agreement exceeds fifty five million.",
        "label": "Outstanding Advances Under Loan Agreement Equals Or Exceeds Fifty Five Million [Member]",
        "terseLabel": "Outstanding principle and advances under the loans agreement exceeds 55 million"
       }
      }
     },
     "localname": "OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsFiftyFiveMillionMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information if the outstanding principle and advances under loan agreement exceeds fifty five million.",
        "label": "Outstanding Advances Under Loan Agreement Equals Or Exceeds Sixty Five Million [Member]",
        "terseLabel": "Outstanding principle and advances under the loans agreement exceeds 65 million"
       }
      }
     },
     "localname": "OutstandingAdvancesUnderLoanAgreementEqualsOrExceedsSixtyFiveMillionMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Pfizer, Inc.",
        "label": "Pfizer Inc [Member]",
        "terseLabel": "Pfizer Inc"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_ProceedsFromFirstAdvanceUsedToRepayPreviousDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from first advance used to repay previous debt.",
        "label": "Proceeds From First Advance Used To Repay Previous Debt",
        "terseLabel": "First advance used to repay previous debt"
       }
      }
     },
     "localname": "ProceedsFromFirstAdvanceUsedToRepayPreviousDebt",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_RevenueMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue milestones.",
        "label": "Revenue Milestones",
        "terseLabel": "Revenue milestones"
       }
      }
     },
     "localname": "RevenueMilestones",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_SecondAmendmentToLoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second amendment to loan and security agreement.",
        "label": "Second Amendment To Loan and Security Agreement [Member]",
        "terseLabel": "Second Amendment To Loan and Security Agreement"
       }
      }
     },
     "localname": "SecondAmendmentToLoanAndSecurityAgreementMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options expired in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period",
        "negatedLabel": "Number of shares, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "axsm_SharePriceFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value price of a single share of a number of saleable stocks of a company",
        "label": "Share Price Fair Value",
        "terseLabel": "Fair value share price"
       }
      }
     },
     "localname": "SharePriceFairValue",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "axsm_SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price not less than three day volume weighted average share price discount rate.",
        "label": "Share price not less than three day volume weighted average share price discount rate"
       }
      }
     },
     "localname": "SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "axsm_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for significant risks and uncertainties.",
        "label": "Significant Risks And Uncertainties Policy Policy [Text Block]",
        "terseLabel": "Significant Risks And Uncertainties"
       }
      }
     },
     "localname": "SignificantRisksAndUncertaintiesPolicyPolicyTextBlock",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "axsm_StockIssuedDuringPeriodSharesFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to a financing arrangement.",
        "label": "Stock Issued During Period Shares Financing",
        "terseLabel": "Issuance of common stock upon financing (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesFinancing",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "axsm_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares Stock Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "axsm_StockIssuedDuringPeriodValueFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to a financing arrangement during the period.",
        "label": "Stock Issued During Period Value Financing",
        "terseLabel": "Issuance of common stock upon financing"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueFinancing",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_StockIssuedDuringPeriodValueNewIssuesNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues Net",
        "terseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesNet",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_StockVestedDuringPeriodSharesRestrictedCommonStockAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock vested during period shares restricted common stock award.",
        "label": "Stock Vested During Period Shares Restricted Common Stock Award",
        "terseLabel": "Issuance of common stock upon vesting of RSUs (in shares)"
       }
      }
     },
     "localname": "StockVestedDuringPeriodSharesRestrictedCommonStockAward",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "axsm_StockVestedDuringPeriodValueRestrictedCommonStockAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock vested during period value restricted common stock award.",
        "label": "Stock Vested During Period Value Restricted Common Stock Award",
        "terseLabel": "Issuance of common stock upon vesting of RSUs"
       }
      }
     },
     "localname": "StockVestedDuringPeriodValueRestrictedCommonStockAward",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subject to FDA approval of AXS zero five and AXS zero seven.",
        "label": "Subject To FDA Approval Of AXS Zero Five And AXS Zero Seven [Member]",
        "terseLabel": "Subject to FDA Approval of AXS-05 and AXS-07"
       }
      }
     },
     "localname": "SubjectToFdaApprovalOfAxsZeroFiveAndAxsZeroSevenMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_SunosiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sunosi.",
        "label": "Sunosi [Member]",
        "terseLabel": "Sunosi"
       }
      }
     },
     "localname": "SunosiMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TermLoan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Term Loan 2019.",
        "label": "Term Loan2019 [Member]",
        "terseLabel": "2019 Term Loan"
       }
      }
     },
     "localname": "TermLoan2019Member",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TermLoan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about term loan two thousand twenty.",
        "label": "Term Loan2020 [Member]",
        "terseLabel": "Term Loan 2020"
       }
      }
     },
     "localname": "TermLoan2020Member",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TermLoan2020TrancheFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about term loan tranche five.",
        "label": "Term Loan2020 Tranche Five [Member]",
        "terseLabel": "Term loan 2020 tranche five"
       }
      }
     },
     "localname": "TermLoan2020TrancheFiveMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TermLoan2020TrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about term loan tranche four.",
        "label": "Term Loan2020 Tranche Four [Member]",
        "terseLabel": "Term loan 2020 tranche four"
       }
      }
     },
     "localname": "TermLoan2020TrancheFourMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TermLoan2020TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about term loan tranche one.",
        "label": "Term Loan2020 Tranche One [Member]",
        "terseLabel": "Term loan 2020 tranche one"
       }
      }
     },
     "localname": "TermLoan2020TrancheOneMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TermLoan2020TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about term loan tranche three.",
        "label": "Term Loan2020 Tranche Three [Member]",
        "terseLabel": "Term loan 2020 tranche three"
       }
      }
     },
     "localname": "TermLoan2020TrancheThreeMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TermLoan2020TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about term loan tranche two.",
        "label": "Term Loan2020 Tranche Two [Member]",
        "terseLabel": "Term loan 2020 tranche two"
       }
      }
     },
     "localname": "TermLoan2020TrancheTwoMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_ThresholdDaysToAchieveFirstMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days to achieve first milestone following such date.",
        "label": "Threshold Days To Achieve First Milestone",
        "terseLabel": "Period to achieve first milestone"
       }
      }
     },
     "localname": "ThresholdDaysToAchieveFirstMilestone",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axsm_ThresholdDaysToAchieveSecondMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days to achieve second milestone following such date.",
        "label": "Threshold Days To Achieve Second Milestone",
        "terseLabel": "Period to achieve second milestone"
       }
      }
     },
     "localname": "ThresholdDaysToAchieveSecondMilestone",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axsm_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche one.",
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TrancheThreeSubTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche three sub tranche one.",
        "label": "Tranche Three Sub Tranche One [Member]",
        "terseLabel": "Tranche Three Sub Tranche One"
       }
      }
     },
     "localname": "TrancheThreeSubTrancheOneMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TrancheThreeSubTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche three sub tranche two.",
        "label": "Tranche Three Sub Tranche Two [Member]",
        "terseLabel": "Tranche Three Sub Tranche Two"
       }
      }
     },
     "localname": "TrancheThreeSubTrancheTwoMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TrancheTwoSubTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche two sub tranche one.",
        "label": "Tranche Two Sub Tranche One [Member]",
        "terseLabel": "Tranche Two Sub-Tranche One"
       }
      }
     },
     "localname": "TrancheTwoSubTrancheOneMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TrancheTwoSubTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche two sub tranche three.",
        "label": "Tranche Two Sub Tranche Three [Member]",
        "terseLabel": "Tranche Two Sub-Tranche Three"
       }
      }
     },
     "localname": "TrancheTwoSubTrancheThreeMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TrancheTwoSubTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche two sub tranche two.",
        "label": "Tranche Two Sub Tranche Two [Member]",
        "terseLabel": "Tranche Two Sub-Tranche Two"
       }
      }
     },
     "localname": "TrancheTwoSubTrancheTwoMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TwoThousandFifteenEquityCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2015 Equity Compensation Plan.",
        "label": "Two Thousand Fifteen Equity Compensation Plan [Member]",
        "terseLabel": "2015 Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityCompensationPlanMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_TwoThousandNineteenShelfRegistrationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen shelf registration.",
        "label": "Two Thousand Nineteen Shelf Registration [Member]",
        "terseLabel": "2019 Shelf Registration"
       }
      }
     },
     "localname": "TwoThousandNineteenShelfRegistrationMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An underwritten sale of stock.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axsm_UnregisteredCommonStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unregistered common stock value.",
        "label": "Unregistered common stock value"
       }
      }
     },
     "localname": "UnregisteredCommonStockValue",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_WarrantsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants (or share units) exercised during the current period.",
        "label": "Warrants Exercised In Period",
        "negatedLabel": "Number of warrants exercised"
       }
      }
     },
     "localname": "WarrantsExercisedInPeriod",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "axsm_WarrantsExercisedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which warrants were exercised.",
        "label": "Warrants Exercised In Period Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "WarrantsExercisedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "axsm_WarrantsIssuedDuringPeriodDebtFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued during period debt financing.",
        "label": "Warrants Issued During Period Debt Financing",
        "terseLabel": "Issuance of warrants upon debt financing"
       }
      }
     },
     "localname": "WarrantsIssuedDuringPeriodDebtFinancing",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axsm_WarrantsIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants (or share units) issued during the current period.",
        "label": "Warrants Issued In Period",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "WarrantsIssuedInPeriod",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "axsm_WarrantsIssuedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which warrants were issued.",
        "label": "Warrants Issued In Period Weighted Average Exercise Price",
        "terseLabel": "Issued (in dollars per share)"
       }
      }
     },
     "localname": "WarrantsIssuedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://axsome.com/20220331",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r233",
      "r361",
      "r362",
      "r363",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Antecip"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r42",
      "r78",
      "r79",
      "r184",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r183",
      "r209",
      "r235",
      "r238",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r412",
      "r414",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r183",
      "r209",
      "r235",
      "r238",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r412",
      "r414",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r131",
      "r230",
      "r231",
      "r378",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r131",
      "r230",
      "r231",
      "r378",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r183",
      "r209",
      "r232",
      "r235",
      "r238",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r412",
      "r414",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r183",
      "r209",
      "r232",
      "r235",
      "r238",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r412",
      "r414",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r78",
      "r79",
      "r184",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r93",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r93",
      "r98",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r93",
      "r98",
      "r157",
      "r236",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate202010Member": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-10 Codification Improvements.",
        "label": "Accounting Standards Update 2020-10 [Member]",
        "terseLabel": "2020-10"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202010Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r366"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r271",
      "r272",
      "r273",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r86",
      "r87",
      "r88",
      "r89",
      "r98",
      "r134",
      "r135",
      "r142",
      "r143",
      "r144",
      "r145",
      "r147",
      "r148",
      "r168",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r289",
      "r290",
      "r291",
      "r292",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r360",
      "r379",
      "r380",
      "r381",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r239",
      "r241",
      "r276",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r241",
      "r263",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r55",
      "r67",
      "r196",
      "r341"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r51",
      "r67",
      "r196",
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r76",
      "r117",
      "r125",
      "r129",
      "r138",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r300",
      "r304",
      "r323",
      "r364",
      "r366",
      "r394",
      "r404"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r39",
      "r76",
      "r138",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r300",
      "r304",
      "r323",
      "r364",
      "r366"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r242",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r234",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r234",
      "r237",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r27",
      "r69"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r63",
      "r69",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r63",
      "r333"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash Equivalents",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r82",
      "r83",
      "r85",
      "r134",
      "r135",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r168",
      "r267",
      "r268",
      "r269",
      "r289",
      "r309",
      "r310",
      "r311",
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r346",
      "r360",
      "r379",
      "r380",
      "r415",
      "r416",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r82",
      "r83",
      "r92",
      "r134",
      "r135",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r168",
      "r267",
      "r268",
      "r269",
      "r289",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r346",
      "r360",
      "r379",
      "r380",
      "r415",
      "r416",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r86",
      "r97",
      "r136",
      "r146",
      "r274",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "periodStartLabel": "Weighted average exercise price, Beginning balance",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Common stock to be issued if warrants are exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Number of warrants outstanding ending balance",
        "periodStartLabel": "Number of warrants outstanding beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r163",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Number of common shares"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r366"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value per share (150,000,000 shares authorized, 38,883,445 and 37,816,794 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively)",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Value of common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r109",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r75",
      "r80",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r200",
      "r201",
      "r202",
      "r203",
      "r344",
      "r395",
      "r396",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Interest rate basis"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r17",
      "r198",
      "r396",
      "r403"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      },
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Total Outstanding Debt",
        "totalLabel": "Total principal payments outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Base interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37",
      "r75",
      "r80",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r200",
      "r201",
      "r202",
      "r203",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r37",
      "r75",
      "r80",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r202",
      "r203",
      "r223",
      "r224",
      "r225",
      "r226",
      "r341",
      "r342",
      "r344",
      "r345",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": {
     "auth_ref": [
      "r341",
      "r345"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.",
        "label": "Debt Instrument, Unamortized Discount, Noncurrent",
        "negatedLabel": "Less: unamortized debt discount, long-term"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r67",
      "r149"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Basic and diluted net loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected vesting period for non-vested share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation cost not yet recognized related to unvested RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to non-vested stock options expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r46",
      "r47",
      "r48",
      "r82",
      "r83",
      "r84",
      "r87",
      "r94",
      "r96",
      "r106",
      "r145",
      "r222",
      "r227",
      "r271",
      "r272",
      "r273",
      "r291",
      "r292",
      "r318",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r417",
      "r418",
      "r419",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r67",
      "r204",
      "r205"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r151",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r77",
      "r95",
      "r96",
      "r116",
      "r283",
      "r294",
      "r295",
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r66",
      "r353"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r56",
      "r195",
      "r202",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r61",
      "r64",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r34"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income (expense)",
        "totalLabel": "Investment Income, Net, Total"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Lessee, operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, operating lease, existence of option to extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments of Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r76",
      "r126",
      "r138",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r301",
      "r304",
      "r305",
      "r323",
      "r364",
      "r365"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r76",
      "r138",
      "r323",
      "r366",
      "r397",
      "r407"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r76",
      "r138",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r301",
      "r304",
      "r305",
      "r323",
      "r364",
      "r365",
      "r366"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r17",
      "r396",
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Line of credit",
        "totalLabel": "Long-term Line of Credit, Total"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r32",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r32",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line Of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum loan amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining credit facility to be drawn"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r32",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line Of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r188",
      "r199",
      "r200",
      "r201",
      "r396",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Outstanding amount",
        "totalLabel": "Long-term Debt, Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r80",
      "r166",
      "r192"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r80",
      "r166",
      "r192"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r80",
      "r166",
      "r192"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r80",
      "r166",
      "r192"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Loan payable, long-term",
        "totalLabel": "Loan payable, long-term"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementScheduleOfOutstandingDebtAndUnamortizedDebtDiscountBalancesDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Loan and Security Agreement"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r37",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r63",
      "r65",
      "r68"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r43",
      "r44",
      "r48",
      "r49",
      "r68",
      "r76",
      "r86",
      "r90",
      "r91",
      "r92",
      "r93",
      "r95",
      "r96",
      "r99",
      "r117",
      "r124",
      "r127",
      "r128",
      "r130",
      "r138",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r320",
      "r323",
      "r398",
      "r409"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r117",
      "r124",
      "r127",
      "r128",
      "r130"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r352",
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease liabilities",
        "totalLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset - operating lease"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r356",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r355",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments of tax withholdings on stock award"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r242",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r366"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding at March 31, 2022 and December 31, 2021, respectively)",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock upon financing, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r58",
      "r266"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r43",
      "r44",
      "r48",
      "r62",
      "r76",
      "r86",
      "r95",
      "r96",
      "r117",
      "r124",
      "r127",
      "r128",
      "r130",
      "r138",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r299",
      "r302",
      "r303",
      "r306",
      "r307",
      "r320",
      "r323",
      "r399"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r150",
      "r366",
      "r400",
      "r408"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Equipment, net",
        "totalLabel": "Property, Plant and Equipment, Net, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r150",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r233",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r233",
      "r361",
      "r363",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r278",
      "r377",
      "r433"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expense recognized"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r227",
      "r274",
      "r366",
      "r406",
      "r421",
      "r426"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r82",
      "r83",
      "r84",
      "r87",
      "r94",
      "r96",
      "r145",
      "r271",
      "r272",
      "r273",
      "r291",
      "r292",
      "r318",
      "r417",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r354",
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Milestone payments or royalties"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r37",
      "r80",
      "r200",
      "r202",
      "r223",
      "r224",
      "r225",
      "r226",
      "r341",
      "r342",
      "r345",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Debt and Unamortized Debt Discount Balances"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r241",
      "r262",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfStockBasedCompensationExpenseRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r241",
      "r262",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Principal Payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r242",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r246",
      "r256",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r228",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares, Outstanding, ending balance",
        "periodStartLabel": "Number of shares, Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value, Outstanding, ending balance",
        "periodStartLabel": "Weighted average grant date fair value, Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of shares, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r248",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, Outstanding, ending balance",
        "periodStartLabel": "Number of shares, Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding, ending balance",
        "periodStartLabel": "Weighted average exercise price, Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of shares, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r240",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r242",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share Price",
        "verboseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "terseLabel": "Non-vested options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average contractual term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r73",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r38",
      "r46",
      "r47",
      "r48",
      "r82",
      "r83",
      "r84",
      "r87",
      "r94",
      "r96",
      "r106",
      "r145",
      "r222",
      "r227",
      "r271",
      "r272",
      "r273",
      "r291",
      "r292",
      "r318",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r417",
      "r418",
      "r419",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r106",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r222",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r222",
      "r227",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of shares, Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r222",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from issuance of common stock, gross"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r222",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r22",
      "r23",
      "r76",
      "r133",
      "r138",
      "r323",
      "r366"
     ],
     "calculation": {
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r86",
      "r87",
      "r88",
      "r89",
      "r98",
      "r134",
      "r135",
      "r142",
      "r143",
      "r144",
      "r145",
      "r147",
      "r148",
      "r168",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r289",
      "r290",
      "r291",
      "r292",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r360",
      "r379",
      "r380",
      "r381",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureLoanAndSecurityAgreementAdditionalInformationDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonSharePotentiallyDilutiveSecuritiesOutstandingDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://axsome.com/20220331/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://axsome.com/20220331/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r434": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r436": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r437": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r438": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r439": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0000950170-22-006901-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-006901-xbrl.zip
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M9Q.&*B!]<.U&IFY_!N3-S]@'NP%2.3WWK(N#>-/$(WN<7^UY/V_:O<E>LYO
M3.Y'H'O8G4SJ'.[:YAA,&8CQM'DW?7=0-^>_V4LOZZ:=G2*,9Q#H=A[\6GF_
MJP@2!*B7\)N(X!>7WD4$4[#$)&F1%V"H .)X &&,(D$X(6"A8J1\J"((/@X"
ME%/Y^'7JN[#NHKGZ:YQ$0-W \=UP6$]J$!:;H=F+ST?9#:V<J3=V/' =Z\GQ
M4":4"XPC%\%<<<4R9#4* CTK0N2!*DI7S=3UH!0'2G$N ,U3QP'<:XTTB1P\
MMI..8!H56SFE'M("WT*^%\F/V15VZ.2;VS "!V! =!(99B#*(AQ#Z.(3"EX*
M:HAF.)FU9@2$@A,8W4LP/2OER1?PY"X\T=P8CG% 24I0CJ@@0"<0L0;",,1,
MWC&U<OSZW0)Y'KS?9?+2ZY  P"/J/0AD< Q9R2*2!OY \.MH4D,3R!(9KHG;
M259( O8..9ES2BEPI /8/8634B!X4:K!I1T&:>UZ]$ V$A:]-H@DFZT=IH"$
MDT="!YZ\Q2':]>;)0(*Q17QU52QV*4S;2_<7?CU,!D!'YCV3 2(O .E<J 0
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M65VBQE'KG$\,<8XIX@P<L,G'[C+)M&. 9^1P-Y-OT+[5AUD?X9+(Z"U% 4L
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MRM7:.EU5=-*5FL103:9=I<B\C=U50)_%@217-**>-MVSQL?YX9]J>#0\MIK
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M0LK2>VF0YJ14&JQO5J';;%2:. Q!C1Y\'V)AR@"94N#4$.&4LB()(1@2*5"
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M($L_;Z'[S<ILL!4<NGS^6#BVZ7ZK$+P A0(4AC[#JX&") E3QAGBV(/3!Y"
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MZGSJ5:F_Y_=#,/'NIQ?;J_#4\!JO5=,_^X5D!*/_]R1['FCA/Y]=3#QF6$)
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M6#PTG=79>= W[K]X])1_GCW ,UHD?J5W,:K=65-#+<[ZW+6Y,^?>N(\6T!4
M,QS__\Y^O.QZ'+A=WOWW#WU()3A$O37@SW-_R2#^$K[I=<P3N'.,5W@-YM]]
MKD G;]XK&O,@9YI.&OE7?91"@968YD072 O#$,,F1XH)&).#L7.LD%K16PN%
M+DP0A/I?HTS?$@WQLR_%!78J+J_NDWI,0F%+S4U:GQ+ P!=G?M=.LO^N0YP-
M-NQ_*?]>3[)7 8:QR?Y3U0)@&]5A>V(VRONRZ@7-VSYP=58#2MA6N\%U&\ZU
MW3K4\? .#F7K#-L6.![8PE*BW $/IU9-=,-ORY]+8B>^[GH!3WFDFEI837E1
M^J/(,6(4DCJ84<AK<*USHPI<[,3N"E58)9E$1&B8C(4=DI7+484M-9(6SFOX
MK4/YUH.W^=K]=>J)OZKG;D_WXALH:U+PDSB8K;8&O;",A(*/6DJ%#?HXMZ85
MBCN)*\@WTGZ;%1*I2OH-QW2.)<L-->6MM^;+C5UQZ.UY:IMS8((--N@V1G.?
M%]X&"U([^HA=&Y)5\Z9E[L>IRJ;^)^ZSM_Y!'3S.W<UI45C+<N0T(8AQ+WTU
M*07R!I(@1DHE[ X:<KC46%B)J-8>-U''D*Z(0X52TG!N7"%V,O!^F<[=Z^J%
MUX[3P]A(.;ZZ#/(8=S9X,K)9[1=>*1/*1*-C["]N:4)X\(5:0,Y_EXG5. @Q
MSNI//SSY=[W,_G2,+[];+.,9&@&:NW'@(Y471.**[=3=[-H5!JF\8'SE!4'4
M??ED)._Q-V3G[(GM!)<.Q NFMLL[77ML<0Z1:$CCF,90,:1NS>HF>'PWQFO(
M>@&_["*X6]5\-5TM_>5M",+;B[VW]F=G(1DG>[]4=BOKY7(6S5_4<H7>&4]X
M]+;V3ZFSYV853<5+C^M<R$O7V<+[(O,;7W?_.WV1O>TS3K)WZ'_V).GT"3K^
MZ?"U/S?>%H?HRGF(D%^!O, I%ND$[U,;?[_.@]<XH&?VS[5_01>\5#&T'E_,
MG_1ZZ4+P*[)HD-,T;4+PO<TQZ#-1FFL5KT4M>:^Z\F"QX'>19,^!Y&&WMGOD
M%P ,0+B681>;#9W"38>/'I==]#AF5,W=I82J8<;!]_Z(>$EBEE/MMZ32]4?W
MPY?"SMD->'PI4^[2#2X%HJ] DN_C<=]^=#C;S>40FUKUHN8+BYID\12JZ.&"
M?,.0YM7&WG&@3"L\NKCJS].E%Y;?\NK=4_PC7IM5#0\ 'R'DD?VP399PD]WH
M?'SS*-N:3C2]!Q0>+[ ?P6YL6CY67;NM?EG]'7_P+P,"*CI)0IYSK+,%+3+S
M"+UYFGT_A3BP\8"KZ=2%E_]SX_]+KO.$(+L?IX5::6R]29DC2Q@T]&&%MU!Q
M@0J=4\TIX[*4ERU4X7)C\L)ZXS3W%BHO*R1S8I D6#HI\IP6Y$L6ZL^M"?97
M]7EZOC[_L5[&8@Y_<OPW^SKX[+-@O^;1+[QP/"T;]K&ZKU4E.1;4H5(QZ?<H
M)4CD'",KG9:Y*6EA^(Z/4"N"-::(:N6O(3I'NBQ@S"^MJJK@4BOU\'M4\M/:
MHY-8A^75SN/<J18:S>*2("H)1\Q8A13F!I%<,>%*3"J2[^Q4JXP6C"&FPS4X
M1_Z#'&&I"ETPKW'++_K[[F>GLA/;J:&\L*\86B_:(.(.5.NL+  >'F=XH!$P
MS6680;\)T41K]1/4)VBTBK=H'F\B$;,4Y[@"+SFT6C96("F-0!4Q1A6RLKK<
M223R8I\I;0NDJ*%P:@"#<(Z$+;#3HJ#^7P]_:O:_;U&:O.*E1*0P!6).,*04
M]>C+XI)5G'EEAR^_;RD4J3S\]DHOQ+Q*C;QPD @7HF2&RI+G(]!G?#_F.B&Q
MX13D"==M+4,ZOR&]P ,P(25&7!&OQIRQ2&EMD-^QC/A-ZC!S.WTFE.(8<X:L
M*_PU)?7XC%..L*F\;:%+(GCU\/LY/S&M-WFD.[001N1:*(2%\]8 \[I&6$L1
MJ0I""UX*OFOE4EMXPT,3Q N5(U91!2-X2J]PN/4VKRF,3COT\ +V\:;"4"-T
MI4B!J'(.,0]LD"K]7WGN!:S?=+E4.[V5<ZF+W&F&C*(E8EA;)&!8E.#",5RX
MW-L<(]BD)^:*F4#A(41BIA\=E$-[N^ JPR#O#(-KVP7U/*;2P-6/%E)09THG
MO/E<.*;\65 ,":$HPEP2)P0IE=AQ^;BR<K@2#I45N'QPB9$LI<<B.<U9Y6SN
M#]?#GP5Z8F<A@.%DRG;N=,*](:M+E+L*TAE9@80A)?(FGV&.DRHO])Z$+\ZQ
MA 8YED"7'(R$UA@5%=7:.6J4V)DT=/_[EB2@<2J;E)3"ZLKX_9D3BI@M..3/
M&N1W*,&JR*N*[P"-L@"D["V[W!0>#6,BD"ZJ N7:%)9IG(MJ!%[*$]NCNSCC
MXP] C7V!3O;-0.-Q;OY<2J4J5B%388N8\X)6,*51SHE'&-Q;>.6.B][FAFC'
M*3(X]P=&<6\^\L*_=4EL+@2X_$=@"O(3V_V/-^!)!';$*2^1C?-[E"N!1(4%
M8H)07?I]J\@.^A6Y-)9;B0IO*R)F9(&DOPAIH0MB"L58R4>P1T\,_<:$P>^O
M%LL\B>5K;7G8WV55$:1HR3PPL=YN PO.$$HA\D$HV:D#JA0OB&;.(Q'GT7-E
MO9%H/8XNL1?B1EA7C$$LETDLG\@>Q3D6A=4,N;+ 'CI@#GDH.7*5(,802QGL
MMTO00?H=J@L*2,,A)K%"2@CGC;M"JLI47.$1B.53\R*'LN9]*:27X_LQ913F
M=(2.B9"D;F9J.:VF4*'<9F-NM4'YNUHN(8U\DR7J7^KCM%XWT*NL:=:Q1T^7
M#GI%!FAS!AW<ZKF_1KO,554$^9M$A"[OH&N^LDE]?;*/+P].^)0/?2A2ONBJ
M(9R]<COL;N,^_7C30*-/\==N]0G:93Y.J5U6TG@$(5&EI4<6@BLDI&%(6T>,
M-)P8O..2T\QJ!1$_A:T'TY9SI$G.D3/86IFSPICMQM6_S:'?<!,RSJ'HI)Z_
M6]7F][^IV=I=LR"3/R;/QB/VON'*&W58.D3+@B#F80/2E=.(VK+,"YX[IW90
M1,FU%$IRA"UDP(;L'^/AAZ-$*4R9-:*\W_TH3FP_MH)UI^GN>D#(T+*DAE?S
MI/26WRI3H,BAL>ARZBT\&"@PZXHKO"QN8OG5]^J'3?M39-5%]K&>06NC^#I0
MR_'1+=6'[C:JQQJV;2*^7^37R^Q[?=-;[R"2GWH,\M(_=;L[HHJO/"@:Z\%/
M: 0?_]ZJJ[;FI,54S[JB/SL))2ZAN&<.#=K];2(*"D5K S+J2#SXN9<3C[.-
M$A%">&O"+UGE_L K6R'A2HFT/_J<2"VLV$E8,<QB7JG*:RFJO:*#- !5%HA7
M6!M6N5PJO"4DW@'1WP#-?ZU7OWB2O_<4?P];Z:6Z^%O82']O]]'SN(TV5\#8
M'BC+>>LWR[9 "3W/8\OSU]7S,(](O:QG'E4WX?+KSV.F)R%B_AB:H0.M.M%P
MW=-ZE4P:BB&00N&>T-2SO: [IE_OB9EF*-V4J[],O4%FH68.D$Q;\Y>]=4WM
MB>^:9 X=LIZ\*^D\BQ,XH$6A'70!][91X^_E#21_:*:A^1[T_^Q@YJ!=#=QV
M.H_];L.-=N_2MQ*OH26Z"^4!;=-"N-FY/[5SYX]I-__$JS>_8/C9D^QY4*_;
M/<VWBU+/%'3'A:+K]?DZ=O\'G["9/N(^HI9@0YTC*"<2>V-+5$CGWE1S1%I>
M*$XI8[>9+-2YU=Z&#HW._J26<\_PYOF&"2\C#ZZ/C&$<E?_3ETMFF'@B3D&#
M]5ZU)-7N0*IM]+K7^J$?1JM#0N\)U9QMS:JIC0?:S:;?!7@<0W@)A!,T/H2K
M0 9N@80I]+_0LZGQWU8.&BHW?:>+_@[^0NOT:KOC!(A<: IQX5;;LYIL&*S0
M/FQW%E4<[J3F<*V&0@EH^@H_C@ZJ5H)FW;PF6_NWOF(4F]*Q81,8(N9LZB_M
MA6[\PKI%J*<'>9_-0V]06!@TCZZ76UTP8:V#V]6Z;>P1FG34GO2;AB+0='WO
MFTU@J@RT4X]SKV .T<RM7"#'HF[\INSN,;AO[8G_H1V'$3AUZ18;NEY)SQDD
MAH96\,&VFKME<S9=;',+M-.NCFO6NEE!TQ2_IAU]!\T(6\YH;^G&'BQQI-'*
M=;T*VPVW?VG'+Q8HYY/N'S(JX0!-R&#'-]O=]()8" <IG*T*M%=KC5=K:)0>
MVB6L_*>+V,:AYWJXLNU0TS:N@1DI*V]RJ\;?X).;?>QGM,0&"UU(>^.-F#8P
M3,A_WG9TC0W98Y^&7FJ%AA8[K>'G+L9'XHI ^L#V_ ?,M/&?GH=A+3OG=I+I
M]2J(H7["9#WIS)[PO76@D=N)<O.P06$=?HUA_MP*FLHV7SC4N\=H#6X..)H:
MVCVW+J)6B(:I7,OI1W@!("4TP>[DZB0(T:Y)3OB@AKX[0+:E17!T+P*3PKK#
M: 1_[ Q,])F& M*)?TGCYL'='V)-'UI&P72^T$@W? /-,&"RPM23)B#=X4^G
M5?O386\E\+!4ZF.]C-VPEJ'+4#M")TSL"<O<K B:_DQM/\5GT.T1:-ABXL!J
M8.H)B(%QHX-MA0[S/9HXA/#!$.4U)E-_-5YX1%P!>?.K:JSZ9_:?LUI[L1+;
MC"?ZWP_] V"%MF[@E>]&E#07Y[J>;:8&_<^[OW8]B+8$4FI]>;#6ES*UOGQ4
MK2_3-+SKC'OTVCJ"SA>O__;J)2(RP:%#"?Y7\\TT4P!#,/(F3K+_?NX^_0"S
MVNNY^CA=KIOL]WG]:0[(]MWSM^_0B_IOB(9A955H@6>]H=YUMOS[^DS-)]E?
MUMI-LS<0I/30=I*]<;6WYS>PZZWK/2?=$ VCVCGVZU60='U0=;@0#\Z]1>5O
MV*^HVQ@Q$-IZ5CYES2),D?T0(,7LXDGV>C-6.L>QJ5\T=OX.<S>ROS@U6YUE
MKY<?U'SZKVB:?/_WO[P.*<BS,#ZW>Y*G4[OXLWB1-P^68:!:GY8&8VN6P8_3
MWA>T[%_6GAW^V^7'*?BA^OM>>;O] X\'\[%;;[A_D:BZFS8Q+_>+;(GW)MZZ
M74;[\- 6]7M&PTRA%T\RRDK[PR1.46@6WBQQ75"M?^>.*X&0[71;LD7&O[S>
M2ZK(@<R?"^O.IVWOQC!1=-H?[C ":/ZA#B-5NDN[*X(QNP(K=SUON0Z#@=1B
M:F<7F?M8SSX&F_GO9]-9;)F_J&&+@U\&PO%UN$=\EO;'T1\CB*;#3>J/+=ZQ
MZ^76D-;=18#QJEV8I#XU8-JMPBPEB*C78="KG9IN:-O.Q; IHT48#PE8U5-_
M'T@$\#MZN5YT#V^IM6D&VP^=B1,"39B1W.Z+UEB<NP\JUC)E*J0;[(]OSKK8
M6DCCA-!D.X<J=.6-[7Q[8QABJ/ZFP:475PZ\V4QOVWG%N+ O/5_#\?;/>9+]
MYQ2\8_"CN>I#0*N+Q=6QV>:L7JY0:#<_G7]T_=S=H2/$UBXZ55OGSA=X ?$B
M_ZK!=1+<P,J_]JJ=D=/NRBO&16\F>77+&!!VJ)S:",6OZQ"K]W^WTX\ [!).
MOAU.)G@;*%\3)=^<\@DHWR%0!K;X@[$;E;W&#NDCG^T9&\R^T5Q@!$/.$,M+
M@Y3F?F,85]*2%)RKG3(O4SB<V[*$>3G&7P.CG$Q!42$(9]380N0[=;CO-D+\
M>=_M^TT] Z=Q\][?^\=9;7[_+G.-40O8=,NU^VY$9O+1&0._>K6>T2?9N_7Y
M>8NN!CS(-DS(.BX,Y?'>7?;UQ5RQR619F8(0C JH\V8.1O/Q2J"<EAYV5I7V
MG]]FD\5,LLW;O9TVOS?/Y_:W>5L^ 5F X34OXK_3AKN#!O:#W148$(#*%@L.
M8HX>+ZGOVCO?1MBZ.,L@IK4G)-TV>X=$H A#(:"RB=%%&!MYN,'7?20'Y(H'
MV-V]VE&),48&S]Z.DSUMQUG$6VX%Q5S3AY)"@ P">=./<2[%5?AV-W3V;/\/
MKQ=F#S&_ .,'<3D(_57]>/%G(<3N5K'O?P#VW>\&,Z)=G#K>^!,%@-G;]-"T
M-0XSBXWP8WC+A'5.NV5WB9:QCM?C[D#S>CGYXMM?7N#7".#MGMI;>:MA_&T3
MY(-1LF%M6Q.OVVRS/M[795SO1#$O+Z;+Z_C2@I9J"N'-UK+:F'%@G;ZJ]ALK
M7TA9^&(FR*1/^O!6Z7K>97P,4@S 4H%W[*[M!B1"B+)-^(C$\)(,-M)6]L?7
M39D#*U1;8<Y+F2,6YK-I0CU@TSDTPV=4Y551N8.@MM\:][KZR1]1,/B:I"P/
MIBP]86&W]J1-FO%0FO&O:JYB"D*?/-!LY70,)DQV626N8T,<,P[#@1=MP@$H
M25!HZV;3,L&_PD)MN< \-_=.),H&JSEOAT5YR37T:/UC;3^<1Q])S&H)^77@
M^-GR.T7IW+T"^-=:M=VO?9AC%M.-0>>T;J3HP.OP 6CR.!5EDC6@ 8+*C5Z^
M@2O+$Z(VTY"\TQ<O#XG3T61 S<%JX&:?SEQ8MW\OO^XV#2;DR0%-^U7& AY/
M54AW]O(UE  !5(DNNWA)](6V#PC3M"*A_ \]ZP-)+J8.W&I9R$()N3*=;W,&
MCCG5U%'T;_C=0@SPV)T'W1B?6*]7D%C=M#)_FX>-@]%4(84Z9AN%35+YAS2!
M3H&1_I-^%?N>#&^S8798?9L%,YUWR4P=8 (W:DCLZ?UN_G5:[R(,N.YN:OLQ
M-5_>K?N'ATV[G;S]V/B@ 0.!:\NI"X&*'C8,MX6M@Z[VA)P#(5ON#A( P?4*
MT\)"C5>7^]< GAS>!G;(@')^*P&3K0L'([Y4>WZO.'V3(><"18;G;K,'.O]P
MGVBFX+$3("8@(WB_YFG,>8E ACR+0[\#)IPWD;1 EGGC(A"#&,_R?)"T%1Z@
MILOL(U0_=I]\BG7\+0X<3$$#> 5G(40.(BK<C,0U=0.7#*;$@6>^0U97@>:Y
M@]"39RC U)7Z'/SQ+<!?NE@& (N+2U9 "\BSNG=HPYRIM# <52)4G>44R4(+
MI)6J:(X+K/*=WE@W@38_UTNO>^8O@H?:7+S?# X&ST'X:QR:UR27P5VAH)8'
M6<>$;$#VA(@.A8A^BI()8J@0WINK-JY6M=0W'?75LAV@/6M_XB4WQ#R]1 ^E
MDUV=G^OF10;;J8W]A,S<^&UX' 0BNSHIJ$KJA<UL&D55:^%WJ[CDO!BLPS\5
M-$YMD0N55(.'=Z @0B%_M^VE5;,U:-)X5UAGM[VBB-U^^]W7G?:.C5Z9OMOH
M2QA+-U@S9#Q'([4/CG51X<NB>/_PRGN6LX2Y@CBB$"&EEYG:$B0YJ5"N"T<X
MC+8O=QIPWLCQ[P*\?>L6];+W^2<W[!W.$8WF!&S(_W3U!_^@,\_T5_-8)98D
MZR''AO;NTB92/<JNKL.>"@G3BWK>R0O_8B&*O%B"ZPM 7LQ3:")"=Z%*>PF%
M/-,-N[:G1,%%;H/3VD8'X*&J!MY;J/\+*0KGZG?P^B[[3Y#_!'X!5%U,HO5F
MIL%H/*L_!5^QAWXF.L6Z(K @W.9M!D?PDKEE6!\ Q*VJA8]3]ZD9NI([V1BA
M>/QJ8Y0VC[.S0FX*3&B1(X=+P+B:(F59A3C/K2LDLX3L=E:X@>S]-3C]7U?]
M/FV%0[-59-I^^*5>;:AQ!DI+/]5+ZRWT[_[#[^F3J"JM+Y_@+G5H&D?C]ELU
M%";V;HZ8^0>6H5I,!P7; X,3HOB_OH,3[6GF+<A[5_"%$*(0,"RF-#"^@$%D
M7V/DS2NI<J;\)MOI\7.33?9"-6?>8H+__/3/]=3+)MAA2<'?E8('0F<#2B=U
M?A<UCQO?,;0'.O./FEVTN6O#I+HNC1;J%2$[;Q"XA-EL;0VCEPZAFU#P82D3
M"A\[KV<H7G,;=EY1@!Q^%NN9MW_?F2B-U]\S&ZJJ873YF3._=Q$\< _-@5A9
M\\FY1>=H^N*C!D_H1") &_]"[J(+ET(%H7^LBSF6:OOND_A[IYH8&%UM^;_F
M,9&R#;IIU4R;_:TKCE"IQ+BM5K.NHOUJWD%6^.-LN%$QKHE0 I5.PM HZ<U/
MJ1D2U&C&G*$>!!VBX<8EM?1\]4(MEQ=^TQVP#1U[4IX$&!H,4 [G'<+YGULG
M^>#PAL!.:"0>G=P09@K^\-!Z[1= 21GQ$F&Q[D3,EF  :!5NY"\(QL0_US6X
M>5JA$K(A8B %>K0-7-+V'^M.ZD(8;1K\2OZ>2Y!Z,)HBA@(:$"M1#JM0'+QR
M'^IE[!;1=,N[=S16,8^>7"Y17DI(@;/@ULXM(KFLF"ZT,'OF4]X$C=5SR%2.
MIA>D8<46SO"GA,$.A\&&5 Y0/U YY+TE/'8H@?1S[R>=SAN_9P>(:QC8[?/<
M!O MY+R9RUPRD4M+SZ4(\)J^5<3EY@LQS2?Z*Z+^7@W\MK">Z2HT/=C HU5H
M@.?_[CY#@YRL<M"X %;H?QY 4,B( Z"S.A64<Z[^X67K%\*.L4N(:F&BOGB<
M#A]A)7<<*R2-@DG#AB!M68G\/I&T$H4IK;T-V@D)T)VWIS\VKP:[]"_1.'CI
M%G4SO>0 &OSN43J!]I[K/K[>M90!3VD@7MC.TWDXYM$S]',\Z5E+W>P5G/>
M_E_4RT5;*Q*E0/BTDP/[FEQ!./_#O&]NU74$A"2,@?@*X:R8,M$:<UWKP:[M
MX/;=!RU\NC"5^^P7&\W085[$4$;Z9P39^'6PE%H;'*YDBZ3>!J=3LK7=V^#
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MY2_M^/LJGK2NB:5_C7]^A>.]H!J<Y:NEYR1STW!O._52?>4%:&ARV_TM,?;
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M?Z@..'.A$&X]'!F\:<,%232FQPZ;C([-,C>EHENC\Z[ !EU50YBHX $N9!&
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M'"+3FX]F.,H1)@#^*WS?,K)^V523\[R&)ODF%YU;< IO]^%TQ>4B=3MV_"6
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MZ$*ZES(#XI<#@'FKN[.QZ=QK)/DD:Q#L7I8XP4[C!"L;_,N]_(Q3DFJ\LHZ
M?%K=ENI"P0E.:Y?#J2N;?JLJT4W.X!#7[6C^8A:[F6RY]_+6S28Y1SQ_7Z];
ME%_,K T#I\**%0/R?R:?PL<P'53#^V4Y3,-E(A \>3INLOITK<8?3U*TRH!J
MJ,+G83-K6EL"<C*=#?\WAYP7+Q@NF7@A/V8.3&)R_QQ@>."2L"@@^77RL<N+
M7^S9PFL 4YU>^Q*+RMPMW^+JQ7?Q*HM8^\VO=$D[WC) ;.L!+CDG/6U70W,9
M'[R2^S&>I$"1L? *URT+?YIWN4)!?E*];;= UK@1G@4N.!\G*' -O !=UBY=
MAVM*<'-W2NM5LUH9O\BKG5AXG[SZS7IY_ZEIJ@_ 8;-V>9>%^:G.8YR8K%EL
M-EWBT7%>W=Q6Y4JD.[=5@QL,9Z,P6%=VP_&@=2(7+'[3-<ZG$X#0J5H?E.9H
MGJM4X+ATH5P8GQ3LY3&M=<Y'IJ+WK-AN2#[.\I"4[6@(3GV3>@ETVV=7JHI_
M[GZ_J7O!*W@44.?5]T,0AG':'VRJGWZJ?O[Y=?7-LKM >\Q:45OJI9 H.?DT
M;O'LJ\_-Y"Q</N%KT%>Q^J'=3(37?ALC/,HT$^WUJ1D"DRS=X>\G9@KX'18,
M=,&L>F_L?!;,?%#]<O+F9,UO'PW/AFEYPV<7<B9-\S <EIML/CUCG^PA>ERR
M2DK<"PLAF^5,OLON%4T#NF:1EYAW>J\RX" I\ 03.FL.7 QRW,E1Y0&5P%*;
MZQMQO&E_O8F95Y5!XK.%!EC3R8#C@7N2B/6HN\V>=A"KUSN(55LW$2L=Q*Y;
ME.?M()9=W-M%HT"7N_A;5[K9I!\-N%.5FS<)DDXODNL%!C=%Y3LX\\E,$X!)
MW77:+% PRO"YZ0!$=L.77UX)7;?&,1VQDKZYNE\_@"- %Z=F0HMKF6J<<CF3
M@3X?!?\A)._M6GC2%K*WB+IIPJP!&/!A;KJG'51G8?HA]?SIDE?SP)G%6X$!
M3T&$V;"U$&%6-684\DM]!#S5PI9T8D;6@V7L_3('QYV:\8=T1O(@FC8$TW2)
MZ0 L1D,XJ.F2G,8^Y1FD?)[NK)/J51OM&XZ'^1E<6\6?T2-X*SD/:IRS9P%.
M92FY[(MT2>UN_=H=[LW&1\E[  <CJ[K5%6BC+:U?Y*?FT[CR )JNKEUWR39%
M*[N[J[^F<)1O.R[Y2=5,!BNN57))FBH1%0#R[/3ZAUN^ZB+FTU%X@:>N>]]<
M7M,&0X$P%RLL^&+5GJXT'>S$.(GK"W;"&/OZY89Z]\/F?&0N7L11^+R5WO@?
MD)9AO%C(5CX1 3M-9R^S=D#P F?-"VN:D%7E=;KD4DI7'VM/E<L:29?T'(XS
MZ3)9[W*/6\B[2C7.I2::\)I@P338@-23]7.N4%DPPPHCK#_47E'WJ^]^6.[+
M+7,BNW*SF\*AE^GO.3ZQ2#&\E-$KEB!'UIH4M4I^3,K4.L[T08&%BKH62(E4
MCZD(0X;R&FD2B:4JA!BNF][J0Z <>1TTXLYCI+!VB)%HK6'6$K?9"F2EP>@=
M$N(/KA= &V X[9*%+\!D3)Q+3<O]>B E[6^!VI_E&V3#T5JU,] 554K7;JUS
MVN[J:D+:%NF)H[L_<P2YO=\R#G.:.QJVF<LYZI<""!LQF<%&G4DG7HM$-+!+
MXRP[B[VWXQ0>PCEG(?#4OT @KFN0&\8DDJ[6T2D2*-YHM,&M5DHHABQ1'G'B
MP$%SC""!:U&+( R/>&TO;55R7BTQS9L$8UYW0.$70%5G\[.TS_:J6:1S+[;;
M[M!6Y^"D+2?==0'K%?.P$<M;2LQB9[RU&W^<O#NI_O[JU6]96'/TN97"=)%'
MJER.E A%2$ X2I]X*B##@T=$>$LH<5S0S9$*F! 90BH@]"I5.TNDA:$HT&!J
M0E0$+7Y7GKK\>L%0?^3X^T_CCY,AF-9VG_!0JIOQX50WSU(M\]6<CF&[:CF
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M*JKQ,8)#>21RIPC7XYI'V^DK%70910*2J6$7-YHC%9U'1F/NJ> "4/AF7Z.
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M"RV-$YX!M12B[Q?1]S 9ZPCRFICSQ$9!D,->(&YPC52-"8HJ1,&9)W7<:')
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MO-NFT^(8^W!?/W3@R\W7;Y@YX(P7P0>*O)$&<<$44MIB))F0DAKE/*.[<#E
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M0P>:T8%B=4G'+KJMA)L.=HGV1GCZ;CY*M5=!%G="%D$YX7FD2$=&$9<<_I*
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M39_O#GG=]_D>^SX_(EJV8(544 #=XA_./^ F)E+%BG]@.Z *>$26_@,^3:Y
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MU&-7XH"+%, %J*_Q,D&9':I<PX'Q'WZ.([T.CT>N#8?3=/W3,!5GK&G2W#U
M:]TB%^R?\''(ET0[%]3RF<9"$M5^?//&I/ODL:3WO\FK<^.DR7:E*S^].3$I
M\D!1!S "9:(%:85!P)>E7 $F9,"R9)3XW9L3T4H$?H';0[)GF/$%5A/D,9&C
M>-]O!2AW[\!\.@&:>O'ES6_O3EX:)6 /KQ=**O4)49N48(!E4<)M=5X5I>$X
M0CELM]U&VPX97L)+8?I2%"84X9U6X;O4K%$0K8391$($5OB=9["U@=&@@&P]
M$5EIIP!OQ,1)\@<<VP7/_YW4:DZ3KL[CLH'QR9OF@[6W;,)VL1!V8P"X;=\U
MN>YXL* J5P])?)XSZEO:.@LI 7=_*$>4WHC128W191XGACL4^N' ,#ZG\C-'
M](=Q2# TK90HCH)(!I.B6&(0Q/C 2\P2>''Z]</+QK^ R\IK$QP_P5?664J3
M70 U4 65NY)AN_^LE 2[WMKI]VJ<U,W?DZM:-$I)EUP9''N*P%&HHS:;Q)0D
M#M&0/0W;?6TC(<IK+@'2!Q4)L$_+;#5^BW>?Y\(_LU7'$$U0Q-.+]4SQ0GJ"
MJ)RU%%WKI0I"=X+<S06E7+ X(4?[!G&.!NT"$]*YC&Q>R/0R@ 09G_ )@H1L
ME97M:>&JA>L&X<J$2HQ\F27H,+Q M^@YDX,7/GU$>8ART<(Y!E>)]<9B!69+
M4;@>V=*RI-*(DIUG:5S(^"TI>(LLQ& LMKR.RZM=Y<?*N95+I>YSA1Q]0CVV
M\YB7Z&O$+!\LUU"^FQ!]FG!5"!@"AH+3%W(@6O&E7^&MZE(QP %I")1=N)*!
MK8>)2^D\]HG[M/(RY2")U8=V9KNTP)JB?QB^XV5,';]; ))25X 6+H3W9"6N
M*C#.DZID"]$U6T#VEJ]%"<K0;E@PRVZA1[Q:/*R!P::G@'YR(:J):IY$[M@X
MDZP)0%9>;06P/%(Y!W.++^<Y_"NQLF3860W65"U+3."04,8M2ANNX)S$/$JN
M3N&-7%IWWL9H.'KAOWSAO&S7Z[1/%W#%^26[JH]0+>)5\@J^YU<,,9=S(-7S
M.4('B Z?@I97T^@0*'^^?E!!J:S]@YLUH(Y_<5418EB8BRT1"N,=@V/Q+0>>
MT7YU<8-^=<W3Q;KJNT +C7%N;%DKR*!";1(%C\V7C+XZFPXTO\+5^15/(+]"
MZSVW<!:2KZXQE,O+S%C&%]0'KL00+598@)CZ0A.:17>5YF_7;,O;5/@5:C.#
M)EW(,1=DZ9V=OOTD9,1_OOWX_M/[^@TR&Q44@Z213RR8Q_Q"3K0"]6:!V@W8
M+4NPQBG3M!9#VQX,CVHM=,E3"^0U*G>8$V[1_*J"11S$=U%6X95,M:MW4YL1
M]+D2;]^^OI$19KFMT\\?WWX3;R29*LUVGC9@7;7?1!<;!=-F99@E#V940.%V
M"Q<5MWK]=]YSP=?>(<I=VG=*LU#"L'ZXZ'Y$&^^@3RQ+#73!5%V>XUP3 #?N
M7L+#6&9+J6 6KYJ560@8L3I\U 9AB\]X 5>]-%MWG?S6W(2A?RF1\?HJS85)
MCPHC'2VE7HA;S]XWM^*S"4U%%0<QZMGP).D;>2]R);   &L26G!4KMON<D%7
M%_%*M$A#&N-)&Z ;2'FK<N)-TOBD^^#REK>MN%J HKF H[T 3:3*.\/?/IZ\
M^7K6]E4558&)$\HK+=1,&6)KCFJ]QM73)/=PJ32H,DNXL,]7GA!2'].!<18#
MEV#HP$G1&4(GC/:Z;7?%ENV)5BHA7P"22O%*F9A2(Q>?V)R/UN&L\=)%)L[0
M$6MIZK+B=!VMM-W,)_4\[%!N#2?2*3N+\Z^:IQ9JJ80.?'^! 0#2OE>8(E-<
M1)ZW#M' MJ[A>6??OKY_\Q9L#[DY<2$8"<9W#E3.,732YFL%)::$<4@.S%ST
M5T8EMA#^E28$@JUHTXV\<8.W:,N&'%.U-?.!Z.&H+Q,0.WY&(B+/</J[*6Q7
M2VA\)B4A+&E\.0XV)4P(YKG&,+N 088BP/WVZWM)?O41:'UFKK%_3-)76R3.
MM0EH:*0DC&8>TC!&JNL3*\5[U&KAZ_KC0CBK5(,!L?,&_<3&-X#LSQM/0=N'
M>YT(?/,_)Y].WZKM[RKI-MPJ;40$!9YGR5I.3D\_*S9L-N=6H=FX!LU@!(;9
M0C1U!?2%.;M4.L Z;KO;54I!2Y!MD; KD+K1V\W(=2!;-:VYO5MLFYS3()D*
MX5Y0HK611W/*RE'1M<;X;3 L*R6:]K=!N[>BV/>;"BSUWU)X15[0A%IU6MIN
M\JYC>;39;$6!551+##4*QD2X5^M7R7"U]WJ;BM.2(M?[YNG6=LN4+SA2 UT7
M7RGX8<IWXEU4![35<;\>=QF0EUY^-E2Q&/7B.$67%$E Z=S%JAL1<;FDQ"I1
MU=)"A5SVUB4T&5$[Q&UT@MR^/:63#9Y2DMF@,C*_R'*_D1L+COE )+[6W:DX
M23U +]AV7^B-T1A83=L9^C$[>_O^]-_^9(_<UR+6"=I04*&Z<Y8EE737O4WG
M*$%#G'^(=69P8D0<Z0=J;$GV \[10@[Q^(.5&+)DP*T^UE\1 (C),<%]4]0R
M>)Z1DH+*(ARM*&&+A73$Y=6Y<!R?G;Q'N4@AB<__:U&: ##[/ZX67#;N%%I4
M?;OR7RV98,/HQ /%<DFRA8M^H"T7+5U*C4+I#@OD'0@72@VD$EQ0O/Z676+-
MF8F:!4K2L+7GN6"Y<$A%!IZ2I@M1E(VBHUA@E6 JLD+J*.8WN$))/I+%HKP.
M(W*$-4&_-<XZON:V_[J-P'8? !0 C2).<:B6/[9H<$LZPI)+<4KG<:E*(9M]
MPD*QC%)U5(7G8:6R:D9 .G#MV55+7T$_CGI<U*<+GR-KIM4!A<]0DZ[SF+=L
M;6!\;0Z9>/3(^MLW^]<_VV^4JUJ%Q0C-!6I305S"-ZEQSH$AJ=30)4@ T)"-
M%Z?_^?7+2POI2TY^*[(P3B2VFN#N'.W84K:@56D^L))SCL6*XB"G61"C9"&W
MO0Q>")F/^>AB[+3*3R5\X"#L]MD7J\"4:B'.FL>GY%Q?WS\YN]6X>-F&EYWO
MS!9V\I]/[NH_U_+DWCU0'7.KJ#7MG6+TUVC?'S]C:=!O'^GPOO_T[>W7T[=?
MOC7.(O&.CC8>9-:J0EYT?$\W/3/=['@RNWIQL\,U5;MF)AVGT\?/_T-U3C?Y
MG92!U;D<J#<$A,1%V12)R]=O<'\0/VTXKT$")6J#7(@F4L&+ K@%L9S:1Z 4
MSVV^":/CF[A9H=[I%-Q&M[X6A;LKV+2A&_3FU>R6W?,/G-'(5/_;CT^W&])R
MVD7-[?R<KQ^V)>&@)+M+$@Y&;?&QRDT2(\^-(^K= 9<4HAJ>5)0\5?551,UJ
M5G7M"L5L*D&(.+Y:V=J?1"@ZK-?<.&3^58$&2\]'\5\_4!X64E+HX"F+1$B=
MFL#$X@%R*=8X);(#(UAE *VZJ@OW)B0Z/C"8@[0LJ"5#T\>2:IA$6@V9\$5W
M'EW1'>3EDPZHDFOP%31PJ!#0"MOO;:7<DA=0S?-.0]J=G)C=:D4/"J(:ORTJ
ML7R9]M\JD\&U <VU#&F5,=;+J.M.85<MXF]A,F(V='M.^LV9-K5I2)[G&W)D
MUM+L'/&&.>P%:Q=Y(J)+;>-H)2EC4QZ&?-3&1(G/(L>#DEC?K.1'7+N^[>YE
MY:ZJG=D(M:W*S.GG3Z=OOWX3"@1&NAH'WB8'WXH+N_4.A'"S0))T,8U*;+GS
M1?>H?U4L+T7Q:"?==H/;^_\^?OG;YT__)U:WFX>03,ZB<2A?*IVF7HU6O?=.
MEYYI\.(>*7,EB[5.@?UIVI0VGC@;:+ZWJEK:.]I2TM)=U]L.".@ GUE@O&-\
M8R$._ J,%I@Z+E<K@A)J&R6RA1P0N(B#UET-X0,ZZCZ'I'20=J2FPHCNUJKL
MA+781)=)X$N[) WH:._*%#8*U8X+*LT;)9A6@]7FTJT"JO:JGHUXPJ[QCKL#
M"-L5YGAN\4$+SLLZ^[96DFDMU+TM;]B+".FL\I=^*@<Z)6NO*5F>3LG2*5E:
M*"L(G\44V*\H#R3+ERKZ"(Q2S4D6@SSP$M"FI+E'M1QH+TH)(VONL_R<I<+%
M24*JQ,:Y6"-"U8ZRH:Z/F2G8#!3E04J&)9J%9+>Q)9:#FVWAJNY%$,KF!#P]
M9^<R<"C*3[!_ .;;7*GH>VTH2P\R)8"<57Z!!K5H/X8/?O_E,V5'4?HQV)H!
MYZ'TU-3-@^4"FDG3PL&$L^]$Z[MEE0<D&6DP]>9[X#+LH%=>2?4&O=-BW*E?
M@N#,165I09U5J/(EK_=5R:+V@G,EO A%% ! 35LU /D0PQM"%9(X%;#$,B58
M3<";7A^@#6>76K?=JWL*\*T".$T%$QPHN(QX6,B7Y-+(1%>*UK483\E%R<$%
M3RNA*H49N7]$5Y[.59UF..(.HQ+-=457'&Q=>TD==,4A5#D%>.+D@ U1OTQ4
MNCI?HZ@"3'<0E5?=81MD3T4J?K92[:6/TWU$*8"Q"KVUC77)A='N$"/9!.:Q
MX7F2%?AG04P=_UF*0.+OK4>UK@-L/G=G@W%G1/-S9S9PZT]J(VOG.8BKV;5$
M&J!_4Y$0FB <]H'JOPB?=Q]"XYT];SJ8JA4(C@\'NJ$%VDH')!U R#@MR8X:
M5'+':CM8B0O\E$A3];3ZO?T.Q$6,M%6_KWY'O+GGYLILGLUDTFH)M=87MY5:
MM>KF%1:?B"YNFXY#U"Y;$:R_6+;5N=I:KBE<M9?U/D1JJ%5W;\7;PPM* \2U
MJ@6V=DW!'Z",)<L;UY3@.#>M>V/UZ(XH1QT@#X4W"!%/Z3H8$,Y94>85#6&2
MT6/D>M152>@?*\[S-K?K]#*^'HTK/G)2&\R&Q:J!2K"6V*\$7&0[))3V0LXW
M.9,UF=*IQW:]ZR>1U=F6\&5!3<GJ*!@=JN;84T![24,*E (V,$X"T/1P[3)9
MDUZ38@)#Z\FRN1*&RQHP"8E"ZVF1%^WD=_D</*9X"VPR7%,:E:(E%@1;_#-.
M4\CC"\2:T(],H1+5KZ=9BN+02CT&TTU%&XW-Z\4L 9GAU:KFQ6E4Y"^@H)KX
M#.="42X)MI]+$L&K(K@%CPQF=%)L1RJE(C<PQ*8?*4$+H4WI9'*>;LK1975!
MB<Q,M)ZG9G)UEZJZ;4G=K*ZE!E"G7:&)UPJR'+=[U4"7L'23.H!N41%3KC40
M>DW-2@E"F)&#>D:1Z19#^VHQ]'_820S _T8E#7[EZ"8QWC1<LGCJP+[7;F$G
M 3"1(JZ3#$#HBS2]O[,__D#_9:MW0/&8[K[=MZ2#@WO.(Q JIS/:E$? .\W1
M4W& </RA,/!7NJ1O.E3&,@F,%__V)]=[O>EK^N*EN:&Q>GL98E9[0"WWC;,J
MS8KXW_YD3[S7PC6Q\;TO1"]0>'R+"-3KF!%6+%&YHW4Q.-D--\4^5!J[D#RJ
M <8E7 -6(LDI3,8)L2/JQD88_$>@>@*Q*TKO+!).KX1;0R&O6O% 4AJ%YD:E
M/W@M:(PIM>AJ<F-4REXK(8;"!_9,-!H0'[^M<M _ )$?91"I !SR-+A2X!*>
MD[<?3Y1WY*6,0@QU-.!(6,$MI ?53VA^N]\!%8T?6393DCD]H<C?$3V4Y! )
M2IUM&O"1Y^$RH^3SBSBK"HR[QD4 UCQF'0A7 I SUIZV1N52^UA1OT;M,<*Z
M]NZTR6WZN)[;="ISFT2GP8^G9NUKE0;]+H4V6SNA@=U2RMZ# +S&Y*MGK"Q8
M""SY$L/,<K*6=&YOV:;J*=5JB*7/[G[/KLPY5">7I6E641V'+"RB7)TF^3"5
MPW8(/5_ -F\\K7* ')D ?Z9>M:6H=,5:!#S.:ZF=+==0NWL8-346YV_-,7';
M$RF:4AF_JF"ZK%K#*2Z!K"SDK0;IK2P\(E1)&W4.X[7A=>=)],#2LO=G9.]$
M\Z_]VCKON)]WA6_7PC$^Q"K3RGB#,53R[9&7=\76^955(?MA_!J#-'Z?!@.T
M<83R++YI].=UTT;>BWH[?':1)55:,F"L),PQ>U?6IP% _EF!GL[%U-6$7185
M1@K.<:)%B0X\R6!^2ZFG+LTQ*'#A91X#'SP%WMCDA=4? _]Y U*3!&M'[9?K
M.@F$J20W(%*9.]]U&GV2XTSV 0"P51B43A)^KJ1"S: G5(6GS8CC3RI:M1ET
M4M$Q)A5IV;X3?->U4@S&@0[,*0#SV^!L8'QA!'EC:HYLQYPX$]*=[:'I36QS
M.)ZH9-++5([0;28*PE^"-V,..MA.<2#:30I)HE+-:U%"/%N,D*CO5&)$_M7H
ML;6XG,B*J8-EWEI)NK.1=[ U<KMTJ1:NC:\?S&TU<FMN#ETC=_<:N1>G'T]?
MKE;*'2Q/T?+OCK;M.Y4"H#GW?CFW#.5ML6W/*(-WQ8X]^Y]?VR.D/GPX%>.B
M.A^;ZT/+4S483Z819=A.'ADF<!/@@0M3]I2I2]06[$HQ6=G2A'[*L61%EI ?
M+LBY,#"I0%:5]B1UJLSJNF0$#YOXT>ZH2X5Y7>8Q?%8M\?7/G>%09=4)EM>
M!A@DSPL>BAEOR L1)EWXF888NU;/2*,(JCTS24'#F!LO+]&/78E$&5SZ!XY
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MIX)G*8(N,R.K<@,N7!A)QM+">%& GB"*/8/7'^)_57$('("><<J6>!J,K[R
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M '-^?^4!JPHNDULSX)J%2MQ1""&DYQDR=,%2^05+*GD8Q.=P.M,P1KV(K/<
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M5<!CRC%S5&I+G@P4].A3L42%;%W\6*\1WIZ=IQ3%B@7.\K#)7$(%PS3\2OH
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M:$WZ;?VJSF11IJ)\ZTF3MG2X-D:_A<+/\9>]#?!ZNU@FV167U/:W"KOX2Y8
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M%@0!Y;N<"_@2>GPAE/(#^I.&*[)E$G,Y-?34LD6R*JH9D%W,V&OZ(JKAHM'
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M8!P1A:H,W.!KU9*Z"99@?ZSHJ;0P[K#Z>S.G;@%%HE1J\ZK=@B79+YO%MJ/
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M;VJZIS3R%S+_8UJ,3*$2#021.2],X&%HD=!JIJM$QD].0]IV.RF'DM>)K+R
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M%DF1=27]E:(7'6O/R^3YTZ>I<H I'J7)/?QB-#&Y[,JJR;FHQ\S\<ETM0"K
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M;T,(%H*UX5^BK9)V)HT(P^*GW^$_E.7DM$<L<";V&[2/=;3 LD9I:^F8\KE
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MT##5(F\QDCQ/D#L)^9&V,MM><'EP[S'2&2Z-L\B6EIJ/T _];&%)-9=FJ2A
MC=2K#QXD[7E+N0A7:),,@A4L!5.89VMBOQ?@2$(+E&\V;I&+G,ZB$XT/BP2E
MJU=K5P<'%&XKA4=4$F"#?K86+EG(\;3<8^I+THQ<A]\=!FH(*.Z/W1^3R2,
M7:$^U>H;\C54BCU*W='S5J;;4+*4$#.N -UA5>+^P\_"<NY6<4/W;J,E"BVF
M==X(3(TI)?R/@A\=U?BS5 "[&!?<Z,UZKG)>?E!C&9:=3!:52V9WZRD_DQ=^
MNP1Y_+;*^9"*CES4@V]46*Y/F V?A)<DA'"@G@^<53:4:@H5Y!WH_9I>E<CK
MI.'5,BL].S'(1$C"K>V82 3HL+1%7)9EY]I*S34>@#.&$^7Y/J#A<4SEQ:P
MH=".P<\4A' +"/ZK[-5-#TH&(NHS&KH#DI(0YM@[/W<N#"F06N^VR+3+4V8-
M!SI!4\D ;EXG(-((,*&OM*<1D(IZA\T$ICINGT8#36_+ZKI4.1#Y=WP WB$.
MC%EDL>1E("P/VFPVTQ@)1*'AQL]4>UTVN1A!;,?T!05B,9#)7/#BX&TC/NP9
M"GD-)9H.O'>ICG&R^IRPPL]H;XO%&U32C>/D6**K\?IU6M8P^2CLQ:S8L,Y
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MJ/H8H^D=4EA84Y@\*'<#%VT/A5TUI'Y?K0$I>RCQE[B8P(5__C3)5A1S^E&
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MBPQDQINM6PC#::2Q"T:X&W*33I'YKR6^Y1'?=S)I"-%EI5OO,0ANN[J!W(/
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MRB-)8!;^9C0Z%J@<R4NPJ0D:& ,9R$;P)#/H1=OB-TM-]V!$'Z@N/_6^/X9
MYT %4. ^J1$)BJH88\[&5,%,UN_GDK>+R];KP%==&VGV[5,)]B0\SRC<N+&
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M++1-Y+(=>+\0R1X.KT\&=\,1@#@4,JQR[&$@O'[?DSBP5TXNXC9=Q,\\I';
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M;V;5?$?KS=%5!A@^?0X*K26&A)GMF$YG<O-_>X,'4U3ERG#\M*P2L#;4.C[
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M-'CS\@JMO]4G,PMD I-=3';QT>U"XC=-M,E P/B!6,YZ;LBK_6#SH)1*<9S
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M?X]^?Y'3XR-'!>%7L.DWKJDA$POU7^XEME7P"!1^\^*'Y5XR?<?+]+V9  F
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MPC:N1"% 9P(^PYL6VV0T4!]5&RV0L-\$"?N9 B.!J6YN@*IHY^,$HB%EYT/
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M$IVC,*<B-/%S7]7E%;N][@-R#+-X6>?TESZ_$ Y-7BT!ZS#.U?L,!,UK4&7
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M;>16!AFK]TXG(:!#M.O$,<.*!9Y%3U3/#@&K)!KA&_+4P<YS5220.FJR!%Q
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M".,(V &G!=>*BF\,;)O"SHQ('>_HEWM-CA:"ZKX" 1C'";BNFG2!PUU(QT)
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M/X"!#ADHI=I) RSD%U?O,'_VZX*&N&\TQ-<+&F)!0RS>RV0K4EQJ$>,W5VQ
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M1=2F.I<%7QT-#K>(0R"\+FL9$3F8'F/ &&#OE"D=(E6R8U-9++@L\B26IH.
MV;X2GB$R6HK;\>I2^K?ON-:&[(Q"/LE[%_D:G+D^ %G&+46'I*-S6BIGO&34
M=,]B'G)#N#@%4IDFI3$XGO=5?5VZ_ +\ W%=^+WP]P\NZ^N3-;6? 1[D540
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M.^)$L8TA%9>21S0!0OG$^5CWXN>86N-T#CX W ;3AHO.VQJ97#87?60XC2"
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M]&0KXUVSJP_(=ICXL[XWMTPQXF<>(:/V;,?ILH=MC[<SHI36J6,KY+'^8^N
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MA!: ;;MD?]LGS/EN*5+4H(/*W/"%*\_;E>B;\#3Y;# +WIZ+LZ*E0TK,*5!
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M')'T=A?&"(3-1B^L$MP#1HR<>:UJTS]RZ3QW,&U?B=2NN34=#T7^WA5]X$8
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MATW;OGT.*UR-KZY7$]\B^"7DX^D3B$,[+/HTUY6RM-N$PXX!CX$Z]7#Z@Z<
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MSTA ^IRD58F!UR_%P]%']*PX-II0>#L=-O8Z%<O6)=2-<1YDY0;R<#<#%'^
M&6IW?GE?TT!_ +CM7WTB%'N1VT9()GNP@!9I3%MO126L[;=XF?KS&'96F0@T
MY)NBG3N.=G90M_64-0+%JN*DZ>_LJ0@Y>APESY0'7+RPF!F<-[_V4RFOA._R
MP\U/A6RX7,QBVP:>*B4 -W3C$2$FHTCTAEZ0.R8E[P=!<51&=07;2S="#"Z"
MP:Z)GT2N;^H;X@7'C!B&00:[X5ID*E-.*,[3$^G44J$95$#<"#/5]5SBX")5
MH[TE/=[\.K!+>S[SX= &+57KEBLY6-;3KE;4,M&<-1[0HT#C 2?8:)Z'V%XX
M9@@$,&'^N5@JK#YE!6ZF8C.8X<;R(_K,5$RW-7@>3A1!V*>?Q.R=PMX0NG,H
MFAT2] P:K5)/O(-#L?,.FH?J<^@I'H>N2ZH_'^@SZ-/XQ.0] RVA> 8:AKY%
M3)#*L8$K8PZG+)%3K#U=3;[TBPAW#(2#&;9L>CXW3(A8^2&#4T!7 *5Z4#)W
M81CI _IT.LKO[RA'KCI6\'*,@^7.;F?$BKFO$"FX"H16-;83T(?N9/%*A*85
M1NI3*9A.W[YF']B5YQF7W-?86,O&PU<Q<]0QVA!Q8N@_"/BLLBK[ZITFWQ82
M2&SC;,S]\6[GY&_<*:*)L7(0\&BAOC42L;H.17;5+XNP5 Z2G\.R 5/]B5:N
MZJZPP"!1S+._A'[2_'U!X0F<]# M3@QB5YJOD8HG8Z58K:O8\O(=E%?LAU:9
ME@:$($>SSJO)^JAL#L$;TR&$])6,[0](Z,?-_B: LE_$*A(*L.M5"N[MP51.
M@7X[' 0A8V?*3T2*2HS%C=W,!A^K0C52_>&MW3$UV!IIX*4-UP,=HL<BQR5
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M?DN\?AA]OW8-%-K(2'/;JQT#<LK(F^?A:)QWWD5!VF*D"5W%Y0DPB$%B)@_
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M9Y5918QQ9B(*-X4DS<%T;E0C)!JOH)PEA6JXC8E]B6B=)DM:FV4G3/;];G6
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MLU4FQO@GG"F4_@[/B_(1'8X%'<2<<R> >&!'4Q(Z(MV! *3:NAOVO$UNX"U
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MAZ\XI1$G7W$Z3??+]$Z^XK2Z)U]Q\A6IK>?HX-4O9_MNL29G<=HFOZ^R(PY
M\H_OW_Z4O"J1?GCNDA<BE9P\8/D4^;,J* >=@VRS<5FM^IRO<)DA2?$%7")K
M,_ ;43'6S;,.I>[;AF_39N>LT.?6,[=8"+^SOT9X'KW?5Q/AT-Z<A_MD.R=O
M;UK=D[<W'6/B[9V=_KCO%FOR]J9MLB_>WKOLJBJK]39Y>06?DB3-V7SEUIEW
M_R:W:V\.IGTR8I/;-:WNR>V:SA-QNTY/?MIWBS6Y7=,VV6.WZS0KYB*91WFS
M&3+=3$[8WAU3^V32)B=L6MV3$S:=+N*$O7CYP[Y;K,D)F[;)'CMA+]PR+TG[
M-?DI+]]//MA^GE+[9-$F'VQ:W9,/-ATNXH/]=/+]OENLR0>;MLD>^V _93-7
M3.[7'A]0^V3,)O=K6MV3^S6=*^)^O7G[<M\MUN1^3=MDC]VO-[5KX(O9E 3;
M\W-JGVS:Y(5-JWORPJ;CA;RPQ_MNK28/;-HBO^<6.:U@2),WV?FN;LD'2[Q9
M*])FN7'8L$D2&RX+F) 9?+-5!\YY!RXO^=?XWWC/#'Z\P.Y,T2QK$@R4IG;*
M_3GK]LDV3I[<M+KOQY.#_X\FB_YSUQ#]Q1Z&AS<9HJ-/+G=VAV?TO@_%GI^C
M__9O/Y"*IK)"'=S)T,H$W^78CEN\3S*ZOT&=[]EA;SQ7/A+;@._"YO!AMH17
M^RXK+K-M\_Q/R=>_YZ(^VKFJE;GM_Y -^A]YR>8/Q-SVCOS!:IF<RKOU&-+V
MR=;H?DCRQ7_\J8&_9&U7NX^?C9OOCUE5+.YDN,]>_?67DS&YWKU^ZG>_OGUY
M=A,K^?3@Z=-O/KF=_ S/H#>&UA"I:VKWOUU>DSIUX[D-W;RK\S:'"[Z\FJ^R
M$@(_(3@$$_(XE1^>YTU;XZ56$/0MNF*;$&?. C[.&_B<1*3A-C.7X)Z!#S#:
M@]O,W"HKEJA0C1<BLR)?:/%H[$KX$5TOZ]I55<,++^[FJ-P/A^SC3[A1AXQ.
M"+_ZP,UW-=T\+\^_.WQ.GSXLLFW5M7"U*[=XSE<^.J3ADA_ LBRR3>.^:]PF
M0P%QR5>:;.9%WD X7N3M]CO]]DA2DR_^!&*!X[_@P(S%+OR=1Q N//W =QX_
M.7AV_#CZTF>0:/T4^;K?.1*(YPQ&%3_YCS\=_VG*W.V3M3_YQ]GKGU\F[WY\
M^?;DS<M?W[TZ/4N35[^<'NQ]-NV+VT/3.$_C_ <9Y\_@B)Z.B[$I?0&.WW?)
MS]DV.4Z3X\/CXWW;1=.TC4W;]]M/-4\2+?BQ>WK\9-,F357DBR1^_VE&?\N,
M?MU\G?SHZCJOVN1=-NM:EW5I\O/!BP\Z;GMJ;[^DXV\:YS_^.$]F:VRN)I,U
M;:5IG/=TG">3-5H/J5V3XW@E6;E(3E>Y6PY51B<+-NVL:9Q_]W&>+-C87#VX
M1AYY_U&ST]Z9QGD:Y\]SG"=#,BWP:9RG<9X*AE^J[[FS8&C?X?=^R&3?MO:T
MEJ8JYI<PHUC%_"6?OT_>Y/_Z5^X^4\O_)1W$TSC_\<=YLE5C<S79J6G_3..\
M3^,\V:E1+@ZJ4/Z0EUDYS[-BJE!.>VD:Y[T9Y\EF?:!"&0P7PBU.YG-XZ#8O
MSV]4L/RC,'+<<0/H1!OQVV@CCCZ2-N+?OYY5B^U__G___O6J71?_^?\ 4$L#
M!!0    (  2)HE3O@G- @1$  /R_   1    87AS;2TR,#(R,#,S,2YX<V3M
M/6USV[C1W_LK^.A+<]/*DIWD>O&<TU'\TJIC6QI)OFN?+S<0"4EH*$ !0-O*
MK^\"?!??93HA[W@S%TO$[F+? .PN0.CGOS]O;>,1<T$8O>B=G@Q[!J8FLPA=
M7_0>YOW1_'(\[OW]XY]^_K]^W[BZ&=\;]_C)&)F2/.(K(DR;"8=CX\W\[@?C
MWY]FM\;<W. M,JZ8Z6PQE4;?V$BY.Q\,GIZ>3JP5H8+9CH3NQ(G)M@.CW_>(
M7W*,U'/C"DELG)\-S\[ZP_?]X=GB],?S]Q_.3W\Z.?OP_J>_#(?GPV$$C>WV
MG*PWTGAC_F H+.B;4FS;>^.&4$1-@FQC[G?Z5V-,S1-C9-O&3&$)8X8%YH_8
M.G%I/@OK7+@R2,376-ZC+18[9.*+GB<)>A9LBS7[JK_AV[>G/0-)R<G2D?B&
M\>T57B''EA<]AWYQD$U6!%N@61LKE<0 (LU@"BK.+<G[<K_#(NA.*>YYR>T3
MQM<#:!ZH9M7SL#\\[9^=^IB8.MNS "O 4( #_"PQ%61IX[X"PURK6O3/E,5=
M=,%E@+Q"8JF1X:$B<*IZ>AOT!#J*<??TUNMI>#KX]]VMZP(^L$WHYW19 /[M
M0#4OD< ^N"/Z:X1V25:\AA1V+$SB8@MLGJS9XP :-/B7=P'GT&S)-"4-WP_<
MQB@HR6$</%F"=P6,@U=L\UW$HYM0B*>^TP\?/@QT:^_CGPQ#>R+9[AB7ANN0
MM\S49LMA2GWK^YSUU:/^Z1FHZ@2(]0R:<.4<L08O8\*WZU%,!$YQ+!.^,57O
M[[/Z3;5^J1Z%CYT8* -L2Z&^]4,_S>H_:Y0=R4)T@+AL>$^JL)(RRJJQDQQ[
MZF/?_9AKB9116[KKHCE2?Q>E'#!MA@WY0)0RJ3M7C_R'NQVA*^8^@6?*?<]]
M'Y[AE:%']3GB)F<VSA_[@QUG.\PEP2(Z-VH"&XY7%STUT?3]6>4W&RU/8&+Q
M01(=Q >6:AX "K9O0_9\7$FD0KY5S<+0$Y'? OJXZ DP@NV-R6\NYX[CJG("
MBH#U5ELK6]QI!*II0EMX555H0"&4Y(M\%< T36 3V54%!A33L0N,?!D"E199
M45] NZ$^/,S&>8O[0*)G1MEV[_(T@W]^\T-@_^^(6M<4^-F/8:[@6\U,SR 0
M2I4']SGT>0RM_?%TJ/Z#>#L2>@<?$;4,EYH1(??SX)#( 7E'8&M"/^K/AZ/)
M0_9 <A /#%0:+^[)J6C>0]]2]=IO#K+J@/V2J:2%6/#5^H1L%1W--QA+$;%>
M"> "VYTJVP5D#)79A)0,CY3ATNH,EV&X,"6]9-LMD4J5 D82Z%)"3@NY+<Q$
M*C^Q'!M/5C>.!- [X';K;&\Q3!U3M-<XD]5DI[,DNM;/Q166B-CBS+7Y-^BG
MP%W.]% /,W#E+P$G>KS'>%&^Y;%CL)7A,F1X'!FZ:\/G20$$7+EMPGCC,08Y
M=N=]+YLVIHA#\P9+ C)6FD/BF 4>\K;"A&*\B9'^H3-Q91,'#\,Q#:U%YLW
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MKEO'.:WBTU4PF^K0R5\LN"54<Q6^FIL'$K.K5/[]RA+I[WD"/8OAV1U6U=]
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M/]G,_!PDS,<A'RI"^DW-.QZW4)2RC\9YS:Y E8[%6?)\LU?W(#A+?;CNU;8
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MOG&<F3D8#: /0T?^?NIW%D+<":<A)'Z4AF^>G;4:PIW0B(;3AB1N]/''EX%
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M '?1P)Q3JC<*6O6.Q'U,D<JX"<<!G0+,IT-;7]1VJ*C(V@]HU;ND#A$7G4@
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MPJ:\O;DZFXC.^+-4SRC,,$U.$2%+1EIV1FN8-LW.EC*W$U,&,_@#^ALO/O_
M]A;"?0L)MZ/5$Z3N UZRIGCP@1OUE"W:E&MD^O?\D8,SMGYIH"YEH]7?V 2P
MG9VMVV1Y$_(C3>1S(<GN=!HFH;F??2P]4#Q-PZM@*ELE.CV-L74^G6(O88?G
M_+V)>_3*G0BG,=]44R9+A?YEPE7\Q!^*B[CO.G_+03V?4*,[ $]G! SNS0JC
M//)/9_R6AEY&Y38!FZ1%V*A4(48VMR5FY FID]J=F7&-ZT_00XQHHWW.K.SC
M7>WS4E]CK*W7Y/DK?QX3?\81GDK+^\A:NR>@W(&X7<T&;%BG +F<S]G_$F9)
MY:H:$)2MH1VJI*/K%=Z\["7SUMJ9;=$8QJ#C@E[%,4@\OW9RWIR1IG1DKWF6
M^V.MYUN6@M:-<8=SSK0<['4 ZNYL2[G62C#;R=-=CF$0NV&MAT25:=8+)@XO
M$AV/>^6)=CW'MG,XM#$-@#SASF$$>@-0>1E4[D=W%J1VCO5*B'R#U]I92+0\
MV%LY87I.96=!T?8JET5$RV_K+"3 [MLR<&U<G\[B!^CZK.BE+JY#1W.7=0_,
M.YJ7=J(RC+E8]K,ZA\,NYJ*N1> <& /H;:E3VUFP;%/2:_>YG5GWP&NQP11U
M#@,+I6K[#L*YQ/9=)$O#GG<NWWD7', V ^=R9'=!"V3=NI(B(JMU#)L4TN/+
M2EM3J?&4TE6'7)(>61%EGS2W-\;"M_Q\;S]OZ>@]H&/BO=OOJ4=#">A71@]?
MUWP;5JRIK696$*Q<2X*&+A)M/J&%V1OSC"!E:%R]U:"+<.NEH?*STNO?AB=)
MFAE7_G50LOI^@;@#:471_PFYP^0Y\&3S*6QF@E":&;(9#52J\N5MW2.Y@RJ2
MI42_TN/W[#O\_W^2FR.B9N:2X%8V!S_>)\O3>+Z(HX:D474?<]D 56J4.Y.X
MK3'2?T6$H$B<>BQN8]79RXD'>N_2QW]C+[F/+WPT7BQ(_(S"R90MPO_#).8%
M*O(ER?_KCM=UE"_@'4?J\P51]3O#JO;#[M?5ERZW]^O*[R:SR3R,?7I!XODE
MI2F#C DL/\Y*S45I![!9KYZF;PA>Y.6T)YZ7$I)[TF+"A#(@-!E'$9-#0K,"
M)J=A3'F,B<SH!1^^3TE7OUJM:F^5RKS%?,=AL'51FHI!P*9@DB:4WX>PP<?^
M,Q=L^L#?<\Q\GRN')]M.44@GY/PU7P;!-%EF-7^",)35/8 >O5>A*]?ZU!.[
M4@^C<W$7O/8X%Y+1X>:"_4IG<>B?H26]C\?>+& [:J:#U@5HA3.BTZ]/B;'B
M876E3J>3:$+&TP23NDIGYDNA[(O7'6$W$[ /]RQE.0T[B%F]8Z]R!O5T_ !R
MMC6IF_F^GP6D/SGK^&$PG,IF8B[[N9Y]H-B_CV\Y]8R'YR!.J<#8W&F('F3O
MY(..P*U;]21E] M*LEO7+W&4S-B$_A,C#1D1=[/ 2,__,B_>T>W99&_Z6$]X
M7/(W<9A2+!X"NL&,OGHVOG8WJW=)Z-GLB0Q+;I(_(QK0NP7!R)]$Y4NC$ZV;
M945WJ[>X_H0$E Q+A&2E!6[S9Y43[#-%X+$?T),L[J/% #T)RMI Y#'33'^5
M:6B>7V7OGBBN?>I+&B;!(@QTQ%'>U9SK)8Z>[HN'B62.E7(3,%#+HV["P<X(
M>HE.XV<<<4]^?CG)41O350S9"CP1VIW'')*[S9]79#Q$"Q3XE]%SS"_AY)L_
MW. &9C-_\^T4+8($A<'O>0CHG,<Z=IM1Q;B&9/8^_HR_\(#S['6 C;3]&B0S
M$;6K(0JEVUW NQ)@&6Z]XS(DWP4YQ0-IN[$F'@.,^O-7'GZ<!G26&5#9;<T%
MQO+%JN[0TW;,DX;#XN##/K:V"#:F2TY(R7G;O%'O,FCOEO0-D^-P+:7;1EW+
MS@;+EN6[;9'@Q2D^?_7"-/.KSWFA@5P=2<P1[>[F2LZ5J%AGM4=/IS&5U@M6
M=NE)LL9/3P0_\0C/;(&VD2MY5TM Y^2NGA5ABV >I',MY$7]'"I[UBJ5H>EM
M+[<+H&FG0@S[0N^P=:'D211RKLM9"Y;RWM-;/):7-/I>^$XAZ;+$AK*<B\+R
MK>=95>)L-Z;WH(:9/,&BFJ!;RV2PE-_&A;V5[U!Y@=1R[M1E&P5Y$ROF:KD+
MEK+7.'FJ/(<5JXIX?>O9EE4C[<2WPSI**_]B4W=8E!)A*<]:&[%6OD2E?( X
M*\%2##1JXZBR+,J,UW(:G&48Y+ YU$/2-E4C[I1UX6PYI"[/I/;VN/9@9>9:
MN24&*\X^P/0W&7O5Q!?GV-M9&:I2:9Q#H9WJ TW8<;:05Q=]6,KUL9/_?MRT
MVWX/.[D?RGA2Y4HYATP['0*9?>5<U3H0%5+.W+(3 7BCJN10LY-EH^M#EA'G
M'%2ME6R+E#KG2CM"*(MRTIZ= ,#K"K$?TT[NAS'-X1(CG4,14J-LI4\Z5_\4
M1*64\C.= Z"71=4U"]1.%/LY"3;<-M@)!;A^:9TV"XO+CU9KFDTVKK-<MY,&
MK31@Y[ 8RK78F',(B]Q/;DB1)#'9.2S,6\$#R]?/%LI7^QQGYS Q;Q@.+&<?
MG)$S=9HT\)6;C6$8K;.P@3&Q\3:V79XW,"!67S=5\L.!&;?6!=P].1T8*6M=
M6X")[L"067M:A\F5!T;+VM/LP#GWP+!:>[P#3LD'ALW&4\N.&?W R-AH9^M4
M"P .0W'$KMZI. $P5(Z8V\HZ!\"0V&QPZU='  ;%1F-<KZ(",!#6VMK:Y1N
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MQ3<,[X*Q?9\+L6.7GN_X"\\1[%X/.F%7_N);-A6"W>%=$;OC$0^?N?NMI"E
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M>IM Q60T#Z8+6!(AOPT#V 7CW:T OJ8^+90-7E(R)4<0Z$U(0V.H>IGV+AO
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M;X%V</)HR 52Z(2H<X<EAV9TXX J#.?%3>#'*SC\_LJ=&J[)XMO:>X=!\.O
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M6Y/Z(AS<57F[=X$0RR L,,E[9&1@>2R'NIU5WS00K)4:?5 K;NC4AT]][TK
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M32U*2P&!)!]XMM0X)NWTP!XNO\)@568+SQ(4FP%/<U&V1J;IM=E*Z$4-8C%
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M$9]&43-G.9$Z"98GVPB6.E)C)RS0HS&!PXU$++6^$IJ,B$Y8(N(#-IU$RG8
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M*MR4_!:-'.O-.<I,[62_'5K".3-89W,KAK\LE F#!>=NA$BWEUX8Q5/W&9U
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M8OH8I]A E$+L[*Y\>#]Y%-]L1>QMA-?L_:9L843%]119MD[HCDNJQ+1XC U
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MXE;-C&_.W)IF+O-]+&<./XMHYAR+Y?K%29M-?2WYB*M=CTM!F)6*,LCW-EO
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M,"@UGC3^-J*<F9L&+JQH2TYK42Y3<X"]R0EWF!*G&@ W?;[W"M^)B(V =U'
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MG1O[%LY:HK@14,GA:-YQ=.LAY%Z*7X[AD*C5]] &@ST]+$P:OE]PWX$7Z#(
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ML+B:-FGN+(?JK'F3MIE@%/MM(IJ/'M#)00#LXPZ/\8NUW!D<S@G#A;X 70V
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M\:.$Y<^13JE+EMNSM@&QJE:L[GS.B&&XK=@DRO.:9+3L-'FTE30,I%4?2I)
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M&;:4:&;"T9X@0:E.\Z//MY04<J;>HOWP-^?^3N:?% M]YIO*[C'/!THNG-D
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M#_<8-YH1I9WG+L#S!(F9UZS6AJ/(&!632]-O(S@U^9%,*[2#\^>9J^_X3J
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MYE";7S7S^I\Z,WXDQE 9[DX^>X_QQ1*SQ-^L55\IUXT1]][=SUSXW&H=)1N
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M :."1_"55,<+"Y]JGG>R#2M!H2Y3M)R $<&R+T?,O -'4:$F,%2RTT@C<!V
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M^20ZSL+,YL8,P#9%K962G ^KM['I84Z[CC$G \)OC$DTVQ@C]3<0+I8$M&<
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M@KK/\9-1+S79C$VD*Q_'<>/KW&;9&HZ"<QPE >4N -5(7#K=6T@=*YJN'AM
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M]/6>$$4)+6_^-CQ)U$2+]J^#DO7%>\U?G&81UOQ]4-)VO%=(VQ>0+A/RQCA
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M4[=<QU8GRS:O&QQ_0F50+MW+PG,=7)ULVKK8T/)"C450JK<!Q+,O7<=6JP'
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M:RBL.](-2>JGQ.0PFPU*Z#U89QA5KR9L;:*H@3AR?95Y#^[FX9\ 7L<^-<Z
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M*_#HK<?[,W2"@N(L$E 69I15 A>?J*$LXX(*UOE+RI"[ ?.('CJ5>2Y'BN:
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MC LIWA<1M>Z.]423GS2=3&4RM]8U?%/5.5BO(M_9XA@.O^ 5')0ZTC*;;W4
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MQV50%*5 +2/)_@>X;RKGOC<RB2J9%)6*SF52?0-1\MF-(IV"%/8UX=HR+DS
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MO6H<<EM@H=$<E>MAF=%AME+HH:*=EY)GQ8ES-AEAQ1,ZJEX[52\N^6U$O40
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M\_\9[.X ^"\AE3-6).S07()-QWP494P2 ?IRI*N'>&#=7I.#14V:>PA45Z[
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M4_81IZ8I7"\*455/X61_/:&6']4CFOB0Y$+SC#2BYQ'7!Q@HQ-=<?BYR96!
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MH)M.06P0?U7S\=NY&!= FFD@;^P[;YO_U'L*>/T2=@YZ7Y?EPE?/Q1 8')Z
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MJ *Y<O5X[,KB!Z>=\?W8F+"%/+B<4\&P3KFI+9VII%1"EL4X-8"_UE"C+J_
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MZ/?HX"B.#O8.#N*V&ZI%/O^9_/%']'&6T,M-S!(Y9'D=??SE) [Z[9'2;C/
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MC_0&Q!(GYE;/&LCN/LFN1AR39O[6MI7O47TFJM&J)UR1VGPC>E&)QB1P\?C
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MT,&V2;;D8@4L%WQE@3"8L-#IDMT$#:X$QNV9F/2H0\&13I=BXWMBE0IY0"(
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M561\6BVTF6K.(GIB) !^ID_%<AY5:CD[O!"#3EQ6+I\"JDB2&4W&#$@2;M@
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ML(:R)!\BGEM!0G<-RG'/55&#GK;Y)'EW7.W[+,Y!/7N,U'/'#.WYH)\-M/@
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M@P.?ETF,T&7XK4G.O%:SNHK]U3?B?\L%UA8-,TA56L,&#ST;9,9-FY7-E\@
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M&"21S,VLMBL16[LZ!P%9+CC)*GJJV(VU2D-7 W(9T1Y S:LD6T[%(FRXF$-
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ML"4UIS71#&<973SSN$KT*T ;><F(F" :-=O+U[LPB&)YS90E^0MNNW U8X?
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MV3C?IUSUQ>I[DKQ*A9.WC1L3J:'IBZ.OY('=(@GL-E'NO@*Z%;5V.HI;([;
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M.4_%XI/X:>O4D(*3.'L89L\D-"TP6[NOHH/M=]N?MRT^VNXST++W'D<[3W;
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MNS:.<APP!^DE!*.G!C-"+&9EY2CB\ \'&] QCBPT:%XF'CP6UH^C>[]*)?D
M=RN;4/"CO^T\ 2GVY(F6Z#IGFU1C7R2@(:*J*&D#5*)XJKD>@T7@-QK)37OA
M.X##8M4.1L *][R_CSL[H_8L1L[@8(1_IL^9EN=F$$7E+FZ(:9FG/QIBY3[=
M:K>S&NF2(L%J5[>VM,*#0H#54?RU2B "=@C.O@6+#H^]$#*RJ1?[Z,"KHPI;
MB$"&& \<SQ' 7GTRK$#W19__YDD8FQ@CJ6NR%V\927TQ1E+O;R1UC.,\A#C.
MLR=C'&>,XZS=MARS.,8LCC&+XZ\$9!@CJ6,D=6WMD#&2.D92QTCJ&$G]:R.I
MH]C_RT UX6#@86C.V&ON>YVN\U*]OA>.C151^IV][;U^F/[YJ]TQ3G\OXO2P
M4L^?[[[8??)L]\6K5R\Q3K^S>7'Z0#VS(<TAVTW=K!1_)9H]4W&DKG&8QVAG
M#3A.R=]&=)F%J^*Z\CIY<[LBR?&P;=QAVWTHATW/V,"Y"4_*@$H54>W[9 4@
M'3L'NL 6@5VQU92GK!_2"V_@]R(W"MH8[%GQ]%Y1'V/&:A>LY=CB+XL)$SB4
M!O">[?>:**$?.#$3]WV'-Q@J^6TRZEJ9H_T0>LK\%IQM9ZE*2QOS80_>I74^
MV@Y[4 7-&6S#4W9A?O/:H&'LHQ[XE.?2B=4]<.K^G[H.8BRC>P;?18_535FF
M C=0&?7$^EM_D:3&_GKDL;JC^-'.&#^Z*QXKU3_60MG8F/MRX$:\VL% W![?
M+^\TM?-ZB<=Q&42*.EWI13)S-'_KGM3V2&BV%$Y??"X::F"B'1H$O>@T.\<_
M&+%&L_'Z_ 8.R";D4>B,2P&!DH#IY3K-?+(: /<&=YIET794R%/B'>A=8<%U
M-^T$SO"BF+S!I=T .V%(K*WWT5P;(V%OPXT$!4AQ/ML5>8.E9""ORJ?RL+]L
M2/TF=G@4!!T&9.ZJA+^Q=F4#3^! [<K9YIU VMUSL%NVH^AP*#W>/M"+R=RF
MKN6\S-L"ICA36"3_@T9>@?9;GL>,(&<!Y"0IGY$I70T"#*HP$@61_':4$WBM
MQW"%%F:>H7I":'@$7F;S,:29!6(UXA->\,?!QHU'_6$?]6SSCOJOQ.;%L<L#
M,"#*/$L3K5D;//O[>"/7F<0S!Z#.B"!,J\BX/7-#M++AGY+=4U;.=\Z'W<.G
M/4V*[-]J2;@DMH4,+FB002KG7#SBBR0! .W1'<IK>^R(VJ. %Q%!/U?\5#^=
MC&+D88N1/S9/C)PD7TV_RM77!!@/E3P'PX<_IC*?"Z1=Q2 :_L;>QM2\:NR@
MUV,&K =LVL.B9M);T@_PYJ[QW^H2\(]K$R(T8Q[)LAS"PD:\X:H^RY;0RY):
MI-*.%C41A&BU'@9<QK+. LMC=;,5%QA25M*2C1B34%HOYLIFM:235083I[YW
M>I/9K*TD<2C+B1*8H*$IIX?\]##ME+K#KT1QUB1?7-1R1D%/ :7EJ %.0SVA
MQ9J;U,%<-]A,5A#J-"P>C!#6K/!A?_VUM5]W/![8S12&?=,,.V*^[ X=K4C:
MJ#77O9RB+WZ><'2)ZR"1I'9999ST2BECM )I!L*.<Z6P:*6=41(2[T6<G0XB
M^HJWP]PA5W22PMCP#:!NFNJ<2W2["=\_[^]_&F^'AWT[?-F\V^&@K,">PLU_
M0*EJ>%-\,%F@%8$0[]5JBVCC+%D&"-"&BF1!1B :<<A'C*+LCQ9$9IK96C/B
M*;:>\[)MHN8".G09;>T^F8"DNZQ5$F.N.Q[H$.8:A! 35=^FMP)]G\A0\92#
M7MU49;Y]BU8JDY<SDJ$XZK/,S#';<=822CL7:I/^21#ZMJ C3SAWS&K&##?P
MFFG(,99;N_S0*X?\1H/%$RV*I?XX[/@I2RP)/.-2PQL+A*W_K<C03#C&*X#N
M['U0P[-9<JM9M.,GF-0&RXCG_DWM:_E;+70RR?EE6+@/EY7CL@;YFA78,%Q>
M51U.3YBPZ3DUMLXGWI!KK4E?VMJ4#H7#67+.@1:O?.(\R5MZ7;O$:?W;[C-;
M.H^#FF?U# 9R"?<]O.^B]SYOL SQ'MD52$T]J[(IZC<%V&A<JOJ3S^%^S:/P
MPJ^3*'C=HIRB3F!TE+%'(;T\*PL$"" _BI1H([A$VZ!QQ?E-"B,@7RI\2'V#
M98#>7/J]X<(*;_S"B@&[  \_>8=X=PCB!JX]] XN>(D"I6:!E,X*S:$4S="5
M,;1^1Z'UW3&T?E>A=='PUD*?VQB5Y'J9].^^3)IFY?(L@4[,#-S$,P(! IG4
M*BH%RMYD2=]9^X:+'E5>W>!2&HCYSV"&Z76-M$BL)^=P8<B-A$&I4T;UF2C&
MT/"=/T3GH9=^/'SA9_5MKWKL8"RI9ME\J$'*H?7!;J8)7#^80<4]EO ZFNWR
ME8>*!#TAE8\)E:B^969<P@$&#=%O2<%\J\.-5M6#MJKRS;.JWAKR-$7[[)>Y
MJ5'EJ\Z'5%&,1]CS66AEMW-=0 /=EW'AF/Q!J"A,W64I2Y2XR\)Z=2N>V7O"
M-$-XY*$[TK@:3(YJJUO$7I2KGW4&BO4FH99HA^JFZT,Y, &7/W3T]KL%.]E@
MD._0A/L%=A7V[ 3,TAKEV%M4=T&;WOK;,X;8FO0QMG 8;&+BQ.G;T2L*'PXN
M921IIEB]-TK ART!%YLG ?O!1Y@:$2EP+,@;[AUL5!HD*"!<@:0^@)0PKK[V
M("_)[?Z6O0^@QR2-ZC^[3\AKQ ?0>9>T07'[^T@"ZGARW'MQ!\@18<70BXX,
M;+67AABK'N?2W\E/?<Y:)*IPV,VICA<^0V\09O9C$&)6&7Z;'QZPR(.WNPZ(
MQA&=3T8T3]+-K&H%@_AGF5%VE17"<!<=S7WIP[7"0^+6PH-HZ-7F.?:BRZR^
MHCN>AE,6Y 0CT=J-)-^VPSPO7#.](M64GNC]\ 8#JZG&^3J N%$./PPY7&R>
M'!Z4&\,\>)(#,GQF^.R^IM0,JCL"T6F#?GG&3+2";NN!DKYPGM4.R(\O?R0[
MH[PH!!%U@&76127E-G Y)O,@<'QET \]I5_ O$9Y#FHN2.3M:.2\?-BGOMR\
M4_\!U:UL9C%0#L]%[WIKYDF;-X,"P"EH/I")E$Z4,T8G<12SO3;'8_2@C]%R
M\X[19W/:Y@F%+"D>6968:8(Y+]F,;M$3ORZWHPAO35N;NVSHK%A7+=)$;^UQ
MG'LB.BWC]5"R$952N/.FN4H=&^KU32XN?W?L=F(W=WN\^&T_\G3M/)#3Q3/W
M'__8RB8;=Z+H-'1B'(/ 7Y)!$7K,0"D\98Q!;$ZJ!1+6$\^S,G<Q<RH?8AZ&
M7TR2-V?1^^3BNA?$XWG:[/.T@0=JX#R1&QZODW=O]ZEZERIIN.0.#@IZWL^3
M''X^0><'N;_((5:W]=*P04=PWN?E%P4TA8LPLTD;OA,-[SBT':D52@Z-%>_2
MAPM,7)P4O>Z3\:1M^DE[0$?MRCL+PV=30\G6=3O]PRN-]Y3+?4HH& _%AA^*
M\\T[$XQ1!->!HDRG9II4Y+7GU$C8Z(R'ON"\E#/2QF:8> .6TFF5+,)?<9W&
M?X-&YQP8<*%<?Y5UO("]@RB?<65)!FICVYR5%0P_M>Q*JP[@F(+XO2F(>V,*
MXH],01RO@7M\#=SH%HBR%#XL9U^QJY69[[U\<<_./)4#>EI2$HCG,/$IUH_8
MV0S26; $6&[79,C+WQZUT^J'%#OH,OI5HT8V*CR)T>QA"+B,TH(0U(>3#[):
M(=#_4/XEY"U#OX/UI=_,^?!.2N[$^W! S)MRX;U/+D9?PZ:?\@=D #'K&?O&
MKU/#V!Z"!FJ#NA>GX:15<D&4?C,\:O!A:C"_#__%)]O:3>*D4 H&Z&V+#&9M
M1=X(2V*[6*#G/&1E<\6C$HSNI$A7'GY!4*X&$N6+EK9J;Y-<NQM[78JINKEJ
ML/\H(TJFA\6A8EFT=,7.C\832!EVGA>,#T"7BC";:*A&>G1@/C2ALH%2A6I(
M]7S5LW)I^&177PQO?#'4;$(?/I<G4Y/3>9DKMPD>I3 99+#JVZD&E#3F>S;Q
ML(XG:--/T"8>(>$[EPL$+B%&O5;WO9#"<ZV/"VE?Z75<&]/;;O*^3?3RGJT3
MEUMTR.Y!8MU'NFDO.GV?NFW1SUD4,$=Y+$6$=$($6_*B;/.48EM>]=H4O9U8
M)<,X*)@(&4=2V -'!&FH6X+89?2[(.4Q=K:HY_I_[U(G!YG2__H)NU4E[)C.
M=0]OQ\%TKO_>O'2NWUC:?A+J.3\)DBI8:Q<ZMUQYHE^^+Y.B=N5K+:)6.:8&
MN(RR@F+=YFO&4 >XA%,0$URQ#,\LB6*0^=CFBL: PJ00_(-N93'14;DB"&6C
MNB@KLD9GR3)K!-/I%(S%BDJ>%8-%@14D1VUX.!>9HZND$4$OK">+:H9!A7A\
M '/4,L$$.J[(4':(W,<P;,8D'-,_'[2\J#9/7O1]Q]M#&9^$JVMAC+@.OQ;7
M$_XI!?Q:OX!%\ O3)42D!^'%LVP).@'YL:]Y[2D6JZY$#; OIFJ[D.)JP"E.
MQ5J=#JH[2G'ZT9@8^.GV6#_QL$]^O7DG_P!.59XY\#^\^%9=<#>D[]QYNKWS
M?"3P_*;J82WX[Z-J#B(5VZ=G;ADQ$=^'+16T \'(PJ\\I2;' %U4M3G'!<1G
M0N$]+_R(GA5XDA\,G^LA*J X7C!@)P)[5N47\=;,HYQT,?B4=4CL',(7+!:E
M(")/O&''3*:P8NCP[52 $5(/)8% VZ2J.DC&"5RK,&*N8D[RVH*YP[_F%?0*
M=%'\-Y<(ZJ18QVGMV\B@Q(+.FS#,6U^I-0K8Z;MJ'>RJK>I3: HRS!-$!<TQ
MA@)SF99(M#N[H7T>W%DITG>;Z) *A[^1AW<\R+<I1%N%>C*$A"L['!_A,][-
M&!CZD8=<OC^?9SE!Q6('JA)CB4'./YZ0%([!K%$7C?X51U\*HNN&+TA;<HCF
M:3EK";X)_7:PX_4/"WJD(.8-\A'6 3DB[$LX277#('^X^3^^VS\ !:^^&A/F
M1\U._,.F!R&K].!B8Q[".TS8:<)PFE32&Q*TI":A0(V=EI_R<O:%N=AK"IE>
M#<D02DZN%1')R13A,)1LVEI@443\B@E)F--"3'6.Q5HH#E#&2OR("2=L=+C;
M)P+;PIY'61 56FO/W)BF^+UIBD_'-,7O3E,<V>Q_]+9T*#.K!2UY%IGA/M9\
M%X9-T*1I8N*"7]HOIB+S?,R;0PMD_+'",/F'<CO:V=O=?:IWC++T>8C']* E
M_T*7(6MS.V].#%PL5593QANC/%#,Q0U#V#^6&6MVJ\='CEESGJ22J7->9BE#
M?6%"$7ELV>-)[@YX3NX+>E!S@Y(&<6J9[9#]G";VT@YQ:@B%ES3:VA"[2D.4
MPU?.RS4#OZ&:^:2G93[9>S8>D5O:B[@;;/C;I($AQ-@DC!FT+,' R<0+3][Q
MM$42.]A?, UL/8#]@Q:'9T1*99N^+1XH466HT:Q2XP_W#&M1):)7VU*##BQS
M<DJ*)"E)@UYW>FC [<ZVX6U[I-W@($30$S%641W.B7#/SZC!UNUHO(['E,-&
M]E[H.+G56%8:Z>,1^C,@0XI@K>.5AD@W5_OJG4X&@NXP3M&\8H?Q6VE3D:Y^
M92XI70H4Q();0F^-60+SA?R3 ]X'XE1AQ9^JD\@;49D4_X8?Y?@SN"=A5V;U
M&0@!]#U,+RE?/+';U)H)Q'Y"H31BFZ'<<!MGTVO!O\1HLF$J* 9(LB2(\-%(
MY%[ZQM#;&*)_2([W9O,<[^^L#_2@/#<%TA3<,K#L;S*[RW>>K@M*^_U9C+]F
MF\-*[>Z]>O'JQ>[+IZ]>;2JS8U9DBW81'23UV:WQY]:2)GS<X=_#%+ZS>5O\
MMZ4XO(\-NHV1?J!(2<WQ47Q[,+*-(PJT\:O_S<7@H#/A>6$]+TH6!#%^2J4R
M@I&+FB96CJN&6;?$3?2N1'?'KZ!=H2+ET+R?/D%H2@;T7N=45GX8^_0:,[ZR
MV<I)7^9MO=9#N0I&H+/,^W__!)N&%CDAHFK""JV[</-31(0JR-O#^VW__QP_
M?O(,EQLT>;1I_K1]=L(,9@0BW]]MN\_&W7;O=MLM=<_Q:MZXJWEW\Z[F(\^A
MMTB^D-_O$O.3E<&GD[>2)S6,#?VI@N9%'*]9!9\NDRHYA;X2L^VQN%I>;+_@
M=$)MFCTA,SQG V_!C&Q+]'=0%N>F:C+T;[PUTR;VJW\9ISVQ))+8C\\F19\^
M?N) W;OB/@X.M2?\XZND/U5OL$RPZ3/B 4XQX1NO(.AXQ%[_V9O!KO"7Z9O1
MBGU(@F3 BMU ,Q:.+3%MH%A0=\TVDDO@$3DJ,@+)&'HH.@'=C&D\,& C6+=]
M4@E/2^.S?ZG%5G#Z,2-EL/%]E#Z#W_S$5)08%_+D@48F5S1W8'\$.E\%?<DO
MQUJ'!W26!QRO[>:=Y4'.A>TH.DQ\'G4^EGCRP IKX&F$ZIAC,4.0<8KG_QPV
M6HH!%0HQ%G"N9H9+'6U4:9CG@<RZK.[Q/=PH;?0-'V0+PIVDYUEM' ^/HFD0
MPH"TGQ5SS,757+XK^F:IE^$5F'D*DU%>W)"R0OOLB*UM"AU\.P558PJ-EP1Z
M I,U-YE@$H&IFS%#I4S$DG&--5F.QN9F0DM!I A%V'[<$B*!!V<)LW+V":%&
MFECR>8G7\:1*0)-)JB_!IP?E\K+"?1>/5+UW= B?/1L3T$:JWGNT83WQL$CJ
M+U2<:L'<%-)(0M9D&,V#Y '\TYR6G/M[9DBS0WWPHD#33.'<;# =<^ L61"U
M"IW4%EF.*3Z,7YV@2;Z>6(-'"J[V[UQM,#3F7<#+PU8L"$N9[78!JQIY-4('
M:+(27*G';,E ,\XHWME*)[%Z+_LX6LSQX'C0;*&+TJ51=S/_GK&I?#4\4=%=
MZW+2L0$VO&T".^?W@%G.;?&WB>3>)+6\>4&%RO_=HHHNS'6838T5&# =]M+Z
MHTU/R93'VF;0F\VLZ92=J(^@RDKJG#R%E=/:7\U,)-[@Y+PDQ=Y>UM3+I=-%
MPHLL-;,LY<1NW8:TS/:>JMD+(=MR!>R7?3KZ2 DK\="V>!UM?9W8I>/^<3Y[
M$^4&W2/S#(0R+.?6SC.F]>!A=Y>YG(?-NVL[HR,5#(:>7#F:ICSE \,=@9V[
MM/O3/W%9PVVG-%/S+#=N7U\]%=$6(?O2&39?*3-2?"=-.0%%ZW+B4?G=>&<*
M-;3=?_=V=Q(CY>J]AE/..MO4^&K4#2=?5,U_3[#DH:S2VQW_&R^QI"2555*8
MLJU5Z&&AB"!RN9_X(_2WV%8]N>G[MI%9#LNZDDZ"+55YE'5#!1XD?!W-^ I!
MBXLXPZEQV8:KA*V5JGB,X:!0%MO<K_KC7<:F1T.GA&\6OE5JOW2D>[78:Z6.
M5^X'OK7PP&!_"@5.%$9U2WF*XFM(#Z]#R*"X<_AMHW+\><=XZ&@WWC8!+3-/
MV8\Z0%UAWO70AD.Z_:T[-^A"PN["R]Q&>'+UM5NN*I*G5,%9N2 B5U3 T/7+
ML/VP^!F-4^OT?9Y6+*]\#'\^)@IH'%XY;RZ2REB[EM IJYD4VI\G64[9?(%Q
M-^D3M&G)9_!S6_IH,+$9#E/M25#814M/<GIEDB) N2AJ:DUVAUM ^_4B(6I6
M3(!D=8[*V2[.,,O>/FH?0X986_F)VV=K9[)JPE@HIKCI4NL^/\!0:8,X)NHS
MMY@G=B=*0>?@!B/J2ICB!0LK6S1!XM=V 5K3-']VY^?)!2TV._;1H6\Q? 4@
ML-M]IZL68/U;Q!<JA..#2SM()G7>-FUE.$U[:W?2&0O=UN(5D1\8Y=5+0 .&
MXY@&2JR;)2J%!>M!BAY$6[#?#HC'CJ= !!5VK,*5<.B( ] SQ %(@\:$U^BM
MWMJC*_1ANT+/-\\5>N)2MK4B0RMG5S#G.F/-X]$-(<ZO+*[U*HY1/@D/;\FR
MI5]4RY+@"[3@JFI=<6\'@;E+*BYU]22ADXG?<$TI-"0 &=89+BWB=D*%FO1?
MO:BN:)^HTNDR06Q#U-:G1#">H'!#4>7):)#,?/LP]!1FVU0+)Y]R4YRB*N -
MG3E%M+(:KB(E)H??WG0&8G(?!..>FN8"K3=T)2Q*47RMPY9>D!7G97X> FK:
M-T*3LXG6?$LD^XB@Y9F&'%20WK<^/-B6X>_?HF(IQ<Q:V2[7E!=<A^?GW?9H
MS\ZIL&CK=*+*! @)P[4V3$[?J5_RW.=E4B$/BE_ 0=J(A.OA&T_5(/@RNGVT
M$LB?<5P5W3JNM*BS)EW\?SQ!6#L$]RM?=WYADBW:2"H8ICKJETF62KEC2G!K
MBX(9J&V"6+_8.[ZV0N5: '.YI4G!QO,$>EX5HGB.7O$?[!5_/GK%1Z_X/=JP
MZH42I?]LTD>JT)BF@#@.2,=E6\W.!!_X$,R AH.,7,<=5,P%:,(.E-)>  W?
M@/X]FI:&KS6&$DJB P1A)Y_*04G8(&0:8E[&J. _; 7_8O,4_%^3O$D\]4-
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MU0(%^N,4+L?S,F]![/"THFPY-Q7B0'(SB66MZ8WY& Z2CEG%V ]JVI_.+N9
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MT@=I2\QLB>=6L75MW5_'D:.M1 L+T^@23!U+.OVDS"(9 69W*;$V#ZX+^C1
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MIZ.3_?=Q=/3A8/M_3JM_O#>GH*V^Q=Q+JKG"S_8Q_9"<9U%T<(;\2OS41\S
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MA4="HNX5#PE?-A9T@'?S9&(Q'7#C*O]2+<S%L$+&\XK#_)PEZ"62G@59AM/
MF^[;O%[]Q(NNK ZWO%US(5KTUUW<.[2]3_'T4=GEI>=Z6STK?1B+0%(S2PW3
M@V, =&"BHHNRS5./SV6@:_&P?*4ARN-<4>8-IC<4CCK4XAWDVDH"#D&V2YHR
M<JS6'C]ZH,_KV@PYSW2L8S[@P[;/-Q PXV?F*,'SFER0(G#SC EWJ+4"1'S2
M@0@=C@;)]4Y:"4KF ]B?< L66=+S3],;K(?=!D]OWB(,ZY,6I:[JCY_-+)?C
ML7#+?_3T19B<M#57O^LV4VAOG5-:!QI?K/796L4"?TFN\E#>!NL?(.7LK3XX
MJ2!BY2[&9/L\XPIA^IGX,'+5)UADSR@4XXE#5?#U50Y3Y8^VRNJ48X2CC'S8
M,O*/S9.1!ZY&^Y_>3J>#^5\(F2_)U'_ ^2(07B+K,WC8T"_7-QI9&\8@,AYB
M3R_NUBCOD#TIP7762"94?2:H$38[AJNP20 /PE!<ESPFZ6%36 6LFA [NFZD
MO'YN4JI_F95MU8#-.A/OYA52\*?+&R=>QSX@J:CC(*3QC9)1T!86K@(_>QUM
M)1/-.Z,,@*(L2,"10;HDPS+) [F$O3T&32^)#I!@,3I ;RW(VH'>OXD($  +
M5FKQ?_PAB\(DL4&[,#W$FW"[%X!]+B8<+B\JUG5MJD:!+@P,+4*&\!2]U#D<
M$&QAY7M)2F/F3IUD*:]2_8830]))E%65.2]G%*!5NY%XO:9XYIC([!)W[ZEH
MTKBE'-S"4&+)S=$[8"L<#]!8%E[JEL,,I"2%F:WRI"2'MA&&>-\#M*KVTP7?
MP1 CJLA5&%J!-3IWV7\NPP77TYW%W6&NRI LV"4%U*L;XL2K,QQ)D$33JUU"
MJQ0+N.RLR0SQ- M:C,LZ1<1>L'5L9129Y%YS&(+@]#S'[58)@:\55[*9> N-
MM_R:W45K<\M_V;Q;_M>V:>'.^-W6*?X3W:0G%5[H?X<_Y&[_K/?V:@#-,=SV
MO>&V9V.X[8[!\488U_LIBQ\$8O5/AIT/.(J6LOB<R=/51#GS\:NFQ29YD,),
M$ &+LFXBT/9F7\2<,-!(N0!["NT+4)K+_-R('HPU+J;*4,"+YP7_;C189=,^
M)*?R B-[GKN8+29*_1*3B;PEJ-]3>O16E;@JG:2:9DTE48LV-YACZ#>.E?18
M\B$F8U:Y"9F:L-^DO;.GYM)E:KI^82\P^6;_X)?HX[OHIX^?/W_\_?!S'.W_
M?/CA)-K_\#8Z^>4P>G_XX>WAY^/H^-/AP=&[HX/]]^__%?V^?_1?A\?PS+^B
MST<__W(2'9U$O^[_*_IE_[\.HY./T<GGH_WWT4__BO[YV^=_8>OXY,'^;\>'
M],?!R=''#W%T\'[_Z%?XS^>/Q\>/]8^/OWTX.?PL?YW\<O3Y;?1I__/)O_CI
MZ.-G:NLC=.VS?+1U\/']^T-H\[\.W_\KMBF/].6QC6Q'^\?'AY]/#M]BMW2P
M,-;]HP_')SSF.!@PO G^//H<?3[$L6/SV,;1SQ\.#_%+:.:VO]*WZ>O5,RA
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M1+THG$VN0LVK*CL#79/J$0<(#IEVH$-O:,W/HE2"2K[@O%B25!EA_G_H' \
M:OP:GD9(%DSMC.F*22>EX+!3WU-+@4\]B%B'@PRA +E*J9:J*/4WVOHA1CIQ
MT3-<-3"MF1=N"PSJ'.]))&IPM8(RAW5 RZX#]JYGU3U6%@XM$=;4$K;@?LBR
M7I534! P*O /6X%O-D^!/T30HZHL0&@?6BH@C$I*W?]'.E!^@0V&R2_**JUM
MF-1R"/4CJ!(6T,\=&#1GF/5_@)\G#5;*N\QI.)K\0B0VR[Z8*%M@8I20*WE@
M.52XI#5W''CG]]R 'D?=:@$R.<T3" -Z@7@=/'5?C1)'K.IE2=0$"]0NEGJU
M]H,KZD>@^,JD%\&@< @G#1NW3':&:KXUO:_@LIV=21V9G[/N^RP(S#FR%65$
M\^,U@6/%+VNN5#UW@*HN.P#_^F+,4M[$=,!T(7H-82/=H(T=H-A$%%;A.X83
M).+H'.142HS3%H,K$0)>BM_#7F:T6!MPLO.A76L%DP"N 3"A'C-#$W=2>UU?
MUK"NPXD6X7TA67'VXIYS-:Z &'G0[5TFW7>"+>\=L&.[<MC$SWDY%<7J@UZ#
M!XBQA!E!^S/Q^GH8LK\5&;%)>RV>N,W*/PF<Y#5LRSRI!/">;FU+5X5M7]U@
MC2W>.2#3[4R@YYMA>6XA_/S^R6^?#X\1G/_=Q_?O/_X^Z5A6?]$4/_D11N8-
M7 JW,3)'5\?WNCI>C:Z.N]F%HF+_R;-Q+]7X__C'T8?H]Z.3#X?'Q]'OOQQ^
M/OSX+KZ.IH+3P=+6O_$[],6HQU%@%3\_UC1,3[.SX=<T82C32P.WXCRK:OAR
M"CJ.ND6V5ZVX;]4]'<!67Y<3L>X;0'E67F_X1-.O.<D39N]UNP1%%)7,OWX%
M]K_6)2C=8,3!6PQ8;3,P(XZ*V7TLV!R/ZQU/L#587C_Z_X;_;UR!NT8YSZ"S
M'\!.'I?@+UJ"DZS)8?9O._WC5'_#Y40,0.RN^Y3D9;2?-Z5/K+/I>L-?OP)(
MH#?.\AW/,M@^![^]/SR.#O8_'9WLOP<-[,/!J,V,VLR&K\"HS?SE2_"-VLQ#
MGOYIF:<_9O*%DW:\7\?[=0-G?;Q?_^H5&._7OWP)[H6W8(SQ;F",]\63,<:[
M/KOP0<H^RH5" #HJ@4OBZ/#K63;-!#'D&$OAD ?[/LWYN/_NS_ZSE9<[KQ^=
M)%]-_08CFYCQ;1"JJ6[NU<Z[-[.]^_K1__.9R$=-^O^.,WP',[SW^I%+CI$:
MZ!-,ZAUG^P=FPO-=%>W#9*?G!*;VF4MCHO\YK?[QZ-$^57-; *GPF7$E?OQ*
M_/3ZT0>JP7I?SFR!&IP KDGP^;8P*UL3R<:5^/$K<?#Z41^,\5/2<#7#B5<B
M=U N+P6<A815-B-"[W%1?ORBO!U:E+>&B*.(^[%5K+XCHA DR:6?CPORXQ?D
M\/6C RP=S.ABP HJ)H4WXV3_^,E^]_K1/\N,5"&;ZCO.\X^?YY]'[?YN)_@7
MT#</?@'!3<HGDQXR.O.XL>]RWH]NN[$?[SS;WGOY[#_?+),4R_PX6+*SM[T7
M0EV,,W_-S/_S\<[K1^^P\K"<1[]M'V]')\G7:/CJC+;@P0C^WR#%EQ:%G!!E
M6(4<>TWT2:B2S[)EC4]RDUI_>53,*.$=WO"IK4 Y,O6-*NW&U?YAJ[W[C:O]
MR=%_CDM^OY9\[X<N^;C<:[[<3W^4/!]7>JU7^O]VZ]QA*+P'"0WK/LD:'XU@
M\(_0D[#(R&>S)KZ:#9OC1X^.VVF=I0QQC1Y^]]W^HT>'7P6UZI.I%E@<C%ZT
MU$SA'XA3&3[_TXKGU>O6>?Q@\/'WF2G"!T%HX3Y@>)@X.FQFV_C]?2S5'%-^
M[B3E9V=,^5F?7?B0Q>FS[9>/,.<"(19AMW7EV*M'CX[@-SD"#;6@R'VJRJ5!
MC+Z#/,D6W:=WGFPEDT<';44$(:A'(J;1T:=QX>YBX6"VT\DC6;?H,R%W,O[D
M3%9 83.=/W)42>YJ*>:31X<![!G<^\A7GCN4NL.OR[Q4O#F$ZAL/RI^U.AF(
M)9)8..]'Q;R"D\(+ TM!_"D1\Z<<?8I^NAQ7YL];F3\FC\;U6*/U^#)YY+,"
M^M?*./MW/OOYY%&P^[V343/GY+@$=[P$Q>31N[?[T<]EF8("5;3S!%3?BDQ^
MQIV&-CT7J>K-XW+<S7*4DQ4FR#CC=S+C.X]L<AI.==K.FIZ9]_31HX-D"9IL
M+@D/]V@MQNJX^[4W7^R.KK+UV87?.Q=_WA[\<> /^V_?'GYX^]NOT0XJP>\_
M[G^(]C^\C8X/#W[[?'3RKVC_Y\^'A[\>?CBY28GVD^V7W0KMQ[L[VWLO7W:#
MG"^VG_X% +7W<8%.]O_/X?$;A(KX?+A_?/@V.OAX?')\,[XC6(^A@GGEAB"2
MBNMG_ IF"IK6QS 7B_HU@K@3U\3@*KCA27S[ON,&_Q7T'S!USW=WG^T\>_GR
MY>[NBV<OD?YC9SWH/W[<CG]KYAFR8P2U9/=G8_S'/[8C2A)92C((XSPCK8>K
M!+T=9<^+[6=[XT'>J(/\_,G3YR^?[>R\V'WU9.?9JST\R<EZG.0?&V%G IT_
MZQC_."ETX(AY7(*7N9?RR'(6+4Q2U%*HZ(V/!H:LY VSI2]0;!$?"T@Q^$W=
M5DRX4QBD-Z+)V!*NN C.30DO1BZB"7/=2#/S*BEF9TA!SNW#=U/Z"&EKY@B_
M0)_?DKUL%(4/0A1.1U&X/J+P\"O1?:4;(P&%]!G)-^9EGI<7Z !G*14*/Z)D
M$UYHHG*+/IM9MB1N42)Y$W)+9G4+29O1N8C47%6Y(-:O2ZW1]QJ)B19SZ,VW
M$;MQ5]9R0?J0M"6Z5:(_0^('>/W^Q+Z8F,Q@L&W>6.I2-]RI(6*UZC0I8#'2
MJ*4B1YQ"HO JYT3S=9:<XV/XOF4%?<Z622Z$J/!UK.2G1&TFS)Z<;1W3;WSR
M,L/4H_+C'(OM"8.;&<C^:*NL3C.^P&@$EM44$WZVA')L6>89LFGF\-441$E6
M9TPS5IER3O?5UD\3=V<-7XTQ<W!V^VY[3MG@<\D&ITT 1V]P2R4++G^&W: <
MI="%N5#$)5P%;2=?,#5ZF[#PYRE#EP;"02#_&S/.E(S#$;EDW9#]%%>,]@&Q
MVRGO6HIY\$A#2*1XN#'\3B0SVNK">>J_E&AQ5KQ6YM=OB&E4:UKN<(UC)%DU
MRR;8HAWB.URID,M5J5!W\67ZQ],!FRNVL]^=4-TU!DF *V-7QV2T'?0)'H K
M:F<N0V3>6RQ,FC&U\=3 :II@Q%,S0T;!)"2 +;L-#S63-3)?Z>!\P;:TXB-I
MFBJ;MDW ?6N/K^OU/,ERI"5<P2C[8F#FA(;V?$)':O4&9Y'P;O_D8'_4ZM;G
M^EL?K6XV:G7KH]71.=T 94XD5QWM/'VQ Z(+>GYZAG\\51WOH$Q-'!"N-<:)
M.<O(ICH#4>(:TN) B")'.?P+B7%9=0!5(<-K<(KLZ$UVCN(:)6E2D>A%65F4
MC:68AV\7*,K+PD#/ZH[<G<3T2LUI166@)=98X3MG+MR*)3XFN]+-"U/<R'>B
MRG SELN\CBC20?H2O'#HOL39VII.MG8FG6E":EEH:Y[5J#:1EBO4ZY?(BIO5
MW*TXJA UD4GF-74D24MB2NF2K5.O3TN81.+^18)9[2IRV9N$J75AC<_AHXPU
M);A?PI\P"@'1L6,OX=KA_%.K^=FMX(UHO(G6Y^RNSTV4CC?1&MU$0=WM!EQ)
M:AK:VP(OA(3MQ$]PD93%*)769_G61RJ942JMCU3"PMI%D<VS#7)\6F]C')7L
MVSA+BBCT[\;7^4#1K2;>S$62&O10HH9:^/XK\K#:3'O5QVSN)7L*R/N'GJ.W
MY:RUA43D:PN]/B@^J;\7Z.),33VKLBD3\LWRI(7/8&"Q>._&J-*:[<+UD:_S
M4;ZNCWP=]K7??R$;#TI,+^03.DT[49<$K&E3JR\ .FG(+-8YFIKFPIBB&YQ1
M>OIKHR).Z+M&H0/P*WR08E6=IB6BHS3WL>.XC]&S77J>;61%79J*>LT.Z](K
MMFHY6%*9F8'?IWJ']+] CP*T8BA\ED0UO!BL_DL7=) ?F.(T.>5;@*X;&ML*
MN3]FJG]OIOK>F*G^W9GJ5VL?H[+Q V8>([Q<HO[Z+,,(UE^J<&R<NM%4<,,E
M?+_X3EZ0V88! M*^6D^9 77)B1$<-:7'PMBU_@J>"7X]&77Y]=D!ZZ/+GXZZ
M_+KI\ANBP$=)G@=:.$?D8%LNEC'HS6U%'Z<BGY+J$O.:FJ0XS::Y(46VK# ]
M(H[F<!-1UE149]"CI IS;=&;P?EA79^*J+CT)3M"4/VFL)OHWY=6U\9*[5C%
MKZ;=5!BI VDM[A>O*=*SEXVG9HN'Y@I5&_T[UO_2,6_B(8$OF3SXC9==<TV>
ME;6)AC*>Z-K QL?K8'V.SOI<!V?C=; ^UX'U'FS 98 BDVG.)#U$LSX3/UUU
M%$KKLX3K(Y2R42BMCU#ZW<M;I0.](<+)!M74"4R#NZ5 &BO%-TT>#52*[ZZ'
M./IQ1_J3AA#>588R.N^M!;H=1?N8P(G)EVA]ZL!^8&S=#_[@#P0J?Q+59_C*
MJ6'+$VVOLFVD@"ES.0 J.^>B!TFR@%IZM:N&@D[[A3S)!8SNB/L=?AYMP<]2
MTR#:>,&1'.S9*:*3S1,T F%WSBIC+=2@\J4GT"?:!1:,*T<@<X@1,6M]DY6J
M)C@.H-\\%1YQ#Z_JA9M/PQ"I5!ZV2+Y(5<C*;N'B\V\;V#4Y>02X1JV%S[AX
MQ=65Z8^QWDRR)2J3FW-TR ZFS5Z2EW6&O@G"=B,CN[,>T(4XRN8N8IAAJFW4
M287Q)J)N%[9<9GH9;D0[#YFENX;E!HO?U'52P927XA# H-$U<W,&OYQBX)/V
MZ!:TF+>IC6W:GW%BL/?#H*0,/0EIFN&#5!"V<(586LV6U3<O*)ITMX(+FDHL
MDR9/%@YV)KQ45@JG+6NBB[*%U3M+SHV+?IXEF#]^S738J1BO^;41XFMSS>]M
MZ#6/1]!S-*.\Z;(KWY_=0E?^25]<^J+_!TEU<M\F#356+GV=@>\K>65ELL6T
MK6JJ.M22U*6=>G;S?GN*W2AZ'H#H>;IIHL=J/DSUOIDR)Y-!7G+9M9>JAM($
MY,O.DRA-+FO1U)!5G5T-%58IQU98^'JJZ-B])&I?=^M_:3./*4_ 5(W-0NZ6
M-W<KZ5F!\W2W?A5SV5'PGD[LKS$6EF1DN732W[X9Y6$@0P\G!!5A4#^IO/SK
MDECH;?H=SRBVU$N[YJ)Q6) S0Q(8'L"D:'I)?QJIBAVN!% JFYPLR-R<4BGB
MT 2+WG[-/8,6:C3S*/.26F\HM^2!%86OS80OPF4-ZH_L'B1C2^IEMOCZ@KXO
M[?W'IAU=8M)3<<<7G&)X@5F1L(_G8BGK'SY"@S5%X"C [JNA*U$RK3G<"E.'
MH4X#_:FV5R40CK?:P[W5GCV 6XU0/)CW\IY>;(>)@]+@\UXC4@Z+/7O#6?EQ
MF\MM*YFLN,T&43=4F,'G()#RRP$,DU $HG>#2@1SN!Y2UUU\CQ-X\[):)?#5
MZX&.NSQ;9(U<)U?Y":%3*72X!-&Z->7QC<G3=Y0\_71,GKZKY&F^@<<+]P=,
M_%^7.SUPZ:[%E?LCA<"U%\:U&$WDD*E*!C$CD L+YK&S_=(Y=130I/+HC?";
M18)Y?07YB4@]]GC-P53!A$$)(V_-^$((*T.OZGP76,ZF^@V86.Y*R_PZ)/%=
M]9,)[]!VNA_VDDL["J?O%F9-H![AC*#9Q7W]M_&SG'!9#79NSO.^Q.V7>+%)
MM;P33N]$[V'$"(H=_6=5(#)()NT$CVP?G#[J8G0<P*S+MH(-G)S";JX;0>SA
MV%AK J-Q**KS;'1;KHU,7!L#[_FF&7B'YQG,*HMY39*XIV;=?@TG'A,@:L69
M8IBM>2/"Q84H7%RH:^@DJX(G?@U3_WKM(4@.Q+=%4(>"ATRO*H,SS!!:B=X$
M(,_)MT77KV;B9W7=&N=\7-%5PVMJ@]XR[EC=97+]PUW75@7\9UE63?=A*WNU
M-=.[A>PE"[T![:%&ACB$_O+'-\K0M3DC:R-#7VR:##UNDJ8E,7"?_6)C7OK:
MK,;ZY*5O(-'(OC.1%'3-3[\#^\-\-0O.?E SL7+I5?,NK'&O!LVF9+KZO ';
M9E G&,[0CC4G@RVHBOY;^_<O!A[!A',FIVU( J[2#M_?Q!PJ6*2Y(>P,>)WB
M=KAR11KPK=^"^M=%AJFIF*S9!#I#+9'1('\T2+BD_).$)QQ>5 D J_<,IH@6
M-CTO#I'AY]\T*\%24']9]0EG @L]!4ZJE[?*F^1;9\JPJV+U@^B!U^370>^$
M H,3W.P?LA'Q)+;+[OQF!96"RN*J[B>A:UHDF.$/98,_0^!:R3B]Q!"(=1#A
M<:HP-5,2<9>HH=*3S06Z!?"PS3#IEQ^F?4:K9<M3.8FUG2Y IY6#Q9F,P9S[
MJ<@#7Z/_ 4;3(,Z\PW1]@6BU"//%_\@F]"[^XWPRF)_)6P"G<VI<&!^VD\+6
M=_QNGH/ICS8]Y1.-_1L>*\5C[% YF5,7RE\_\> H(C (#YMKA>9 36JY>+3(
M?44M>0#"L [0'Z1!(+X%]$TQ7.YB82J"!4:DG\:?<'[U>/VOSQVU/M?_!I+K
M_#X4_ 0AB_%?-)XMVTME3DLJS1<18,Z'0[*8^.X#ML:W.TD[S];1YMW9?F[Y
M6<>3=*N3M+/]ZN7.TV<O=O$T[<%1>KFA!9Y)7Y$.#L)M5%S)W5M666F?#&EF
M.CPI)?8Q"0,(791^? .#6:#>C*W2?S&FP4[!=BF,-MYU+JI;+PG"U\<FL=.6
M9^4R8^;.H\_'R.:YB'Y__$J\>)<L8)*>EL8F!O<N( 4:T-F:Y.N;4::LS<9?
M(YFRH4(E1'EG,1)W4J,RDC<:?/4->$I5BF\H=K8RL2N*=C'%4S[7 PVVF0V:
M.G-NS'NZH[RG9V/>TUWE/<EM, K_>YSX-'P!;)STMPDS4@PQN:%>V+DQUD _
MI,X1_V://C3S2XUOR>^^.T9(-TNS>[J]N[/[Y-GSG9TG.Z]>/GU"YWI_\_2Z
M'B5JY\C.\B1;J#MF:@I#3+2,Y"",MF '*0,8G%4^_?CT;T6&JAE&8;$PK+8H
MXUM?)ZN#,^6\@UTX#$YXE97W\J?##WCN.Q\]/HR@43C<67W&OO-.1"GNAI2N
M)H;MI9XHLI+VWT+]4))F[C(UO!FC7,W+_GRX;#DOH!$"K@]-S!K-PK2MX3S4
MM=(7V]F YO49'B'OHQO,UBW-[5$H/P2A_-/F">5KQ-OAP=%X$M9GO=;F)!QL
MWDGX9O5$()?U7D-;I:P:4/:SLJM?:&+YRY<[6#41<*FBJI($10"6-E;*$C4J
MM< ?'GX] S.TB?[Y>,?ZQ9BBW3F;.R.PW(+VWDR*+_8NE I'JOTP22'85V&/
MM_8FR/4><L#:YG:>8,+'3%);*H-7MT;,\3+NF$O7O/#%SM89O?"GS@LI15;?
M25D(8%=A6;V,=E96L "4'6#?3=4M _7D!"GF,83UAWL0O!TLQNC^HEJ2<H6*
MU &F*&14VW/@-MQ]S%G4%9Y8]?8;%794%L>;;FU6=FUNNK>;=].%893>12?7
MA+OF*&FHO"B(1^OJTW7TZ[]B0IA:+$&B<_);1Y_L68Z]#QX?QAI&7BVL;GH[
M$C*?^W,O>-LKJA?\NRUT<+<O7@*::%:SBY *%OLS$D![O^&BD)1J\3$@SE='
M?X;900$-@&F\)-E5%I3/1?SO:8;5A9RJ)__6QZVMVFD3RR<#%65 ";%:2CS8
MQ"*YU.[_N/E_&L*LT"1R&A^/B\C9.X,<8]WK(R[6*=8]!KO_[&#WYD1C!BXN
MY_@DL75E<C<Q;\+1APZCA6<E;;]0(!DS!.XJ0^#YF"$P9@BL_TX=,P3N5 RX
M@!%<9E?%B^!2;/T:)[Q33[EPAF)@=%/5+0AZ(]QLG=J2I":=>&JNOALPILB%
M3C<LW\&/.R4Y#KV[@R")=5)O\!8?=>*UV8-KI!.?;YY*G,T]<%0J$R10AFN
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MZ_?'K4?L!RAL5&*X\XHY [8C+_&*,7H8L#0 [&]G.WF(I2^CK67>UGS$#.S
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MW;,WL#L\"]M[%CG\H SJ!]DY.@RB#S=X/@R]4*T_"X:YE)J5F&MAT/,$50N
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M*(G<"_VM"9BC4[<@R]L]GSUK^XR"$#Q4+YH*;S()P>RG%8%=0Y]=>O@;Y*1
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MITC.%\*6W7Y/2L(*/*.@\I+@=,"/@J&TQX30ZR&8,#[)H9&^V?G!L#P.\3:
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MHHM#J1!UR)G.+''15/4_@"]JNB*4 ,?RQR0HTW>2D5!::7UB[S5H58FBG6"
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M=$Z=>?Q6V5[S3)ZHVNG NO\"5IVG%9MERJDCNMZ.HYO,6)/;*I!%.%JEV73
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MSDY$;@AMGBX%?M93<;;LO.,6YURW']I\M9)9:S!?SRS@2:7I"G\F1@\(/T!
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M??# )M?@B_"L[[T[?K._\W8A]?+(4N'U5S +A68>OR2_LPLXC"?D=FUQ>+1
MO%FMNCF^L?UR49S'O^7[ND&_^*B$\Z6>W*QO]3^WOHC_[8TG'\3OK?Y?.N<]
M<79V^9R*?O_U3?OASJ'X G]=Q6.,V_6R1,I,&Y1[.SO/:U&^OOGO>9'XE"!=
M>SK41N7N[O,:E:]PVL&I!7_VLQ>,Q?_GA=E_P[5.T)_+CC_8/7RS?WSXYMW.
M\:&;]>>RX\VLOSMR=OPS!N45EOH)P_$N$:*4^M]Z%U_:V VUV[IL?^UW3GH<
MD1?_9Y#,QC&+#C$ZEHF7[>W!BB59Z$5^9LRAW;?/[$O=8!YQZ(5J-6"AK2EZ
MVSQZY QEU^OH$XI/81SSZN#%W^+D>T/H?SV9*N/S8KVWE0M)N)"$.\(?.<.G
M9RUQV;EL=S$,(;:^]K:?TUC=>X4S?K@K_AQ?@T/<%'^1482L-9??;Z<Z'+&[
MM\KYK?W=YM$"16*KO@;<!>)S$(8I'+)_%CM'.T?OGJKR[*DFV57BN4J\M9FR
MY2FQ@QJ+]>#U'2,<W&O#;X)8=+VK./4:HIW^P7Z@%8@Z/MI_L[=[^&;OW<X!
M?6>%2_"[_9TC^._.0LGF1_H8;UWM)*T9$U=87!L*<(J04B):*WC^?(G<GTAO
M@24R09;*<(1(W##XKOV,I32HKTW.N9['#UW;EV6PN'Y-U1OM*$-*?5-#\$&T
M-%79FI9T5.B!BX "\^](?F&OU+FFZ&FOB,OL C'5EB.(3%V%NJ"VKD*!X',L
M<)"^JNQ6%6ZZ&U:0J&$0?^A4=1=#"C0X=]"(1DHUD5Y+B51#H:0FS W=%H8K
MC$T12<$P%"?%:Z4-P^2C4?OXBP3K4Q:O$=DJ2I5GP.(%U9 >N!HIL37[HB<G
MF1P/X.^]AMC;V=O9QLX0D;R'FD[SPQ%CGL0^U52A@Z6!5,R=)?2V!7\T?%/0
M:E97[>'TSL=/RT54H]SW';?F\RGWX#4I]\](S1M=K:TBQ\)?4(TY[F9/4V',
M=))*L(0ME0DJ@Q'1%$4W,N+6]G$43JVJ)&KNR SUI2;2"3=Q@9?*RHT02[5U
MK*HKC, /U#!'S9WCO2?M25^C8=XZ OGGTB__?$WZI>7KTM83;L*TGHJF76,^
MF 9RQ.O(!@83CI-3J6Q"S6..C6.1Q":G<D=L%X5]+JA/%?(NYE' A8_JFFTV
MP9 '6'>OFFVGV# $Y5B\J1G3;&(&Q>N3(K%/M-W _XOY_R;\?W]LD^Z#?R5S
M6Z<_BF1\>82XCF3\A135]]>DJ+!5=98$<.R?</,:VCCKJ:WZLZXIE>?39]AX
M$.T@[%"0A5/-R&UYCLQPE7BCS+BZ91JQ"A<-.&*#X(I:78!:HUIT92 QHTJ-
M\00V6RIG6\36-1"BMD T&FO0JNM#Y25QW!%2@LLT'T\T)^4@3WP9*78%PVI
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M!;HI"KP%./>8")53G8O>MBE.+:U5ZCX_,[A*S]U::D'XP\_EG0^<UY?WB@2
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M*=F788G%['A50P>*/*2L1@E71(.G)Y1N#'-%=&0/?0*VB."F:YC1Q^!PB@
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M"BI P,=PF.2R%K*:P"TTLMY$!0M2HI$7A#E;P"JZ9Q==Q0/8PJH(H1;O2L=
MX:#?15AD]*9=KR\LMW\&MTM!A2J2U[!461 ?+@53J4L"N]0\HLH,4/!034VV
MX<K#!\#,@F7/$?JZ!\!K:4B;6D@%Y**$*9K)7"K' *M,07-H@LIO@PAIS$OX
M\H\<#R)5;0;7@26N&;+0UN?A%>0L,9YJ!D\W=Z!SQ@/WYRHW^W%P' =IEBZY
MB.SM\H\<5T+V; =._IH.G+,XQ?9<61Q*</F_@"?+L%;8.J?@,"?Q5)I,RGH>
M1)U1.4<)_PSII5/UTF/[I7W]THU2/@F,]P:B+DF#L*YGQ"I*Z3A2! A%A "Y
M"Q@)S"<1X4/IE).EM@8-@SCQ4J[]M8:C1JPS<%)Q\24,(F45&X_ [ _2-,=@
M;@33H5\3"Q:0P!0V46PJS<CBEEBSBZ.W9P6,_45FI2E:6O?:#YLQ\2WWP*34
M$#U0'*V5L[E@)&0L*>-NPU!>21^F;I&Q54:#5<Y6&73ER(7/P;1PT9E5TT@O
MJ_IO7I7JA[T5^>L:F(E5:6W&L'I"HW,,NPPO:93UG(DY7(,+DLZ4OZ$FI9^B
M;F7;?\O\1 [SA $.^K*&\.&Q0^2E(72,_JLA\DD<,=E@DBIM1UJS_KD-Q-N#
M2MK642(X*A(DSO$99.-AG)DXBC 44XPCI"6DL$X^P.!U%I#Q3R'O. SC6S2(
MT;]Y?Q_X?0FMV@Y_&KJZ=\@WJ=. :PY>)>Q-KWWRM=OI(TZI)\XO^N)CNWTN
MNNW?.KU^N]L^%5_/$=>#^!UU:0=13B=]1"WM'N_O-P3\L/6E#9>=BBV\3J.-
MX"(#-6IHE%+K\O*L<]+Z> ;WZ[?ZI;N>M7[O-1!GM13@\E*7?S.0W!L(:G=U
M ,\F/7MUI W+KRY:=;6)H$Y6E*)W<7;:$)=G[=/?0/F!AB,,YN^=7EOTNZWS
MWJ=V%U7H[YW^YXNO?=!LHOWI$\,RE8KMMA#W20T=VZ!0"V6+&A81IXOI3'CT
MY==N[VOKO(^HRNY7N'3WX("5KFC_K?WEDI[SJ7OQA6Y?>GJW_1]?.]TVZ/!^
M3Z->'_+\:NW!(_7UNUIOY6$2IFK@+!$;2LS[K)N0_;TKQU[ (.>1N 35)CJ1
MZNY)]M09[!SQ,?2B[_]8Y=E?8W6W@9K?'9;+D9X9JHS%6E7M_6Q_;A4[6#=E
MUCG'(_"\W>N)W_F@*R-+;5I8*H#QRQYRD;MB?)C=2R.@HCAJ;JQ8^O((F:MS
M!) 2.RH,GJJW572O;>"NIUXVTT:IUOD\>'BG,O ;ZOI>K6_+RY^ W'#9QT+=
MP1\QT[O[S3TWT7<V!U]DYO>/K8+<!TAY#9;E-<[]Q^E3]E!^_+@6ZJ'\J+6O
M[77Z[A4N_;DWEN^YMR(RT"ZDYU9[QN\SL1X_5XMW!UWM&5IUF2P593[9R;M7
MR^/Y&M4_'+DG7\_:/7'2NNST6V?NW'7G[I/IN#K'\C6N/1V\"\WSWFSV\+AY
MO+-[WTS__$0O%A%;]9F^V[!YH/@^UZ2N0J#H=<;,7)AQ.3;P3O-=56V]V=MM
M[K][]Z</$\]':#%?N'O4/+@_(/F3TP;[],52*X,X]!<#'^T]OM#AY//_W][9
M];8)0V'XNOL5EM;MHJ(42,AG5:E+NZE2JE9MMJO=F. N3"1$X*2-U!\_0R!-
M$\@'H1FT[T64+]M8QX]?'WQL<WD1!,YD%:VS=>MDT@:MF^OKJTX0B'R_3;!.
M6M*;+U9:>'A TY+UZ(@[32/8LQS41EBKH32#Y,<VG3@C+HI_8F9S>BE5":0Y
MS"! L>G08XUH]][K%5)!V8'*BPK,A@-_RX=AV1:?-*+\82*1RIS9)[A<72Z7
M@B60IR?<3$A3DVOEO"01OGQ-+50QRVG$!W>QS5XF4GPJEULKY"'T[121B'B.
M;9G--4H3YHL6U,WG?!1_3;V&QM1W\'^(,H0=?S[]JZXN(*WJUJ Y9O[S!:D=
M=D51OZB$F1L05T94GVDA,4Y"DM,2==EY7WN-NBA%$?@L[R7:_DK!NWEYCT5T
M;U@!G@+!XZ^J$FX:4<])Y_+NFKSX"^ )/.W TS?P!)ZRXTF#/H&G+'F"/H&G
M+'EJ+?)T!*  5'J@2ACPP%.6/"T->! H +4#4&7H$W#*#B<=\@2>LN!I XI2
M1640? %N,>M4F=OU'[A#6G1H<?^@U*M!5UXK75"HCXO,H2ZNJ@0O< ).DCDI
MJ5)5T\$).%G-B5:6*M4E3O)NUO]NMVA'0;3&"WT+?6N#OI5+AD$OZ(WS(&:>
MYOK9%(#R@4%1%4F'S('>8M*K0^7 R583+P %H*SRFZ H &6CV\.**E7TQ+E<
M!)J 6M:!IMOPV<\MEYD6)]]%C<D5:<NW,EQW"&C!J#Y$: -XK,"CNCBZYDO;
M(&Z@=^6\1#W/] )>P MX >\[A!=N)?!8-6TCZ= VP%M,>*%MP -X  _@ 3RR
M]XPT24W>FX!X%DA[JWC6#]LQJ$U^B;]'KOCJ.H^\%Q?>@G !)XQKP&/+V<P*
MME(!DW68E*72\DXJ8 ),@ DP@4\"/#+=="/5H"+ !"H"/( '\  >P&/_/DA%
MTK!_!:2]_;E\-YWS-HE_'!ET";3@C#1PDF8F3@<GX&2;'=W@!)R $W""D[4
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MXE082E^=%S,NUW5A51E @2R&<9J48TTJPD)RR@9P6TZ(31J,,WQ27:T%\+\
MB!"/$^=#=$A1J8;]?P_VP3VPWSL<;J%__T"ZMQ- QS$7$6&;&Y5QRABX0;]
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M7)/'>#9]+A=\:5Q(&K;\]\$,6^Z;9/X&4$L#!!0    (  2)HE2C!QX'N 0
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M.5GF92_OMJO?];OM\A\!_P!02P,$%     @ !(FB5 ]/57^V!   '2    \
M  !A>'-M+65X,S)?,BYH=&WM6EMOVD@4?M]?<=1JJR!AL)U+&YM%\A*C16J
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MN=_KEO\6\"]02P$"% ,4    "  $B:)4<KR2,@_+ @"1.AX $0
M    @ $     87AS;2TR,#(R,#,S,2YH=&U02P$"% ,4    "  $B:)4[X)S
M0($1  #\OP  $0              @ $^RP( 87AS;2TR,#(R,#,S,2YX<V10
M2P$"% ,4    "  $B:)4*'\:4T *  !3AP  %0              @ 'NW (
M87AS;2TR,#(R,#,S,5]C86PN>&UL4$L! A0#%     @ !(FB5&V.NGT,(0
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M<VTM97@Q,%\Q+FAT;5!+ 0(4 Q0    (  2)HE0^'A^@)P@   9'   /
M          "  2J?!0!A>'-M+65X,S%?,2YH=&U02P$"% ,4    "  $B:)4
M;GM[WQ((  !01@  #P              @ %^IP4 87AS;2UE>#,Q7S(N:'1M
M4$L! A0#%     @ !(FB5*,''@>X!   &"    \              ( !O:\%
M &%X<VTM97@S,E\Q+FAT;5!+ 0(4 Q0    (  2)HE0/3U5_M@0  !T@   /
M              "  :*T!0!A>'-M+65X,S)?,BYH=&U02P4&      L "P"[
) @  A;D%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
